{"title": "PDF", "author": "PDF", "url": "https://minerva.usc.es/xmlui/bitstream/10347/10295/1/rep_639.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \u0014\r\n\u0015\u0006\u0011\u0012\n\u0005\u0002\u0005\u0001\u0005\u0006\u0001\u0012\u0002\r\u0013\n\u0002\b\u000e\u0001\u0005\u0006\u0001\u0004\u000e\f\u000f\u000e\u0012\u0013\u0006\u000b\u0002\u0001\n\u0001\n\u0007\u0002\u0004\u0014\u000b\u0013\u0002\u0005\u0001\u0005\u0006\u0001\u0007\u0002\u0011\f\u0002\u0004\n\u0002\u0001\n\u0005\u0006\u000f\u0002\u0011\u0013\u0002\f\u0006\r\u0013\u000e\u0001\u0005\u0006\u0001\u0010\u0014\u0017\f\n\u0004\u0002\u0001\u000e\u0011\b\u0016\r\n\u0004\u0002\u0001\n \n \n \n \n\u0001\n\u0001\u0001\n\u0001\u0001\nF\u000f3\u001d\u001f%\u001f(+/\u0001%*/,%.\u001d +/\u0001!*\u0001,.+ 1\u001f0+/\u0001*\u001d01.\u001d(!/A\u0001\u0001\n2!./\u001d0%(% \u001d \u0001-18)%\u001f+C\"\u001d.)\u001d\u001f+(;#%\u001f\u001dG\u0001\n\u0001\n\u0001\nF\u000f3\u001d\u001f4\u001f(!/\u0001%*/,%.! \u0001%*\u0001*\u001d01.\u001d(\u0001,.+ 1\u001f0/A\u0001\n\u001f$!)%\u001f+C,$\u001d.)\u001d\u001f+(+#%\u001f\u001d(\u00012!./\u001d0%(%04G\u0001\n\u0001\n\r!)+.%\u001d\u0001-1!\u0001,\u001d.\u001d\u0001+,0\u001d.\u0001\u001d(\u0001#.\u001d +\u0001 !\u0001\u0005+\u001f0+.\u001d\u0001,.!/!*0\u001d\u0001\n\u0001\n\u0005(\u0018,\u0001\u0012\u0018\u001d\u001a\"\u0018\u0001\u0015%$ #\u001a$\u0001\u0011\u001f\u0019!&\u001b#\u001a$\u0001\n\u0001\n\u0005%.!\u001f0+.!/A\u0001\n\u0001\n\u0001\u00061#!*%+\u0001\u0015.%\u001d.0!\u0001\u0016%((\u001d.!/\u0001\n\f+1. !/\u0001\u0013\u001d*0\u001d*\u001d\u0001\u0010!*8*\u0001\n\u0001\n\u0001\n\u0013\u001d*0%\u001d#+\u0001 !\u0001\u0004+),+/0!(\u001d@\u0001\u0006*!.+\u0001 !\u0001MKLO\u0001\n\u0001\n \n \u0005B\u0001 \u00061#!*%+\u0001 \u0015.%\u001d.0!\u0001 \u0016%((\u001d.!/\u0001 4\u0001 \u0005:\u001dB\u0001 \f+1. !/\u0001 \u0013\u001d*0\u001d*\u001d\u0001 \u0010!*8*@\u0001\n\u0004\u001d0! .60%\u001f+/\u0001 !(\u0001\u0005!,\u001d.0\u001d)!*0+\u0001 !\u0001\u001118)%\u001f\u001d\u0001\u000f.#6*%\u001f\u001d\u0001 !\u0001(\u001d\u0001\u0015*%2!./% \u001d \u0001 !\u0001\n\u0013\u001d*0%\u001d#+\u0001 !\u0001\u0004+),+/0!(\u001d\u0001\n\u0004\u0006\u0012\u0014\n\u0007\n\u0004\u0002\u000eA\u0001\n\u00111!\u0001 (\u001d\u0001 \r!)+.%\u001d\u0001 0%01(\u001d \u001dA\u0001 F\u000f\u0017\u0002\u0004\n\u0004\f\u000f\u0013\u0001 \n\u000e\u0013\u0010\n\u0012\u0002\u0005\u000f\u0013\u0001 \u0006\u000e\u0001\n\u0010\u0012\u000f\u0005\u0015\u0004\u0014\u000f\u0013\u0001 \u000e\u0002\u0014\u0015\u0012\u0002\f\u0006\u0013A\u0001 \u0016\u0006\u0012\u0013\u0002\u0014\n\f\n\u0005\u0002\u0005\u0001 \u0011\u0015\u001b\r\n\u0004\u000fC\u0007\u0002\u0012\r\u0002\u0004\u000f\f\u001c\b\n\u0004\u0002G@\u0001\n-1!\u0001,\u001d.\u001d\u0001+,0\u001d.\u0001\u001d(\u0001#.\u001d +\u0001 !\u0001\u0005+\u001f0+.\u001d\u0001,+.\u0001(\u001d\u0001\u0015*%2!./% \u001d \u0001 !\u0001\u0013\u001d*0%\u001d#+\u0001 !\u0001\n\u0004+),+/0!(\u001d\u0001,.!/!*0\u001d\u0001\u0013\u0002\f\u0006\u0014\u0002\u0001\u0016\u001a\u0019\u0011\u0015\u0006\u0019\u0001\u0012\u000f\u0005\u0012\u001b\b\u0015\u0006\u0019@\u0001$\u001d\u0001/% +\u0001.!\u001d(%5\u001d \u001d\u0001\n\u001e\u001d&+\u0001*1!/0.\u001d\u0001 %.!\u001f\u001f%;*@\u0001!*\u0001!(\u0001\u0005!,\u001d.0\u001d)!*0+\u0001 !\u0001\u001118)%\u001f\u001d\u0001\u000f.#6*%\u001f\u001d\u0001 !\u0001(\u001d\u0001\u0007\u001d\u001f1(0\u001d \u0001 !\u0001\u0007\u001d.)\u001d\u001f%\u001d\u0001 !\u0001(\u001d\u0001\u0015*%2!./% \u001d \u0001 !\u0001\u0013\u001d*0%\u001d#+\u0001 !\u0001\u0004+),+/0!( \u001dB\u0001\n\u0018\u0001\u001f+*/% !.\u001d* +\u0001-1!\u0001!(\u00010.\u001d\u001e\u001d&+\u0001\u001f+*/0%014!\u00010!)\u001d\u00014\u0001(\u001d\u001e+.\u0001 !\u0001\u0014!/%/\u0001\n\u0005+\u001f0+.\u001d(@\u0001\u001d10+.%5\u001d)+/\u0001/1\u0001,.!/!*0\u001d\u001f%;*\u0001!*\u0001(\u001d\u0001\u0015*%2!./% \u001d \u0001 !\u0001\u0013\u001d*0%\u001d#+\u0001 !\u0001\u0004+),+/0!(\u001dB\u0001\n\u0018\u0001,\u001d.\u001d\u0001-1!\u0001\u001f+*/0!@\u0001!3,! %)+/\u0001!(\u0001,.!/!*0!\u0001\u001f!.0%\"%\u001f\u001d +\u0001!*\u0001\u0013\u001d*0%\u001d#+\u0001\n !\u0001\u0004+),+/0!(\u001d\u0001\u001d\u0001R\u0001 !\u0001\u0006*!.+\u0001 !\u0001\u0005\u000f\u0013\u0001\r\n\f\u0001\u0004\u0002\u0014\u000f\u0012\u0004\u0006\u0001\n\u0001\n\u0001\u0001\n\u0001\n\u0001\n\u0007 +B\u0001\u00061#!*%+\u0001\u0015.%\u001d.0!\u0001\u0016%((\u001d.!/\u0001\u0001 \u0001 \u0007 +B\u0001\f+1. !/\u0001\u0013\u001d*0\u001d*\u001d\u0001\u0010!*8*\u0001 \n \u0001\n\u0001 \ni \u0002\u0013\u001c\r\u0010\u0011\u000f\u0014\u0018\u0014\u0011\u0019\u001e\u001a\u001d\u0001\n\u0002\u000f\u0016\u0019\u001a!\u0017\u0011\u0010\u0013\u0011\u0018\u0011\u0019\u001e\u001d\u0001\n\u0001\n\u201cSon m\u00e1s de agradecer las palabras de aliento tras una derrota, que una mano \npor la espalda tras una gran victoria\u201d. An\u00f3nimo. \n \nPor eso, la llegada a este puerto s\u00f3lo ha sido posible gracias a la maravillosa \ntripulaci\u00f3n que me ha ayudado a gobernar mi barco, mientras navegaba por el temido Poseid\u00f3n, capeando temporales y disfrutando de los d\u00edas soleados. Y es que yo nac\u00ed \nen una burbuja y viv\u00ed en mi mundo de cristal\u2026  \nA toda mi tripulaci\u00f3n\u2026 A los profesores Eugenio Uriarte y Lo urdes Santana, o como siento que debo \nllamarlos, a Eugenio y Lourdillas, o al \u201cjefe\u201d y a la \u201cjefa\u201d, por  abrirme las puertas no s\u00f3lo \nde su laboratorio, sino tambi\u00e9n de su amistad. A Eugenio por las mil y una horas \n\u201cdiscutiendo, debatiendo, arreglando y destruyendo\u201d este pa\u00eds (y suma y sigue), por su esp\u00edritu siempre deportivo , por su vitalidad y energ\u00eda constante, por su capacidad para \nvisualizar la \u201cU.M.P.\u201d, y por animarme siempre a volar. A Lourdillas, por las incalculables horas de conversaci\u00f3n, hablan do de lo divino y lo humano, por su insaciable esp\u00edritu \naventurero de Willy Fog  que comparto hasta las entra\u00f1as, por el apoyo y \u00e1nimo en los \nmomentos duros, por ese car\u00e1cter \u00fanico y por se r la reina del \u201cScifinder\u201d que de tantos \napuros nos ha sacado!. A los dos, por que juntos form\u00e1is un gran equipo. \nA vosotros, Pap\u00e1 y Mam\u00e1, que lo sois TODO para m\u00ed. Por haberme dado la \nvida, en m\u00e1s de una ocasi\u00f3n... Por estar a mi lado en los momentos m\u00e1s dif\u00edciles, sufriendo conmigo pero manteniendo siempre el  barco a flote, y por disfrutar de mis \n\u00e9xitos como si fuesen los vuestros. Porque sin vosotros NADA de lo que soy y ser\u00e9, \nser\u00eda posible. Porque me hab\u00e9is dado siempre m\u00e1s de lo que necesitaba e incluso de lo \nque pod\u00edais, anteponiendo siempre a \u201cla nena\u201d  antes que a vosotros mismos. Porque \nvosotros s\u00ed que form\u00e1is el mejor equipo que conozco\u2026 A ti, Mam\u00e1, por haberme dado siempre las fuerzas que en muchos moment os me han faltado, por demostrarme con \nhechos el significado de la palabra \u201cvaliente\u201d, por luchar como nadie d\u00eda a d\u00eda con el \u00fanico fin de ver una sonrisa en la cara de los tuyos y por la generosidad y el altruismo \ninfinito que demuestras en todos los aspectos de la vida. A ti, Pap\u00e1, por haberme \nlevantado del suelo con garra y decisi\u00f3n, por  ense\u00f1arme a descubrir no s\u00f3lo lo mejor \nde las personas siempre, sino tambi\u00e9n \u201c el lado bueno de las cosas \u201d; por tener siempre \npresente que todo es \u201c cuesti\u00f3n de principios \u201d, por hacerme ver qu\u00e9 es lo importante y \npor inculcarme los mejores valores que existen. Por tu capacidad de di\u00e1logo y an\u00e1lisis, acompa\u00f1ada siempre del amor infinito q ue me transmites constantemente y por  \nii haberme dedicado tantas y t antas horas, aguantando mis \u201cal borde del abismo\u201d\u2026 A los \ndos, porque siempre trabaj\u00e1is de la mano y porque es imposible que existan padres \nque se entreguen m\u00e1s a sus hijos que vosotros. \nA mi hermano Marcos, que desde que t engo uso de raz\u00f3n ha sido un referente \npersonal y profesional. Gracias a \u00e9l he aprend ido a vivir y disfrutar de una de las cosas \nque siempre hace que todos los males desaparezcan: el mar. Por su capacidad \nindestructible para escalar paredes como las de \u201cEl Capit\u00e1n\u201d, y franquear los \nobst\u00e1culos m\u00e1s dif\u00edciles con arte y pericia.  Por los sue\u00f1os, inquietudes y experiencias \ncompartidas; por la determinaci\u00f3n que pr esenta a la hora de tomar decisiones, y \nporque me demuestra siempre que el que quiere puede. \u201cDo or do not, there is no try\u201d \nA mis abuelos (en memoria) Mercedes, Rafael, Alicia y Pepe. Ellos han sido \nsiempre, sin saberlo, el motor de que me  haya sumergido en esta aventura. Porque lo \nhan dado todo, literalmente, por un futuro mejor para nosotros. \nA mi pilar n\u00famero dos: \u201c Villachunguita \u201d a.k.a. Laura, Reyes y Ana. A todas ellas \ncomo uno, porque cuando estamos juntas f uncionamos como tal. Por todas las \nvivencias compartidas (las que se pueden contar y las que no!). Por los viajes, la \n\u201ccalceta\u201d, las ma\u00f1anas, tardes y noches y por el \u201cal matadero con casta\u00f1uelas!\u201d. Por las \n\u201cbroncas\u201d, los consejos, los llantos y las ri sas, las merecidas y l as irracionales. Porque \nsin duda alguna, ellas han sufrido conmigo no s\u00f3lo este viaje rumbo a todav\u00eda no s\u00e9 d\u00f3nde, sino todas mis idas y venidas a todos  los niveles, estando SIEMPRE al pie del \nca\u00f1\u00f3n. Por ver, escuchar y sentir conmigo. Po r SER y ESTAR. A Laura por transmitirme \nsu fuerza para superar hasta el mayor de los obst\u00e1culos, siempre con una sonrisa. A \nReyes por su capacidad para \u201cdesnudar mis entra\u00f1as\u201d sin necesidad de contarlas y por ser la gestora de mis sentimientos. A Ana por su vitalidad y predisposici\u00f3n constante \npara tender la mano y ense\u00f1arme el significado de \u201cyonqui de la felicidad\u201d. A Villachunguita por darme lo que necesito, por estar siempre a mi lado, y por ense\u00f1arme \ny demostrarme cada d\u00eda que son \u00fanicas. \nA mis t\u00edos Tito, Luchi, Fernando, Fernanda,  Nena, Pili y, Tante y Abd\u00f3n (en \nmemoria). Unas palabras especiales se merecen Tito y Luchi, por ser mis segundos \npadres desde que tengo uso de raz\u00f3n, y por tratarme como una hija en todos los \naspectos. A Marina y Jose, que ellos saben que para m\u00ed son tambi\u00e9n mi familia, por preocuparse por cada uno de mis pasos, se guirlos de cerca, y haber hecho que sacase \nmi esp\u00edritu \u201crevolucionario\u201d. \nA mis primos Hugo, Jorge y Adri, porque han hecho posible que viviese la \ninfancia m\u00e1s feliz que un ni\u00f1o puede desear. Por compartir ilusiones, preocupaciones y \nsue\u00f1os, y por descubrir juntos el significado de la palabra \u201ccrecer\u201d.  \niii A mis frik\u00edmicos  Luc\u00eda, Dani, Diego, Iria, Lara, Ol alla y Ainara, por compartir no \ns\u00f3lo las aulas, sino tambi\u00e9n la vida del d\u00eda a d\u00eda durante la carrera, y grandes \nresponsables de que la universidad haya pasado por m\u00ed, y no yo por ella. A Ainara por su predisposici\u00f3n para \u201cla rampa\u201d. A Olalla por su sentido del humor y su buena \nvoluntad para la amistad a pesar de \u201clas piedras del camino\u201d. A Lara por compartir las \ninquietudes y preocupaciones cient\u00edficas y seguir de cerca mi camino durante el \ndoctorado estando siempre \u201cah\u00ed\u201d. A Diego por estar siempre dispuesto a compartir \ncualquier instante, con un buen \u201cdanone\u201d. A Iria por transmitirme su ilusi\u00f3n por las peque\u00f1as cosas, y por ser la bondad en persona. A Dani por compartir lo que con \npocos he compartido. Y a Luc\u00eda, mi cuca, por estar SIEMPRE a mi lado de forma \nincondicional, con raz\u00f3n o sin ella, proporcion\u00e1ndome la calma (o la euforia!) en el \nmomento oportuno. \nA la mafia del 5\u00baC, mis otras compa\u00f1er as de batallas unive rsitarias, Adri \n\u201cSpunyyyyy\u201d, Marta, Cris, y Elena, por compa rtir altruistamente una de las mejores \netapas de mi vida y formar parte de historias inolvidables  grabadas a fuego. \u201c\u00a1\u00bfQui\u00e9n-\nme-ha-robado-la-mochilaaaaaa?!\u201d.  A Marta (de la Toweeeeerrr!!), por ser la compa\u00f1\u00eda y \namiga perfecta en nuestros \u201czulos\u201d.  \nA \u201cJuanchu\u201d, por su cari\u00f1o infinito, las conversaciones hasta altas horas de la \nmadrugada (chilena o espa\u00f1ola), y por las ca\u00f1as  que se van de las manos. Gracias por \naparecer. \nA los ni\u00f1os de Santiago Jano, Nacho, Juli, Fraga, Rilo y Rebo. Unas palabras \nen especial para Fraga, por compartir inquietudes y parte de nuestra vida en el \u201cexilio\u201d \nen Newcastle. Y por supuesto, a Jano, por todo lo que \u00e9l ya sabe\u2026  \nA los limensianos en general como \u201cclan\u201d , ya sea el de los mayores, los \nmedianos, o los peque\u00f1os de una saga que encierra mucho m\u00e1s que la pasi\u00f3n por el \nmar y un rinc\u00f3n especial que representa mi peque\u00f1o para\u00edso ( 42\u00ba15\u2019 N, 8\u00ba48\u2019 O). Sois \ntantos que espero que os deis todos por aludidos! Pero en especial a todos aquellos \nque comparten las eternas noches de verano alrededor de una hoguera de \u201cpi\u00f1as con \nsal\u201d o un \u201cba\u00f1o\u201d, desafiando ciclog\u00e9nesis explosivas, temperaturas extremas y \u201cchuzos \ncomo pelotas\u201d. Porque la alianza de Eolo y Poseid\u00f3n es el mejor matrimonio para \nnosotros. Un huequecito especial  tienen: V\u00edctor, el Gur\u00fa, por que fue el primero que me \nmeti\u00f3 en el agua cuando era una enana, entre una jaur\u00eda de machos alpha dominantes, y me puso encima de una tabla, trat\u00e1ndome siempre como la \u201cprotegida\u201d pero \n\u201cd\u00e1ndome ca\u00f1a\u201d. A Iagui\u00f1o, Nanus y Ra, por las charlas y delirios compartidos en \ntantas y tantas noches de ve rano. A Laura, Carmen, Erea y Sara, por las incalculables \nhoras viendo m\u00e1s all\u00e1, por los bautizos de  \u201cCharlie\u201d y de \u201cHarry\u201d, y porque siempre \nest\u00e1n en el para\u00edso. A los hermanos Rivas,  Alex y Du, por sus ideas, inventos y esa  \niv actitud incansable de revolucionar el mundo. A Alex \u201c2\u201d, qui\u00e9n en cierto modo me ha \ninculcado el esp\u00edritu insaciable de recorrer mundo. A Gus, por ser amigo en momentos \nclave. A los hermanos Montouto Escudeiro (y familia), en especial a Samu, por \nense\u00f1arme, soportarme y compartir momentos inolvidables; y a Dieguito \u201cCu\u201d, porque \npas\u00f3 de ser \u201cel enano\u201d, a ser amigo, confidente y compa\u00f1ero de batallas varias, en \nmay\u00fasculas. A la familia Ortega Villal\u00f3n, por el apoyo y cari\u00f1o transmitido a lo largo de \nlos a\u00f1os, en especial, a L\u00faa, por su amistad de tantos y tantos a\u00f1os que tanto me ha \naportado.  \nA mis compa\u00f1eros de laboratorio: Al equi po Sardo de Silvia, Giulio y Ricci, que \nha estado al pie del ca\u00f1\u00f3n (\u201caqu\u00ed no duerme  ni dios!\u201d). A Javi, Dolo, Santi, Chachi, Edu, \nAndr\u00e9 y Tati, por soportarme d\u00eda a d\u00eda entre reactivos y disolventes y mantenerse con \nuna sonrisa ante mis altos y bajos. Un rinc\u00f3n especial me lo reservo para El\u00edas, que \nsupo entenderme desde el mi nuto dos (en el minuto uno t odav\u00eda ten\u00eda dudas de si \nmord\u00edas\u2026!!!) y para Mar\u00eda, por ser amiga y compa\u00f1era de viajes, por apoyarme y \nescucharme entre caf\u00e9s y congresos, y porq ue desde luego, sin duda alguna, esta \nTesis no habr\u00eda sido posible sin su ayuda.  GRACIAS. A Xos\u00e9, por tener ese carisma \nentra\u00f1able y la predisposici\u00f3n indiscutible  para echar una mano en cualquier cosa y en \ncualquier momento. \nUna menci\u00f3n se merecen los \u201cni\u00f1os\u201d que  han pasado por nuestro laboratorio: \nPablo, Andrea (Dr. Bucci), Miguel, Veronika, Carla, Mannuel, Jose, Jo\u00e3o, Francesco, \nNicolo, Mar\u00eda, Andrea, Rita y Gabriel, que de alg\u00fan modo han contribuido al desarrollo \nde este trabajo, o al meno s, a hacerlo mucho m\u00e1s ameno. \nA todos aquellos profesores e investig adores que han empleado un poco de su \ntiempo en transmitirme tanto los conocimientos , como la pasi\u00f3n y motivaci\u00f3n por esta \nespecie en peligro de extinci\u00f3n que es la ciencia. A Roger Griffi n, Ian Hardcastle y \nBernard Golding, de la University of Ne wcastle upon-Tyne, por iniciarme en este \nmundo. A Antonio Figueras y Beatriz Novoa,  del Instituto de Investigaciones Marinas-\nCSIC de Vigo por acogerme y sumergirme entre peces y PCRs. A Marcus Tius, de la \nUniversity of Hawai\u2019i at Manoa, por abrirme las puertas de su grupo durante mi estancia \ny ense\u00f1arme los secretos de la qu\u00edmica sint\u00e9tica.  \nA los profesores e investigadores que han contribuido de forma activa al \ndesarrollo de esta tesis gracias a su incesante colaboraci\u00f3n, especialmente a Fernanda \nBorges de la Universidade do Porto, Karl-Norbert Klotz de la Universit\u00e4t Wurzb\u00fcrg, \nClaudio Olea-Azar de la Universidad de Chile, Giovanna Delogu de la Universit\u00e0 degli \nStudi di Cagliari y a Dolores Vi\u00f1a, \u00c1ngeles M u\u00f1oz e Ysabel Santos, de la Universidad de \nSantiago de Compostela. \n   \nv A la tripulaci\u00f3n del IIM-CSIC: Ana Mato, Iv \u00e1n, Pep, Sonia, Laur a, Ariana, Rub\u00e9n, \nJorge y Mar\u00eda, quienes me han mostrado de cerca el maravilloso mundo de la \ninmunolog\u00eda y la gen\u00f3mica de organismos marinos. Una menci\u00f3n especial se merece \nMarimar, qui\u00e9n se preocup\u00f3 y me ense\u00f1\u00f3 todo lo que s\u00e9 a nivel cient\u00edfico de la gen\u00e9tica \nde \u201cpeixes e bivalvos\u201d con una paciencia infinita a la par que un cari\u00f1o muy t\u00edpico del \n\u201cMorrazo\u201d. \nA la compa\u00f1\u00eda insaciable de Villac hunguita: Mago (villachunguito\u2026 con lo que \neso implica! jeje), Laura Barrera, Jaime, Cris , Nanes, Flo, Sabela y Rubi, por las cenas \nque se van de las manos, las fiestas tem\u00e1ti cas, las churrascadas y pi cnics contra viento \ny marea, y por compartir su alegr\u00eda.  \nA los \u201cbomberitos\u201d Mario Richards  \u201crock star\u201d, porque aunque no lo crea, s\u00e9 \nque est\u00e1 ah\u00ed (pero paga tus deudas con \u201cGlobetrotter\u201d !) y a David \u201ccu\u00f1aaaaaoooo\u201d, \nporque sin quererlo, pas\u00f3 de se r \u201cel de Laura\u201d, a ser un amigo. \nA Amelia \u201cgunilla\u201d por los \u201csaraos\u201d, el \u201cvon biiiiisssssss mmmaaarrrkkk!\u201d, las \ncharlas, el cari\u00f1o y los \u201cbuboletos\u201d hechos con tanto amor!. Ya sabes que eres de la Jet \nSet! \nA los vecinos, y casi familia, Fuji, Nanda,  Pili y Sergio, que me han visto crecer. \nA los \u201cni\u00f1os\u201d de Hispanidad, \u00c1lvaro \u201cchiquipulpi\u201d, Zapa, Carmen, Mar\u00eda Porto, \nSonia y Marina, porque me acogieron co mo una m\u00e1s en una etapa de transici\u00f3n.  \nAl verdadero Team T , el gran descubrimiento de la \u00faltima temporada, que \napareci\u00f3 en un momento cr\u00edtico y me inyect\u00f3 una dosis peligrosa de \u201cganas de comerme el mundo\u201d. A Evelyn, por su apoyo constante, por su capacidad de an\u00e1lisis y \npor esa inocencia y coraz\u00f3n infinito que mezc lada con su af\u00e1n de superaci\u00f3n la hacen \n\u00fanica. A Fer, por ser \u201cuna mente maravillosa\u201d y transmitir la calma y sosiego a cualquier \npersona que est\u00e9 a menos de dos metros de \u00e9l. Y a Diego, por el cari\u00f1o, el apoyo y la \npreocupaci\u00f3n incesantes, por las \u201cbombas\u201d que siempre sacan una sonrisa, y por las \nconfidencias compartidas (\u201c nos vemos en las trincheras de Vietnam\u2026que quiero saber \na qu\u00e9 huele el Napalm \u2026\u201d).   \nTo my Ohana  \u201calways Alo)(a spirit\u201d: Philip, Pe ter, Anais, Sandra, F\u00e9lix, Lucho, \nDaniela, Pavi\u00e7a, Patrick, Florian, Silvia \u201citalian\u201d, Silvia \u201cswiss\u201d, Johannes, Marcelo, \nCharito and Bruno \u201cAbuelo\u201d. Special t hanks to Johannes, for taking care of the \nfriendship even from the distance and who always tries harder to set a reunion. To \nPhilip, because he was a key support every time  I was in Hawai\u2019i. To \u201cAbueeeelooooo\u201d, \nbecause of all the shooting stars we dreamt of . To Anais, for being my \u201ctraining leader\u201d \nduring my PhD stay in Hawai\u2019i, but overa ll, for her friendship. To Patrick, because he \nappeared at the right time and at the righ t moment and he showed me the magnificent \nworld of the \u201calternative music\u201d.   \nvi To all my Aussie friends, Kari na, Fe, Justin, Gabriel, Ma rie, Nicola, Giorgia, the \ntwins Edu and Marcelo, Mori, Edu \u201cdudu\u201d and Zack for sharing one of the most amazing \nand adventurous experiences of my life during my time in Australia. Day by day, in Byron \nBay\u2026 you know\u2026 \u201ca couple of good ones and no worries mate!\u201d  \nTo my \u201cItalo-Geordie\u201d friends Francesco and Elisa for being my main support in \nNewcastle. Special thanks to  Francesco, who was already a known member among my \nfamily, and serendipity, put us together.  \nY desde los or\u00edgenes, no puedo olvidarme del Mart\u00edn C\u00f3dax, ese lugar que \npretend\u00eda ser s\u00f3lo un colegio pero que siempre fue especial para todos los que pas\u00e1bamos por sus aulas. Porque siempre ha sido un lugar diferente, o como muchos \nde mis amigos denominan, \u201cel co legio rojo y raro ese al que fuiste\u201d. Gracias a Eloy, gran \nculpable de que hoy en d\u00eda sea cient\u00edfica y de que cada vez que alzo la vista hacia el \ncielo, no s\u00f3lo vea estrellas, sino tambi\u00e9n galaxias, y divag ue sobre el significado de la \nteor\u00eda de cuerdas. A Fernando,  qui\u00e9n ha sido capaz de transmitirme su pasi\u00f3n por la \nHistoria y el Arte (\u00bfa qui\u00e9n no se le ha pasado ser historiador tras un curso con \u00e9l?). A \nF\u00e9lix (en memoria), que me inculc\u00f3 otra de mis grandes pasiones, la m\u00fasica. A \nYdalinda, Pepa, Jaime y Tet\u00e9.  \nY, como dir\u00edan los anglosajones, \u201clast but not least\u201d, a los perri\u00f1os: Rocky, \nPinta, Naish, Atreyu, Gandalf, Maui y Nemo, porque con su simple presencia, me \nalegran el d\u00eda y est\u00e1n a mi la do, siendo la mejor compa\u00f1\u00eda. \n \n \n \n  \nvii \u000f\u0002\u0003\u0004\t\u0003\u0007\u0001\u0006\b\u0005\r\u000e\u0001\n\u0001\n\u2022 \u0006(\u0001 !/0;)\u001d#+@\u0001 /%*\u0001 /1\u0001 \u001f\u001d,\u001d\u0001  !\u0001 )1\u001f+/% \u001d @\u0001 -1!\u0001 \u001f+*0%!*!\u0001 \u001e%\u001f\u001d.\u001e+*\u001d0+ \u0001! * \u0001/ 1 \u0001\n/1,!.\"%\u001f%!\u0001,\u001d.\u001d\u0001*!10.\u001d(%5\u001d.\u0001!(\u00016\u001f% +\u0001\u001f(+.$8 .%\u001f+\u0001!/0+)\u001d\u001f\u001d(@\u0001/!\u0001  %#!.%.8\u001d\u0001\u001d\u0001/8\u0001)%/)+@\u0001\n4\u001d\u0001-1!\u0001!(\u0001,\t\u0001 !(\u0001!/0;)\u001d#+\u0001!/\u0001 !\u0001LBPB\u0001\n\u2022 \f\u001d\u0001\u001f%.1!(\u001d\u0001'\u001d'\u001d 1\u0001\u001d1/0.\u001d(%\u001d*\u001d\u0001\u001f+* 0%!*!\u0001LKK\u00012!\u001f!/\u0001)6/\u00012%0\u001d)%*\u001d\u0001\u0004 \u0001-1!\u00011*\u001d\u0001*\u001d.\u001d*&\u001dB\u0001\n\u2022 \u0004\u001d \u001d\u00012\u001d\u001f\u001d\u0001 +)7/0%\u001f\u001d\u0001!)%0!\u0001\u001d,.+3%)\u001d \u001d)!*0!\u0001LPK\u0001\u000b#/\u0001 !\u0001)!0\u001d*+\u0001\u001d(\u0001 \u001d:+B\u0001\n\u2022 \f\u001d\u0001 \f1\u001f%\"!.%*\u001d\u0001 !/\u0001 (\u001d\u0001 )+(7\u001f1(\u001d\u0001 -1%)%+(1)%*%/\u001f!*0!\u0001 .!/,+*/\u001d\u001e(!\u0001  !\u0001 -1!\u0001 (\u001d/\u0001\n(1\u001f%7.*\u001d#\u001d/\u0001!)%0\u001d*\u0001(15B\u0001\n\u2022 \f\u001d\u0001\u001f\u001d,/\u001d%\u001f%*\u001d\u0001!/\u0001!(\u0001\u001f+),1!/0+\u0001.!/,+*/\u001d\u001e(!\u0001 !\u0001-1!\u0001(+/\u0001,%)%!*0+/\u0001  !\u0001\u0010\u001d .;*\u0001\n,%-1!*B\u0001\n\u2022 \f\u001d\u0001/!.+0+*%*\u001d@\u0001(\u001d\u0001 +,\u001d)%*\u001d\u00014\u0001(\u001d\u0001*+.!,%*!\".%*\u001d\u0001/+*\u0001(\u001d/\u0001)+(7\u001f1(\u001d/ \u0001.!/,+*/\u001d\u001e(!/\u0001 !\u0001\n(\u001d\u0001F-18)%\u001f\u001d\u0001 !(\u0001\u001d)+.G@\u00014\u00011*\u0001 !/\u001d&1/0!\u0001!*\u0001/1/\u0001*%2!(!/\u0001,.+2+\u001f\u001d\u0001!( \u0001((\u001d)\u001d +\u0001F\u001f+(+\u001f;*\u0001\n !(\u0001\u001d)\u001d*0!GB\u0001\n\u2022 \f\u001d\u0001 +/%/\u0001(!0\u001d(\u0001)! %\u001d\u0001 !\u0001(\u001d\u0001\u001f\u001d\"!8*\u001d\u0001!*\u0001$1)\u001d*+/\u0001!/\u0001 !\u00011*+/\u0001MKK\u0001)# \u0001,+.\u0001\u000b#\u0001 !\u0001)\u001d/\u001d\u0001\n\u001f+.,+.\u001d(@\u0001+\u0001(+\u0001-1!\u0001!-1%2\u001d( .8\u001d\u0001\u001d\u00011*\u001d/\u0001NK\u00010\u001d5\u001d/\u0001 !\u0001\u001f\u001d\"7B\u0001\n\u2022 \u0015*\u001d\u0001)+(7\u001f1(\u001d\u0001 !\u0001\u001f(+.+\u0001(\u001d*5\u001d \u001d\u0001\u001d\u0001(\u001d\u0001\u001d0);/\"!.\u001d\u0001 !/0.14!\u00011*\u001d/\u0001 %!5 \u0001)%(\u0001)+(7\u001f1(\u001d/\u0001\n !\u0001+5+*+B\u0001\n\u2022 \f\u001d\u0001\"\u001d.)\u001d\u001f710%\u001f\u001d\u0001\u0003\u001d4!.\u0001\u001f+)!.\u001f%\u001d(%5 ;\u0001(!#\u001d()!*0!\u0001(\u001d\u0001$!.+8*\u001d\u0001 1.\u001d*0 !\u0001LP\u0001\u001d:+/@\u00014\u001d\u0001-1!\u0001\n%*%\u001f%\u001d()!*0!\u0001/!\u0001!),(!\u001d\u001e\u001d\u0001\u001f+)+\u0001\u001d*0%01/%2+\u00014\u0001\u001f+)+\u00011*\u0001/1/0%010+\u0001*+ \u0001\u001d %\u001f0%2+\u0001 !\u0001(\u001d\u0001\n)+.\"%*\u001dB\u0001\u0001\n\u2022 \u0015*\u0001(%0.+\u0001 !\u0001\u001d#1\u001d\u0001 !\u0001)\u001d.\u0001\u001f+*0%!*!\u0001)6/\u0001 !\u0001NP\u0001#.\u001d)+/\u0001 !\u0001/\u001d(!/@\u0001\"1*  \u001d)!*0\u001d()!*0!\u0001\n!*\u0001\"+.)\u001d\u0001 !\u0001\u001f(+.1.+/\u00014\u0001/1(\"\u001d0+/B\u0001\u0010+.\u0001!/+\u0001(\u001d\u0001/\u001d(%*% \u001d \u0001 !\u0001(+/\u0001+\u001f 7\u001d*+/\u0001!/\u0001 !\u00011*+/\u0001NP\u0001\n#.\u001d)+/\u0001,+.\u0001(%0.+B\u0001\u0013%*\u0001!)\u001e\u001d.#+@\u0001!*\u0001!(\u0001)\u001d.\u0001)1!.0+\u0001!/\u0001 !\u0001NQK\u0001#.\u001d)+ /\u0001,+.\u0001(%0.+@\u0001(+\u0001\n-1!\u0001%),% !\u0001-1!\u0001$\u001d4\u001d\u00012% \u001d@\u0001\u001d\u0001!3\u001f! ,\u001f%;*\u0001 !\u0001\u001d(#1*\u001d/\u0001\u001e\u001d\u001f0!.%\u001d/\u0001!30.!);\"%(\u001d/B\u0001\u0001\n\u2022 \f\u001d\u0001)\u001d4+.\u0001)%*\u001d\u0001 !\u0001+.+\u0001/!\u0001!*\u001f1!*0.\u001d\u0001!*\u0001!(\u0001)\u001d.@\u0001,!.+\u00010+ \u001d28\u001d\u0001*+\u0001!3 %/0!\u00011*\u0001/%/0!)\u001d\u0001\n.!*0\u001d\u001e(!\u0001,\u001d.\u001d\u0001/!,\u001d.\u001d.\u0001(\u001d/\u0001 +.\u001d \u001d/\u0001,\u001d.08\u001f1(\u001d/\u0001!*\u0001/1/,!*/%;*B\u0001\n\u2022 \u00063%/0!*\u00010.!/\u0001(\u001d#+/\u0001!*\u0001!(\u00012+(\u001f6*\u0001\u000b!(%)101@\u0001!*\u0001\n* +*!/%\u001d@\u0001-1!\u0001*+\u0001/;(+\u00010%!*!*\u0001\u001f+(+.!/\u0001\n %\"!.!*0!/\u0001H01.-1!/\u001d@\u0001\u001f\u001d\"7\u00014\u0001\u001d51(\u0001+/\u001f1.+\u0001\u001f\u001d/%\u0001*!#.+I\u0001/%*+\u0001-1!\u0001/ %#1!*\u0001\u001f\u001d)\u001e%\u001d* +\u0001\n !\u0001\u001f+(+.\u0001\u001d\u0001(+\u0001(\u001d.#+\u0001 !(\u00010%!),+\u0001 !\u001e% +\u0001\u001d\u0001(\u001d\u0001+3% \u001d\u001f%;*\u0001 !\u0001(+/\u0001!(! )!*0+/\u0001,.!/!*0!/\u0001\n!*\u0001!((+/\u0001H\u001e\u001d.%+@\u0001\u001f+\u001e.!@\u0001\u001d51\".!\u00014\u0001\u001d./7*%\u001f+I\u0001,.+ 1\u001f% \u001d\u0001,+.\u0001(\u001d\u0001\u001d\u001f0 %2% \u001d \u00012+(\u001f6*%\u001f\u001dB\u0001\n\u2022 \u0015*+/\u0001LK\u0001/!#1* +/\u0001 !/,17/\u0001 !(\u0001\u0003%#\u0001\u0003\u001d*#@\u0001(\u001d\u00010!),!.\u001d01.\u001d\u0001 !(\u00011*%2! ./+\u0001!.\u001d\u0001 !\u00011*+/\u0001\n)%(\u0001)%((+*!/\u0001 !\u0001#.\u001d +/\u0001'!(2%*B\u0001\u0002\u0001 8\u001d\u0001 !\u0001$+4@\u0001(\u001d\u0001/1,!.\"%\u001f%!\u0001 !(\u0001 ,(\u001d*!0\u001d\u0001)6/\u0001\u001f\u001d(%!*0!\u0001\n !(\u0001/%/0!)\u001d\u0001/+(\u001d.\u0001!/\u0001(\u001d\u0001  !\u0001\u0016!*1/@\u0001\u001d\u00011*+/\u0001OQKJ\u0004\u0001 \n \u0001\n\u0001 \n \u0001\n\u0001\n\u0001\n\u0001\u0001\n\u0001\n\u0001\n\u0001\n\u0001\nA mis padres. \n \nEn memoria de mis abuelos. \n \n \n \n   \n  \n  \n  \n \n \n  \n \n  \n \n  \n \n  \n \n  \n \n  \n \n  \n \n  \nYY mientras las olas se estrellaban en las rocas, el mar que me miraba me \ndec\u00eda: \u201cCuando siento dudas respecto a mi poder para destruir las rocas, \nme volteo a ver las grandes playas de arena\u2026\u201d \n \n Jackseli ns Arteaga   \n   \n \n\u0011\u001d\u001f\u0018\u0011\u0019 \u0001\n \n \nEn la presente Memoria se describe una selecci\u00f3n del trabajo realizado de \ndise\u00f1o, s\u00edntesis y estudio preliminar de compuestos oxac\u00edclicos con inter\u00e9s \nfarmacol\u00f3gico inspirados en productos natura les. De la amplia quimioteca preparada, \nse presenta m\u00e1s en detalle los resultados de aquellos compuestos que hasta el \nmomento han sido publicados o est\u00e1n en fase de publicaci\u00f3n. La mayor\u00eda de los \ncompuestos presentados son h\u00edbridos co n n\u00facleo cumar\u00ednico sobre el cual se \nincorpora el esqueleto de estilbeno o de chalcona en 3 y 8 de la cumarina, o bien con \nmodificaciones en los anillos arom\u00e1ticos de los mismos. Se presentan tambi\u00e9n \nmetodolog\u00edas sint\u00e9ticas para la preparaci \u00f3n de derivados de la rocaglamida. Respecto \nde los h\u00edbridos cumarina-chalcona, se presentan 4 series principales de compuestos \nsintetizados, en las que se han realizado modificaciones sencillas como la introducci\u00f3n \nde sustituyentes de distinta naturaleza, en distinto n\u00famero y en diferentes posiciones de \nmodo que nos fuese posible obtener una relaci \u00f3n estructura-actividad para cada serie y \npara cada diana estudiada. Las metodolog\u00ed as y rutas sint\u00e9ticas empleadas han sido \nseleccionadas de manera que nos permities en acceder a las estructuras dise\u00f1adas de \nla forma m\u00e1s sencilla, eficiente, directa y vers \u00e1til posible en la cantidad y con la pureza \nnecesaria para la realizaci\u00f3n de los estudi os estructurales y biol\u00f3gicos. Hasta el \npresente, fueron realizados estudios preliminares de series seleccionadas de los \ncompuestos sintetizados como inhibidores enzim\u00e1ticos (MAO-A y MAO-B), ligandos de \nreceptores de adenosina, ant ioxidantes, antiparasitarios y antibacterianos.  \n   \n  \n  \n \u000b\u001f\u0018\u0018\r\u001c#\u0001\n \nIn the present dissertation a selection of works on the design, synthesis and \npreliminary studies of oxacyclic compounds wi th pharmacological interest inspired in \nnatural products is described. From the ext ended prepared compound library, more in \ndetail results are presented for those compound s that have been published so far or are \nin publication process. Most of  the compounds presented ar e hybrid compounds with a \ncoumarinic nucleus, in which the stilbene or  chalcone scaffolds are incorporated in \npositions 3 or 8 of the coumarin. Synthet ic methodologies for the preparation of \nrocaglamide derivatives are al so presented. Four main seri es of synthesized coumarin-\nchalcone compounds are shown, each of them  having undergone simple modifications \nsuch as the introduction of substituents of different nature, in different number and \npositions. Those modifications made possible to establish structure-activity relationships \nfor each series and for each studied target. The methodologies and the synthetic routes \nemployed have been selected in order to access to the designed structures in the most \nsimple, efficient, versatile and direct way, in  the amount and with the purity required to \ncarry out the biological stud ies. To date, preliminary st udies on selected series of the \nsynthesized compounds were carried out as enzymatic inhibitors (MAO-A and MAO-B), adenosine receptors ligands, as antioxidants, as antiparasitic and as antibacterial \nagents.  \n  \n  \n Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez \n \n \f\u0019\u0010\u0014\u000f\u0011\u0001\n\b\u0014\u001d\u001e\u0001\u001a\u0012\u0001\u000f\u001a\u0019\u001e\u0011\u0019\u001e\u001d\u0001\n \n \nRelaci\u00f3n de abreviaturas 11 \nIntroducci\u00f3n 3 3 \nAntecedentes y Objetivos 449 \nResultados y discusi\u00f3n 557 \nParte Experimental 993 \nConclusiones 2 289 \nBibliograf\u00eda 2 293 \n \n  \n  \n \n\u0001Relaci\u00f3n de Abreviaturas \n \n 1 \u0002\u0004\u001c\u0006\u0001 \u0002\u001f!0%(\u001f+(%*!/0!.\u001d/\u001d\u0001\n\u0002\f\u000f\u0002\u0001 \u0012!\u001f!,0+.!/\u0001  !\u0001 6\u001f% +\u0001 \u03b1C\u001d)%*+CNC$% .+3%CPC)!0%(C\n%/+3\u001d5+(,.+,%;*%\u001f+\u0001\n\u0002\u0011\u0001 \u0012!\u001f!,0+.\u0001 !\u0001\u001d !*+/%*\u001d\u0001\n\u0003\u0002\u0006\u0004\u0001 \u00047(1(\u001d/\u0001!* +0!(%\u001d(!/\u0001 !\u0001\u001d+.0\u001d\u0001\u001e+2%*\u001d\u0001\n\u0003\u0002\u0004\u0006-/\u0001 \u0003!0\u001d\u0001/!\u001f.!0\u001d/\u001d\u0001L\u0001\n\u0004\t\u000e\u0001 \u00047(1(\u001d/\u0001 !\u0001+2\u001d.%+\u0001 !\u0001$6)/0!.\u0001\u001f$%*+\u0001\n\u0004\u000b\u0001 \u0004+),1!/0+\u0001(8 !.\u0001\n\u0004\u001f\u0002\u0001 \u0004+!*5%)\u001d\u0001\u0002\u0001\n\u0005\r\u0002\u0001 \u001a\u001f% +\u0001 !/+3%..%\u001e+*1\u001f(!%\u001f+\u0001\n\u0006\u0002\u0001 \u0006*\"!.)! \u001d \u0001 !\u0001\u0002(5$!%)!.\u0001\u0001\n\u0007\u0005\u0004\u0001 \u0004+)\u001e%*\u001d\u001f%;*\u0001\u001d\u0001 +/%/\u0001\"%&\u001d\u0001\n\b\u0002\u0003\u0002\u0001 \u001a\u001f% +\u0001\u03b3C\u001d)%*+\u001e108.%\u001f+\u0001\n\b\u000f\u0004\u0011\u0001 \u0012!\u001f!,0+.\u0001\u001d\u001f+,(\u001d +\u0001\u001d\u0001,.+0!8*\u001d\u0001\b\u0001\n\t\n\u0015\u0001 \u0016%.1/\u0001 !\u0001(\u001d\u0001%*)1*+ !\"%\u001f%!*\u001f%\u001d\u0001$1)\u001d*\u001d\u0001\n\t\u000f\u000b\u0004\u0001 \t%#$\u0001\u0010!.\"+.)\u001d*\u001f!\u0001\f%-1% \u0001\u0004$.+)\u001d0+#.\u001d,$4\u0001\n\n\u00040.\u0001 \u0004+*\u001f!*0.\u001d\u001f%;*\u0001  !\u0001 \u001f+),1!/0+@\u0001 -1!\u0001 %* 1\u001f!\u0001 1*\u001d\u0001\n.! 1\u001f\u001f%;*\u0001 !(\u0001\u001f.!\u001f%)%!*0+\u0001\u001f!(1(\u001d.\u0001 !(\u0001PKS\u0001\n\f\u0002\u000e\u0001 \r+*+\u001d)%*++3% \u001d/\u001d\u0001\n\f\u0012\u0001 \u0006/,!\u001f0.+/\u001f+,8\u001d\u0001 !\u0001)\u001d/\u001d/\u0001\n\f\u0013\u0005\u000b\u0001 \f%#\u001d* +/\u0001 %.%#% +/\u0001\u001d\u0001)1(0%C %\u001d*\u001d/\u0001\n\r\f\u0011\u0001 \u0012!/+*\u001d*\u001f%\u001d\u0001\r\u001d#*70%\u001f\u001d\u0001\u000e1\u001f(!\u001d.\u0001\n\u000e\u0011\u0002\u0004\u0001 \u0004\u001d,\u001d\u001f% \u001d \u0001 !\u0001\u001d\u001e/+.\u001f%;*\u0001 !\u0001.\u001d %\u001f\u001d(!/\u0001+38#!*+\u0001\n\u000f\u0002\u000b\u0001 \u0007!*%(\u001d(\u001d*%*\u001d\u0001\u001d)+*%+(%\u001d/\u001d\u0001\n\u0010\u0012\u0002\u0011\u0001 \u0012!(\u001d\u001f%;*\u0001!/0.1\u001f01.\u001dC\u001d\u001f0%2% \u001d \u0001\u001f1\u001d*0%0\u001d0%2\u001d\u0001\n\u0011\u000e\u0012\u0001 \u0006/,!\u001f%!/\u0001.\u001d %\u001f\u001d(\u001d.%\u001d/\u0001 !\u0001+38#!*+\u0001\n\u0012\u0002\u0011\u0001 \u0012!(\u001d\u001f%;*\u0001!/0.1\u001f01.\u001dC\u001d\u001f0%2% \u001d \u0001\n\",\u0018,\u0001 \u0014!),!.\u001d01.\u001d\u0001\u001d)\u001e%!*0!\u0001\n\u0014\u0015\u0001\u0001 1(0.\u001d2%+(!0\u001d\u0001\n\u0001\u0001\n1 \n\u0001\n\u0001Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez \n \n 3\u0007\u0019\u001e\u001c\u001a\u0010\u001f\u000f\u000f\u0014'\u0019\u0001\n\u0007\u0019\u001e\u001c\u001a\u0010\u001f\u000f\u001e\u0014\u001a\u0019\u0001\n \n1. Productos naturales y desarrollo de f\u00e1rmacos  55 \n2. Las Cumarinas  99 \n       2.1. Origen de las cumarinas  99 \n       2.2. Bios\u00edntesis de cumarinas  111 \n       2.3. S\u00edntesis de cumarinas  113 \n       2.4. Actividad biol\u00f3gica de las cumarinas  220 \n3. Las Chalconas  225 \n       3.1. Origen de las chalconas  225 \n       3.2. Bios\u00edntesis de chalconas  226 \n       3.3. S\u00edntesis de cumarinas  228 \n       3.4. Activi dad biol\u00f3gica de las chalconas  330 \n4. Los Estilbenos  336 \n5. La Rocaglamida  338 \n6. Farmacomodulaci\u00f3n  442 \n       6.1. Hibridaci\u00f3n molecular y terapia multi-diana 442 \n       6.2. Bioisosterismos 444 \n       6.3. Vinilog\u00eda 446 \n \n \n3 \n \n \n\u0001Introducci\u00f3n                                          1. Productos naturales y desarrollo de f\u00e1rmacos  \n \n5 \u0001\n1. Productos naturales y desarrollo de f\u00e1rmacos \n \nDesde los primeros tiempos, el ser humano ha acudido a la naturaleza para \nobtener sustancias que, o bien le ayudasen a paliar el dolor o los s\u00edntomas de sus \nenfermedades, o bien le facilitasen la obtenci \u00f3n de alimentos (veneno para la caza) y \nsus relaciones sociales y religiosas (estimulantes y alucin\u00f3genos). Esta circunstancia ha \npermitido disponer de una amplia informaci \u00f3n, que sometida a la observaci\u00f3n y al \nestudio cr\u00edtico, ha dado lugar al pl anteamiento de ideas que, debidamente \ndesarrolladas, han llevado a la obtenci\u00f3n de nuev os medicamentos. Esta historia previa \nes la causa de que en la actualidad el mode lo de aproximadamente la mitad de los \nproductos farmac\u00e9uticos de que se dispone sean de origen natural. Estos modelos, \nobtenidos a partir de un organismo vivo, han sufrido diferentes modificaciones en el \nlaboratorio, encaminadas a la obtenci\u00f3n de mol\u00e9culas m\u00e1s potentes y menos t\u00f3xicas \nque las originales, las cuales en realidad no hab\u00edan sido dise\u00f1adas  para un tratamiento \nespec\u00edfico. \nHace alrededor de unos 200 a\u00f1os, un joven farmac\u00e9utico de 21 a\u00f1os llamado \nFriedrich Sert\u00fcrner, aisl\u00f3 uno de los prim eros compuestos puros farmacol\u00f3gicamente \nactivos procedente de una planta: la morfina, un alcaloide  presente en el opio obtenido \nde las c\u00e1psulas de la adormidera Papaver somniferum .1 Fue en este momento en el que \nempez\u00f3 a dejarse atr\u00e1s la \u00e9poca de las \u201c pociones\u201d y se inici\u00f3 una era en la que los \ncompuestos activos de las plantas pod\u00edan ser purificados, estudiados y administrados \nen dosis precisas que no variaban seg\u00fan la fuente o la edad del material.2  La \ninvestigaci\u00f3n farmac\u00e9utica se expandi\u00f3 despu\u00e9s de las segunda Guerra Mundial para incluir la detecci\u00f3n masiva de  microorganismos para nuevo s antibi\u00f3ticos debido al \ndescubrimiento de la penicilina. En 1990, alrededor del 80% de los f\u00e1rmacos eran productos naturales o an\u00e1logos insp irados en ellos. Antibi\u00f3ticos (p. ej.: la penicilina, la \ntetraciclina, la eritromicina), antiparasitarios (p. ej. la avermectina), antimal\u00e1ricos (p. ej.: la \nquinina, la artemisinina), agentes de contro l de l\u00edpidos (p. ej.: lovastatina y an\u00e1logos), \ninmunosupresores para trasplantes de \u00f3rganos (p. ej.: ciclosporina, rapamicinas ) y medicamentos contra el c\u00e1ncer (p. ej.: taxol, doxorrubicina) revolucionaron la medicina. \nLa esperanza de vida en buena parte del mundo ha aumentado desde entonces de \nunos 40 a\u00f1os a principios del siglo XX a m\u00e1s de 77 a\u00f1os en la actualidad. \n5Introducci\u00f3n                                          1. Productos naturales y desarrollo de f\u00e1rmacos  \n \n6 La elucidaci\u00f3n estructural, que eclosion\u00f3 a principios del siglo XX con el \ndesarrollo de nuevas t\u00e9cnicas y conocimientos , permiti\u00f3 el desarrollo de t\u00e9cnicas de \ns\u00edntesis como estrategia para el descub rimiento de nuevos f\u00e1rmacos. Empezaron a \njugar un papel importante los mecanismos de acci\u00f3n de los f\u00e1rmacos, as\u00ed como la \nmodificaci\u00f3n estructural partiendo de un co mpuesto altamente activo, o compuesto \nl\u00edder, de modo que ambos aspectos pasaron a ser objeto de estudio.3 El crecimiento ha \nsido exponencial y \u00e1reas como la Biolog\u00eda, la Fisiolog\u00eda, la Biolog\u00eda Molecular, la \nGen\u00e9tica y la Qu\u00edmica pasaron a coordinar se con un objetivo claro: aumentar la \nactividad de los f\u00e1rmacos, di sminuyendo su toxicidad y efectos adversos. El desarrollo \nde t\u00e9cnicas te\u00f3ricas como el QSAR, el docking  o la qu\u00edmica combinatoria, entre otras, \nhan a\u00f1adido herramientas adicionales que permiten el dise\u00f1o racional de f\u00e1rmacos y la producci\u00f3n a gran escala.\n4  \nAunque la expansi\u00f3n de la qu\u00edmica sint\u00e9tica medicinal en la d\u00e9cada de 1990 \nhizo que el porcentaje de nuevos medicam entos basados en productos naturales \ndisminuyese hasta ~ 50% (Figura 1),5 entre los a\u00f1os 2005-2010 han sido aprobados 19 \nf\u00e1rmacos basados en compuestos natural es, 10 de los cuales son considerados \nproductos naturales  semisint\u00e9ticos.6  \n \n   \n \n    \nFFigura 1 .  N\u00famero de f\u00e1rmacos aprobados en los EEUU entre 1981-2007  \n \n6Introducci\u00f3n                                          1. Productos naturales y desarrollo de f\u00e1rmacos  \n \n7 Tal es el caso de algunos f\u00e1rmacos aprobados en los Estados Unidos en ese \nper\u00edodo (Figura 2)7, entre ellos estructuras polip ept\u00eddicas como la exenatida \n(hipoglicemiante oral) aprobado por la FDA en 2005. En el mismo a\u00f1o se aprueba el \nprimer f\u00e1rmaco de origen ma rino, el analg\u00e9sico ziconotida de estructura pept\u00eddica \ncomercializado como Prialt\u00ae y dos a\u00f1os m\u00e1s tarde se introduce en el mercado el primer antineopl\u00e1sico tambi\u00e9n de origen marino, descubierto en el tunicado colonial\n \nEcteinascidia turbinata , la trabectedina (Yondelis\u00ae) designado en 2007 f\u00e1rmaco para el \ntratamiento de sarcomas blandos y c\u00e1ncer de ovario, y desarrollado en nuestro pa\u00eds por \nla compa\u00f1\u00eda espa\u00f1ola PharmaMar del grupo Zeltia.8  \nY m\u00e1s relacionados con nuestro trabajo, queremos hacer referencia al origen \nnatural no solo de los prototipos de es tructura flavonoide como podr\u00edan considerarse \nlas cumarinas y chalconas que ser\u00e1n ext ensamente consideradas en las p\u00e1ginas \nsiguientes, sino a estructuras oxigenadas m\u00e1s complejas. Tal es el caso de las \nflavaglinas, la familia de productos na turales aislados especies del g\u00e9nero Alglaia  a la \nque pertenece rocaglamida con potencial actividad antic\u00e1ncer, neuroprotectora,9 y \nantimal\u00e1rica adem\u00e1s del inte r\u00e9s agroqu\u00edmico como pesticidas de algunos de sus \nderivados.10  \n \n  \n \n     \n \nFigura 2 .F\u00e1rmacos aprobados durante el per\u00edodo 2005-2010.  \n7Introducci\u00f3n                                          1. Productos naturales y desarrollo de f\u00e1rmacos  \n \n8  \nQueda patente por tanto, que la naturaleza ha sido la fuente principal de gran \nn\u00famero de f\u00e1rmacos utilizados como tale s en terap\u00e9utica o bien proporcionando \ncabezas de serie o compuestos l\u00edder a partir de los cuales y me diante modificaciones \nestructurales se han introducido m\u00faltiples compuestos en el arsenal terap\u00e9utico. La \nabundante diversidad de esqueletos de prod uctos naturales se acopla con el \u201cdise\u00f1o \n\u00fatil\u201d generalmente para proporcionar una mejora del perfil farmacol\u00f3gico del producto \nnatural.  \n \n8Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 9  \n2. Las cumarinas \n2.1. Origen de las cumarinas \nLas cumarinas constituyen un grupo de  compuestos naturales ampliamente \nencontrados en plantas y otro s microorganismos. Las cumarinas pertenecen a la familia \nde las lactonas, por poseer  un sistema 1-benzopiran-2-ona, que corresponde a la \nbenzo-\u03b1-pirona (2H-1-benzopiran-2-ona) y cuya nomenclatura sistem\u00e1tica fue \nestablecida por la IUPAC.11 El nombre de esta familia qu\u00edmica deriva del Coumarouna \nodorata Aube  (Dypterix odorata ),12 planta de la cual fue ai slada por primera vez el \nmiembro m\u00e1s simple de esta clase, la propia cumarina.13 Plantas como la Asp\u00e9rula, la \nhierba dulce y el tr\u00e9bol dulce, en particular, se conocen por su olor dulce, que a su vez \nse debe a su alto contenido de esta sustancia. Es por este motivo por el que este \nmetabolito secundario producido ampliamente en una gran variedad de plantas y \naceites esenciales ha sido utilizado como fragancia de productos alimenticios y \ncosm\u00e9ticos (Figua 3). \n \n      \n \n \nFFigura 3. Estructura de la cumarina y fuentes naturales en las que se encuentra.  \n \nHabas de Tonka, Dypterix odorata\r\nGramas de olor, Anthoxanthum odoratum\r Canela, procedente de Cinnamomum verum\rCassia odorata\r\nO O\ncumarina34 5\n6\n7\n8\n9Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n10 Adem\u00e1s del aislamiento de  cumarinas procedentes de cientos de especies de \nplantas y otros microorganismos, cabe destacar los derivados de origen sint\u00e9tico, que \naumentan significativam ente el n\u00famero de estructuras de cumarina conocidos hasta \nhoy,14 as\u00ed como la complejidad de las mismas.15 La diversidad estructural de los \ncompuestos derivados de las cumarinas permite su clasificaci\u00f3n en cumarinas simples, \nfurocumarinas, piranocumarinas, biscumarin as, cumarinolignanos, triscumarinas, etc. \n(Figura 4). \n \nFigura 4. Cumarina, como n\u00facleo central para la  obtenci\u00f3n de derivados de inter\u00e9s \nfarmacol\u00f3gico  \nAdem\u00e1s, las cumarinas simples m\u00e1s importantes, pueden ser divididas a su vez \nen funci\u00f3n de sus sustituyentes m\u00e1s caracter\u00edsticos (Figura 5). 16  Seg\u00fan el tipo de \nsustituyentes que posean dichas cumarinas, la finalidad para la que pueden ser \nutilizadas var\u00eda: aditivos alimentarios, perfumes, cosm\u00e9ticos, productos agroqu\u00edmicos o \nf\u00e1rmacos, entre otros.17 O O OOO O OOOO\nOOc f\ng\nh\nn\nO\nAngelicinas Psoralenosn = 0 n = 1\nO\nO\nPiranocumarinas(c-h)\nOW\nOH\nN\nO\nFurocumarinasOOH\nORO\nROR\nOAzucar\n4-Hidroxicumarinas 3-amidocumarinas\n10Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 11 \n \n \n     \n \n \nFigura 5.  Cumarina, como n\u00facleo central para la obtenci\u00f3n de cumarinas simples  \n Teniendo en cuenta el avance tecnol \u00f3gico que ha permitido facilitar la \ndeterminaci\u00f3n de estructuras qu\u00edmicas, uno se ve obligado a preguntarse cu\u00e1l es el \nfactor que despierta inter\u00e9s en los compuesto s de esta familia. Entre varios que podr\u00edan \nser enumerados, se har\u00e1 hincapi\u00e9 en uno, que sin duda es de gran importancia: la \ndiversidad de actividades biol\u00f3gicas q ue estos compuestos exhiben. Pr \u00e1cticamente \ndesde el inicio del estudio de las cumarinas, la atenci\u00f3n de su investigaci\u00f3n se centr\u00f3 en la posibilidad de su actividad terap\u00e9utica.\n18 \n2.2 Bios\u00edntesis de cumarinas \nLa bios\u00edntesis de las cumarinas empieza con la L-fenilalanina como precursor \nen plantas como la Melilotus alba , (Figura 6), conocida col oquialmente como tr\u00e9bol de \nolor. La L-fenilalanina es convertida en \u00e1cido trans -cin\u00e1mico mediante la acci\u00f3n de la \nfenilalanina amonioliasa (PAL, de sus siglas en ingl\u00e9s), y posteriormente convertida a \n\u00e1cido orto-cum\u00e1rico mediante la acci \u00f3n de la \u00e1cido cin\u00e1mico orto- hidroxilasa. La orto \nhidroxilaci\u00f3n de \u00e1cidos cin\u00e1micos es un paso crucial para la formaci\u00f3n de cumarinas. Los \u00e1cido orto-cin\u00e1micos sufren posteriormente un cam bio de la configuraci\u00f3n de la \ncadena lateral, transfo rm\u00e1ndose del is\u00f3mero trans , al is\u00f3mero cis, menos estable.  O O\ncumarinaO O\nO O\nO O\nO O\nO OO OO OO O(R)O\nOH\nCOR\nRXHS\nO2NTiocumarinasAlcoxi/hidroxicumarinas\nFormil y carboxicumarinas\narilcumarinas\nalquilcumarinashalocumarinasnitrocumarinas\n11Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n12  \n \nFigura 6 .Bios\u00edntesis de cumarinas simples encontradas en plantas. \n \nMientras que la isomerizaci\u00f3n cis/trans ser\u00eda desfavorable en el caso de un solo \ndoble enlace aislado, en el caso de los \u00e1cidos cin\u00e1micos el sistema altamente \nconjugado permite que este proceso ocurra f \u00e1cilmente, y que la ra diaci\u00f3n ultravioleta, \ncomo por ejemplo la luz del sol, sea suficiente para producir mezclas en equilibrio. Por \u00faltimo, tiene lugar una lactonizaci\u00f3n, que da lugar a el esqueleto final de cumarina. \nTanto la isomerizaci\u00f3n cis/trans, como la lactonizaci\u00f3n, son procesos que en la \nnaturaleza est\u00e1n mediados por enzimas, y la lu z no es necesaria para la bios\u00edntesis de \nlas cumarinas. Aunque el \u00e1cido cin\u00e1mico si rve como precursor directo de la propia \ncumarina, la mayor\u00eda del resto de la s cumarinas simples derivan del \u00e1cido para -\ncum\u00e1rico y de la umbeliferona. Los grupos  hidroxilo adicionales presentes en otras \ncumarinas se suelen a\u00f1adir a la mol\u00e9cula una vez que el n\u00facleo de la cumarina haya \nsido construido. \nA pesar de que la cumarina en s\u00ed se encuentra en plantas como la \nanteriormente mencionada Melilotus alba  o tr\u00e9bol de olor, hay evidencias de que las \nplantas realmente conti enen los gluc\u00f3sidos de el trans  y cis  \u00e1cido orto-cum\u00e1rico, y que \nla cumarina s\u00f3lo se libera como resultado de una hidr\u00f3lisis en zim\u00e1tica y lactonizaci\u00f3n \nmediante el da\u00f1o del tejido de la planta durante los procesos de cosecha. \n O2C\nNH3\nL-fenilalaninaCO2H\n\u00e1cido trans -cin\u00e1micoCO2H\nOHPAL o-hidroxilasa\n\u00e1cido trans-orto- cum\u00e1ricoCO2HOH OO\ncumarina\nCO2H\nHO\n\u00e1cido para- cum\u00e1ricoCO2H\nHO OHCO2HOH HO OO HO\numbeliferona\nOO HOHO\nesculetinaOO HOMeO\nescopoletina\u00e1cido cis-orto- cum\u00e1rico\no-hidroxilasaisomerizaci\u00f3n \ncis/translactonizaci\u00f3n\nlactonizaci\u00f3n\n12Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 13 \n2.3. S\u00edntesis de cumarinas  \nPor otra parte, la s\u00edntesis de cumarinas  y de sus derivados es un \u00e1rea de gran y \npermanente inter\u00e9s por el gran n\u00famero de compuestos de esta familia y el amplio \nespectro de actividades biol\u00f3gicas que presentan. En otros casos, el esqueleto \ncumar\u00ednico es utilizado como intermedio en la s\u00edntesis de compuestos m\u00e1s complejos19 \ntales como piranocumarinas,20 furocumarinas o 2-acil-resorcinoles.21,22 \nSi estudiamos los procedimi entos sint\u00e9ticos para la preparaci\u00f3n de cumarinas, \nnos encontramos con una amplia variedad de reacciones cl\u00e1sicas que permiten obtener \nel n\u00facleo cumar\u00ednico.23,24 Entre estos procedimientos cl\u00e1sicos, destacan las reacciones \nde Perkin,25 Pechman26 o Knoevenagel,27 aunque otros procedimientos como la \nreacci\u00f3n de Wittig,28 Kostanechi-Robisnson o Reformatsky29 han sido tambi\u00e9n \nconvenientemente aplicados para la s\u00edntesis de estos heterociclos (Figura 7). Sin \nembargo, es necesario adecuarlos a s\u00edntesis espec\u00edficas y los rendimientos no siempre \nson satisfactorios,30 haciendo que el desarrollo de nuevos y fiables m\u00e9todos de alto \nrendimiento para la s\u00edntesis de l as cumarinas sea un tema importante. \n Entre estas reacciones cl\u00e1sicas, la que ha sido m\u00e1s utilizada es la reacci\u00f3n de \nPechmann debido a la sencillez y disponibilidad de  los materiales de partida, es decir, \nfenoles y \u03b2-ceto\u00e9steres en presencia de  agentes \u00e1cidos, as\u00ed como por los satisfactorios \nrendimientos obtenidos en ciertos casos.31,12 El uso de diversos reactivos, tales como \nH2SO4, P2O5, FeCl3, ZnCl2, POCl3, AlCl3, PPA, HCl, \u00e1cido fosf\u00f3rico, \u00e1cido \ntrifluoroac\u00e9tico, montmorillonita y otras arcillas  est\u00e1 bien documentada en la literatura.32 \n \n \n13Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n14  \nFFigura 7.  Reacciones cl\u00e1sicas para la  s\u00edntesis de cumarinas.  \n \nLa reacci\u00f3n original de Pechmann se lleva a cabo a temperatura elevada. \nComo se emplean condiciones fuertem ente \u00e1cidas, la r eacci\u00f3n produce aguas \nresiduales \u00e1cidas da\u00f1inas. Adem\u00e1s, las condic iones severas implican limitaciones en los \nreactivos posibles o requieren la aplicaci\u00f3n de los grupos protectores. Varias mejoras \nhan sugerido el empleo de \u00e1cidos de Br\u00f6n sted (libres, o con soporte s\u00f3lido): HCl, \nHCl/CH3CO2H, HCl/CH3CH2OH, H3PO4,33 disoluciones acuosas de l\u00edquidos i\u00f3nicos,34 \nresinas de inte rcambio i\u00f3nico,35 as\u00ed como \u00e1cidos de Lewis, tales como AlCl3, ZnCl233 o \nInCl3.36 \nA pesar de la importancia de las cumarinas y de la relevancia tecnol\u00f3gica de su \nproducci\u00f3n, el mecanismo su byacente es poco conocido. Anteriormente se hab\u00edan \npropuesto dos mecanismos diferentes para esta reacci\u00f3n33, 37 que han sido \nposteriormente adaptados aunque con ligeras modificaciones.  \n \n  O OR4\nR3R5\nR6\nR7\nR8OO O CHO\nOHR4 OO O\nR3OH R7\nCHO\nOHRO ORO O\nCHO\nOHR Ph3PCHCO2EtR4\nO\nOHR3OR3O OOHR4\nO\nBrOO+\n+\n+\n+++ Pechmann\nPerkin\nKnoevenagel\nWittigKostanechi-RobinsonReformatsky\n14Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 15 \n \n \nFFigura 8.  Mecanismo de la reacci\u00f3n de P echmann propuesto por Robertson et al. \n \nEl mecanismo propuesto por Robertson et al. (Figura 8) empieza por un ataque \nelectrof\u00edlico por el grupo \u03b2-carbon\u00edlico del acetoacetato de etilo  al anillo arom\u00e1tico. Ellos \nse apoyan en esta propuesta mediante el  aislamiento del \u00e1cido cin\u00e1mico como \nintermedio de reacci\u00f3n, y convierten los \u00e1cidos cin\u00e1micos en cumarinas.33,37 \nRecientemente, tambi\u00e9n ha sido observado otro intermedio (2,4-dihidroxi-etil- trans -\u03b2-\ncinamato de metilo), apoyando esta secuencia.38  \nPor otro lado, la propuesta mecan\u00edstica de Ahmed y Desai (Figura 9), tiene \ncomo caracter\u00edstica la este rificaci\u00f3n como primer paso, seguido por un ataque \nelectrof\u00edlico para cerrar el anillo.33 Este mecanismo tambi\u00e9n tiene en cuenta la posible \nformaci\u00f3n de la cromona como producto secundario, asumiendo que tambi\u00e9n puede \ntener lugar una migraci\u00f3n de Fries despu\u00e9s del paso de la esterificaci\u00f3n. \nAmbas propuestas mecan\u00edsticas han sido afirmadas como \u201cel mecanismo de la \nreacci\u00f3n\u201d en la literatura. Algunos art\u00edculos se prefieren el mecanismo propuesto por Robertson,\n39 otros se han referido al mecanismo de Ahmed y Desai39,40,35,41 y otros \nmencionan y aceptan ambos.33,42 HOO\nOO\nRHOO\nO H\nHOHHHO\nH2ORHOO\nO\nOR\nHOHH\nH-H2OHOO\nOR\nHHHO\nH\nHOO\nOROO\nOR\nHHOH2\nO RHOEtOHOH2\nO ROHOH2\nO ROHO\n-C2H5OH\nH\nH2OO RO\n15Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n16  \n \n \n     \n \n  \nFigura 9. Mecanismo de la reacci\u00f3n de P echmann propuesto por Ahmed y Dasai. \n \nOtra de las reacciones cl\u00e1si cas empleadas para la s\u00edntesis de cumarinas y que \ndestacaremos en esta memoria por ser la metodolog\u00eda elegida para el desarrollo de \ngran parte de la misma, es la reacci\u00f3n de Knoevenagel. \nLa reacci\u00f3n de condensaci\u00f3n de Knoevenagel es una reacci\u00f3n cl\u00e1sica en \nqu\u00edmica org\u00e1nica empleada para la formaci\u00f3n de enlaces carbono-carbono.43 El \nprototipo de la r eacci\u00f3n de Knoevenagel44,45 es la condensaci\u00f3n de un aldeh\u00eddo o una \ncetona con un \u00e9ster mal\u00f3nico pa ra generar un \u00e9ster carbox\u00edlico \u03b1,\u03b2-insaturado. Sin \nembargo, el t\u00e9rmino de reacci\u00f3n de Knoevenagel tambi\u00e9n se utiliza para reacciones \nan\u00e1logas en las que un aldeh\u00eddo o una cet ona reaccionan con varios tipos de \ncompuestos que poseen un metileno activado, y cuya reacci\u00f3n est\u00e1 mediada por una amina primaria o secundaria que act\u00faa como catalizador en disolventes org\u00e1nicos. La \nreacci\u00f3n de Knoevenagel est\u00e1 considerad a como una modifi caci\u00f3n de la reacci\u00f3n \nald\u00f3lica; la principal difer encia entre ambas apro ximaciones es la elevada acidez del \nhidr\u00f3geno activo del metileno cuando se compara con un hidr\u00f3geno \u03b1 -carbon\u00edlico.\n46 \nPara evitar que reacciones ald\u00f3licas compitan con la reacci\u00f3n de Knoevenagel, el \naldeh\u00eddo empleado no debe tener  protones  en la posici\u00f3n \u03b1. Adem\u00e1s, con el fin de OO\nOO\nRC2H5 H\nHOH2\nO HO\nO O\nC2H5H\nOH2-C2H5O O\nOH\nH2OMigraci\u00f3n\nFries\nO O\nOHR\nR\nH\nHOHR\nO O\nOHR\nHH\nHOO O\nOHR\nHOHHO OR\nH\nHHO\nH-H2O\nO OR\nHOHHO ORHO\nO OO\nOR R\n16Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 17mejorar los rendimientos de la reacci\u00f3n, en los \u00faltimos a\u00f1os se han desempe\u00f1ado la \nreacci\u00f3n en microondas47,48 o empleado l\u00edquidos i\u00f3nicos.49  \nPosteriormente a la primera descripci\u00f3n de la reacci\u00f3n de Knoevenagel, se \nintrodujeron cambios en las condiciones de reacci\u00f3n y el los reactivos empleados. De \neste modo, cuando la base empleada es piridina con trazas de piperidina (en lugar de \ndietilamina) y el \u00e1cido mal\u00f3nico es el precursor del enolato, la reacci\u00f3n pasa a llamarse \ncondensaci\u00f3n de Doebner o modificaci\u00f3n de Doebner.50,51  \nLa reacci\u00f3n de Henry,52,53 tambi\u00e9n conocida como la reacci\u00f3n de Kamlet,54  es \notra modificaci\u00f3n de la condensaci\u00f3n de K noevenagel que utiliza compuestos con un \n\u03b1-nitro metileno activo, y por ello es frecuentemente llamada reacci\u00f3n nitro ald\u00f3lica. \nSupone la condensaci\u00f3n de nitrometano (u otro nitroalcano) con aldeh\u00eddos o cetonas. \nUn resumen esquem\u00e1tico de la reacci\u00f3n de  Knoevenagel y y las modificaciones de \nDoebner y Henry se representa en la Figura 10.  \nUn amplio n\u00famero de cumarinas han sido sintetizadas empleando esta \nmetodolog\u00eda, como por ejempl o los \u00e1cidos 3-cumarincarbox\u00edlicos55,56 y amidas,57,58 \namino y alquilamino cumarinas,48 3-acetil59 y trifluoroacetil cumarinas,60 3-ciano y \nazidocumarina,61 aril y arilsulfonamido cumarinas,62 , 63 \u00e9teres corona 3-\nbenzoilcumarinas64 y heterociclos puente unidos a cumarinas.65 Esta estrategia tambi\u00e9n \nse ha aplicado para la obtenci\u00f3n de derivados de 4-hidroxicumarinas.66 Bodwell y \ncolaboradores tambi\u00e9n han presentado la s\u00ed ntesis de 3-amino cumarinas de forma \nr\u00e1pida y sencilla empleando la reacci\u00f3n de Knoevenagel.67 Las cumarinas 3-\ncarboxamidas tambi\u00e9n has sido obtenidas mediante una reacci \u00f3n de condensaci\u00f3n de \ntipo Knoevenagel, con o sin radiaci\u00f3n de microondas.68,69 \nLa reacci\u00f3n de Knoevenagel tambi\u00e9n se ha llevado a cabo con metilenos \nactivados por heterociclos.70,71 Adem\u00e1s, derivados C-glicos\u00edlicos de cumarina tambi\u00e9n \nhan sido sintetizados mediante una reacci\u00f3n de condensaci\u00f3n de Knoevenagel en una sola etapa.\n72 \n \n   \n17Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n18  \n \n \n \n \n   \n \n  \n \nFigura 10.  Esquema general de las reacciones de Knoevenagel, Doebner y Henry. \n \nPodemos encontrar en la bibliograf\u00eda, propuestas de varias modificaciones del \nm\u00e9todo que han tomado una gran importancia. As\u00ed, los \u00e1cidos 3-cumarincarbox\u00edlicos se \npueden obtener con elevados rendimientos a partir de los correspondientes orto-\nbenzaldeh\u00eddos y \u00e1cidos de Meldrum.73 La isofraxidina (7-hydroxy-6,8-\ndimetoxicumarina), por ejemplo, una cumari na ampliamente conocida, ha sido obtenida \nmediante este r\u00e1pido procedim iento sint\u00e9tico utilizando un de rivado del si ringaldeh\u00eddo y \nel \u00e1cido de Meldrum en presencia de Zn O. El \u00e1cido 3-cumari ncarbox\u00edlico obtenido es \nposteriormente descarboxilado con cobre (Figura 11a).74 Otro proceso similar pero que \nemplea una metodolog\u00eda en fase s\u00f3lida, y en la que el malonato de etilo unido a la \nresina de Wang y los orto-hidroxialdeh\u00eddos se emplean como materiales de partida, \npermite obtener tambi\u00e9n 3-carbox icumarinas sustituidas, tras la descarboxilaci\u00f3n \nt\u00e9rmica de los interm edios (Figura 11b).75,76 RO ORO O\nR1R2O\nHO OHO O\nR1R2ORO ORO O\nR2 R1\nHO R1O R2\nR3NO2 R1R2OR2\nR1 R3O2NReacci\u00f3n de Knoevenagel cl\u00e1sica\nReacci\u00f3n de Doebner\nReacci\u00f3n de Henrymetileno activado\n(\u00e9steres mal\u00f3nicos)\n\u00e1cido mal\u00f3nico\n\u03b1\u2212nitroalcanocat. amina/base\nN\n-CO 2\ncat. amina/base\n+++\n18Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 19 \n \nFigura 11.  S\u00edntesis de \u00e1cidos 3-cumarincarbox\u00edlicos me diante a) \u00e1cido de Meldrum y b) resinas.  \n \nAlgunos procedimientos sint\u00e9ticos tambi\u00e9n se basan en la ciclaci\u00f3n directa de \n\u00e1cidos cin\u00e1micos propiament e sustitu\u00eddos. Estos reactivos est\u00e1n disponibles \ncomercialmente, o bien se obtienen por ciclaci\u00f3n de Knoev enagel o mediante la ruptura \ndel anillo de pirona de la cumarina correspondiente.77 La s\u00edntesis de nitrocumarinas,78 \nde 3-fenilcumarinas79 o de 6-acilcumarinas80 ha sido posible tambi\u00e9n empleando esta \nmetodolog\u00eda. \nRespecto del mecanismo general de la reacci \u00f3n de Knoevenagel (Figura 12), el \nproceso comienza con la desprotonaci\u00f3n de l derivado mal\u00f3nico por la piperidina, \ngenerando el carbani\u00f3n correspondiente, resonante con sus correspondientes \nenolatos. A continuaci\u00f3n, se produce el at aque nucle\u00f3filo del carbani\u00f3n sobre el \ncarbono carbon\u00edlico del aldeh\u00eddo o cetona que da lugar a la formaci\u00f3n de un nuevo \nenlace carbono-carbono, generando un intermed io que tras pasos de transferencia \nprot\u00f3nica con la base protonada g eneran un intermedio ald\u00f3lico que sufre \ndeshidrataci\u00f3n para dar el compuesto final \u03b1,\u03b2-insaturado. \n OR2COR1\nR1, R2 = H, MeOR2O\nO\nOO\nO OCOOH\nO OR R R R\u00e1cido de\nMeldrum\ncatalizadorH+Cua)\nCHO\nOHR1\nR2O OO O\nResina\npiridina, piperidina1)\n2) TFA, CH 2Cl2R1\nR2O OCOOHb)\n19Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n20  \nFigura 12.  Mecanismo general de la  reacci\u00f3n de Knoevenagel.  \n \n2.4. Actividad biol\u00f3gica de las cumarinas \nEl origen del descubrimiento del prim er f\u00e1rmaco de estructura cumar\u00ednica \nintroducido en terap\u00e9utica, est\u00e1 \u00edntimamente relacionado con la bios\u00edntesis y m\u00e1s \nconcretamente con los procesos qu\u00edm icos de fermentaci\u00f3n del tr\u00e9bol Melilotus \nofficinalis fuente importante de cumarinas. En 1941 Link comprob\u00f3 que la enfermedad \nhemorr\u00e1gica ya detectada en 1920 y conocida como \u201cenfermedad del tr\u00e9bol dulce\u201d que \nafectaba al ganado, pr oven\u00eda de la ingesti\u00f3n de heno contaminado con dicho tr\u00e9bol y \nconservado en malas condiciones. La cumarina presente en el proceso de fermentaci\u00f3n \nes oxidada a 4-hidroxicumarina la cual sufre un proceso de condensaci\u00f3n con una \nmol\u00e9cula de formaldehido generado en dicha fermentaci\u00f3n para formar el compuesto \nd\u00edmero responsable de dichas hemorragias: el dicumarol, comercializado ya en 1942  \n(Figura 13).81 \n \n \n  \nFigura 13. Formaci\u00f3n del dicumarol tras procesos de fermentaci\u00f3n en tr\u00e9bol Melilotus officinalis.  \n EtO OEtO O\nHHN\nHEtO OEtO O\nEtO OEtO O\nOEt EtOO O\nH H H\nOH R\nEtO OEtO O\nR ONHH\n-\nNH\nHEtO OEtO O\nH R\nHO NHEtO OEtO O\nR\nO OOH OH\nOO\nDicumarolOO OOOH\nHCHO\n20Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 21 Aparec\u00eda as\u00ed el primer de rivado cumar\u00ednico con actividad farmacol\u00f3gica, cuyo \ndescubrimiento ha servido de inspiraci\u00f3n para el desarrollo de la warfarina, \ncomercializada en Espa\u00f1a con el nombre  de Aldocumar\u00ae, o el acenocumarol, \ncomercializado como Sintrom\u00ae, ambos empleados en cl\u00ednica como f\u00e1rmacos \nanticoagulantes.82 El carbocromeno, tambi\u00e9n disponibl e actualmente, es otro ejemplo \nde una conocida cumarina con actividad  cardioprotectora de bido a su acci\u00f3n \nvasodilatadora e inhibidora de la agregaci\u00f3n plaquetaria A partir de este momento, el \nestudio de los compuestos cumar\u00ednicos ha crecido incesantemente de forma que hoy \nd\u00eda se conocen estructuras con una gran divers idad estructural, moti vo por el cual es \ntambi\u00e9n elevada su diversidad f\u00e1rmaco-terap\u00e9utica. De este modo, se pueden encontrar cumarinas con propiedades antioxidantes,\n83 anti-inflamatorias,84 , 85 \nantivirales,86 , 87 , 88 antimicrobianas,89 , 90 cardioprotectoras91 , 92 o como inhibidores \nenzim\u00e1ticos,93,94 entre otras. (Figura 14).15 \n \n \n \n \n \n   \n \n \nFFigura 14.  Cumarinas empleadas actualmente como f\u00e1rmacos comerciales. \n \nAdem\u00e1s de las cumarinas mencionadas,  las furocumari nas o psoralenos, \nproductos tric\u00edclicos de  condensaci\u00f3n con el anillo de  furano, presentan una gran \nvariedad de propiedades farmacol\u00f3gicas de rivadas fundamentalmente de su capacidad OOH\nOO\nR\nR = H, Warfarina\nR = NO2, SintromO ONEt2\nOEt O\nCarbocromeno BucumololO O\nO NHOH\nO OOH\nH\nN\nOOH\nO OOO\nOHNH2\nO\nNovobiocinaO ONN\nNN\nHS\nOO OO\nCalanolida AOHAnticoagulantes Vasodilatador Cardioprotector\nAntiviral, VIH Antibacteriano Antiviral, VHC\n21Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n22 de fotorreacci\u00f3n con el ADN.95 El compuesto de referencia y principal responsable de la \naplicaci\u00f3n farmacol\u00f3gica de esta  familia es la furo[3,2- g]cumarina lineal conocida \npropiamente como  psoraleno.96 , 97 De hecho, ya desde tiempos remotos \n(aproximadamente 200 A.C.) extractos o part es de plantas que contienen esta mol\u00e9cula \neran utilizados en el antiguo Egipto e India pa ra tratar enfermedades hiperproliferativas \nde la piel. \nEl descubrimiento de fuentes de luz ultravioleta supuso un significativo avance \nen el uso de la fototerapia98 y en 1974 fue introducido el t\u00e9rmino fotoquimioterapia para \ndescribir el uso de radiaci\u00f3n ultravioleta junto con un fotosensibilizador.99 La terapia \nPUVA (Psoralero + ra diaci\u00f3n ultra violeta-A)100 es el ejemplo m\u00e1s conocido de la \naplicaci\u00f3n de estos compuestos y fue introducido por El Motif, que en 1948 aisl\u00f3 y \naplic\u00f3 el 8-metilpsoraleno (8-MOP ) en el tratamiento del vit\u00edligo.101 En la actualidad, el 8-\nMOP sigue siendo el deriva do m\u00e1s com\u00fan empleado en la terapia humana, aunque el \n5-MOP, el 4,8,5\u2019-trimetilpsoraleno (TMP) o el mismo psoraleno (Figura 15) tambi\u00e9n son \nutilizados en el tratamiento de diferentes de s\u00f3rdenes hiperproliferativos de la piel \nincluyendo el vit\u00edligo, la psoriasis, o la dermatitis at\u00f3pica. \n \nFigura 15. Furocumarinas lineales (psoralenos) act ualmente empleados para tratar des\u00f3rdenes \nhiperproliferativos de la piel.  \n \nPor \u00faltimo, adem\u00e1s de las actividades farmacol\u00f3gicas mencionadas, queremos \nreferirnos de modo especial a la actividad de las cumarinas como inhibidores \nenzim\u00e1ticos, campo en el que podemos encontra r una amplia variedad de estructuras, \ntanto de cumarinas simples como de sus derivados, que act\u00faan sobre diferentes \nsistemas enzim\u00e1ticos. Un especial inter\u00e9s mostraron algunos inhibidores de diferentes \nenzimas con potencial aplicaci\u00f3n en el tratamient o de las enfermedades \nneurodegenerativas (Figura 16). Entre estas enzimas se encuentra la \u03b2-secretasa, \ngeneralmente referenciada como BACE (beta-site APP cleaving enzyme), y para cuya O O O34 54'\n5'\nO O O\nOMeO O O\nMeO O OMe\nMeOMe\nPsoraleno 8-MOP\n8-met\u00f3xipsoraleno\nxantotoxina5-MOP\n5-met\u00f3xipsoraleno\nbergaptenoTMP4,8,5'-trimetilpsoraleno\nmetoxaleno\n22Introducci\u00f3n                                                                                          2. Las cumarinas \n \n 23isoforma 1 (BACE-1) se encontraron 3-amido cumarinas con potencial uso en la terapia \nde la enfermedad de Alzheimer (EA).73 Otra de las enzimas implicada en la EA y cuyos \ninhibidores han sido ampliame nte estudiados es la acetilcolinesterasa (AChE), para la \nque tambi\u00e9n se han encontrado derivados de cumarina, 102,103, con gran actividad y una \npotencial aplicaci\u00f3n  terap\u00e9utica.104,105 \n \n \nFFigura 16. Derivados de cumarina como inhibidores de enzimas implicadas en enfermedades \nneurodegenerativas. \n \nPor otro lado, es conocido el papel clave que las monoaminoxidasas (MAOs) \ndesempe\u00f1an en la inactivaci\u00f3n de los neurotr ansmisores, responsables de algunos \ntrastornos neurol\u00f3gicos.106 , 107 En a\u00f1os recientes, se ha encontrado que algunos \nan\u00e1logos cumar\u00ednicos presentan una interes ante actividad inhibidora de la MAO \n(IMAO).108 Esta enzima presenta dos isoformas, MAO-A, cuya regulaci\u00f3n puede tener \nimplicaciones terap\u00e9uticas para el  tratamiento de la depresi\u00f3n109, y la MAO-B, con \nimplicaciones en la terapia em pleada contra el Parkinson.110 En este campo se \nprofundizar\u00e1 un poco m\u00e1s a lo largo de la discusi\u00f3n de esta memoria, pero cabe \ndestacar que en los \u00faltimos a\u00f1os se han encontrado derivados cumar\u00ednicos con una \nactividad inhibidora se lectiva de la MAO-B.111,112,113 \nTambi\u00e9n se han descrito derivados cumar\u00ednicos multi-diana que presentan una \nactividad dual inhibidora de la BACE1 y de la AChE, 114,115 o monoaminoxidasa (MAO) y \nAChE,116 todos con inter\u00e9s en la terapia de la EA. Algunos de los compuestos \nmultifuncionales descritos se muestran en la. Muchos son los ejemplos de los \ncompuestos multifuncionales descritos (Figur a 17), como ocurre con las estructuras \nsiguientes. O O\nInhibidor BACE1N\nHN\nOOBr\nO OO\nInhibidor AChENH\nON\nO O ONN\nSN\nInhibidor MAO-AO O\nInhibidores MAO-BBr, Me, OMe\nBr, Me, OMe\n23Introducci\u00f3n                                                                                         2. Las Cumarinas  \n \n24  \nFigura 17. Inhibidores duales de a) AChE y BACE1 y b) AChE y MAO. \n \nAdem\u00e1s de los sistemas enzim\u00e1ticos exp uestos, es preciso considerar otros \naspectos muy directamente re lacionados con la etiopato log\u00eda de las enfermedades \nneurodegenerativas. En los \u00faltimos a\u00f1os se demostr\u00f3 que en los pacientes de EA \naumenta la actividad MAO-B cerebral y es te hecho origina un aumento de radicales \nlibres, responsables del estr\u00e9s oxidativo, muerte celular, y desarrollo de las placas amiloides. En este sentido es una teor\u00eda am pliamente aceptada el efecto beneficioso de \nla terapia antioxidante con dietas ricas en flavonoides, terapia que est\u00e1 recibiendo cada d\u00eda mayor atenci\u00f3n con objeto de det ener o retrasar la neurodegeneraci\u00f3n.\n117 As\u00ed pues, \nes importante considerar el inter\u00e9s de los an\u00e1logos cumar\u00ednicos antes descritos y su potencialidad terap\u00e9utica en dichas enfermedades debido a su capacidad antioxidante, \naspecto que tambi\u00e9n estudi aremos en esta Memoria. \n \n \n O O MeOMeO NMe\nO ON\nEt ON\nHO\nF Fa)\nb)\nO OR1R2\nO OR1H\nN R2\nO\n24Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 25 \n3. Las chalconas \n3.1. Origen de las chalconas \nLas chalconas, que est\u00e1n consideradas como los precursores biosint\u00e9ticos de \notros flavonoides e isoflavonoides, representan una de las mayores clases de \ncompuestos naturales ampliament e distribu\u00edda en el reino ve getal (Figura 18). Adem\u00e1s, \nlas chalconas tambi\u00e9n pueden ser precursores sint\u00e9ticos clave de muchos heterociclos \nbiol\u00f3gicamente impor tantes, tales como las benzotiacepinas, pirazolinas y las 1,4-\ndicetonas. \n \nFFigura 18.  Fuentes naturales y origen bi osint\u00e9tico de las chalconas. \n \nQu\u00edmicamente, los compuestos de la  clase de las chalconas poseen un \nesqueleto estructural com\u00fan de 1,3-dif enil-2-propen-1-ona y son consideradas como \nflavonoides de cadena abierta, en los cuales lo s dos anillos arom\u00e1ticos (anillos A y B) \nest\u00e1n unidos por un sistema carbon\u00edlico \u03b1,\u03b2-insaturado de tres \u00e1tomos de carbono. Las \nchalconas pueden existir en dos formas isom\u00e9ricas, cis  y trans , de las cuales el is\u00f3mero \ntrans  es el considerado m\u00e1s favorabl e termodin\u00e1micamente (Figura 19).  \nPolifenoles\r\nFlavonoides\r\nEstilbenos\r\nLignanos\r\n\u00c1cidos Fen\u00f3licos\r\nIso\ufb02avonoides\r\nAntocianinas\r\nFlavanonas\r\nFlavonas\r\nFlavonoles\r\nCChalconas\r\n25Introducci\u00f3n                                                                                          3. Las Chalconas \n \n26  \n \n \n \n \nFigura 19.  Is\u00f3meros trans y cis del esqueleto b\u00e1sico de chalcona  \n \nLa presencia del dobles enlaces conjugados en las chalconas, as\u00ed como la \nexistencia de un sistema \u03c0-electr\u00f3nico completamente deslocalizado en ambos anillos \nbenc\u00e9nicos, hace que estas mol\u00e9culas suel an poseer bajos potenciales redox y una \nelevada probabilidad de que den lugar a reacciones de transfe rencia electr\u00f3nica.  \nLas chalconas de origen natural, as\u00ed co mo sus an\u00e1logos sint\u00e9ticos, muestran \nun amplio espectro de actividades biol\u00f3gicas.118,119 Por esta raz\u00f3n, las chalconas se han \nconvertido en objeto de inter\u00e9s continuo tanto en el mundo acad\u00e9mico como en la \nindustria. Se cree que el fragmento cet\u00f3nico \u03b1,\u03b2-insaturado es probable que sea el \nresponsable de muchas de las actividades bi ol\u00f3gicas observadas, ya que la eliminaci\u00f3n \nde esta caracter\u00edstica estruct ural resulta en la p\u00e9rdida de bioactividad. Con este \nfragmento intacto, se han sintetizado nuevas mol\u00e9culas derivadas realizando \nmodificaciones en ambos anillos.120 \n \n3.2. Bios\u00edntesis de chalconas \n \nLas chalconas act\u00faan como precursores de un vasto n\u00famero de derivados de \nflavonoides encontrados en todo el reino vegetal los cuales, en su mayor\u00eda, contienen \nun anillo heteroc\u00edclico de 6 miembros, que se forma a partir de ataques nucle\u00f3filos de \ntipo Michael por parte de un grupo fenol sobre la cetona insaturada, dando lugar a flavanonas. Como se muestra el la Figura 20, la bios\u00edntesis de las chalconas empieza \ncon la L-fenilalanina. A continuaci\u00f3n, la condensaci\u00f3n de la cinamoil-CoA derivada de la \nL-fenilalanina con tres mol\u00e9culas de maloni l-CoA catalizada por la chalcona sintetasa, O\nO\ntrans -chalcona cis-chalconaAB\nA B\n2'\n3'4'5'6'\n2\n3456\n2'\n3'4'6'\n5'234\n5\n6\n26Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 27da lugar a la chalcona. La flavanona corres pondiente es posteriormente sintetizada por \nla enzima chalcona isomerasa, que cataliza la reacci\u00f3n de forma estereoespec\u00edfica.121,122   \n \n \nFigura 20.  Ruta biosint\u00e9tica general de las chalconas  \n \nEl continuo y exhaustivo estudio de las di stintas rutas biosint\u00e9 ticas (en especial \nla del \u00e1cido shik\u00edmico y la del malonato) ha permitido explicar tanto la formaci\u00f3n como \nmuchas de las transformaciones metab\u00f3licas que experimentan estas mol\u00e9culas. Se \nobserv\u00f3 que en estos procesos, juegan un papel fundamental enzimas como la \nchalcona-sintetasa y la chalcona-isomerasa, que se encargan de la bios\u00edntesis y de las \ntrasformaciones biosint\u00e9ticas de diversificaci\u00f3n estructural que experimentan las \nchalconas naturales, y que conducen a diversos miembros de la familia de los \nflavonoides. (Figura 21) \n \n  \n \n  \n \nFigura 21.  N\u00facleos estructurales de los principales grupos de flavonoides  O2C\nNH3SO\nCoA S OHO O\nCoA3 X\nchalcona sintetasa\n3 CO 2 + 3 CoA-SHO O\nO\nSO\nCoA\nO OH\nOH HOCoA-SH\nchalconaOO OH\nHO\n\ufb02avanonaL-fenilalanina\nchalcona isomerasa\nO O\nO\nFlavonas Chalconas\nO\nO\nFlavonolesO\nO\nFlavanonas\nOH\nOO\nAuronasO\nAntocianinasO\nO\nIso\ufb02avonas\n27Introducci\u00f3n                                                                                          3. Las Chalconas \n \n28 3.3. S\u00edntesis de chalconas \n \nDesde el punto de vista preparativo, tradicionalmente las chalconas se obtienen \nmediante la condensaci\u00f3n de Claisen-Schm idt en medio \u00e1cido o b\u00e1sico, que act\u00faa \ncomo catalizador, bajo condiciones homog\u00e9neas.123,124 (Figura 22). A pesar de tratarse \nde una de las reacciones m\u00e1s cl\u00e1sicas de la qu\u00edmica org\u00e1nica, destaca por su sencillez \nexperimental y por su robustez, permitien do la formaci\u00f3n de forma eficiente del doble \nenlace carbono-carbono independi entemente de la complejidad estructural de las \nmol\u00e9culas a ensamblar. \n \n  \n \nFigura 22.  Reacci\u00f3n de Claisen-Schmidt para  la s\u00edntesis de chalconas.  \n Esta reacci\u00f3n ha sido ampliamente utiliz ada no solo para la preparaci\u00f3n de \nchalconas, sino tambi\u00e9n para la s\u00edntesis de  flavanonas, derivados del 1,3-diarilpropano \ny para la s\u00edntesis de una nueva familia de macrociclos, todas ellas en un \u00fanico paso.  \nEn cuanto al mecanismo, la reacci\u00f3n de Claisen-Schmidt pertenece al grupo de \nlas condensaciones ald\u00f3licas,\n125,126 transformaciones catal\u00edticas que pueden transcurrir \na trav\u00e9s de dos mecanismos distintos. Dep endiendo del tipo de catalizador que se \nemplee en la reacci\u00f3n, de su naturaleza \u00e1cida o b\u00e1sica, la reacci\u00f3n trascurre v\u00eda enol o \nenolato respectivamente (Figura 23).  \nCuando lo que se emplea es un cataliz ador \u00e1cido, la etapa inicial en el \nmecanismo de reacci\u00f3n conlleva la tautomerizaci \u00f3n de la cetona para formar el enol. \nAdem\u00e1s, el \u00e1cido tambi\u00e9n activa el gr upo carbon\u00edlico del aldeh\u00eddo mediante su \nprotonaci\u00f3n, haciendo al tamente electr\u00f3filo dicho \u00e1tom o de carbono. El enol formado \nact\u00faa como nucle\u00f3filo en su carbono- \u03b1, permiti\u00e9ndole atacar al  aldeh\u00eddo protonado y \nconduciendo posteriormente a la formaci\u00f3n del aldol, que sufre una deshidrataci\u00f3n para dar lugar al compuesto carbon\u00edlico insaturado final. HO O\nR RO\nCatalizador\nR R\n28Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 29Sin embargo, cuando lo que se emplea es una base moderada, el mecanismo \nde reacci\u00f3n transcurre v\u00eda enolato produci\u00e9ndose el ataque nucle\u00f3filo del mismo al \ncarbono carbon\u00edlico del aldeh\u00eddo. El producto resultante es la sal del alc\u00f3xido del \nproducto ald\u00f3lico, que tras da r lugar al aldol, puede sufrir  f\u00e1cilmente una deshidrataci\u00f3n \npara generar el compuesto carbon\u00edlico insaturado, en este caso la chalcona. \n \nFFigura 23. Mecanismos de la reacci\u00f3n de Claisen-Schm idt en condiciones \u00e1cidas (via enol) o \nb\u00e1sicas (v\u00eda enolato). \n \nA pesar de que los agentes de cat\u00e1lisis  b\u00e1sica para la reacci\u00f3n de Claisen-\nSchmidt son abundantes, el uso de cataliz adores \u00e1cidos puede tener la ventaja de \nevitar que ocurra tanto la reacci\u00f3n compet itiva de Cannizzaro del aldeh\u00eddo como otras \nreacciones laterales secundarias no deseadas cuando existen grupos sensibles a las condiciones b\u00e1sicas.  \nAdem\u00e1s de los catalizadores cl\u00e1sicos, existe un amplio y heterog\u00e9neo arsenal \nde sustancias qu\u00edmicas capaces de servir como catalizadores en esta reacci\u00f3n. Entre \nlos catalizadores m\u00e1s novedosos se encuentran las hidrotalcitas activadas,\n127 \nhidroxipatita,128 zeolitas,129 s\u00edlica aminopropilada sol-gel,130 BiCl3,131 K2CO3 anhidro132 o \nl\u00edquidos i\u00f3nicos \u00e1cidos133 entre otros.  RO OH H R'O\nR R'O OH\nR R'O\nH+\nenol aldol\nproducto de \ncondensaci\u00f3n ald\u00f3licaH\nH\nH2OR R'O OH2\nH-H2OV\u00cdA ENOL\nV\u00cdA ENOLATO\nRO\nHBRO-\nenolatoHO\nR'\nR R'O O-\nHtautomer\u00edaceto-en\u00f3lica H\n+\nR R'O\nHB\nR R'O OH\nH\naldolB\n29Introducci\u00f3n                                                                                          3. Las Chalconas \n \n30 Aunque como se ha dicho anteriormente la  reacci\u00f3n de Claisen-Schmidt es la \nm\u00e1s utilizada, otras t\u00e9cnicas de renombre tamb i\u00e9n han sido empleadas para la s\u00edntesis \nde chalconas.134 As\u00ed, podemos encontrar m\u00e9todos como la reacci\u00f3n de acoplamiento \nde Suzuki,135 la reacci\u00f3n de cross-coupling directa,136 la reacci\u00f3n de Heck,137,138 las \nreacciones mediante radiaci\u00f3n microondas,139 la acilaci\u00f3n de Friedel-Crafts140 o la \nolefinaci\u00f3n de Julia-Kocienski,141 representadas de forma esquem\u00e1tica en la Figura 24. \n \n \nFigura 24.  Reacciones cl\u00e1sicas empleadas para la s\u00edntesis de chalconas  \n \n3.4. Actividad biol\u00f3gica de las chalconas \n \nLa actividad biol\u00f3gica de las chalconas es tan relevante y variada como la \nmetodolog\u00eda sint\u00e9tica previamente menci onada. De hecho, no muchos patrones \nestructurales manifi estan un rango tan amplio de actividades farmacol\u00f3gicas. Dimmock \ny colaboradores realizaron una profunda revi si\u00f3n de las propiedades de las chalconas \nen 1999.142  Desde entonces, las chalconas han seguido siendo una de las \u00e1reas de OXO\nBHOOH\nSuzuki\nClO\nKF3BCross-coupling\nO\nX\nX = B(OH)2; IHeck\nO\nXROFriedel-CraftsO\nSO2Het\nO\nHJulia-Kocienski+\n+ +\n++\n30Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 31investigaci\u00f3n m\u00e1s activas, y prueba de ello son las m\u00faltiples re visiones que se pueden \nencontrar actualmente y en las que se recoge el potencial farmacol\u00f3gico de las \nmismas.143,144,145,146,120 \nLa mayor parte de los estudios farmacol\u00f3gi cos realizados sobre esta familia de \ncompuestos org\u00e1nicos han estado dirigidos hacia la identificaci\u00f3n de nuevos agentes antibacterianos,\n147 , 148 antiprotozoarios,149 antif\u00fangicos,150 antivirales,151 , 152, \nantineopl\u00e1sicos153 o antioxidantes154 entre otros. \nAdem\u00e1s de las actividades farmacol \u00f3gicas mencionadas, cabe destacar que \nestas mol\u00e9culas tambi\u00e9n presentan m\u00faltiple s propiedades derivadas de su capacidad \nde interacci\u00f3n con biomol\u00e9culas. Dentro de es te grupo, es de r ecalcar el potencial de \nlas chalconas como analg\u00e9sicos,155 anti-inflamatorios,156 , 157 antihistam\u00ednicos,158 \nantimit\u00f3ticos159 o inmunomoduladores.160  \nRespecto a la actividad antioxidante, se sabe que las plantas producen una \ngran variedad de antioxidantes como re spuesta al da\u00f1o molecular que producen las \nespecies reactivas de ox\u00edgeno (ROS, por sus siglas en ingl\u00e9s), y que los compuestos \nfen\u00f3licos forman la mayor clase de antioxid antes derivados del mundo vegetal. Entre los \nm\u00faltiples compuestos fen\u00f3licos, los flavonoides son quiz\u00e1 el grupo m\u00e1s importante, ya que tienen la capacidad de atrapar radical es libres y prevenir la peroxidaci\u00f3n \nlip\u00eddica.\n161 , 162 Muchas hidroxichalconas tanto simples como con sustituyentes \nisopren\u00edlicos en sus anillos fe n\u00edlicos poseen un elevado poten cial antioxidante (Figura \n25).163  \n \nFigura 25.  Estructuras qu\u00edmicas de chalconas antioxidantes de origen natural  \n \n O\nHO\nR1R OHOH\nBute\u00edna, R = OH; R1 = H\nSappanchalcona, R = OCH3; R1 = H\nOkanina, R = R1 = OHO OH\nHOOH\nOH\nBroussochalcona AO OH\nO OH O\nR2 R1\nXanthohumol, R1 = H; R2 = CH3\nDesmetilcanthohumol, R1 = R2 = H\n31Introducci\u00f3n                                                                                          3. Las Chalconas \n \n32 As\u00ed, podemos encontrar 3,4-dihidroxichalconas como la bute\u00edna, la \nsappanchalcona o la okanina, que son antioxid antes particularmente efectivos y en los \nque la presencia tanto de un grupo hidroxilo en C-2\u2019 en el anillo A como del grupo \ncatecol en el anillo B, parecen ser favorables pa ra su actividad anti-radicalaria, mientras \nque la falta del enlace \u03b1,\u03b2-insaturado hace que su eficacia disminuya.164 \nMuy estrechamente relacionada con la activ idad antioxidante, la actividad anti-\ninflamatoria es tambi\u00e9n un campo en el que las chalconas presentan resultados muy \nprometedores165,166 si bien igual que ocurre con aquella, es muy dif\u00edcil establecer una \nrelaci\u00f3n estructura-actividad. La inflamaci\u00f3n es una respuesta biol\u00f3gica compleja asociada a m\u00faltiples condiciones fisiopa tol\u00f3gicas. Como respuesta a un est\u00edmulo \ninflamatorio, los macr\u00f3fagos liberan varias mo l\u00e9culas pro-inflamator ias, entre las que se \nincluye el radical libre de corto periodo de vida como el \u00f3xido n\u00edtrico (NO). Una serie de \nderivados de chalcona con posibles efecto s anti-inflamatorios fueron ensayados por \nHeredia y colaboradores\n167 y entre los que encontraron un compuesto \nsignificantemente activo como atrapador de aniones super\u00f3xido. Adem\u00e1s, estudios in \nvitro de dimetilamino-chalconas168 analizaron la actividad inhibidora en la producci\u00f3n de \nNO y de los mediadores de la prostaglandina E2 (PGE 2) y se observ\u00f3 que se produc\u00eda \nuna inhibici\u00f3n de la producci\u00f3n de NO depend iente de la concentraci\u00f3n. Adem\u00e1s de las \ndimetil-aminochalconas, 3,4-dihidroxichalco nas fluoradas, 3\u2019,4\u2019,5\u2019-trimetoxichalconas o \nla 2\u2019,4\u2019,6\u2019-tris(metoximetoxi)chalcona (TMMC ), presentaron potentes efectos anti-\ninflamatorios (Figura 26). \n \n     \n \nFigura 26.  Estructuras qu\u00edmicas de derivados de chalcona con actividad anti-inflamatoria.  \n O\nOMeMeO NMe\nMe\ndimetilamino-chalconasO OMe\nMeO F OHOH\n3,4-dihidroxichalcona \ufb02uorada\nO O\nOMeO\nMeO O\nMeO\n2',4',6'-Tris(metoximetoxi)chalcona\n(TMMC)O OMe\nMeO OMe\n3',4',5'-trimetoxichalcona\n32Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 33 \nEstudios recientes se han centrado en la s actividades anti-proliferativa y de \nreducci\u00f3n tumoral de algunas chalconas, e incluso se ha observado que una ingesta de \nflavonoides presentes en una dieta vegetal es segura y no est\u00e1 asociada con ning\u00fan \nefecto de salud adverso, de modo que se ha vuelto a generar un elevado inter\u00e9s en \nesta clase de mol\u00e9culas.169 Entre los actuales agentes antitumorales identificados, las \nchalconas representan una impor tante clase de mol\u00e9culas  peque\u00f1as \u00fatiles en la \nquimioterapia del c\u00e1ncer.170 El Xanthohumol por ejemplo (Figura 25), que es uno de los \nmayores ingredientes presentes en la cerveza,  puede ser potencialmente \u00fatil no s\u00f3lo \ncomo antioxidante, sino como agente quimioprotector durante la hiperplasia y \ncarcinog\u00e9nesis de pr\u00f3stata y decrece su proliferaci\u00f3n.171 Otras chalconas (Figura 27), \ncomo algunas chalconas bor\u00f3ni cas, chalconas C-metiladas  aisladas de la pulpa y las \nsemillas de los frutos de Syzygium samarangense , conocida como la manzana de java, \nbases de Mannich de chalconas heteroc\u00edcli cas o chalconas aril o aroil sustituidas, \nrepresentan tambi\u00e9n compuestos con pot encial actividad antitumoral.  \n \n   \n \n    \nFigura 27.  Chalconas con actividad antitumoral. a) chalcona bor\u00f3nica; b) chalcona C-metilada \nextra\u00edda de de los frutos de Syzygium samarangense ; c) base de Mannich de una chalcona; d) \nchalcona aril-sustitu\u00edda. \n O\nN\nMeB BOH\nOHHO\nOHO OH\nMe\nHO\nMeOMe\nO OH\nMeO OH\nN\nOO\nMeO\nMeO\nOMe\nOMeOMeOHa) b)\nc) d)\n33Introducci\u00f3n                                                                                          3. Las Chalconas \n \n34 Respecto a la actividad anti-infeccio sa, la estructura de chalcona puede \nconsiderarse como un importante cabeza de  serie a partir del cual se han obtenidos \nderivados con actividad mu y diversa: antibacteriana,147 antif\u00fangica,172 antiviral,173 \nantimal\u00e1rica174,175 o anti-leishmania entre otras. Algunos ejemplos de chalconas que \nmuestran este tipo de actividad es se muestran en la Figura 28. \n \nFFigura 28. Estructuras qu\u00edmicas de derivados de chalcona con diferentes actividades anti-\ninfecciosas. \n \nPor \u00faltimo, debemos hacer una breve refe rencia a la activid ad inhibidora de \nciertos sistemas enzim\u00e1ticos. Adem\u00e1s de la actividad inhi bidora de la ciclooxigenasa-2  \n(COX-2)176 relacionada con su acci\u00f3n antiinflamatoria ya mencionada, nos referimos a la \nactividad inhibidora MAO encontrada por primera vez en 2009 para estos prototipos177, \nas\u00ed como para algunas furano-chalconas178 (Figura 29). En otros casos se da cuenta de \ndicha actividad en  los vinil is\u00f3steros,179 o de la elevada actividad iMAO-B en \nisoflavonoides estructuralmente pr\u00f3ximas.180 Por \u00faltimo, querem os mencionar la \nactividad sobre la tirosinasa181 , 182 encontrada en determinadas chalconas, muy \nrelacionadas con sus an\u00e1logos cumar\u00ednicos y otros flavonoides naturales y sint\u00e9ticos, \nmotivo por el cual es muy dif\u00edcil poder establecer de forma inequ\u00edvoca y predictiva la O Cl\nSNO\nOCOOH\nantibacteriano\nO\nMeMe OH\nHO OH\nantif\u00fangico\nO OH\nMe\nMeO\nCHOOHOH\nantiviralN ClO\nCl ClOMe\nOMe\nantimal\u00e1ricoO\nSOONH\nOMe\nanti-leishmania\n34Introducci\u00f3n                                                                                          3. Las chalconas  \n \n 35relaci\u00f3n estructura\u2013actividad sobre las m\u00faltiples dianas farmacol\u00f3gicas sobre las que \npueden interaccionar. \n \nFFigura 29. Derivados de chalconas como inhibidores enzim\u00e1ticos. \n \nToda esta informaci\u00f3n justifica que varios  autores incluyan a esta familia de \ncompuestos en la lista de estructuras privilegiadas, un concepto enunciado \noriginalmente por Evans183 y que agrupa a aquellos n\u00facleos que por su alta bioactividad \nconstituyen estructuras de alto inter\u00e9s farmacol\u00f3gico. \n O\nMeO\niMAO-BOH\nCl\niMAO A/BOO\nNMe2O OH\nHOHO\nH, OH\nInhibidor tirosinasa\n35Introducci\u00f3n                                                                                          4. Los Estilbenos \n \n36  \n4. Los estilbenos \nLos estilbenos son polifenoles de bajo peso molecular producidos por plantas \ncomo respuesta a una infecci\u00f3n tras la exposici\u00f3n a un microorganismo. Se encuentran \nampliamente distribu\u00eddos en el mundo vegetal y presentan un amplio rango de \nactividades biol\u00f3gicas tales como antib acterianos, antif\u00fangicos, antitumoral, \ncardioprotectora e inhibidores de  la tirosinasa entre otros.184,185 Existe un gran inter\u00e9s en \nsu potencial beneficioso para la salud y en su capacidad para mejorar la resistencia en \nenfermedades en plantas.186 \nDentro de los estilb enos, el resveratrol187 es un estilbeno presente en la piel de \nla uva188,189 que se origina en respuesta a un da\u00f1o externo o interno de, por ejemplo, \nuna infecci\u00f3n por hongos o exposici\u00f3n a la radiaci\u00f3n UV.190 El inter\u00e9s por este \ncompuesto y sus derivados se increment\u00f3 cuando los estudios epidemiol\u00f3gicos \nestablecieron una relaci\u00f3n inve rsa entre el consumo de vino tinto y la incidencia de \nenfermedades cardiovasculares, adem\u00e1s de las propi edades hemost\u00e1ticas y del \naumento del HDL circulante de scrita para el etanol.191,192 \nEl resveratrol (3,4\u2019,5-trihidroxiestilbeno), est\u00e1 formado por dos anillos \narom\u00e1ticos conectados medi ante un doble enlace de estireno que hace posible que \nexista como is\u00f3meros cis- y trans-  (Figura 30).193,194 La forma trans  del resveratrol, \nparece ser la responsable de las principa les propiedades farmacol\u00f3gicas de esta \nmol\u00e9cula. Es, hoy en d\u00eda, un producto comercial com\u00fan, a partir del que se puede obtener por irradiaci\u00f3n UV la forma cis.\n \n  \n \n \n \n \n \n \n \n \nFigura 30.  Is\u00f3meros cis- y trans-resveratrol y fuente natural en la que se encuentra ( Vitis vin\u00edfera ) \n \nOH\nHO\nOH\nHO\nOH OHtrans- resveratrol\ncis-resveratrol\n36Introducci\u00f3n                                                                                          4. Los Estilbenos  \n \n 37Por su gran inter\u00e9s farmacol\u00f3gico y su elevado potencia como estructura \nprivilegiada en el campo de la qu\u00edmica fa rmac\u00e9utica, el resveratrol ha sido muy \nampliamente estudiado en los \u00faltimos a\u00f1os.195 , 196 En concreto, destacaremos su \nactividad inhibidora de  la MAO, siendo el cis-resveratrol menos efectivo que el trans -\nresveratrol, sobre dicha enzima.197 \n \n37Introducci\u00f3n                                                                                       5. La Rocaglamida \n \n38  \n5. La Rocaglamida \nLa rocaglamida (Figura 31) es un comp uesto de origen nat ural perteneciente a \nuna clase de mol\u00e9culas denominadas flavaglinas, nombre que hace alusi\u00f3n a la \nestructura flavonoide a partir de la que se or igina y a la especie en la que est\u00e1 presente. \nDe hecho los procedimientos sint\u00e9ticos ut ilizan rutas biomim\u00e9ticas a partir de las 3-\nhidroxiflavonas y su cicloadici\u00f3n con esteres cin\u00e1micos (Figura 32).198,199 Fue aislada por \nprimera vez en 1982 por King y colabor adores bas\u00e1ndose en su actividad \nantileuc\u00e9mica.200 Desde entonces, alrededor de otras 50 flavaglinas como el rocaglaol o \nel silvestrol han sido encontradas, principalmente por los laboratorios de farmacognosia \nde Kinghorn, Pezzuto and Proksch201,202  en las plantas del g\u00e9nero Aglaia  que se \nencuentran mayoritariamente en los bosques del sudeste asi\u00e1tico y de las islas del \nPac\u00edfico. \n \n \n   \n \nFigura 31.  Estructura de la rocaglamida encontrada en la planta Aglaia elliptifolia . \n King demostr\u00f3 por primera vez que la  rocaglamida presentaba una actividad in \nvivo significante en ratones infectados con leucemia linfoc\u00edtica P388.\n203 Desde \nentonces, la rocaglamida y sus compuesto s relacionados, han mostrado actividad \ncitost\u00e1tica y citot\u00f3xica frente a diversas l\u00edneas celulares tumorales humanas, con valores \nde IC50 en el rango de 1.0-6.0 ng/mL204,205,206 Sin embargo, otro tipo de actividades han \nsido encontradas para este tipo de comp uestos, que presentan tambi\u00e9n actividad \ncomo insecticidas, anti-f\u00fangicos, anti-inflamatorios o como agentes \nneuroprotectores.207,208  Aunque como ya hemos indi cado, esta estructura solo est\u00e1 \npresente en las especies Alglaia , estructuras muy pr\u00f3ximas son sin embargo mucho OOMe\nMeOHOOH\nCONMe2\nOMe\nRocaglamida\n38Introducci\u00f3n                                                                                       5. La Rocaglamida  \n \n 39m\u00e1s abundantes. Tal es el caso de la viniferina, un estilbenoide aislado de la Vitis \nvin\u00edfera  que incorpora tambi\u00e9n un anillo de benzofurano en su estructura y que puede \nconsiderarse d\u00edmero del resveratrol a partir  del que se biosintetiza (Figura 32) y que \ncomo \u00e9l, tiene propiedades antio xidantes e inhibidoras de la formaci\u00f3n de las placas \nbeta amiloides.209,210  \n \n \n      \n \n \nFigura 32. Precursores biosint\u00e9ticos de algunas flavaglinas.  \n \nEl grupo de las flavaglinas es un grupo de productos naturales que incorporan \nen su estructura un esqueleto benzofur\u00e1nico, motivo por el cual ha merecido la atenci\u00f3n \nde los investigadores que intentaron su s\u00edntesis y elucidaci\u00f3n estr uctural, estudio que ha \npermitido la identificaci\u00f3n de otros miembros de la serie as\u00ed como su potencialidad terap\u00e9utica. \nDebido a la escasa abundancia natural de este tipo de compuestos la s\u00edntesis \nqu\u00edmica, ya sea s\u00edntesis total o semis\u00edntesis, es necesaria para que este tipo de compuestos y sus derivados puedan ser empleados como f\u00e1rmacos.  \nTanto la complejidad estructural como su importante actividad antitumoral han \nhecho que este esqueleto sea una diana sint \u00e9tica muy atractiva. La s\u00edntesis OO\nOHOMe\nMeO\nOMe\nHO O\nOHOH\nOH\nE-ViniferinaHOOH\nOHOHOOMe\nMeOHOOH\nCONMe2\nOMe\nRocaglamida\n39Introducci\u00f3n                                                                                       5. La Rocaglamida \n \n40 estereoselectiva del denso patr\u00f3n de sustituci\u00f3n de estas dianas presenta un gran reto \nsint\u00e9tico, ya que esta mol\u00e9cula contiene 5 estereocentros contiguos y grupos arilo en \nposici\u00f3n cis en carbonos adyacentes. En los \u00fatimos  a\u00f1os, tan s\u00f3lo contadas s\u00edntesis \ntotales han sido descritas, poniendo en evidencia las dificultades asociadas con su \ns\u00edntesis. Una de las reacciones que est\u00e1n cobrando gran importancia para la s\u00edntesis de \nla rocaglamida y sus derivado, as\u00ed como su  aplicaci\u00f3n en la s\u00ednt esis de oxac\u00edclos \nderivados de compuestos naturales, tiene como base el empleo de la reacci\u00f3n de \nciclaci\u00f3n  Nazarov,211,212,213. \nLa reacci\u00f3n de ciclaci\u00f3n Nazarov fu e originalmente descubierta por Ivan \nNikolaevich Nazarov en 1949.214 La reacci\u00f3n t\u00edpica de ciclaci\u00f3n de Nazarov es el \nproceso que convierte divinil cetonas tales como I I (Figura 33) en ciclopentenonas I IV y/\u00f3 \nV.215 La reacci\u00f3n est\u00e1 catalizada por \u00e1cidos de Bronsted o de Lewis. El primer \nintermedio que se forma es el cati\u00f3n pentadienilo I II. El conf\u00f3rmero s-trans/s-trans  IIIB \ndel cati\u00f3n da lugar a una electrociclaci\u00f3n 4 \u03c0 conrotatoria permitida \ntermodin\u00e1micamente que da lugar  al cati\u00f3n al\u00edlico c\u00edclico I III como segundo intermedio. \nLa p\u00e9rdida de un prot\u00f3n finaliza la reacci\u00f3n. En ausencia de una corriente de \npolarizaci\u00f3n en I III, el prot\u00f3n se puede eliminar de dos formas, dando lugar a I IV y VV. \n \n \nFigura 33. Mecanismo de la ciclaci\u00f3n de Nazarov.  \n \nEsta reacci\u00f3n ha sido empleada por Frontier y colaboradores como paso clave \npara la s\u00edntesis de (D,L)-rocaglamida, de manera que esta reacci\u00f3n de ciclaci\u00f3n es \ncapaz de formar el esqueleto carbo nado completo de la rocaglamida,216 aunque ha sido \ntambi\u00e9n empleada para la s\u00edntesis de otros compuestos naturales como la (D,L)-\nterpestacina.217 A pesar de que esta reacci\u00f3n supone una excelente herramienta para la \ns\u00edntesis total de compuestos naturales, la presencia de m\u00faltiples estereocentros en el n\u00facleo de ciclopentenona, supone un reto sint\u00e9tico. Por este motivo, el estudio y R1 R4R3R2O\nR1 R4R3R2OH\nR1 R4R3R2O s-transs-trans\nR1R2OH\nR4\nR3s-cis\nH+4\u03c0\nCONOH\nR2\nR3\nR1R4H+\ny/o\nR1 R4R3 R2O\nIIA I IIB III IV V\n40Introducci\u00f3n                                                                                       5. La Rocaglamida  \n \n 41optimizaci\u00f3n de esta reacci\u00f3n de ciclaci\u00f3n que permita contro lar la estereoqu\u00edmica de \nlos estereocentros generados ha supuesto un constante tema de estudio.  \nEn esta Memoria se presentar\u00e1 un estudi o para la optimizaci\u00f3n de la ciclaci\u00f3n \nde Nazarov que permita la uni\u00f3n de dos \u00e1tomos de carbono a trav\u00e9s de un enlace \u03c3  \nde modo que se forme \u00e1tomos de carbono vecinos con todos sus \u00e1tomos de carbono \ncuaternarios y con un buen control de la ester eoqu\u00edmica de la ciclopentenona formada.  \n \n \n \n41Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n42  \n6. Farmacomodulaci\u00f3n \n \n6.1. Hibridaci\u00f3n molecular y terapia multi-diana. \n \nEn base a lo anteriormente mencionado,  y teniendo en cuenta la gran variedad \nde actividades farmacol\u00f3gicas que pueden mostrar los prototipos descritos, es \nimportante considerar el dise\u00f1o de com puestos multi-diana en los que sobre el \nesqueleto cumar\u00ednico se i ncorporan grupos farmac\u00f3foros distintos con objeto de \nobtener estructuras h\u00edbridas. \nLa naturaleza multifactorial de gran n\u00famer o de enfermedades y la resistencia a \nlos f\u00e1rmacos antimicrobianos han motivado la aparici\u00f3n de la metodolog\u00eda multi-diana \nMTDL (multitarget-directed-lig ands) en el descubrimiento de f\u00e1rmacos como una clara \nalternativa a la polifarmacol og\u00eda mediante combinaci \u00f3n de varios f\u00e1rmacos FDC (Fixed \ndose combination). La metodolog\u00eda MTDL permite utilizar una \u00fanica entidad qu\u00edmica \nque pueda actuar sobre varias dianas terap\u00e9uticas. Esta t\u00e9cnica puede tener efectos \nbeneficiosos en varios aspectos farmacol\u00f3gi cos tales como el disminuir problemas \nasociados a dosificaci\u00f3n m\u00faltiple, interacciones medicamentosas, disminuir o retardar la \naparici\u00f3n de resistencias, etc.  \nMediante esta t\u00e9cnica de dise\u00f1o, se han preparado deriva dos de naturaleza \nflavonoide multi-diana que presentan una actividad dual inhibidora de la BACE 1/AChE, o bien MAO/AChE, todos con inter\u00e9s en la terapia de la EA.\n218 En otros casos \nproductos naturales de estructura flavonoide como la linarina muestran actividad \nneuroprotectora debido a su capacidad antioxid ante y a la vez inhibidora de la AChE \n(Figura 17).  \nEn otros casos, nuestro grupo de invest igaci\u00f3n utiliza esta t\u00e9cnica e incrementa \nlas propiedades cardiovascular es de la cumarina mediante la incorporaci\u00f3n del \nesqueleto resveratrol con propiedades tambi\u00e9n tambi\u00e9n cardioprotectoras.237 En el \nmismo campo destacan h\u00edbridos de chal cona, flavona as\u00ed como cumarinas que \nincorporan en su estructura el anillo pirimi d\u00ednico presente en el vasodilatador minoxidilo \n(Figura 34).219,220  \n \n42Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n 43 \nFFigura 34. H\u00edbridos multi-diana con actividad cardiovascular.  \n \nPor su parte, la elevada morbilidad y mo rtalidad originada por la infecciones \nprotozoarias demanda cada vez m\u00e1s nuevas estrategias terap\u00e9uticas, y en este campo \nla terapia multidiana se compite cada vez m\u00e1s con la terapia multif\u00e1rmaco221. Destacan \nentre los compuestos m\u00e1s importantes el h\u00edbrido chalcona-benzoxaborol, farmac\u00f3foros \ncon demostrada actividad frente a Tripanosoma brucei y Trapanosoma cruzi ,222 el \nh\u00edbrido chalcona-cloroquina activo frente a Plasmodium falciparum .223 Finalmente, el \nh\u00edbrido cumarina-PABA eficaz antibacteriano224 o el antiviral h\u00edbrido chalcona-anilida  \ninhibidor dual de la integrasa y del receptor de transmenbrana viral CCR5 (C-C \nquimiocina receptor)239 de son ejemplos que ilustran la aplicaci\u00f3n de la metodolog\u00eda \nmultidiana en el dise\u00f1o de nuevos prototipos (Figura 35).  \n \n  \n \n    \n \nFigura 35. H\u00edbridos multi-diana empleados como antimicrobianos.  O\nH2NMeO\nOBOH\nChalcona/benzoxaborol\nAntitripanosomaO\nO\nChalcona/cloroquina\nAntimalaricoOMe\nMeO\nChalcona/anilida\nAntiviral HIVO\nNHHOO\nOHS\nO OMeO\nMeON\nHCO2HO\nCumarina/PABA\nAntibacterianoNNN\nNClO\nHOOH\nO\nOHOHOH\nIsoprenil- \ufb02avonaO\nHO OOOH\nO\nONO2\nChalcona/nitratoO OOH\nCumarina/resveratrolHOOH\nO\nCumarina/minoxidiloOHN N\nNR\n43Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n44  \n6.2. Bioisosterismo.  \nFue en 1919 cuando Langmuir,225 estudiando el comportamiento qu\u00edmico y la \nreactividad de determinadas sustancias que pose\u00edan \u00e1tomos o grupos con el mismo \nn\u00famero de electrones de valencia, por ejempl o, isoelectr\u00f3nicos, cre\u00f3 el concepto de \nisosterismo para definir \u00e1tomos o mol\u00e9cu las org\u00e1nicas o inorg\u00e1nicas que pose\u00edan el \nmismo n\u00famero y/o la misma distribuci\u00f3n de electrones. A\u00f1os m\u00e1s tarde, en 1932, \nErlenmeyer226 propuso ampliar el t\u00e9rmino isoste rismo, definiendo los is\u00f3steros como \nelementos, mol\u00e9culas o iones que presentaban el mismo n\u00famero de electrones en el \nnivel de valencia. Su contribuci\u00f3n incluye la propuesta de que los elementos de la misma columna de la tabla peri\u00f3dica son is\u00f3s teros entre ellos (por ejemplo, carbono, \nSilicio y Germanio), y la creaci\u00f3n del concep to de anillos electr\u00f3ni camente equivalentes, \nque ser\u00eda posteriormente ampliado al t\u00e9rmino bioisosterismo de anillos.  \nEl t\u00e9rmino bioisosterismo fue acu\u00f1ado po r Friedman y Thornber a principios de \nlos a\u00f1os 50. Friedman introdujo el t\u00e9rmino bioisosterismo para describir el fen\u00f3meno \nobservado entre sustancias relacionad as estructuralmente que presentaban \npropiedades biol\u00f3gicas similares o antag\u00f3nicos.\n227 M\u00e1s tarde, Thornber propuso \nampliar el t\u00e9rmino de biois\u00f3steres, defi ni\u00e9ndolos como subunidades, grupos, o \nmol\u00e9culas que pose\u00edan propiedades fisicoqu\u00edmicas de efectos biol\u00f3gicos similares.228  \nA lo largo de los a\u00f1os, se han identificado innumer ables relaciones \nbioisost\u00e9ricas en compuestos tanto de origen nat ural como sint\u00e9tico.  En la naturaleza, \nse han identificado muchos ejemplos de isosterismo como una manera de ampliar la quimiodiversidad (Figura 36), siendo notables las relaciones bioisost\u00e9ricas cl\u00e1sicas  que \nse encuentran entre los amino\u00e1cidos esenciales serina y ciste\u00edna, o tirosina y ciste\u00edna; \nentre las bases de purina y pirimidina como ci tosina y uracilo, o adenina y guanina; o \nentre los \u00e1cidos salic\u00edlicos y antran\u00edlicos, que originaron dos importantes clases de f\u00e1rmacos antiinflamatorios no esteroideos como el \u00e1cido acetilsalic\u00edlico y los \u00e1cidos \nmefen\u00e1micos, respectivamente.  Adem\u00e1s, tambi\u00e9n podemos encontrar ejemplos en la \nnaturaleza de la aplicaci\u00f3n de bioisosterismo no cl\u00e1sico, tal y como la relaci\u00f3n \nbioisost\u00e9rica exist ente entre el \u00e1cido \u03b3- aminobut\u00edrico (GABA) y el muscimol (Figura 36), \no entre los neurotransmisores glutamato y AMPA. \n \n44Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n 45 \nFFigura 36. Ejemplos de bioisoster ismo cl\u00e1sico y no cl\u00e1sico encontrados en compuestos \nnaturales \n \nPor tanto, el bioisosterismo es una estrategia empleada en qu\u00edmica medicinal \npara el dise\u00f1o racional de nuevos f\u00e1rmacos, aplicada sobre un compuesto l\u00edder (CL) \ncomo un proceso especi al de modificaci\u00f3n.229 El \u00e9xito de esta estrategia para el \ndesarrollo de nuevas sustancias que sean atractivas terap\u00e9uticamente ha experimentado un crecimiento significativo en distintas clases terap\u00e9uticas, siendo HO OHO\nNH2HS OHO\nNH2OHO\nNH2OHO\nNH2HOHN\nN\nserina ciste\u00edna tirosina histidinaBioisosterismo cl\u00e1sico\nN\nN ONH2\nHN\nN OOH\nH\ncitosina uraciloN\nN NN\nHNH2\nadenina guaninaHN\nN NN\nHO\nHN\nN OO\nH\nOHO\nOHOHO\nNH2\n\u00e1cido salic\u00edlico \u00e1cido antran\u00edlico\nBioisosterismo no cl\u00e1sico\nHONH2O\nHONH2N O\nGABA muscimolHO OHO O\nNH2HOO\nNH2 ONOH\nglutamato AMPA\n45Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n46 ampliamente utilizada por la industria fa rmac\u00e9utica para descub rir nuevos an\u00e1logos de \ninnovaciones terap\u00e9uticas comercialmente atr activas, y tambi\u00e9n como una herramienta \nmuy \u00fatil en la modificaci\u00f3n molecular. \nExisten innumerables razones para empl ear el bioisosterismo para dise\u00f1ar \nnuevos f\u00e1rmacos, incluyendo la necesidad de mejorar la actividad biol\u00f3gica , ganar \nselectividad frente a un determinado recepto r o subtipo de isoforma enzim\u00e1tica, o \nincluso para optimizar la farmaco cin\u00e9tica que un CL puede presentar. \n \n6.2.1 Vinilog\u00eda.  \nEl principio de vinilog\u00eda fue formulado por Claisen en 1926230 al observar la \nsimilar acidez de la formil acetona y del \u00e1cido ac\u00e9tico. Hoy d\u00eda, la vinilog\u00eda es explicada \npor el efecto mesom\u00e9rico que puede ser aplicado a otros sist emas conjugados tales \ncomo grupos imino y etin il y sistemas arom\u00e1ticos. \nEste principio tiene importantes aplicaciones en el dise\u00f1o de f\u00e1rmacos si bien \nes de aplicaci\u00f3n cuando la actividad farmacol\u00f3gica dependa de asp ectos electr\u00f3nicos y \nno est\u00e9 determinada por la distancia entre los grupos sobre los que se aplica. \nFrecuentemente, los vin\u00edlogos originados  son m\u00e1s sensibles a la degradaci\u00f3n \nmetab\u00f3lica como ocurre con los vin\u00edlogos de la fenilbutazona231 (Figura 37). Sin \nembargo, en otros casos, como el de la acetilc olina, la formaci\u00f3n de su vin\u00edlogo origina \nun derivado menos sensible a la acci\u00f3n de la acetilcolinesterasa.232 \nPor su parte, la introducci\u00f3n de un an illo benc\u00e9nico en la procainamida xantina \norigina  an\u00e1logos que conservan su actividad anest\u00e9sica local de la misma. \nM\u00e1s relacionado con nuestro trabajo, debemos mencionar que la aplicaci\u00f3n de \nla vinilog\u00eda a la chalcona con actividad inhibi dora sobre la MAO-B, origina un bios\u00f3stero \nque conserva dicha actividad.179  \nAs\u00ed pues y teniendo en cuenta que nuestro tr abajo parte de tres farmac\u00f3foros: \nla estructura de chalcona, el anillo cumar\u00ed nico (su an\u00e1logo c\u00edclic o), y el resveratrol, \nreconocidos compuestos l\u00edder por todo lo  expuesto, emplearemos como punto de \npartida la hibridaci\u00f3n estruct ural cumarina-resveratrol, y posteriormente centraremos el \ntrabajo en los h\u00edbridos cumarina-chalcona. Sobre los prototipos  generados, haremos \n46Introducci\u00f3n                                                                                 6. Farmacomodulaci\u00f3n   \n \n 47uso de la bioisoster\u00eda y vinilog\u00eda para el dise\u00f1o y la s\u00edntesis algunos compuestos que se \npresentan en la presente Memoria. \n \n   \n \n      \n \n  \nFigura 37. Principio de vinilog\u00eda aplicada al dise\u00f1o de nuevos f\u00e1rmacos. H2NN\nHNEt2O\nProcainamidaH2NNHO\nBenz\u00f3logoNEt2N\nNOH\nOnButN\nNOH\nOnBut\nFenilbutazonaEstirilbutazona\nAcci\u00f3n mas corta\nOO\nNO\nO\nACh Resistente a la AChENO\nCl OH MeOO\nOH MeO Cl\nChalcona Vinil chalcona\n47 \n \n \n Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez   \n \n 49 \u0002\u0019\u001e\u0011\u000f\u0011\u0010\u0011\u0019\u001e\u0011\u001d\u0001#\u0001\u001a\u000e\u0015\u0011\u001e\u0014 \u001a\u001d \u0001\n\u0003\r\u000f\u0016\u0013\u001c\u001a\u001f\u0019\u0010\u0001\r\u0019\u0010\u0001\r\u0014\u0018\u001d\u0001\n \n  \n \n   \n1. Antecedentes 5\n51 \n2. Objetivos 553 \n \n \n49 \n \n  \n Antecedentes y objetivos                                                                        1. Antecedentes  \n \n51 \u0001\n\u0001\n1. Antecedentes \n \nDesde hace tiempo, nuestro grupo de investigaci\u00f3n ha estado trabajando en el \ncampo de las cumarinas, no s\u00f3lo buscando nuevas metodolog\u00edas sint\u00e9ticas e \nintentando optimizar sus efectos vasodilatadores y/o cardioprotectores, sino tambi\u00e9n \ncon el fin de encontrar nuevas aplicaciones en el campo de la qu\u00edmica m\u00e9dicinal. Por \ntanto, el estudio del esqueleto cumar\u00ednico94,82,233, y sus modificaciones estructurales \ndirigidas a diferentes actividades farmacol\u00f3gicas234 , 235 , 236 ha sido una l\u00ednea de \ninvestigaci\u00f3n en la que hemos profundizado am pliamente, y en la que se han realizado \nrevisiones recientes.16,17 \nEn los \u00faltimos tiempos, nuestro grupo de investigaci\u00f3n de ha centrado en la \npreparaci\u00f3n de compuestos h\u00ed bridos cumarina-resveratro l (3-arilcumarinas) en los \ncuales el anillo cumar\u00ednico comparte el an illo benc\u00e9nico y el doble enlace de la pirona, \ncon el resveratrol, de modo que el resveratrol queda fijado como is\u00f3mero trans  (Figura \n38). 237 Los estudios de actividad de estos prototipos llevados a cabo por el grupo de \nFarmacolog\u00eda de la Facultad de Farmacia de la Universidad de Santiago de Compostela, con el que mantenemos una estrecha colaboraci\u00f3n, han demostrado que \npresentan una muy buena actividad vasodilata dora e inhibidora de  la agregaci\u00f3n \nplaquetaria.\n238 \n \nFFigura 38. Compuestos h\u00edbtridos cumarina-resvera trol sintetizados en nuestro laboratorio.  \n \nEstudios m\u00e1s recientes han revelado adem\u00e1s que estos prototipos muestran \nuna gran actividad como inhibidores de monoamino oxidasa (MAO)111,239 presentando \nadem\u00e1s una elevada selectividad por la isoenzima MAO-B, lo que permite que sean O OOH\nOHHOcumarina resveratrol\nO ORR\nh\u00edbridos cumarina-resveratrol\n51Antededentes y objetivos                                                                       1. Antecedentes  \n \n52 considerados como nuevos prot otipos estructurales  en el dise\u00f1o de nuevos inhibidores \nenzim\u00e1ticos. Adem\u00e1s, la reciente obtenci\u00f3n de una patente por parte de nuestro grupo \nde investigaci\u00f3n240 en la que se reivindica su utilidad en enfermedades \nneurodegenerativas tales como Parkinson o Alzheimer, corrobora una vez m\u00e1s el \ninter\u00e9s farmacol\u00f3gico de estos cabeza de serie. \nAdem\u00e1s de los resultados mencionados, nuestro grupo de investigaci\u00f3n ha \nelaborado una base de datos con la activid ad iMAO experiment al de m\u00e1s de mil \ncompuestos que ha permitido desarrollar un modelo QSAR235, 236 capaz de predecir con \nalta eficacia la actividad iMAO de nuevas mol\u00e9culas. Los estudios previos de relaci\u00f3n \nestructura-actividad ( SAR, por sus siglas en ingl\u00e9s) que se han llevado a cabo sobre las \n3-arilcumarinas, han permitido concluir que la posici\u00f3n para sustituida result\u00f3 ser la m\u00e1s \nfavorable para una buena actividad iMAO, pero sobre todo, result\u00f3 ser crucial para la \nselectividad sobre MAO-B, mientras que los orto derivados presentan una menor \nactividad que sus correspondientes is\u00f3meros meta  y para. \nIs\u00f3steros de cumarinas como pueden ser las cromonas y sus derivados \nflavonoides, han estado ampliamente asociad os a propiedades antioxidantes. En la \n(Figura 39) se muestran las estructuras de quercetina y catequina, que nos han servido \ncomo inspiraci\u00f3n para el dise\u00f1o de nuevos compuestos y el estudio de propiedades \nantioxidantes. \n \n    \n \nFigura 39. Antioxidantes asociados a estructuras flavonoides. \n \n \n OO\nOHOHOHOH\nHO\nquercetinaO\nOHOHOHOH\nHO\ncatequina\n52Antecedentes y objetivos                                                                               2. Objetivos  \n \n53 2. Objetivos \n \nTomando como punto de partida el descubrimiento de la actividad iMAO de las \n3-arilcumarinas, y teniendo en cuenta los result ados obtenidos y la amplia experiencia \nde nuestro grupo de investigaci\u00f3n en el campo de los an\u00e1logos cumar\u00ednicos, \ninicialmente se plante\u00f3 ampliar la serie de 3-arilcumarinas trabaj ando de forma conjunta \ncon la Dra. Maria Matos, qu ien obtuvo resultados muy prom etedores y que se recogen \nen su Tesis Doctoral.241 Posteriormente, se plante\u00f3 el dise\u00f1o, la s\u00edntesis y el estudio de \ncompuestos h\u00edbridos en los que se incluyese en lugar del resveratrol, otro compuesto de origen natural, una de las \u201cestructuras privilegiadas\u201d que Evans defini\u00f3: las \nchalconas. De este modo, los esqueletos de cumarina y chalcona estar\u00edan incluidos en \nla misma estructura, de forma paralela a lo s h\u00edbridos cumarina-resveratrol (Figura 40). \n  \n      \n \n \nFFigura 40.  Dise\u00f1o de h\u00edbridos cumarina- resveratrol y cumarina-chalcona  \n \nAunque inicialmente se plante\u00f3 el dise\u00f1o y la s\u00edntesis de h\u00edbridos cumarina-\nchalcona de tipo 3-benzoilcumari na, la versatilidad estructural  de ambos esqueletos de \nnos permite dise\u00f1ar diversos tipos estructurales de h\u00edbridos. El desarrollo de esta \nMemoria se centrar\u00e1 en aquellos h\u00edbridos en los que realizando sustituciones en las O OOH\nOHHO\ncumarinaresveratrol\nO OO\nO OO\nh\u00edbrido cumarina-chalconachalcona\nh\u00edbrido cumarina-resveratrolO\n53Antecedentes y objetivos                                                                               2. Objetivos  \n \n54 posiciones 3 y 8 del n\u00facleo cumar\u00ednico podamos obtener las diferentes mol\u00e9culas \nh\u00edbridas cumarina-chalcona y en las que aplicarem os el principio de vinilog\u00eda (Figura 41). \n \n \nFFigura 41.  Prototipos estructural es de h\u00edbridos cumari na-chalcona dise\u00f1ados.  \n \nLos derivados de la Figura 41 que denominamos \u201cendo\u201d cumarina-chalconas, \ncontienen el doble enlace de la  chalcona en la posici\u00f3n 3,4 del anillo cumar\u00ednico, \nquedando englobada dicha estructura en el  mismo y fijando as\u00ed la isomer\u00eda trans . Por \notro lado, la introducci\u00f3n del grupo \u201cvinilic o\u201d a ambos lados del grupo carbonilo \nexoc\u00edclico origina los h\u00edbridos denomina dos \u201cexo\u201d cumarina-chalconas, que presentan \nun mayor grado de libertad tanto confor macional como de posible isomer\u00eda cis/trans, ya \nque ambos farmac\u00f3foros comparten \u00fanicamente un anillo arom\u00e1tico, ya sea el de la \npirona en el caso de las cumari nas 3-sustitu\u00eddas, o bien un anillo benc\u00e9nico en el caso \nde las cumarinas 8-sustitu\u00eddas. \nSe plantea el desarrollo de procedimientos sint\u00e9ticos sencillos, directos, \neficientes y vers\u00e1tiles que nos permitan acceder  a este tipo de estructuras en la pureza \ny cantidad suficiente para realizar los ensayos farmacol\u00f3gicos frente a diferentes dianas. \nAdem\u00e1s, estas rutas sint\u00e9ticas deben permitirnos introducir sustituyentes de diferente \nnaturaleza en distinto n\u00famero y posici\u00f3n, de modo que se puedan suplir las m\u00faltiples \ncombinaciones de variabilidad es t\u00e9rica, electr\u00f3ni ca y/o lipof\u00edlica. \nInicialmente, se estudiar\u00e1 el efecto que pudiese presentar la introducci\u00f3n de un \ngrupo carbonilo puente entre la cumarina y el grupo fenilo de las 3-fenilcumarinas \n(Figura 40), o h\u00edbridos cumarina-resveratro l, sobre la actividad  farmacol\u00f3gica iMAO \nobservada en los prototipos previos. Sin embargo, ser\u00eda tambi \u00e9n un objetivo constante \nla b\u00fasqueda de nuevas dianas farmacol\u00f3gicas as\u00ed como el an\u00e1lisis de propiedades con O OO\nRR\nO ORRO\nO OR\nR\nO\nO OO\nR\nR\n\"Exo\" chalconas \"Exo\" vinilchalconas \"Exo\" vinilchalconas\n\"exo\" cumarina-chalconas\"endo\" cumarina-chalcona\n54Antecedentes y objetivos                                                                               2. Objetivos  \n \n55 posible aplicaci\u00f3n terap\u00e9utica. De este modo,  entre otros objetivos farmacol\u00f3gicos, se \npens\u00f3 en explorar actividades quimioter\u00e1 picas de diferente tipo (antibacteriana y \nantiparasitaria), la interacci\u00f3n con receptore s como los de adenosina y las propiedades \nantioxidantes, entre otras. \nAdem\u00e1s de la s\u00edntesis y el estudio de la actividad biol\u00f3gica de los compuestos \nsintetizados, o de series seleccionadas de lo s mismos, se intentar\u00e1 realizar un posterior \ndise\u00f1o racional de nuevas series de compuestos, ayud\u00e1ndonos cuando fuese \nnecesario, de herramientas computacionales  como QSAR o modelizaci\u00f3n molecular.. \nDe este modo, los objetivos anteriorme nte mencionados podr\u00edan resumirse en un \nproceso c\u00edclico de s\u00edntesis, actividad bi ol\u00f3gica y dise\u00f1o raci onal (Figura 42). \n \n \n     \nFFigura 42. Esquema de trabajo empleado para el di se\u00f1o racional, s\u00edntesis y estudio de los \nobjetivos planteados. \n \nPor \u00faltimo, y dado el inter\u00e9s del grupo en la s\u00edntesis de compuestos oxac\u00edclicos \ninspirados en productos naturales, se plante\u00f3 el objetivo de desarrollar nuevas \nmetodolog\u00edas sint\u00e9ticas basadas en la reacci\u00f3n de ciclaci\u00f3n de Nazarov para la \nobtenci\u00f3n de compuestos derivados de pr oductos naturales como la rocaglamida. \n \n \n\u000b$\u0019\u001e\u0011\u001d\u0014\u001d\u0001\n\u0002\u000f\u001e\u0014 \u0014\u0010\r\u0010\u0001\n\u0003\u0014\u001a\u0017'\u0013\u0014\u000f\r\u0001\n\u0005\u0014\u001d\u0011&\u001a\u0001\n\n\r\u000f\u0014\u001a\u0019\r\u0017\u0001\n55 \n \n Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n57 \n\u0011\u001d\u001f\u0017\u001e\r\u0010\u001a\u001d\u0001#\u0001\u0010\u0014\u001d\u000f\u001f\u001d\u0014'\u0019\u0001\n\n\u0011\u001d\u001f\u0017\u001e\u001d\u0001\r\u0019\u0010\u0001\u0010\u0014\u001d\u000f\u001f\u001d\u001d\u0014\u001a\u0019\u0001\n\u0001\n1. Generalidades 559 \n2. Estrategia sint\u00e9tica 660 \n       2.1. S\u00edntesis de 3-arilcumarinas 660 \n       2.2. S\u00edntesis de \u201cendo\u201d cumarina-chalconas 661 \n          2.2.1. S\u00ednt esis de 3-benzoilcumarinas 6 62 \n          2.2.2. S\u00edntesis de 3-benzoil-4-hidroxicumarinas 6 64 \n       2.3. S\u00edntesis de \u201cexo\u201d cumarina-chalconas 664 \n           2.3.1. S\u00ed ntesis de 3-cinam oilcumarinas 6 65 \n           2.3.2. S\u00edntesi s de 3-cinamoil-4-hidroxicumarinas 6 66 \n           2.3.3. S\u00edntesis de 3-(3-aril-3-oxo-propenil)-4-clorocumarinas 667 \n           2.3.4. S\u00ed ntesis de 8-cinamoilcumarinas 6 68 \n       2.4. Optimizaci\u00f3n de la reacci\u00f3n de Nazarov: aplicaciones  \n              en la s\u00edntesis de productos naturales oxac\u00edclicos. 669 \n       2.5. Series de compuestos sintetizados 771 \n3. Estudios Biol\u00f3gicos 887 \n       3.1. Estudio como inhibidores de MAO 887 \n       3.2. Estudio de las propiedades antioxidantes 889 \n       3.3. Estudio de la actividad tripanocida 990 \n       3.4. Estudio como ligandos de receptores de adenosina 990 \n       3.5. Estudio de la actividad antibacteriana 991 \n \n57 \n \n Resultados y discusi\u00f3n                                                                          1. Generalidades  \n \n59  \n1. Generalidades \n \nEn el trabajo que a continuaci\u00f3n se pr esenta en esta Memoria se incluye la \ndescripci\u00f3n de las metodolog\u00edas sint\u00e9ticas empleadas para la preparaci\u00f3n de series de \ncompuestos seleccionadas, su correspondiente purificaci\u00f3n y caracterizaci\u00f3n \nestructural, la evaluaci\u00f3n bi ol\u00f3gica frente a dife rentes dianas farmacol\u00f3gicas y estudios \nde modelizaci\u00f3n molecular. Dado el car\u00e1cter multidisciplinar que supone trabajar en el \ncampo de la qu\u00edmica farmac\u00e9utica, es importa nte mencionar que muchos estudios aqu\u00ed \npresentados han sido fruto de incesantes e interesantes co laboraciones con diversos \ngrupos de investigaci\u00f3n tanto nacionales como internacionales.  \nEn la Universidad de Santiago de Compostela, los estudios de iMAO han sido \nrealizados por la Profesora Dolores Vi\u00f1a, y los ensayos de la actividad antibacteriana \nhan sido realizados por las Profesoras Ysabel Santos y \u00c1ngeles Mu\u00f1oz. En la \nUniversidad de Santiago de Chile se han llevado a cabo los estudios de la actividad y propiedades antioxidantes a car go del Profesor Claudio Olea-Azar, y los estudios de la \nactividad antitripanocida, por el grupo del profesor Juan Di ego Maya. Los estudios de \ncitotoxicidad y citoprotecci\u00f3n han sido realiz ados por el grupo del Profesor Frederick \nVillamena, de la Ohio State University. En la Universidad de Wurzb\u00fcrg se han realizado \nlos estudios de interacci\u00f3n con receptores de  adenosina, en colaboraci\u00f3n con el grupo \ndel Profesor Karl-Norbert Klot z. En la University of Ha wai\u2019i at Manoa en colaboraci\u00f3n \ncon el grupo del Profesor Ma rcus Tius se ha llevado a cabo el desarrollo y optimizaci\u00f3n \nde metodolog\u00edas sint\u00e9ticas empleando la reacci \u00f3n de Nazarov para la aplicaci\u00f3n en la \npreparaci\u00f3n de compuestos oxac\u00edclicos basados en productos naturales como los derivados de la rocaglamida. Y por \u00faltimo, los estudios de docking  han sido realizados \npor Giulio Ferino y Santiago Vilar. Sin todas estas colaboraciones, este trabajo no \nhubiese sido posible. \nLa versatilidad de las diferentes v\u00edas sint\u00e9ticas nos ha permitido obtener \namplias series de derivados , muchos de los cuales han sido posteriormente estudiados \nfrente a diversas dianas farmacol\u00f3gicas y que nos han permitido establecer interesantes \nrelaciones de estructura y actividad (SAR) y que nos permiten un dise\u00f1o racional de \nnuevos f\u00e1rmacos basados en las estructuras de los receptores y en las estructuras de \nlos ligandos de los mismos. \n59Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n60  \n2. Estrategia Sint\u00e9tica \n\u0001\nPara la consecuci\u00f3n de los objetivos si nt\u00e9ticos anteriormente expuestos, ha \nsido necesario estudiar la metodolog\u00eda sint\u00e9tica que resultar\u00eda m\u00e1s apropiada para la \nobtenci\u00f3n de los distintos tipos de esqueletos planteados. Estos procedimientos, tal y \ncomo es preceptivo en estos primeros estudi os de dise\u00f1o de nuevos prototipos, deben \nser sencillos, directos, r\u00e1pidos, eficientes y de gran versatilidad. Hemos buscado las rutas sint\u00e9ticas m\u00e1s r\u00e1pidas y cuyos react ivos, preferentemente de bajo coste, se \nadaptaban mejor a nuestras necesidades. Las reacciones m\u00e1s empleadas se describen brevemente a continuaci\u00f3n, y la descripci\u00f3n se realizar\u00e1 en funci\u00f3n del tipo de \nesqueleto h\u00edbri do a preparar. \nCon el objetivo de dis poner de una amplia quimioteca de compuestos que \nfacilite la exploraci\u00f3n de las relaciones estructura-actividad, as\u00ed como el establecimiento de comparaciones con derivados afines previamente obt enidos en nuestro laboratorio, \nse han preparado series de compuestos en cuy a estructura general, para el caso de los \nh\u00edbridos m\u00e1s ampliamente estudiados en esta memoria (h\u00edbridos cumarina-chalcona), \ntendremos tres puntos de variabilidad: el an illo benc\u00e9nico de la cumarina, y los anillos \narom\u00e1ticos A y B de la chalcona. \n2.1. S\u00edntesis de 3-arilcumarinas. \nLas 3-arilcumarinas, o h\u00edbr idos cumarina-resveratrol,  han sido las primeras \nestructuras que han sido objet o de nuestro estudio dada la prometedora actividad \nencontrada como inhibi dores de la MAO. Se ampli\u00f3 la  serie de 3-arilcumarinas que \nestaba siendo sintetizada por la Dra. Maria Matos, quien puso a punto las metodolog\u00edas \nsint\u00e9ticas desarrolladas. Las reacciones emplead as para la s\u00edntesis de los distintos \nderivados fueron la reacci\u00f3n de Perkin,242,243 la reacci\u00f3n de Perkin modificada244 y la \nreacci\u00f3n de Suzuki245 (Figura 43) y se encuentran amplia y detalladamente descritas en \nla Tesis Doctoral de la Dra. Maria Matos.241 \n \n \n60Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n61  \n \n \n     \n \nFFigura 43. Rutas sint\u00e9ticas empleadas para la s\u00edntesis de 3-arilcumarinas.  \n \n2.2. S\u00edntesis de \u201cendo\u201d cumarina-chalconas. \nLas \u201cendo\u201d cumarina-chalconas fueron l as siguientes estructuras que han sido \nobjeto de nuestro estudio dada su relaci\u00f3n estructural con las 3-arilcumarinas \npreviamente sintetizadas en nuestro labo ratorio como ya se ha comentado en el \napartado de antecedentes. En el dise\u00f1o de estas estructuras, hemos tenido en cuenta que la sustituci\u00f3n sobre el anillo de cumarina se realizar\u00eda en la posici\u00f3n 3. \nIncorporar\u00edamos un grupo be nzo\u00edlico en dicha posici\u00f3n, de  modo que en la estructura \nfinal, el anillo B de la chalcona corr esponder\u00eda al anillo benc\u00e9nico del n\u00facleo de \ncumarina, mientras que el anillo A se encontrar\u00ed a como grupo benzoilo en la posici\u00f3n 3. \nDe este modo, la configuraci\u00f3n trans  de la chalcona quedar\u00eda fijada a trav\u00e9s del enlace \n\u03b1,\u03b2-insaturado del anillo de pirona (Figura 44). \n O OR'\nRHO\nO OHHO\nRR'\nDCC, DMSO\n110 \u00baC, 24hPerkin\nNaH, Ac2OPerkin modi \ufb01cada\nHO\nO OHHO\nRR'\nPd(OAc)2-salen\nNa2CO3, DMF/H2O (1:1)\n110\u00baC, 4hSuzuki\nO OX(HO)2B\nR't.a., 3h\nRR \u00f3 R' = NO2\n61Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n62  \nFFigura 44. Dise\u00f1o de h\u00edbridos 3- endo cumarina-chalcona.  \n \n2.2.1. S\u00edntesis de 3-benzoilcumarinas. \nLas 3-benzoilcumarinas han sido las pr imeras estructuras que nos hemos \nplanteado dise\u00f1ar. La etapa clave para la obtenci\u00f3n de este tipo de compuestos tiene \ncomo base la reacci\u00f3n de Knoevenagel44 entre un salicilaldeh\u00eddo y un \u03b2-cetoester \narom\u00e1tico. La reacci\u00f3n puede llevarse a ca bo en medio \u00e1cido o b\u00e1sico, pero en este \ncaso las reacciones fueron llevadas a cabo en medio b\u00e1sico sigu iendo la literatura.246,91 \nDada la sencillez y la versatilidad de esta reacci\u00f3n, hemos podido obtener una amplia \nfamilia de compuestos con rendimientos sati sfactorios de entre el  42 y el 98%, siendo \nlos derivados que conten\u00edan anillos heteroarom\u00e1ticos aquellos que presentaron un \nmenor rendimiento (Figura 45). \n \n   \nFigura 45. Esquema de reacci\u00f3n para la s\u00ed ntesis de 3-benzoilcumarinas.  \n Esta s\u00edntesis v\u00eda reacci\u00f3n de Knoevenagel ha sido llevada a cabo en etanol y en \npresencia de piperidina, dejando la reacci\u00f3n a reflujo de  2 a 8 horas, dependiendo del \ntipo de derivado sintetizado. S\u00f3lo en el  caso de los derivados que conten\u00edan grupos \nhidroxilo y/o grupos amino, fue necesar ia la s\u00edntesis de los precursores \netoxi/metoxilados y/o con grupos nitro que fueron posteriormente derivatizados \nmediante procesos de hidr\u00f3lisis y/o reducci\u00f3n. La purificaci\u00f3n de todos los compuestos CHO\nOHEtO Ar/HetO O\nO OAr/HetO\nR REtOH, piperidina\nre\ufb02ujo, 2-8h+\n32-98%O Osustituci\u00f3n en 3O\nA BO\nA B\nO O\n\"endo\" cumarina-chalcona\n62Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n63 finales se realiz\u00f3 bien mediante cromat ograf\u00eda en columna o bien mediante \nrecristalizaci\u00f3n. \nLa s\u00edntesis de los derivados hidroxilados se llev\u00f3 a cabo en condiciones \ndr\u00e1sticas, tratando los \u00e9teres precursores con BBr3 en diclorometano (DCM) durante 48 \nhoras a 80 \u00baC. En el caso de los derivados  amino, los compuestos h\u00edbridos precursores \ncon grupos nitro fueron tratados con cloruro de esta\u00f1o  dihidrato (SnCl2.2H2O) en etanol \na reflujo durante 3-7 h (Figura 46). \n \n   \n \nFigura 46. S\u00edntesis de hidroxi/am ino-3-benzoilcumarinas.  \n \nLa caracterizaci\u00f3n de todos los compuestos obtenidos se ha realizado \nmediante resonancia magn\u00e9tica nuclear (NMR, por sus siglas en ingl\u00e9s) tanto de prot\u00f3n \ncomo de carbono, por espectrometr\u00eda de masas, an\u00e1lisis elemental y puntos de fusi\u00f3n. \nLa identificaci\u00f3n estructural de este tipo de  compuestos resulta bastante clara debido a \nlas se\u00f1ales caracter\u00edsticas del anillo cumar\u00ednico. \nSe realiz\u00f3 tambi\u00e9n un estudio estruct ural mediante Rayo s X de una cumarina \nseleccionada de esta serie de compuestos (compuesto 1 16, Tabla 1). De este modo el \nan\u00e1lisis de este compuesto nos ayuda a contri buir a la elucidaci\u00f3n de los requisitos \nestructurales necesarios para entender la planaridad parcial del n\u00facleo de cumarina en \neste tipo de compuestos, y la torsi\u00f3n del grupo 3-benzoilo respecto a este n\u00facleo.247 \n \n  \n O OO\nRO OR\nO OO\nHO OH\nO OO\nO2N NO2\nO OO\nH2N NH2BBr3, DCM\n80 \u00baC, 48h\nSnCl2, EtOH\nre\ufb02ujo, 2-7h\n63Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n64 2.2.2. S\u00edntesis de 3-benzoil-4-hidroxicumarinas. \nLa presencia en la posici\u00f3n 4 del anillo de  la cumarina de un grupo hidroxilo \nhace que el planteamiento sint\u00e9tico var\u00ede re specto de las 3-benzoilcumarinas no \nsustituidas en esta posici\u00f3n. Para la s\u00edntesis  de este tipo de derivados, se sigui\u00f3 una \nruta de dos etapas: una primera etapa en la  que generamos el \u00e9ster arom\u00e1tico en la \nposici\u00f3n 4, y una segunda etapa en la q ue, mediante una transposici\u00f3n de Fries, \ndejamos el hidroxilo libre en la posici\u00f3n 4 y el grupo benzoilo se transpone a la posici\u00f3n \n3 de la cumarina (Figura 47) \n \nFigura 47. S\u00edntesis de 3-benzoil -4-hidroxicumarinas. \n \nPara la s\u00edntesis del \u00e9ster, se trata la 4- hidroxicumarina propiamente sustituida \ncon el correspondiente clor uro de \u00e1cido en dicloromet ano a 0 \u00baC en presencia de \ntrietilamina (Et3N) durante un periodo de entre 1 y 4 horas.248 La reacci\u00f3n transcurre en \nla mayor\u00eda de los casos con rendimientos casi cuantitativos. En la segunda etapa, el \u00e9ster obtenido se trata con tric loruro de aluminio (AlCl\n3), preparando una mezcla \ntriturada de ambos reactivos, y la reacci\u00f3n transcurre a 160 \u00baC durante un tiempo de entre 2 y 4 horas en ausencia de disolvente.\n249 Los rendimientos globales para la \nobtenci\u00f3n de los compuestos finales, teniendo en cuenta ambas etapas, oscilan entre un 42 y un 93%. \n \n2.3. S\u00edntesis de \u201cexo\u201d cumarina-chalconas\u201d. \nEl siguiente objetivo sint\u00e9tico que nos planteamos fue la preparaci\u00f3n de \nh\u00edbridos cumarina-chalcona \u201cexo\u201d, que como  ya se ha comentado anteriormente en el \napartado de objetivos, supon\u00eda otorgar una mayo r grado de libertar conformacional a la \nmol\u00e9cula. Estudiamos las posiciones 3 y 8 de la cumarina para la incorporaci\u00f3n del \nn\u00facleo de chalcona. De este modo, nos plant eamos preparar 3 tipos de derivados \n\u201cexo\u201d: una clase de 8-exo(cumarina-chalco nas), y dos clases de 3-exo(cumarina-\nchalconas) (Figura 48).  O OOH\nR\nO OO\nR\nO OOH\nRAr/HetO\nAr/HetO\nAr/Het ClO\n+Et3N, DCM\n0 \u00baC, 1-4h AlCl3\n160 \u00baC, 2-4h\n64Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n65  \nFFigura 48.  Dise\u00f1o de h\u00edbridos cumar ina-chalcona tipo \u201cexo\u201d. \n \nSe estudi\u00f3 primeramente la sustituci\u00f3n en la posici\u00f3n 3 del esqueleto \ncumar\u00ednico en la que realizar\u00edamos la sustituci\u00f3n bien del anillo benz\u00edlico A, o bien del \nanillo benz\u00edlico B de la chalcona, por el anillo  de pirona de la cumarina. Posteriores \nmodificaciones llevar\u00edan a la sustituci\u00f3n bioisost\u00e9r ica de ambos anillos benz\u00edlicos por \nanillos heteroarom\u00e1ticos. En el caso de las  8-exo(cumarina-chalco nas), se conservar\u00eda \nla estructura cl\u00e1sica de chalco na, y s\u00f3lo se har\u00edan modificaci ones en el anillo B de la \nchalcona por anillos heteroarom\u00e1 ticos en casos puntuales.  \nCabe destacar que en pr\u00e1cticamente la to talidad de los derivados preparados, \nlos is\u00f3meros obtenidos para este tipo de co mpuestos h\u00edbridos han sido los is\u00f3meros \ntrans . \n \n2.3.1. S\u00edntesis de 3-cinamoilcumarinas. \nLa s\u00edntesis de 3-cinamoilcumarinas se ha llevado a cabo siguiendo una ruta en \ndos etapas en la que el primer paso con lleva la preparaci\u00f3n de 3-acetilcumarinas \npropiamente sustituidas, seguida de la s\u00ednt esis de los compuestos finales mediante una \nreacci\u00f3n de Claisen-Schmidt como se muestra en la Figura 49. \n \n O OO\nO\nA BA BO Osustituci\u00f3n en 3\ncambio de fenilo \npor pirona\nO OB AO O O\nOsustituci\u00f3n en 8\nA\nB\nDerivados 8-exo(cumarina-chalcona) Derivados 3-exo(cumarina-chalcona)\n65Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n66  \nFigura 49. S\u00edntesis de derivados 3-cinamoilcumarina.  \n \nPara la s\u00edntesis de las 3-acetilcumarinas sustituidas se emple\u00f3 la reacci\u00f3n de \nKnoevenagel en la que se trataron el correspondiente salicilaldeh\u00eddo propiamente \nsustituido y el acetoacetato de etilo con piperidina a te mperatura ambi ente durante 30 \nminutos en ausencia de disolvente.59 Se obtuvieton as\u00ed las 3-acetilcumarinas con \nexcelentes rendimientos (entre 78 y 94%). A continuaci\u00f3n , las 3-acetilcumarinas se \nmezclaron con los benzaldeh\u00eddos apropiados y se trataron con piperidina en etanol a reflujo durante 4-12 horas,\n250 lo que dio lugar a las 3-cinamoilcumarinas deseadas con \nrendimientos (entre 58 y 91%). \n \n2.3.2. S\u00edntesis de 3-cinamoil-4-hidroxicumarinas.  \nAl igual que en el caso de las 3-benzoi l-4-hidroxicumarinas , cuando se plante\u00f3 \nla s\u00edntesis de las 3-cinamoil- 4-hidroxicumarinas, hubo que recurrir a una ruta sint\u00e9tica \nalternativa respecto de las 3- cinamoilcumarinas. Esta ruta  tambi\u00e9n constar\u00eda de dos \netapas. Una primera etapa en la que en l ugar de preparar me diante reacci\u00f3n de \nKnoevenagel las 3-acetilcumarinas , empleamos 4-hidroxicumarinas sustituidas que \ndar\u00edan lugar a las correspondientes 3-acetil -4-hidroxicumarinas, y una segunda etapa \nen la que sobre las 3-acetil-4-hidroxicumar inas emplear\u00edamos la  misma reacci\u00f3n de \nClaisen-Schmidt que la utilizada en la segunda etapa de la s\u00edntesis de 3-\ncinamoilcumarinas (Figura 50). \n \nFigura 50. Ruta sint\u00e9tica para la preparaci\u00f3n de 3-cinamoil-4- hidroxicumarinas  CHO\nOHR\nEtOO O\nR\nO OO\nR\nO OO\nAr/Het+piperidina\nt.a., 30 minpiperidina, EtOH\nre\ufb02ujo, 4-12hAr/Het HO\nR\nO OOH\nR\nO OOH O\nR\nO OO\nAr/Het piperidina, EtOH\nre\ufb02ujo, 4-12hAr/Het HO\nPOCl3, Ac2O\nre\ufb02ujo, 30 minOH\n66Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n67 Para preparar las 3-acetil-4-hidroxicumari nas se trataron las 4-hidroxicumarinas \nsustituidas con oxicloruro de f\u00f3sforo (POCl3) en \u00e1cido ac\u00e9tico glacial (Ac2O) a reflujo \ndurante 30 minutos,251 con rendimientos del 72 al 93% . La \u00faltima etapa del proceso \nsint\u00e9tico para este tipo de estructuras correspondi\u00f3 a la condensaci\u00f3n de Claisen-\nSchmidt mencionada previam ente en la s\u00edntesis de 3-cinamoilcumarinas, con \nrendimientos que oscilan entre 52 y 97 %. \n \n2.3.3. S\u00edntesis de 3-(3-aril-3-oxo-propernil)-4-clorocumarinas.  \nPara la preparaci\u00f3n de 3-(3-aril-3- oxo-propenil)-4-clorocumarinas se ha \nempleado la reacci\u00f3n de Wittig, ampliamente utilizada para la s\u00edntesis de alquenos o \ncompuestos \u03b1,\u03b2-insaturados, y en la que reaccionan un aldeh\u00eddo o una cetona, con un \niluro de f\u00f3sforo. La s\u00edntesis de los compuestos finales consta de dos etapas: una \nprimera etapa en la que se prepara el  iluro de f\u00f3sforo a partir de una \u03b1-haloarilcetona, y \nuna segunda etapa en la que se produce el acopla miento entre el iluro de f\u00f3sforo y la 3-\nformilcumarina para formar el oxafosfet ano intermedio que se rompe liberando el \nalqueno final (Figura 51). \n \nFigura 51. S\u00edntesis de 3-(3-aril-3-oxo- propenil)-4-clorocumarinas.  \n \nPara sintetizar el iluro precursor, se disolvieron la \u03b1-haloarilcetona y la \ntrifenilfosfina (PPh3) en diclorometano y la reacci\u00f3n se dej\u00f3 bajo agitaci\u00f3n en atm\u00f3sfera \nde arg\u00f3n entre 12 y 24 horas.252 Tras la elaboraci\u00f3n y purificaci\u00f3n, se obtuvieron los \niluros con rendimientos cuantitativos. A cont inuaci\u00f3n, el iluro obtenido se mezcl\u00f3 con la \n3-formil-4-clorocumarina pr opiamente sustituida en pres encia de met\u00f3xido s\u00f3dico \n(NaOMe) en tolueno, y la mezcla resultante se dej\u00f3 a 80 \u00baC durante 12-18 horas.253 El \ncompuesto final fue aislado y purificado con rendimientos  de entre el 61 y el 83%. \n R\nO OCl\nHO\nBrO\nRPPh3O\nR PPh3+Br\nDCM\nt.a., 12-24 hNaOMe, tolueno\n80\u00baC, 12-18hR\nO OCl O\nR\n67Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n68 2.3.4. S\u00edntesis de 8-cinamoilcumarinas.  \nSe decidi\u00f3 ampliar la versatilidad es tructural del n\u00facleo de cumarina a la \nsustituci\u00f3n en la posici\u00f3n 8 con el fin de introducir la estructura de chalcona en esta \nposici\u00f3n, de modo que el anillo A de la chalcona permanecer\u00eda integrado dentro del \nesqueleto cumar\u00ednico, ya que se comparti r\u00eda el anillo benc\u00e9nico de dicha estructura, \nmientras que el anillo B del esqueleto de  chalcona permanecer\u00eda como anillo benc\u00e9nico \no bien como un anillo heteroarom\u00e1tico.  \nPreparamos inicialmente el precursor 8- acetil-7-hidroxicumarina en dos pasos, \npartiendo de la umbeliferona (7-hidroxicumari na). En el primer paso realizar\u00edamos la \nacetilaci\u00f3n del grupo hidroxilo en la posici\u00f3n 7, y a cont inuaci\u00f3n, mediante una \ntransposici\u00f3n de Fries, obtendr\u00edamos el  precursor 8-acetil-7-hidroxicumarina. La \ncumarina obtenida se hizo reaccionar con el  aril o heteroaril-aldeh\u00eddo correspondiente y \nmediante una reacci\u00f3n de condensaci\u00f3n de Claisen-Schmidt dio lugar a la 8-cinamoilcumarina des eada (Figura 52). \n \nFigura 52. S\u00edntesis de 8-ci namoilcumarinas  \n \nLa s\u00edntesis de la 7-acetoxicumarina se realiz\u00f3 disolviendo la umbeliferona en \nanh\u00eddrido ac\u00e9tico y tratando la mezcla de  reacci\u00f3n con una cantidad catal\u00edtica de \npiridina a reflujo durante 12 horas. El preci pitado obtenido se trat\u00f3 posteriormente con \ntricloruro de aluminio anhidro a 160 \u00baC dura nte 2 horas, y tras dejar enfriar la reacci\u00f3n, \nse agreg\u00f3 \u00e1cido clorh\u00eddrico al 5%, dejando la mezcla de reacci\u00f3n durante 1 hora a 100 \n\u00baC. El compuesto final, la 8-acetil-7-hidroxi cumarina, que utilizar\u00edamos como precursor, \nse purific\u00f3 mediante cromatograf\u00eda en columna con un rendimiento global de 85%.249 \nObtenida la cumarina acetilada en la posici\u00f3n 8, \u00e9sta se mezcl\u00f3 con el aril/heteroaril \naldeh\u00eddo apropiado, se disolvie ron en etanol y se trataron con piperidina a reflujo entre 2 \ny 8 horas.254 Tras su purificaci \u00f3n mediante cromatograf\u00eda en columna y/o \nrecristalizaci\u00f3n, se obtuvieron las 8-cinamoil cumarinas deseadas con unos rendimientos \nde entre 58 y 96%. O O HO O O OO\nO O HO\nO Ar/HetO O HO\nOEtOH, piperidina\nre\ufb02ujo, 2-8hAr/Het HO\nAc2O, piridina\nre\ufb02ujo,12h1. AlCl3, 160\u00baC\n2. HCl, 5%, 100\u00baC, 1h\n68Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n69 2.4. Optimizaci\u00f3n de la reacci\u00f3n de Nazarov: aplicaciones en la \ns\u00edntesis de productos naturales oxac\u00edclicos. \nComo se ha mencionado en la introducci \u00f3n, la reacci\u00f3n de ciclaci\u00f3n de \nNazarov supone una excelente herra mienta sint\u00e9tica para la s\u00edntesis total de productos \nnaturales oxac\u00edclicos tales como la rocaglamida. Sin embargo, la formaci\u00f3n de \u00e1tomos \nde carbono cuaternarios adyacentes durante la ciclaci\u00f3n de Nazarov est\u00e1 limitada a un \nn\u00famero muy peque\u00f1o de ejemplos. La investigaci\u00f3n para el desarrollo de una metodolog\u00eda sint\u00e9tica que nos permitiese generalizar este proceso ha sido objeto de \nnuestro estudio.  \nPara ello, se desarroll\u00f3 y se puso a punto una metodolog\u00eda sint\u00e9tica que nos \npermitiese obtener primeramente los su stratos dienona tetrasustitu\u00eddos, y a \ncontinuaci\u00f3n, se optimizaron las condiciones de reacci\u00f3n que nos permitieron llevar a \ncabo la reacci\u00f3n de ciclaci\u00f3n de Nazarov di astereoespec\u00edfica. Los resultados que se \nobtuvieron fueron muy sorprendentes y promete dores, ya que nos permit\u00eda expandir el \n\u00e1mbito de la reacci\u00f3n de Nazarov para la obtenci\u00f3n de cicl opentenonas altamente \nsustutuidas.\n255 En base a los resultados obtenidos, parece que la reacci\u00f3n de ciclaci\u00f3n \nde Nazarov nos permite generar centros v ecinales con todos los \u00e1tomos de carbono \ncuaternarios con \u00e9xito y de forma diastereoespec\u00edfica empleando unos par\u00e1metros de \nreacci\u00f3n cuidadosamente definidos.  \nDe forma resumida, la metodolog\u00eda sint\u00e9tica que se desarroll\u00f3 consta de cuatro \netapas fundamentales: 1) s\u00ed ntesis de \u00e1cidos carbox\u00edlicos \u03b1,\u03b2-insaturados \ncompletamente sustitu\u00eddos; 2) s\u00edntesis de (((trimetilsilil)etoxi)metoxi)\u00e9steres; 3) s\u00edntesis de \nlos sustratos dienona; 4) s\u00edntesis de productos de la ciclaci\u00f3n de Nazarov \ndiastereoespec\u00edfica (Figura 53). \n \n    \n \n69Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n70  \n \n \n     \n \n      \n \n     \nFFigura 53. Metodolog\u00eda sint\u00e9tica para ciclaci\u00f3n de Naza rov diastereoespec\u00edfica.  R1 OEtO O\nR1 OEtO O\nR2R2 CO2Et\nOTf R1\nR2 CO2Et\nR3 R1R2 CO2H\nR3 R1K2CO3,R2X\nDMF, 60 \u00baC1) NaH, PhMe, 85 \u00baC\n2) Tf2O, 0 \u00baC a t.a.\nR3Li, CuCN\nTHF, -50 \u00baCs\u00f3lo is\u00f3mero ( Z)\ns\u00f3lo is\u00f3mero ( E) s\u00f3lo is\u00f3mero ( E)THF/MeOH/H2O (4:1:1)\nt.a.LiOH.H2O1) Preparaci\u00f3n de \u00e1cidos carbos\u00edxicos \u03b1,\u03b2-insaturados completamente sustitu\u00eddos\n2) Preparaci\u00f3n de (((trimetilsilil)etoxi)metoxi) \u00e9steres\nR4O2C R5O H\nR4O2C R5OSEM\nR5 R4O2C\nR4O2C R5TiCl4, HCO2Et, Et3N\nDCM, 0 \u00baC a t.a.Ruta A\n1) LDA, THF, -78 \u00baC\n2) HCO2Et, -78 \u00baC a t.a.Ruta B\nOSiSEM =\n3) S\u00edntesis de los sustratos dienona\nOSEM\nR5 R4O2COSEMO\nR2\nR1R3CO2R4R51) TMPMgCl.LiCl, THF, t.a., 30 min.\n2) CuCN.2LiCl, THF, -30 \u00baC, 30 min.\nR2 CO2H\nR3 R1\ns\u00f3lo is\u00f3mero ( E)THF, -30 \u00baC a t.a.3)\n4) S\u00edntesis de productos de la ciclaci\u00f3n de Nazarov diastereoespec\u00ed \ufb01ca\nOSEMO\nR2\nR1R3CO2R4R5s\u00f3lo is\u00f3mero ( E,E)\ns\u00f3lo is\u00f3mero ( E,E)Tf2NH\nDCM, t.a.R2OH\nO\nR1CO2R4R3R5\ns\u00f3lo un diastereois\u00f3mero\n70Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n71 2.5. Series de compuestos sintetizados  \nDe las series de compuestos anteri ormente descritas, se ha preparado una \namplia quimioteca que se encuentra resumida en forma de tablas. \nLas tablas se han dividido de acuerdo a los tipos de esqueletos sintetizados \nseg\u00fan las diferentes metodolog\u00edas (secciones 2. 2 y 2.3): 3-benzoilcumarinas (Tabla 1), \n3-benzoil-4-hidroxicumarinas (Tabla 2), 3- cinamoilcumarinas (Tab la 3), 3-cinamoill-4-\nhidroxicumarinas (Tabla 4), 3-(3-aril-3-ox o-propenil)-4-clorocumarinas (Tabla 5) y 8-\ncinamoil cumarinas (Tabla 6).  \nTabla 1. 3-benzoilcumainas.  \n \nCCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n11 H H H H H H H \n22 H OCH3 H H H H H \n33 H Br H H H H H \n44 H H H OCH3 H H H \n55 H H H OCH2CH3 H H H \n66 H Br H OCH3 H H H \n77 H CH3 H H H H H \n88 H H H CH3 H H H \n99 H NO2 H H H H H \n110 OCH3 H OCH3 H H H H \n111 H Cl H H H H H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n71Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n72  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n12 H H OCH3 H H H H \n13 H H H H H OCH3 H \n14 H OCH3 H H H OCH3 H \n15 H Br H H H OCH3 H \n16 H NO2 H H H OCH3 H \n17 H H H CH3 H OCH3 H \n18 H Br H OCH3 H OCH3 H \n19 OCH3 H OCH3 H H OCH3 H \n20 H CH3 H H H OCH3 H \n21 H H H OCH2CH3 H OCH3 H \n22 H H H OCH3 H OCH3 H \n23 H Cl H H H OCH3 H \n24 H H OCH3 H H OCH3 H \n25 H H H H OCH3 OCH3 H \n26 H OCH3 H H OCH3 OCH3 H \n27 H Br H H OCH3 OCH3 H \n28 H H H OCH3 OCH3 OCH3 H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n72Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n73  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n29 H Br H OCH3 OCH3 OCH3 H \n30 OCH3 H OCH3 H OCH3 OCH3 H \n31 H CH3 H H OCH3 OCH3 H \n32 H H H CH3 OCH3 OCH3 H \n33 H NO2 H H OCH3 OCH3 H \n34 H H H OCH2CH3 OCH3 OCH3 H \n35 H Cl H H OCH3 OCH3 H \n36 H H OCH3 H OCH3 OCH3 H \n37 H H H H H NO2 H \n38 H OCH3 H H H NO2 H \n39 H Br H H H NO2 H \n40 H H H OCH3 H NO2 H \n41 H H H OCH2CH3 H NO2 H \n42 H Br H OCH3 H NO2 H \n43 H CH3 H H H NO2 H \n44 H H H CH3 H NO2 H \n45 H NO2 H H H NO2 H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n73Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n74  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n46 OCH3 H OCH3 H H NO2 H \n47 H Cl H H H NO2 H \n48 H H OCH3 H H NO2 H \n49 H OCH3 H H H Cl H \n50 H Br H H H Cl H \n51 H H H OCH3 H Cl H \n52 H Br H OCH3 H Cl H \n53 H CH3 H H H Cl H \n54 H NO2 H H H Cl H \n55 OCH3 H OCH3 H H Cl H \n56 H Cl H H H Cl H \n57 H H H H H CH3 H \n58 H OCH3 H H H CH3 H \n59 H Br H H H CH3 H \n60 H NO2 H H H CH3 H \n61 OCH3 H OCH3 H H CH3 H \n62 H H OCH3 H H CH3 H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n74Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n75  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n63 H H H H OCH3 OCH3 OCH3 \n64 H OCH3 H H OCH3 OCH3 OCH3 \n65 H Br H H OCH3 OCH3 OCH3 \n66 H H H OCH3 OCH3 OCH3 OCH3 \n67 H H H OCH2CH3 OCH3 OCH3 OCH3 \n68 H Br H OCH3 OCH3 OCH3 OCH3 \n69 H CH3 H H OCH3 OCH3 OCH3 \n70 H H H CH3 OCH3 OCH3 OCH3 \n71 H NO2 H H OCH3 OCH3 OCH3 \n72 OCH3 H OCH3 H OCH3 OCH3 OCH3 \n73 H Cl H H OCH3 OCH3 OCH3 \n74 H H OCH3 H OCH3 OCH3 OCH3 \n75 H H H H NO2 H H \n76 H OCH3 H H NO2 H H \n77 H Br H H NO2 H H \n78 H H H OCH3 NO2 H H \n79 H H H OCH2CH3 NO2 H H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n75Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n76  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n80 H Br H OCH3 NO2 H H \n81 H CH3 H H NO2 H H \n82 H H H CH3 NO2 H H \n83 H NO2 H H NO2 H H \n84 OCH3 H OCH3 H NO2 H H \n85 H Cl H H NO2 H H \n86 H H OCH3 H NO2 H H \n87 H OH H H H H H \n88 H Br H OH H H H \n89 H H H OH H H H \n90 OH H OH H H H H \n91 H H OH H H H H \n92 H H H H H OH H \n93 H OH H H H OH H \n94 H Br H H H OH H \n95 H H H CH3 H OH H \n96 H Br H OH H OH H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n76Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n77  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n97 OH H OH H H OH H \n98 H CH3 H H H OH H \n99 H H H OH H OH H \n100 H H OH H H OH H \n101 H H H H OH OH H \n102 H OH H H OH OH H \n103 H Br H H OH OH H \n104 H CH3 H H OH OH H \n105 H H H OH OH OH H \n106 H Br H OH OH OH H \n107 OH H OH H OH OH H \n108 H H H CH3 OH OH H \n109 H H OH H OH OH H \n110 H H H H OH OH OH \n111 H OH H H OH OH OH \n112 H Br H H OH OH OH \n113 H CH3 H H OH OH OH O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n77Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n78  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n114 H Cl H H OH OH OH \n115 H Br H OH OH OH OH \n116 H H H OH OH OH OH \n117 H H H CH3 OH OH OH \n118 OH H OH H OH OH OH \n119 H H OH H OH OH OH \n120 H OH H H H CH3 H \n121 H H OH H H CH3 H \n122 OH H OH H H CH3 H \n123 H H H H H NH2 H \n124 H Br H H H NH2 H \n125 H OCH3 H H H NH2 H \n126 H CH3 H H H NH2 H \n127 H NH2 H H H NH2 H \n128 H Cl H H H NH2 H \n129 H H H CH3 H NH2 H \n130 H H H OCH2CH3 H NH2 H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n78Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n79  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n131 H H H OCH3 H NH2 H \n132 H Br H OCH3 H NH2 H \n133 H H OCH3 H H NH2 H \n134 OCH3 H OCH3 H H NH2 H \n135 H H H H NH2 H H \n136 H Br H H NH2 H H \n137 H OCH3 H H NH2 H H \n138 H CH3 H H NH2 H H \n139 H Cl H H NH2 H H \n140 H H H CH3 NH2 H H \n141 H H H OCH2CH3 NH2 H H \n142 H H H OCH3 NH2 H H \n143 H Br H OCH3 NH2 H H \n144 H H OCH3 H NH2 H H \n145 OCH3 H OCH3 H NH2 H H \n146 H NH2 H H H H H \n147 H NH2 H H H OCH3 H O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n79Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n80  \nCompuesto R5 R6 R7 R8 R3\u2019 R4\u2019 R5\u2019 \n148 H NH2 H H OCH3 OCH3 H \n \n \nTabla 2.  3-benzoil-4-hidroxicumarinas.  \n \nCompuesto R6 R7 R \n149 H H \n \n150 H H \n \n151 H H \n \n152 H H \n \n153 H H \n \n154 H H \n \n155 H H \n OCH3\nCl\nNO2\nCH3\nCl\nCl\nSOOOOH\nRR6\nR7O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n80Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n81  \nCompuesto R6 R7 R \n156 H H \n \n157 CH3  \n \n158 CH3  \n \n159 CH3 CH3 \n \n \nTabla 3.  3-cinamoilcumarinas y an\u00e1logos.  \n \n160-183  \n184-186 \nCompuesto R6 R8 R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n160 H H H H H H H \n161 H H H H OCH3 H H \n162 H H H H Cl H H \n163 H H H H CH3 H H \n164 H H OCH3 H OCH3 H H \n165 H H OCH3 H OCH3 OCH3 H O\nS\nO OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8OOOOH\nRR6\nR7\n81Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n82  \n160-183  \n184-186 \nCompuesto R6 R8 R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n166 H H OCH3 H OCH3 H OCH3 \n167 H H OCH3 H NO2 H H \n168 H H H NO2 H H H \n169 H H H OCH3 OCH3 H H \n170 H H OCH3 OCH3 H H H \n171 H H OCH3 H H OCH3 H \n172 Cl H H H OCH3 H H \n173 Cl H H H CH3 H H \n174 Cl H OCH3 H OCH3 H H \n175 Cl H OCH3 H OCH3 OCH3 H \n176 Cl H OCH3 H OCH3 H OCH3 \n177 Cl H OCH3 H H OCH3 H \n178 Cl H H OCH3 H OCH3 H \n179 H OCH3 H H OCH3 H H \n180 H OCH3 OCH3 H OCH3 H H \n181 H OCH3 OCH3 H OCH3 OCH3 H O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\n82Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n83  \n160-183  \n184-186 \nCompuesto R6 R8 R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n182 H OCH3 OCH3 H H OCH3 H \n183 H OCH3 H OCH3 H OCH3 H \n184 H H \n \n185 H H \n \n186 Cl H \n \n \nTabla 4.  3-cinamoil-4-hidroxicumarinas y derivados. \n \n187-202  \n203-206 \nCompuesto R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n187 H H H H H \n188 H H OCH3 H H \n189 H H Cl H H \n190 H H CH3 H H O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\nS\nN\nS\nO OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\n83Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n84  \n187-202  \n203-206 \nCompuesto R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n191 OCH3 H OCH3 H H \n192 OCH3 H OCH3 OCH3 H \n193 OCH3 H OCH3 H OCH3 \n194 H OCH3 OCH3 H H \n195 OCH3 H NO2 H H \n196 OCH3 H H OCH3 H \n197 OCH3 OCH3 H H H \n198 Cl H H NO2 H \n199 OCH3 H H H H \n200 H OCH3 H H H \n201 H NO2 H H H \n202 H OCH3 H OCH3 H \n203 \n \n204 \n O OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\nS\nN\n84Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n85  \n187-202  \n203-206 \nCompuesto R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n205 \n \n206 \n \n \nTabla 5.  3-(3-aril-3-oxo-propenil)-4-clorocumarinas.  \n \nCompuesto R2\u2019 R3\u2019 R4\u2019 R5\u2019 \n207 H H H H \n208 H H CH3 H \n209 H H OCH3 H \n210 H H NO2 H \n211 H OCH3 H H \n212 H NO2 H H \n213 OCH3 H H OCH3 \n \n O OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\nN\nO\nO OCl O\nR2' R4'R5'\nR3'\n85Resultados y discusi\u00f3n                                                                   2. Estrategia Sint\u00e9tica  \n \n86 Tabla 6.  8-cinamoilcumarinas y derivados.  \n \n214-223  \n \n \n224 \nCompuesto R2\u2019 R3\u2019 R4\u2019 R5\u2019 R6\u2019 \n214 H H OCH3 H H \n215 OCH3 H OCH3 H H \n216 OCH3 H OCH3 OCH3 H \n217 OCH3 H OCH3 H OCH3 \n218 H OCH3 OCH3 H H \n219 OCH3 H NO2 H H \n220 OCH3 H H OCH3 H \n221 H NO2 H H H \n222 OCH3 OCH3 H H H \n223 H OCH3 H OCH3 H \n224 \n \n \n O HO O\nO\nR2'\nR3'R4'R5'R6'\nSO HO O\nO Het\n86Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n87  \n3. Estudios biol\u00f3gicos  \nDado el elevado potencial de las mol\u00e9cu las sintetizadas sobr e diferentes dianas \nfarmacol\u00f3gicas, en esta Memoria se presenta de forma resumida los distintos tipos de \nensayos biol\u00f3gicos llevados a cabo, as\u00ed como la relaci\u00f3n estructura-actividad (SAR) de \ndichas series de compuestos. La descripci\u00f3n completa de dichos ensayos, al igual que \nen el caso de la descripci\u00f3n sint\u00e9tica, se encontrar\u00e1 ex pl\u00edcitamente detallada en los \nart\u00edculos publicados que se adjuntan en esta Memoria.  \n 3.1. Estudio como inhibidores de MAO.  \nEn base a los antecedentes de nuestro grupo de investigaci\u00f3n con h\u00edbridos \ncumarina-resveratrol (3-arilcum arinas) como i nhibidores MAO256 ,239 se establecieron \nimportantes conclusiones de la relaci\u00f3n es tructura-actividad de dichos compuestos, \nencontr\u00e1ndose que los compuestos descritos er an potentes inhibidores selectivos de la \nMAO-B259,111 y que de todas las posiciones estudiadas, la introducci\u00f3n de grupos poco \nvoluminosos (metilo, bromo o metoxilo ) tanto en posici\u00f3n 6 y/o 8 como en las \nposiciones 3\u2019 y/o 4\u2019 del n\u00facleo de la  3-arilcumarina eran muy favorables.257  \nDada la estrecha relaci\u00f3n estructural de los h\u00edbridos \u201cendo\u201d cumarina-chalcona, \ncomo se coment\u00f3 en el apartado de ant ecedentes y objetivos, la primera diana \nfarmacol\u00f3gica a estudiar frente  a este tipo de compuestos fue la MAO. Seg\u00fan estos \nestudios, apoyados por estudios de docking  (Figuras 54 y 55) se encontr\u00f3 que el hecho \nde introducir un grupo carbon\u00edlico entre el gr upo arilo y el n\u00facleo de cumarina hac\u00eda que \nla actividad inhibidora MAO frente a la isof orma B disminuyese. Sin embargo, para la \nserie estudiada, la afinidad por el receptor MAO-A aumentaba.258 Por tanto observamos \nque un peque\u00f1o cambio como es la introducci\u00f3n de un grupo carbonilo, causaba un gran cambio en la afinidad y selectividad de las mol\u00e9culas para este receptor. Un \nestudio continuado sobre este receptor y un am plio an\u00e1lisis bibliogr\u00e1fico nos permiti\u00f3 \nestablecer qu\u00e9 tipo de derivados cumar\u00ednicos podr\u00edan ser m\u00e1s interesantes como \ninhibidores de MAO.\n259,260  \n \n \n87Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n88   \nFigura 54.  Interacci\u00f3n de los compuestos 8 88 (izquierda) y 9 96 (derecha) con el sitio activo de \nMAO-A. \n \nFigura 55. Interacci\u00f3n de los compuestos 8 88 (izquierda) y 9 96 (derecha) con el sitio activo de \nMAO-B.  \n \n  \n88Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n89 3.2. Estudio de las propiedades antioxidantes.  \nEl consumo de antioxidantes naturales, tales como los flavonoides, ayuda al \nsistema de defensa antioxidante end\u00f3geno. Tant o los antioxidantes procedentes de la \ndieta como los enzim\u00e1ticos son component es de sistemas interrelacionados que \ninteract\u00faan entre s\u00ed para controlar la pr oducci\u00f3n de especies reactivas de ox\u00edgeno \n(ROS), asegurando as\u00ed una defensa ad ecuada contra el estr\u00e9s oxidativo.261,262 En este \nsentido, se han llevado a cabo numerosos estudios sobre la capacidad antioxidante de \ncompuestos fen\u00f3licos de diferentes tipos (flav onoides, cumarinas o taninas entre otros) \ny se han correlacionado sus caracter\u00edsticas estructurales con sus propiedades \nantioxidantes.263  \nEn general, el atrapamiento de radicales libres, el potencial redox y la actividad \nantioxidante de estos compuestos depende principalmente del n\u00famero y posici\u00f3n de \nlos grupos hidroxilo donadores de  hidr\u00f3geno en el anillo arom\u00e1tico de los compuestos \nfen\u00f3licos, aunque existen otros factores que tambi\u00e9n afectan a estas propiedades.83 \nTeniendo en cuenta la importancia de los sustituyentes hidroxilo en las \npropiedades antioxidantes de los compuestos,83, 264 inicialmente el estudio de las \npropiedades antioxidantes se ha centr\u00f3 en  h\u00edbridos hidroxi- cumarina-chalcona tipo \n\u201cendo\u201d (compuestos 8 87,88, 92-95, 103, 105 y 106). Se encontr\u00f3 que la serie de \ncompuestos estudiados result\u00f3 tener unas propiedades antioxidantes excelentes, ya \nque los compuestos presentaron bajos potenciales de oxidaci \u00f3n, elevados \u00edndices de \ncapacidad de absorci\u00f3n del radical ox\u00edgeno  (ORAC, por sus siglas en ingl\u00e9s), con \nvalores mucho m\u00e1s elevados que los compuestos de referencia quercetina y catequina, y adem\u00e1s, los compuestos presentaron baja  o nula citotoxicida d en c\u00e9lulas BAEC y \nbuenos efectos citopr otectores frente a per\u00f3xido de  hidr\u00f3geno y peroxinitrito.\n265 De esta \nserie de compuestos estudiada, el m\u00e1s prometedor fue el compuesto 9 93, que present\u00f3 \nel mayor \u00edndice ORAC (14.1), con un valor que doblaba el de los patrones de referencia, buena capacidad para atrapar radicales, baja citotoxicidad y elevados valores de \ncitoprotecci\u00f3n.  \nUn estudio similar se llev\u00f3 a cabo con los h\u00edbridos hidr oxi-cumarina-chalcona \nque conten\u00edan un grupo catecol en su estructura (compuestos 1\n101, 1102, 1104, 1106 y \n107) observ\u00e1ndose tambi\u00e9n excelent es propiedades antioxidantes.266 Esta serie de \ncompuestos que conten\u00edan el grupo catecol, present\u00f3 una act ividad antioxidante menor \nque la serie anteriormente mencionad a a pesar de que los compuestos 1 106 y 1107 \npresentan valores del \u00edndice ORAC del orden de la quercetina y catequina.  \n89Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n90 Otras series de derivados  cumar\u00ednicos hidroxi-sustituidos como las 3-\narilcumarinas preparadas en nuestro grupo tambi\u00e9n han sido estudiadas, obteni\u00e9ndose \ntambi\u00e9n resultados prometedores que verifican el elevado potencial del n\u00facleo \ncumar\u00ednico como esqueleto pa ra agentes antioxidantes.267,268  \n3.3. Estudio de la actividad tripanocida. \nLa enfermedad de Chagas est\u00e1 causada por el par\u00e1sito Trypanosoma cruzi  (T. \ncruzi) y representa un problema de salud importa nte en la mayor\u00eda de los pa\u00edses de \nLatinoam\u00e9rica y el sur de Estados Unidos. Durante el transcurso de la infecci\u00f3n por T. \ncruzi y del desarrollo de la enfermedad, se pueden producir ROS como consecuencia \nde la destrucci\u00f3n de tejido causada por secreciones t\u00f3xicas del par\u00e1sito, por \nreacciones citot\u00f3xicas mediadas por el sistema inmune y por da\u00f1o secundario en el miocardio. Por tanto, la intervenci\u00f3n con compuestos antioxidantes que puedan reducir \nlas ROS, pueden presentar efect os beneficiosos para prevenir o detener el estr\u00e9s \noxidativo generado por el par\u00e1sito tras la infecci\u00f3n.\n269,270  \nPor tanto, dada la posible relaci\u00f3n entre las propiedades antioxidantes y la \nactividad tripanocida, se realizaron estudios de la actividad tripanocida sobre la serie de \ncompuestos previamente mencionados q ue conten\u00edan grupos catecol (compuestos \n101, 1102, 1104, 1106 y 1107). Todos los compuestos, a excepci\u00f3n del compuesto 1 106, \npresentaron una actividad tripanocida moderada. Sin embargo, se observ\u00f3 que \naquellos compuestos que presentaban mayor actividad, eran aquellos que ten\u00edan \nvalores de ORAC m\u00e1s bajos, de modo que estos resultados pueden ser tomados en \ncuenta para futuros estudios a cerca del mecanismo de acci\u00f3n de este tipo de \ncompuestos frente a T. cruzi . \n3.4. Estudio como ligandos de receptores de adenosina.  \nLos receptores de adenosina (ARs) s on receptores acoplados a prote\u00ednas G \n(GPCRs) que exhiben un enorme n\u00famero de actividades fisiol\u00f3gicas a trav\u00e9s de la \nactivaci\u00f3n de cuatro subtipos diferentes de receptores: A1, A2A, A2B y A3.271 La mayor\u00eda \nde los antagonistas de los receptores de adenosina son nuevos y prometedores \ncandidatos a f\u00e1rmacos para un gran n\u00famero de procesos patol\u00f3gicos, tales como \ninflamaci\u00f3n, fallos renales y card\u00edacos o des\u00f3rdenes neurol\u00f3gicos como las \nenfermedades de Parkinson y Alzheimer.272,273 Entre los antagonistas no cl\u00e1sicos, los \nderivados de flavonas e isoflavonas present an un papel destacado, como el caso de la \ngenisteina, que ha sido descrita como un antagonista competitivo frente al receptor A1 \n90Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n91 en c\u00e9lulas FRTL (tiroides),274 o como la galanginina, que presenta actividad micromolar \npara el receptor A3.275  \nPor tanto, dada la similitud estructur al entre flavonas, cumarinas, y chalconas, \nhemos considerado evaluar la actividad de algunos tipos de h\u00edbridos cumarina-\nchalcona frente a los cuatro su btipos de receptores de adenosina humanos expresados \nen c\u00e9lulas ov\u00e1ricas de h\u00e1mster chino (CHO cells). Los compuestos estudiados en este \ntipo de ensayos poseen el esqueleto de chalcona como n\u00facleo estructural principal, y \nlos diferentes derivados han sido preparados bas\u00e1ndonos en la sustituci\u00f3n de uno o ambos anillos benc\u00edlicos (anillos A y/o B) de  la chalcona por una cumarina y/o un grupo \ntiofeno con diferentes sustituyentes. Los compuestos estudiados y sobre los que \nhemos hecho el estudio de relaci\u00f3n estruct ura-actividad han sido los compuestos 1\n161, \n184, 1188,203 , 2214 y 2224, llegando a la conclusi\u00f3n de que una selectividad hacia el \nreceptor de adenosina hA3 se consegu\u00eda fundamentalment e cuando el anillo B de la \nchalcona era sustituido por un ti ofeno, y el anillo A era sustit uido por el anillo de pirona \nincluido en el esqueleto de cumarina (compuesto 1 184).276 \nSiguiendo la l\u00ednea del trabajo anterior, decidimos seguir estud iando el potencial \nde los h\u00edbridos cumarina-chalcona como ligandos de adenosina. Realizamos un estudio sobre h\u00edbridos metoxi/hidroxi-3 -benzoilcumarina (compuestos 1\n19, 225, 226, 330 y 997, \n101, 1102 y 1107, respectivamente). Un estudio prelim inar de la relaci\u00f3n estructura-\nactividad de los derivados estudiados most r\u00f3 que, en general, los derivados metoxi \nsustitu\u00eddos (1 19, 225, 226, 330) presentaron buenas afinidades de uni\u00f3n y selectividad \nhacia el h A3AR, mientras que los derivados hidroxi sustitu\u00eddos (1 101, 1102 y 1107) \npresentaron una actividad moderada  pero selectividad hacia el hA1AR. Se observ\u00f3 \ntambi\u00e9n que las posiciones 5 y 7 del anillo de cumarina resultab an cruciales par la \npotencia y selectividad de ambas series de compuestos.277  \n3.5. Estudio de la actividad antibacteriana.  \nSe conocen m\u00faltiples ej emplos de cumarinas278 y chalconas144 que presentan \nun amplio rango de actividades antibacteriana s. Estudios realizados en nuestro grupo, \nmuestran que tanto el n\u00facleo cumar\u00ednico simple, como deri vados de 3-arilcumarinas, \npresentan interesantes actividades frente a bacterias pat\u00f3genas humanas.279,280  \nCon la intenci\u00f3n de ampliar el tipo de  estudios antibacterianos no s\u00f3lo sobre \npat\u00f3genos humanos, y teniendo en cuenta la importancia de la acuicultura tanto en \nnuestra regi\u00f3n como sobre la econom\u00eda mundia l, se realizaron ensayos antibacterianos \n91Resultados y discusi\u00f3n                                                                  3. Estudios biol\u00f3gicos  \n \n92 con pat\u00f3genos marinos con el fin de enco ntrar candidatos para tratamientos en \nacuicultura. As\u00ed, adem\u00e1s del estu dio con bacterias humanas como Escherichia coli , \nPseudomona aeruginosa  o Staphylococcus aureus , los pat\u00f3genos marinos a estudiar \nfueron aquellos pertenecientes al g\u00e9nero Tenacibaculum , siendo Tenacibaculum \nmaritimum  el m\u00e1s estudiado. Esta bacteria es la causante de la tenacibaculosis, una \nenfermedad que produce desagradables lesiones  sobre la superficie del cuerpo de los \npeces tales como \u00falceras, necrosis, malform aciones en la boca, o aletas y colas de \naspecto putrefacto, entre otras,281,282 por lo que aunque estos pat\u00f3genos son inocuos \npara el ser humano, sus efectos sobre lo s organismos marinos producen da\u00f1o y hacen \nque su aspecto no sea bueno para su comercializaci\u00f3n.  \nLos compuestos empleados para estos estudios y sobre los que hemos hecho \nel estudio de relaci\u00f3n estructur a-actividad han sido los compuestos 1 1, 33-5 y 1123, \n124, 1130, 131, 135, 136, 141  y  142. Observamos que de la serie estudiada, \nninguno de los compuestos fue activo frente a las bacterias pat\u00f3genas humanas \nestudiadas. Sin embargo, los compuest os que pose\u00edan un grupo amino en su \nestructura (1 123, 124 , 1130, 131, 135, 136, 141  y  142), mostraban de moderada a \ngran actividad frente a todas las cepas de Tenacibaculum maritimum , con \u00f3rdenes \niguales o superiores a los patrones empleados  y que actualmente se emplean para el \ntratamiento de la tenacibaculosis, como la enrof loxacina, cuya actividad no es selectiva \nfrente a T. maritimum , ya que tambi\u00e9n es altamente activa frente a las bacterias \nhumanas ensayadas. La presencia de este grupo amino result\u00f3 ser clave para la \nactividad de los compuestos, as\u00ed como la sustituci\u00f3n en la posici\u00f3n 8 del n\u00facleo de \ncumarina, siendo los compuestos 1 130,  131,  141 y 1142 los m\u00e1s activos.283 Por tanto, \nla elevada actividad de estos compuestos y su  selectividad solo frente a distintas cepas \nde la bacteria marina T. maritimum  pueden evitar futuros problemas de resistencia en \npat\u00f3genos humanos, haciendo a estos co mpuestos buenos candidatos para el \ntratamiento de la tenacibaculosis.  \n \n \n92Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n93  \n\t\r\u001c\u001e\u0011\u0001\u0006\"\u001b\u0011\u001c\u0014\u0018\u0011\u0019\u001e\r\u0017 \u0001\n\u0006\"\u001b\u0011\u001c\u0014\u0018\u0011\u0019\u001e\r\u0017\u0001\t\r\u001c\u001e\u0001\n\u0001\n\u0001\n\u0001\n\u0001\u0001\n1. Art\u00edculos publicados  o en fase de publicaci\u00f3n \u0001 997 \n2. Compuestos preparados bajo es tudio y pendientes de publicaci\u00f3n \u0001 2257 \n\u0001\u0001\u0001\n\u0001\n\u0001\u0001\n93 \n\u0001\n\u0001Parte experimental                                                                                     Generalidades  \n \n95 \u0001\n \nLa presentaci\u00f3n de esta Me moria incluye los art\u00edculos publicados, enviados y \nen fase de preparaci\u00f3n. Las rutas sint\u00e9ticas utilizadas para los compuestos ya \npublicados, la caracterizaci\u00f3n de los mismos, los ensayos farmacol\u00f3gicos y \nelectroqu\u00edmicos realizados, as\u00ed como los es tudios estructurales y de SAR se presentan \na continuaci\u00f3n de forma detallada y discutida en cada uno de los respectivos \nmanuscritos. Por tanto, dichos art\u00edculos se r\u00e1n incluidos en este apartado de parte \nexperimental de esta Memoria.  \nAquellos compuestos que a la hora de presentar esta Memoria todav\u00eda no han \nsido publicados pero que han sido preparados y se encuentran bajo estudio, se \nencuentran caracterizados en la secci\u00f3n 2 del apartado de Parte Experimental. \n \n  \n95 \n \n Parte Experimental                                                                                         1. Art\u00edculos  \n \n97  \n1.1. Art\u00edculos publicados.  \n1. \u201cDiastereospecific Nazarov Cyclizat ion of Fully Substituted Dienones: \nGeneration of Vicinal All-Carbon-Atom Quat ernary Stereocenters\u201d (Jolit, A.*; Vazquez-\nRodriguez, S.; Yap, G.P.A.; Tius, M.A.) \u2013 Angewandte Chemie International Edition  \n2013 , 52, 1-5. \n2. Synthesis of 3-Arylcoumarins via Su zuki-cross-coupling Reactions of 3-\nChlorocoumarin\u201d  (Matos, M.J.*; Vazquez-Rodriguez, S .; Borges, F.; Santana, L.; Uriarte, \nE.) \u2013 Tetrahedron Letters 2011 , 52, 1225-1227. \n3. \u201c3-(4-Methoxybenzoyl)-6-nitrocoumarin \u201d (Vazquez-Rodriguez, S.*; Uriarte, E.; \nSantana, L. Acta Cryst.  22013, E69 , o345. \n4. \u201cFocusing on New Monoamine Oxidase Inhibitors: Differently Substituted \nCoumarins As An Interesting Scaffold\u201d (M atos, M.J.; Vi\u00f1a, D.; Vazquez-Rodriguez, S.; \nUriarte, E.; Santana, L.*) \u2013 Current Topics in Medicinal Chemistry  22012, 12, 2210-2239. \n5. \u201cMAO Inhibitory Activity M odulation: 3-Phenylcoumarins versus 3-\nBenzoylcoumarins\u201d (Matos, M.J.; Vazquez-Rodr iguez, S.; Uriarte, E.; Santana, L.; Vi\u00f1a, \nD.*) \u2013 Bioorganic & Medicinal Chemistry Letters 2011 , 21, 4224-4227. \n6. \u201cHydroxycoumarins as Sel ective MAO-B Inhibitors\u201d (Serra, S.*; Ferino, G.; \nMatos, M.J.; V\u00e1zquez-Rodr\u00edguez, S.; Delogu,  G.; Vi\u00f1a, D.; Cadoni, E.; Santana, L.; \nUriarte, E.) \u2013 Bioorganic & Medicinal Chemistry Letters  22012, 22, 258-261. \n7. \"Synthesis, electrochem ical and biologi cal studies on novel coumarin-\nchalcone hybrid compounds\" (P\u00e9rez-Cruz, F.; Vazquez-Rodriguez, S.*; Matos, M.J.; \nHerrera-Morales, A.; Villamena, F.; Das, A.; Gopalakrishnan, B.; Olea-Azar, C.; Santana, \nL.; Uriarte, E.) \u2013 Journal of Medicinal Chemistry , 22013, 56, 6136-6145. \n8. \u201cSynthesis of coumarin-chalcone hybrid s and evaluation of their antioxidant \nand trypanocidal properties\u201c (Vazquez-Rodr iguez, S.*; Figueroa-Gu\u00ed\u00f1ez, R.; Matos, \nM.J.; Santana, L.; Uriarte, E.; Lapier, M.; Maya, J.D.; Olea-Azar, C.*) \u2013 MedChemComm  \n2013 , 4, 993-1000. \n \n97Parte Experimental                                                                                         1. Art\u00edculos  \n \n98 9. \u201cSynthesis and evaluati on of antioxidant and try panocidal properties of a \nselected series of coumarin derivatives\u201d (Figueroa Gu\u00ed\u00f1ez, R.; Matos, M.J.*; Vazquez-\nRodriguez, S.; Santana, L.; Uriarte, E. ; Olea-Azar, C.*; Maya, J.D.) \u2013 Future Medicinal \nChemistry, 2 2013, 5, 1911-1922. \n10. \u201cRemarkable antioxidant properties of a series of hydroxy-3-arylcoumarins\u201d \n(Matos, M.J.*; P\u00e9rez-Cruz, F.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Borges, \nF.; Olea-Azar, C.) \u2013 Bioorganic & Medicinal Chemistry  22013, 21, 3900\u20133906. \n11. \u201cChalcone-based derivati ves as new scaffolds for hA3 adenosine receptor \nantagonists\u201d (Vazquez-Rodriguez, S.*; Matos, M.J.; Santana, L.; Uriarte, E.; Borges, F.; \nKachler, S.; Klotz, K.-N.) \u2013 Journal of Pharmacy & Pharmacology  22013, 65, 697-703. \n12. \u201cSynthesis and Structur e-Activity Relationships  of Novel Amino/Nitro \nSubstituted 3-Arylcoumari ns as Antibacterial Agents\u201d (Matos, M.J.*; Vazquez-\nRodriguez, S.; Santana, L.; Uriarte, E.; Fuentes -Edfuf, C.; Santos, Y.; Mu\u00f1oz-Crego, A.) \n- Molecules  22013, 18, 1394. \n13. \u201cLooking for New Targets: Simple  Coumarins as Antibacterial Agents\u201d \n(Matos, M.J.;* Vazquez-Rodriguez, S.; S antana, L.; Uriarte, E.; Fuentes-Edfuf, C.; \nSantos, Y.; Mu\u00f1oz-Crego, A.) \u2013 Medicinal Chemistry  22012, 8, 1140-1145. \n \n   \n \n     \n98Parte Experimental                                                                                         1. Art\u00edculos  \n \n99 1.2. Art\u00edculos en fase de publicaci\u00f3n. \n14. \u201cSynthesis and Antibact erial Evaluation of Coum arin-Chalcone Hybrids as \nNew and Potent Agents for Tenacibaculosis\u201d (V azquez-Rodriguez, S.*; D\u00edaz, A.; Matos, \nM.J.; Serra, S.; Uriarte, E.; Santana, L .; Mu\u00f1oz-Crego, A.; Sa ntos, Y.) \u2013Enviado. \n15. \u201c3-Benzoylcoumarins as new select ive scaffolds for modulation of the hA1 \nand hA3 binding affinity. Synthesi s, Biological assays and docking studies.\u201d (Vazquez-\nRodriguez, S.*; Serra, S.; Uriarte, E.; Santana,  L.; Kachler, S.; Klotz, K.N.; Vilar, S.) \u2013 \nEnviado. \n \n \n99 \n \n Synthetic MethodsDOI: 10.1002/anie.201305218\nDiastereospecific Nazarov Cyclization of Fully Substituted Dienones:\nGeneration of Vicinal All-Carbon-Atom Quaternary Stereocenters**\nAnais Jolit, Saleta Vazquez-Rodriguez, Glenn P. A. Yap, and Marcus A. Tius*\nThe joining of two carbon atoms through a sbond so as to\nform vicinal all-carbon-atom quaternary centers remains\na difficult challenge in organic synthesis.[1]An effective\nstrategy to address the problem is to exploit an orbital-\nsymmetry-controlled process.[2]We describe herein\na diastereospecific Nazarov cyclization[3]that leads to cyclo-\npentenones bearing adjacent all-carbon-atom quaternarycenters.\nWe are aware of only three examples of Nazarov\ncyclizations that lead to two contiguous all-carbon-atomquaternary stereocenters during the ring-forming step\n(Scheme 1). The efforts of Harding and co-workers [Eqs. (1)\nand (2), Scheme 1] culminated in the total synthesis of dl-\ntrichodiene.\n[4]The reaction conditions in both cases were\nharsh, but the yield of cyclic products 2and 4, which lack\nsensitive functionality, was high. In both reactions theC3a,C3b relative configuration (see compound 2) was deter-\nmined by the conrotation that is required by the selection rule\ngoverning the thermal 4 p-electron process. The third example\nis the oxidative Nazarov cyclization of allenyl ether 5that was\nreported by Frontier and co-workers in 2011 [Eq. (3) in\nScheme 1].[5]The oxyallyl zwitterion that forms spontane-\nously from the allene oxide following the treatment of 5with\ndimethyldioxirane (DMDO) underwent stereospecific cycli-\nzation to 6in moderate yield. The zwitterion intermediate is\nstrongly polarized, hence the mild reaction conditions.\nFrontier and co-workers also described a diastereoselec-\ntive tandem Nazarov\u2013Wagner\u2013Meerwein reaction that leads\nto cyclopentenones bearing vicinal all-carbon-atom stereo-centers.\n[6]Finally, there are two reported examples of the\nNazarov cyclization of 3,5-dibromo-2,6-dimethylhepta-2,5-\ndien-4-one; in each case the reaction led to vicinal gem-\ndimethyl groups in the cyclic product.[7,8]To the best of our\nknowledge, the formation of adjacent quaternary carbon\natoms during the Nazarov cyclization is limited to this verysmall number of examples. These cyclizations representa special challenge because the two \u201cinside\u201d substituents, R\n1\nand R6[Eq. (4)], destabilize the U-shaped s-trans /s-trans\nconformer of the dienone that is able to form a ring, therebydisplacing the equilibrium to the s-cisconformers, which\ncannot cyclize. Herein we will demonstrate how this problem\ncan be overcome through judicious experimental design.\nIt has been shown that polarized dienones undergo\naccelerated Nazarov cyclizations.\n[9,10]An especially effective\nway to activate the dienone toward cyclization is to incorpo-\nrate a \u201cpush\u2013pull\u201d vinylogous carbonate.[11]A synthesis of\nactivated dienones that are ideally suited for the presentapplication is shown in Scheme 2. Metalation of the 2-(trimethylsilyl)ethoxymethyl (SEM) enol ether 7according\nto a procedure described by Knochel and Bresser\n[12]and\nScheme 1. Generation of vicinal all-carbon-atom quaternary stereocen-\nters in the Nazarov cyclization.\nScheme 2. Preparation of the dienone substrate. TMP =2,2,6,6-tetra-\nmethylpiperidinyl.[*] A. Jolit, S. Vazquez-Rodriguez, Dr. G. P. A. Yap, Prof. M. A. Tius\nChemistry Department, University of Hawaii at Manoa\n2545 The Mall, Honolulu, HI 96822 (USA)\nE-mail: tius@hawaii.edu\nD r .G .P .A .Y a p\nDepartment of Chemistry and Biochemistry, University of Delaware236 Brown Laboratory, Newark, DE 19716 (USA)\nProf. M. A. Tius\nUniversity of Hawaii Cancer Center\n701 Ilalo Street, Honolulu, HI 96813 (USA)\n[**] We thank the NIH-NIGMS (R01 GM57873) for partial support and\nthe NSF for CRIF-MRI 1048367.\nSupporting information for this article is available on the WWWunder http://dx.doi.org/10.1002/anie.201305218... AngewandteCommunications\n11102\n /C23 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2013,52, 11102 \u201311105\n\u0018\u0017\u0018101subsequent exposure to (E)-2-methyl-3-phenylbut-2-enoyl\nchloride ( 8) led to dienone 9in 88% yield from the carboxylic\nacid as a single ( E,E) geometrical isomer. The isomeric purity\nof9is critical because contamination by the geometrical\nisomer of either double bond would erode the stereoisomeric\npurity of the derived cyclic product. The substituted acryloylchlorides used in this study were synthesized according toreported procedures from the appropriate acetoacetateesters.\n[13]\nWe optimized the reaction conditions for the Nazarov\ncyclization by using dienone 9(Table 1). No special effort was\nmade to exclude traces of water from the reaction mixture.\nThe first conditions that were examined, trifluoroacetic acid\n(TFA; 90 equiv) in dichloromethane at 0 88C, were successful\nand led to the a-hydroxycyclopentenone 10as a single\ndiastereomer in 63% yield after a reaction time of 1 min\n(Table 1, entry 1). A reduction in the amount of acid used to4 equivalents resulted in a slower reaction that led toa mixture in which 10was a minor product (Table 1,\nentry 2). One of the by-products appeared to be the acyclica-diketone resulting from loss of the SEM group. We\nreasoned that a Br\u00f8nsted acid with a less nucleophiliccounterion would suppress this unwanted reaction. Support\nfor this hypothesis was obtained by the exposure of 9to\ntriflimide (4 equiv), which led to the production of 10in 81%\nyield as a single diastereomer (Table 1, entry 3). In an effort to\nreduce the amount of acid required, the reaction was\nconducted in the presence of 1 and 0.2 equivalents of\ntriflimide (Table 1, entries 4 and 5), but in each case mixtures\nof products were observed. Because the reaction was onlysuccessful when excess acid was used, the mode of additionwas changed. When a solution of 9was added with a syringe\npump to a concentrated solution of triflimide (0.2 equiv;Table 1, entry 6), 10was produced in 80% yield by the time\nthe transfer was complete. When even less triflimide was used(0.1 equiv), it was necessary to increase the addition time, and\nthe yield of 10was 78% (Table 1, entry 7). For all subsequentinvestigations we used the conditions described in entry 6 of\nTable 1. The requirement of a high acid concentration isconsistent with the cyclization of a diprotonated intermediateof the type that West and co-workers postulated for certain\nNazarov cyclizations.\n[14,15]\nThe reaction scope is indicated by the examples in\nScheme 3 of compounds obtained under the optimized\nreaction conditions (Table 1, entry 6). All compounds were\nformed as single diastereomers, and their configuration was\ndetermined by NMR spectroscopy on the basis of NOE data.The configuration of 10was confirmed by single-crystal X-ray\ncrystallographic analysis.\n[16]The yield of the cyclic products\nvaried from 53 to 88%. The cyclization is surprisingly tolerantof sterically demanding substrates. For example, even cyclo-pentenone 16, which bears isopropyl and 2-naphthyl groups\non adjacent carbon atoms, was formed in 53% yield.\nSignificantly, there is no requirement for a baryl group to\nactivate the dienone, as demonstrated by examples 17\u201322.\nThe success of these Nazarov reactions rests in a delicate\nbalance, as the following examples demonstrate. Exposure ofdienone 23, which differs from 9only in the presence of an\nisopropyl group in place of the phenyl group, to the optimized\ncyclization conditions led to an approximately 1.5 :1 mixtureof the anticipated product 24and its diastereomer 25in 81%\nyield [Eq. (5)]. The appearance of 25is evidence of the\noccurrence of double-bond isomerization in 23in competition\nwith cyclization. It is unlikely that isomerization of the enolether took place, because this isomerization would then haveTable 1: Optimization of the reaction conditions.\nEntry Acid (equiv) T[8C] t[min][a]Yield [%][b]\n1[c]TFA (90) 0 1 63\n2[c]TFA (4) 0 10 \u2013\n3[c]Tf2NH (4) 0 2 81\n4[c]Tf2NH (1) 0 2 \u2013\n5[d]Tf2NH (0.2) 0 2 \u2013\n6[e]Tf2NH (0.2) 23 60 80\n7[f]Tf2NH (0.1) 23 180 78\n[a] Total reaction time. [b] Yield of isolated 10. [c] The acid was added\nneat. [d] Triflimide was added as a 0.27 msolution in CH2Cl2. [e] Inverse\naddition at 5 mLmin/C01o fa1msolution of 9to a 1msolution of triflimide.\n[f] Inverse addition at 1.7 mLmin/C01of a 1msolution of 9to a 1msolution\nof triflimide. Tf =trifluoromethanesulfonyl.\nScheme 3. Products formed with vicinal quaternary carbon atoms in\nthe Nazarov cyclization.Angewandteewan\nChemi e\n11103 Angew. Chem. Int. Ed. 2013,52, 11102 \u201311105 /C23 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org\n\u0018\u0017\u0019102been observed for some of the compounds in Scheme 3 under\nthe identical reaction conditions. Furthermore, double-bond\nisomerization was observed during the preparation of ( E)-\n2,3,4-trimethylpent-2-enoyl chloride in the presence of anacid.\n[17]There is a higher barrier to the isomerization of 9\nbecause it requires the disruption of conjugation to the phenylgroup. The formation of 25is remarkable, because it\ndemonstrates that cyclization can even take place efficiently\nwith an \u201cinside\u201d isopropyl group [see Eq. (4)].\nThe use of lactone 26as a substrate revealed an\nunanticipated process [Eq. (6)]. Cyclization according to the\npredicted pathway led to nearly equal amounts of a single\ndiastereomer of 27and by-product 28. The ketene acetal 28\nmay have been formed by means of an intramolecularMichael addition of the oxygen atom of the lactone carbonylgroup. This process is facile in this example because of theenforced coplanarity of the lactone carbonyl group with the\ndienone. It is also possible that 28was formed through an\nelectrocyclization.\n[18]\nDiethylamide 29failed to undergo cyclization even upon\nexposure to triflimide (4 equiv) for 24 h and was recoveredfrom the reaction mixture [Eq. (7)]. This result demonstrates\nthe effect of double-bond polarization on the rate of cycliza-\ntion. The amide group, which is less electron withdrawingthan the ester, apparently does not enable the cyclization\nunder the same conditions.\nIn dienone 31, the SEM group has been replaced with a 4-\nmethoxyphenyl group [Eq. (8)]. Cyclization proceeded in\ngood yield but led to an approximately 1:3 mixture of\ndiastereomers 32and33. This result underscores the critical\nrole that the SEM group plays in the successful cyclization.Favorably polarized 31is expected to cyclize as fast as 9, but\nthe hydrolytic loss of the 4-methoxyphenyl group is probablyslower than SEM cleavage, which does not require theparticipation of water. A slow termination step leading to\na reversible Nazarov\u2013 retro-Nazarov\n[19]process might provide\nan opportunity for enol ether isomerization in 31to compete\nwith cyclization.On the basis of these results, it appears that the Nazarov\ncyclization to produce vicinal all-carbon-atom quaternary\ncenters is successful and diastereospecific within a carefully\ndefined range of reaction parameters. The strongly polarized\n\u201cpush\u2013pull\u201d vinylogous carbonate is required to lower the\nbarrier to cyclization. The SEM group also plays a critical role\nby collapsing rapidly through the loss of ethylene and\nformaldehyde to suppress processes that lead to erosion of\nthe stereochemical integrity of the cyclic product. Inverseaddition of the dienone to the acid leads to a rapid cyclizationthat suppresses undesired competing acid-catalyzed process-\nes. The examples described in Scheme 3 suggest broad\nsynthetic utility, and it is also likely that other \u201cpush\u2013pull\u201d\nalkenes can be used in place of the vinylogous carbonates thathave been described herein. This study greatly expands thescope of the Nazarov reaction by making highly congested\ncyclopentenones readily available. An asymmetric version of\nthis cyclization is under investigation.\n[20]\nExperimental Section\nA reaction vial equipped with a membrane cap was loaded with\nTf2NH (15 mg, 0.054 mmol, 0.2 equiv) in dry CH2Cl2(0.05 mL, 1 m). A\nsmall needle was inserted through the cap to relieve pressure. A\nsolution of dienone 9(112 mg, 0.268 mmol, 1 equiv) in dry CH2Cl2\n(0.27 mL, 1 m) was added dropwise with a syringe pump (5 mLmin/C01)\nto the solution of Tf2NH at room temperature. The reaction mixture\nwas placed on a vortex stirrer during the addition. The reaction\nmixture was then diluted with CH2Cl2(2 mL) and quenched with 5%\naqueous NaHCO3. The aqueous layer was extracted twice with\nCH2Cl2. The combined layers were washed with water and brine and\nthen dried over Na2SO4. Evaporation of the solvent and column\nchromatography (silica gel, 2% Et2O/CH2Cl2) afforded 10(61 mg,\n80%) as a white solid. M.p.: 141\u2013145 88C;1H NMR (300 MHz, CDCl3):\nd=7.28\u20137.06 (m, 5H), 5.31 (s, 1H, OH), 3.49\u20133.39 (m, 1H), 3.32\u20133.18\n(m, 1H), 1.90 (s, 3H), 1.61 (s, 3H), 1.46 (s, 3H), 0.83 ppm (t, J=\n7.2 Hz, 3H);13C NMR (75 MHz, CDCl3):d=200.4, 170.8, 148.2,\n147.5, 141.5, 128.0 (2C), 127.8 (2C), 127.1, 61.5, 60.8, 52.7, 21.3, 18.4,13.4, 10.9 ppm; IR (neat): ~n\u00bc3366, 2982, 1708, 1661, 1445, 1404, 1363,\n1249, 1193, 1083, 777, 733 cm\n/C01; HRMS (ESI+):m/zcalcd for\nC17H20O4: 311.1260 [M +Na]+; found: 311.1253.\nReceived: June 18, 2013\nRevised: July 23, 2013\nPublished online: September 3, 2013\n.Keywords: diastereoselectivity \u00b7 Nazarov cyclization \u00b7\nquaternary stereocenters \u00b7 rearrangement \u00b7 synthetic methods\n[1] A. Peterson, L. E. Overman, Proc. Natl. Acad. Sci. USA 2004,\n101, 11943 \u2013 11948.\n[2] For an especially elegant example, see: J. R. Fuchs, R. L. Funk, J.\nAm. Chem. Soc. 2004,126, 5068 \u2013 5069.\n[3] For reviews of the Nazarov reaction, see: a) W. T. Spencer III, T.\nVaidya, A. J. Frontier, Eur. J. Org. Chem. 2013, 3621 \u2013 3633; b) T.\nVaidya, R. Eisenberg, A. J. Frontier, ChemCatChem 2011,3,\n. AngewandteCommunications\n11104 www.angewandte.org /C23 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2013,52, 11102 \u201311105\n\u0018\u0017\u001a1031531 \u2013 1548; c) N. Shimada, C. Stewart, M. A. Tius, Tetrahedron\n2011,67, 5851 \u2013 5870; d) W. Nakanishi, F. G. West, Curr. Opin.\nDrug Discovery Dev. 2009,12, 732 \u2013 751; e) T. N. Grant, C. J.\nRieder, F. G. West, Chem. Commun. 2009, 5676 \u2013 5688; f) A. J.\nFrontier, C. Collison, Tetrahedron 2005,61, 7577 \u2013 7606; g) H.\nPellissier, Tetrahedron 2005,61, 6479 \u2013 6517; h) M. A. Tius, Eur.\nJ. Org. Chem. 2005, 2193 \u2013 2206; i) M. Harmata, Chemtracts 2004,\n17, 416 \u2013 435.\n[4] a) K. E. Harding, K. S. Clement, C. Y. Tseng, J. Org. Chem. 1990,\n55, 4403 \u2013 4410; b) K. E. Harding, K. S. Clement, J. Org. Chem.\n1984,49, 3870 \u2013 3871.\n[5] W. T. Spencer III, M. D. Levin, A. J. Frontier, Org. Lett. 2011,13,\n414 \u2013 417.\n[6] a) D. Leboeuf, V. Gandon, J. Ciesielski, A. J. Frontier, J. Am.\nChem. Soc. 2012,134, 6296 \u2013 6308; b) D. Leboeuf, J. Huang, V.\nGandon, A. J. Frontier, Angew. Chem. 2011,123, 11173 \u2013 11177;\nAngew. Chem. Int. Ed. 2011,50, 10981 \u2013 10985.\n[7] a) C. W. Shoppee, R. E. Lack, J. Chem. Soc. C 1969, 1346 \u2013 1349;\nb) M. Pawlowski, J. K. Maurin, A. Leniewski, K. Wojtasiewicz,\nZ. Czarnocki, Heterocycles 2005,65, 9 \u2013 22.\n[8] For an example of a Nazarov cyclization that creates vicinal\nquaternary carbon atoms bearing a heteroatom, see: W. He, X.\nSun, A. J. Frontier, J. Am. Chem. Soc. 2008,130, 300 \u2013 308.\n[9] W. He, I. R. Herrick, T. A. Atesin, P . A. Caruana, C. A.\nKellenberger, A. J. Frontier, J. Am. Chem. Soc. 2008,130,\n1003 \u2013 1011.[10] M. A. Tius, C.-K. Kwok, X.-q. Gu, C. Zhao, Synth. Commun.\n1994,24,\n871 \u2013 885.\n[11] A. K. Basak, N. Shimada, W. F. Bow, D. A. Vicic, M. A. Tius, J.\nAm. Chem. Soc. 2010,132, 8266 \u2013 8267.\n[12] P . Knochel, T. Bresser, Angew. Chem. 2011,123, 1954 \u2013 1958;\nAngew. Chem. Int. Ed. 2011,50, 1914 \u2013 1917.\n[13] a) D. Babinski, O. Soltani, D. E. Frantz, Org. Lett. 2008,10,\n2901 \u2013 2904; b) M. Ide, M. Nakata, Synlett 2001, 1511 \u2013 1515.\n[14] Y. K. Wu, T. Niu, F. G. West, Chem. Commun. 2012,48, 9186 \u2013\n9188.\n[15] R. L. Davis, D. J. Tantillo, Curr. Org. Chem. 2010,14, 1561 \u2013\n1577.\n[16] CCDC 949925 contains the supplementary crystallographic data\nfor this paper. These data can be obtained free of charge fromThe Cambridge Crystallographic Data Centre via www.ccdc.\ncam.ac.uk/data_request/cif.\n[17] To suppress isomerization, the acid chloride in this case was\nprepared via the sodium carboxylate.\n[18] We thank a referee for pointing out this possibility.[19] a) M. Harmata, D. R. Lee, C. L. Barnes, Org. Lett. 2005,7, 1881 \u2013\n1883; b) M. Harmata, P . R. Schreiner, D. R. Lee, P . L. Kirch-\nhoefer, J. Am. Chem. Soc. 2004,126, 10954 \u2013 10957; c) M.\nHarmata, D. R. Lee, J. Am. Chem. Soc. 2002,124, 14328 \u2013 14329.\n[20] Optically enriched 11(e.r. 74:26) has been formed with a chiral\nBr\u00f8nsted acid catalyst.Angewandteewan\nChemi e\n11105 Angew. Chem. Int. Ed. 2013,52, 11102 \u201311105 /C23 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org\n\u0018\u0017\u001b104Synthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions\nof 3-chlorocoumarin\nMaria Joao Matosa,b,\u21d1, Saleta Vazquez-Rodrigueza, Fernanda Borgesb, Lourdes Santanaa, Eugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, Portugal\narticle info\nArticle history:\nReceived 15 November 2010Revised 5 January 2011Accepted 12 January 2011\nAvailable online 18 January 2011\nKeywords:\n3-Arylcoumarins\nSuzuki reaction\n3-ChlorocoumarinN,N\n0-Bis(salicylidene)-ethylenediamino-\npalladium catalystabstract\nA convenient, new, and effective protocol for a rapid synthesis of different substituted 3-arylcoumarins is\nreported. The developed synthetic route involves Pd-catalyzed cross-coupling reaction, using a catalytic\ncomplex Pd-salen. Under these conditions, a series of different substituted boronic acids have been suc-\ncessfully reacted with a coumarin halide to afford the coupling products in good yields.\n/C2112011 Elsevier Ltd. All rights reserved.\nCoumarins are an important class of benzopyrones that are\nfound in the vegetable kingdom, either in free or combined state.1\nThey occupy an important place in the realm of natural products\nand synthetic organic chemistry. The diverse biological and phar-\nmaceutical properties of natural and synthetic coumarins as anti-\noxidants,2anti-HIV,3anticancer,4vasorelaxants5or enzymatic\ninhibitors6are well-known.1In the last few years our research\ngroup has been engaged in the synthesis of new biologically active\ncoumarins. In particular, the 3-phenylcoumarin\u2019s scaffold has been\nthe focal point of our most recent studies. In fact we have demon-\nstrated that some 3-phenylcoumarins play an important role in the\nmonoamino oxidase (MAO) enzymatic inhibition.7\u20139Accordingly,\nthe interesting application potential of the 3-arylcoumarins inthe Health Sciences promotes their preparation as an interesting\ntopic in synthetic organic chemistry.\nTwo different strategies can be used to obtain the phenylcouma-\nrins. One is the construction of the coumarin nucleus by condensa-\ntion\u2013cyclization-type reactions. Wittig,\n10Pechmann,5,7,11,12\nPerkin8,9,13\u201317or Knoevenagel18,19reactions are some of the syn-\nthetic routes frequently described to prepare 3-arylcoumarins, start-\ning from phenols or aromatic carbonyl compounds. The classical\nPerkin condensation is perhaps the most direct and simple method\nknown for the preparation of 3-arylcoumarins.16Although this\nmethod is often used, it has some drawbacks such as the application\nof strong acids and high temperatures and sometimes the request of\nmulti-step reactions.An alternative strategy consists in the direct 3-arylation of the\ncoumarin scaffold by metal cross-coupling reactions. In recent\nyears, palladium-catalyzed coupling reactions have been develop-\ning into a versatile and ef\ufb01cient method for the C\u2013C bond forma-\ntion. Suzuki20,21and Stille have described simple synthetic routes\nto obtain C\u2013C liaisons throughout the coupling arylboronic or\norganotin compounds with organic halides catalyzed by a palla-\ndium-complex. In these reactions, Pd complexes are used as cata-\nlysts in which the ligands are P and/or N lone pairs donors or\nactive Pd complexes are generated in situ.22In the \ufb01rst case, some\nof these ligands are expensive, toxic, and sensitive to air and a ma-jor challenge lies in the separation of product from the expensive\ncatalyst, much to the dismay of large-scale producers.\n22Ionic liq-\nuids,23free of organic solvent systems or phase-transfer catalysts24\nhave been used to provide a green alternative chemistry to the\nconventional organic methodologies, but they are not devoid of\ntoxicity. In turn, phosphine ligands25had played an important role\nin C\u2013C bond formation, in homogeneous reaction medium. Severalefforts have been made in order to discover air and moisture-stable\npalladium ligands.\n25However, these ligands are air- and moisture-\nsensitive and the P\u2013C bond degradation frequently occurs at ele-vated temperature.\n26The degradation of the catalyst strongly af-\nfects conversion and selectivity of the derivatives.27So, different\nmethods using phosphine-free ligands have been explored for\napplication in this kind of reactions.28\nBecause of its versatility, palladium catalyzed coupling reac-\ntions were widely used to synthesize different arylcoumarins.\nThe arylation in 4-position of the coumarin nucleus is usually\nachieved by arylation of 4-hydroxycoumarins with arylboronic\n0040-4039/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.tetlet.2011.01.048\u21d1Corresponding author.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Tetrahedron Letters 52 (2011) 1225\u20131227\nContents lists available at ScienceDirect\nTetrahedron Letters\njournal homepage: www.elsevier.com/locate/tetlet\n\u0018\u0017\u001c105acids via C\u2013OH bond activation.29Accordingly, the 4-hydroxy\ngroup is converted in pseudo halides, such as tri\ufb02ates or tosylates\nwhich are used instead of halides in a coupling reaction with aryl-\nboronic acids (via a Suzuki type reaction). In other cases, the aryl\nsubstituents have been successfully incorporated in 4-position of\nthe hydroxycoumarin using organostannanes30or organozinc com-\npounds31under Stille or Negishi conditions, respectively.\nHowever, the formation of the aryl C\u2013C bond using coumarin as\nstarting material is till now an uncommon subject.32,33To our\nknowledge, few papers have been published so far concerning the\n3-arylation of coumarin nucleus by direct coupling under Suzuki\nconditions: in all these cases, the halide was 3-bromocoumarin.\nAnd the catalysts were the classic palladium acetate (Pd(OAc) 2), tet-\nrakis(triphenylphosphine)palladium (0) Pd(PPh3) 434,35, and [1,10-\nbis(diphenylphosphino)ferrocene]palladium(II) dichloride.36,37\nSalen ligand has been found to be a highly active catalyst for the Su-\nzuki reaction performed with aryl iodides, bromides, and chlorides,\ngiving excellent yields, in a short reaction time.38,39Salen ligand is a\nbright yellow solid, soluble in polar organic solvents, and effective inC\u2013C bond forming reactions with high selectivity. This symmetrical\npalladium(II) complex was a product of the reaction of the Salen li-\ngand with palladium acetate (for 20 h at room temperature) in a\ngood yield. This complex promotes a catalytic activity in a low con-\ncentration (0.5 mol %).\n40Noteworthy to mention that Salen is a che-\nlating ligand generally used in coordination chemistry and\nhomogeneous catalysis.41\nAlthough signi\ufb01cant advances have been performed in the metal-\ncatalyzed synthesis, the palladium-catalyzed cross-couplingreaction using 3-chlorocoumarin to afford 3-arylcoumarins has\nnever been described. This constraint encourages us to explore this\nsynthetic strategy. Accordingly, preliminary experiments were done\nto examine the effect of various ligands for Pd-based coupling.42,43\nThe most promising one was N,N0-bis(salicylidene)-ethylenediami-\nno-palladium (salen-Pd). In fact, Pd(OAc) 2-salen couple in presence\nof a Na 2CO3in DMF/H 2O (1:1) was found to be an ef\ufb01cient catalytic\nsystem to obtain a variety of 3-arylcoumarin derivatives (Scheme\n1).40As coumarins are sensitive substrates to alkaline conditions,\nand may result in the cleavage of the lactone ring, the solvent, and\nbase for the coupling reaction were carefully studied. To optimize\nthe reaction the in\ufb02uence of the palladium source in the catalytic\nactivity was also performed. Pd(OAc) 2was found to be the best op-\ntion.40After reaction optimization, the in\ufb02uence of the Pd-salen\ncomplex in the Suzuki reaction involving cross-coupling of a couma-\nrin halide and different arylboronic acids was investigated. The Su-\nzuki reaction developed herein was found to be effective when\nusing arylboronic acids with a variety of functional groups. Further-\nmore the reaction works with iodo-, bromo- or chloro-coumarin\nsubstrates. Different reaction times are required for each coumarin\nhalide type. Although it is well-known that in Suzuki reaction the\nchloride derivatives are less reactive than the bromide or the iodide\nones, the use of the 3-chlorocoumarin as starting material in the\nreaction is related with its commercial availability. The synthesis\nof 3-iodocoumarin and 3-bromocoumarin involves the introduction\nof other synthetic steps in the overall reaction.\nComparing the synthetic route herein proposed with the classic\none, previously reported by us,7,8one can verify that both are easy\nand not too expensive methodologies. The main advantage of this\nnew synthetic approach is that it can afford 3-arylcoumarins with\ndifferent substitution patterns. By means of the traditional meth-\nodology, hydroxyl and nitro derivatives could not be obtained\nand/or puri\ufb01ed. The reaction was not clean and the obtained crude\nproduct was a complex mixture with several sub-products and the\npuri\ufb01cation process was worthless. The reaction versatility is the\nmain advantage of this synthetic strategy comparing to the classic\nPerkin reaction. Compounds 4\u2013744\u201346and1047are exclusively pre-\npared by the Suzuki methodology while compounds 1\u20133,8, and 9\ncan be prepared by both methods (Table 1 ).48\u201350The proposed syn-\nthetic strategy operates from micro- to macro-scale and avoids the\nformation of undesired sub-products. The palladium complex can\nbe easily and almost totally recuperated at the end of the process.\nThe catalyst is recovered from the reaction mixture when the prod-\nuct is puri\ufb01ed by \ufb02ash chromatography and it is ready to be reused.\nThis subject has great interest because of the toxicity and the cost\nof palladium complexes.\nIn conclusion, a novel and versatile route for the synthesis of 3-\narylcoumarins is proposed. The palladium cross-coupling reactioncan be applied to obtain a series of different functionalized deriv-\natives. In addition, we have shown that N,N\n0-bis(salicylidene)-eth-\nylenediamino-palladium proved to be a good catalyst for theSuzuki reaction of heterocyclic activated chlorides with arylbo-\nronic acids, under aerobic conditions. This methodology is an ef\ufb01-\ncient synthetic route for obtaining different 3-arylcoumarins.\nAcknowledgments\nThe authors thank the Spanish Ministry (PS0900501) and Xunta\nda Galicia (INCITE09E2R203035ES and PGIDIT09CSA030203PR) for\nthe \ufb01nancial support. M.J.M. thanks Funda\u00e7\u00e3o de Ci\u00eancia e Tecno-\nlogia for the SFRH/BD/61262/2009 scholarship.\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887\u2013916.O O O OCl\n1-9\n(a)R\nO ON\n10\n60 %Cl 1:R=H\n2:R=p-OMe\n3:R=m-OMe\n4:R=m-OH\n5:R=p-NO 2\n6:R=m-NO 2\n7:R=m-NH2\n8:R=p-Me\n9:R=p-Cl(a)\n61 %\n58 %\n56 %64 %\n65 %\n55 %\n59 %\n63 %\n61 %\nScheme 1. Synthesis of 3-arylcoumarin derivatives. Reagents and conditions: (a) 3-\nchlorocoumarin (1.0 equiv), phenylboronic acid/2-chloro-5-pyridineboronic acid\n(1.25 equiv), sodium carbonate (2.0 equiv), palladium complex (0.5 mol %), DMF/\nH2O (1:1), 110 /C176C, 120\u2013180 min.\nTable 1\nSynthesis of 3-arylcoumarins ( 1\u201310) by Perkin reaction and/or via Suzuki-cross-\ncoupling reaction\nCompounds Perkin reactionaSuzuki reactionb\nTime (min) Yield (%) Time (min) Yield (%)\n1 1440 60 120 61\n2 1440 65 120 58\n3 1440 68 120 56\n4 \u2044\u2044 180 64\n5 \u2044\u2044 160 65\n6 \u2044\u2044 160 55\n7 \u2044\u2044 160 59\n8 1440 70 120 63\n9 2160 63 140 61\n10 \u2044\u2044 140 60\n*Compounds 4\u20137and10are exclusively prepared by the Suzuki methodology.\naConditions: phenylacetic acids, DCC, DMSO, 110 /C176C, 24\u201336 h.\nbReactions with 3-chlorocoumarin. Compound 1was synthesized using 3-bro-\nmocoumarin\u2014reaction time: 100 min; yield: 70%.1226 M. J. Matos et al. / Tetrahedron Letters 52 (2011) 1225\u20131227\n\u0018\u0017\u001d1062. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18,\n63\u201369.\n3. Spino, C.; Dodier, M.; Sotheeswaran, S. Bioorg. Med. Chem. Lett. 1998 ,8, 3475\u2013\n3478.\n4. Kempen, I.; Papapostolou, D.; Thierry, N.; Pochet, L.; Counerotte, S.; Masereel,\nB.; Foidart, J. M.; Reboud-Ravaux, M. J.; Noel, A.; Pirotte, B. Br. J. Cancer 2003 ,88,\n1111\u20131118.\n5. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257\u2013261.\n6. Quezada, E.; Delogu, G.; Picciau, C.; Santana, L.; Podda, G.; Borges, F.; Garcia-\nMoraes, V.; Vina, D.; Orallo, F. Molecules 2010 ,15, 270\u2013279.\n7. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740\u20136751.\n8. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268\u20133270.\n9. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053\u20135055.\n10. Mali, R. S.; Joshi, P. P. Synth. Commun. 2001 ,31, 2753\u20132767.\n11. Ming, Y.; Boykin, D. W. Heterocycles 1987 ,26, 3229\u20133231.\n12. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect B 1996 ,11,\n1159\u20131162.\n13. Khiri, C.; Ladhar, F.; El Gharbi, R.; Le Bigot, Y. Synth. Commun. 1999 ,29, 1451\u2013\n1461.\n14. Mohanty, S.; Makrandi, J. K.; Grove, S. K. Indian J. Chem., Sect B 1989 ,28B, 766\u2013\n769.\n15. Langmuir, M. E.; Yang, J. R.; Moussa, A. M.; Laura, R.; Lecompte, K. A.\nTetrahedron Lett. 1995 ,36, 3989\u20133992.\n16. Mashraqui, S.; Vashi, D.; Mistry, H. D. Synth. Commun. 2004 ,34, 3129\u20133134.\n17.\nKabeya, L. M.; de Marchi, A. A.; Kanashiro, A.; Lopes, N. P.; da Silva, C. H. Bioorg.\nMed. Chem. 2007 ,15, 1516\u20131524.\n18. Bogdal, D. J. Chem. Res. (S) 1998 , 468\u2013469.\n19. Mali, R. S.; Tilve, S. G. Synth. Commun. 1990 ,20, 1781\u20131791.\n20. Suzuki, A. J. Organomet. Chem. 2002 ,653, 83\u201390.\n21. Wang, J.; Meng, F.; Zhang, L. Organometallics 2009 ,28, 2334\u20132337.\n22. Cobert, J. P.; Mignani, G. Chem. Rev. 2006 ,106, 2651\u20132710.\n23. Dupont, J.; de Souza, R. F.; Suarez, A. Z. Chem. Rev. 2002 ,102, 3667\u20133691.\n24. Paetzold, E.; Oehme, G. J. Mol. Catal. A: Chem. 2000 ,152, 69\u201376.\n25. Genet, J. P.; Savignac, M. J. Organomet. Chem. 1999 ,576, 305\u2013317.\n26. Sa\ufb01n, D. A.; Babashkina, M. G. Catal. Lett. 2009 ,130, 679\u2013682.\n27. Mingji, D.; Liang, B.; Wang, C.; You, Z.; Xiang, J.; Dog, G.; Chen, J.; Yang, Z. Adv.\nSynth. Catal. 2004 ,346, 1669\u20131673.\n28. Farina, V. Adv. Synth. Catal. 2004 ,346, 1553\u20131582.\n29. Luo, Y.; Wu, J. Tetrahedron Lett. 2009 ,50, 2103\u20132105.\n30. Schio, L.; Chatreaux, F.; Klich, M. Tetrahedron Lett. 2000 ,41, 1543\u20131547.\n31. Wu, J.; Liao, Y.; Yang, Z. J. Org. Chem. 2001 ,66, 3642\u20133645.\n32. Nemeryuk, M. P.; Dimitrova, V. D.; Sedov, A. L.; Anisimova, O. S.; Traven, V. F.\nChem. Heterocycl. Compd. 2002 ,38, 249\u2013250.\n33. Martins, S.; Branco, P. S.; de la Torre, M. C.; Sierra, M. A.; Pereira, A. Synlett\n2010 ,19, 2918\u20132922.\n34. Schiedel, M.-S.; Briehn, C. A.; Bauerle, P. Angew. Chem., Int. Ed. 2001 ,40, 4677\u2013\n4680.\n35. Chen, L.; Hu, T.-S.; Yao, Z.-J. Eur. J. Org. Chem. 2008 ,36, 6175\u20136182.36. Guo, H.-M.; Tanaka, F. J. Org. Chem. 2009 ,74, 2417\u20132424.\n37. Zhang, L.; Meng, T.; Fan, R.; Wu, J. J. Org. Chem. 2007 ,72, 7279\u20137286.\n38. Miller, K. J.; Baag, J. H.; Abu-Omar, M. M. Inorg. Chem. 1999 ,38, 4510\u20134514.\n39. Audisio, D.; Messaoudi, S.; Peyrat, J. F.; Alami, M. Tetrahedron Lett. 2007 ,48,\n6928\u20136932.\n40. Borhade, S. R.; Waghmode, S. B. Tetrahedron Lett. 2008 ,49, 3423\u20133429.\n41. Bahkerad, M.; Keivanloo, A.; Bahramian, B.; Hashemi, M. Tetrahedron Lett. 2009 ,\n50, 1557\u20131559.\n42. Crociani, B.; Antonaroli, S.; Burattini, M.; Benetollo, F.; Scrivanti, A.; Bertoldini,\nM.J. Organomet. Chem. 2008 ,693, 3932\u20133938.\n43. Blug, M.; Guibert, C.; Le Goff, X.; M\u00e9zailles, N. Chem. Commun. 2009 ,2, 201\u2013\n203.\n44. Leitao, A.; Andricopulo, A. D.; Oliva, G.; Pupo, M. T.; de Marchi, A. A.; Vieira, P.\nC.; da Silva, M. F.; Ferreira, V. F.; de Souza, M. C.; Sa, M. M.; Moraes, V.;\nMontanari, C. A. Bioorg. Med. Chem. Lett. 2004 ,14, 2199\u20132204.\n45. Mashraqui, S. H.; Vashi, D.; Mistry, H. D. Synth. Commun. 2004 ,34, 3129\u20133134.\n46. General method to prepare 3-arylcoumarins: To a 20 mL two neck round-\nbottomed \ufb02ask was added a solution of 3-chlorocoumarin (0.83 mmol), aryl\nboronic acid (1.04 mmol), Na 2CO3(1.66 mmol), and Pd-salen complex\n(0.5 mol %) in DMF/H 2O (1:1). The reaction mixture was heated at 110 /C176C for\n120\u2013180 min. The reaction was monitored by chromatography. After the\ncompletion of the reaction, the mixture was extracted with ethyl acetate\n(3/C220 mL). The organic extracts were dried over anhydrous sodium sulphate,\n\ufb01ltrated, and the solvent was evaporated under vacuum. The obtained crude\nproduct was puri\ufb01ed by column chromatography (hexane/ethyl acetate 9:1) to\ngive the coumarins ( 1\u20139).3-(30-Nitrophenyl)coumarin (6): yellow solid, yield\n55%; mp 252\u20133 /C176C.1H NMR (CDCl 3):d= 7.17\u20137.22 (m, 2H, H-7, H-8), 7.39\u20137.48\n(m, 3H, H-5, H-6, H-50), 7.52\u20137.54 (m, 1H, H-60), 7.60\u20137.71 (m, 2H, H-4, H-40),\n8.44 (s, 1H, H-20).13C NMR (CDCl 3):d= 110.0, 114.2, 116.7, 117.6, 119.3, 122.8,\n125.5, 128.5, 131.1, 132.6, 132.7, 141.4, 149.1, 152.8, 158.6. MS: m/z(%) = 268\n(26), 267 (M+, 100), 239 (24), 221 (38), 193 (17) 165 (52), 164 (16), 163 (19),\n139 (12), 82 (11). Anal. calcd. for C 15H9NO 4(267.24): C, 67.42; H, 3.39. Found:\nC, 67.38; H, 3.36. 3-(30-aminophenyl)coumarin (7): white solid, yield 59%; mp\n154\u20135 /C176C.1H NMR (CDCl 3):d= 4.12 (s, 2H, \u2013NH 2), 7.27\u20137.38 (m, 4H, H-20, H-40,\nH-60, H-8), 7.47 (dd, 2H, H-6, H-7, J= 7.74, J= 1.31), 7.53\u20137.58 (m, 2H, H-5, H-\n50), 7.88 (s, 1H, H-4).13C NMR (CDCl 3):d= 116.8, 118.8, 122.4, 125.0, 125.2,\n127.2, 127.8, 128.7, 131.9, 133.3, 140.1, 152.6, 155.2, 157.3, 158.8. MS: m/z\n(%) = 239 (10), 238 (19), 237 (M+, 100), 182 (36), 181 (12), 152 (50), 124 (18),\n89 (45), 63 (28), 62 (18). Anal. calcd. for C 15H11NO 2(237.25): C, 75.94; H, 4.67.\nFound: C, 76.00; H, 4.72.\n47. 3-(40-Chloropyridin-30-yl)coumarin (10): white solid, yield 60%; mp 234\u20135 /C176C.\n1H NMR (CDCl 3):d= 7.32\u20137.37 (m, 2H, H-50, H-8), 7.46 (d, 2H, H-6, H-7,\nJ= 7.51), 7.52\u20137.58 (m, 2H, H-5, H-60), 7.88 (s, 1H, H-4), 8.58 (s, 1H, H-20).13C\nNMR (CDCl 3):d= 116.8, 118.8, 122.3, 124.7, 125.0, 125.2, 127.2, 131.8, 137.0,\n140.0, 147.7, 149.6, 152.7, 157.3. MS: m/z(%) = 260 (5), 259 (32), 258 (15), 257\n(M+, 100), 223 (18), 182 (34), 152 (44) 123 (13), 89 (40), 85 (23), 71 (30), 63\n(18), 57 (35). Anal. calcd. for C 14H8ClNO 2(257.57): C, 65.26; H, 3.13. Found: C,\n65.24; H, 3.10.\n48. Castaneda, F. Rendiconti Istituto Superiore di Sanita (Italian Edition) 1964 ,27, 99.\n49. Sabitha, G.; Rao, A. V. Synth. Commun. 1987 ,17, 341\u2013354.\n50. Archer, J. F.; Grimshaw, J. J. Chem. Soc., Sect B: Phys. Org. 1969 ,3, 266\u2013270.M. J. Matos et al. / Tetrahedron Letters 52 (2011) 1225\u20131227 1227\n\u0018\u0017\u001e107 electronic reprint\nActa Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\nEditors: W. T. A. Harrison, H. Stoeckli-Evans,\nE. R. T. Tiekink and M. Weil\n3-(4-Methoxybenzoyl)-6-nitrocoumarin\nSaleta Vazquez-Rodriguez, Eugen io Uriarte and Lourdes Santana\nActa Cryst. (2013). E 69, o345\nThis open-access article is distributed under the terms of the Creative Commons Attribution Licence\nhttp://creativecommons.org/licenses/by/2.0/uk/legalcode , which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original authors and source are cited.\nActa Crysta llographica Section E: Structure Re ports Online is the IUCr\u2019s highly popu-\nlar open-access structural j ournal. It provides a simple and easily accessi ble publication\nmechanism for the growing number of inorganic, metal-organic and organic crystal struc-\nture determinations. The electronic submission, validation, refereeing and publication\nfacilities of the journal ensure very rapid and high-quality publication, whilst key indica-\ntors and validation reports provide measures of structural reliability . The journal publishes\nover 4000 structures per year. The average publication time is less than one month.\nCrystallography Journals Online is available from journals.iucr.org\nActa Cryst. (2013). E 69, o345 Vazquez-Rodriguez et al. \u00b7C17H11NO 6\n\u0018\u0017 1093-(4-Methoxybenzoyl)-6-nitrocoumarin\nSaleta Vazquez-Rodriguez,* Eugenio Uriarte and Lourdes\nSantana\nDepartment of Organic Chemistry, University of Santiago de Compostela, Santiago\nde Compostela, A Coruna, Spain\nCorrespondence e-mail: svre77@gmail.com\nReceived 21 January 2013; accepted 29 January 2013\nKey indicators: single-crystal X-ray study; T= 100 K; mean /C27(C\u2013C) = 0.003 A \u02da;\nRfactor = 0.043; wRfactor = 0.126; data-to-parameter ratio = 13.1.\nIn the title coumarin derivative (also known as 2 H-chromen-2-\none or 2 H-1-benzopyran-2-one), C 17H11NO 6, the coumarin\nring system is nearly planar, with a dihedral angle of 3.35 (9)/C14\nbetween the pyrone and the benzene rings. The dihedral angle\nbetween the planes formed by the coumarin ring system and\nthe benzene substituent is 54.60 (7)/C14, clearly showing the non-\ncoplanarity of the whole aromatic system. The crystal studiedwas a non-merohedral twin; the minor component re\ufb01ned toapproximately 0.44.\nRelated literature\nFor the synthesis of the title compound, see: Raju et al. (2010).\nFor examples of the biological activity of coumarin derivatives,see: Borges et al. (2009), Matos et al. (2011 a,b,c), Vin \u02dcaet al.\n(2012 a,b); Vazquez-Rodriguez et al. (2013).\nExperimental\nCrystal data\nC17H11NO 6\nMr= 325.27\nMonoclinic, P21=n\na= 8.875 (3) A \u02dab= 17.266 (5) A \u02da\nc= 9.174 (3) A \u02da\n/C12= 95.401 (15)/C14\nV= 1399.6 (7) A \u02da3Z=4\nMoK/C11radiation\n/C22= 0.12 mm/C01T= 100 K\n0.67/C20.14/C20.03 mm\nData collection\nBruker APEXII CCD\ndiffractometer\nAbsorption correction: multi-scan\n(SADABS ; Bruker, 2007)\nTmin= 0.604, Tmax= 0.74530736 measured re\ufb02ections\n2864 independent re\ufb02ections\n2200 re\ufb02ections with I>2/C27(I)\nRint= 0.054\nRe\ufb01nement\nR[F2>2/C27(F2)] = 0.043\nwR(F2) = 0.126\nS= 0.91\n2864 re\ufb02ections219 parameters\nH-atom parameters constrained\n/C1/C26max= 0.39 e A \u02da/C03\n/C1/C26min=/C00.26 e A \u02da/C03\nData collection: APEX2 (Bruker, 2007); cell re\ufb01nement: SAINT\n(Bruker, 2007); data reduction: SAINT ; program(s) used to solve\nstructure: SIR97 (Altomare et al. , 1999); program(s) used to re\ufb01ne\nstructure: SHELXL97 (Sheldrick, 2008); molecular graphics:\nORTEP-3 for Windows (Farrugia, 2012); software used to prepare\nmaterial for publication: WinGX (Farrugia, 2012).\nThis work was partially supported by the funds of the Xunta\nda Galicia (09CSA030203PR) and the Ministerio de Sanidad y\nConsumo (PS09/00501). SVR thanks the FPU program for her\nPhD grant AP2008\u201304263.\nSupplementary data and \ufb01gures for this paper are available from the\nIUCr electronic archives (Reference: GO2080).\nReferences\nAltomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C.,\nGuagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J.\nAppl. Cryst. 32, 115\u2013119.\nBorges, F., Roleira, F., Milhazes, N., Uriarte, E. & Santana, L. (2009). Front.\nMed. Chem. 4, 23\u201385.\nBruker (2007). APEX2 ,SAINT andSADABS . Bruker AXS Inc., Madison,\nWisconsin, USA.\nFarrugia, L. J. (2012). J. Appl. Cryst. 45, 849\u2013854.\nMatos, M. J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M. B., Era,\nB. & Fais, A. (2011 c).Bioorg. Med. Chem. Lett. 21, 3342\u20133345.\nMatos, M. J., Tera \u00b4n, C., Pe \u00b4rez-Castillo, Y., Uriarte, E., Santana, L. & Vin \u02dca, D.\n(2011 a).J. Med. Chem. 54, 7127\u20137137.\nMatos, M. J., Vazquez-Rodriguez, S., Santan, L., Uriarte, E. & Vin \u02dca, D.\n(2011 b).Bioorg. Med. Chem. Lett. 21, 4224\u20134227.\nRaju, B. C., Tiwari, A. K., Kumar, J. A., Ali, A. Z., Agawane, S. B., Saidachary,\nG. & Madhusudana, K. (2010). Bioorg. Med. Chem. 18, 358\u2013365.\nSheldrick, G. M. (2008). Acta Cryst. A64, 112\u2013122.\nVazquez-Rodriguez, S., Matos, M. J., Santana, L., Uriarte, E., Borges, F.,\nKachler, S. & Klotz, K.-N. (2013). J. Pharm. Pharmacol. DOI: 10.1111/\njphp.12028.\nVin\u02dca, D., Matos, M. J., Ferino, G., Cadoni, E., Laguna, R., Borges, F., Uriarte,\nE. & Santana, L. (2012 b).Chem. Med. Chem. 7, 464\u2013470.\nVin\u02dca, D., Matos, M. J., Ya \u00b4n\u02dcez, M., Santana, L. & Uriarte, E. (2012 a).Med.\nChem. Commun. 3, 213\u2013218.organic compounds\nActa Cryst. (2013). E 69, o345 doi:10.1107/S1600536813002948 Vazquez-Rodriguez et al. o345Acta Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\n\u0018\u0018\u0017110supplementary materials\nsup-1 Acta Cryst.  (2013). E 69, o345    supplementary materials\nActa Cryst.  (2013). E 69, o345    [doi:10.1107/S1600536813002948]\n3-(4-Methoxybenzoyl)-6-nitrocoumarin\nSaleta Vazquez-Rodriguez, Eugenio Uriarte and Lourdes Santana\nComment\nCoumarin derivative compounds present a great interest in the medicinal chemistry field due to the displayed biological \nproperties that they present (Borges et al.  2009, Matos et al.  2011 a, Matos et al.  2011 b, Matos et al.  2011 c, Vazquez-\nRodriguez et al.  2013, Vi\u00f1a et al.  2012 a and Vi\u00f1a et al.  2012 b). The title structure is a 3-substituted coumarin derivative \ncontaining a 4-methoxybenzoyl ring at the mentioned position and a nitro group at position 6 of the coumarin scaffold. \nTherefore, the X-ray analysis of this compound (figure 1)  aims to contribute to the elucidation of structural requirements \nneeded to understand the partial planarity of the compound (coumarin nucleus) and the torsion of the 3-benzoyl moiety \nregarding to this nucleus. From the single-crystal diffraction measurements one can conclude that both the pyrone and \nbenzene rings in the coumarin motif are essentially planar, presenting dihedral angle of 3.35 (9)\u00b0. The planarity of the \ncoumarin moiety is also evident by the torsion angle value between their carbons C3\u2014C2\u2014C7\u2014C8 (-175.89 (18)\u00b0).\nIn addition, the torsion angles of the carbonyl group versus  the coumarin moiety and the phenyl ring are C10\u2014C9\u2014\nC15\u2014O16 (43.2 (2)\u00b0) and O16\u2014C15\u2014C17\u2014C18 (-152.9 (2)\u00b0) respectively. These values are typical of the torsion \npermitted by the rotation present at position 3. Presence of the carbonyl group at position 3 provokes a non coplanarity of the benzoyl moiety regarding to the coumarin scaffold. This fact is evident taking into account the dihedral angles formed \nby the planes of the coumarin, the carbonyl and the phenyl groups. Dihedral angle between the coumarin moiety and the \ncarbonyl group is 38.66 (9)\u00b0; between the carbonyl and the phenyl group is 25.76 (10)\u00b0 and between the coumarin \nscaffold and the phenyl group is 54.60 (7)\u00b0.\nExperimental \n3-(4-Methoxybenzoyl) -6-nitrocoumarin was prepared according to the following protocol: to a solution of 2-hydroxy-5-\nnitrobenzaldehyde (1 mmol) and ethyl 4-methoxybenzoylacetate (1 mmol) in ethanol (4 ml), a catalytic amount of \npiperidine (5%) was added dropwise and the reaction was stirred at refluxed for 4 h. The precipitated was filtered and the \nsolid obtained was recrystallized in dichlomethane/methanol in a 73% yield. Mp 257\u2013259 \u00b0C.\nRefinement\nH atoms were treated as riding atoms with C\u2014H(aromatic), 0.95\u00c5 with U\niso = 1.2U eq(C), C\u2014H(methyl) = 0.98\u00c5, with \nUiso = 1.5U eq(C). The positions of methyl hydrogens were checked on a final difference map. The structure was refined as \na two-component non-merohedral twin with a BASF parameter of 0.4374.\nComputing details \nData collection: APEX2  (Bruker, 2007); cell refinement: SAINT  (Bruker, 2007); data reduction: SAINT  (Bruker, 2007); \nprogram(s) used to solve structure: SIR97  (Altomare et al. , 1999); program(s) used to refine structure: SHELXL97  \n(Sheldrick, 2008); molecular graphics: ORTEP- 3 for Windows  (Farrugia, 2012); software used to prepare material for \npublication: WinGX  (Farrugia, 2012).\n\u0018\u0018\u0018111supplementary materials\nsup-2 Acta Cryst.  (2013). E 69, o345    \nFigure 1\nMolecular structure of the title compound with the atom-numbering scheme. Displacement ellipsoids are drawn at the \n50% probability level. \nFigure 2\nPacking diagram of the title structure viewed along the b axis. \n3-(4-Methoxybenzoyl)-6-nitrocoumarin \nCrystal data  \nC17H11NO 6\nMr = 325.27\nMonoclinic, P21/n\na = 8.875 (3) \u00c5\nb = 17.266 (5) \u00c5\nc = 9.174 (3) \u00c5\u03b2 = 95.401 (15)\u00b0\nV = 1399.6 (7) \u00c53\nZ = 4\nF(000) = 672\nDx = 1.544 Mg m\u22123\nMo K\u03b1 radiation, \u03bb  = 0.7107 \u00c5\n\u0018\u0018\u0019112supplementary materials\nsup-3 Acta Cryst.  (2013). E 69, o345    Cell parameters from 1848 reflections\n\u03b8 = 2.4\u201326.2\u00b0\n\u00b5 = 0.12 mm\u22121T = 100 K\nPrism, colourless0.67 \u00d7 0.14 \u00d7 0.03 mm\nData collection \nBruker APEXII CCD \ndiffractometer\nRadiation source: fine-focus sealed tube\nGraphite monochromator\u03c9 and phi scans\nAbsorption correction: multi-scan \n(SADABS ; Bruker, 2007)\nT\nmin = 0.604, Tmax = 0.74530736 measured reflections2864 independent reflections2200 reflections with I > 2\u03c3(I)\nR\nint = 0.054\n\u03b8max = 26.5\u00b0, \u03b8min = 2.4\u00b0\nh = \u221211\u219211\nk = 0\u219221l = 0\u219211\nRefinement \nRefinement on F\n2\nLeast-squares matrix: full\nR[F2 > 2\u03c3(F2)] = 0.043\nwR(F2) = 0.126\nS = 0.91\n2864 reflections219 parameters0 restraintsPrimary atom site location: structure-invariant \ndirect methodsSecondary atom site location: difference Fourier \nmap\nHydrogen site location: inferred from \nneighbouring sites\nH-atom parameters constrainedw = 1/[ \u03c3\n2(Fo2) + (0.0871 P)2 + 0.3903 P] \nwhere P = (F o2 + 2Fc2)/3\n(\u0394/\u03c3)max < 0.001\n\u0394\u03c1max = 0.39 e \u00c5\u22123\n\u0394\u03c1min = \u22120.26 e \u00c5\u22123\nSpecial details  \nExperimental . 1H NMR (250 MHz, DMSO- d6) \u03b4 p.p.m. 8.29 (d, J = 3.2 Hz, 1H, H-4), 7.75 (dd, J = 9.8, 3.1 Hz, 1H, \nH-7), 7.69\u20137.56 (m, 3H, H-5, o-H-2, o -H-6), 7.04 (d, J = 8.3 Hz, 2H, m-H-3, m -H5), 6.08 (d, J = 9.6 Hz, 1H, H-8), 3.83 \n(s, 3H, \u2013OMe); 13C NMR (63 MHz, DMSO-d 6) \u03b4 p.p.m. 192.91, 177.98, 166.65, 162.34, 138.75, 131.40, 130.83, 130.47, \n129.32, 128.05, 127.28, 121.24, 120.67, 113.84, 55.61; MS EI m/z (%): 326 ([ M+1]+, 25), 325 ([ M]+, 93), 190 (34), 135 \n(100), 92 (27), 77 (37); Elem. Anal. Calcd. for C 17H11NO 6: C, C, 62.77; H, 3.41; Found: C, 62.72; H, 3.32.\nGeometry . All s.u.'s (except the s.u. in the dihedral angle between two l.s. planes) are estimated using the full covariance \nmatrix. The cell s.u.'s are taken into account individually in the estimation of s.u.'s in distances, angles and torsion angles; correlations between s.u.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell s.u.'s is used for estimating s.u.'s involving l.s. planes.\nRefinement . Refinement of F\n2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, \nconventional R-factors R  are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2\u03c3(F2) is \nused only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based \non F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.\nFractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\u00c52) \nxyz U iso*/Ueq\nC2 0.0307 (2) 0.13803 (12) 0.5978 (2) 0.0137 (4)\nC3\u2212 0.0864 (2) 0.16362 (12) 0.6744 (2) 0.0153 (5)\nH3\u2212 0.1256 0.2145 0.6595 0.018*\nC4\u2212 0.1455 (2) 0.11473 (12) 0.7723 (2) 0.0164 (5)\nH4\u2212 0.2265 0.1310 0.8257 0.020*\nC5\u2212 0.0842 (2) 0.04053 (13) 0.7918 (2) 0.0156 (5)\nC6 0.0352 (2) 0.01480 (13) 0.7193 (2) 0.0147 (5)\nH6 0.0751 \u22120.0358 0.7364 0.018*\nC7 0.0969 (2) 0.06452 (12) 0.6200 (2) 0.0131 (4)\n\u0018\u0018\u001a113supplementary materials\nsup-4 Acta Cryst.  (2013). E 69, o345    C8 0.2244 (2) 0.04597 (12) 0.5416 (2) 0.0135 (4)\nH8 0.2701\u2212 0.0036 0.5544 0.016*\nC9 0.2809 (2) 0.09697 (11) 0.4506 (2) 0.0131 (4)\nC10 0.2034 (2) 0.17126 (12) 0.4186 (2) 0.0149 (5)\nC15 0.4152 (2) 0.07478 (12) 0.3707 (2) 0.0146 (5)\nC17 0.5336 (2) 0.13255 (12) 0.3473 (2) 0.0147 (5)\nC18 0.5631 (2) 0.19667 (12) 0.4378 (2) 0.0144 (5)\nH18 0.5055 0.2041 0.5189 0.017*\nC19 0.6746 (2) 0.24980 (13) 0.4121 (2) 0.0154 (5)\nH19 0.6941 0.2928 0.4756 0.018*\nC20 0.7579 (2) 0.23946 (12) 0.2922 (2) 0.0154 (5)\nC21 0.7319 (2) 0.17463 (12) 0.2022 (2) 0.0171 (5)\nH21 0.7901 0.1671 0.1216 0.021*\nC22 0.6222 (2) 0.12166 (12) 0.2302 (2) 0.0146 (5)\nH22 0.6064 0.0773 0.1694 0.018*\nC24 0.9071 (3) 0.35368 (12) 0.3471 (2) 0.0205 (5)\nH24A 0.9528 0.3331 0.4406 0.031*\nH24B 0.8180 0.3847 0.3641 0.031*\nH24C 0.9809 0.3862 0.3027 0.031*\nN11\u2212 0.1513 (2)\u2212 0.01184 (11) 0.89252 (19) 0.0186 (4)\nO1 0.08130 (16) 0.18773 (8) 0.49739 (15) 0.0152 (3)\nO12\u2212 0.11434 (19)\u2212 0.08064 (9) 0.89156 (18) 0.0273 (4)\nO13\u2212 0.24056 (19) 0.01484 (9) 0.97419 (17) 0.0248 (4)\nO14 0.23187 (18) 0.21826 (9) 0.32929 (17) 0.0224 (4)\nO16 0.42438 (17) 0.00770 (9) 0.32955 (17) 0.0196 (4)\nO23 0.86233 (17) 0.29040 (8) 0.24994 (16) 0.0185 (4)\nAtomic displacement parameters (\u00c52) \nU11U22U33U12U13U23\nC2 0.0131 (10) 0.0141 (10) 0.0138 (10) \u22120.0044 (9) 0.0010 (8) 0.0002 (8)\nC3 0.0147 (11) 0.0139 (11) 0.0172 (11) 0.0022 (9) 0.0008 (9) \u22120.0025 (8)C4 0.0141 (11) 0.0192 (11) 0.0163 (11)\u2212 0.0001 (9) 0.0030 (9)\u2212 0.0046 (9)\nC5 0.0140 (10) 0.0202 (11) 0.0127 (10) \u22120.0056 (9) 0.0020 (8)\u2212 0.0014 (9)C6 0.0145 (11) 0.0150 (11) 0.0143 (11)\u2212 0.0009 (9) 0.0004 (9)\u2212 0.0011 (8)C7 0.0102 (10) 0.0157 (10) 0.0132 (10) \u22120.0015 (9) 0.0003 (8) \u22120.0033 (8)C8 0.0139 (10) 0.0110 (10) 0.0154 (10) 0.0009 (9) \u22120.0006 (8) \u22120.0031 (8)C9 0.0120 (10) 0.0137 (11) 0.0140 (10) \u22120.0018 (9) 0.0023 (8) \u22120.0032 (8)C10 0.0112 (11) 0.0165 (11) 0.0172 (11)\u2212 0.0016 (9) 0.0034 (9)\u2212 0.0018 (9)\nC15 0.0134 (11) 0.0176 (12) 0.0130 (10) 0.0009 (9) 0.0017 (8) 0.0011 (8)\nC17 0.0132 (11) 0.0170 (12) 0.0143 (10) 0.0037 (9) 0.0038 (8) 0.0031 (8)C18 0.0120 (11) 0.0180 (12) 0.0136 (10) 0.0028 (9) 0.0037 (8) 0.0011 (8)C19 0.0155 (11) 0.0161 (10) 0.0145 (11) 0.0022 (9) 0.0014 (8) \u22120.0008 (9)C20 0.0112 (10) 0.0180 (12) 0.0171 (11) 0.0019 (9) 0.0020 (8) 0.0054 (9)C21 0.0154 (11) 0.0212 (12) 0.0155 (11) 0.0034 (9) 0.0063 (8) 0.0008 (9)\nC22 0.0163 (11) 0.0129 (11) 0.0149 (10) 0.0034 (9) 0.0020 (8)\u2212 0.0015 (8)\nC24 0.0198 (12) 0.0183 (11) 0.0232 (12)\u2212 0.0040 (10) 0.0013 (9) 0.0031 (9)N11 0.0188 (10) 0.0222 (11) 0.0151 (10)\u2212 0.0038 (8) 0.0033 (8)\u2212 0.0001 (8)O1 0.0138 (8) 0.0141 (7) 0.0183 (8) 0.0015 (6) 0.0047 (6) 0.0019 (6)O12 0.0319 (10) 0.0213 (9) 0.0304 (10)\u2212 0.0009 (7) 0.0119 (7) 0.0048 (7)\n\u0018\u0018\u001b114supplementary materials\nsup-5 Acta Cryst.  (2013). E 69, o345    O13 0.0268 (9) 0.0303 (9) 0.0195 (8)\u2212 0.0015 (8) 0.0134 (7)\u2212 0.0017 (7)\nO14 0.0203 (9) 0.0209 (8) 0.0271 (9) 0.0003 (7) 0.0076 (7) 0.0086 (7)\nO16 0.0204 (8) 0.0160 (8) 0.0234 (9) 0.0007 (7) 0.0070 (7)\u2212 0.0037 (6)O23 0.0174 (8) 0.0188 (8) 0.0200 (8)\u2212 0.0043 (7) 0.0060 (6) 0.0018 (6)\nGeometric parameters (\u00c5, \u00ba)  \nC2\u2014O1 1.365 (2) C15\u2014C17 1.479 (3)\nC2\u2014C3 1.381 (3) C17\u2014C18 1.394 (3)\nC2\u2014C7 1.405 (3) C17\u2014C22 1.403 (3)\nC3\u2014C4 1.372 (3) C18\u2014C19 1.386 (3)\nC3\u2014H3 0.9500 C18\u2014H18 0.9500\nC4\u2014C5 1.397 (3) C19\u2014C20 1.393 (3)\nC4\u2014H4 0.9500 C19\u2014H19 0.9500\nC5\u2014C6 1.377 (3) C20\u2014O23 1.361 (3)\nC5\u2014N11 1.459 (3) C20\u2014C21 1.397 (3)\nC6\u2014C7 1.400 (3) C21\u2014C22 1.377 (3)\nC6\u2014H6 0.9500 C21\u2014H21 0.9500\nC7\u2014C8 1.433 (3) C22\u2014H22 0.9500\nC8\u2014C9 1.343 (3) C24\u2014O23 1.442 (3)\nC8\u2014H8 0.9500 C24\u2014H24A 0.9800\nC9\u2014C10 1.472 (3) C24\u2014H24B 0.9800\nC9\u2014C15 1.506 (3) C24\u2014H24C 0.9800\nC10\u2014O14 1.197 (3) N11\u2014O13 1.230 (2)\nC10\u2014O1 1.387 (3) N11\u2014O12 1.233 (2)\nC15\u2014O16 1.223 (3)\nO1\u2014C2\u2014C3 116.95 (18) C18\u2014C17\u2014C22 118.4 (2)\nO1\u2014C2\u2014C7 120.40 (19) C18\u2014C17\u2014C15 123.04 (19)\nC3\u2014C2\u2014C7 122.65 (19) C22\u2014C17\u2014C15 118.55 (19)\nC4\u2014C3\u2014C2 119.25 (19) C19\u2014C18\u2014C17 121.4 (2)\nC4\u2014C3\u2014H3 120.4 C19\u2014C18\u2014H18 119.3\nC2\u2014C3\u2014H3 120.4 C17\u2014C18\u2014H18 119.3\nC3\u2014C4\u2014C5 118.7 (2) C18\u2014C19\u2014C20 119.3 (2)\nC3\u2014C4\u2014H4 120.7 C18\u2014C19\u2014H19 120.3\nC5\u2014C4\u2014H4 120.7 C20\u2014C19\u2014H19 120.3\nC6\u2014C5\u2014C4 122.8 (2) O23\u2014C20\u2014C19 124.6 (2)\nC6\u2014C5\u2014N11 118.98 (19) O23\u2014C20\u2014C21 115.35 (19)\nC4\u2014C5\u2014N11 118.18 (19) C19\u2014C20\u2014C21 120.0 (2)\nC5\u2014C6\u2014C7 118.8 (2) C22\u2014C21\u2014C20 120.1 (2)\nC5\u2014C6\u2014H6 120.6 C22\u2014C21\u2014H21 119.9\nC7\u2014C6\u2014H6 120.6 C20\u2014C21\u2014H21 119.9\nC6\u2014C7\u2014C2 117.68 (19) C21\u2014C22\u2014C17 120.7 (2)\nC6\u2014C7\u2014C8 124.40 (19) C21\u2014C22\u2014H22 119.6\nC2\u2014C7\u2014C8 117.91 (19) C17\u2014C22\u2014H22 119.6\nC9\u2014C8\u2014C7 121.61 (19) O23\u2014C24\u2014H24A 109.5\nC9\u2014C8\u2014H8 119.2 O23\u2014C24\u2014H24B 109.5\nC7\u2014C8\u2014H8 119.2 H24A\u2014C24\u2014H24B 109.5\nC8\u2014C9\u2014C10 120.03 (19) O23\u2014C24\u2014H24C 109.5\nC8\u2014C9\u2014C15 119.64 (18) H24A\u2014C24\u2014H24C 109.5\n\u0018\u0018\u001c115supplementary materials\nsup-6 Acta Cryst.  (2013). E 69, o345    C10\u2014C9\u2014C15 120.09 (18) H24B\u2014C24\u2014H24C 109.5\nO14\u2014C10\u2014O1 116.33 (19) O13\u2014N11\u2014O12 123.53 (18)\nO14\u2014C10\u2014C9 127.0 (2) O13\u2014N11\u2014C5 118.57 (18)\nO1\u2014C10\u2014C9 116.64 (18) O12\u2014N11\u2014C5 117.90 (18)\nO16\u2014C15\u2014C17 121.65 (19) C2\u2014O1\u2014C10 123.03 (16)\nO16\u2014C15\u2014C9 118.01 (19) C20\u2014O23\u2014C24 117.96 (17)\nC17\u2014C15\u2014C9 120.31 (18)\nO1\u2014C2\u2014C3\u2014C4 177.38 (18) O16\u2014C15\u2014C17\u2014C18\u2212 152.9 (2)\nC7\u2014C2\u2014C3\u2014C4\u2212 2.6 (3) C9\u2014C15\u2014C17\u2014C18 25.3 (3)\nC2\u2014C3\u2014C4\u2014C5 0.4 (3) O16\u2014C15\u2014C17\u2014C22 25.9 (3)\nC3\u2014C4\u2014C5\u2014C6 1.4 (3) C9\u2014C15\u2014C17\u2014C22\u2212155.83 (19)\nC3\u2014C4\u2014C5\u2014N11\u2212 177.98 (19) C22\u2014C17\u2014C18\u2014C19 1.4 (3)\nC4\u2014C5\u2014C6\u2014C7\u2212 1.0 (3) C15\u2014C17\u2014C18\u2014C19\u2212 179.72 (19)\nN11\u2014C5\u2014C6\u2014C7 178.44 (18) C17\u2014C18\u2014C19\u2014C20 0.8 (3)\nC5\u2014C6\u2014C7\u2014C2\u2212 1.2 (3) C18\u2014C19\u2014C20\u2014O23 175.13 (19)\nC5\u2014C6\u2014C7\u2014C8 177.66 (19) C18\u2014C19\u2014C20\u2014C21\u22122.1 (3)\nO1\u2014C2\u2014C7\u2014C6\u2212 176.97 (17) O23\u2014C 20\u2014C21\u2014C22\u2212 176.26 (18)\nC3\u2014C2\u2014C7\u2014C6 3.1 (3) C19\u2014C20\u2014C21\u2014C22 1.2 (3)\nO1\u2014C2\u2014C7\u2014C8 4.1 (3) C20\u2014C21\u2014C22\u2014C17 1.0 (3)\nC3\u2014C2\u2014C7\u2014C8\u2212 175.89 (19) C18\u2014C17\u2014C22\u2014C21 \u22122.3 (3)\nC6\u2014C7\u2014C8\u2014C9\u2212 178.2 (2) C15\u2014C17\u2014C22\u2014C21 178.75 (19)\nC2\u2014C7\u2014C8\u2014C9 0.6 (3) C6\u2014C5\u2014N11\u2014O13 168.4 (2)\nC7\u2014C8\u2014C9\u2014C10\u2212 5.7 (3) C4\u2014C5\u2014N11\u2014O13\u221212.2 (3)\nC7\u2014C8\u2014C9\u2014C15 179.94 (18) C6\u2014C5\u2014N11\u2014O12 \u221211.2 (3)\nC8\u2014C9\u2014C10\u2014O14 \u2212171.9 (2) C4\u2014C5\u2014N11\u2014O12 168.27 (19)\nC15\u2014C9\u2014C10\u2014O14 2.5 (3) C3\u2014C2\u2014O1\u2014C10 176.38 (18)\nC8\u2014C9\u2014C10\u2014O1 6.1 (3) C7\u2014C2\u2014O1\u2014C10\u2212 3.6 (3)\nC15\u2014C9\u2014C10\u2014O1\u2212 179.58 (17) O14\u2014C10\u2014O1\u2014C2 176.75 (18)\nC8\u2014C9\u2014C15\u2014O16 35.9 (3) C9\u2014C10\u2014O1\u2014C2\u2212 1.4 (3)\nC10\u2014C9\u2014C15\u2014O16\u2212 138.5 (2) C19\u2014C20\u2014O23\u2014C24 9.7 (3)\nC8\u2014C9\u2014C15\u2014C17 \u2212142.4 (2) C21\u2014C20\u2014O23\u2014C24\u2212 172.89 (18)\nC10\u2014C9\u2014C15\u2014C17 43.2 (3)\n\u0018\u0018\u001d116\f\u0012\u0018\u0011\u0001\n\u001b\u0011\u0012\u001b\u001c\u0001\u0019\u0013\u0001\u000b\u0012\u001a\u001b\u0015\u0018\u001d\u001c\u0001\u000e\u001d\u0001\u000f\u001c\u001a\u001c\u000e\u0015\u0013\u0007\u0012\u0017\u0015\u001b\u000e\u001d\u0012\u001c\u0004\u0018\u0012\u001d\u0004\u000e\u0012 \u0001\n\t\t\b\u0007\u0001 \b\u001e\u001b\u001b\u0012\u0018\u001d\u0001\r\u0019\u001a\u0015\u0010\u001c\u0001\u0015\u0018\u0001\t\u0012\u0011\u0015\u0010\u0015\u0018\u000e\u0016\u0001\b\u0014\u0012\u0017\u0015\u001c\u001d\u001b\u001f\u0002\u0001 \t\u0007\b\t\u0002\u0001\u0005\u0006\u0002\u0001\t\t\b\u0007\u0003\t\t\n\u000e\u0001\n\u0001 \u0001\b\u000b\f\r\u0004\u0007\t\f\f\u0006\b\t\u0001\u0002\u000b\r\u0005\u0007\u0007\u0003\u0005\u0007\u0007\u0001 3\u0001\t\u0007\b\t\u0001\u0011#*.&\u001f)\u0001\u001c!'#*!#\u0001\u001a/ ('-&#,-\u0001 \u0001\u0014+!/-'*%\u0001+*\u0001\u0018#0\u0001\u0017+*+\u001f)'*#\u0001\u00191'\"\u001f-#\u0001\u0015*&' '.+,-\u000f\u0001\u0013'$$#,#*.(2\u0001\u001c/ -. './.#\"\u0001\n\u0012+/)\u001f,'*-\u0001\u0010-\u0001\u0010*\u0001\u0015*.#,#-.'*%\u0001\u001c!\u001f$$+(\"\u0001\n!->5-\u0001\u001f;H;\u0001!-@;?\u000b\u0006\u0001\u001a;8;>1?\u0001*5J-\f\u0006\u0001'-81@-\u0001*-F=A1F\u0007&;0>53A1F\u000b\u0006\u0001\u001bA31:5;\u0001)>5->@1\u000b\u0001-:0\u0001\u0001\n ;A>01?\u0001'-:@-:-\u000b\u0006\u0005\u0001\n\u0004\t\u0016\u001f\u0013 \"\u0013\u001c\u0016\u001d\"\u001e\u0001 \u0015\u0016\u0001 \u000f#(\u001c\u001a\u0014\u0013\u0001 \r \u0018'\u001d\u001a\u0014\u0013\u0002\u0001 \n\u0013\u0014#\u001b\"\u0013\u0015\u0001 \u0015\u0016\u0001 \n\u0013 \u001c\u0013\u0014\u001a\u0013\u0002\u0001 \u0012\u001d\u001a$\u0016 !\u001a\u0015\u0013\u0015\u0001 \u0015\u0016\u0001 \u0010\u0013\u001d\"\u001a\u0013\u0018\u001e\u0001 \u0015\u0016\u0001 \b\u001e\u001c\u001f\u001e!\"\u0016\u001b\u0013\u0002\u0001 \u0010\u001f\u0013\u001a\u001d\u0006\u0001\n\u0005\t\u0016\u001f\u0013 \"\u0013\u001c\u0016\u001d\"\u001e\u0001\u0015\u0016\u0001\n\u0013 \u001c\u0013\u0014\u001e\u001b\u001e\u0018(\u0013\u0002\u0001\n\u0013\u0014#\u001b\"\u0013\u0015\u0001\u0015\u0016\u0001\n\u0013 \u001c\u0013\u0014\u001a\u0013\u0002\u0001\u0012\u001d\u001a$\u0016 !\u001a\u0015\u0013\u0015 \u0001\u0015\u0016\u0001\u0010\u0013\u001d\"\u001a\u0013\u0018\u001e\u0001\u0015\u0016\u0001\b\u001e\u001c\u001f\u001e!\"\u0016\u001b\u0013\u0002\u0001\u0010\u001f\u0013\u001a\u001d\u0001\n\u0010 -.,\u001f!.\u000f\u0001\u001e@\u00015?\u0001/;99;:8E\u0001-//1<@10\u0001@4-@\u00019;:;-95:1\u0001;D50-?1\u0001\u0003!\u0017#\u0004\u00019-E\u0001<8-E\u0001-\u0001/>5@5/-8\u0001>;81\u00015:\u0001@41\u0001>13A8-@5;:\u0001;2\u0001@41\u0001/1:\u0007\n@>-8\u0001:1>B;A?\u0001?E?@19\u0001-/@5B5@E\u0001-:0\u0001/;:@>5.A@1\u0001@;\u0001@41\u0001<-@4;31:1?5?\u0001;2\u00014A9-:\u0001:1A>;0131:1>-@5B1\u0001-:0\u000101<>1??5B1\u000105?;>01>?\b\u0001(45?\u0001\n4-?\u00011:/;A>-310\u0001-:\u0001-/@5B1\u0001>1?1->/4\u00015:\u0001@41\u000101B18;<91:@\u0001;2\u0001:1C\u00010>A 3?\u0006\u0001!\u0017#\u00015:45.5@;>?\u0006\u0001?5:/1\u0001@41E\u00019-E\u0001>1<>1?1:@\u0001-:\u000159<;>\u0007\n@-:@\u0001-0B-:/1\u00015:\u0001@41\u0001@>1-@91:@\u0001;2\u0001/;9<81D\u000105?1-?1?\u0001?A/4\u0001-?\u0001\u00178F41 591>\u0001-:0\u0001$->75:?;:\u0006\u0001C45/4\u0001->1\u0001.1/;95:3\u0001<>1B-81:@\u0001<-\u0007\n@4;8;351?\u00010A1\u0001@;\u0001@41\u00015:/>1-?1\u0001;2\u0001-35:3\u0001<;<A8-@5;:\u0001;2\u000101B18;<10\u0001 /;A:@>51?\u0001?;/51@51?\b\u0001\u001a5221>1:@\u0001>1?1->/4\u00013>;A<?\u0001->1\u00015:@1:\u0007\n?5B18E\u0001C;>75:3\u00015:\u0001@45?\u0001->1-\u0001C5@4\u0001@41\u0001-59\u0001;2\u000125:05:3\u0001:1C\u0001!\u0017#\u0001?18 1/@5B1\u00015:45.5@;>?\b\u0001\u001a5221>1:@8E\u0001?A.?@5@A@10\u0001/;A9->5:?\u00014-B1\u0001\n.11:\u0001?E:@41?5F10\u0001-:0\u00011B-8A-@10\u0001-?\u0001!\u0017#\u0007\u0017\u0001-:0\u0001!\u0017#\u0007\u0018\u00015:45.5@;>?\b\u0001(41\u0001<A><;?1\u0001;2\u0001@45?\u0001>1B51C\u00015?\u0001@;\u0001?A99->5F1\u0001@41\u000125:0\u00075:3?\u0001>1<;>@10\u00015:\u0001@45?\u0001->1-\u0006\u0001<->@5/A8->8E\u00012;/A?1?\u0001;:\u0001@41\u0001/;A9->5 :\u0001?/-22;80\b\u0001\n\u0016#20+,\"-\u000f \u0001\u0019;A9->5:?\u0006\u0001\u00178F41591>\u000105?1-?1\u0006\u0001<->75:?;:\u000105?1-?1\u0006\u00019;:;-95:1\u0001;D5 0-?1\u0006\u0001!\u0017#\u00015:45.5@;>?\b\u0001\n\b\u0005\u0001\u0015\u0018\u001d\u001b\u0019\u0013\u001e\u0012\u001d\u0015\u0019\u0018\u0001\n\u0001 !;:;-95:1\u0001;D50-?1\u0001\u0003!\u0017#\u0004\u00015?\u0001-\u0001\u001c\u0017\u001a\u000701<1:05:3\u00011:FE91\u0001\n2;A:0\u00015:\u0001@41\u0001;A@1>\u000195@;/4;:0>5-8\u0001919.>-:1\u0001;2\u0001:1A>;:-8\u0006\u0001\n385-8\u0001-:0\u0001;@41>\u00019-99-85-:\u0001/188?\u0001+\u000b,\b\u0001(45?\u00011:FE91\u00015?\u0001>1?<;:\u0007\n?5.81\u0001 2;>\u0001 /-@-8EF5:3\u0001 @41\u0001 ;D50-@5B1\u0001 01-95:-@5;:\u0001 ;2\u0001 :1A>;\u0007@>-:?95@@1>?\u0001-:0\u0001051@->E\u0001-95:1?\u0006\u0001>13A8-@5:3\u00015:@>-/188A8->\u000181B\u000718?\u0001;2\u0001.5;31:5/\u0001-95:1?\u00015:\u0001@41\u0001.>-5:\u0001-:0\u0001@41\u0001<1>5<41>-8\u0001@5??A1?\u0001+\f\u0006\u0001\r,\b\u0001\u001e@\u00015?\u0001C188\u00077:;C:\u0001@4-@\u0001!\u0017#\u0001<8-E?\u0001-\u0001/>5@5/-8\u0001>;81\u00015:\u0001@41\u0001\n>13A8-@5;:\u0001;2\u0001/1:@>-8\u0001:1>B;A?\u0001?E?@19\u0001-/@5B5@E\u0001-:0\u0001/;:@>5.A@1?\u0001\n@;\u0001@41\u0001<-@4;31:1?5?\u0001;2\u00014A9-:\u0001:1A>;0131:1>-@5B1\u0001-:0\u000101<>1?\u0007?5B1\u000105?;>01>?\u0001+\u000e,\b\u0001\u001c52@E\u0001E1->?\u0001-3;\u0001@41\u000125>?@\u000131:1>-@5;:\u0001;2\u0001!\u0017#\u0001 5:45.5@;>?\u0001\u0003!\u0017#\u001e?\u0004\u0001C-?\u000101B18;<10\u0001-:0\u0001-<<8510\u00015:\u0001@41>-<E\u0001-?\u0001-:@5\u000701<>1??5B1\u0001/;9<;A:0?\b\u0001\u001d;C1B1>\u0006\u00012;>\u00019-:E\u0001E1->?\u0001!\u0017#\u001e?\u0001C1>1\u0001/;:?501>10\u0001A?181??\u00015:\u0001@41>-<E\u00010A1\u0001@;\u0001@41\u0001\n?1>5;A?\u0001?501\u00011221/@?\u00015:0A/10\u0001.E\u0001@41?1\u00010>A3?\u0001+\u000f,\b\u0001 -@1>\u0006\u0001@C;\u0001\n1:FE9-@5/\u00015?;2;>9?\u0006\u0001:-910\u0001!\u0017#\u0007\u0017\u0001-:0\u0001!\u0017#\u0007\u0018\u0006\u00014-B1\u0001.11:\u0001501:@52510\u0001;:\u0001@41\u0001.-?5?\u0001;2\u0001@415>\u0001-95:;\u0001-/50\u0001?1=A1:/1?\u0001+\u0010,\u0006\u0001@4>11\u00070591:?5;:-8\u0001?@>A/@A>1\u0001+\u0011,\u0006\u0001@5??A1\u000105?@>5.A@5;:\u0001+\u0012,\u0006\u00015:\u000745.5@;>\u0001?181/@5B5@E\u0001+\u0013,\u0001-:0\u0001?A.?@>-@1\u0001<>121>1:/1?\u0001+\u000b\n,\b\u0001(41\u0001!\u0017#\u0007\u0017\u0001 5?;2;>9\u0001 4-?\u0001 45341>\u0001 -225:5@E\u0001 2;>\u0001 ?1>;@;:5:\u0001 -:0\u0001\n:;>-0>1:-85:1\u0006\u0001C41>1-?\u0001@41\u0001!\u0017#\u0007\u0018\u00015?;2;>9\u0006\u0001<>121>1:@5-88E\u0001\n01-95:-@1?\u0001 \u0001\u0007<41:E81@4E8-95:1?\u0001-:0\u0001.1:FE8-95:1\u0001+\u000b\u000b\u0006\u0001\u000b\f,\b\u0001\n#:\u0001@41\u0001;@41>\u00014-:0\u0006\u00010;<-95:1\u0001-:0\u0001@E>-95:1\u0001->1\u0001/;99;:\u0001?A.\u0007?@>-@1?\u00012;>\u0001.;@4\u00015?;2;>9?\b\u0001\u0017?\u0001-\u0001>1?A8@\u0001;2\u0001@41?1\u0001<4E?5;8;35/-8\u0001\n<>;<1>@51?\u0006\u0001!\u0017#\u001e?\u0001.1/-91\u0001-3-5:\u0001@41\u0001/1:@1>\u0001;2\u0001?/51:@525/\u0001-:0\u0001\n<4->9-/;8;35/-8\u00015:@1>1?@\u0006\u0001<>;B505:3\u0001:1C\u00010>A3?\u00012;>\u0001@41\u0001@41>\u0007\n-<E\u0001;2\u0001$->75:?;:K?\u000105?1-?1?\u0001\u0003$\u001a\u0004\u0006\u0001\u00178F41591>K?\u000105?1-?1\u0001\u0003\u0017\u001a\u0004\u0001\n-:0\u0001 B->5;A?\u0001 @E<1?\u0001 ;2\u0001 01<>1??5;:\u0001 +\u000b\r,\b\u0001 \u0017005@5;:-88E\u0006\u0001 @41\u0001\u0001\u0001\n\u0005\u001700>1??\u0001/;>>1?<;:01:/1\u0001@;\u0001@45?\u0001-A@4;>\u0001-@\u0001@41\u0001\u001a1<->@-91:@;\u000101\u0001% AI95/-\u0001\n#>3G:5/-\u0006\u0001\u001c-/A8@-0\u000101\u0001\u001c->9-/5-\u0006\u0001):5B1>?50-0\u000101\u0001'-:@5-3;\u000101\u0001\u0019;9< ;?@18-\u0006\u0001\n'<-5:\u0015\u0001(18\u0014\u0001\n\n\r\u000e\u0001\u0012\u0012\u000b\u0012\u000b\u000b\n\n\n\u000b\u000e\u0013\r\u0010\u0015\u0001\u001b\u00079- 58\u0014\u00018;A>01?\b?-:@-:-\u0016A?/\b1?\u0001\n\u0001\n\u0011\u0019\u001a!\u0001\u001c\u0013\u001d#!\u0014 \u001a\u001f\"\u0001\u001a!\u0001\u0015\u0016\u0015\u001a\u0014\u0013\"\u0016\u0015\u0001\"\u001e\u0001\u000e \u001e\u0017\u0001\n \u0013\u001d\u0014\u001a!\u0014\u001e\u0001\r \u0013\u001b\u001b\u001e\u0001\u001a\u001d\u0001\u001c\u0016\u001c\u001e \u001a\u0013\u001c\u0002\u0001%\u0019\u001e\u0001\n\u0019\u0013\u0015\u0001\u001a\u001d\" \u001e\u0015#\u0014\u0016\u0015\u0001\u0013\u001d\u0015\u0001\u001a\u001d\u0014\u0016\u001d\"\u001a$\u0013\"\u0016\u0015\u0001#!\u0001\u001a\u001d\u0001\"\u0019\u0016\u0001!\"#\u0015&\u0001\u001e\u0017\u0001\"\u0019\u0016\u0001\f\u0007\r\u000b!\u0003 \u000101?/>5<@5;:\u0001;2\u0001@41\u0001/>E?@-8\u0001?@>A/@A>1\u0001;2\u0001@41\u0001@C;\u0001!\u0017#\u00015?;2;>9?\u0001\n.E\u0001\u0019\b\u0001\u00185:0-\u0001 \u0016\"\u0001\u0013\u001b\u0003\u00014-?\u0001<>;B5010\u0001>181B-:@\u00015:2;>9-@5;:\u0001-.;A@\u0001\n@41\u0001?181/@5B1\u00015:@1>-/@5;:?\u0001-:0\u0001@41\u0001<4->9-/;<4;>5/\u0001>1=A5>1\u000791:@?\u0001:11010\u00012;>\u0001@41\u000101?53:\u0001;2\u0001<;@1:@\u0001-:0\u0001?181/@5B1\u00015:45.5\u0007@;>?\u0001+\u000b\u000e\u0007\u000b\u0012,\b\u0001\u0001\n\u0001 !\u0017#\u0007\u0017\u0001<8-E?\u0001-:\u000159<;>@-:@\u0001>;81\u00015:\u0001:1A>;<?E/45-@>5/\u0001-:0\u0001\n.14-B5;A>-8\u000105?;>01>?\b\u0001(41\u0001 59<;>@-:/1\u0001;2\u0001@45?\u00015?;2;>9\u0001 5?\u0001\n?A331?@10\u0001.E\u0001@41\u0001-33>1??5B1\u0001<41:;@E<1\u0001?11:\u00015:\u00019-81\u000195/1\u0001\n0125/51:@\u00015:\u0001!\u0017#\u0007\u0017\u0001-:0\u00015:\u00019-81?\u00015:\u0001-\u0001\u001aA@/4\u000175:0>10\u0001.1->5:3\u0001\n-\u0001?<;:@-:1;A?\u00019A@-@5;:\u0001\u0003>1?A8@5:3\u00015:\u0001-\u0001<>19-@A>1\u0001?@;<\u0004\u00015:\u0001@41\u0001\n\u001c\u0013\u001e\u0007\u0017\u0001 31:1\u0001 +\u000b\u0013,\b\u0001 '5958->8E\u0006\u0001 9-8@>1-@10\u0001 /4580>1:\u0006\u0001 C4;?1\u0001\n31:;@E<1\u0001/;:21>?\u00018;C\u000181B18?\u0001;2\u0001!\u0017#\u0007\u0017\u00011D<>1??5;:\u0006\u00019;>1\u0001;2@1:\u000101B18;<\u0001/;:0A/@\u000105?;>01>\u0006\u0001-:@5?;/5-8\u0001<1>?;:-85@E\u0001-:0\u0001\n-0A8@\u0001B5;81:@\u0001/>591\u0001@4-:\u0001/4580>1:\u0001C5@4\u0001-\u00014534\u0007-/@5B5@E\u0001!\u0017#\u0007\n\u0017\u000131:;@E<1\u00010;\u0001+\f\n,\b\u0001&18-@5B18E\u00019;01?@\u0001/4-:31?\u00015:\u0001!\u0017#\u0007\u0017\u0001-/@5B5@E\t2A:/@5;:\u0001/-:\u00014-B1\u000159<;>@-:@\u0001:1A>;<?E/45-@>5/\u0001/;:?1\u0007=A1:/1?\u0001 -?\u0001 019;:?@>-@10\u0001 .E\u0001 @41\u0001 2-/@\u0001 @4-@\u0001 +\n\u000b\u000b\u0019,\u00074->95:1\u0007\n8-.1810\u00015?\u0001181B-@10\u0001.E\u0001;:8E\u0001\r\u000e\u0002\u0001@4>;A34;A@\u0001@41\u0001.>-5:\u0001;2\u0001A:\u0007@>1-@10\u000101<>1??10\u0001<-@51:@?\u0001/;9<->10\u0001@;\u0001/;:@>;8?\u0006\u0001E1@\u00015@\u0001-<\u0007\n<1->?\u0001@;\u0001.1\u0001@41\u00019-6;>\u0001/;:@>5.A@;>\u0001@;\u0001@41\u00019;:;-95:1\u000191@-.;\u0007\n85?9\u00015:\u0001@41?1\u0001?-91\u0001<-@51:@?\u0001+\f\u000b,\b\u0001\u001a1<>1??5;:\u0001:;@\u0001;:8E\u00019-E\u0001<>;9;@1\u0001/;3:5@5B1\u000159<-5>91:@\u0006\u0001.A@\u0001-8?;\u00019-E\u0001.1\u0001-\u0001>5?7\u00012-/@;>\u00012;>\u0001\u0017\u001a\u0001+\f\f,\b\u0001\";@\u0001?A><>5?5:38E\u0006\u0001!\u0017#\u0007\u0017\u0001C45/4\u00015?\u0001;2@1:\u0001-\u0001@->\u000731@\u00012;>\u0001@41\u0001@>1-@91:@\u0001;2\u000101<>1??5;:\u0006\u00015?\u0001-8?;\u0001-\u0001<;@1:@5-8\u0001>5?7\u00012-/@;>\u00012;>\u00018-@1\u0007;:?1@\u0001\u0017\u001a\u0001+\f\r\u0007\f\u0010,\b\u0001\u001e:\u0001/;:@>-?@\u0001@;\u00015>>1B1>?5.81\u0001\n!\u0017#\u001e\u0007\u0017\u0001-?\u0001/8;>3E85:1\u0006\u0001>1B1>?5.81\u00015:45.5@;>?\u0001->1\u0001.1@@1>\u0001@;81>\u0007\n-@10\u0001-:0\u00014-B1\u0001.11:\u0001<->@5/A8->8E\u00011225/-/5;A?\u00015:\u0001@>1-@5:3\u000101\u0007<>1??5;:\u0001+\f\u0011,\u0001-:0\u0001/;3:5@5B1\u000105?;>01>?\u0001+\f\u0012,\u00015:\u0001@41\u00011801>8E\b\u0001\u001e:\u0001-005@5;:\u0006\u00015:45.5@5;:\u0001;2\u0001!\u0017#\u0007\u0017\u0001-/@5B5@E\u0001<>;@1/@\u0001-3-5:?@\u0001?@>5\u0007-@-8\u00010-9-31\u0001<>;0A/10\u0001.E\u0001@41\u000195@;/4;:0>5-8\u0001<;5?;:\u00019-8;:-@1\u0001-:0\u0001-<<1->?\u0001@;\u0001>18E\u0001;:\u0001-@@1:A-@5;:\u0001;2\u00010;<-95:1\u000701>5B10\u0001>1-/\u0007\n@5B1\u0001;DE31:\u0001?<1/51?\u0001\u0003&#'\u0004\u0001+\f\u0013,\u0006\u0001C4581\u0001-<;<@;?5?\u00012;88;C5:3\u0001\n?1>A9\u0001?@->B-@5;:\u00015?\u0001>10A/10\u00015:\u0001!\u0017#\u0007\u0017\u00010125/51:@\u0001/;>@5/-8\u0001.>-5:\u0001/188?\u0001+\r\n,\b\u0001\n\u0018\u0018\u001e117\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \u0007\u0005\u0006\u0007\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \u0007\u0007\u0006\u0006\u0001\n\u0001 \u001d1\u00017,)\u000127,)5\u0001,%1(\u0004\u0001-7\u0001,%6\u0001&))1\u0001()021675%7)(\u00017,%7\u00016)/)'7-9)\u0001\n%1(\u0001-55)9)56-&/)\u0001\u001b\u0012\u001d\u00186\u0005\u0013\u0004\u000168',\u0001%6\u00016)/)+-/-1)\u0001%1(\u00015%6%+-/-1)\u0004\u0001%5)\u0001-03257%17\u000102/)'8/)6\u0001-1\u00017,)\u00017,)5%3<\u00012*\u0001\u001e\u0015\u0001%6\u0001:)//\u0001%6\u0001-1\u00013%7-)176\u0001:-7,\u00010-/(\u0001\u0012\u0015\u00057<3)\u0001()0)17-%\u0001#\u000b\t\u0005\u000b\u000b$\u0006\u0001\u001327,\u0001\u001b\u0012\u001d\u0005\u0013\u0001326-7-9)\u0001%6752'<7)6\u0001#\u000b\f$\u0001%1(\u0001\u001f\u001d \u0001#\u000b\r$\u0001,%9)\u0001&))1\u0001*281(\u0001-1\u00017,)\u0001\n9-'-1-7<\u00012*\u0001 \u0001\u0005%0</2-(\u0001\u0002\u0012 \u0001\u0003\u00013/%48)6\u0006\u0001 )/)+-/-1)\u0001%1(\u00015%6%+-/-1)\u0001\n'%1\u0001%/62\u0001);)57\u00011)8523527)'7-21\u0001%7\u0001/2:)5\u0001'21')175%7-216\u00017,%1\u0001\n7,26)\u00015)48-5)(\u0001*25\u0001-1,-&-7-21\u00012*\u00017,)\u0001)1=<0)\u0001#\u000b\u000e$\u0006\u0001\u00187\u0001,%6\u0001&))1\u0001%662'-%7)(\u0001:-7,\u0001%'7-9%7-21\u00012*\u0001\u0013'/\u0005\n\u0001*%0-/<\u00010)0&)56\u0004\u0001-17)5%'\u00057-21\u0001:-7,\u00017,)\u00010-72',21(5-%/\u0001325)\u0001'203/);\u0001%1(\u000102(8/%7-21\u00012*\u0001%0</2-(\u000135)'85625\u00013527)-1\u0001'/)%9%+)\u0001#\u000b\u000f$\u0006\u0001\u0001\n\u0001 !,)\u0001-03257%1')\u00012*\u00017,)\u0001(-6'29)5<\u00012*\u0001(58+6\u0001%662'-%7)(\u0001:-7,\u0001\n1)852()+)1)5%7-9)\u0001(-6)%6)6\u0001\u0002\u001c\u0015\u0003\u0001,%6\u0001)0)5+)(\u0001:-7,\u00017,)\u00016-+\u00051-*-'%17\u0001-1'5)%6)\u00012*\u0001/-*)\u0001);3)'7%1'<\u0006\u0001\n\u0001 \u0014280%5-16\u0001%5)\u0001%\u0001:-()\u0001*%0-/<\u00012*\u0001'203281(6\u000135)6)17\u0001-1\u0001\n5)0%5.%&/)\u0001%028176\u0001-1\u00017,)\u00011%785)\u0001#\u000b\u0010\u0004\u0001\u000b\u0011$\u0006\u0001\u001f)35)6)17%7-9)\u0001\n'203281(6\u00012''85\u0001*25\u0001-167%1')\u0001 -1\u00017,)\u00019)+)7%&/)\u0001.-1+(20\u0004\u0001)-7,)5\u0001-1\u0001*5))\u000125\u0001'20&-1)(\u000167%7)\u0001#\f\b\u0004\u0001\f\t$\u0006\u0001!,)\u00019)56%7-/)\u0001%1(\u0001\n)**-'-)17\u00016<17,)7-'\u0001%'')66-&-/-7<\u0001%1(\u00017,)\u000168&67-787-21\u0001'%3%&-/\u0005\n-7<\u00010%.)\u00017,)0\u000135-9-/)+)(\u00016'%**2/(6\u0001127\u000121/<\u0001-1\u000125+%1-'\u0001',)0\u0005-675<\u0001&87\u0001%/62\u0001-1\u00017,)\u00010)(-'-1%/\u0001',)0-675<\u0001*-)/(\u0001#\f\n$\u0006\n\u0001\u00181\u00017,)\u0001\n/-7)5%785)\u0004\u0001'280%5-1\u0001()5-9%7-9)6\u0001,%9)\u0001&))1\u0001()6'5-&)(\u0001%6\u0001%17-\u0005'%1')5\u0001#\f\u000b\u0004\u0001\f\f$\u0004\u0001%17-2;-(%17\u000125\u0001%17-\u0005-1*/%00%725<\u0001#\f\r\u0004\u0001\f\u000e$\u0004\u00019%625)/%;%17\u0001#\f\u000f$\u0004\u0001%17-0-'52&-%/\u0001#\f\u0010\u0004\u0001\f\u0011$\u0004\u0001%17-9-5%/\u0001#\r\b\u0004\u0001\r\t$\u0004\u0001%1(\u0001)1=<0%7-'\u0001-1,-&-7256\u0001#\r\n\u0005\r\f$\u0006\u0001\u0001\n\u0001 \u00181\u0001\t\u0011\u0010\t\u0004\u0001-7\u0001:%6\u0001*281(\u0001*25\u00017,)\u0001*-567\u00017-0)\u0001%1\u0001-17)5)67-1+\u0001\n\u001b\u0012\u001d\u0018\u0001%'7-9-7<\u00012*\u00017,)\u0001'280%5-1\u000102-)7<\u0004\u0001:,)1\u0001%1\u000125+%12\u0005\n3,263,%7)\u0001+5283\u0001:%6\u0001%77%',)(\u000172\u00017,)\u000180&)//-*)521)\u00015-1+\u0001#\r\r$\u0006\u0001\u001387\u0001-7\u0001:%6\u000121/<\u0001-1\u00017,)\u0001\t\u0011\u0011\b?6\u0001:,)1\u00017,)\u0001'280%5-1\u000118'/)86\u0001)0)5+)(\u0001%6\u0001%\u00013520-6-1+\u00016'%**2/(\u0001*25\u0001\u001b\u0012\u001d\u00186\u0001#\r\u000e$\u0006\u0001\u00181\u00013%57-'8\u0005/%5\u0004\u0001620)\u0001'280%5-16\u0001-62/%7)(\u0001*520\u0001 \u0005\u0014\u0011\u0013\u0006\u000e\t\u0006\u0001\u0007\u0011\u0013\u0018\u000e\u000b\n\u0011\u000e\u000b\u0006\u0001 \u001a\u0006\u0004\u0001\n\u0005\t\u0016\u0007\t\b\u0006\u0010\u0016\u000f\u0001\f\u0006\u0012\u0011\u0010\u000b\u0007\u0016\u000f\u0001 \u001a\u0006\u000125\u0001\u0004\u0011\u0010\u0006\u0014\u0007\u0016\u0014\u0001\u0006\u0010\r\u0006\u0001\u0019\u0006\u0001,%9)\u0001&))1\u0001\n()6'5-&)(\u0001%6\u0001\u001b\u0012\u001d\u00186\u0001#\r\u000f\u0005\r\u0011$\u0006\n\u0001\u0012/7,28+,\u00011%785%/\u0001'280%5-16\u0001\n+)1)5%//<\u00016,2:\u0001/2:\u0001\u001b\u0012\u001d\u0001-1,-&-725<\u0001327)1'<\u0004\u00013523)5/<\u000102(-\u0005*-)(\u00011%785%/\u0001'280%5-16\u0001,%9)\u0001&))1\u0001',%5%'7)5-=)(\u0001%6\u0001327)17\u0001%1(\u00016)/)'7-9)\u0001\u001b\u0012\u001d\u00186\u0006\u0001\u001625\u0001);%03/)\u0004\u00017,)\u0001()60)7,</\u0001'21+)1)5\u00012*\u0001+)-3%59%5-1\u0004\u0001%\u00011%785%/\u0001\u000f\u000568&67-78)(\u0001'280%5-1\u0001*520\u00017,)\u0001/)%9)6\u00012*\u0001\u0003\t\u000b\f\t\u0013\u0006\u0001 \u0012\u0006\u0013\u0017\u000b\n\u000e\u0011\u0013\u0006 \u0001 \u001a\u0006\u0004\u0001 );,-&-7)6\u0001 327)17\u0001 %1(\u0001 6)/)'7-9)\u0001\n\u001b\u0012\u001d\u0005\u0013\u0001-1,-&-7-21\u0001\u0016-+\u0006\u0001\u0002 \u0006\u0003\u0001#\u000e\b$\u0006\u0001\n\r\u0019\u0018\u0004\u0001\u0002\u0006\u0003\u0004\u0001\"0&)//-*)521)\u0001%1(\u0001+)-3%59%5-1\u0001()5-9%7-9)6\u0006\u0001\n\u0001\n\u0001  )9)5%/\u00015)6)%5',\u0001+52836\u0001,%9)\u0001&))1\u0001);3/25-1+\u00017,)\u0001-0325\u0005\n7%1')\u00012*\u00017,)\u0001180&)5\u0001%1(\u0001326-7-21\u00012*\u0001(-**)5)17\u000168&67-78)176\u000121\u00017,)\u0001'280%5-1\u000118'/)86\u0004\u00017%.-1+\u0001-172\u0001%''2817\u000192/80)\u0004\u0001/-323,-/\u0005\n-'-7<\u0004\u000167)5-'\u0001-03)(-0)17\u0004\u0001)/)'7521\u0001:-7,(5%:-1+\u0001%1(\u0001)/)'7521\u0001\n(21%7-1+\u0001',%5%'7)5-67-'6\u0006\u0001\u0015-**)5)17\u000168&67-78)176\u0001:)5)\u0001%77%',)(\u000172\u00017,)\u0001'280%5-1\u00016.)/)721\u0001:-7,\u00017,)\u0001%-0\u00012*\u0001-03529-1+\u0001&27,\u0001%'7-9-7<\u0001%1(\u00016)/)'7-9-7<\u0001\u0016-+\u0006\u0001\u0002 \u0007\u0003\u0006\u0001\u0012/7,28+,\u0001326-7-216\u0001\u000b\u0001%1(\u0001\u000f\u0001\n2*\u00017,)\u0001'280%5-1\u00015-1+\u0001:)5)\u00017,)\u00010267\u0001678(-)(\u0004\u0001%//\u00017,)\u000168&67-78\u00057-21\u00013266-&-/-7-)6\u0001:)5)\u00017%.)1\u0001-172\u0001%''2817\u0001%1(\u0001%\u0001&-+\u0001180&)5\u0001\n2*\u0001'280%5-1\u0001()5-9%7-9)6\u0001,%9)\u0001&))1\u00016<17,)6-=)(\u0001%1(\u0001)9%/8%7)(\u0001%6\u0001\u001b\u0012\u001d\u00186\u0004\u0001&)-1+\u00010267\u00012*\u00017,)0\u0001%'7-9)\u0001%1(\u00016)/)'7-9)\u0001%+%-167\u0001\n\u001b\u0012\u001d\u0005\u0013\u0001-62)1=<0)\u0001#\u000e\t\u0005\u0010\t$\u0006\u0001\n\u0001 \u00187\u0001-6\u0001-03257%17\u000172\u00010)17-21\u00017,%7\u00017,)\u0001\u0018\u0014\n\r\b\u00019%/8)6\u0001+-9)1\u0001-1\u00017,)\u0001\n*2//2:-1+\u00017%&/)6\u00015)68/7)(\u0001*520\u0001(-**)5)17\u0001);3)5-0)17%/\u00016)7\u0005\n7-1+6\u0006\u0001\u0001\n\u0007\u0004\u0001\n\u0011\u0015\u000f\t\u0012\u000e\u0010\u0001\u000b\f\u0012\u000e\u0016\t\u0014\u000e\u0016\f\u0013\u0001\t\u0010\u000b\u0001\u000f\t\u0011\u0001\t\n\u0014\u000e\u0016\u000e\u0014\u0017\u0001\n\u0001 !,)\u0001 *-567\u0001 6758'785)\u0005%'7-9-7<\u0001 5)/%7-216,-3\u0001 678(-)6\u0001 \u0002 \u0012\u001f\u0003\u0001\n%&287\u0001'280%5-1\u0001()5-9%7-9)6\u000168++)67)(\u00017,%7\u00016)/)'7-9-7<\u0001:%6\u00010%-1/<\u0001()7)50-1)(\u0001&<\u00017,)\u00011%785)\u00012*\u00017,)\u0001/-1.%+)\u0001&)7:))1\u00017,)\u0001'280%5-1\u0001%1(\u00017,)\u000168&67-78)17\u0001+5283\u0001%7\u0001326-7-21\u0001\u000f\u0006\u0001\u0012\u00016)5-)6\u00012*\u0001\n\u000f\u0005,<(52;<'280%5-1\u0001()5-9%7-9)6\u0001 \u000e\u0001&)%5-1+\u0001%7\u0001326-7-21\u0001\u000f\u0001)7,)5\u0004\u0001\n)67)5\u000125\u0001'%5&%0%7)\u0001*81'7-216\u00012*\u00019%5<-1+\u00016-=)\u0001%1(\u0001/-323,-/-'-7<\u0001\n,%9)\u0001&))1\u0001-19)67-+%7)(\u0001*25\u00017,)-5\u0001 \u000b\u0010\u0001\u0017\u000b\u0015\u0013\u0011\u0001\u001b\u0012\u001d\u0005\u0012\u0001%1(\u0001\u0005\u0013\u0001-1\u0005\n,-&-725<\u0001%'7-9-7-)6\u0006\u0001\u001b267\u00012*\u00017,)6)\u0001'203281(6\u00015)68/7)(\u000172\u0001&)\u000135)*)5)17-%//<\u0001\u001b\u0012\u001d\u00186\u0005\u0013\u0006\u0001 \u0012\u001f\u0001678(-)6\u0001%/62\u00016,2:)(\u00017,%7\u0001/-32\u00053,-/-'-7<\u0001-6\u0001%1\u0001-03257%17\u00013523)57<\u000172\u000102(8/%7)\u00017,)\u0001\u001b\u0012\u001d\u0005\u0013\u0001\n-1,-&-7-21\u0001327)1'<\u00012*\u00017,)\u0001%&29)\u00010)17-21)(\u0001'280%5-16\u0001#\u000e\t\u0005\n\u000e\u0010$\u0006\u0001\u0012\u0001\u000f\u0005&)1=</2;<\u0001+5283\u00013529)(\u000172\u0001&)\u00017,)\u0001*%9285-1+\u000168&\u000567-78)17\u0001*25\u00017,)\u0001&-1(-1+\u00012*\u0001'280%5-16\u000172\u0001\u001b\u0012\u001d\u0005\u0013\u0004\u0001:,)5)%6\u0001%\u0001\u0001\u0005)/)'7521\u00053225\u00013,)1</\u00015-1+\u0001%7\u0001326 -7-21\u0001\u000f\u00016))06\u000172\u0001-03529)\u0001\n&27,\u0001\u001b\u0012\u001d\u0005\u0012\u0001%1(\u0001\u001b\u0012\u001d\u0005\u0013\u0001-1,-&-7-25<\u0001%'7-9-7-)6\u0004\u0001/)%(-1+\u000172\u0001025)\u0001%'7-9)\u0001&87\u00016/-+,7/<\u0001/)66\u00016)/)'7-9)\u0001-1,-&-7256\u0001#\u000e\n$\u0006\u0001\u0012\u0006\u0001\u0014%\u0005\n5277-\u0001\t\u0015\u0001\u0006\u000e\u0002\u0001()6'5-&)(\u0001%\u0001/%5+)\u0001*%0-/<\u00012*\u0001'203281(6\u00015)/%7)(\u000172\u0001\n7,)6)\u00016758'785)6\u0006\u0001\u001d1\u00017,)\u000127,)5\u0001,%1(\u0004\u0001-7\u0001,%6\u0001&))1\u00013529)(\u00017,%7\u0001\n%1\u0001%/.</68/*21</2;<\u0001+5283\u0001%7\u0001326-7-21\u0001\u000f\u00013529-()(\u0001\u001b\u0012\u001d\u00186\u0005\u0012\u0001/-.)\u0001)683521)\u0006\u0001!,-6\u0001)**)'7\u0001-6\u0001)9)1\u0001025)\u00013521281')(\u0001-1\u00017,)\u00013,)1</\u000168/*21%7)6\u0001 -1\u0001:,-',\u00017,)\u000168&67-787-21\u0001:-7,\u0001)/)'7521\u0001:-7,(5%:-1+\u0001+52836\u0001/)%(\u000172\u0001025)\u0001327)17\u0001%1(\u0001,-+,/<\u00016)/)'7-9)\u0001\n\u001b\u0012\u001d\u00186\u0005\u0012\u0006\u0001\u0012/62\u0004\u0001\u0013\u0006\u0001\u001f)1()1&%',\u0005\u001b8)//)5\u0001 \t\u0015\u0001\u0006\u000e\u0002\u00016<17,)6-=)(\u0001\n%1(\u0001678(-)(\u00017,)\u0001327)17-%/\u00012*\u0001)7,)5\u0001()5-9%7-9)6\u0001%1(\u000168/*21-'\u0001\n%'-(\u0001)67)56\u0001\u0016-+\u0006\u0001\u0002 \b\u0003\u0004\u0001',)'.-1+\u00017,%7\u0001-1752(8'7-21\u00012*\u0001%\u000168/*21-'\u0001\n)67)5\u0001 /-1.%+)\u0004\u0001 -167)%(\u0001 2*\u0001 7,)\u0001 )7,)5\u0001 &5-(+)\u0004\u0001 (5%0%7-'%//<\u0001',%1+)(\u00017,)\u0001%'7-9-7<\u0001352*-/)\u00012*\u00017,)\u00011):\u0001'203281(6\u0001#\u000e\u000b$\u0006\u0001\n\u0001  8&67-787-216\u0001%7\u0001326-7-21\u0001\u000b\u0001%1(\u000725\u0001\f\u00012*\u00017,)\u0001'280%5-1\u000118\u0005\n'/)86\u0001%/62\u0001'2175-&87)\u000172\u000102(8/%7)\u0001\u001b\u0012\u001d\u0005\u0013\u0001-1,-&-725<\u0001%'7-9-7<\u0001%1(\u0001\u0012\u0007\u0013\u00016)/)'7-9-7<\u00012*\u00017,)\u000135)9-286/<\u0001()6'5-&)(\u0001()5-9%7-9)6\u0006\u0001\u00187\u0001'%1\u0001&)\u0001-1*)55)(\u00017,%7\u00017,)\u0001\u001b\u0012\u001d\u0005\u0013\u0001&-1(-1+\u00016-7)\u00016,28/(\u0001%'')37\u0001/-323,-/-'\u000168&67-78)176\u00012*\u0001/-0-7)(\u00016-=)\u0001%7\u0001326-7-216\u0001\u000b\u0001%1(\u000725\u0001\f \u0001\n2*\u00017,)\u0001'280%5-1\u000118'/)86\u0004\u0001:,)5)%6\u0001,<(523,-/-'\u000125\u0001/%5+)5\u0001,<\u0005\n(523,2&-'\u0001+52836\u0001%5)\u0001127\u0001:)//\u000172/)5%7)(\u0001#\u000e\n$\u0006\u0001\u00172:)9)5\u0004\u0001()\u0005\n5-9%7-9)6\u00012*\u0001\u000f\u0005&)1=</2;<'280%5-16\u0001&)%5-1+\u00013523)5/<\u00016)/)'7)(\u000132/%5\u000168&67-78)176\u0001%7\u0001326-7-21\u0001\f\u0001/)(\u000172\u00011):\u0001\u001b\u0012\u001d\u00186\u0005\u0013\u0001:-7,\u0001%1\u0001-03529)(\u00013,%50%'2.-1)7-'\u0001352*-/)\u0001%1(\u0001%\u0001,-+,)5\u0001(58++%&-/-7<\u0001#\u000e\f$\u0006\u0001\u0001\n\u0001 \u0013\u0006\u0001\u001f)1()1&%',\u0005\u001b>//)5\u0001 \t\u0015\u0001\u0006\u000e\u0002\u0001%/62\u0001);3/25)(\u00017,)\u0001-0325\u0005\n7%1')\u00012*\u00017,)\u000135)6)1')\u00012*\u0001%\u0001,)7)52%5</%/.2;<\u0001+5283\u0001%7\u0001326-7-21\u0001\n\u000f\u00012*\u00017,)\u0001'280%5-1\u00016'%**2/(\u000172\u000102(8/%7)\u00017,)\u0001%'7-9-7<\u0001%+%-167\u0001\u001b\u0012\u001d\u0001-62*2506\u0001#\r\u000e$\u0006\u0001\u00181\u00017,-6\u0001678(<\u0004\u000160%//\u0001%/.</\u0004\u00013,)1</\u000125\u0001,%/2+)1\u0001+52836\u0001:)5)\u0001-1752(8')(\u0001%7\u0001326-7-216\u0001\u000b\u0001%1(\u0001\f\u00012*\u00017,)\u00016.)/)721\u0006\u0001!,)\u00016%0)\u0001 %87,256\u0001 )9%/8%7)(\u0001 %1(\u0001()6'5-&)(\u0001,)7\u0005\n)52%5</%/.2;<'280%5-16\u0001%6\u0001327)17\u0001%1(\u00016)/)'7-9)\u0001\u001b\u0012\u001d\u00186\u0005\u0013\u0001\n#\u000e\u000b\u0004\u0001\u000e\r\u0004\u0001\u000e\u0010$\u0006\u0001\u001d1/<\u000160%//\u000168&67-78)176\u0004\u0001%6\u00010)7,</\u0001+52836\u0004\u0001:)5)\u0001-1752(8')(\u0001%7\u0001326-7-216\u0001\u000b\u0001%1(\u0001\f\u00012*\u00017,-6\u0001'280%5-1\u000118'/)86\u0006\u0001\u0001\n\u0001 \u0013%6)(\u000121\u000135)9-286/<\u0001()6'5-&)(\u0001 \u0012\u001f\u0001678(-)6\u0004\u0001-1752(8'7-21\u0001\n2*\u0001'<'/2%/-3,%7-'\u000125\u0001&)1=)1)\u00015-1+6\u0001*86)(\u0001%7\u0001\u000b\u0004\f\u0005326-7-216\u0001:%6\u0001\n3)5*250)(\u000121\u0001\u000f\u0005,<(52;<'280%5-1\u0001()5-9%7-9)6\u0006\u0001\u0012\u0006\u0001\u0014%5277-\u0001 \t\u0015\u0001\n\u0006\u000e\u0002\u0001%1(\u0001\u0013\u0006\u0001\u001f)1()1&%',\u0005\u001b8)//)5\u0001 \t\u0015\u0001 \u0006\u000e\u0002\u0001()6'5-&)(\u00016)5-)6\u00012*\u0001\n7,)6)\u0001()5-9%7-9)6\u0001:-7,\u0001-17)5)67-1+\u0001\u001b\u0012\u001d\u0005\u0013\u00013523)57-)6\u0001#\u000e\n\u0004\u0001\u000e\r\u0004\n\u0018\u0018\u001f118\b\b\u0007\b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\b\u0006\u0007\b\u0004\u0001\n\u0014\u0011\u0005\u0001\u0004\u0005\u0004\u0001\b\u0014\u0005\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0001\n\f\u0010\u000f\u0005\u0001\u0002\b\u0003\u0005\u0001\u0015&#*'!\u001f)\u0001/0.1!01.#/\u0001,$\u0001(+,3+\u0001!,1*\u001f.'+/\u0001\u001f/\u0001\u0019\u0013\u001a\u0016/\u0006\u0001\n\u0001\n\u0001\n\f\u0010\u000f\u0005\u0001\u0002\t\u0003\u0005\u0001\u000f\u0005\u0013)(5),45\u0001\u001f+\"\u0001/1)$,+5),45\u0001!,1*\u001f.'+\u0001\"#.'2\u001f0'2#/\u0006\u0001\n\u0001\n\u000e\u000e\u001e\u0006\u0001\u0018\u0006\u0001\u001b\u001f+0\u001f+\u001f\u0001 \u0004\f\u0001\u0003\u0006\u0002\u0001&\u001f2#\u0001.#-,.0#\"\u00010&\u001f0\u0001\u001f++#)\u001f0',+\u00013'0&\u0001\r\u0005\u0001\n\u001f+\"\u0001\u000e\u0005*#* #.#\"\u0001.'+%/\u0001,+\u00010&#\u0001!,1*\u001f.'+\u0001+1!)#1/\u0004\u0001'+\u0001\u001f\"\"'0',+\u0001\n0,\u0001 \u000f\u0005\u001f!#0,+5),45\u0005/1 /0'010#+0/\u0004\u0001 /&,3#\"\u0001 &'%&#.\u0001 \u001f!0'2'05\u0001\u001f%\u001f'+/0\u0001 ,0&\u0001\u0019\u0013\u001a\u0001'/,$,.*/\u00010&\u001f+\u00010&#\u0001\u000f\u0005&5\".,45\u0001-.#!1./,./\u0001\n\u001d\u000e\u000e\u001e\u0006\u0001\u001c&#/#\u0001\"#.'2\u001f0'2#/\u0001-.#/#+0#\"\u0001\"'$$#.#+0\u0001\u0019\u0013\u001a\u0005\u0013\u0007\u0019\u0013\u001a\u0005\u0014\u0001\n/#)#!0'2'05\u0001-.,$')#/\u0004\u0001\u001f/\u0001/&,3+\u0001'+\u00010&#\u0001\u0002\u001c\u001f )#\u0001 \b\u0003\u0006\n\u0001\n\u0001 \u0016+\u0001,.\"#.\u00010,\u0001!,*-)#0#\u00010&#\u0001/01\"5\u0001,$\u0001\u000f\u0005/1 / 0'010#\"\u0001!,1*\u001f.'+\u0001\n\"#.'2\u001f0'2#/\u0004\u0001\u0013\u0006\u0001\u0015\u001f.,00'\u0001 \u0004\f\u0001\u0003\u0006\u0002\u0001/5+0&#/'6#\"\u0001\u001f+\"\u0001#2\u001f)1\u001f0#\"\u00010&#\u0001 \u0005\b\u0001\n\r\u0005\f\u000b\t\u0001 ',),%'!\u001f)\u0001\u0019\u0013\u001a\u0001\u001f!0'2'05\u0001,$\u0001+,2#)\u0001/#.'#/\u0001,$\u0001!,1*\u001f.'+/\u0001\n #\u001f.'+%\u0001\"'$$#.#+0\u0001/1 /0'01#+0/\u0001\u001f0\u0001-,/'0',+\u0001\u000f\u0006\u0001\u001b1!&\u0001/1 /0'01#+0/ \u0001\n!,+/'/0#\"\u0001 ,$\u0001 \u001f\u0001 -&#+5)\u0001 .'+%\u0001 )'+(#\"\u0001 0,\u0001 \u001f\u0001 !,1*\u001f.'+\u0001 !,.#\u0001  5\u0001 .'\"%#/\u0001,$\u0001\"'$$#.#+0\u0001/'6#\u0004\u0001)#+%0&\u0001\u001f+\"\u0001)'-,-&')'!\u0001\u001f+\"\u0001#)#!0.,+'! \u0001\n+\u001f01.#\u0006\u0001\u0016+\u0001%#+#.\u001f)\u0004\u0001'/,/0#.'!\u00012\u001f.'\u001f0',+/\u0001,$\u00010&#\u0001,45*#0&5)#+#\u0001)'+(#.\u0001)#\u001f\"\u00010,\u0001'+&' '0,./\u00013'0&\u0001),3#.\u0001\u0019\u0013\u001a\u0005\u0014\u0001\u001f$$'+'05\u0001\u001f+\"\u0001\u0014\u0007\u0013\u0001/#)#!0'2'05\u0001\u001d\u000e\n\u0004\u0001\u000e\u000f\u001e\u0006\u0001\n\u0001 \u001c&#\u0001.#-,.0#\"\u0001.#/1)0/\u0001$,.\u0001\u000f\u0005/1 /0'010#\"\u0001!,1*\u001f.'+/\u0001!,+0\u001f'+\u0005\n'+%\u0001\u001f\u0001 #+6#+#\u0001.'+%\u0001$1/#\"\u0001\u001f0\u0001\u000b\u0004\f\u0001-,/'0',+/\u0001#+!,1.\u001f%#\"\u0001\u0019\u0006\u0001\u0017\u0006\u0001\u0019\u001f0,/\u0001\u0004\f\u0001\u0003\u0006\u0002\u00010,\u0001\u001f+\u001f)56#\u00010&#\u0001'*-,.0\u001f+!#\u0001,$\u00010&#\u0001\u001f.5)\u0001/1 /0'01#+0\u0001\n,+\u00010&#\u0001-5.,+#\u0001.'+%\u0004\u0001/5+0&#/'6'+%\u0001\u001f\u0001/#.'#/\u0001,$\u0001\u000b\u0005\u001f.5)!,1*\u001f.'+\u0001\"#.'2\u001f0'2#/\u0001 \r\u000e\u0006\u0001 \u001c&#\u0001 /1 /0'010',+\u0001 \u001f0\u0001 \u0015\u000f\u0001 3\u001f/\u0001 .#*,2#\"\u0001 \u001f+\"\u0001/*\u001f))\u0001 /1 /0'01#+0/\u0001 3#.#\u0001 '+0.,\"1!#\"\u0001 #'0&#.\u0001 \u001f0\u0001 \u0015\u000e\u0001 \u001d\u000e\u0011\u0005\u000f\f\u001e\u0001,.\u0007\u001f+\"\u0001\u0015\u0010\u0001\u001d\u000f\r\u0004\u0001\u000f\u000e\u001e\u0001-,/'0',+/\u0006\u0001\u001c&#\u0001&'%&\u0001\u0019\u0013\u001a\u0005\u0014\u0001/#)#!0'2'05\u0001$,1+\"\u0001$,.\u00010&'/\u0001+#3\u0001\u000b\u0005\u001f.5)!,1*\u001f.'+\u0001/!\u001f$$,)\"\u0001#+!,1.\u001f%#\"\u00010&#\u0001\u001f10&,./\u00010,\u0001/5+0&#/'6#\u0001\u001f+\"\u0001/01\"5\u00010&#\u0001\u0019\u0013\u001a\u0001'+&' '0,.5\u0001\u001f!0'2'05\u0001\n,$\u0001+#3\u0001\u001f+\u001f),%1#/\u0006\u0001\u0013\u00012\u001f.'#05\u0001,$\u0001%.,1-/\u00013'0&\u0001\"'$$#.#+0\u0001/'6#\u0004\u0001\n#)#!0.,+'!\u0001\u001f+\"\u0001)'-,-&')'!\u0001-.,-#.0'#/\u00013#.#\u0001'+0.,\"1!#\"\u0001'+\u0001 ,0&\u0001\u001f.,*\u001f0'!\u0001.'+%/\u0004\u0001'+\u0001,.\"#.\u00010,\u0001!)\u001f.'$5\u00010&#\u0001'+$)1#+!#\u0001,$\u00010&#\u0001/1 /0' \u0005\n010',+\u0001-\u001f00#.+\u0001'+\u00010&#\u0001\u0019\u0013\u001a\u0001'+&' '0,.5\u0001\u001f!0'2'05\u0001\u001f+\"\u0001/#)#!0'2'05\u0001,$\u00010&#\u0001\u000b\u0005\u001f.5)!,1*\u001f.'+\u0001/(#)#0,+\u0001\u001d\u000e\u0011\u0005\u000f\u000e\u001e\u0006\n\u0001\u0019,/0\u0001\u001f!0'2#\u0001 !,*\u0005\n-,1+\"/\u0001-.#/#+0\u0001 \n\u0003\u000b\u0003\u0001,.\u0001\u0007\u0004\f\u0003\u0001/1 /0'010',+/\u0001'+\u00010&#\u0001\u000b\u0005-&#+5)\u0001\n.'+%\u0006\u0001\u001c&#\u0001 #/0\u0001!,*-,1+\"\u0001,$\u00010&#\u0001\"#/!.' #\"\u0001/#.'#/\u0001'/\u00010&#\u0001\u000e\u0005\n*#0&5)\u0005\u000b\u0005\u0002\f7\u0005*#0&5)-&#+5)\u0003!,1*\u001f.'+\u0001\u0002!,*-,1+\"\u0001 \b\n\u000b\u0003\u0004\u00013'0&\u0001\n\u001f+\u0001\u0016\u0015\r\b\u0001,$\u0001\b\u0006\u000b\t\u0001+\u0019\u0006\u0001\u001c&'/\u0001!,*-,1+\"\u0001-.,2#\"\u00010,\u0001 #\u0001+,0\u0001,+)5\u0001\u000e\f\u0001\n0'*#/\u0001*,.#\u0001\u001f!0'2#\u0001 \u0005\b\u0001\r\u0005\f\u000b\t\u00010&\u001f+\u0001/#)#%')'+#\u0001\u00020&#\u0001.#$#.#+!#\u0001!,*\u0005\n-,1+\"\u0003\u0001 10\u0001\u001f)/,\u0001/#2#.\u001f)\u00010'*#/\u0001*,.#\u0001/#)#!0'2#\u00010&\u001f+\u0001'0\u0001\u0002!,*\u0005\n-,1+\"\u0001\b\n\u000b\u0001'/\u0001\u0012\u0001\u0011\u000f\u0001$,)\"\u0001*,.#\u0001/#)#!0'2#\u00010&\u001f+\u0001/#)#%')'+#\u0003\u0001\u001d\u000f\n\u001e\u0006 \u0001\n\u0001 \u0013\"\"'0',+\u001f))5\u0004\u0001\u001f\u0001 &5\".,45)\u0001%.,1-\u0001\u001f0\u0001-,/'0',+\u0001\f\u0001,$\u00010&#\u0001!,1\u0005\n*\u001f.'+\u0001/(#)#0,+\u00013\u001f/\u0001'+0.,\"1!#\"\u0006\u0001\u001c&'/\u0001*,\"'$'!\u001f0',+\u0001\u001f)),3#\"\u00010,\u0001\n!,+/'\"#.\u0001 0&#\u0001 /'*')\u001f.'05\u0001 ,$\u0001 0&#\u0001 !,.#\u0001 /0.1!01.#\u0001 ,$\u0001 0&#\u0001 \f\u0005&5\".,45!,1*\u001f.'+\u0001!,*-\u001f.'+%\u00013'0&\u00010&#\u0001\n\u0005&5\".,45'/,$)\u001f2,+#\u0006\u0001\u001c\u001f('+%\u0001'+0,\u0001\u001f!!,1+0\u00010&#\u0001, 0\u001f'+#\"\u0001.#/1)0/\u0004\u0001'0\u0001!,1)\"\u0001 #\u0001#/0\u001f \u0005\n\u0018\u0018 119\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\u0007\t\u0001\n\u0019\u001a\u001b\"\u001e\u0001\u0007\u0005\u0001 \u0012 \u001e#!\u001c\u001a\"\u0001\u0018)'*\u001c)*'\u001e(\u0001\u001a$\u001d\u0001\u0015\u0010\u0016\u0001\u0014$ !\u001b!)!%$\u0001\u0013\u001a)\u001a\u0001%\u001f\u0001\r\u0004 -\u001d'%,-\u001c%*#\u001a'!$\u0001\u0013\u001e'!+\u001a)!+\u001e(\u0001\u0014\u0001\u0002\u0012%#&%*$\u001d(\u0001\u0007\u0004\u0007\u000f\b\u0003\u0001\n\u0006\u0006 \u0007\u0006\u0007\u0002\n\u0007\u0001 \u0007\u0004\n\u0007\u0005\u0007\u0003\n\u0001\n\u0001\n\u0012&\u001d(\u0001 \u0017\u0001 \u0017\t\u0001\u0017 \n\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002.\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002.\u0015\u0003\u0001\u0017\u001e\u001f\u0005\u0001\n\u0007\u0001 \u0012\u0001 \u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001 \u0014 \u0011\u0012\t\u0001 \u000e\u0006\u0005\t\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\b\u0001 \u0012\u0001 \u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001\u0011 \u0012\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u0007\u0005\t\b\u0001 \f\f\u0001\n\t\u0001 \u0012\u0001 \u0012\u0001 \u0011\u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u000e\u0006\u0005\n\u0007\u0001 \f\f\u0001\n\n\u0001 \u0012\u0001 \u0013\u0012 \b\u0001\u0012 \u0001 \u0012 \u0001 \u0012 \u0001 \u0014 \u0011 \u0012 \t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\u000b\u0001\n\u0004\u0002\u0003\u0001 \u0003\u0001\u0002\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0007 \u0007\u0005\u0006\u0001 \u0006 \u0005\u0006\u0006\n\u0001 \f \u0007\u0001\n\f\u0001\u0003\u0001\u0002\u0004\n\u0004\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u000f \u0005\b\u0006\u0001 \u0006 \u0005\u000f\n\u0001 \f \u0007\u0001\n\r\u0001\n\u0004\u0004\n\u0003\u0001\u0002 \u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u000b \u0005\u000f\u0006\u0001 \u0006 \u0005\u0007\u0007\u0001 \f \u0007\u0001\n\u000e\u0001\u0004\n\u0004\u0002\u0003\u0001 \u0003\u0001\u0002\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \r \u0005\r\u0006\u0001 \u0006 \u0005\u0006\u0007\n\u0001 \f \u0007\u0001\n\u000f\u0001 \u0004\n\u0004\u0002\u0003\u0001 \u0003\u0001\u0002\u0002\u0003\u0001\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \n \u0005\u0007\u0006\u0001 \u0006 \u0005\u0006\u0006\n\u0001 \f \u0007\u0001\n\u0007\u0006\u0001\u0001\n\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \b\u0006\u0001\u0003\u0007\u000b\u0002\u0004\u0001 \u0006\u0005\u0006\b\u000e\u0001 \f\u0007\u0001\n\u0007\u0007\u0001\u0001\n\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0007\u0006\u0001\u0003\u0006\u0002\u0004\u0001 \u0007\u0006\u0001\u0003\b\r\u0002\u0004\u0001 \f\u0007\u0001\n\u0007\b\u0001\u0001\n\u0002\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \t \n\u0005\u0006\u0001 \u0006 \u0005\u000e\u000f\u0001 \f \u0007\u0001\n\u0007\t\u0001\u0004\n\u0003\u0005\n\u0003\u0001\u0002\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0006 \u0005\r\u0006\u0001 \u0006 \u0005\u000e\n\u0001 \f \u0007\u0001\n\u0007\n\u0001\u0004\u0003\u0002\u0003\u0001\n\u0003\u0001\u0002\u0005\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0007 \u0005\u0007\t\u0001 \u0006 \u0005\u0007\n\u0001 \f \u0007\u0001\n\u0007\u000b\u0001 \u0003\u0001\u0002\u0004\n\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u0006\n\n\u0001 \f\f\u0001\n\u0007\f\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\n\u0007\u0001 \u0006\u0005\u0006\u0006\f\u0001 \f\f\u0001\n\u0007\r\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001 \u0014 \u0011\u0012\t\u0001 \b\u0005\f\f\u0001 \u0006\u0005\u000e\f\u0001 \f\f\u0001\n\u0007\u000e\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001\u0011 \u0012\t\u0001 \u0006\u0005\u0006\u0006\r\u0001 \u0006\u0005\u0006\u0007\u0007\u0001 \f\f\u0001\n\u0007\u000f\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \n\t\u0005\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\b\u0006\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001 \u0014 \u0011\u0012\t\u0001 \u0007\u000b\u0005\n\u000b\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\b\u0007\u0001\u0001\n\u0001\u0012\u0001 \u0011\u0012 \t\u0001\u0012 \u0001 \u0012 \u0001\u0011 \u0012\t\u0001 \u0006\u0005\n\u0006\u0001 \u0006\u0005\u0006\u0006\n\u0001 \f\f\u0001\n\b\b\u0001 \u0011\u0012\t\u0001\u0011 \u0012 \t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\r\u0007\u0001 \u0006\u0005\u0006\u0006\u0006\u000b\u0001 \f\t\u0001\n\u0018\u0019\u0017120\t\t\b\u000b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\b\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017\u0001 \u0017\n\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0017\u001d\u001e\u0006\u0001\n\t\n\u0001\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \t\u0007\u0005\f\u0006\u0001 \t\u0005\b\n\u0001 \f\r\u0001\n\t\u000b\u0001\n\u0002\u0003\u0001\u0003\u0001\u0002\n\u0001\u0011\u0015\u0001 \u0011\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\n\u0001 \u000b\f\u0001\n\t\f\u0001\u0001\u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \f\u0005\r\f\u0001 \u0006\u0005\u0006\u000b\u000b\u0001 \f\b\u0001\n\t\r\u0001\u0001\u0011\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u000b\u0005\u000b\u0006\u0001 \u0006\u0005\u0006\u0006\r\u0001 \f\r\u0001\n\t\u000e\u0001\u0001\u0013\u0001 \u0011\u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0007 \u0005\u000f\u000b\u0001 \u0006 \u0005\u0006\u0007\u000e\u0001 \f \b\u0001\n\t\u000f\u0001\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0006 \u0005\f\u000f\u0001 \u0006 \u0005\u0006\u0006\n\u0001 \f \b\u0001\n\t\u0010\u0001\u0001\u0013\u0001 \u0014\u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0007\u000b\u0001\u0003\b\f\u0002\u0004\u0001 \u0007\u0005\u000b\u000e\u0001 \f\b\u0001\n\n\u0007\u0001\u0001\u0013\u0001 \u0011\u0012 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0010 \u0001\u000b\u0001 \u0007 \u0005\t\u000e\u0001 \f \b\u0001\n\n\b\u0001\u0001\u0001\u0011\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \t\u0001\u0003\n\u0002\u0004\u0001 \t\u0001\u0003\u000e\u0002\u0004\u0001 \f\b\u0001\n\n\t\u0001\u0001\u0013\u0001\n\u0001\u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\n\u0001 \u0010\u0001\n\u0001 \f\b\u0001\n\n\n\u0001\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001\u0013 \u0001 \u0013 \u0001\u0011 \u0013\t\u0001 \u0006\u0005\u000b\f\u0001 \t\u0005\t\u0007\u0001 \f\b\u0001\n\n\u000b\u0001\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001\u0013 \u0001\n\u0001\u0001\u0013\u0001 \u0010\u0001\u0006\u0005\n\u0001 \u0010\u0001\u0006\u0005\n\u0001 \f\b\u0001\n\n\f\u0001\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0014\u0013\u0001 \u0013\u0001 \u0007\u0007\b\u0005\b\u0006\u0001 \t\u0005\u0006\u000f\u0001 \f\b\u0001\n\n\r\u0001\u0002\u0003\u0001\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \t \u0005\u000b\u000b\u0001 \u0006 \u0005\t\b\u0001 \f \b\u0001\n\n\u000e\u0001\u0002\u0003\u0001\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0010 \u0001\u0006\u0005\u000b\n\u0001 \u0006 \u0005\u0006\u0006\u0007\u0001 \u000b \f\u0001\n\n\u000f\u0001\u0003\u0001\u0002\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0006 \u0005\t\u000f\u0001 \u0006 \u0005\u0006\u0006\u0007\u0001 \u000b \f\u0001\n\n\u0010\u0001\u0003\u0001\u0002\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0006 \u0005\u000b\f\u0001 \u0006 \u0005\u0006\u0006\u0007\u0001 \u000b \f\u0001\n\u000b\u0007\u0001\u0002\u0003\u0001\n\u0003\u0001\u0002\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\n\u0001 \u000b\f\u0001\n\u000b\b\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\b\u0001 \u000b\f\u0001\n\u000b\t\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0013\u0001 \u0011\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\u000b\u0001 \u000b\f\u0001\n\u000b\n\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0011\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\t\u0001 \u000b\f\u0001\n\u000b\u000b\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\r\u0001 \u000b\f\u0001\n\u000b\f\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0011\u0015\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\t\u0007\u0001 \u000b\f\u0001\n\u000b\r\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001\u0013 \u0001 \u0013 \u0001\u0011 \u0013\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\t\u0001\n\u000b\u000e\u0001\u0003\u0001\u0002\n\u0003\u0001\u0002\u0002\u0003\u0001\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0007\u0006\u0005\u0006\u0001 \f\t\u0001\n\u000b\u000f\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0003\u0001\u0002\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\t\b\u0001 \u000b\f\u0001\n\u000b\u0010\u0001\u0001\u0001\n\u0001\n\u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013 \u0001\u0013 \u0001\u0013 \u0001 \u0006 \u0005\t\u0006\u0001 \u0006 \u0005\u0006\u0006\u0007\u0001 \u000b \f\u0001\n\f\u0007\u0001\u0001\n\u0001\n\u0001 \u0001\u0011\u0013\t\u0001\u0011 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\b\u0001 \u000b\f\u0001\n\u0018\u0019\u0018121\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\u0007\u000b\u0001\n\u0002\u0017\u0018\u0019\u001e\u001c\u0001\u0007\u0003\u0001\u001a \u001f#\u001b$\u0005\u0001\n\u0012!\u001b\"\u0001 \u0016\u0001 \u0016\t\u0001\u0016 \n\u0001\u0016 \u000b\u0001\u0016 \f\u0001\u0016 \u000e\u0001\u0014\u0010\u0015\u0004\u0010\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0014\u0010\u0015\u0004\u0011\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0016\u001c\u001d\u0005\u0001\n\u000b\u0007\u0001\u0003\u0001\u0002\u0004\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0002\b\u0004\u0001 \u0003 \u0002\u0003\u0003\u0007\u0001 \t \u0005\u0001\n\u000b\b\u0001\u0003\u0001\u0002\u0004\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0005 \u0002\u0004\u0003\u0001 \u0003 \u0002\u0003\u0003\u0003\t\u0001 \b \t\u0001\n\u000b\t\u0001\u0002\u0001\n\u0001\n\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \b \u0002\u000b\f\u0001 \u0003 \u0002\u0003\u0004\u0004\u0001 \t \u0005\u0001\n\u000b\n\u0001\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\b\u000b\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \u0005\u0001\n\u000b\u000b\u0001\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0005\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \u0005\u0001\n\u000b\f\u0001\u0001\n\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0005\u0001 \u0003 \u0002\u0003\u0003\u0004\u0001 \t \u0005\u0001\n\u000b\r\u0001\u0001\n\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\t\u000b\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \u0005\u0001\n\u000b\u000e\u0001\u0002\u0003\n\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0004\u0001 \u0003 \u0002\u0003\u0003\n\u0001 \t \u0005\u0001\n\u000b\u000f\u0001\u0001 \u0001\n\u0001\n\u0001 \u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\t\f\u0001 \u0003 \u0002\u0003\u0003\t\u0001 \t \u0005\u0001\n\f\u0006\u0001\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0004\u0005\u0002\b\f\u0001 \u0003\u0002\u0003\u0003\b\u0001 \t\n\u0001\n\f\u0007\u0001\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0002\u0004\u0005\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \u0005\u0001\n\f\b\u0001\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0005\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \u0005\u0001\n\f\t\u0001\u0003\u0001\u0002\n\u0001\u000f\u0001 \u000e\u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0006\u0001 \u0003 \u0002\u0003\u0004\u0006\u0001 \t \u0005\u0001\n\f\n\u0001\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0003\u0002\u0003\n\t\u0001 \u0003\u0002\u0003\u0003\u0006\u0001 \t\u0005\u0001\n\f\u000b\u0001\u0003\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u000b\u0006\u0001 \u0003 \u0002\u0003\u0003\f\u0001 \t \u0005\u0001\n\f\f\u0001\u0003\u0001\u0002\n\u0003\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u000b\u0001 \u0003 \u0002\u0003\u0003\t\u0001 \t \u0005\u0001\n\f\r\u0001\u0002\u0001\u0003\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0004\u0002\u0003\u0001 \u0003\u0002\u0003\u0006\b\u0001 \t\u0005\u0001\n\f\u000e\u0001\u0003\n\u0004\n\u0005\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \n \u0002\u0003\u000b\u0001 \u0003 \u0002\u0005\b\u0001 \t \u0005\u0001\n\f\u000f\u0001\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0007\u0005\u0001 \u0003 \u0002\u0003\u0004\u0003\u0001 \t \u0005\u0001\n\r\u0006\u0001\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0007\u0005\u0001 \u0003 \u0002\u0003\u0005\u0006\u0001 \t \u0005\u0001\n\r\u0007\u0001\u0002\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0005\u0005\u0001 \u0003 \u0002\u0003\u0004\u0004\u0001 \t \u0005\u0001\n\r\b\u0001\u0002\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0003 \u0002\u0004\u0003\u0001 \u0003 \u0002\u0003\u0003\u0007\u0001 \t \u0005\u0001\n\r\t\u0001\u0001\u0004\u0005\u0003\u0002\u0003\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0004\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\t\u0001 \t\u0005\u0001\n\r\n\u0001\u0001\u0004\u0005\u0003\u0002\u0003\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001\u000f \u0001 \u000e \u000f\u0005\u000e\u000f\u0006\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0004\u0003\u0001 \b\t\u0001\n\r\u000b\u0001\n\u0002\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\n\u0004\u0001 \t \n\u0001\n\u0018\u0019\u0019122\t\t\b\r\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\b\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017\u0001 \u0017\n\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0017\u001d\u001e\u0006\u0001\n\u000e\r\u0001\n\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u000f \u0005\r\r\u0001 \u0006 \u0005\u0006\u0007\u000e\u0001 \f \r\u0001\n\u000e\u000e\u0001\u0001\u0005\u0006\u0003\u0002\u0004\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0007\u0005\u000b\u0006\u0001 \u0006\u0005\u0006\u0006\n\u0001 \u000b\f\u0001\n\u000e\u000f\u0001\u0001\u0005\u0006\u0003\u0002\u0004\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0007 \u0005\b\u0006\u0001 \u0006 \u0005\u0006\u0006\n\u0001 \u000b \f\u0001\n\u000e\u0010\u0001 \u0001\u0004\u0005\u0003\u0002\u0003\n\u0006\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0007\u0006\u0005\b\t\u0001 \u0006\u0005\u0006\b\r\u0001 \f\r\u0001\n\u000f\u0007\u0001\u0001\n\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \t\u0007\u0005\f\b\u0001 \u0006\u0005\u0007\u0007\u0001 \f\r\u0001\n\u000f\b\u0001\u0001\n\u0001\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0007\u0006\u0006\u0005\u0006\u0001 \u0006\u0005\u0006\u000b\u000e\u0001 \f\r\u0001\n\u000f\t\u0001\u0001\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0007 \u0005\u000e\u0006\u0001 \u0006 \u0005\u0006\u0006\u000f\u0001 \f \t\u0001\n\u000f\n\u0001\u0001\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0011\u0013\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\u0006\r\u0001 \f\u000b\u0001\n\u000f\u000b\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0007\u0007\u0001 \f\u000b\u0001\n\u000f\f\u0001\u0001\n\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0007 \u0006\u0005\u0006\u0001 \u0006 \u0005\u0006\u0006\u000e\u0001 \f \u000b\u0001\n\u000f\r\u0001\u0001\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\b\u0001 \f\u000b\u0001\n\u000f\u000e\u0001\u0006\u0005\u0001\n\u0004\u0002\u0003\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0007\u0007\u0006\u0005\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\t\u0001\n\u000f\u000f\u0001\u0006\u0005\u0001 \u0004\u0002\u0003\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0006\u000e\u0001 \u000b\u0005\u0006\u0001 \f\t\u0001\n\u000f\u0010\u0001\t\n\b\u0003\u0001\u0006\u0007\u0003\u0002\u0005\n\u0007\u0004\u0006\u0001 \u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0007\f\u0001 \b\u0005\b\u0006\u0001 \f\t\u0001\n\u0010\u0007\u0001\t\b\u0003\u0001\u0006\u0007\u0003\u0002\u0005\n\u0007\u0004\u0006\u0001 \u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\t\n\u0001 \u0010\u0001\u0007\u0006\u0001 \f\t\u0001\n\u0010\b\u0001\u0003\u0002\u0001\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\n\u000b\u0001 \u000b\n\u0005\u000f\u000b\u0001 \f\r\u0001\n\u0010\t\u0001\u0003\u0002\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\b\n\u0001 \u0007\u0005\u0007\u0006\u0001 \f\t\u0001\n\u0010\n\u0001\u0006\u0005\u0001 \u0004\u0002\u0003\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\n\r\u0001 \u0007\u000b\u0001\u0003\u0007\r\u0002\u0004\u0001 \f\b\u0001\n\u0010\u000b\u0001\u0006\u0005\u0001 \u0004\u0002\u0003\u0005\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0006 \u0005\u0006\r\u0007\u0001 \u0007 \f\u0005\u000f\u000e\u0001 \f \b\u0001\n\u0010\f\u0001\u0004\u0003\u0001 \u0002\u0005\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0006\u000b\u0001 \u0006\u0005\u0006\u0006\n\u0001 \f\t\u0001\n\u0010\r\u0001\u0005\u0004\u0001 \u0003\u0002\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0006\u000e\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\t\u0001\n\u0010\u000e\u0001\u0004\u0003\u0001 \u0002\u0005\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0006\f\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\t\u0001\n\u0010\u000f\u0001\u0004\u0003\u0001 \u0003\u0001\u0002\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0006\u0005\u0006\u0007\t\u0001 \b\u0001\u0003\b\u0006\u0002\u0004\u0001 \f\b\u0001\n\u0010\u0010\u0001\u0003\u0002\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \b \u0005\u0006\u0001 \u0007 \u0006\u0006\u0005\u0006\u0001 \f \r\u0001\n\b\u0007\u0007\u0001\n\u0003\u0002\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \b \u0005\u000e\b\u0001 \u0006 \u0005\u000e\r\u0001 \f \r\u0001\n\b\u0007\b\u0001\u0002 \u0001\u0003\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0007\r\u0001 \f\u000b\u0001\n\b\u0007\t\u0001 \u0004\u0003\u0001\u0002\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0006 \u0005\t\u000b\u0001 \u0006 \u0005\u0006\u0006\u0006\u000b\u0001 \f \u000b\u0001\n\b\u0007\n\u0001\u0004\n\u0002\u0003\u0001\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012 \u0001\u0012 \u0001\u0012 \u0001 \u0006 \u0005\b\t\u0001 \u0006 \u0005\u0006\u0006\u0006\u000b\u0001 \f \u000b\u0001\n\b\u0007\u000b\u0001 \u0004\u0003\u0001\u0002\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0011\u0012\t\u0001\u0011 \u0012 \t\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\u0007\u0001 \f\u000b\u0001\n\u0018\u0019\u001a123\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\u0007\r\u0001\n\u0002\u0017\u0018\u0019\u001e\u001c\u0001\u0007\u0003\u0001\u001a \u001f#\u001b$\u0005\u0001\n\u0012!\u001b\"\u0001 \u0016\u0001 \u0016\t\u0001\u0016 \n\u0001\u0016 \u000b\u0001\u0016 \f\u0001\u0016 \u000e\u0001\u0014\u0010\u0015\u0004\u0010\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0014\u0010\u0015\u0004\u0011\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0016\u001c\u001d\u0005\u0001\n\u0007\u0006\u000b\u0001\u0005\n\u0004\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \b\u0001\n\u0007\u0006\f\u0001\u0002\n\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0006 \u0002\u0005\u0003\u0001 \u0003 \u0002\u0003\u0003\t\u0001 \t \b\u0001\n\u0007\u0006\r\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0004\u0001 \t \u000b\u0001\n\u0007\u0006\u000e\u0001\u0005\n\u0004\u0003\u0001\u0002\n\u0002\u0003\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0006\u0001 \t\b\u0001\n\u0007\u0006\u000f\u0001\u0005\n\u0004\u0003\u0001\u0002\n\u0003\u0001\u0002\u0001\u000e\u0010\u0001 \u000e\u000f \u0006\u0001 \u000f\u0001 \u000e\u0010\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\b\u0001\n\u0007\u0007\u0006\u0001\u0002\n\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0004\u0001 \t \b\u0001\n\u0007\u0007\u0007\u0001\u0002\n\u0001\n\u0001\u000e\u0010\u0001 \u000e\u000f \u0006\u0001 \u000f\u0001 \u000e\u0010\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\b\u0001\n\u0007\u0007\b\u0001\n\u0004\n\u0005\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0002\b\u0003\u0001 \u0003 \u0002\u0003\u0003\u0005\u0001 \t \b\u0001\n\u0007\u0007\t\u0001\u0004\u0005\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0005\u0001 \t \b\u0001\n\u0007\u0007\n\u0001\u0004\u0005\u0005\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\b\u0001 \t \b\u0001\n\u0007\u0007\u000b\u0001\n\u0004\u0005\u0003\u0001\u0002\u0002\u0003\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \t \u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0003\n\u0001 \t \b\u0001\n\u0007\u0007\f\u0001\n\u0004\u0005\u0003\u0001\u0002\u0005\u0002\u0003\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0005 \u0002\f\u0003\u0001 \u0003 \u0002\u0003\u0003\u0004\u0001 \t \b\u0001\n\u0007\u0007\r\u0001\u0004\u0005\u0003\u0001\u0002\n\u0002\u0003\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0005\u0001 \t \b\u0001\n\u0007\u0007\u000e\u0001\n\u0004\u0005\u0002\u0003\u0001\n\u0003\u0001\u0002\n\u0003\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\u0007\u0007\u000f\u0001\n\u0001\n\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\u0007\b\u0006\u0001\n\u0002\n\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \n\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\u0007\b\u0007\u0001\n\u0001\n\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\u0007\b\b\u0001\n\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\u0007\b\t\u0001\u0001\u0002\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0004\u0007\u0001 \t\b\u0001\n\u0007\b\n\u0001\n\u0004\n\u0005\u0002\u0003\u0001\n\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0005\u0003\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\u0003\t\u0001 \t\b\u0001\n\u0007\b\u000b\u0001\n\u0001\u0002\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \b\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\u0007\u0001 \t\b\u0001\n\u0007\b\f\u0001\n\u0004\u0004\u0003\u0001\u0002\u0002\u0003\u0001\n\u0002\u0003\u0001\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\b\u0001 \t \b\u0001\n\u0007\b\r\u0001\n\u0004\n\u0004\u0003\u0001\u0002\u0002\u0003\u0001\n\u0003\u0001\u0002\u0001\u000e\u000f\u0006\u0001\u000e \u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\b\u0001\n\u0018\u0019\u001b124\t\t\b\u000f\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\b\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017\u0001 \u0017\n\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0017\u001d\u001e\u0006\u0001\n\b\t\u000f\u0001\n\u0004\u0004\u0002\u0003\u0001\n\u0003\u0001\u0002\n\u0003\u0001\u0002\u0001\u000f\u0011\u0001 \u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\b\u0001\n\b\t\u0010\u0001\n\u0004\u0004\u0002\u0003\u0001\n\u0003\u0001\u0002\n\u0003\u0001\u0002\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001\u0010 \u0001 \u000f \u0010\u0005\u000f\u0010\u0006\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\f\u0001 \t\b\u0001\n\b\n\u0007\u0001\u0004\u0004\u0003\u0001\u0002\n\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0004\u0003\u0001 \t\b\u0001\n\b\n\b\u0001\u0004\n\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010 \u0001\u0010 \u0001\u0010 \u0001 \b \u0002\t\u0003\u0001 \u0003 \u0002\u0003\u0004\b\u0001 \t \b\u0001\n\b\n\t\u0001\u0001\n\u0001\n\u0002\n\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010 \u0001\u0010 \u0001\u0010 \u0001 \u0004 \u0003\u0002\u0003\u0001 \u0003 \u0002\u0003\u0003\u0004\u0001 \t \b\u0001\n\b\n\n\u0001\u0004\u0004\n\u0005 \u0005 \u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u000b\u0001 \t\b\u0001\n\b\n\u000b\u0001\u0004\n\u0004\u0005\u0003\u0001\u0002\n\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0007\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\u0007\u0001 \t\b\u0001\n\b\n\f\u0001\u0004\n\u0004\n\u0005\u0002\u0003\u0001\n\u0003\u0001\u0002\n\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\b\n\r\u0001\u0001\n\u0001\n\u0002\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \n\u0002\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\b\n\u000e\u0001\u0004\n\u0004\u0004\n\u0003\u0001\u0002\u0002\u0003\u0001\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0004\u0006\u0001 \t\b\u0001\n\b\n\u000f\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002\n\u0002\u0003\u0001\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\u000b\u0001\n\b\n\u0010\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002\n\u0002\u0003\u0001\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u000f\u0011\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0006\u0001 \t\u000b\u0001\n\b\u000b\u0007\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010 \u0001\u0010 \u0001\u0010 \u0001 \u0006 \u0002\t\u0003\u0001 \u0003 \u0002\u0003\u0003\u0006\u0001 \t \b\u0001\n\b\u000b\b\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001\u0010 \u0001 \u000f \u0010\u0005\u000f\u0010\u0006\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\n\u0001 \t\b\u0001\n\b\u000b\t\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0004\b\u0001 \t\b\u0001\n\b\u000b\n\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0011\u0001 \u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\t\u0001 \t\b\u0001\n\b\u000b\u000b\u0001\u0004\u0004\n\u0005\u0003\u0001\u0002 \u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u000e\u0012\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\b\u0001\n\b\u000b\f\u0001\u0004\u0004\n\u0005\u0002\u0003\u0001\n\u0001\u000f\u0010\u0006\u0001\u000f \u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\u000b\u0001\n\b\u000b\r\u0001\u0001\u0010\u0001\u0003\u0002\u0003\u0002\u0001\u0004\n\u0001\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0004\u0002\u0007\u0007\u0001 \u0003\u0002\u0003\u0007\u0003\u0001 \t\u0007\u0001\n\b\u000b\u000e\u0001\u0001\u0002\n\u0001\u0010\u0001\u0003\u0002\u0003\u0002\u0001\u0004\n\u0001\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0005\u0002\b\u0003\u0001 \u0003\u0002\u0003\f\u0003\u0001 \t\u0007\u0001\n\b\u000b\u000f\u0001\u0001\u0002\n\u0001\u0010\u0001\u0003\u0002\u0004\n\u0003\u0002\u0001\u0001\u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0001 \t\u0007\u0001\n\u0018\u0019\u001c125\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\u0007\u000f\u0001\n\u0002\u0017\u0018\u0019\u001e\u001c\u0001\u0007\u0003\u0001\u001a \u001f#\u001b$\u0005\u0001\n\u0012!\u001b\"\u0001 \u0016\u0001 \u0016\t\u0001\u0016 \n\u0001\u0016 \u000b\u0001\u0016 \f\u0001\u0016 \u000e\u0001\u0014\u0010\u0015\u0004\u0010\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0014\u0010\u0015\u0004\u0011\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002%\u0014\u0003\u0001\u0016\u001c\u001d\u0005\u0001\n\u0007\n\u000f\u0001\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u000b\u0002\u0003\u0001 \u0003\u0002\u0005\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\u0006\u0001\u0001\u0002\n\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\t\u0002\u0003\u0001 \u0003\u0002\u0003\u0006\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\u0007\u0001\u0001\n\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \n\u0003\u0002\u0003\u0001 \u0003\u0002\u0003\b\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\b\u0001\u0001\u0002\n\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0007\u0002\u0005\n\u0001 \u0004\u0002\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\t\u0001\u0001\u000e\u0001\u0005\u0004\u0001\u0003\u0004\u0002\u0006\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\u0002\u000b\u0003\u0001 \u0003\u0002\u0003\u0004\b\u0001 \t\u0007\u0001\n\u0007\u000b\n\u0001\u0001\u0002\n\u0001\u000e\u0001\u0005\u0004\u0001\u0003\u0004\u0002\u0006\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0003\u0002\b\u0003\u0001 \u0003\u0002\u0003\u0005\u0007\u0001 \t\u0007\u0001\n\u0007\u000b\u000b\u0001\u0001\u0002\n\u0001\u000e\u0001\u0004\u0003\u0005\n\u0002\u0003\u0001\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\f\u0001\u0001\u0002\n\u0001\u000e\u0001\u0002\u0001\u0003\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \b\u0002\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\r\u0001\u0001\u000e\u0001 \u0004\u0005\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\u0006\u0002\u0004\u0003\u0001 \u0003\u0002\u0007\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\u000e\u0001\u0001\u0002\n\u0001\u000e\u0001 \u0004\u0005\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0007\u0003\u0001 \t\u0007\u0001\n\u0007\u000b\u000f\u0001\u0001\u0002\n\u0001\u000e\u0001\u0004\u0005\n\u0002\u0003\u0001\n\u0002\u0003\u0001\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0001 \t\u0007\u0001\n\u0007\f\u0006\u0001\n\u0001\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\u0004\u0002\u0003\u0001 \u0004\u0002\u0006\u0003\u0001 \t\u0007\u0001\n\u0007\f\u0007\u0001\u0001\n\u0001\u000e\u0001\u0003\u0002\u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\t\u0002\b\u0003\u0001 \u0005\u0002\u0003\u0001 \t\u0007\u0001\n\u0007\f\b\u0001\u0001\u000e\u0001 \u0005\u0004\u0001\u0006\n\u0004\u0002\u0003\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \t\u0002\u0005\t\u0001 \u0003\u0002\u0004\u0003\u0001 \t\u0007\u0001\n\u0007\f\t\u0001\u0001\n\u0001\u000e\u0001 \u0005\u0004\u0001\u0006\n\u0004\u0002\u0003\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0005\u0002\u0003\u0001 \u0003\u0002\u0004\u0003\u0001 \t\u0007\u0001\n\u0007\f\n\u0001\u0001\u000e\u0001\u0003\n\u0004\n\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0004\b\u0002\u0007\u0003\u0001 \u0003\u0002\u0003\u0005\u000b\u0001 \t\u0007\u0001\n\u0007\f\u000b\u0001\u0001\u0002\n\u0001\u000e\u0001\u0003\u0004\n\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \b\u0002\f\u0007\u0001 \u0003\u0002\u0003\u0004\u0006\u0001 \t\u0007\u0001\n\u0007\f\f\u0001\u0001\n\u0001\u000e\u0001\u0003\u0004\n\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u000e\u0001 \u0004\u0006\u0002\b\u0003\u0001 \u0003\u0002\u0003\u0004\u000b\u0001 \t\u0007\u0001\n\u0018\u0019\u001d126\t\t\t\u0007\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\b\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017\u0001 \u0017\n\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0017\u001d\u001e\u0006\u0001\n\b\r\u000e\u0001\u0001\n\u0001\n\u0001\u0011\u0001\u0003\n\u0004\n\u0002\u0003\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u000b\u0005\n\u0006\u0001 \u0006\u0005\u0006\b\u0006\u0001 \f\n\u0001\n\b\r\u000f\u0001\u0001\n\u0001\u0011\u0001\u0003\n\u0004 \u0002\u0003\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \b\b\u0005\f\u0006\u0001 \u0006\u0005\u0007\u0006\u0001 \f\n\u0001\n\b\r\u0010\u0001\u0001\n\u0001\u0011\u0001\u0003\n\u0004 \u0002\u0003\u0001\n\u0002\u0003\u0001\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u000f\u0007\u0005\u0006\u0001 \t\u0005\u000e\u0006\u0001 \f\n\u0001\n\b\u000e\u0007\u0001\u0001\u0002\n\u0001\u0011\u0001\u0001\u0002\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \t\u0005\f\u0006\u0001 \f\n\u0001\n\b\u000e\b\u0001\u0001\u0011\u0001\u0004\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0007\u0006\u0006\u0005\u0006\u0001 \u0007\u0005\u000e\u0006\u0001 \f\n\u0001\n\b\u000e\t\u0001\u0001\u0002\n\u0001\u0011\u0001\u0004\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u000b\u0006\u0005\u000e\u0006\u0001 \u0007\u0005\u0007\b\u0001 \f\n\u0001\n\b\u000e\n\u0001\u0001\n\u0001\u0011\u0001\u0004\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u000b\u0007\u0001 \f\n\u0001\n\b\u000e\u000b\u0001\u0001\u0002\n\u0001\u0011\u0001\u0004\u0003\u0001\u0002\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u000e\u0005\u0006\u0001 \f\n\u0001\n\b\u000e\f\u0001\u0001\u0011\u0001\u0003\u0002\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \n\u0005\n\u0006\u0001 \u0006\u0005\u0006\b\u0007\u0001 \f\n\u0001\n\b\u000e\r\u0001\u0001\u0002\n\u0001\u0011\u0001\u0003\u0002\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \b\u0005\u0006\u0001 \u0006\u0005\u0006\u0007\u000b\u0001 \f\n\u0001\n\b\u000e\u000e\u0001\u0001\u0011\u0001\u0001\u0002\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0006\u0005\b\u0006\u0001 \u0006\u0005\b\t\u0001 \f\n\u0001\n\b\u000e\u000f\u0001\u0001\u0002\n\u0001\u0011\u0001\u0001\u0002\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0006\u0005\n\r\u0001 \u0006\u0005\u0006\u0007\f\u0001 \f\n\u0001\n\b\u000e\u0010\u0001\u0001\u0011\u0001\u0002\u0003\u0003\u0002\u0001\n\u0004\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0007\u0006\u0006\u0005\u0006\u0001 \u0006\u0005\f\u000e\u0001 \f\n\u0001\n\b\u000f\u0007\u0001\u0001\u0002\n\u0001\u0011\u0001\u0002\u0003\u0003\u0002\u0001\n\u0004\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0007\u0006\u0001\u0003\t\u000b\u0002\u0004\u0001 \u0006\u0005\b\u0007\u0001 \f\n\u0001\n\b\u000f\b\u0001\u0001\u0011\u0001 \u0003\u0003\u0002\u0001\n\u0004\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u000f\u000f\u0005\u000e\u0006\u0001 \u0007\f\u0005\u0007\u0006\u0001 \f\n\u0001\n\b\u000f\t\u0001\u0001\u0002\n\u0001\u0011\u0001 \u0003\u0003\u0002\u0001\n\u0004\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0007\u0006\u0001\u0003\u000b\u0002\u0004\u0001 \u000f\u0005\f\u0006\u0001 \f\n\u0001\n\b\u000f\n\u0001\u0001\u0002\n\u0001\u0011\u0001 \u0003\u0004\u0004\u0003\u0001\n\u0005\u0002\u0003\u0001\u0005\u0003\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \b\u0005\n\u0006\u0001 \f\n\u0001\n\b\u000f\u000b\u0001\u0001\u0011\u0001\u0002\n\u0003\u0004\n\u0003\u0002\u0001\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \b\b\u0005\r\u0006\u0001 \u0007\u0005\u000e\u0006\u0001 \f\n\u0001\n\b\u000f\f\u0001\u0001\u0011\u0001\u0003\u0004\n\u0003\u0002\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \t\u000b\u0005\u0006\u0001 \u0006\u0005\t\u000e\u0001 \f\n\u0001\n\b\u000f\r\u0001\u0001\n\u0001\u0011\u0001\u0003\u0004\n\u0003\u0002\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u000e\u000b\u0001 \f\n\u0001\n\u0018\u0019\u001e127\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \t\u0007\b\t\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \t\t\t\b\u0001\n\u0002\u001a\u001b\u001c$\u001f\u0001\b\u0003\u0001\u001d'&+\u001e0\u0006\u0001\n\u0013(\u001e*\u0001 \u0018\u0001 \u0018\n\u0001\u0018 \u000b\u0001\u0018 \f\u0001\u0018 \r\u0001\u0018 \u000f\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00021\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00021\u0016\u0003\u0001\u0018\u001f \u0006\u0001\n\b\u000f\u000e\u0001\u0001\u0002\n\u0001\u0012\u0001\u0003\u0002\u0001\n\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \t\u0007\u0005\u000e\u0006\u0001 \u0006\u0005\b\u000b\u0001 \f\n\u0001\n\b\u000f\u000f\u0001\u0001\u0002\n\u0001\u0012\u0001\u0004\u0003\n\u0002\u0003\u0001\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \r\n\u0005\u0006\u0001 \u0006\u0005\t\u0006\u0001 \f\n\u0001\n\b\u000f\u0010\u0001\u0001\u0012\u0001\u0004\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u0012\u0001 \u0012\u0001 \u0012\u0001 \b\u000b\u0005\u000f\u0006\u0001 \u0006\u0005\n\f\u0001 \f\n\u0001\n\b\u0010\u0007\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001 \u0012\u0001\n\u0001\u0001\u0012\u0001 \b\t\u0005\n\n\u0001 \b\u0005\u0006\n\u0001 \f\b\u0001\n\b\u0010\b\u0001 \u0012\u0001 \u0011\u0012 \t\u0001\u0011 \u0012 \t\u0001\u0012 \u0001\n\u0001\u0001\u0012\u0001 \u0007\u0007\b\u0005\b\u0006\u0001 \t\u0005\u0006\u000f\u0001 \f\b\u0001\n\b\u0010\t\u0001 \u0012\u0001 \u0011\u0012 \t\u0001\u0011 \u0012 \t\u0001\n\u0001\u0001\u0012\u0001 \u0012\u0001 \t\u0006\u0001\u0003\t\u000b\u0002\u0004\u0001 \t\u0006\u0001\u0003\u0007\u000e\u0002\u0004\u0001 \f\b\u0001\n\u0001\n\u001a\u001b\u001c$\u001f\u0001\t\u0006\u0001 \u0013\"\u001f%#\u001d\u001b$\u0001\u0019+),\u001d+,)\u001f*\u0001\u001b&\u001e\u0001\u0016\u0011\u0017\u0001\u0015&\"#\u001c#+#'&\u0001\u0014\u001b+\u001b\u0001' \u0001\u0019,\u001c*+#+ ,+\u001f\u001e\u0001\u0013',%\u001b)#&*\u0001-#+\"\u0001\n\u0004\u000b\u0005 ,*\u001f\u001e\u0001\u0013.\u001d$'\u001b$#(\"\u001b+#\u001d\u0001')\u0001\u0012\u001f&/\u001f&\u001f\u0001\u0018#&!*\u0001\n\u0015\u0015\u0001\u0002\u0013'%(',&\u001e*\u0001\b\u0010\n\u0005\t\b\b\u0003\u0001\n\u0002\u0002 \u0003\u0002\n\u0003\u0001 \u0001\n\u0013(\u001e*\u0001 \u0018\u0001 \u0018\n\u0001\u0018 \u000b\u0001\u0018 \u000f\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00021\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00021\u0016\u0003\u0001\u0018\u001f \u0006\u0001\n\b\u0010\n\u0001\u0001 \u0001\u0012\u0001 \u0007\u0005\u000b\u000e\u0001 \u0006\u0005\u0006\u0006\t\u0001 \f\b\u0001\n\b\u0010\u000b\u0001\u0001\u0001\u0012\u0001 \u0007\u0005\u000b\u000e\u0001 \u0006\u0005\u0006\u0006\t\u0001 \f\b\u0001\n\b\u0010\f\u0001\u0001\u0001\u0012\u0001 \u0007\u0001\u0003\r\u0002\u0004\u0001 \u0006\u0005\u0006\u000b\u0006\u0001 \f\b\u0001\n\b\u0010\r\u0001\n\u0004\u0004\u0005\u0003\u0001\u0002\n\u0001 \u0001\u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0006\u0006\r\u0001 \f\u000b\u0001\n\b\u0010\u000e\u0001\u0004\u0004\u0003\u0001\u0002\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u0001\u0012\u0001 \u0010\u0001\u0007\u0006\u0001 \u0006\u0005\u0007\u0006\u0001 \f\u000b\u0001\n\b\u0010\u000f\u0001 \u0012\u0001\u0001\u0012\u0001 \n\u000e\u0005\b\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\b\u0010\u0010\u0001 \u0012\u0001\u0001\u0013\u0011\u0012\t\u0001 \f\t\u0005\u000b\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\t\u0007\u0007\u0001 \u0012\u0001\u0001\u0011\u0012\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\t\u0007\b\u0001 \u0012\u0001\n\u0001\u0013\u0011\u0012\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u000b\u0006\u0005\b\u0006\u0001 \f\f\u0001\n\t\u0007\t\u0001 \u0012\u0001\n\u0001\u0011\u0012\t\u0001 \f\u0006\u0005\u0007\u0007\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \f\f\u0001\n\t\u0007\n\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0013\u0011\u0012\t\u0001 \u0006\u0005\u0007\b\u0001 \u0007\b\u0005\u000f\u000e\u0001 \f\f\u0001\n\u0018\u0019\u001f128\t\t\t\t\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u001b\u001c\u001d% \u0001\t\u0003\u0001\u001e(',\u001f/\u0006\u0001\n\u0013)\u001f+\u0001 \u0019\u0001 \u0019\n\u0001\u0019 \u000b\u0001\u0019 \u000f\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0019 !\u0006\u0001\n\t\u0007\u000b\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0010\u0011\t\u0001 \u0006\u0005\b\n\u0001 \u0006\u0005\u0007\r\u0001 \f\f\u0001\n\t\u0007\f\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0012\u0010\u0011\t\u0001 \u0006\u0005\t\r\u0001 \u0007\b\u0005\u0007\b\u0001 \f\f\u0001\n\t\u0007\r\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0010\u0011\t\u0001 \u0006\u0005\u0006\u0006\n\u0001 \u0007\r\u0005\t\u0006\u0001 \f\f\u0001\n\t\u0007\u000e\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0012\u0010\u0011\t\u0001 \u0007\u0007\u0005\u000f\t\u0001 \u000f\u0005\t\f\u0001 \f\f\u0001\n\t\u0007\u000f\u0001\u0003\u0001\u0002 \u0004\n\u0001\u0001\u0010\u0011\t\u0001\b \u0005\u000b\f\u0001 \b \u000e\u0005\u0007\t\u0001\f \f\u0001\n\t\u0007\u0010\u0001\u0001\u0003\n\u0002\n\u0001\u0001\u0010\u0011\t\u0001 \u0006\u0005\u0007\t\u0001 \u0007\u0005\u0007\u000e\u0001 \f\f\u0001\n\t\b\u0007\u0001\u0001\u0003\n\u0002\n\u0001 \u0001\u0010\u0011\t\u0001 \u0006\u0005\r\u0006\u0001 \u0006\u0005\b\n\u0001 \f\f\u0001\n\t\b\b\u0001\u0001\u0003\n\u0002\n\u0001 \u0001\u0010\u0011\t\u0001 \b\u0005\t\u000e\u0001 \u0006\u0005\u0006\u0006\u0007\u0001 \f\f\u0001\n\u0001\n\u001b\u001c\u001d% \u0001\n\u0006\u0001 \u0013# &$\u001e\u001c%\u0001\u001a,*-\u001e,-* +\u0001\u001c'\u001f\u0001\u0016\u0011\u0017\u0001\u0015'#$\u001d$,$('\u0001\u0014\u001c,\u001c\u0001(!\u0001\u0013(-&\u001c*$'+\u0001\u0012 \u001c*$'\"\u0001\u001c\u0001\u0013\u001c*\u001d(\u0004\u0001\u001b#$(\u0001(*\u0001\u0011.\u001c\u0001\u001a)\u001c\u001e *\u0001\u001c,\u0001\u0018(+$,$('\u0001\u000e\u0001\u0015\u0015\u0015\u0001\u0002\t\b\t\u0005\n\t\t\f\u0003\u0001\n\u0004\u0004 \u0005\u0003\u0005\u0002\n\u0005\u0001\n\u0001\n\u0001\n\u0013)\u001f+\u0001 \u0019\u000e\u0001\u0019 \n\u0001\u0019 \u000b\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0019 !\u0006\u0001\n\t\b\t\u0001\u0001\n\u0001\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \u0006\u0005\n\u0007\u0001 \u0006\u0005\u0006\b\u000e\u0001 \f\b\u0001\n\t\b\n\u0001\n\u0001\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \u0007\u0006\u0005\u0006\u0001 \u0006\u0005\u0006\n\u0006\u0001 \f\r\u0001\n\t\b\u000b\u0001\u0002\n\u0001\n\u0001\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \u0007\u000e\u0005\f\b\u0001 \b\u0005\r\u000b\u0001 \f\r\u0001\n\t\b\f\u0001\u0007\u0006\u0001\n\u0005\u0004\u0002\u0003\n\u0004\u0002\u0003\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \n\u0005\u000b\r\u0001 \t\u0007\u0005\f\b\u0001 \f\r\u0001\n\t\b\r\u0001\u0007\u0006\u0001\n\u0004\u0005\u0004\u0002\u0003\n\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \f\r\u0005\f\u0007\u0001 \n\u0006\u0001\u0003\b\u000f\u0002\u0004\u0001 \f\b\u0001\n\t\b\u000e\u0001\n\u0001\u0002\u0003\n\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \u0007\u0005\t\u000e\u0001 \u0006\u0005\u0007\u000f\u0001 \f\b\u0001\n\t\b\u000f\u0001\n\u0001\u0002\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \u0007\u0005\u000b\u000e\u0001 \u0006\u0005\u0007\f\u0001 \f\b\u0001\n\t\b\u0010\u0001\u0001\u0010\u0011\t\u0001\u0010 \u0011\t\u0001 \r\u0005\u0006\u000e\u0001 \u0006\u0005\n\f\u0001 \f\r\u0001\n\u0018\u0019 129\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\b\t\u0001\n\u0002\u0019\u001b\u001c#\u001f\u0001\t\u0003\u0001\u001d&%*\u001e-\u0005\u0001\n\u0012'\u001e)\u0001 \u0017\r\u0001\u0017 \t\u0001\u0017 \n\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0017\u001f \u0005\u0001\n\b\b\u0006\u0001\u0001\n\u0001\u0010\u0001 \u0010\u0001 \u0003\u0002\u0006\f\u0001 \u0003\u0002\u0003\u000b\b\u0001 \t\u0005\u0001\n\b\b\u0007\u0001\u0002\u0001\n\u0001\u0010\u0001 \u0010\u0001 \u0007\u0004\u0002\t\f\u0001 \u0005\u0002\u0004\u0007\u0001 \t\u0005\u0001\n\b\b\b\u0001\u0001\n\u0001\u0010\u0001 \u0010\u0001 \u0006\u0002\u000b\u0003\u0001 \u0004\u0002\u0005\f\u0001 \t\n\u0001\n\b\b\t\u0001\u0002\u0001\n\u0001\u0010\u0001 \u0010\u0001 \t\u0002\u0004\n\u0001 \u0003\u0002\b\u000b\u0001 \t\n\u0001\n\b\b\n\u0001\u0002\u0001\n\u0001\u0001\u0010\u0001 \u0010\u0001 \u0005\u0004\u0002\u000b\u000b\u0001 \u0005\b\u0002\n\u0003\u0001 \t\n\u0001\n\b\b\u000b\u0001\n\u0001\u0001\n\u0001\u0010\u0001 \u0010\u0001 \f\u0002\b\b\u0001 \u0005\u0002\u0007\u0003\u0001 \t\n\u0001\n\u0001\n\u0019\u001b\u001c#\u001f\u0001\n\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001\u0018*(+\u001d*+(\u001f)\u0001\u001b%\u001e\u0001\u0015\u0010\u0016\u0001\u0014%!\"\u001c\"*\"&%\u0001\u0013\u001b*\u001b\u0001& \u0001\u0013\"  \u001f(\u001f %*#,\u0001\u0018+\u001c)*\"*+*\u001f\u001e\u0001\t\u0004\u001b(,#\u001d&+$\u001b(\"%)\u0001\u0014\u001a\u0001\u0002\u0012&$'&+%\u001e)\u0001\b\b\f\u0004\b\u000e\f\u0003\u0001\n\t\t\n\u0003\u0001\n\n\u0004\u0001\n\n\u0006\n\u0004\n\u0002\u0001\n\n\u0005\u0001\n\n\u0007\n\n\b \u0001\n\u0001\n\u0012'\u001e)\u0001 \u0017 \b.\u0001\u0017 \t.\u0001\u0017 \n.\u0001\u0017 \u000b.\u0001\u0017 \n\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002\u0001\u0015\u0003\u0001\u0017\u001f \u0001\n\b\b\f\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0004\u0002\u000b\u0004\u0001 \n\u0007\u0001\n\b\b\r\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000f\u0012\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0007\u0007\u0001 \t\f\u0001\n\b\b\u000e\u0001 \u0010\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000f\u0012\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\u0004\u0001 \t\f\u0001\n\b\b\u000f\u0001 \u0010\u0001 \u0010\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u000f\u0012\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0004\u0006\u0001 \t\f\u0001\n\b\t\u0006\u0001 \u0011\u000f\u0010\u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000f\u0012\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \t\f\u0001\n\b\t\u0007\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000f\u0012\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \t\f\u0001\n\b\t\b\u0001 \u0010\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0003\u0007\u0001 \t\f\u0001\n\b\t\t\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0007\u000b\u0001 \t\f\u0001\n\b\t\n\u0001 \u0010\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\f\u0001 \t\f\u0001\n\b\t\u000b\u0001 \u0010\u0001 \u0010\u0001 \u0011\u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\t\u0007\u0001 \t\f\u0001\n\b\t\f\u0001 \u0011\u000f\u0010\u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \t\f\u0001\n\b\t\r\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0003\u0005\u0001 \t\f\u0001\n\b\t\u000e\u0001 \u0010\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0003\t\u0001 \t\f\u0001\n\b\t\u000f\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u000b\u0006\u0001 \n\u0006\u0001\n\b\n\u0006\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0011\u0010\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0006\u0003\u0002\f\u0004\u0001 \n\u0006\u0001\n\b\n\u0007\u0001 \u0010\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \u0010\u0001 \u0010\u0001 \u000e\u0013\u0001 \u0010\u0001 \u0011\u000f\u0010 \u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0002\u0006\b\u0001 \n\u0006\u0001\n\u0001\n\u0018\u001a\u0017130\t\t\t\u000b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\u000b\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017 \t&\u0001\u0017 \n&\u0001\u0017 \u000b&\u0001\u0017 \f&\u0001\u0017 \u000b\u0001\u0017 \r\u0001\u0017 \u000e\u0001\u0017 \u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002'\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002\u0001\u0015\u0003\u0001\u0017\u001d\u001e\u0001\n\t\u000b\t\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0011\u0001 \u0011\u0001 \u0011\u0001 \u000f\u0013\u0001 \u0011\u0001 \u0012\u0011\u0001 \u0006\u0004\u0003\u000b\b\u0001 \u0005\n\u0003\f\u000b\u0001 \u000b\u0007\u0001\n\t\u000b\n\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0006\u000f\u0013\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\b\u0007\u0001 \n\r\u0001\n\t\u000b\u000b\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0006\f\u0001 \u000b\u0006\u0001\n\t\u000b\f\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001\u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0007\u0005\u0014\u0001\u0005\u0004\u0002\u0007\u0001 \u000b\u0006\u0001\n\t\u000b\r\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0005\t\u0001 \u000b\u0006\u0001\n\t\u000b\u000e\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\f\u0004\u0014\u0001\u0005\u0004\u0002\u0007\u0001 \u000b\u0006\u0001\n\t\u000b\u000f\u0001 \u0011\u0001 \u0012\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u0007\t\u0003\u0004\b\u0001 \u0004\u0003\n\t\u0001 \u000b\u0006\u0001\n\t\u000b\u0010\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0005\u0007\u0001 \u000b\u0006\u0001\n\t\f\u0007\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0005\n\u0001 \u000b\u0006\u0001\n\t\f\b\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u0006\t\u0003\u0005\b\u0001 \u0004\u0003\u0004\u0004\u0007\u0001 \u000b\u0006\u0001\n\t\f\t\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\r\u0001 \u000b\u0006\u0001\n\t\f\n\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0005\n\u0001 \u000b\u0006\u0001\n\t\f\u000b\u0001 \u0011\u0001 \u000f\u0013\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u000b\b\u0014\u0001\u0005\u0004\u0002\u0007\u0001 \u000b\u0006\u0001\n\t\f\f\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001 \u000f\u0013\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\u0007\u0001 \u000b\u0006\u0001\n\t\f\r\u0001 \u0011\u0001\u0004\n\u0003\u0001\u0002\u0004\n\u0001\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0005\f\u0001 \u000b\u0006\u0001\n\t\f\u000e\u0001 \u0012\u0010\u0011\u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u000b\u0006\u0001\n\t\f\u000f\u0001 \u0012\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u0006\u0005\u0003\t\f\u0001 \u0004\u0003\u0005\u0006\u0001 \u000b\u0006\u0001\n\t\f\u0010\u0001 \u000f\u0013\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \b\u0003\u0007\b\u0001 \u000b\t\u0001\n\t\r\u0007\u0001 \u000f\u0013\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \t\b\u0003\u0004\u0007\u0001\u000b\u0006\u0001\n\t\r\b\u0001 \u000f\u0013\u0001 \u0012\u0010\u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u000b\u0006\u0001\n\t\r\t\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u000f\u0013\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0005\u0005\u0001 \u000b\t\u0001\n\t\r\n\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u000f\u0013\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\u0007\u0001 \u000b\t\u0001\n\t\r\u000b\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0011 \u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u000f\u0013\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\u000b\u0001 \u000b\t\u0001\n\t\r\f\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0012 \u0010 \u0011 \u0007\u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u000f\u0013\u0001 \u0007\u0005\u0003\u0006\u0004\u0001 \b\u0003\f\r\u0001 \u000b\t\u0001\n\t\r\r\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0012 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0005\f\u0001 \u000b\u0006\u0001\n\t\r\u000e\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001 \u0012 \u0010 \u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\u0006\u0001 \u000b\u0006\u0001\n\t\r\u000f\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0011\u0001 \u0011\u0001 \u0011\u0001 \u0006\b\u0003\r\u0004\u0001 \u0004\u0003\u0004\n\u000b\u0001 \u000b\u0006\u0001\n\t\r\u0010\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001\u0004\n\u0003\u0001\u0002\u0004\n\u0001\u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \t\u0003\t\u0006\u0001 \u000b\u0006\u0001\n\t\u000e\u0007\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001\u0011 \u0001 \u0011 \u0001\u0001\n\u0001\u0011\u0001 \u0011\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0005\b\u0003\b\u000b\u0001 \u000b\u0006\u0001\n\t\u000e\b\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \n\u0003\u0006\n\u0001 \u0004\u0003\u0004\u000b\f\u0001 \u000b\n\u0001\n\t\u000e\t\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u0006\u0005\u0003\n\u0004\u0001 \u0004\u0003\u0004\u0004\u0007\u0001 \u000b\n\u0001\n\t\u000e\n\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u0011 \u0001\u0011 \u0001\u0011 \u0001\u0011 \u0001 \u0010 \u0011 \u0007\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\t\u0001 \u000b\n\u0001\n\t\u000e\u000b\u0001 \u0011\u0001 \u0011\u0001 \u000f\u0013\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0010\u0011 \u0007\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0006\u0004\u0001 \u000b\n\u0001\n\t\u000e\f\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0005\t\u0001 \u000b\n\u0001\n\t\u000e\r\u0001 \u0011\u0001 \u0011\u0001 \u000f\u0013\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0007\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0004\u0003\u0004\u0004\u0007\u0001 \u000b\n\u0001\n\t\u000e\u000e\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0011\u0001 \u0012\u0010\u0011 \u0006\u0010\u0011\u0007\u0001 \u000e\u0001\u0005\u0004\u0004\u0001 \u0005\u0003\u0004\n\u0001\u000b\n\u0001\n\u0018\u001a\u0018131\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\b\u000b\u0001\n\u0002\u0019\u001b\u001c#\u001f\u0001\n\u0003\u0001\u001d&%*\u001e-\u0005\u0001\n\u0012'\u001e)\u0001 \u0017 \b.\u0001\u0017 \t.\u0001\u0017 \n.\u0001\u0017 \u000b.\u0001\u0017 \n\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002\u0001\u0015\u0003\u0001\u0017\u001f \u0001\n\b\r\u000e\u0001 \u000f\u0001 \u000f\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001\u000f \u0001 \u0010 \u000e \u000f \u0005\u000e\u000f\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\u0004\u0001 \n\t\u0001\n\b\r\u000f\u0001 \u000f\u0001 \u000f\u0001 \u000e\u000f \u0006\u0001 \u000f \u0001\u000f \u0001\u000f \u0001\u000f \u0001 \u0010 \u000e \u000f \u0005\u000e\u000f\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0004\b\u0001 \n\t\u0001\n\b\u000e\u0006\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001\n\n\u0001\n\b\u000e\u0007\u0001 \u000f\u0001 \u000f\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \t\f\u0002\b\f\u0001 \n\n\u0001\n\b\u000e\b\u0001 \u000f\u0001 \u000f\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000e\u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0006\u0005\u0002\u0003\u0007 \u0001\n\n\u0001\n\b\u000e\t\u0001 \u000f\u0001 \u000f\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000e\u0011\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003 \u0001\n\n\u0001\n\b\u000e\n\u0001 \u000f\u0001 \u000e\u0011\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \f\u0002\u0005\t\u0001 \n\n\u0001\n\b\u000e\u000b\u0001 \u000f\u0001 \u000e\u0011\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000e\u000f \u0006\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0007\u0005\u0002\t\u000b\u0001 \n\n\u0001\n\b\u000e\f\u0001 \u000f\u0001 \u000e\u0011\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \u0010\u000f\u0001 \u000e\u0011\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0005\u0002\n\f\u0001 \n\n\u0001\n\u0001\n\u0019\u001b\u001c#\u001f\u0001\u000b\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001\u0018*(+\u001d*+(\u001f)\u0001\u001b%\u001e\u0001\u0015\u0010\u0016\u0001\u0014%!\"\u001c\"*\"&%\u0001\u0013\u001b*\u001b\u0001& \u0001\u0013\"  \u001f(\u001f%*#,\u0001\u0018+\u001c)*\"*+*\u001f\u001e\u0001\t\u0004!\u001f*\u001f(&\u001b(,#\u001d&+$\u001b(\"%)\u0001\u001a \u0001\u0002\u0012&$'&+%\u001e)\u0001\b\u000e\r\u0004\b\u000f\u000e\u0003\u0001\n\u0005\u0005\u0004\b\f\b\u000b\n\u0007\r\u0007\t\b\u0006\u0001\n\u0006\u0002\n\u0006\u0003 \u0001\n\u0001\n\u0012'\u001e)\u0001 \u0017\t\u0001\u0017 \u000b\u0001\u0017 \f\u0001\u0017 \r\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002/\u0015\u0003\u0001\u0017\u001f \u0001\n\b\u000e\r\u0001\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \t\u0002\u0006\n\u0001 \n\f\u0001\n\b\u000e\u000e\u0001\u0001\n\u0001\u000f\u0001 \u0010\u000e\u000f \u0006\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\t\u0006\u0001 \n\f\u0001\n\b\u000e\u000f\u0001\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u0010\u000e\u000f \u0006\u0001\r \u0001\u0004\u0003\u0003\u0001 \u0003 \u0002\u0005\t\u0001 \n \f\u0001\n\b\u000f\u0006\u0001\u0001\n\u0001\u0010\u000e\u000f\u0006\u0001\u000f \u0001\u0010 \u000e\u000f\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001\n\f\u0001\n\b\u000f\u0007\u0001\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0006\u0002\u0006\u0003\u0001\n\f\u0001\n\b\u000f\b\u0001\u0001\n\u0001\u000f\u0001 \u0010\u000e\u000f\u0006\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\u0006\u0001 \n\f\u0001\n\b\u000f\t\u0001\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u0010\u000e\u000f\u0006\u0001 \u0007\u0002\u0004\t\u0001 \u0003\u0002\u0003\b\t\u0001 \n\f\u0001\n\b\u000f\n\u0001\u0001\n\u0001\u0010\u000e\u000f\u0006\u0001\u000f \u0001\u0010 \u000e\u000f\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\f\u0001\n\b\u000f\u000b\u0001\u0001\n\u0002\n\u0001\u000f\u0001 \u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0002\f\u0005\u0001\n\f\u0001\n\u0018\u001a\u0019132\t\t\t\r\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u001a\u001c\u001d$ \u0001\f\u0003\u0001\u001e'&+\u001f/\u0006\u0001\n\u0013(\u001f*\u0001 \u0018\n\u0001\u0018 \f\u0001\u0018 \r\u0001\u0018 \u000e\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0018 !\u0001\n\t\u0010\r\u0001\u0001\n\u0002\n\u0001\u0013\u0001 \u0016\u0012\u0013\t\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000f\u0001\n\t\u0010\u000e\u0001\u0001\n\u0002\n\u0001\u0013\u0001 \u0013\u0001 \u0016\u0012\u0013\t\u0001 \u000f\u0005\f\r\u0001 \u0006\u0005\u0006\n\f\u0001 \r\u000f\u0001\n\t\u0010\u000f\u0001\u0001\u0002\n\u0001\u0016\u0012\u0013\t\u0001\u0013 \u0001\u0016 \u0012\u0013\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000f\u0001\n\u0001\n\u001a\u001c\u001d$ \u0001\r\u0006\u0001 \u0013\" %#\u001e\u001c$\u0001\u0019+),\u001e+,) *\u0001\u001c&\u001f\u0001\u0016\u0011\u0017\u0001\u0015&\"#\u001d#+#'&\u0001\u0014\u001c+\u001c\u0001'!\u0001\n\u0005\u001e\u001c)\u001d' &.$\u001e',%\u001c)#&\u0001\u0014 )#-\u001c+#- *\u0001\u001b\u0015 \u0001\u0002\u0013'%(',&\u001f*\u0001\t\u0010\u0010\u0005\n\b\r\u0003\u0001\n\u0004\u0004\u0005\u0004\n\u0005\u0001\n\u0005\u0002\n\u0005\u0003 \u0001\n\u0001\n\u0013(\u001f*\u0001 \u0018\u0001 \u0018\r\u0001\u0018 \u000e\u0001\u0018 \u000f\u0001\u0016\u0011\u0017\u0005\u0011\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0016\u0011\u0017\u0005\u0012\u0001\n\u0015\u0013\f\u0007\u0001\u00020\u0016\u0003\u0001\u0018 !\u0001\n\t\u0010\u0010\u0001 \u0012\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\n\u0005\n\u000b\u0001 \r\u000e\u0001\n\n\u0007\u0007\u0001 \u0012\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0013\u0001 \t\u000f\u0005\t\f\u0001 \n\b\u0005\u0007\t\u0001 \r\u000e\u0001\n\n\u0007\b\u0001 \u0012\u0013\t\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0013\u0001\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\u0007\t\u0001 \u0012\u0013\t\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0013\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \f\n\u0005\u0007\r\u0001 \r\u000e\u0001\n\n\u0007\n\u0001 \u0012\u0013\t\u0001\u0013 \u0001 \u0016 \u0012\u0013\t\u0001 \u0013\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \u0007\u000b\u0005\n\u0006\u0001 \r\u000e\u0001\n\n\u0007\u000b\u0001 \u0012\u0013\t\u0001\u0013 \u0001 \u0015 \u0003\u0012\u0013\b\u0012\u0013\t\u0004\b\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u000e\u0005\u0006\r\u0001 \r\u000e\u0001\n\n\u0007\f\u0001 \u0012\u0013\t\u0001\u0012 \u0013\t\u0001 \u0013\u0001 \u0013\u0001\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\u0007\r\u0001 \u0012\u0013\t\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\r\u0005\r\b\u0001 \r\u000e\u0001\n\n\u0007\u000e\u0001 \u0012\u0013\t\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0013\u0001 \u000b\u0007\u0005\f\t\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\u0007\u000f\u0001 \u0012\u0013\t\u0001\n\u0001\u0013\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \b\u0005\u0006\u0007\u0001 \r\u000e\u0001\n\n\u0007\u0010\u0001 \u0012\u0013\t\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0011\u0018\u0001 \u000b\u000b\u0005\u0007\f\u0001 \u0006\u0005\u0007\n\u0001 \r\u000e\u0001\n\n\b\u0007\u0001 \u0012\u0013\t\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\b\u0006\u0001 \r\u000e\u0001\n\n\b\b\u0001 \u0012\u0013\t\u0001 \u0014\u0001 \u0013\u0001 \u0014\u0001\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\b\t\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\f\u0006\u0001 \u0006\u0005\u0007\b\u0001 \u000e\u0006\u0001\n\n\b\n\u0001 \u0012\u0017\u0001 \u0012\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\b\u000f\u0001 \u0006\u0005\u0007\u0006\u0001 \u000e\u0006\u0001\n\n\b\u000b\u0001 \u0012\u0017\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\b\u0006\u0001 \u0006\u0005\u0007\u0007\u0001 \u000e\u0006\u0001\n\n\b\f\u0001 \u0012\u0017\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\t\u0006\u0001 \u0006\u0005\u0006\u0007\u0006\u0001 \u000e\u0006\u0001\n\n\b\r\u0001 \u0012\u0017\u0001 \u0015\u0016 \b\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\b\u000f\u0001 \u0006\u0005\u0007\u0006\u0001 \u000e\u0006\u0001\n\u0018\u001a\u001a133\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\b\r\u0001\n\u0019\u001b\u001c#\u001f\u0001\r\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001\u0018*(+\u001d*+(\u001f)\u0001\u001b%\u001e\u0001\u0015\u0010\u0016\u0001\u0014%!\"\u001c\"*\"&%\u0001\u0013\u001b*\u001b\u0001& \u0001\t\u0004\u001c\u001f%/&.#\u001d&+$\u001b(\"%\u0001\u0013\u001f(\",\u001b*\",\u001f)\u0001\u001a\u0014\u0014\u0001\u0002\u0012&$'&+%\u001e)\u0001\t\u0007\r\u0004\t\t\b\u0003\u0001\n\u0006\u0006 \u0007\u0002\u0001\u0007\u0003\n\u0007\u0004\n\u0007\u0005\u0006\n\u0001\n\u0001\n\u0012'\u001e)\u0001 \u0017\n0\u0001\u0017 \f\u0001\u0017 \r\u0001\u0017 \u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u00021\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u00021\u0015\u0003\u0001\u0017\u001f \u0001\n\t\u0007\r\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\t\u0007\u000e\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\t\u0007\u000f\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0016\u0012\u0013 \t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\t\u0001\n\t\b\u0006\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0016\u0013\u0001 \n\f\u0005\u000e\u0007\u0001 \r\t\u0005\u000f\b\u0001 \r\t\u0001\n\t\b\u0007\u0001 \u0016\u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0007\u000f\u0005\u0007\r\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\t\u0001\n\t\b\b\u0001 \u0016\u0012\u0013\t\u0001\u0011 \u0018\u0001 \u0013 \u0001\u0016 \u0012\u0013\t\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\t\u0001\n\t\b\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0013\u0001 \n\u0006\u0005\n\r\u0001 \b\r\u0005\u0007\u0007\u0001 \r\u000e\u0001\n\t\b\n\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0013\u0001 \u000b\u0007\u0005\f\f\u0001 \u0007\r\u0005\u000f\r\u0001 \r\u000e\u0001\n\t\b\u000b\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\t\b\f\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0012\u0013 \t\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\t\b\r\u0001 \u0013\u0001 \u0013\u0001 \u0015\u0003\u0012\u0013 \b\u0012\u0013\t\u0004\b\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \b\t\u0005\u000e\n\u0001 \r\u000e\u0001\n\t\b\u000e\u0001 \u0013\u0001 \u0012\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\t\b\u000f\u0001 \u0013\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\t\t\u0006\u0001 \u0013\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\t\t\u0007\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\t\t\b\u0001 \u0013\u0001 \u0014\u0001 \u0013\u0001 \u0014\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\u0001\n\u0019\u001b\u001c#\u001f\u0001\u000e\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001\u0018*(+\u001d*+(\u001f)\u0001\u001b%\u001e\u0001\u0015\u0010\u0016\u0001\u0014%!\"\u001c\"*\"&%\u0001\u0013\u001b*\u001b\u0001& \u0001\t\u0004\u001d\u001b(\u001c& -.\u001d&+$\u001b(\"%\u0001\u0013\u001f(\",\u001b*\",\u001f)\u0001\u001a\u0014\u0014\u0014\u0001\u0002\u0012&$'&+%\u001e)\u0001\t\t\t\u0004\t\f\u000e\u0003\u0001\n\u0004\u0004\u0004\u0005\u0005\u0001\n\u0005\u0002\n\u0005\u0003\u0004\n\u0001\n\u0001\n\u0012'\u001e)\u0001 \u0017\u0001 \u0017\f\u0001\u0017\r\u0001\u0017\u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u00021\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u00021\u0015\u0003\u0001\u0017\u001f \u0001\n\t\t\t\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\b\t\u0001 \u000b\u0005\u0006\u0007\u0001 \u000e\u0006\u0001\n\t\t\n\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0013\u0001 \n\u0006\u0005\u000b\u000b\u0001 \u0007\n\u0005\u000e\u0007\u0001 \r\u000e\u0001\n\t\t\u000b\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\t\t\f\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0013\u0001 \n\u000f\u0005\u0006\r\u0001 \u0007\u0006\u0005\u0006\f\u0001 \r\u000e\u0001\n\t\t\r\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001 \u0016 \u0012\u0013\t\u0001 \u0013\u0001\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \b\t\u0005\n\f\u0001 \r\u000e\u0001\n\u0018\u001a\u001b134\t\t\t\u000f\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\u000f\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017\u0001 \u0017\r\u0001\u0017\u000e\u0001\u0017\u000f\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002&\u0015\u0003\u0001\u0017\u001d\u001e\u0001\n\n\n\u000f\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0016 \u0012 \u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \b\u0007\u0005\f\t\u0001 \r\u000e\u0001\n\n\n\u0010\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0013\u0001 \u0015\u0003\u0012\u0013 \b\u0012\u0013\t\u0004\b\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \n\u000b\u0005\u000b\b\u0001 \r\u000e\u0001\n\n\u000b\u0007\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\r\u0005\u000b\u0007\u0001 \r\u000e\u0001\n\n\u000b\b\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0011\u0018\u0001\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\u000b\t\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0014\u0001 \u0013\u0001 \u0014\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\u000b\n\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001\n\u0001\u0001\u0013\u0001 \n\f\u0005\t\u000b\u0001 \u0006\u0005\u0006\b\u0007\u0001 \r\u000e\u0001\n\n\u000b\u000b\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0012 \u0013\t\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0007\u000f\u0001 \u0007\u0005\u0006\u0001 \u000e\u0006\u0001\n\n\u000b\f\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\b\u0007\u0001 \u0007\u0005\u0006\u0001 \u000e\u0006\u0001\n\n\u000b\r\u0001 \u0012\u0013\b\u0012\u0013\t\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u000b\u0006\u0001 \u0007\u0005\u0006\u0001 \u000e\u0006\u0001\n\n\u000b\u000e\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0015 \u0016\b\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\b\f\u0001 \u0007\u0005\u0006\u0001 \u000e\u0006\u0001\n\n\u000b\u000f\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001\u0001\n\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u0006\u0006\r\u0001 \r\u000e\u0001\n\n\u000b\u0010\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001\u0002\u0001\u0003\n\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u0006\f\u0007\u0001 \r\u000e\u0001\n\n\f\u0007\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001\u0004 \u0003\u0001\u0002\n\u0003\u0001\u0002\n\u0003\u0001\u0002\n\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \t\u0005\r\u000b\u0001 \r\u000e\u0001\n\n\f\b\u0001 \u0012\u0013\b\u0012\u0013\t\u0001\u0013 \u0001\u0002\u0001\u0003\n\u0001\u0003\n\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0006\u0005\u0006\u0006\u000f\u0001 \r\u000e\u0001\n\n\f\t\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0007\u000b\u0005\u0007\n\u0001 \u0006\u0005\u0006\u0007\r\u0001 \u000e\u0006\u0001\n\n\f\n\u0001 \u0013\u0001 \u0012\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0007\b\u0005\u0006\b\u0001 \u0006\u0005\u0006\u0007\u000f\u0001 \u000e\u0006\u0001\n\n\f\u000b\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0013\u0001 \u0007\u0005\u0006\u0001 \u0006\u0005\u0006\t\t\u0001 \u000e\u0006\u0001\n\n\f\f\u0001 \u0013\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u000b\u0006\u0001 \u0006\u0005\u0006\b\t\u0001 \u000e\u0006\u0001\n\n\f\r\u0001 \u0013\u0001 \u0015\u0016 \b\u0001 \u0013\u0001 \u0013\u0001 \u0006\u0005\u0006\f\u000e\u0001 \u0006\u0005\u0006\u0007\u000f\u0001 \u000e\u0006\u0001\n\n\f\u000e\u0001 \u0013\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0013\u0001 \u000b\u000f\u0005\f\u0007\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\f\u000f\u0001 \u0013\u0001 \u0016\u0013\u0001 \u0013\u0001 \u0013\u0001 \n\u0006\u0005\b\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\f\u0010\u0001 \u0013\u0001 \u0013\u0001 \u0016\u0012\u0013 \t\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0006\u0006\u0001\u0003\n\u000b\u0002\u0004\u0001 \r\u000e\u0001\n\n\r\u0007\u0001 \u0013\u0001 \u0016\u0012\u0013 \t\u0001 \u0013\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\r\b\u0001 \u0013\u0001 \u0013\u0001 \u0015\u0003\u0012\u0013 \b\u0012\u0013\t\u0004\b\u0001 \u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\r\t\u0001 \u0013\u0001 \u0012\u0017\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\r\n\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0013\u0001 \u0011\u0018\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \r\u000e\u0001\n\n\r\u000b\u0001 \u0013\u0001 \u0014\u0001 \u0013\u0001 \u0014\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\r\u0005\r\u000e\u0001 \r\u000e\u0001\n\n\r\f\u0001 \u0013\u0001 \u0013\u0001\n\u0001\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u000e\u0005\f\b\u0001 \r\u000e\u0001\n\n\r\r\u0001 \u0013\u0001 \u0013\u0001\u0002\u0001\u0003\n\u0001\u0013\u0001 \u0010\u0001\u0007\u0006\u0006\u0001 \u0007\u0005\u000e\u0006\u0001 \r\u000e\u0001\n\u0001\n\u0018\u001a\u001c135\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\b\u000f\u0001\n\u0002\u0019\u001b\u001c#\u001f\u0001\u000e\u0003\u0001\u001d&%*\u001e0\u0005\u0001\n\u0012'\u001e)\u0001 \u0017\u0001 \u0017\f\u0001\u0017\r\u0001\u0017\u000e\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u00022\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u00022\u0015\u0003\u0001\u0017\u001f \u0001\n\t\f\r\u0001 \u000e\u0001 \u000e\u0001\u0004 \u0003\u0001\u0002\n\u0003\u0001\u0002\n\u0003\u0001\u0002\n\u0001\u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u000b\u0001\n\t\f\u000e\u0001 \u000e\u0001 \u000e\u0001\u0002\u0001\u0003\n\u0001\u0003\n\u0001\u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0007\u0004\u0001 \n\u000b\u0001\n\u0001\n\u0019\u001b\u001c#\u001f\u0001\u000f\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001 \u0018*(+\u001d*+(\u001f)\u0001 \u001b%\u001e\u0001 \u0015\u0010\u0016\u0001 \u0014%!\"\u001c\"*\"&%\u0001 \u0013\u001b*\u001b\u0001 & \u0001 \t\u0004\u001d\u001b(\u001c&-.!.\u001e(\u001b/\"\u001e\u001f\u0001 \u001b%\u001e\u0001 \t\u0004\u001d\u001b(\u001c&-\u001b$\"\u001e\u001f\u0001 \u0012&+$\u001b(\"%\u0001 \u0013\u001f(\",\u001b*\",\u001f)\u0001 \u0014\u001a\u0001\n\u0002\u0012&$'&+%\u001e)\u0001\t\f\u000f\u0004\n\t\b\u0003\u0001\n\u0004 \u0004\u0004\n\u0003\n\u0005\u0002\u0005\u0001\u0001\n\u0005\u0001\n\u0001\n\u0001\n\u0012'\u001e)\u0001 \u00171\u0001 \u001711\u0001 \u0017\r\u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u00022\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u00022\u0015\u0003\u0001\u0017\u001f \u0001\n\t\f\u000f\u0001 \u000f\u000e\u0005\u0001 \u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0003\u0003\u0006\u0001 \n\u000b\u0001\n\t\r\u0006\u0001 \u0001\u0002\n\u0001\u000e\u0001 \u000e\u0001 \u0007\u0004\u0002\u0007\u0003\u0001 \u0007\u0002\b\u0005\u0001 \n\u000b\u0001\n\t\r\u0007\u0001\n\u0002\u0003\u0004\u0001\u0003\n\u0001\u000e\u0001 \u000e\u0001 \u0006\f\u0002\b\t\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u000b\u0001\n\t\r\b\u0001 \u0003\u0004 \u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \b\u000b\u0002\u0007\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u000b\u0001\n\t\r\t\u0001 \u0002\u0003 \u0001\u0004\n\u0001\u000e\u0001 \u000e\u0001 \u0007\u000b\u0002\u0003\u0005\u0001 \u0004\u0002\u0004\f\u0001 \n\u000b\u0001\n\t\r\n\u0001\n\u0002\u0003 \u0003\u0004\u0001\u0004\u0001\u0003\n\u0001\u000e\u0001 \u000e\u0001 \t\u0003\u0002\u0007\f\u0001 \b\t\u0002\u0004\u0005\u0001 \n\u000b\u0001\n\t\r\u000b\u0001\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\b\u0003\u0001 \u000b\u0004\u0001\n\t\r\f\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0005\b\u0002\u0006\t\u0001 \u000b\u0004\u0001\n\t\r\r\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0006\u0002\u0005\n\u0001 \u000b\u0004\u0001\n\t\r\u000e\u0001\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\t\r\u000f\u0001\u0003\u0002\u0001\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u0002\t\u000b\u0001 \u000b\u0004\u0001\n\t\u000e\u0006\u0001\u0001\u000e\u0001 \u000e\u0001 \u0004\u0006\u0002\u0004\u0005\u0001 \u0003\u0002\n\t\u0001 \u000b\u0004\u0001\n\t\u000e\u0007\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\f\u0004\u0001 \u000b\u0004\u0001\n\u0018\u001a\u001d136\t\t\n\u0007\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u0019\u001a\u001f\u001d\u0001\u0010\u0003\u0001\u001b! $\u001c%\u0006\u0001\n\u0013\"\u001c#\u0001 \u0017&\u0001 \u0017&&\u0001 \u0017\u000e\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002'\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002'\u0015\u0003\u0001\u0017\u001d\u001e\u0001\n\n\u000f\t\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\u0007\u0002\b\u0003\u0001 \u0003\u0002\t\u0003\u0001 \u000b\u0004\u0001\n\n\u000f\n\u0001\u0004\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\t\u0007\u0001 \u000b\u0004\u0001\n\n\u000f\u000b\u0001\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\b\u0001 \u000b\u0004\u0001\n\n\u000f\f\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0005\b\u0001 \u000b\u0004\u0001\n\n\u000f\r\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\f\u0002\u0007\b\u0001 \u0003\u0002\n\u0004\u0001 \u000b\u0004\u0001\n\n\u000f\u000e\u0001\n\u0002\u0003\u0001\u0001\u000e\u0001 \u000e\u0001 \u0004\b\u0002\t\n\u0001 \u0003\u0002\u000b\f\u0001 \u000b\u0004\u0001\n\n\u000f\u000f\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\b\u0002\u0004\u0007\u0001 \u0003\u0002\t\b\u0001 \u000b\u0004\u0001\n\n\u000f\u0010\u0001\n\u0005\u0005\u0003\u0004\u0001\u0003\u0004\u0002\n\u0001\u000e\u0001 \u000e\u0001 \u0004\b\u0002\f\u000b\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0010\u0007\u0001\u0004\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u000b\u0005\u0001 \u000b\u0004\u0001\n\n\u0010\b\u0001\u0004\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\u0007\u0002\n\t\u0001 \u0005\u0002\u000b\u0007\u0001 \u000b\u0004\u0001\n\n\u0010\t\u0001\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\u0006\u0002\u0003\t\u0001 \u0003\u0002\u0003\t\n\u0001 \u000b\u0004\u0001\n\n\u0010\n\u0001\u0002\u0004\u0001\u0003\n\u0001\u000e\u0001 \u000e\u0001 \f\u0002\f\n\u0001 \u0004\u0002\u0004\u0007\u0001 \u000b\u0004\u0001\n\n\u0010\u000b\u0001\u0001\u0002\u0001\u0003\n\u0001\u000e\u0001 \u000e\u0001 \f\u0002\t\n\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0010\f\u0001\u0006\u0005\u0001\u0003\u0004\u0002\n\u0001\u000e\u0001 \u000e\u0001 \f\u0002\u0006\u0006\u0001 \u0003\u0002\u0003\u0003\u0004\u0001 \u000b\u0004\u0001\n\n\u0010\r\u0001\u0002\u0001\n\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u000b\u0003\u0001 \u000b\u0004\u0001\n\n\u0010\u000e\u0001\u0002\u0004\n\u0003\u0001\u0002\u0001\u000e\u0001 \u000e\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\f\u0002\u0003\n\u0001 \u000b\u0004\u0001\n\n\u0010\u000f\u0001\n\u0003\u0001\u0002\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\b\u0002\f\b\u0001 \u0005\u0005\u0002\u0007\b\u0001 \u000b\u0004\u0001\n\n\u0010\u0010\u0001\n\u0003\u0001\u0002\u0002\u0003\u0001\n\u0001\u000e\u0001 \u000e\u0001 \u0004\u0005\u0002\u0006\u0005\u0001 \u0004\u0006\u0002\n\u0007\u0001 \u000b\u0004\u0001\n\u000b\u0007\u0007\u0001\n\u0003\u0001\u0002 \u0002\u0003\u0001\u0001\u000e\u0001 \u000e\u0001 \u0005\u0003\u0002\t\u0006\u0001 \u0004\u000b\u0002\u0005\n\u0001 \u000b\u0004\u0001\n\u000b\u0007\b\u0001\n\u0003\u0001\u0002\u0003\u0001\u0002\n\u0001\u000e\u0001 \u000e\u0001 \f\u0002\n\f\u0001 \u0004\u0002\u0005\f\u0001 \u000b\u0004\u0001\n\u0001\n\u0001\n\u0018\u001a\u001e137\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\t\u0007\u0001\n\u0002\u0017\u0018\u0019\u001e\u001c\u0001\u000f\u0003\u0001\u001a \u001f#\u001b$\u0005\u0001\n\u0012!\u001b\"\u0001 \u0016%\u0001 \u0016%%\u0001 \u0016\r\u0001\u0014\u0010\u0015\u0004\u0010\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002&\u0014\u0003\u0001\u0014\u0010\u0015\u0004\u0011\u0001\n\u0013\u0012\u000b\u0006\u0001\u0002&\u0014\u0003\u0001\u0016\u001c\u001d\u0001\n\n\u0006\b\u0001\n\u0001\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u0004\u0005\u0002\n\t\u0001 \f\u0002\u0005\u0006\u0001 \u000b\u0004\u0001\n\n\u0006\t\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u0004\u000b\u0002\n\n\u0001 \u0003\u0002\u0006\u000b\u0001 \u000b\u0004\u0001\n\n\u0006\n\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u000f\u0001 \u000f\u0001 \f\u0002\u0007\b\u0001 \u0003\u0002\u000b\t\u0001 \u000b\u0004\u0001\n\n\u0006\u000b\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000f\u0001 \u000f\u0001 \u0004\n\u0002\b\t\u0001 \u0003\u0002\n\u0003\u0001 \u000b\u0004\u0001\n\n\u0006\f\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u000f\u0001 \u000f\u0001 \t\u0004\u0002\u0007\t\u0001 \u0007\u0002\u0004\u000b\u0001 \u000b\u0004\u0001\n\n\u0006\r\u0001\n\u0001\u0001 \u0001\n\u0001\n\u0001 \u0001\u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\u0007\t\u0001 \u000b\u0004\u0001\n\n\u0006\u000e\u0001\n\u0002\u0002 \u0002\n\u0001\u0003\n\u0002 \u0001\u000f\u0001 \u000f\u0001 \u0004\t\u0002\u0003\u0007\u0001 \u0003\u0002\u000b\t\u0001 \u000b\u0004\u0001\n\n\u0006\u000f\u0001\u0002\n\u0001\u0001 \u0001\n\u0001\u0001\u000f\u0001 \u000f\u0001 \u0004\u0004\u0002\u0007\u0006\u0001 \u0003\u0002\b\u000b\u0001 \u000b\u0004\u0001\n\n\u0007\u0006\u0001\n\u0001\u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0002\f\t\u0001 \u000b\u0004\u0001\n\n\u0007\u0007\u0001\n\u0001\u000f\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0007\b\u0001\u0001\u000e\u000f\u0006\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0002\u000b\f\u0001 \u000b\u0004\u0001\n\n\u0007\t\u0001\n\u0001\u000e\u000f\u0006\u0001 \u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0007\n\u0001\u0001 \u0001\u000f\u0001 \r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0007\u000b\u0001\u0001\u000f\u0001\u0001\u0001\r\u0001\u0004\u0003\u0003\u0001 \t\u0007\u0002\u0007\b\u0001 \u000b\u0004\u0001\n\n\u0007\f\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000f\u0001\u0001\u0001\t\u0006\u0002\b\u0005\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u000b\u0004\u0001\n\n\u0007\r\u0001\n\u0002\u0003\u0001\u0002\u0003\u0001\n\u0001\u000f\u0001\u0001\u0001\b\u000b\u0002\t\u0007\u0001 \f\u0002\b\f\u0001 \u000b\u0004\u0001\n\n\u0007\u000e\u0001\u0002\u0003\u0001\n\u0002\u0003\u0001\u0001\u000f\u0001\u0001\u0001\t\u0003\u0002\f\u0006\u0001 \u0006\u0002\t\f\u0001 \u000b\u0004\u0001\n\n\u0007\u000f\u0001\n\u0002\u0002 \u0002\n\u0001\u0003\n\u0002 \u0001\u000f\u0001\u0001\u0001\t\u0004\u0002\u0006\u000b\u0001 \u0004\t\u0002\b\u0007\u0001 \u000b\u0004\u0001\n\u0018\u001a\u001f138\t\t\n\t\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018 \u0001\t\u0014\u0015\u0010\f\u0017 \u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0004\u0001\t\u0007\b\t\u0004\u0001\n\u0014\u0011\u0006\u0001\u0004\u0005\u0004\u0001\b\u0014\u0006\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0002\u0018\u001a\u001b \u001e\u0001\u0010\u0003\u0001\u001c\"!%\u001d&\u0006\u0001\n\u0013#\u001d$\u0001 \u0017'\u0001 \u0017''\u0001 \u0017\u000e\u0001\u0015\u0011\u0016\u0005\u0011\u0001\n\u0014\u0013\f\u0007\u0001\u0002(\u0015\u0003\u0001\u0015\u0011\u0016\u0005\u0012\u0001\n\u0014\u0013\f\u0007\u0001\u0002(\u0015\u0003\u0001\u0017\u001e\u001f\u0001\n\u000b\t\u0007\u0001\n\u0001\u0019\u0001\u0001\u0001\r\t\u0006\u0010\u0011\u0001 \u000e\u000b\u0006\r\n\u0001 \u0010\t\u0001\n\u000b\t\b\u0001\n\u0003\u0001\u0002\u0002\u0004\n\u0001\u0019\u0001\u0001\u0001\f\u0011\u0006\u000f\r\u0001 \u000e\t\u0006\f\u0011\u0001 \u0010\t\u0001\n\u000b\t\t\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u0019\u0001\u0001\u0001\u0012\u0001\t\b\b\u0001 \f\u0006\u000b\u0011\u0001 \u0010\t\u0001\n\u000b\t\n\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u0019\u0001\u0001\u0001\r\n\u0006\u0010\u0011\u0001 \u000b\u0006\u000b\u000e\u0001 \u0010\t\u0001\n\u000b\t\u000b\u0001\n\u0001\u0019\u0001\u0001\u0001\u0012\u0001\t\b\b\u0001 \b\u0006\u0011\u0011\u0001 \u0010\t\u0001\n\u000b\t\f\u0001\u0001\u0002\n\u0001\u0019\u0001\u0001\u0001\f\t\u0006\f\b\u0001 \f\u0006\r\n\u0001 \u0010\t\u0001\n\u000b\t\r\u0001\n\u0002\u0002 \u0002\n\u0001\u0003\n\u0002 \u0001\u0019\u0001\n\u0002\u0001\n\u0001\r\u0010\u0006\f\u0011\u0001 \u000b\u0006\f\r\u0001 \u0010\t\u0001\n\u000b\t\u000e\u0001\n\u0001\u0019\u0001\n\u0002\u0001\n\u0001\r\r\u0006\u0010\u000b\u0001 \u0012\u0001\t\b\b\u0001 \u0010\t\u0001\n\u000b\t\u000f\u0001\n\u0003\u0001\u0002\u0002\u0004\n\u0001\u0019\u0001\n\u0002\u0001\n\u0001\r\u0011\u0006\r\u000e\u0001 \f\t\u0006\u000e\f\u0001 \u0010\t\u0001\n\u000b\t\u0010\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u0019\u0001\n\u0002\u0001\n\u0001\f\u0011\u0006\n\b\u0001 \n\u0006\u0010\u000f\u0001 \u0010\t\u0001\n\u000b\n\u0007\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u0019\u0001\n\u0002\u0001\n\u0001\r\n\u0006\u000e\n\u0001 \n\t\u0006\r\u000e\u0001 \u0010\t\u0001\n\u000b\n\b\u0001\u0002\u0003\u0001\n\u0002\u0003\u0001\u0001\u0019\u0001\n\u0002\u0001\n\u0001\u0012\u0001\t\b\b\u0001 \u0012\u0001\t\b\b\u0001 \u0010\t\u0001\n\u000b\n\t\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\u0015\u0019\u000b\u0001\u0001\u0001\u0012\u0001\t\b\b\u0001 \n\u0006\u000b\u000f\u0001 \u0010\t\u0001\n\u0001\n,*2)&%\u0001 \"\u0001 0/3&.3*\",\u0001 3)&1\"0&43*$\u0001 \"00,*$\"3*/.\u0001 /'\u0001 3)&2&\u0001 ',\"5/.\u0005\n/*%2\u0007$/4-\"1*.2\u0001\".\",/(4&2\u0001\"2\u0001\"\u0001.&6\u0001*.3&1&23*.(\u00012$\"''/,%\u00016*3)\u0001\n*.3&1&23\u0001\"(\"*.23\u0001\"(&\u00051&,\"3&%\u0001.&41/%&(&.&1\"3*5&\u0001%*2&\"2&2\u000124$)\u0001\"2\u0001\u001d\u0016\u0001/1\u0001\u0013\u0016\u0001 \u000f\u000f!\u0006\u0001\n\u0001 \u0018\u0006\u0001\u0016&,/(4\u0001 \u0004\u0006\u0001\u0003\u0005\u0002\u000128.3)&2*9&%\u0001.&6\u0001$/4-\"1*.\u0001%&1*5\"3*5&2\u0001 \u0019\u0001\n*.\u00016)*$)\u00013)&\u0001\u000b\u0005\"18,\u00011*.(\u0001*2\u0001$)\".(&%\u0001'/1\u0001\"\u0001)&3&1/\"18,\u0001(1/40\u0001\n\".%\u0001&70,/1&%\u00013)&\u0001*-0/13\".$&\u0001/'\u00013)&\u0001.4-#&1\u0001\".%\u00010/2*3*/.\u0001/'\u0001\n-&3)/78\u0001(1/402\u0001/.\u0001\u0002\t\u0019\u0003\u0005#&.9/081\".\u00012314$341&\u0001 \u000f\u0011!\u0006\u0001\u001a.\u0001(&.\u0005\n&1\",\u0004\u0001 3)&2&\u0001 %&1*5\"3*5&2\u0001 6&1&\u0001 '/4.%\u0001 3/\u0001 #&\u0001 2&,&$3*5&\u0001 '/1\u0001 3)&\u0001\n\u001b\u0013\u001c\u0005\u0014\u0001 *2/'/1-\u0004\u0001 6*3)\u0001 \u000f\u0005-&3)/78\u0005\u000b\u0005)&3&1/\"18,$/4-\"1*.2\u0001&7)*#*3*.(\u0001*.)*#*3*/.\u00010/3&.$*&2\u0001*.\u00013)&\u0001,/6\u0001.\"./\u001b/,\"1\u00011\".(&\u0001 \u000f\u0011!\u0006\u0001\u0001 \u001e4#23*343*/.\u0001 /'\u0001 3)&\u0001 $/4-\"1*.\u0001 .4$,&42\u0001 \"3\u0001 0/2*3*/.\u0001 \u000b\u0001 )\"2\u0001\n#&&.\u00016*%&,8\u0001$\"11*&%\u0001/43\u00016*3)\u00010)&.8,\u0001\".%\u0001-&3)8,\u0001(1/402\u0004\u0001#43\u0001\n,&22\u0001%\"3\"\u0001)\"5&\u0001#&&.\u00011&0/13&%\u00016*3)\u00010/,\"1\u0001(1/402\u0001,*+&\u0001+&3/.&\u0001\",+8,*$\u0001\u0002\u001f\"#,&\u0001 \r\u0003\u0004\u0001+&3/.&\u0001\"18,*$\u0001\u0002\u001f\"#,&\u0001 \u000e\u0003\u0001\".%\u0001$\"1#/78,*$\u0001\"$*%\u0001\n/1\u0001&3)8,\u0001&23)&1\u0001\u0002\u001f\"#,&\u0001 \u000f\u0003\u0006\u0001\u0016\u0006\u0001\u001e&$$*\u0001 \u0004\u0006\u0001\u0003\u0005\u0002\u0001)\"5&\u0001%&%*$\"3&%\u00010\"1\u0005\n3*$4,\"1\u0001\"33&.3*/.\u00013/\u00013)&\u0001234%8\u0001/'\u00013)&\u0001*.',4&.$&\u0001/'\u00013)&2&\u0001(1/402 \u0001\n/.\u0001\u001b\u0013\u001c\u0001*.)*#*3/18\u0001\"$3*5*38\u0001\".%\u0001/.\u0001\u0013\u0007\u0014\u00012&,&$3*5*38\u0006\u0001\u0017/1\u00013)&2&\u0001\n%&1*5\"3*5&2\u0004\u00013)&\u000123&1*$\u0001)*.%1\".$&\u0001/'\u00013)&\u000124#23*34&.3\u0001\"3\u00010/2*3*/.\u0001\n\u000e\u0001*2\u00010\"13*$4,\"18\u0001*-0/13\".3\u0004\u0001*.\u00016)*$)\u0001/.,8\u00012-\",,\u000124#23*34&.32\u0001\"1&\u0001 3/,&1\"3&%\u0001  \u000f\u0010\u0004\u0001 \u0010\b!\u0006\u0001 \u000b\u0005\u0015\"1#/.8,\u0001 $),/1*%&\u0001 $/4-\"1*.2\u00012)/6&%\u0001\"\u0001)*()\u00010/3&.$8\u0001\"(\"*.23\u0001#/3)\u0001*2/'/1-2\u0001 \u0010\b!\u0006\u0001\u0001\n\u0018\u001a 139\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \u0005\u0003\u0004\u0005\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \u0005\u0005\u0006\u0006\u0001\n\u0001 \u0013>\u0001&3&1>?.3,\u00019-*\u0001)&9&\u00017*5479*)\u0001.3\u00019-*\u000157*;.4:8\u0001\u0002\"&'1*\u0001 \b\u0003\u0004\u0001\n.9\u0001(&3\u0001'*\u00018**3\u00019-&9\u0001\u000b\u00052*9->10*943*\u0001 (4:2&7.3\u0001)*7.;&9.;*8\u0001\n8-4<*)\u0001 '*99*7\u0001 .3-.'.947>\u0001 &(9.;.9>\u0001 &3)\u0001 8*1*(9.;.9>\u0001 &,&.389\u0001\u001d\u0012\u001e\u0005\u0013\u00019-&3\u00019-*.7\u0001(477*8543).3,\u0001&7>10*943*8\u0001 \u0018\u0011\u0011\u0001\u0002\"&'1*\u0001\t\u0003\u0006\u0001\n\u001c.0*<.8*\u0004\u0001&3\u0001.25479&39\u00011489\u00014+\u00019-*\u0001\u001d\u0012\u001e\u0005\u0013\u0001.3-.'.947>\u0001&(9.;.9>\u0001\n<&8\u0001;*7.+.*)\u0001<-*3\u00019-*\u0001\u000b\u00055-*3>1\u000180*1*943\u0001<&8\u00018:'89.9:9*)\u0001+47\u0001\n9-*\u0001\u000b\u0005'*3?4>1\u000143*\u0001$\u000f\u000b%\u0006\u0001\"-*7*+47*\u0004\u00019-*\u00018.251*\u0001.3974):(9.43\u00014+\u0001&\u0001(&7'43>1\u0001'7.),*\u0001'*9<**3\u00019-*\u0001(4:2&7.3\u0001&3)\u00019-*\u0001\u000b\u00055-*3>1\u00017.3,\u0001(-&3,*8\u0001)7&2&9.(&11>\u00019-*\u0001&(9.;.9>\u0001574+.1*8\u0006\u0001\n\u0001 \u00144254:3)8\u0001'*&7.3,\u0001&\u0001\u0014\u001e\n\n\u00169\u000124.*9>\u0001&9\u0001\u0014\u000b\u0001548.9.43\u0004\u0001.2\u0005\n574;*)\u00019-*\u0001.3-.'.947>\u0001&(9.;.9>\u0001&3)\u00018*1*(9.;.9>\u000194<&7)8\u0001\u001d\u0012\u001e\u0005\n\u0013\u0006\u0001\u00184<*;*7\u0004\u00019-*\u0001->)741>8.8\u00014+\u0001*9->1\u0001*89*78\u000194\u00019-*\u0001(477*8543)\u0005.3,\u0001(&7'4=>1.(\u0001&(.)8\u0001)*(7*&8*)\u00019-*\u00018*1*(9.;.9>\u0001&3)\u00019-*\u0001.3-.'.\u0005947>\u0001&(9.;.9>\u000194<&7)8\u0001\u001d\u0012\u001e\u0005\u0013\u0001$\u000f\u0010\u0004\u0001\u0010\b%\u0006\u0001 *8:198\u00014+\u0001\u001d\u0012\u001e\u0001&(\u00059.;.9>\u0001&7*\u00018-4<*)\u0001.3\u0001\u0002\"&'1*\u0001 \n\u0003\u0006\u0001\n\u0001\u0015 \u0006 \u0001 ! * ( ( . \u0001 \u0007\u000e\u0001\u0006\t\u0004\u0001&184\u0001)*8(7.'*)\u0001&\u00018*7.*8\u00014+\u0001\u000b\u0005(&7'4=>\u0001->\u0005\n)7&?.)*\u0001(4:2&7.3\u0001)*7.;&9.;*8\u0001$\u000f\u0010%\u0001&8\u0001<*11\u0001&8\u0001&\u00018*7.*8\u00014+\u0001\u000b\u0005(&7'4=&2.)*\u0001(4:2&7.3\u0001)*7.;&9.;*8\u0001\u0002\"&'1*\u0001 \u000b\u0003\u0001$\u0010\t%\u0006\u0001\u00199\u0001(&3\u0001'*\u0001\n8**3\u00019-&9\u00019-*\u00012&/47.9>\u00014+\u00019-*\u0001(4254:3)8\u00018-4<\u0001&\u00018*1*(9.;*\u0001.3-.'.947>\u0001&(9.;.9>\u000194<&7)\u00019-*\u0001\u001d\u0012\u001e\u0005\u0013\u0001.84*3?>2*\u0006\u0001!:'89.9:\u00059.43\u0001&9\u0001548.9.43\u0001\u000f\u000143\u00019-*\u0001(4:2&7.3\u00017.3,\u0001'>\u0001&\u0001'*3?>14=>\u0001,74:5\u0001\n1*&)8\u000194\u0001&\u0001)*(7*&8*\u0001.3\u00019-*\u0001&(9.;.9>\u0001&,&.389\u0001'49-\u0001\u001d\u0012\u001e\u0001.84\u0005\n+4728\u0006\u0001\u00193-.'.947>\u0001&(9.;.9>\u0001.3(7*&8*)\u0001<-*3\u00019-*\u00013.974,*3\u0001.8\u00018:'\u000589.9:9*)\u0001'>\u0001&\u00015-*3>1\u0001,74:5\u0006\u0001\n\u0001 \"&0.3,\u0001.394\u0001&((4:39\u00019-*\u0001&(9.;.9>\u00014+\u00019-*\u0001&'4;*\u00012*39.43&9*)\u0001\n&2.)4\u0001(4:2&7.8\u0004\u0001\u001d\u0006\u0001\u001a\u0006\u0001\u001d&948\u0001 \u0007\u000e\u0001\u0006\t\u0004\u00018>39-*9.?*)\u0001&3&14,8\u0001 \u0019\u0001\n&3)\u000189:).*)\u00019-*\u00015488.'.1.9>\u00014+\u00011.30.3,\u00019-*\u0001&2.).(\u0001,74:5\u000194\u00019-*\u0001(4:2&7.3\u0001'>\u00019-*\u00013.974,*3\u0001&942\u0001$\u000f\f%\u0006\u0001\"-*8*\u0001(4254:3)8\u0001(4:1)\u0001'*\u0001(438.)*7*)\u0001.3;*78*\u0001&2.).(\u0001)*7.;&9.;*8\u0001<.9-\u00017*85*(9\u000194\u00019-*\u00011&89\u0001)*8(7.'*)\u0001241*(:1*8\u0001 \u0011\u0019\u0006\u0001\u00193\u000185.9*\u00014+\u00019-*8*\u0001(438.)*7&9.438\u0004\u0001\n9-*\u00013*<\u0001(4254:3)8\u00017*8:19*)\u000194\u0001'*\u00015447\u0001\u001d\u0012\u001e\u00198\u0006\u0001\u00184<*;*7\u0004\u0001\n842*\u00014+\u00019-*2\u00018-4<*)\u0001\u0012\u0014-\u0016\u0001.3-.'.947>\u0001&(9.;.9>\u0004\u0001'*.3,\u0001(43\u0005\n8.)*7*)\u00019-*7*+47*\u0001&8\u0001):&1\u0001\u001d\u0012\u001e\u0007\u0012\u0014-\u0016\u0001.3-.'.9478\u0001$\u000f\f%\u0006\u0001\u001442\u0005\n54:3)8\u0001<.9-\u00018:(-\u0001):&1\u0001.3-.'.947>\u0001&(9.;.9.*8\u0001&7*\u0001*=5*(9*)\u000194\u0001-&;*\u0001549*39.&1\u0001+47\u00019-*\u000197*&92*39\u00014+\u0001\u0012\u0015\u0001'*(&:8*\u00019-*>\u00012.,-9\u0001)*(7*&8*\u0001 \u0001\u0005&2>14.)\u0001)*548.9.43\u0001$\u0010\n%\u0006\u0001\n\u0006\u0002\u0001\u0016\u001a\u0014\u0017\u0010\u000e\u0017\u0011\f\u0001\u0013\u000e\u0017\u0010\u0015\r\u0015\u0012\u0015\u000f\u0011\u000e\u0016\u0001\n\u0001 \u0015:*\u000194\u00019-*\u0001.39*7*89\u00014+\u0001(4:2&7.38\u0001.3\u0001.3):897>\u0001&8\u0001&)).9.;*8\u0001\n.3\u0001+44)\u0004\u0001&,74(-*2.(&18\u0004\u0001(482*9.(8\u0001&3)\u00015-&72&(*:9.(&18\u0004\u00018>3\u0005\n9-*8.8\u00014+\u00019-*\u0001(4:2&7.3\u00019*251&9*\u0001.8\u0001&\u0001945.(\u00014+\u0001(:77*39\u0001.39*7*89\u0001.3\u000147,&3.(\u0001(-*2.897>\u0006\u0001\u0015.++*7*39\u00012*9-4)414,.*8\u0001(&3\u0001'*\u0001:8*)\u000194\u00014'9&.3\u00019-*\u0001)*8(7.'*)\u0001(4254:3)8\u0004\u0001)*5*3).3,\u000143\u00019-*\u000189&79.3,\u00012&9*7.&18\u0001&3)\u000143\u00019-*\u0001)*8.7*)\u0001+.3&1\u00018:'89.9:*398\u0006\u0001\u00141&88.(&11>\u0004\u00019-*\u00012489\u0001.25479&39\u00018>39-*9.(\u00012*9-4)414,.*8\u000194\u00014'9&.3\u00018.251*\u0001\n(4:2&7.38\u0001&7*\u00019-*\u0001\u001f*(-2&33\u0004\u0001\u001f*70.3\u0004\u0001\u001b34*;*3&,*1\u0001&3)\u0001#.9\u0005\n9.,\u00017*&(9.438\u0006\u0001\n\u0001 \"-*\u0001\u001f*(-2&33\u00017*&(9.43\u0001&114<8\u000194\u00014'9&.3\u00019-*\u0001(4:2&7.3\u0001\n8(&++41)\u0001'>\u0001(43)*38&9.43\u00014+\u00015-*3418\u0001<.9-\u0001 \u0001\u00050*94*89*78\u0004\u0001.3\u00019-*\u0001\n57*8*3(*\u00014+\u0001&(.)\u0001(&9&1>898\u0001\u0002:8:&11>\u00018:15-:7.(\u0001&(.)\u0003\u0001\u0002!(-*2*\u0001\n\u0004\u0003\u0006\u0001\u001219-4:,-\u00019-.8\u0001.8\u00019-*\u00012489\u0001(1&88.(&1\u00018>39-*9.(\u000174:9*\u000194\u00014'\u0005\n9&.3\u00019-*\u0001(4:2&7.3\u00013:(1*:8\u0001<.9-\u0001&10>1\u0004\u0001&7>1\u0004\u0001-&14,*3\u0004\u0001-&14,*\u0005\n342*9->1\u000147\u0001->)74=>\u00018:'8 9.9:*398\u0004\u0001842*\u000181.,-9\u000124).+.(&9.438\u0001\n94\u00019-*\u000197&).9.43&1\u0001\u001f*(-2&33\u00017*&(9.43\u0001<*7*\u00015*7+472*)\u0004\u0001)*\u00055*3).3,\u000143\u00019-*\u000189&'.1.9>\u0001&3)\u00017*&(9.;.9>\u00014+\u00019-*\u0001:8*)\u00015-*3418\u0001&3)\u0001\u0001\u0005).(&7'43>18\u0001$\u000e\n\u0004\u0001\u000e\f\u0004\u0001\u000e\u000e\u0004\u0001\u0010\u000b\u0005\u0010\r%\u0006\u0001!*;*7&1\u0001*++4798\u0001&7*\u000189.11\u0001\n'*.3,\u0001)*;49*)\u000194\u0001.2574;*\u0001.98\u00015*7+472&3(*\u0001'>\u00019-*\u0001:8*\u00014+\u000185*\u0005(.+.(\u0001(&9&1>898\u0001&3)\u000747\u00012.(74<&;*\u00017&).&9.43\u0001.3\u0001.43.(\u00011.6:.)8\u00012*).&\u000147\u0001841;*39\u0005+7**\u0001(43).9.438\u0001$\u0010\u000e\u0005\u0010\u0011%\u0006\u0001\"-*\u0001:8*\u00014+\u00015*7(-14\u00057.(\u0001&(.)\u0001&8\u00019-*\u0001(43)*38.3,\u0001&,*39\u0001&114<8\u0004\u0001+47\u0001*=&251*\u0004\u00019-*\u0001\n8>39-*8.8\u00014+\u0001).++*7*391>\u00018:'89.9:9*)\u0001\u000f\u0005->)74=>(4:2&7.3\u0001)*\u00057.;&9.;*8\u0001$\u0011\b%\u0006\u0001\n\u0001 \"-*\u0001\u001f*70.3\u00017*&(9.43\u0001.8\u0001&3\u0001&1)41.(\u0001(43)*38&9.43\u00014+\u0001&3\u0001 \u000b\r\u0003\n\u000e\b\u000b\u0005->)74=>'*3?&1)*->)*\u0001&3)\u00019-*\u0001(43;*3.*391>\u00018:'89.9:9*)\u0001\n&(.)\u0001&3->)7.)*8\u0004\u0001.3\u00019-*\u000157*8*3(*\u00014+\u0001&3\u0001&10&1.\u00018&19\u00014+\u00019-*\u0001&(.)\u0001\n\u0002!(-*2*\u0001 \u0005\u0003\u0006\u0001\"-.8\u00012*9-4)414,>\u0001.8\u00015*7-&58\u00019-*\u00012489\u0001).7*(9\u0001&3)\u0001\n8.251*\u00012*9-4)\u0001034<3\u0001+47\u00019-*\u000157*5&7&9.43\u00014+\u0001\u000b\u0005&7>1(4:\u00012&7\u0005.38\u0006\u0001\u00184<*;*7\u0004\u00019-*\u00014;*7&11\u0001>.*1)8\u00014+\u00019-*\u0001+.3&1\u0001574):(98\u0001.3\u00019-*8* \u0001\n7*&(9.438\u0001&7*\u0001.3;&7.&'1>\u000114<\u0001&3)\u00019-*\u0001;&7.*9>\u00014+\u00018:'897&9*8\u0001.8\u0004\u0001\n.3\u00012489\u0001(&8*8\u0004\u00011.2.9*)\u0001$\f\u000f%\u0006\u0001\"-:8\u0004\u0001&\u00011.,-91>\u000124).+.*)\u0001;*78.43\u0001\n4+\u00019-.8\u00012*9-4)414,>\u0001.8\u0001(422431>\u0001:8*)\u0001+47\u00019-*\u00018>39-*8.8\u00014+\u00019-*\u0001\u000b\u0005&7>1\u000147\u0001\u000b\u0005-*9*74&7>1\u00018:'89.9:9*)\u0001(4:2&7.38\u0001$\u000e\u0011\u0005\u000f\u000b\u0004\u0001\u000f\r\u0004\u0001\u000f\u000e\u0004\u0001\u0011\t%\u0006\u0001\u00193\u00019-.8\u00017*&(9.43\u0004\u00019-*\u0001(4:2&7.3\u00013:(1*:8\u0001.8\u00014'9&.3*)\u0001\n89&79.3,\u0001+742\u00019-*\u0001 \u000b\r\u000e\b\u000b\u0005->)74=>'*3?&1)*->)*\u0001&3)\u00019-*\u0001(43\u0005\n;*3.*391>\u00018:'89.9:9*)\u0001&7>1&(*9.(\u0001&(.)\u0004\u0001.3\u00019-*\u000157*8*3(*\u00014+\u0001 \u0005\u0002\u0005\u000f\u0005\n).(>(14-*=>1(&7'4)..2.)*\u0001 \u0002\u0015\u0014\u0014\u0003\u0004\u0001 9-*\u0001 )*->)7&9.3,\u0001 &,*39\u0004\u0001\n:3)*7\u0001\u0015\u001d!\u001e\u00017*+1:=\u0006\u0001\u0001\n\u0001 \"-*\u0001\u001b34*;*3&,*1\u00017*&(9.43\u0001.8\u0001&\u0001(43)*38&9.43\u00017*&(9.43\u00019-&9\u0001\n&++47)8\u0001 9-*\u0001 (4:2&7.3\u0001 )*7.;&9.;*8\u0001 89&79.3,\u0001 +742\u0001 \u000b\r\u000e\b\u000b\u0005\n->)74=>'*3?&1)*->)*8\u0001&3)\u0001&(9.;*\u00012*9->1*3*\u0001(4254:3)8\u0004\u0001.3\u0001\n57*8*3(*\u00014+\u0001&2243.&\u000147\u0001&2.3*8\u0001\u0002!(-*2*\u0001 \u0005\u0003\u0006\u0001\"-*\u00017*&(9.43\u0001.8\u0001\n:8:&11>\u0001(&9&1>8*)\u0001'>\u0001<*&0\u0001'&8*8\u000147\u0001'>\u00018:.9&'1*\u0001(42'.3&9.438\u0001\n4+\u0001&2.3*8\u0001\u0002:8:&11>\u00015.5*7.).3*\u0003\u0001&3)\u0001(&7'4=>1.(\u000147\u0001\u001c*<.8\u0001&(.)8\u0001:3)*7\u0001-424,*3*4:8\u0001(43).9.438\u0001$\u000f\u0010\u0004\u0001\u0010\t%\u0006\u0001\"-*\u0001:8*\u00014+\u0001\u001d*1\u0005)7:2@8\u0001&(.)\u0001.3\u000157*8*3(*\u0001.43.(\u00011.6:.)8\u0004\u00017*8:198\u0001&\u00018.251*\u0001&3)\u0001\n&19*73&9.;*\u00012*9-4)\u000194\u00014'9&.3\u0001\u000b\u0005(&7'4=>(4:2&7.38\u0001$\u0011\n%\u0006\u0001\u0012\u0001\n1&7,*\u0001 1.89\u0001 4+\u0001 (4:2&7.38\u0001 -&8\u0001 '**3\u0001 8>39-*8.8*)\u0001 :8.3,\u0001 9-*\u0001\n\u001b34*;*3&,*1\u0001(43)*38&9.43\u0006\u0001\u0013*3?4>1\u0001(4:2&7.38\u0001$\u000f\u000b%\u0004\u0001&8\u0001<*11\u0001&8\u0001&2.34\u0001$\u0011\u000b%\u0004\u0001&2.)*8\u0001$\u0011\f%\u0004\u0001&3)\u0001\u000b\u0005&10>1&2.34\u00018:'89.9:9*)\u0001(4:2&7.38\u0001&7*\u0001842*\u0001*=&251*8\u00014+\u00019-*\u0001549*39.&1\u00014+\u00019-.8\u00012*9-\u00054)414,>\u0001$\r\u000e\u0004\u0001\u000e\u0010%\u0006\u0001\n\u0001 \u00193\u000147)*7\u000194\u0001&++47)\u00012:19.,7&2\u00018(&1*\u00018>39-*8.8\u0001&3)\u0001*&8>\u0001\n5:7.+.(&9.43\u0004\u0001\u0017\u0006\u0001\u0014-.2*39.\u0001 \u0007\u000e\u0001\u0006\t\u0004\u0001)*8(7.'*)\u00019-*\u000157*5&7&9.43\u00014+\u0001\n9-*\u0001 \u000b\u0005(&7'4=>(4:2&7.3\u0001 8(&++41)\u0001 '>\u0001 9-*\u0001 -*9*74(>(1.?&9.43\u00017*&(9.43\u00014+\u0001\n\u0005->)74=>'*3?&1)4=.2*8\u0001&3)\u0001(&7'43\u00018:'4=.)*\u0001\u0002!(-*2*\u0001 \u0006\u0003\u0001$\u0010\b%\u0006\u0001\"-*\u0001'&8.(\u0001->)741>8.8\u00014+\u00019-*\u0001(&7'4=&2.)*\u0001\n.39*72*).&9*\u0001&3)\u00019-*\u00018:'8*6:*39\u0001+:3(9.43&1.?&9.43\u00014+\u00019-*\u0001(&7\u0005\n'4=>1.(\u0001&(.)\u0001.39*72*).&9*\u0004\u0001&++47)8\u0001(&7'4=>(4:2&7.3\u0001)*7.;&\u0005\n9.;*8\u0001<.9-\u0001-.,-\u0001\u001d\u0012\u001e\u0001.3-.'.947>\u0001&(9.;.9>\u0006\u0001\n\u0001 #.99.,\u00017*&(9.43\u0001.8\u0001&184\u0001&3\u0001*++.(.*39\u0001&3)\u0001*&8>\u00012*9-4)\u0001+47\u0001\n9-*\u00018>39-*8.8\u00014+\u0001(4:2&7.38\u0001\u0002!(-*2*\u0001 \u0007\u0003\u0006\u0001\"-.8\u00012*9-4)\u0001(438.898\u0001\n.3\u0001 9-*\u0001 7*&(9.43\u0001 4+\u0001 \u000b\r\n \u000e\b\u000b\u0005->)74=>(&7'43>1\u0001 &742&9.(\u0001 (42\u0005\n54:3)8\u0001<.9-\u00015-485-43.:2\u0001>1.)*8\u0001&3)\u00019-*\u00018:'8*6:*39\u0001.3\u000597&241*(:1&7\u0001(>(1.?&9.43\u0001$\u0011\r%\u0006\u0001\"-.8\u00019>5*\u00014+\u00017*&(9.43\u0001.8\u0001&\u0001:8*\u0005+:1\u00012*9-4)\u000194\u00014'9&.3\u000157*3>1&9*)\u0001(4:2&7.38\u0001$\u0011\u000e\u0004\u0001\u0011\u000f%\u0006\u0001\u0012184\u0004\u0001&7>1\u0005\u0004\u0001&104=>\u0005\u0004\u000147\u0001(&7'4=>(4:2&7.3\u0001)*7.;&9.;*8\u0001(&3\u0001'*\u00014'\u00059&.3*)\u0001;.&\u0001#.99.,\u00017*&(9.43\u0004\u0001:3)*7\u0001(1&88.(&1\u0001(43).9.438\u000147\u0001.2\u0005574;*)\u000157494(418\u0001$\u000f\b\u0004\u0001\u0011\u0010\u0004\u0001\u0011\u0011%\u0006\u0001\u0012\u0001;&7.*9>\u00014+\u00013.974\u0007&2.3*\u0001(4:\u0005\n2&7.38\u0001<&8\u000157*5&7*)\u0001:8.3,\u00012.(74<&;*\u0001.77&).&9.43\u0001.3\u0001841;*39\u0001\n+7**\u0001(43).9.438\u0001$\u0011\u000e%\u0001&3)\u00011&7,*\u0001(42'.3&947.&1\u00011.'7&7.*8\u00014+\u0001\u000b\u0005\n-&14,*34(4:2&7.38\u0001<*7*\u00014'9&.3*)\u0001'>\u0001 \u000b\n\u0007\u0003\f\u000b\u000e\u00019-7**\u0001(4254\u0005\n3*39\u0001'742.3&9.43\u0007#.99.,\u0007(>(1.?&9.43\u0001574(*88\u0001$\t\b\b%\u0006\u0001\n\u0001 \" - * \u00015 & 1 1 & ) . : 2 \u0001( & 9 & 1 > 8 * ) \u0001( - * 2 . 8 9 7 > \u0001. 8 \u0001& 3 \u0001& 1 9 * 7 3 & 9 . ; * \u0001\n2*9-4)414,>\u0001+47\u00019-*\u000157*5&7&9.43\u00014+\u0001\f\u00058:'89.9:9*)\u0001(4:2&7.3\u0001\n)*7.;&9.;*8\u0006\u0001\f\u0005\u00127>1\u0007&10>1(4:2&7.38\u0001(&3\u0001'*\u00014'9&.3*)\u0001+742\u00019-*\u0001(477*8543).3,\u00015-*3418\u0001'>\u00015&11&).:2\u0005(&9&1>8.8\u00017*&(9.43\u0001<.9-\u00019-*\u0001&557457.&9*)\u00015745.41&9*8\u000147\u0001&(7>1&9*8\u0001$\t\b\t\u0005\t\b\u000b%\u0006\u0001\n\u0018\u001b\u0017140\u0006\u0006\u0007\b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0002\u0001\u0006\u0004\u0005\u0006\u0002\u0001\n\u0014\u0011\u0003\u0001\u0004\u0005\u0002\u0001\b\u0014\u0003\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0001\n\n\u000b\r\f\u000e\f\u0001\u0005\u0003\u0001 \u0019$\"'+ ,,\u0001/$ \"1(-,\u0006\u0001\n\u0001\n\n\u000b\r\f\u000e\f\u0001\u0006\u0003\u0001 \u0019$/)(,\u0001 ,#\u0001\u0016,-$3$, &$*\u0001/$ \"1(-,0\u0006\u0001\n\u0001\n\u0001\n\n\u000b\r\f\u000e\f\u0001\u0007\u0003\u0001 \u0015$1$/-\"6\"*(7 1(-,\u0001/$ \"1(-,\u0001-%\u0001\n\u0005'6#/-56!$,7 *#-5(+$0\u0001 ,#\u0001\" /!-, \u000102!-5(#$\u0006\u0001\n\u0001\n\u0001\n\n\u000b\r\f\u000e\f\u0001\b\u0003\u0001 \u001d(11(&\u0001/$ \"1(-,\u0006\u0001\n\u0001\n\u0001 \u001b.$\"( *\u0001 +$,1(-,\u0001 +201\u0001 !$\u0001 + #$\u0001 /$& /#(,&\u0001 1'$\u0001  /6*\"-2\u0005\n+ /(,\u0001#$/(3 1(3$0\u0006\u0001\u0012##(1(-, **6\u00011-\u00011'$\u0001 !-3$\u0001+$,1(-,$#\u0001\"6\u0005\"*-\u0005\"-,#$,0 1(-,\u0001/$ \"1(-,0\u0004\u0001\u000b\u0005\u0001 ,#\u0001-/\u0001\f\u0005 /6*\"-2+ /(,0\u0001\" ,\u0001!$\u0001-!1 (,$#\u0004\u0001 01 /1(,&\u0001 %/-+\u0001 ' *-&$,\u0001 -/\u0001 '6#/-56\"-2+ /(,0\u0001 !6\u0001#(/$\"1\u0001\"/-00\u0005\"-2.*(,&\u0001. ** #(2+\u0001 /6* 1(-,\u0006\u0001\u001c'$\u0001+-01\u0001\"-++-,\u0001' *-&$,\"-2+ /(,\u0001 20$#\u0001  0\u0001 01 /1(,&\u0001 + 1$/( *\u0001(0\u0001 1'$\u0001 \u000b\u0005!/-+-\u0001\n#$/(3 1(3$\u0006\u0001\u001c'$/$%-/$\u0004\u0001*(!/ /($0\u0001-%\u0001\u000b\u0005 /6*\"-2+ /(,0\u00014$/$\u0001./$\u0005\n. /$#\u000101 /1(,&\u0001%/-+\u00011'$\u0001\u000b\u0005!/-+-\"-2+ /(,\u0001!6\u0001\u0019#\u0005\" 1 *67$#\u0001\"-2.*(,&\u00014(1'\u0001!-/-,(\"\u0001$01$/0\u0004\u0001 \"$16*$,$0\u0004\u0001-/\u00013(,6*\u0001\"-+.-2,#0\u0001\u001e\t\b\f\u001f\u0006\u0001\u0015-4$3$/\u0004\u00013$/6\u0001/$\"$,1*6\u0001-2/\u0001/$0$ /\"'\u0001&/-2.\u0001' 0\u000120$#\u0001%-/\u00011'$\u0001%(/01\u00011(+$\u00011'$\u0001\u000b\u0005\"'*-/-\"-2+ /(,\u0001 0\u000101 /1(,&\u0001+ 1$/( *\u0001 ,#\u0001 ' 0\u0001 ./$. /$#\u0001 #(%%$/$,1\u0001 \u000b\u0005 /6*\"-2+ /(,0\u0001 !6\u0001  \u0001 \u0019#\u0005\n\" 1 *67$#\u0001\"/-00\u0005\"-2.*(,&\u0001/$ \"1(-,\u000120(,&\u0001 \u0001\" 1 *61(\"\u0001\"-+.*$5\u0001\n\u0019#\u00050 *$,\u0001\u001e\t\b\r\u001f\u0006\u0001\n\u0001 \u00181'$/\u000101 /1(,&\u0001+ 1$/( *0\u0001%-/\u00011'$\u0001 /6* 1(-,\u0001-%\u00011'$\u0001\"-2+ /(,\u0001\n/(,&\u0001 /$\u00011'$\u0001\f\u0005'6#/-56\"-2+ /(,\u0001#$/(3 1(3$0\u0006\u0001\u00132$\u00011-\u00011'$\u00010.$\u0005\"( *\u0001/$ \"1(3(16\u0001-%\u00011'$\u0001\f\u0005'6#/-56\"-2+ /(,\u0001/(,&\u0004\u00011'$\u0001\"-2.*(,&\u0001\n /6* 1(-,\u0001\" ,\u00011 )$\u0001.* \"$\u0001(,\u0001$(1'$/\u0001\u000b\u0001-/\u0001\f\u0001.-0(1(-,0\u0004\u0001#$.$,#(,&\u0001\n-,\u00011'$\u0001/$ \"1(-,\u0001\"-,#(1(-,0\u0006\u0001\u001c'$\u0001&$,$/ *\u0001. ** #(2+\u0001./-1-\"-*\u0001-/\u00011'$\u0001 \u001b272)(\u0005\u0017(6 2/ \u0001 \"-2.*(,&0\u0001  /$\u0001  ,\u0001 $%%(\"($,1\u0001 +$1'-#\u0001 %-/\u0001\"-2.*(,&\u0001 \f\u0005'6#/-56\"-2+ /(,0\u0006\u0001 \u001c'/-2&'\u0001 1'$\u0001 (,1$/+$#( 1$#\u00011/(%* 1$\u0001 ,#\u00011-06* 1$\u0001#$/(3 1(3$0\u0004\u0001\f\u0005 /6*\"-2+ /(,0\u0001\" ,\u0001!$\u0001./$\u0005. /$#\u0001(,\u0001'(&'\u00016($*#0\u0001\u001e\u0011\u0010\u0004\u0001\t\b\u000e\u0004\u0001\t\b\u000f\u001f\u0006\u0001\u0015-4$3$/\u0004\u00011'$\u0001\"-2.*(,&\u0001 /6* 1(-,\u0001\" ,\u00011 )$\u0001.* \"$\u0001 *0-\u0001 1\u0001.-0(1(-,\u0001\u000b\u0006\u0001\u001a$ \"1(-,\u0001-%\u0001\f\u0005'6#/-56\"-2+ /(,0\u00014(1'\u0001(-#-!$,7$,$\u0001#( \"$1 1$\u0001&(3$0\u00011'$\u0001\u000b\u0005.'$,6*(-#-,(2+\u000174(11$/(-,\u0001(,1$/+$#( 1$0\u00014'(\"'\u0001\"-2.*$\u00014(1'\u000102!01(121$#\u0001 /6*!-/-,(\"\u0001 \"(#0\u0001(,\u00011'$\u0001. ** #(2+\u0005\" 1 *67$#\u0001\u001b2\u000572)(\u000516.$\u0001 /$ \"1(-,0 \u0001\u001e\u000f\u000f\u001f\u0006\u0001 \u001c'$\u0001 $5\"$**$,1\u0001 6($*#0\u0001 + )$\u0001 1'(0\u0001\n+$1'-#\u0001 \u00013 *2 !*$\u00011--*\u0001%-/\u0001&$,$/ 1(,&\u0001#(3$/0(%($#\u0001\f\u0005'6#/-56\u0005\n\u000b\u0005 /6*\"-2+ /(,\u0001#$/(3 1(3$0\u0006\u0001\u0012\"\"-/#(,&\u00011-\u00011'$0$\u0001+$1'-#-*-\u0005\n&($0\u0004\u0001 4'$,\u0001 1'$\u0001 01 /1(,&\u0001 \"-+.-2,#0\u0001  /$\u0001 \f\u0005'6#/-56\u0005\u000b\u0005!/-+-\"-2+ /(,0\u0004\u0001(1\u0001(0\u0001.-00(!*$\u00011-\u0001#$0(&,\u0001 ,\u0001$%%(\"($,1\u0001./-1-\"-*\u0001%-/\u0001 1'$\u0001 06,1'$0(0\u0001 -%\u0001 \u000b\u0005\u0001  ,#\u0007-/\u0001 \f\u0005 /6*\"-2+ /(,\u0001 #$/(3 1(3$0\u0001\u001e\t\b\u0010\u001f\u0006\u0001\n\u0001 \u001c'$\u0001\u001b\u0012\u001a\u0001012#($0\u0001.$/%-/+$#\u00014(1'\u0001 \"-2+ /(,\u0001#$/(3 1(3$0\u0001\n02&&$01$#\u0001 1' 1\u0001  \"1(3(16\u0001  ,#\u0001 0$*$\"1(3(16\u0001 4$/$\u0001 + (,*6\u0001 #$1$/\u0005+(,$#\u0001!6\u00011'$\u0001\"' / \"1$/(01(\"0\u0001-%\u00011'$\u000102!01(12$,10\u0001(,\u00011'$\u0001\"-2\u0005+ /(,\u0001+-($16\u0001\u001e\u000e\t\u0004\u0001\u000e\f\u001f\u0006\u0001\u0014-/\u00011'(0\u0001/$ 0-,\u0004\u0001#2/(,&\u00011'$\u0001* 01\u00016$ /0\u0001,$4\u000106,1'$1(\"\u000101/ 1$&($0\u0001' 3$\u0001!$$,\u0001#$0\"/(!$#\u000120(,&\u0001 0\u000101 /1\u0005(,&\u0001+ 1$/( *0\u00011'$\u0001./$3(-20*6\u000106,1'$0(7$#\u0001\"-2+ /(,\u0001/(,&\u0006\u0001\u0017-01\u0001\n-%\u00011'$\u0001\"-2+ /(,\u0001#$/(3 1(3$0\u00014$/$\u0001./$. /$#\u0001!6\u0001,2\"*$-.'(*(\"\u0001\n02!01(121(-,\u0001-%\u00010(+.*$\u0001'6#/-56\u0004\u0001 +(,$\u0001-/\u0001' *-&$,\"-2+ /(,0\u00012,#$/\u0001/$%*25\u0001-%\u0001  \"$1-,$\u0004\u000156*$,$\u0004\u0001$1' ,-*\u0004\u0001-/\u0001-1'$/\u00010-*3$,10\u0001(,\u0001\n1'$\u0001./$0$,\"$\u0001-%\u0001.-1 00(2+\u0001\" /!-, 1$\u0001\u0002\u001b\"'$+$\u0001 \t\u0003\u0006\u0001\u001c'$/$%-/$\u0004\u0001\n\"-2+ /(,0\u00014(1'\u0001!$,76*-56\u0001\u001e\u000e\f\u0004\u0001\u0010\f\u001f\u0001 ,#\u00010-+$\u0001 *)6*02*%-,6\u0005*-56\u0001\u001e\u000e\u000f\u001f\u0001&/-2.0\u00014$/$\u0001$51$,0(3$*6\u000106,1'$0(7$#\u0001 0\u0001 \"1(3$\u0001 ,#\n\u0018\u001b\u0018141\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \b\u0006\u0007\b\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \b\b\t\u000b\u0001\n\u0019\u001b\u001c#\u001f\u0001\u0007\u0006\u0005\u0001 \u0012!\u001f$\"\u001d\u001b#\u0001\u0018*(+\u001d*+(\u001f)\u0001\u001b%\u001e\u0001\u0015\u0010\u0016\u0001\u0014%!\"\u001c\"*\"&%\u0001\u0013\u001b*\u001b\u0001& \u0001\t\u0004\u001d\u001b(\u001c &-\u001b$\"\u001e&\u001d&+$\u001b(\"%\u0001\u0013\u001f(\",\u001b*\",\u001f)\u0001\u001a\u0001\u0002\u0012&$'&+%\u001e)\u0001\n\t\t\u0004\n\n\u000b\u0003\u0001\n\u0004\u0002\n\u0003\n\u0004\u0005\u0001 \u0004\n\u0005\n\u0001\n\u0001\n\u0012'\u001e)\u0001 \u0017\f\u0001\u0017 \u0001\u0015\u0010\u0016\u0004\u0010\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002.\u0015\u0003\u0001\u0015\u0010\u0016\u0004\u0011\u0001\n\u0014\u0012\u000b\u0006\u0001\u0002.\u0015\u0003\u0001\u0017\u001f \u0001\n\n\t\t\u0001 \u0010\u0001\u0001\r\u0001\u0004\u0003\u0003\u0001 \u0003\u0002\n\t\u0001 \n\u0007\u0001\n\n\t\n\u0001 \u000f\u0010 \u0006\u0001\u0002\u0003\u0001\n\u0001\u0007\b\u0002\f\n\u0001 \u0003\u0002\u0004\n\u0001 \n\u0007\u0001\n\n\t\u000b\u0001 \u0010\u0001\u0002\u0003\u0001\u0001\r\u0001\u0004\u0003\u0003\u0001 \n\u0002\f\t\u0001 \n\u0007\u0001\n\n\t\f\u0001 \u0010\u0001\u0004\u0002\u0003\u0001\n\u0001\r\u0001\u0004\u0003\u0003\u0001 \u0006\u0003\u0002\b\u0003\u0001 \n\u0007 \u0001\n\n\t\r\u0001 \u0010\u0001\u0001\u0002\u0001 \r\u0001\u0004\u0003\u0003\u0001 \u0004\u0002\f\b\u0001 \n\u0007\u0001\n\n\t\u000e\u0001 \u0010\u0001\u0002\u0003\u0001\n\u0001\r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u0007 \u0001\n\n\t\u000f\u0001 \u0010\u0001\u0004\u0002\u0003\u0001\n\u0004\u0002\u0003\u0001\u0001\r\u0001\u0004\u0003\u0003\u0001 \b\u000b\u0002\u0006\u000b\u0001 \n\u0007\u0001\n\n\n\u0006\u0001 \u0010\u0001\u0004\u0002\u0003\u0001\n\u0004\u0002\u0003\u0001\u0004\u0002\u0003\u0001\n\u0001\r\u0001\u0004\u0003\u0003\u0001 \n\u0005\u0002\b\u000b\u0001 \n\u0007 \u0001\n\n\n\u0007\u0001 \u0010\u0001\u0001\u0002\n\u0001\u0002\u0001\r\u0001\u0004\u0003\u0003\u0001 \b\u0002\f\b\u0001 \n\u0007\u0001\n\n\n\b\u0001 \u0010\u0001\u0001\r\u0001\u0004\u0003\u0003\u0001 \u0007\f\u0002\f\t\u0001 \n\u0007 \u0001\n\n\n\t\u0001 \u0010\u0001 \u000f\u0010 \u0006\u0001 \u0006\u000b\u0002\f\u0006\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u0007\u0001\n\n\n\n\u0001 \u0010\u0001 \u000f\u0010 \u0005\u000e\u001e\u0001\r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u0007\u0001\n\n\n\u000b\u0001 \u0010\u0001 \u000f\u0010 \u0005\u000f\u0019\u0001\r\u0001\u0004\u0003\u0003\u0001 \r\u0001\u0004\u0003\u0003\u0001 \n\u0007\u0001\n\u0001\n\u0001\n\u0018\u001d!\u001f$\u001f\u0001\u000b\u0005\u0001 \u0011#\u001b \u0017\u0015 \u0018\u0013\u0001\u001f \u001e\u0012 \u0015\u0016\u0018\u0015\u001f\u0001!\u001f\u0018\u001b\u0016\u0001\u0012\u001f\u0001\u001f \u0012\u001e \u0018\u001b\u0016\u0001\u001a\u0012 \u0015\u001e\u0018\u0012\u0019\u001f\u0001 \u0017\u0015\u0001\u001d\u001e\u0015\"\u0018\u001c!\u001f\u0019# \u0001\u001f#\u001b \u0017\u0015\u001f\u0018$\u0015\u0014\u0001\u0013\u001c!\u001a\u0012\u001e\u0018\u001b\u0001\u001e\u0018\u001b\u0016\u0002\u0001\n\u0018\u001b\u0019142\u0006\u0006\u0007\b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0002\u0001\u0006\u0004\u0005\u0006\u0002\u0001\n\u0014\u0011\u0003\u0001\u0004\u0005\u0002\u0001\b\u0014\u0003\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n\u0001\n\u0018\u001c\u001e\u001d\u001f\u001d\u0001\b\u0003\u0001\u001aA:/@5;:-85F-@5;:\u0001;2\u0001/;A9->5:?\u0001@;\u0001-22;>0\u0001@41\u0001/;>>1?<;:05:3\u0001-95: ;\u0005\u0001/->.;D-950;\u0001;>\u0001-950;/;A9->5:\u000101>5B-@5B1?\u0007 \u0001\n\u0001\n?181/@5B1\u0001 \u0015\"\u00015:45.5@;>?\u0007\u0001&41\u00011@41>525/-@5;:\u0001;2\u00014E0>;DE\u0006\n/;A9->5:?\u0001-:0\u0001-95:;/;A9->5:?\u0001C1>1\u0001/;99;:8E\u0001<1>2;>910\u0001.E\u0001)5885-9?;:\u0006@E<1\u0001>1-/@5;:?\u0001+\u0010\r,\u0007\u0001%;\u0005\u000105221>1:@\u0001?A.?@5@A@10\u0001.>;9501?\u0001C1>1\u00012A>:5?410\u0001@->31@\u0001/;A9->5:?\u00015:\u0001@41\u0001<>1?1:/1\u0001;2\u0001<;@-??5A9\u0001/->.;:-@1\u0001-:0\u00011@4-:;8\u0005\u0001A:01>\u0001>128AD\u0001+\u000f\r\u0005\u0001\u000f\u000f\u0005\u0001\u000f\u0010\u0005\u0001\u0011\r,\u0007\u0001&41\u0001?-91\u00011@41>525/-@5;:\u0001>1-/@5;:\u0001;//A>?\u0001-005:3\u0001?A5@-.81\u0001\n.>;9501?\u0001-:0\u0001<;@-??5A9\u0001/->.;:-@1\u00015:\u00010>E\u0001-/1@;:1\u0005\u0001A?5:3\u0001\n\u000f\u0002\u000f&\u000605/E/8;41DE8\u0006\n\u0011\u0006/>;C:\u0006\u000f\u00061@41>\u0001-?\u0001/418-@5:3\u0001-31:@\u0001+\u0011\n,\u0007\u0001\n&45?\u0001@E<1\u0001;2\u0001>1-/@5;:\u0001C-?\u0001-8?;\u0001<;??5.81\u0001?@->@5:3\u00012>;9\u0001@41\u00012;>9-@5;:\u0001;2\u0001@41\u0001.>;9;91@4E8/;A9->5:\u0001-:0\u0001@41\u0001?A.?1=A1:@\u0001:A/81;<4585/\u000105?<8-/191:@\u0001;2\u0001.>;9501\u0001.E\u00014E0>;DE\u0001;>\u0001-95:1\u0001?A.?@5@A@10\u00019;81/A81?\u0001\u00032;>\u00011D-9<81\u0001<41:;8\u0001;>\u0001-:585:1\u0004\u0001+\u000f\u000b,\u0007\u0001\n\u001c:\u000131:1>-8\u0005\u0001@41?1\u00011@41>525/-@5;:?\u0001C1>1\u0001@41\u00019;?@\u0001/;99;:\u0001?A.\u0006\n?@5@A@5;:?\u0001A:01>\u0001@41\u0001/;A9->5:\u0001:A/81A?\u0001@;\u0001-22;>0\u0001@41\u000101?5>10\u0001 \u0015\"\u0001-/@5B5@E\u0007\u0001&41\u0001?E:@41?5?\u0001;2\u0001-87E8?A82;:E8;DE\u000101>5B-@5B1?\u0001C-?\u0001/->>510\u0001;A@\u0001?@->@5:3\u00012>;9\u0001@41\u0001/;>>1?<;:05:3\u00014E0>;DE\u0006/;A9->5:?\u0001C5@4\u0001-\u0001/;:B1:51:@8E\u0001?A.?@5@A@10\u0001?A82;:E8\u0001/48;>501\u00015:\u0001<E>505:1\u0001+\u000f\u0010,\u0007\u0001&41\u0001@45;1@41>\u000101>5B-@5B1?\u0001C1>1\u0001<>1<->10\u0001.E\u0001\n>128AD5:3\u0001.>;9501?\u0001-:0\u0001@45;8?\u00015:\u0001 1\u0017!\u00015:\u0001@41\u0001<>1?1:/1\u0001;2\u0001\n<;@-??5A9\u0001/->.;:-@1\u0007\u0001%A82;D501\u0001-:0\u0001?A82;:1\u000101>5B-@5B1?\u0001C1>1\u0001;.@-5:10\u0001.E\u0001;D50-@5;:\u0001;2\u0001@45;1@41>?\u0001C5@4\u0001?;05A9\u0001<1>5;0-@1\u0001;>\u0001<;@-??5A9\u0001<1>9-:3-:-@1\u0005\u0001>1?<1/@5B18E\u0001+\u000f\n,\u0007\u0001%;91\u00012A:/@5;:\u0006-85F-@5;:?\u0001/-:\u0001-8?;\u0001.1\u0001<1>2;>910\u0001.E\u000195/>;C-B1\u00015>>-05-@5;:\u0001+\u0011\r,\u0007\u0001\n\u0001 \u001b-8;31:;\u0005\u0001/->.;DE\u0001;>\u0001:5@>;/;A9->5:?\u0001/-:\u0001-8?;\u0001.1\u0001A?10\u0001-?\u0001\n?@->@5:3\u0001?E:@4;:?\u00012;>\u0001@41\u0001?A.?1=A1:@\u00012A:/@5;:-85F-@5;:\u0001-22;>0\u00065:3\u0001-:\u0001->>-E\u0001;2\u0001@41\u0001/;>>1?<;:05:3\u0001-95:;\u0005\u0001/->.;D-950;\u0001;>\u0001-950;/;A9->5:?\u0005\u0001/;9<;A:0?\u0001C5@4\u00015:45.5@;>E\u0001 \u0015\"\u0001-/@5B5@E\u0001\u0003%/4191\u0001 \b\u0004\u0007\u0001\n\u0001 \u001a5:-88E\u0001 5@\u0001 9A?@\u0001 .1\u0001 91:@5;:10\u0001 @4-@\u0001 \f\u0006->E8\u0001 -:0\u0001 \f\u0006.1:F;E8/;A9->5:?\u0001/-:\u0001.1\u00012A>@41>\u0001?A.?@5@A@10\u00015:\u000105221>1:@\u0001<;\u0006?5@5;:?\u0001;2\u0001.;@4\u0001->;9-@5/\u0001>5:3?\u0001A?5:3\u0001@41\u0001?-91\u0001-2;>191:@5;:10\u000191@4;0;8;351?\u0001+\u000f\u0012\u0006\u0010\f\u0005\u0001\u0010\u000e\u0005\u0001\u0010\u000f,\u0007\u0001\u0016>;95:-@5;:\u0001;2\u0001@41\u000101>5B-\u0006@5B1?\u0001C-?\u0001<1>2;>910\u0001C5@4\u0001 \u000f\u0006.>;9;?A//5:59501\u0001\u0003!\u0016%\u0004\u0005\u00015:\u0001\n/->.;:\u0001@1@>-/48;>501\u0001\u0003\u0017\u00178\n\r\u0004\u0001A:01>\u0001>128AD\u0005\u0001A?5:3\u0001\u000b\u0005\u000bH\u0006-F;\u0006.5?\u0006\n5?;\u0006.A@E>;:5@>581\u0001\u0003\u0015\u001c\u0016!\u0004\u0001-?\u0001/-@-8E?@\u0001+\u000f\u0012\u0005\u0001\u0010\t,\u0007\u0001&41\u000191@4;DE\b\u00011@4;DE\u000101>5B-@5B1?\u0001/-:\u0001.1\u00014E0>;8EF10\u000115@41>\u0001C5@4\u00014E0>5;05/\u0001-/50\u0005\u00015:\u0001@41\u0001<>1?1:/1\u0001;2\u0001-/1@5/\u0001-/50\u0001-:0\u0001-/1@5/\u0001-:4E0>501\u0001;>\u0001\u0016\u0016>\n\f\u00015:\u0001\u0018\u0017 \u0001+\u000f\u0012\u0005\u0001\u0010\u000b\u0005\u0001\u0010\f\u0005\u0001\u0010\u000e,\u0007\u0001&41\u0001)5885-9?;:\u0001>1-/@5;:\u0001;2\u0001\n@41\u00014E0>;DE8\u0001?A.?@5@A@10\u0001->E8/;A9->5:?\u0005\u0001-?\u000101?/>5.10\u00012;>\u0001\n?59<81\u0001/;A9->5:?\u0005\u0001C-?\u0001<1>2;>910\u0001C5@4\u000105221>1:@8E\u0001?A.?@5\u0006@A@10\u0001/48;>501?\u0001;>\u0001.>;9501\u0001@;\u000135B1\u0001@41\u0001/;>>1?<;:05:3\u00011@41>?\u0001\n+\u0010\u000b,\u0007\u0001\n\u0007\u0003\u0001\f\u0016\u0015\f\u0013\u001a\u0018\u0011\u0016\u0015\u0001\n\u0001 %5:/1\u0001@41\u0001<5;:11>5:3\u0001C;>7\u0001;2\u0001\u001b\u0007\u0001\u0015\u0007\u0001\u001e-05>\u0001 \u0014 \u0001\u0011\u0019\u0003\u0001+\u000e\u000e,\u0005\u0001-:0\u0001\n@41\u000105?/;B1>E\u0001;2\u0001@41\u0001<;@1:@5-8\u0001;2\u0001@41\u0001/;A9->5:\u0001?/-22;80\u0001\n-3-5:?@\u0001.;@4\u0001 \u0015\"\u00015?;2;>9?\u0005\u0001:1C\u000131:1>-@5;:?\u0001;2\u000105221>1:@8E\u0001\n?A.?@5@A@10\u00019;81/A81?\u00014-B1\u0001.11:\u0001?E:@41?5F10\u0001-:0\u00011B-8A-@10\u0001\n\u0018\u001b\u0001 \"\u0018 \u001e\u001c\u00015:\u0001<4->9-/;8;35/-8\u0001-??-E?\u0007\u0001%;91\u0001;2\u0001@41\u000101?/>5.10\u0001\n01>5B-@5B1?\u0001->1\u0001B1>E\u0001-/@5B1\u0001-:0\u0001?181/@5B1\u0001/;9<;A:0?\u0005\u0001C5@4\u0001\u001c\u0017\n\u000e\t\u00015:\u0001@41\u00018;C\u0001:-:;9;8->\u0001>-:31\u0007\u0001&41?1\u000125:05:3?\u0001<-B1\u0001@41\u0001\nC-E\u00012;>\u0001:1C\u0001<>;95?1\u00012;>\u00011225/51:@\u0001-:0\u0001?-21\u0001@41>-<1A@5/\u0001?;8A\u0006@5;:?\u0001;2\u0001-:\u00015:/>1-?5:3\u0001-:0\u000159<;>@-:@\u0001<>;.819\u0001;2\u0001@41\u000101B18\u0006\n;<10\u0001/;A:@>51?\u0013\u0001@41\u0001:1A>;0131:1>-@5B1\u000105?1-?1?\u0007\u0001\u001aA>@41>9;>1\u0005\u0001\n.-?10\u0001;:\u0001@41?1\u000159<;>@-:@\u0001?@A051?\u0005\u0001@41>1\u0001->1\u0001?1B1>-8\u0001;:3;5:3\u0001<>;61/@?\u00012;>\u0001@41\u0001>-@5;:-8\u0001?@>A/@A>1\u0006.-?10\u00010>A3\u000101?53:\u0001;2\u0001:1C\u00019;81/A81?\u0007\u0001\u0001\n\f\u0016\u0015\u000f\u0013\u0011\f\u0019\u0001\u0016\u000f\u0001\u0011\u0015\u0019\u000e\u0017\u000e\u0018\u0019\u0001\n\u0001 &41\u0001-A@4;>\u0003?\u0004\u0001/;:25>9\u0001@4-@\u0001@45?\u0001->@5/81\u0001/;:@1:@\u00014-?\u0001:;\u0001/;:\u0006\n285/@?\u0001;2\u00015:@1>1?@\u0007\u0001\n\u000b\f\u0012\u0015\u0016\u001b\u0013\u000e\r\u0010\u000e\u0014\u000e\u0015\u0019\u0018\u0001\n\u0001 \u00181/8->10\u0001:;:1\u0007\u0001\n\u0017\u000e\u000f\u000e\u0017\u000e\u0015\f\u000e\u0018\u0001\n+\n,\u0001&5<@;:\u0005\u0001\u001e\u0007\u0001\u001a\u0007\u0001\u0019:FE9;8;3E\u0001;2\u00019;:;-95:1\u0001;D50-?1\u0007\u0001 \t\u0014\u0019\u0019\u0003\u0001\b\u0018\u001c\u0012\u0017\u0014\u001a\u0003\u0001\n\u000b!\u001b\u0012 \u0003\u0005\u0001\u0005\n\t\b\u0005\u0001\u0005\u0005\u0001\u0010\u0012\u0006\u0011\u0010\u0007\u0001\n+\u000b,\u0001\u0018;?@1>@\u0005\u0001#\u0007\u0014\u0001%@>;85:\u0005\u0001\u0016\u0007\u0001 \u0007\u0014\u0001\u001d-2>1\u0005\u0001 \u0007\u0001 ;:;-95:1\u0001;D50-?1\u0013\u0001.-?5/ \u0001-:0\u0001\n/85:5/-8\u00012>;:@51>?\u0007\u0001\u001c:\u0001 \n#\u0012\u0014\u001e\u001d \u0011\u0001\u000e\u0014\u0013\u0018\u0012\u0011 \u0014\u0001\u00198?1B51>\u0013\u0001\u00159?@1>0-:\u0005\u0001\n\u0012\u0011\u000b\u0005\u0001\n<<\u0007\u0001\n\u0012\u0010\u0007\u0001\n+\f,\u0001%5:31>\u0005\u0001&\u0007\u0001#\u0007\u0001\u001c: \u0001 \t\u0017\u0014\u001a\u0018\u001f \u001e$\u0001 \u0011\u001b\u0013\u0001 \b\u0018\u001c\u0012\u0017\u0014\u001a\u0018\u001f \u001e$\u0001 \u001c\u0015\u0001 \u000b\u0019\u0011\"\u001c\u0014\u001b%$\u001a\u0014\u001f \u0014\u0001\n A881>\u0005\u0001\u001a\u0007\u0005\u0001\u00190\u0007\u0014\u0001\u0017$\u0017\u0001#>1??\u0013\u0001\u0016;/-\u0001$-@;:\u0001\u001a\u001f\u0005\u0001\n\u0012\u0012\n\u0014\u0001(;8\u0007\u0001\u000b\u0005\u0001<<\u0007\u0001\r\f\u0010\u0007\u0001\n+\r,\u0001*;A059\u0005\u0001 \u0007\u0001\u0016\u0007\u0014\u0001\u0016-7481\u0005\u0001*\u0007\u0001%\u0007\u0001 ;:;-95:1\u0001;D50-?1\u0013\u00015?;2;>9?\u0001-:0\u0001\n5:45.5@;>?\u00015:\u0001#->75:?;:G?\u000105?1-?1\u0001-:0\u000101<>1??5B1\u0001588:1??\u0007\u0001 \b\u001e\u0003\u0001 \r\u0003\u0001\n\u0010\u0017\u0011\u001e\u001a\u0003\u0005\u0001\u0006\u0004\u0004\b\u0005\u0001\u0004\u0005\u0006\u0005\u0001%\u000b\u0011\u0010\u0006%\u000b\u0012\u000f\u0007 \u0001\n+\u000e,\u0001*;A059\u0005\u0001 \u0007\u0001\u0016\u0007\u0014\u0001\u001a5:.1>3\u0005\u0001\u001d\u0007\u0001#\u0007\u0001 \u0007\u0014\u0001&5<@;:\u0005\u0001\u001e\u0007\u0001\u001a\u0007\u0001 ;:;-95:1\u0001;D5\u0006\n0-?1\u0007\u0001\u001c:\u0013\u0001 \u0007\u0013\"\u0011\u001b\u0012\u0014\u001f\u0001\u0018\u001b\u0001\n#\u001d\u0014\u001e\u0018\u001a\u0014\u001b \u0011\u0019\u0001\u0010\u0017\u0011\u001e\u001a\u0011\u0012\u001c\u0019\u001c\u0016$\u0003\u0001\t\u0011 \u0014\u0012\u0017\u001c\u0019\u0011\u001a\u0018\u001b\u0014\u0003\u0001\n\f\f\u0003\u000110\u0007\u0001&>1:0181:.A>3\u0005\u0001'\u0007\u0001\u0002\u0001)15:1>\u0005\u0001'\u0007\u0005\u0001\u00161>85:\u0013\u0001%<>5:31>\u0006(1>8-3\u0005\u0001\n\n\u0012\u0011\u0011\u0005\u0001<<\u0007\u0001\n\n\u0012\u0006\n\u0012\u000b\u0007\u0001\n+\u000f,\u0001\u0016-/4\u0005\u0001\u0015\u0007\u0001)\u0007\u0001\u001d\u0007\u0014\u0001\u001f-:\u0005\u0001!\u0007\u0001\u0017\u0007\u0014\u0001\u001d;4:?;:\u0005\u0001\u0018\u0007\u0001\u001f\u0007\u0014\u0001\u0015.188\u0005\u0001\u0017\u0007\u0001)\u0007\u0014\u0001\u001619\u0006.1:17\u0005\u0001 \u0007\u0001\u0019\u0007\u0014\u0001\u001eC-:\u0005\u0001%\u0007\u0001)\u0007\u0014\u0001%11.A>3\u0005\u0001#\u0007\u0001\u001b\u0007\u0014\u0001%454\u0005\u0001\u001d\u0007\u0001\u0017\u0007\u0001/\u0018!\u0015\u0001/8; :\u0006\n5:3\u0001;2\u00014A9-:\u000185B1>\u00019;:;-95:1\u0001;D50-?1\u0001\u0015\u0001-:0\u0001\u0016\u0013\u00019;81/A8->\u0001.-?5?\u0001; 2\u0001\n\u0018\u001b\u001a143\n\u001f\u0016$\"\u001b\u001e\u0019\u0001\u001f\u001e\u0001\u000e\u0018%\u0001\r\u001f\u001e\u001f\u0014\u001d\u001b\u001e\u0018\u0001\u000f&\u001b\u0017\u0014\"\u0018\u0001\u000b\u001e\u001a\u001b\u0015\u001b#\u001f!\"\u0001 \b$!!\u0018\u001e#\u0001\u0011\u001f \u001b\u0016\"\u0001\u001b\u001e\u0001 \r\u0018\u0017\u001b\u0016\u001b\u001e\u0014\u001c\u0001\b\u001a\u0018\u001d\u001b\"#!'\u0002\u0001 \u0005\u0003\u0004\u0005\u0002\u0001\u0013\u001f\u001c\u0003\u0001\u0005\u0006\u0002\u0001\u000e\u001f\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \u0005\u0005\u0006\n\u0001\n49665B5>35C\u00019>\u00015>JI=1D93\u0001@B?@5BD95C\u0006\u0001 \u001a,*!\u0003\u0001\u0018\u001f.'\u0003\u0001\u000e!\u001f\"\u0003\u0001\u001c!& \u0006\u0001\u001e\u0001\u001c\u0001\u000e\u0004\u0001\n\u0004\f\u000b\u000b\u0004\u0001\f\t\u0004\u0001\f\u0011\u000b\f\u0005\f\u0011\u000b\u0010\u0006\u0001\u0001\n/\u000f0\u0001+?ED5BC\u0004\u0001\u001e\u0006\u0001'DBE3DEB1<\u00011C@53DC\u0001?6\u0001=?>?1=9>5\u0001?H941C5\u00011>4\u00019DC\u0001B5\u0005\nF5BC92<5\u00019>8929D9?>\u0006\u0001 \u0010/,,\u0003\u0001\u0017#\"\u0003\u0001\u0010%#( \u0006\u0004\u0001\u0004\f\f\u000b\u0004\u0001\t\u0004\u0001\t\u000b\u000f\u0005\t\u000e\n\u0006\u0001\n/\u00100\u0001\u001bB9=C2I\u0004\u0001\u001e\u0006\u0013\u0001 1>\u0004\u0001\"\u0006\u0001\u0017\u0006\u0013\u0001\"5F5\u0004\u0001&\u0006\u0013\u0001\u001785>\u0004\u0001\u001f\u0006\u0013\u0001'898\u0004\u0001\u001e\u0006\u0001\u0017\u0006\u0001(9CCE5 \u0001\n49CDB92ED9?>\u0001?6\u00018E=1>\u0001=?>?1=9>5\u0001?H941C5\u0001\u0015\u00011>4\u0001\u0016\u0001=&\"\u0015\u0006\u0001 \u0015\u0003\u0001\u0018#/\u0002\n,*!%#(\u0003\u0004\u0001\u0004\f\f\u0003\u0004\u0001\t\t\u0004\u0001\t\t\u000e\u000e\u0005\t\t\u000e\u0011\u0006\u0001\u0001\n/\u00110\u0001\u001f1<7ED;1B\u0004\u0001\u0015\u0006\u0001'\u0006\u0013\u0001\u00171CD17>?<9\u0004\u0001\"\u0006\u0001\u001eB\u0006\u0013\u0001(5CD1\u0004\u0001\u0016\u0006\u0001'5<53D9F5\u00019>892 9D?BC\u0001\n?6\u0001=?>?1=9>5\u0001?H941C5\u0001\u0002!\u0015#\u0005\u0015\u00011>4\u0001!\u0015#\u0005\u0016\u0003\u00011C\u0001@B?25C\u0001?6\u00019DC\u000131D1\u0005\n<ID93\u0001C9D5\u00011>4\u0001=5381>9C=\u0006\u0001 \u0017#\"\u0003\u0001\u001b#-\u0003\u0001\u001b#0\u0003 \u0004\u0001\u0004\f\f\b\u0004\u0001\u0005\t\u0004\u0001\u000b\n\r\u0005\u000b\u0010\u0010\u0006\u0001\n/\t\b0\u0001\u001b581\u0004\u0001&\u0006\u0001!\u0006\u0013\u0001&52B9>\u0004\u0001\u001d\u0006\u0013\u0001\u001785>\u0004\u0001\u001f\u0006\u0013\u0001'898\u0004\u0001\u001e\u0006\u0001\u0017\u0006\u0001'E2CDB1D5\u00011>4\u00019> 8929\u0005\nD?B\u0001C@5396939D95C\u00016?B\u00018E=1>\u0001=?>?1=9>5\u0001?H941C5\u0001\u0015\u00011>4\u0001\u0016\u00011B5\u00019>6<E \u0005\n5>354\u00012I\u00011\u0001C9>7<5\u00011=9>?\u00011394\u0006\u0001 \u0015\u0003\u0001\u000f&*'\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\u0004\u0004\u0001\u0006\u000b\n\u0004\u0001\u0011\u0010\u000f\u000f\u0005\n\u0011\u0010\u0010\n\u0006\u0001\n/\t\t0\u0001!1\u0004\u0001\u001e\u0006\u0013\u0001-?C89=EB1\u0004\u0001!\u0006\u0013\u0001-1=1C89D1\u0004\u0001\u0019\u0006\u0013\u0001\"1;171G1\u0004\u0001\u0015\u0006\u0013\u0001\u001dD?\u0004\u0001\u0015\u0006\u0013\u0001\n(CE;981B1\u0004\u0001( \u0003\u0001'DBE3DEB5\u0001?6\u0001B1D\u0001=?>?1=9>5\u0001?H941C5\u0001\u0015\u00011>4\u00019DC\u0001C@539693\u0001\nB53?7>9D9?>C\u00016?B\u0001CE2CDB1D5C\u00011>4\u00019>8929D?BC\u0006 \u0001\u0015\u0003\u0001\u0017*'\u0003\u0001\u000f&*'\u0003 \u0004\u0001\u0005\u0003\u0003\u0007\u0004\u0001\u0007\u0007\f\u0004\u0001\n\t\b\u000b\u0005\t\t\r\u0006\u0001\n/\t\n0\u0001+5I<5B\u0004\u0001+\u0006\u0013\u0001\u001cCE\u0004\u0001-E>\u0001$\u0006\u0001$\u0006\u0013\u0001\u0016B51;5695<4\u0004\u0001,\u0006\u0001#\u0006\u0001\u00169?385=9CDBI\u00011>4 \u0001\n75>5D93C\u0001?6\u0001=?>?1=9>5\u0001?H941C5\u0006\u0001 \u001a%\u001f,(\u001f!*'\u0003\u0001\u001d%#,\u0003 \u0004\u0001\u0004\f\f\u0003\u0004\u0001\b\u000b\u0004\u0001\u000b\u0011\t\u0005\n\f\t\u000f\u0006\u0001\u0001\n/\t\u000b0\u0001'=9D8\u0004\u0001&\u0006\u0001\u001b\u0006\u0001(85\u0001179>7\u0001@B?35CC\u0012\u0001G85B5\u00011B5\u0001D85\u00014BE7\u0001?@@?BDE> 9D95C\u0014\u0001\n\u0010/,,\u0003\u0001\u0019+&)\u0003\u0001\u0010%#(\u0003\u0001\u000f&*'\u0003 \u0004\u0001\u0005\u0003\u0003\u0003\u0004\u0001\b\u0004\u0001\u000b\u000f\t\u0005\u000b\u000f\u000e\u0006\u0001\n/\t\f0\u0001\u00169>41\u0004\u0001\u0017\u0006\u0013\u0001\"5GD?>\u0005*9>C?>\u0004\u0001$\u0006\u0013\u0001\u001cE21<5;\u0004\u0001\u001a\u0006\u0013\u0001\u00194=?>4C?>\u0004\u0001\u0018\u0006\u0001\u0019\u0006\u0013\u0001\n!1\nDD5F9\u0004\u0001\u0015\u0006\u0001'DBE3DEB5\u0001?6\u00018E=1>\u0001=?>?1=9>5\u0001?H941C5\u0001\u0016\u0004\u00011\u00014BE7\u0001D1B\u0005\n75D\u00016?B\u0001D85\u0001DB51D=5>D\u0001?6\u0001>5EB?<?7931<\u000149C?B45BC\u0006\u0001 \u0018\u001f.\u0003\u0001\u001c.,/!.\u0003\u0001\u0017*'\u0003\u0001\n\u000f&*'\u0003\u0004\u0001\u0005\u0003\u0003\u0005\u0004\u0001\r\u0004\u0001\n\n\u0005\n\u000e\u0006\u0001\n/\t\r0\u0001\u00169>41\u0004\u0001\u0017\u0006\u0013\u0001 9\u0004\u0001!\u0006\u0013\u0001\u001cE2K<5;\u0004\u0001\u001a\u0006\u0013\u0001&5CD5<<9\u0004\u0001\"\u0006\u0013\u0001\u00194= ?>4C?>\u0004\u0001\u0018\u0006\u0001\u0019\u0006\u0013\u0001\n!1DD5F9\u0004\u0001\u0015\u0006\u0001\u001d>C978DC\u00019>D?\u0001D85\u0001=?45\u0001?6\u00019>8929D9?>\u0001?6\u00018E=1>\u0001=9D?\u0005\n38?>4B91<\u0001=?>?1=9>5\u0001?H941C5\u0001\u0016\u00016B?=\u00018978\u0005B5C?<ED9?>\u00013BICD1<\u0001CDBE3\u0005\nDEB5C\u0006\u0001\u001a,*!\u0003\u0001\u0018\u001f.'\u0003\u0001\u000e!\u001f\"\u0003\u0001\u001c!&\u0003\u0001\u001e\u0001\u001c\u0001\u000e \u0004\u0001\u0005\u0003\u0003\u0006\u0004\u0001\u0005\u0004\u0004\u0004\u0001\u0011\u000f\r\b\u0005\u0011\u000f\r\r\u0006\u0001\n/\t\u000e0\u0001\u00185\u0001\u0017?<92EC\u0004\u0001 \u0006\u0013\u0001 9\u0004\u0001!\u0006\u0013\u0001\u00169>41\u0004\u0001\u0017\u0006\u0013\u0001 ECD97\u0004\u0001\u0015\u0006\u0013\u0001\u00194=?>4C?>\u0004\u0001\u0018\u0006\u0001\u0019\u0006 \u0013\u0001\n!1DD5F9\u0004\u0001 \u0015\u0006\u0001 (8B55\u000549=5>C9?>1<\u0001 CDBE3DEB5\u0001 ?6\u0001 8E=1>\u0001 =?>?1=9>5\u0001\n?H941C5\u0001\u0015\u0001\u0002!\u0015#\u0005\u0015\u0003\u0012\u0001&5<1D9?>\u0001D?\u0001D85\u0001CDBE3DEB5C\u0001?6\u0001B1D\u0001!\u0015#\u0005\u0015\u00011>4\u0001\n8E=1>\u0001!\u0015#\u0001\u0016\u0006\u0001 \u001a,*!\u0003\u0001\u0018\u001f.'\u0003\u0001\u000e!\u001f\"\u0003\u0001\u001c!& \u0006\u0001\u001e\u0001\u001c\u0001\u000e\u0004\u0001\u0005\u0003\u0003\b\u0004\u0001\u0005\u0004\u0006\u0004\u0001\t\n\u000e\u0010\f\u0005\n\t\n\u000e\u0010\u0011\u0006\u0001\n/\t\u000f0\u0001\u00169>41\u0004\u0001\u0017\u0006\u0013\u0001\u001cE21<5;\u0004\u0001\u001a\u0006\u0013\u0001 9\u0004\u0001!\u0006\u0013\u0001\u001c5BJ97\u0004\u0001-\u0006\u0013\u0001'D5B<9>7\u0004\u0001\u001e\u0006\u0013\u0001\u00194=?> 4\u0005\nC?>\u0004\u0001\u0018\u0006\u0001\u0019\u0006\u0013\u0001!1DD5F9\u0004\u0001\u0015\u0006\u0001\u0017BICD1<\u0001CDBE3DEB5C\u0001?6\u0001=?>?1=9>5\u0001?H941C5 \u0001\u0016\u0001\n9>\u00013?=@<5H\u0001G9D8\u00016?EB\u00019>8929D?BC\u0001?6\u0001D85\u0001\"\u0005@B?@1B7I<1=9>?9>41>5\u0001\n3<1CC\u0006\u0001\u0015\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\u0007\u0004\u0001\b\u000b\u0004\u0001\t\u000f\u000e\u000f\u0005\t\u000f\u000f\f\u0006\u0001\n/\t\u00100\u0001!9<3J5;\u0004\u0001\u0019\u0006\u0001!\u0006\u0013\u0001\u0016?>9F5>D?\u0004\u0001\u0018\u0006\u0013\u0001\u00169>41\u0001\u0017\u0006\u0013\u0001!1DD5F9\u0004\u0001\u0015\u0006\u0013\u0001!3\u0018?>1<4\u0004 \u0001\n\u001d\u0006\u0001\u0015\u0006\u0013\u0001\u00194=?>4C?>\u0004\u0001\u0018\u0006\u0001\u0019\u0006\u0001'DBE3DEB1<\u00011>4\u0001=5381>9CD93\u0001CDE495C\u0001?6\u0001\n=?6579<9>5\u00019>8929D9?>\u0001?6\u0001B53?=29>1>D\u00018E=1>\u0001=?>?1=9>5\u0001?H941C5\u0001\n\u0016\u0006\u0001\u0015\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\u000b\u0004\u0001\t\u0005\u0004\u0001\u0010\b\t\u0011\u0005\u0010\b\n\u000e\u0006\u0001\u0001\n/\t\u00110\u0001\u0016BE>>5B\u0004\u0001\u001c\u0006\u0001\u001b\u0006\u0013\u0001\"5<5>\u0004\u0001!\u0006\u0013\u0001\u0016B51;5695<4\u0004\u0001,\u0006\u0001#\u0006\u0013\u0001&?@5BC\u0001\u001c\u0006\u0001\u001c\u0006\u0013\u0001F1>\u0001\n#?CD\u0001\u0016\u0006\u0001\u0015\u0006\u0001\u00152>?B=1<\u00012581F9?EB\u00011CC?391D54\u0001G9D8\u00011\u0001@?9>D\u0001=ED1D9?>\u0001 9>\u0001\nD85\u0001CDBE3DEB1<\u000175>5\u00016?B\u0001=?>?1=9>5\u0001?H941C5\u0001\u0015\u0006\u0001 \u001c!&#)!#\u0004\u0001\u0004\f\f\u0006\u0004\u0001\u0006\n\u0006\u0004\u0001\n\r\u000f\u0010\u0005\r\u0010\b\u0006\u0001\n/\n\b0\u0001\u00171C@9\u0004\u0001\u0015\u0006\u0013\u0001!3\u0017<1I\u0004\u0001\u001e\u0006\u0013\u0001!?669DD\u0004\u0001(\u0006\u0001\u0019\u0006\u0013\u0001!9<<\u0004\u0001\u001e\u0006\u0013\u0001!1BD9>\u0004\u0001\u001e\u0006\u0013\u0001\u0017B 197\u0004\u0001\u001d\u0006\u0001\n+\u0006\u0013\u0001(1I<?B\u0004\u0001\u0015\u0006\u0013\u0001$?E<D?>\u0004\u0001&\u0006\u0001&?<5\u0001?6\u000175>?DI@5\u00019>\u0001D85\u00013I3<5\u0001?6\u0001F9?\u0005\n<5>35\u00019>\u0001=1<DB51D54\u0001389<4B5>\u0006\u0001 \u001c!&#)!#\u0004\u0001\u0005\u0003\u0003\u0005\u0004\u0001\u0006\r\u000b\u0004\u0001\u0010\r\t\u0005\u0010\r\f\u0006\u0001\n/\n\t0\u0001!5I5B\u0004\u0001\u001e\u0006\u0001\u001c\u0006\u0013\u0001\u001b9>?F1BD\u0004\u0001\"\u0006\u0013\u0001\u0016??F1B9G1<1\u0004\u0001\u0015\u0006\u0013\u0001'17B1D9\u0004\u0001'\u0006\u0013\u0001\u001cECC5I\u0004 \u0001\n\u0018\u0006\u0013\u0001\u001b1B3L1\u0004\u0001\u0015\u0006\u0013\u0001-?E>7\u0004\u0001(\u0006\u0013\u0001$B1C381;\u0005&9545B\u0004\u0001\"\u0006\u0013\u0001 +9<C?>\u0004\u0001\u0015\u0006\u0001\u0015\u0006\u0013\u0001\n\u001c?E<5\u0004\u0001'\u0006\u0001\u0019<5F1D54\u0001=?>?1=9>5\u0001?H941C5\u00011\u0001<5F5<C\u00019>\u0001D85\u00012B19>\u0012\u00011>\u0001 5H\u0005\n@<1>1D9?>\u00016?B\u0001D85\u0001=?>?1=9>5\u00019=21<1>35\u0001?6\u0001=1:?B\u000145@B5CC9?>\u0006\u0001 \u000e,!%\u0003\u0001\n\u0013#)\u0003\u0001\u001a-2!%\u0003 \u0004\u0001\u0005\u0003\u0003\t\u0004\u0001\n\u0007\u0004\u0001\t\n\b\u0011\u0005\t\n\t\u000e\u0006\u0001\n/\n\n0\u0001(8?B@5\u0004\u0001 \u0006\u0013\u0001\u001bB?E<H\u0004\u0001\u0016\u0006\u0001\u00185@B5CC9F5\u0001CI>4B?=5C\u00019>\u000145=5>D91\u0006\u0001\u00171>\u0006\u0001\u001e \u0006\u0001\n\"5EB?<\u0006\u0001'39\u0006\u0004 \u0001\u0005\u0003\u0003\u0004\u0004\u0001\n\u0010\u0004\u0001\u0010\u000b\u0005\u0011\r\u0006\u0001\n/\n\u000b0\u0001\"9C89=EB1\u0004\u0001\u0015\u0006\u0001 \u0006\u0013\u0001\u001bE9>41<9>9\u0004\u0001\u0017\u0006\u0013\u0001#<9F59B1\u0004\u0001\u001e\u0006\u0001&\u0006\u0013\u0001\"9DB9>9\u0004\u0001&\u0006\u0013 \u0001\u00161891\u0004\u0001\n*\u0006\u0001'\u0006\u0013\u000145\u0001\u0016B9D?\u0005!1BAE5C\u0004\u0001$\u0006\u0001&\u0006\u0013\u0001#DD?\u0004\u0001$\u0006\u0001\u0015\u0006\u0013\u0001.1DJ\u0004\u0001!\u0006\u0001!?>?1=9>5 \u0001\n?H941C5\u00011\u0001@?<I=?B@89C=\u00019>\u0001\u0016B1J9<91>\u0001@1D95>DC\u0012\u0001B9C;\u0001613D?B\u00016?B\u0001< 1D5\u0005\n?>C5D\u0001\u0015<J859=5BMC\u000149C51C5\u0014\u0001 \u0015\u0003\u0001\u0017*'\u0003\u0001\u0018#/,*-!&\u0003 \u0004\u0001\u0005\u0003\u0003\b\u0004\u0001\u0006\u000b\u0004\u0001\n\t\u000b\u0005\n\t\u000f\u0006\u0001\n/\n\f0\u0001+E\u0004\u0001\u0017\u0006\u0001\u001f\u0006\u0013\u0001!5CE<1=\u0004\u0001!\u0006\u0001!\u0006\u0013\u0001\u001b5E<1\u0004\u0001\u0017\u0006\u0001\u001575\u0005B5<1D54\u0001<?CC\u0001?6\u000131<\u0005\n29>49>\u00016B?=\u00018E=1>\u000121C1<\u00016?B52B19>\u000138?<9>5B793\u0001>5EB?>C\u0006\u0001 \u0018#/,*,#\u0002\n+*,.\u0006\u0004\u0001\u0004\f\f\n\u0004\u0001\f\u0004\u0001\n\n\b\u0011\u0005\n\n\t\u000b\u0006\u0001\n/\n\r0\u0001\u0019=9<CC?>\u0004\u0001 \u0006\u0013\u0001'15DB5\u0004\u0001$\u0006\u0013\u0001\u00161<39E>95>5\u0004\u0001\u001e\u0006\u0013\u0001\u00171CD5>CC?>\u0004\u0001\u0015\u0006\u0013\u0001\u001719B >C\u0004\u0001\n\"\u0006\u0013\u0001\u001e1J9>\u0004\u0001\u0019\u0006\u0001\u0019\u0006\u0001\u001d>3B51C54\u0001=?>?1=9>5\u0001?H941C5\u0001=5CC5>75B\u0001&\"\u0015\u00015H\u0005@B5CC9?>\u0001<5F5<C\u00019>\u00016B?>D1<\u00013?BD5H\u0001?6\u0001\u0015<J859=5BMC\u000149C51C5\u0001@1D95> DC\u0006\u0001\n\u0018#/,*-!&\u0003\u0001\u0016#..\u0003\u0004\u0001 \u0005\u0003\u0003\u0005\u0004\u0001\u0007\u0006\n\u0004\u0001\r\u000e\u0005\u000e\b\u0006\u0001\n/\n\u000e0\u0001(1;581C89\u0004\u0001!\u0006\u0013\u0001(1>1;1\u0004\u0001'\u0006\u0013\u0001!1C<918\u0004\u0001\u0019\u0006\u0013\u0001)541\u0004\u0001\u001f\u0006\u0001\u0015CC?391D9?>\u0001?6 \u0001\n=?>?1=9>5\u0001?H941C5\u0001\u0015\u000175>5\u0001@?<I=?B@89C=\u0001G9D8\u0001\u0015<J859=5BMC\u000149C\u0005\n51C5\u0001@1D95>DC\u0006\u0001 \u0018#/,*-!&\u0003\u0001\u0016#..\u0003 \u0004\u0001\u0005\u0003\u0003\u0005\u0004\u0001\u0007\u0006\u000b\u0004\u0001\u000f\u0011\u0005\u0010\n\u0006\u0001\n/\n\u000f0\u0001\u0015=B59>\u0004\u0001&\u0006\u0013\u0001!1BD9>\u0004\u0001\u001e\u0006\u0001&\u0006\u0013\u0001\u00171=5B?>\u0001\u0015\u0006\u0001!\u0006\u0001!?3<?25=941\u00019>\u0001@1D95>D C\u0001\nG9D8\u000145=5>D91\u00011>4\u000145@B5CC9?>\u0006\u0001 \u000e\"0\u0003\u0001\u0018#/,*'\u0003 \u0004\u0001\u0004\f\f\f\u0004\u0001\f\u0004\u0004\u0001\r\b\u0011\u0005\r\t\u0011\u0006\u0001/\n\u00100\u0001\u001b1B5B9\u0004\u0001$\u0006\u0013\u0001\u001a1<3?>9\u0004\u0001)\u0006\u0013\u0001\u00185\u0001\u001a1J9?\u0004\u0001$\u0006\u0013\u0001\u00185\u0001'1BB?\u0004\u0001\u001b\u0006\u0001\u0017?>F5>D9?>1 <\u0001\n1>4\u0001>5G\u00011>D945@B5CC1>D\u00014BE7C\u00019>\u0001D85\u00015<45BI\u0006\u0001 \u001a,*$\u0003\u0001\u0018#/,* &*'\u0003 \u0004\u0001\u0005\u0003\u0003\u0003\u0004\u0001\n\n\u0005\u0004\u0001\u000b\r\u000b\u0005\u000b\u0011\u000e\u0006\u0001\n/\n\u00110\u0001!1B17?C\u0004\u0001+\u0006\u0001\u001a\u0006\u0013\u0001-?E>7\u0004\u0001\u001f\u0006\u0001 \u0006\u0013\u0001\u0015<D=1>\u0001\u0017\u0006\u0001'\u0006\u0013\u0001$?35B>938\u0004\u0001\u0017\u0006\u0001\u0016\u0006\u0013\u0001\n\u0018B1;5\u0004\u0001\u001e\u0006\u0013\u0001\u0016EDD5B695<4\u0004\u0001\u0018\u0006\u0001\u0015\u0006\u0013\u0001'596\u0004\u0001\u001d\u0006\u0013\u0001\u001c?<C38>5945B\u0004\u0001\u0018\u0006\u0001$\u0006\u0013\u0001\u0017 85>\u0004\u0001\u001f\u0006\u0013\u0001\n'898\u0001\u001e\u0006\u0001\u0017\u0006\u0001'DB91<\u000141=175\u00011>C\u0001?H941D9F5\u0001CDB5CC\u00019>4E354\u00012I\u0001D85\u0001=9 D?\u0005\n38?>4B91<\u0001D?H9>\u0001=1<?>1D5\u00011B5\u0001B54E354\u00019>\u00013<?B7I<9>5\u0005DB51D54\u0001B1DC\u00011>4\u0001\n!\u0015#\u0005\u0015\u00014569395>D\u0001=935\u0006\u0001 \u0018#/,*!%#(\u0003\u0001\u001b#-\u0003 \u0004\u0001\u0005\u0003\u0003\u0007\u0004\u0001\u0006\r\u0004\u0001\u000f\f\t\u0005\u000f\f\u000e \u0002\u0001\n/\u000b\b0\u0001#E\u0004\u0001,\u0006\u0001!\u0006\u0013\u0001\u001785>\u0001\u001f\u0006\u0013\u0001'898\u0001\u001e\u0006\u0001\u0017\u0006\u0001!?>?1=9>5\u0001?H941C5\u0001\u0015\u00011>4\u0001B5\u0005\n@B5CC?B\u0001&\u001d\u00011B5\u00015>F?<F54\u00019>\u00011@?@D?D93\u0001C97>1<9>7\u0001@1D8G1I\u0006\u0001$B?3\u0006\u0001\" 1D<\u0006\u0001\n\u0015314\u0006\u0001'39\u0006\u0001)\u0001'\u0001\u0015\u0004\u0001 \u0005\u0003\u0003\t\u0004\u0001\t\b\u000b\u0004\u0001\t\b\u0011\n\u000b\u0005\t\b\u0011\n\u0010\u0006\u0001\n/ \n\u000b\t0\u0001\u001b5B<138\u0004\u0001!\u0006\u0013\u0001\u0018?E2<5\u0004\u0001\u001f\u0006\u0013\u0001&5938=1>>\u0004\u0001\u001c\u0006\u0013\u0001&9545B5B\u0004\u0001$\u0006\u0001\u0015B7E=5>DC\u0001\n6?B\u0001D85\u0001EC5\u0001?6\u00014?@1=9>5\u0001B535@D?B\u000117?>9CDC\u00019>\u00013<9>931<\u00011>4\u0001@B53< 9>931<\u0001\n$1B;9>C?>MC\u000149C51C5C\u0006\u0001 \u0015\u0003\u0001\u0018#/,\u001f'\u0001\u001d,\u001f)-(\u0003\u0001\u001c/++' \u0006\u0004\u0001\u0005\u0003\u0003\u0006\u0004\u0001\t\u000e\u000f\u0005\t\u0011\u000b\u0006\u0001\n/\u000b\n0\u0001\u001a5B>1>45J\u0004\u0001\u001c\u0006\u0001\u001c\u0006\u0013\u0001\u001785>\u0004\u0001\u001e\u0006\u0001\u001e\u0006\u0001!?>1=9>5\u0001?H941C5\u00019>8929D?BC\u0012\u00013EBB 5>D\u0001\n1>4\u00015=5B79>7\u0001175>DC\u00016?B\u0001$1B;9>C?>\u000149C51C5\u0006\u0001 \u0010'&)\u0003\u0001\u0018#/,*+%\u001f,(\u001f!*'\u0003 \u0004\u0001\n\u0005\u0003\u0003\n\u0004\u0001\u0007\u0004\u0004\u0001\t\r\b\u0005\t\u000e\u0010\u0006\u0001\u0001\n/\u000b\u000b0\u0001&9545B5B\u0004\u0001$\u0006\u0013\u0001\u00181>95<3JI;\u0004\u0001+\u0006\u0013\u0001\u001bBE>2<1DD\u0004\u0001\u0019\u0006\u0001!?>?1=9>5\u0001?H941C5\u0005\u0016 \u0001\n9>8929D9?>\u00019>\u0001\u0015<J859=5BMC\u000149C51C5\u0006\u0001 \u0018#/,*.*1&!*'*$2 \u0004\u0001\u0005\u0003\u0003\u0007\u0004\u0001\u0006\t\u0004\u0001\n\u000f\t\u0005\n\n\u000f\u000f\u0006\u0001\n/\u000b\f0\u0001'1EB1\u0004\u0001\u001e\u0006\u0013\u0001 EAE5\u0001\u001e\u0006\u0001!\u0006\u0013\u0001\u00175CEB1\u0004\u0001\u0015\u0006\u0001!\u0006\u0013\u0001\u00181\u0001$B141\u0004\u0001!\u0006\u0013\u0001\u001781>\u0005$1<1I \u0004\u0001\n*\u0006\u0013\u0001\u001cE25B\u0004\u0001\u001b\u0006\u0013\u0001 ?66<5B\u0004\u0001\u001e\u0006\u0013\u0001&9381B4C\u0004\u0001\u001e\u0006\u001b\u0006\u0001\u001d>3B51C54\u0001=?>?1=9>5\u0001\n?H941C5\u0001\u0016\u000113D9F9DI\u00019>\u0001@<1AE5\u00051CC?391D54\u00011CDB?3ID5C\u0001?6\u0001\u0015<J859=5B \u0001\n2B19>C\u0001B5F51<54\u00012I\u0001AE1>D9D1D9F5\u00015>JI=5\u0001B149?1ED?7B1@8I\u0006\u0001 \u0018#/,*-!&\u0002\n#)!#\u0004\u0001\u0004\f\f\u0007\u0004\u0001\n\u0006\u0004\u0001\t\r\u0005\u000b\b\u0006\u0001\n/\u000b\r0\u0001!3 5<<1>\u0004\u0001!\u0006\u0001\u0019\u0006\u0013\u0001\u001f1:41CJ\u0004\u0001'\u0006\u0001(\u0006\u0013\u0001\u001cI=1>\u0004\u0001\u0016\u0006\u0001(\u0006\u0013\u0001\u001613C;19\u0004\u0001\u0016\u0006\u0001\u001e\u0006\u0001 \u0014)\u0001\n0&0*\u00019=179>7\u0001?6\u0001B513D9F5\u0001?HI75>\u0001C@5395C\u0001C@5396931<<I\u00011CC?391D54\u0001\nG9D8\u0001D89?6<1F9>5\u0001'\u0005@?C9D9F5\u00011=I<?94\u0001@<1AE5C\u00012I\u0001=E<D9 @8?D?>\u0001=9\u0005\n3B?C3?@I\u0006\u0001 \u0015\u0003\u0001\u0018#/,*-!& \u0006\u0004\u0001\u0005\u0003\u0003\u0006\u0004\u0001\u0006\u0007\u0004\u0001\n\n\t\n\u0005\n\n\t\u000f\u0006\u0001\n/\u000b\u000e0\u0001!17I1B\u0004\u0001\u001f\u0006\u0013\u0001'J5>45\u0004\u0001\u0016\u0006\u0001\u00185@B5>I<\u0004\u00011\u0001C5<53D9F5\u0001!\u0015#\u0005\u0016\u00019>8929D?B\u0004\u0001\nG9D8\u0001 1@?@D?D93\u0001 1>4\u0001 1>D9\u00051@?@D?D93\u0001 @B?@5BD95C\u0006\u0001 \u0018#/,*.*1&!*'*$2 \u0004\u0001\n\u0005\u0003\u0003\u0007\u0004\u0001\u0006\t\u0004\u0001\n\u000b\u000b\u0005\n\f\n\u0006\u0001\n/\u000b\u000f0\u0001-?E49=\u0004\u0001!\u0006\u0001\u0016\u0006\u0013\u0001\u00194=?>4C?>\u0004\u0001\u0018\u0006\u0013\u0001(9@D?>\u0004\u0001\u001f\u0006\u0001\u001a\u0006\u0001(85\u0001D85B1@5ED93\u0001\n@?D5>D91<\u0001?6\u0001=?>?1=9>5\u0001?H941C5\u00019>8929D?BC\u0006\u0001 \u0018\u001f.\u0003\u0001\u001b#0\u0003\u0001\u0018#/,*-!&\u0003 \u0004\u0001\n\u0005\u0003\u0003\t\u0004\u0001\u000b\u0004\u0001\n\u0011\r\u0005\u000b\b\u0011\u0006\u0001\n/\u000b\u00100\u0001!EBB1I\u0004\u0001&\u0006\u0001\u0018\u0006\u0001\u001c\u0006\u0013\u0001!5>45J\u0004\u0001\u001e\u0006\u0013\u0001\u0016B?G>\u0004\u0001'\u0006\u0001\u0015\u0006 \u0001(85\u0001>1DEB1<\u00013?E=1B9>C\u0001\n?33EBB5>35\u0006\u0001\u001d> \u0001\u0010%#(&-.,2\u0001\u001f)\"\u0001\u000f&*!%#(&-.,2 \u0013\u0001\u001e?8>\u0001+9<5I\u00011>4\u0001'?>C\u0012\u0001\n\u001789385CD5B\u0004\u0001\t\u0011\u0010\n\u0006 \u0001\n/\u000b\u00110\u0001!EBB1I\u0004\u0001 &\u0006\u0001 \u0018\u0006\u0001 \u001c\u0006\u0001 \"1DEB1<<I\u0001 ?33EBB9>7\u0001 @<1>D\u0001 3?E=1B9>C\u0006 \u0001 \u001a,*$\u0003\u0001\n\u0010%#(\u0003\u0001\u0019,$\u0003\u0001\u0018\u001f.\u0003\u0001\u001a,*\"\u0003 \u0004\u0001\u0005\u0003\u0003\u0005\u0004\u0001\f\u0007\u0004 \u0001\t\u0005\u000e\u000f\u000b\u0006\u0001\n/\f\b0\u0001\u0016?B75C\u0004\u0001\u001a\u0006\u0013\u0001&?<59B1\u0004\u0001\u001a\u0006\u0013\u0001!9<81J5C\u0004\u0001\"\u0006\u0013\u0001'1>D1>1\u0004\u0001 \u0006\u0013\u0001)B91BD5\u0004\u0001\u0019\u0006 \u0001'9=\u0005\n@<5\u00013?E=1B9>C\u00011>4\u00011>1<?7E5C\u00019>\u0001=54939>1<\u0001385=9CDBI\u0012\u0001?33EBB5>35\u0004 \u0001\nCI>D85C9C\u00011>4\u000129?<?7931<\u000113D9F9DI\u0006\u0001 \u0010/,,\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\b\u0004\u0001\u0005\u0006\u0004\u0001\u0010\u0010\u000f\u0005\n\u0011\t\u000e\u0006\u0001\n/\f\t0\u0001\u0016?B75C\u0004\u0001\u001a\u0006\u0013\u0001&?<59B1\u0004\u0001\u001a\u0006\u0013\u0001 \r\u001b\u001c\u001a\u0014(\u0018\"\u0002\u0001\u000e\u0003\u0007\u0001\u0012!\u001b\u0014!#\u0018\u0002\u0001\t\u0003\u0007\u0001\u0010\u0014\u001e#\u0014\u001e\u0014\u0002\u0001\f\u0003 \u0001\n'9=@<5\u0001\u0017?E=1B9>C\u0012\u0001$B9F9<5754\u0001'3166?<4C\u00019>\u0001!54939>1<\u0001\u001785=9CDBI\u0006\u0001\n\u0012,*).\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\f\u0004\u0001\b\u0004\u0001\n\u000b\u0005\u0010\r\u0006\u0001\n/\f\n0\u0001#M\u001f5>>54I\u0004\u0001 &\u0006 \u0001\u0017?E=1B9>C\u0006\u0001 \u00169?<?7I\u0004\u0001 1@@<931D9?>C\u00011>4\u0001 =?45\u0001 ?6\u0001\n13D9?>\u0004\u0001(8?B>5C\u0001&\u0006\u0018\u0006\u0001\u0002\u00194\u0003\u0004\u0001\u001e?8>\u0001 +9<5I\u00011>4\u0001'?>C\u0012\u0001\"5G\u0001-?B;\u0004\u0001 \t\u0011\u0011\u000f\u0006\u0001\n/\f\u000b0\u0001\u00165<<ED9\u0004\u0001\u001a\u0006\u0013\u0001\u001a?>D1>1\u0004\u0001\u001b\u0006\u0013\u0001\u0016?\u0004\u0001 \u0006\u0013\u0001\u00171B5>9>9\u0004\u0001\"\u0006\u0013\u0001\u001b9?==1B5<<9\u0004\u0001\u0017\u0006 \u0013\u0001\n.E>9>?\u0004\u0001\u001a\u0006\u0001\u00185C97>\u0004\u0001CI>D85C9C\u00011>4\u00011>D931>35B\u000113D9F9D95C\u0001?6\u0001CD9<2 5>5\u0001\u0005\u0001\n3?E=1B9>\u00018I2B94\u00013?=@?E>4C\u0012\u0001945>D96931D9?>\u0001?6\u0001>?F5<\u0001@B?1@?@D?D93 \u0001\n175>DC\u0006\u0001\u000f&**,$\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0004\u0003\u0004\u0001\u0005\f\u0004\u0001\u000b\r\f\u000b\u0005\u000b\r\r\b\u0006\u0001\n/\f\f0\u0001&9F59B?\u0004\u0001!\u0006\u0001\u0019\u0006\u0013\u0001!?7<9?>9\u0004\u0001\u0015\u0006\u0013\u0001*1JAE5J\u0004\u0001&\u0006\u0013\u0001\u001b?=5J\u0004\u0001\"\u0006\u0013\u0001\u001a13?BB?\u0004\u0001\u001b\u0006\u0013\u0001$958<\u0004\u0001 \u0006\u0013\u000145\u0001\u00175<9C\u0004\u0001\u0019\u0006\u0001&\u0006\u0013\u0001'81I?\u0004\u0001\u0017\u0006\u0013\u0001\u00181F9?\u0004\u0001\u0017\u0006\u0001'DBE3DEB1< \u00019>\u0005\nC978DC\u0001 9>D?\u0001 8I4B?HI3?E=1B9>\u00059>4E354\u0001 1@?@D?C9C\u0001 9>\u0001 )\u0005\u0011\u000b\u000f\u0001 35<<C\u0006\u0001\u000f&**,$\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003 \u0004\u0001\u0005\u0003\u0003\u000b\u0004\u0001\u0005\n\u0004\u0001\n\u000e\u000e\r\u0005\n\u000e\u000f\r\u0006\u0001\n/\f\r0\u0001\u001aI<1;D1;94?E\u0004\u0001\u001f\u0006\u0001\u0017\u0006\u0013\u0001\u001c14:9@1F<?E\u0005 9D9>1\u0004\u0001\u0018\u0006\u0001\u001e\u0006\u0013\u0001 9D9>1C\u0004\u0001\u001f\u0006\u0001\u0019\u0006\u0013 \u0001\"93?\u0005\n<1945C\u0004\u0001\u0018\u0006\u0001\"\u0006\u0001\"1DEB1<\u00011>4\u0001CI>D85D93\u00013?E=1B9>\u000145B9F1D9F5C\u0001G9D8\u00011 >D9\u0005\n9>6<1==1D?BI\u00071>D9?H941>D\u000113D9F9D95C\u0006\u0001 \u0010/,,\u0003\u0001\u001a%\u001f,(\u0003\u0001\u0011#-\u0003 \u0004\u0001\u0005\u0003\u0003\u0007\u0004\u0001\u0005\u0004\u0004\u0001\n\u000b\u0010\t\u000b\u0005\u000b\u0010\u000b\u000b\u0006\u0001\n/\f\u000e0\u0001&?ECC1;9\u0004\u0001!\u0006\u0013\u0001\u001f?>D?79?B79C\u0004\u0001\u0017\u0006\u0013\u0001\u001c14:9@1F<?E\u0005 9D9>1\u0004\u0001\u0018\u0006\u0001\u001e\u0006\u0013\u0001\u001c1=9\u0005<1;9C\u0004\u0001'\u0006\u0001\u0015\u0001>?F5<\u0001CI>D85C9C\u0001?6\u0001\u000b\u00051BI<\u00013?E=1B9>C\u00011>4\u00015F1<E1D9?>\u0001?6\u0001\nD859B\u00011>D9?H941>D\u00011>4\u0001<9@?HI75>1C5\u00019>8929D?BI\u000113D9F9DI\u0006\u0001 \u000f&**,$\u0003\u0001\u0017#\"\u0003\u0001\n\u0010%#(\u0003\u0001\u0016#..\u0006\u0004\u0001\u0005\u0003\u0004\u0003\u0004\u0001\u0006\u0004\u0004\u0001\u000b\u0010\u0010\u0011\u0005\u000b\u0010\u0011\n\u0006\u0001\u0001\n/\f\u000f0\u0001*9<1B\u0004\u0001'\u0006\u0013\u0001%E5J141\u0004\u0001\u0019\u0006\u0013\u0001'1>D1>1\u0004\u0001 \u0006\u0013\u0001)B91BD5\u0004\u0001\u0019\u0006\u0013\u0001-1>5J\u0004\u0001!\u0006\u0013\u0001\u001aB 19J\u0004\u0001\n\"\u0006\u0013\u0001\u0015<31945\u0004\u0001\u0017\u0006\u0013\u0001\u00171>?\u0004\u0001\u0019\u0006\u0013\u0001#B1<<?\u0004\u0001\u001a\u0006\u0001\u00185C97>\u0004\u0001CI>D85C9C\u0004\u00011>4\u0001F1 C?B5\u0005\n<1H1>D\u0001 1>4\u0001 @<1D5<5D\u0001 1>D9177B571D?BI\u0001 13D9F9D95C\u0001 ?6\u0001 3?E=1B9>\u0005\nB5CF5B1DB?<\u00018I2B94C\u0006\u0001 \u000f&**,$\u0003\u0001\u0017#\"\u0003\u0001\u0010%#(\u0003\u0001\u0016#.. \u0006\u0004\n \u0001\u0005\u0003\u0003\t\u0004\u0001\u0005\n\u0004\u0001\n\r\u000f\u0005\n\u000e\t\u0006\u0001\n/\f\u00100\u0001#CDB?F\u0004\u0001\u0018\u0006\u0001\u0015\u0006\u0013\u0001\u001c5B>K>45J\u0001$B141\u0004\u0001\u001e\u0006\u0001\u0015\u0006\u0013\u0001\u0017?BC9>?\u0004\u0001$\u0006\u0001\u0019\u0006\u0013\u0001\u001a9>D?>\u0004\u0001 \u001f\u0006\u0001\n\u0015\u0006\u0013\u0001 5\u0004\u0001\"\u0006\u0013\u0001&?G5\u0004\u0001(\u0006\u0001\u0017\u0006\u0001\u00189C3?F5BI\u0001?6\u0001>?F5<\u0001\u0018\"\u0015\u00017IB1C5\u00019>8929D?BC\u0001\n2I\u0001 8978\u0005D8B?E78@ED\u0001 F9BDE1<\u0001 C3B55>9>7\u0006\u0001 \u000e).&(&!,* \u0003\u0001 \u000e$#).-\u0001 \u0010%#\u0002\n(*.%#,\u0003\u0004\u0001\u0005\u0003\u0003\n\u0004\u0001\t\u0005\u0004\u0001\u000b\u000e\u0010\u0010\u0005\u000b\u000e\u0011\u0010\u0006\u0001\n/\f\u00110\u0001\u001789=5>D9\u0004\u0001\u001a\u0006\u0013\u0001\u00169JJ1BB9\u0004\u0001\u0016\u0006\u0013\u0001\u0016?<1C3?\u0004\u0001\u0015\u0006\u0013\u0001'5339\u0004\u0001\u0018\u0006\u0013\u0001\u001789=5>D9\u0004\u0001$ \u0006\u0013\u0001\n\u001bB1>5C5\u0004\u0001\u0015\u0006\u0013\u0001\u00171BB14?B9\u0004\u0001'\u0006\u0013\u0001&9F1>5B1\u0004\u0001\u0018\u0006\u0013\u0001.931B9\u0004\u0001\u0015\u0006\u0013\u0001'31<DB9D? \u0004\u0001!\u0006\u0001\n!\u0006\u0013\u0001'9CD?\u0004\u0001\u001a\u0006\u0001'I>D85C9C\u0004\u0001C5<53D9F5\u00011>D9\u0005\u001c5<93?213D5B\u0001@I<?B9\u000113D 9F9DI\u0004\u0001\n\u0018\u001b\u001b144\u0006\u0006\u0007\u000b\u0001\u0001\u0001\u0001\u0006\u0019\u0016\u0016\u000e\u0013\u0018\u0001\t\u0014\u0015\u0010\f\u0017\u0001\u0010\u0013\u0001\u0007\u000e\r\u0010\f\u0010\u0013\u000b\u0011 \u0001\u0006\u000f\u000e\u0012\u0010\u0017\u0018\u0016\u001a \u0002\u0001\u0006\u0004\u0005\u0006\u0002\u0001\n\u0014\u0011\u0003\u0001\u0004\u0005\u0002\u0001\b\u0014\u0003\u0001\u0005\u0003\u0001 \u0007\u000b\u0018\u0014\u0017\u0001\u000e\u0018\u0001\u000b\u0011\u0002\u0001\n/<2\u00011GB=B=F717BG\u0001=4\u0001<=D3:\u0001 \u0005AC0AB7BCB32\u0005\t\u0005 =F=\u0005\t\u001a\u0005\b\u000503<H=>G@/<\u0005\n\u0005\n1/@0=F/;723A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e(( \u0006\u0004\u0001\u0006\u0004\u0005\u0004\u0004\u0001\u0005\u0003\u0004\u0001\u000b\u0010\t\t\u0005\u000b\u0010\t\r\u0006\u0001\n-\f\u0007.\u0001 3GBA\u0004\u0001\u001c\u0006\u0012\u0001\u00163\u0001\u0015:3@1?\u0004\u0001\u0017\u0006\u0012\u0001%7<56/\u0004\u0001$\u0006\u0012\u0001\u00156/<5\u0004\u0001+\u0006\u0001\u001a\u0006\u0012\u0001\u0016/A\u0004\u0001\u0013\u0006\u0001$\u0006\u0012 \u0001\n\u00156/9@/0=@BG\u0004\u0001%\u0006\u0001\u001d\u0006\u0012\u0001\u001a=<5\u0004\u0001%\u0006\u0001\u0015\u0006\u0012\u0001&A/G\u0004\u0001%\u0006\u0005\u0015\u0006\u0012\u0001\u001aAC\u0004\u0001\u001f\u0006\u0005\u001a\u0006\u0012\u0001\u001aEC\u0004\u0001 \u001c\u0006\u0001\n$\u0006\u0001%B@C1BC@3\u0005/1B7D7BG\u0001@3:/B7=<A67>\u0001=4\u0001<3E\u0001/<B7\u0005\u001a3>/B7B7A\u0001\u0015\u0001D7@C A\u0001\n/53<BA\u0011\u000163B3@=071G1:3\u00051=C;/@7<\u00011=<8C5/B3A\u0006 \u0001\u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\f\u0004\u0001\n\b\u0005\u0004\u0001\b\u000b\u000f\r\u0005\b\u000b\u0010\u0007\u0006\u0001\n-\f\b.\u0001\u001d=AB=D/\u0004\u0001\u001b\u0006\u0001\u0015=C;/@7<A\u0001/A\u00017<6707B=@A\u0001=4\u0001\u001a\u001b(\u0001@3D3@A3\u0001B@/<A1@7>B/A3\u0006\u0001\n\u000f)&&\u0002\u0001\u0012\u0013\u001a\u0001\u0018\u001e'\u0006\u0004\u0001 \u0006\u0004\u0004\t\u0004\u0001\u0007\u0004\u0001\n\u000b\u000e\u0005\n\r\n\u0006\u0001\n-\f\t.\u0001\u001567:7<\u0004\u0001\u0013\u0006\u0012\u0001\u0014/BB7ABCBB/\u0004\u0001$\u0006\u0012\u0001\u0014=@B=:/B=\u0004\u0001\u0013\u0006\u0012\u0001\u0015=HH/\u0004\u0001\u0019\u0006\u0012\u0001,/</BB/\u0004 \u0001%\u0006\u0012\u0001\n\"=:3BB=\u0004\u0001\u0019\u0006\u0012\u0001\u001f/HH=@/</\u0004\u0001\u001f\u0006\u0012\u0001,/5=BB=\u0004\u0001\u0019\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001\u0019C7=BB=\u0004\u0001 \u0013\u0006\u0012\u0001\n\u001f3557=\u0004\u0001\u0018\u0006\u0012\u0001\u001f=@=\u0004\u0001%\u0006\u0001\u0015=C;/@7<\u0001/A\u0001/BB@/1B7D3\u00011/A37<\u000197</A3\u0001\t\u0001\u0002\u0015\u001d \t\u0003\u0001\n7<6707B=@\u0001A1/44=:2\u0011\u0001/<\u00017<B35@/B3\u0001/>>@=/16\u0001B=\u00013:C172/B3\u0001B63\u0001>CB/ B7D3\u0001\n07<27<5\u0001;=B74\u0001/<2\u00013F>:/7<\u0001AB@C1BC@3\u0005/1B7D7BG\u0001@3:/B7=<A67>A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\n\u000f \u001e#\u0002\u0004\u0001\u0006\u0004\u0004\u000b\u0004\u0001\b\u0004\u0004\u0001\u000e\f\t\u0005\u000e\f\u0010\u0006\u0001\n-\f\n.\u0001,6=C\u0004\u0001*\u0006\u0012\u0001)/<5\u0004\u0001*\u0006\u0001\u0014\u0006\u0012\u0001)/<5\u0004\u0001&\u0006\u0012\u0001\u001d=<5\u0004\u0001\u001e\u0006\u0001+7\u0006\u0001\u00163A75<\u0004\u0001AG<B63A7A \u0004\u0001\n/<2\u0001/13BG:16=:7<3AB3@/A3\u00017<6707B=@G\u0001/1B7D7BG\u0001=4\u0001<=D3:\u00011=C;/@7<\u0001/</\u0005\n:=5C3A\u0006\u0001\u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\u000b\u0004\u0001\u0004\t\u0004\u0001\u000f\u0007\b\b\u0005\u000f\u0007\t\b\u0006\u0001\n-\f\u000b.\u0001\u0019/@7<=\u0004\u0001\u0015\u0006\u0012\u0001&=;7B/\u0004\u0001&\u0006\u0012\u0001\"73B@/<1=AB/\u0004\u0001 \u0006\u0012\u0001\u001e/@/A\u0004\u0001+\u0006\u0012\u0001$=A/A\u0004\u0001$\u0006\u0012 \u0001\n\u001a3@03BB3\u0004\u0001\u0019\u0006\u0012\u0001\u001f/75@3B\u0004\u0001\u0014\u0006\u0012\u0001#CJ:JD3@\u0004\u0001\u0019\u0006\u0012\u0001\u001bE/BAC0=\u0004\u0001&\u0006\u0012\u0001\u001d@/CA\u0004\u0001\u001c \u0006\u0001\u001e\u0006\u0001\n />6B6G:\u0001/<2\u00011=C;/@7<G:\u000107/@G:>7>3@/H7<3\u000123@7D/B7D3A\u0001/A\u00016756:G\u0001 >=\u0005\nB3<B\u00016C;/<\u0001 \u0001\u0005A31@3B/A3\u00017<6707B=@A\u0006\u0001\u00163A75<\u0004\u0001AG<B63A7A\u0004\u0001/<2\u00013<HG;/B71\u0001\n\u0014\u0013\u0015\u0017\u0005\b\u0001/<2\u000113::\u0001/AA/GA\u0006 \u0001\u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\t\u0004\u0001\u0007\f\u0004 \u0001\u000b\t\u000e\f\u0005\u000b\t\u000f\f\u0006\u0001\n-\f\f.\u0001\u001d/27@\u0004\u0001\u001a\u0006\u0001\u0013\u0006\u0012\u0001\u001d<=E:3A\u0004\u0001\u0015\u0006\u0001!\u0006\u0001\u001b<6707B7=<\u0001=4\u0001@/B\u00010@/7<\u0001;=<=/;7<3\u0001\n=F72/A3\u00010G\u00017<A31B71723A\u0004\u0001/1/@71723A\u0001/<2\u0001@3:/B32\u00011=;>=C<2A\u0001 \u0011\u001e$\u0002\u0001\n\u0017 \u001b&#\u001b\u001c%\"\u0002\u0004\u0001\u0005\f\u000b\u0005\u0004\u0001\u0004\u0005\u0004\u0001\t\n\u0010\u0005\t\u000b\u000e\u0006\u0001\n-\f\r.\u0001$3<23<0/16\u0004\u0001\u0014\u0006\u0012\u0001)3743<0/16\u0004\u0001\u001a\u0006\u0012\u0001&3A163<2=@4\u0004\u0001\u001a\u0006\u0001\u001c\u0006\u0001\"@3>/@/B7=<\u0001=4\u0001\n\u000e\u0005\u0002/@G:/:9=FG\u00031=C;/@7<A\u0001/A\u000113<B@/:\u0001<3@D=CA\u0001AGAB3;\u0001/53<BA\u0006\u0001\u00193@\u0006\u0001 !4\u0005\n43<\u0006\u0001\u0002\b\u0010\u0010\u0007\u0003\u0004\u0001\u0016\u0017\u0001\n\u000f\n\u000b\u000f\r\b\u0001\u0013\b\u0001\b\u0010\u0010\u0007\u0007\u000b\b\u0010\u0006\u0001\u0001\n-\f\u000e.\u0001\u001d=<5\u0004\u0001\u001e\u0006\u0001\u0016\u0006\u0012\u0001&/<\u0004\u0001$\u0006\u0001*\u0006\u0012\u0001)==\u0004\u0001\u0013\u0006\u0001+\u0006\u0012\u0001\u001563<5\u0004\u0001\u0015\u0006\u0001\u001a\u0006\u0001\u001b<670 7B7=<\u0001=4\u0001@/B\u0001\n0@/7<\u0001;=<=/;7<3\u0001=F72/A3\u0001/1B7D7B73A\u00010G\u0001>A=@/:3<\u0001/<2\u00017A=>A=@/:3<\u0011 \u0001\n7;>:71/B7=<A\u00014=@\u0001B63\u0001B@3/B;3<B\u0001=4\u0001/4431B7D3\u000127A=@23@A\u0006\u0001 \u0017 \u001b&#\u001b\u001c%\"\u0002\u0001\n\u0019%+!\u001c%\"\u0002\u0004\u0001\u0006\u0004\u0004\u0005\u0004\u0001\u000b\u000b\u0004\u0001\u000e\f\u0005\u000f\u0007\u0006\u0001\n-\f\u000f.\u0001\u001aC=<5\u0004\u0001\u0016\u0006\u0001&\u0006\u0012\u0001\u00156=7\u0004\u0001\u001a\u0006\u0001\u0015\u0006\u0012\u0001$6=\u0004\u0001&\u0006\u0001\u0015\u0006\u0012\u0001\u001e33\u0004\u0001\u001a\u0006\u0001%\u0006\u0012\u0001\u001e33\u0004\u0001\u001f\u0006\u0001\u001d\u0006\u0004\u0001 \u001d7;\u0004\u0001\n+\u0006\u0001\u001a\u0006\u0001\u001b<6707B=@G\u0001/1B7D7BG\u0001=4\u0001;=<=/;7<3\u0001=F72/A3\u00010G\u00011=C;/@7<A\u00014@= ;\u0001\n\"3C132/<C;\u00018/>=<71C; \u0002\u0001\r&\u001c \u0002\u0001\u0017 \u001b&#\u0002\u0001\u0018\u001e'\u0002 \u0004\u0001\u0005\f\f\f\u0004\u0001\u0005\u0005\u0004\u0001\n\t\u000b\u0005\n\t\r\u0006\u0001\n-\f\u0010.\u0001\u001a=AA/7<\u0004\u0001\u0015\u0006\u0001\u0018\u0006\u0012\u0001!9CG/;/\u0004\u0001\u0017\u0006\u0012\u0001+/;/H/97\u0004\u0001\u001f\u0006\u0001\u0013\u0001<3E\u0001A3@73A\u0001=4\u00011=C\u0005\n;/@7<\u000123@7D/B7D3A\u00016/D7<5\u0001;=<=/;7<3\u0001=F72/A3\u00017<6707B=@G\u0001/1B7D7BG\u0001\n4@=;\u0001\u001f=</A1CA\u0001/<9/\u0006\u0001 \u000f \u001e#\u0002\u0001\u0017 \u001b&#\u0002\u0001\u000e)\"\"\u0002 \u0004\u0001\u0005\f\f\t\u0004\u0001\u0007\u0007\u0004\u0001\b\f\n\f\u0005\b\f\n\u0010\u0006\u0001\n-\r\u0007.\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001\u0015/@@73@7\u0004\u0001\u0013\u0006\u0012\u0001\u001567;7167\u0004\u0001%\u0006\u0012\u0001\u0014= 11/:7<7\u0004\u0001\u001f\u0006\u0012\u0001\u0015=A7;3::7\u0004\u0001\u0014\u0006\u0012\u0001\n\u0019<3@@3\u0004\u0001\u0015\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001\u0015/@@C>B\u0004\u0001\"\u0006\u0005\u0013\u0006\u0012\u0001&3AB/\u0004\u0001\u0014\u0006\u0001 /BC@/:\u0001/<2\u0001 AG<\u0005\nB63B71\u0001\u001937>/@/D7<A\u0001/@3\u0001AB@=<5\u0001/<2\u0001A3:31B7D3\u0001\u001f\u0013!\u0005\u0014\u00017<6707B=@A\u0006\u0001% G<\u0005\nB63A7A\u0001/<2\u0001%\u0013$\u0001ABC273A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002 \u0004\u0001\u0006\u0004\u0004\u0006\u0004\u0001\u0004\u0005\u0004\u0001\n\f\f\b\u0005\n\n\f\f\f\u0006\u0001\n-\r\b.\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001\u0013:B=;/@3\u0004\u0001\u0015\u0006\u0012\u0001\u0015/BB=\u0004\u0001\u001f\u0006\u0012\u0001\u0019<3@@3\u0004\u0001\u0015\u0006\u0012\u0001%C;;=\u0004\u0001\u001e\u0006\u0012\u0001\u00163 \u0001\n\u001f/@1=\u0004\u0001\u0013\u0006\u0012\u0001$=A3\u0004\u0001%\u0006\u0012\u0001\u001c3<<3@\u0004\u0001\"\u0006\u0012\u0001&3AB/\u0004\u0001\u0014\u0006\u0001\u001e7>=>6 7:717BG\u0001>:/GA\u0001/\u0001;/\u0005\n8=@\u0001@=:3\u00017<\u0001;=2C:/B7<5\u0001B63\u00017<6707B7=<\u0001=4\u0001;=<=/;7<3\u0001=F72/A3\u0001\u0014\u00010G\u0001\u000e\u0005\nAC0AB7BCB32\u00011=C;/@7<A\u0006\u0001 \u000f \u001e#\u0002\u0001\u000e!%\u001d!*\u001e&'\u0002 \u0004\u0001\u0006\u0004\u0004\t\u0004\u0001\u0006\u0004\u0001\b\n\u000b\u0005\b\u000b\u0010\u0006\u0001\u0001\n-\r\t.\u0001\u0019<3@@3\u0004\u0001\u0015\u0006\u0012\u0001\u0015/BB=\u0004\u0001\u001f\u0006\u0012\u0001\u0018@/<13A1=\u0004\u0001\u001e\u0006\u0012\u0001)303@\u0004\u0001\"\u0006\u0012\u0001\u0015/@@C>B\u0004\u0001\"\u0005\u0013\u0006\u0012 \u0001\n\u0013:B=;/@3\u0004\u0001\u0015\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001&3AB/\u0004\u0001\u0014\u0006\u0001\u001b<6707B7=<\u0001=4\u0001;=<=/;7<3\u0001=F 7\u0005\n2/A3\u00010G\u00014C<1B7=</:7H32\u00011=C;/@7<\u000123@7D/B7D3A\u0011\u000107=:=571/:\u0001/1B7D7B73A\u0004\u0001\n#%\u0013$\u0004\u0001/<2\u0001\n\u0016\u0005#%\u0013$A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e# \u0006\u0004\u0001\u0006\u0004\u0004\u0004\u0004\u0001\u0007\u0006\u0004 \u0001\u000b\u000e\u000b\u000e\u0005\u000b\u000e\f\u000f\u0006\u0001\n-\r\n.\u0001$3<23<0/16\u0005\u001fM::3@\u0004\u0001\u0014\u0012\u0001%16:3193@\u0004\u0001$\u0006\u0012\u0001&@/CB\u0004\u0001\u001f\u0006\u0012\u0001)3743<0/16\u0004\u0001\u001a\u0006\u0001\n%G<B63A7A\u0001=4\u00011=C;/@7<A\u0001/A\u0001AC0BG>3\u0005A3:31B7D3\u00017<6707B=@A\u0001=4\u0001;=<=\u0005\n/;7<3\u0001=F72/A3\u00017<6707B=@A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002 \u0004\u0001\u0005\f\f\b\u0004\u0001\u0007\u0004\u0001\b\b\u0010\f\u0005\n\b\b\u0010\u000f\u0006\u0001\n-\r\u000b.\u0001\"7A/<7\u0004\u0001\u001e\u0006\u0012\u0001\u001fC<17>7<B=\u0004\u0001\u0019\u0006\u0012\u0001\u001f7A17=A17/\u0004\u0001&\u0006\u0001\u0018\u0006\u0012\u0001 71=:=BB7\u0004\u0001!\u0006\u0012\u0001\u001e 3=<\u0005\n3BB7\u0004\u0001\u0018\u0006\u0012\u0001\u0015/BB=\u0004\u0001\u001f\u0006\u0012\u0001\u0015/117/\u0004\u0001\u0015\u0006\u0012\u0001%/:D/B7\u0004\u0001\"\u0006\u0012\u0001%=B=\u0005!B3@=\u0004\u0001$\u0006\u0012\u0001\u001f 3<23H\u0005\n\u0013:D/@3H\u0004\u0001\u0017\u0006\u0012\u0001\"/AA3:3C\u0004\u0001\u0015\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0001\u00167A1=D3@G\u0001=4\u0001/\u0001<=D3:\u00011:/ AA\u0001=4\u0001\n>=B3<B\u00011=C;/@7<\u0001;=<=/;7<3\u0001=F72/A3\u0001\u0014\u00017<6707B=@A\u0011\u000123D3:=>;3<B\u0001/<2\u0001 07=>6/@;/1=:=571/:\u0001 >@=47:7<5\u0001 =4\u0001 \u000e\u0005-\u0002\n\u000516:=@=03<HG:\u0003 =FG.\u0005\u000b\u0005\n-\u0002;3B6G:/;7<=\u0003;3B6G:.\u0005\t\u001a\u000516@=;3<\u0005\t\u0005=<3\u0001 ;3B6/<3AC:4=</B3\u0001\u0002 )\u0005\b\u000e\u000e\t\u0003\u0001/A\u0001/\u00016756:G\u0001>=B3<B\u0004\u0001A3:31B7D3\u0004\u0001@3D3@A70:3\u0004\u0001/<2\u0001=@/::G \u0001/1\u0005\nB7D3\u0001;=<=/;7<3\u0001=F72/A3\u0001\u0014\u00017<6707B=@\u0006\u0001 \u0014\u0002\u0001 \u0016\u001e\u001d\u0002\u0001 \u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\f\u0004\u0001\b\u0005\u0004\u0001\n\r\r\u000f\f\u0005\r\u000e\u0007\r\u0006\u0001\n-\r\f.\u0001\u0018@7193:\u0004\u0001 \u0018\u0006\u0005\u0018\u0006\u0012\u0001 \u001dC393<6=36<3@\u0004\u0001 &\u0006\u0012\u0001 $3<23<0/16\u0005\u001fM::3@\u0004\u0001 \u0014\u0006\u0012\u0001\n)3743<0/16\u0004\u0001 \u001a\u0006\u0012\u0001 &3A163<24=@4\u0004\u0001 \u001a\u0006\u0005\u001c\u0006\u0001 \"@3>/@/B7=<\u0001 =4\u0001 \u000e\u0005\n\u000263B3@=1G1:G:;3B6=FG\u00031=C;/@7<A\u0001/A\u0001;=<=/;7<3\u0001=F72/A3\u00017<6707B=@A\u0006 \u0001\n\u00193@\u0006\u0001!443<\u0006\u0001\u0002\b\u0010\u0010\u0007\u0003\u0004\u0001\u0016\u0017\u0001\n\u000f\n\u000b\u000f\r\u0007\u0001\u0013\b\u0001\b\u0010\u0010\u0007\u0007\u000b\b\u0010\u0006\u0001\n-\r\r.\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001\u0019=<HI:3H\u0005\u0016K/H\u0004\u0001\u001a\u0006\u0012\u0001#C3H/2/\u0004\u0001\u0017\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001+IL3H \u0004\u0001\n\u001f\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001!@/::=\u0004\u0001\u0018\u0006\u0001#C/<B7B/B7D3\u0001AB@C1BC@3\u0005/1B7D7BG\u0001@3:/B7 =<A67>\u0001\n/<2\u00011=;>:3F\u0001<3BE=@9\u0001/>>@=/16\u0001B=\u0001;=<=/;7<3\u0001=F72/A3\u0001\u0013\u0001/<2\u0001\u0014\u00017<\u0005\n6707B=@A\u0006\u0001\u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\u000b\u0004\u0001\b\u0004\u0004\u0001\r\u000e\u000b\u0007\u0005\r\u000e\f\b\u0006\u0001\n-\r\u000e.\u0001\u0015/BB=\u0004\u0001\u001f\u0006\u0012\u0001 71=:=BB7\u0004\u0001!\u0006\u0012\u0001\u001e3=<3BB7\u0004\u0001\u0018\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001\u0018/D7/\u0004\u0001\u0013\u0006\u0001 \u0016\u0006\u0012\u0001\n%=B=\u0005!B3@=\u0004\u0001$\u0006\u0012\u0001\u001fJ<23H\u0005Q:D/@3H\u0004\u0001\u0017\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0001%B@C1BC@/:\u0001\u001b<A7 56BA\u0001\n7<B=\u0001\u001f=<=/;7<3\u0001!F72/A3\u0001\u001b<6707B=@G\u0001\"=B3<1G\u0001/<2\u0001%3:31B7D7BG\u0001=4\u0001\u000e\u0005%C0AB7BCB32\u0001 \u0015=C;/@7<A\u0001 4@=;\u0001 \u001e75/<2\u0005\u0001 /<2\u0001 &/@53B\u0005\u0014/A32\u0001 \u0013>\u0005\n>@=/163A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\t\u0004\u0001\u0007\f\u0004\u0001\u000b\u0010\b\t\u0005\u000b\u0010\t\f\u0006\u0001\n-\r\u000f.\u0001$3<23<0/16\u0005\u001fM::3@\u0004\u0001 \u0014\u0006\u0012\u0001 \u0014C:@716\u0004\u0001 \u001d\u0006\u0012\u0001 )3743<0/16\u0004\u0001 \u001a\u0006\u0001\n-\u0002\u0013@G:\u0003/:9G:=FG.B67=1=C;/@7<A\u0004\u0001>@=13AA\u00014=@\u0001B637@\u0001>@3>/@/B7=<\u0001/< 2\u0001\nB63@/>3CB71/:\u0001/53<BA\u00011=<B/7<7<5\u0001B63;\u0006\u0001\u0017C@\u0006\u0001\"/B\u0006\u0001\u0013>>:\u0006\u0001\u0002\b\u0010\u0010\u000b\u0003\u0004\u0001\u0017 \"\u0001\n\f\u0010\u000b\u0007\n\r\u0001\u0013\b\u0001\b\u0010\u0010\u000b\u0007\u000b\t\u000e\u0006\u0001\n-\r\u0010.\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001!@/::=\u0004\u0001\u0018\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u001c\u0006\u0012\u0001#C3H/2/\u0004\u0001\u0017\u0006\u0012\u0001+/ L3H\u0004\u0001\n\u001f\u0006\u0012\u0001(7:/@\u0004\u0001%\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0001'A3\u0001=4\u0001\r\u0005AC0AB7BCB32\u0001\n\u0005>63<G:1=C;/@7 <A\u0001/A\u0001\nA3:31B7D3\u0001;=<=/;7<3\u0001=F72/A3\u0001\u0014\u00017<6707B=@A\u00014=@\u0001B@3/B7<5\u0001<3C@=2353 <\u0005\n3@/B7D3\u000127A3/A3A\u0001/<2\u0001=03A7BG\u0001/<2\u0001>@3>/@/B7=<\u0001=4\u0001<3E\u000123@7D/B7D3A \u0006\u0001\n%>/<\u0006\u0001\u0002\t\u0007\b\u0007\u0003\u0004\u0001\u0017%\u0001\t\n\u000b\n\n\u000b\u000e\u0001\u0013\b\u0001\t\u0007\b\u0007\u0007\u000e\t\u000f\u0006\u0001\u0001\n-\u000e\u0007.\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001#C3H/2/\u0004\u0001\u0017\u0006\u0012\u0001\"7117/C\u0004\u0001\u0015\u0006\u0012\u0001\u00163:=5C\u0004\u0001\u0019\u0006\u0012\u0001\n!@/::=\u0004\u0001\u0018\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0001\u0013\u0001<3E\u0001A3@73A\u0001=4\u0001\n\u0005>63<G:\u00011 =C\u0005\n;/@7<A\u0001/A\u0001>=B3<B\u0001/<2\u0001A3:31B7D3\u0001\u001f\u0013!\u0005\u0014\u00017<6707B=@A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\n\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002\u0004\u0001\u0006\u0004\u0004\f\u0004\u0001\u0004\f\u0004\u0001\n\t\r\u000f\u0005\n\t\u000e\u0007\u0006\u0001\n-\u000e\b.\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\"7117/C\u0004\u0001\u0015\u0006\u0012\u0001!@/::=\u0004\u0001\u0018\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001' @7/@B3\u0004\u0001\n\u0017\u0006\u0001%G<B63A7A\u0001/<2\u00013D/:C/B7=<\u0001=4\u0001\r\u0005;3B6G:\u0005\n\u0005>63<G:1=C;/@7<A\u0001/A\u0001>= \u0005\nB3<B\u0001/<2\u0001A3:31B7D3\u0001\u001f\u0013!\u0005\u0014\u00017<6707B=@A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002 \u0004\u0001\n\u0006\u0004\u0004\f\u0004\u0001\u0004\f\u0004\u0001\f\u0007\f\n\u0005\f\u0007\f\f\u0006\u0001\n-\u000e\t.\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001&3@I<\u0004\u0001\u0015\u0006\u0012\u0001\"J@3H\u0005\u0015/AB7::=\u0004\u0001+\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001%/<B/ </\u0004\u0001\u001e\u0006\u0012\u0001\n(7L/\u0004\u0001\u0016\u0006\u0001%G<B63A7A\u0001/<2\u0001%BC2G\u0001=4\u0001/\u0001%3@73A\u0001=4\u0001\n\u0005\u0013@G:1=C;/@7<A\u0001/A\u0001 \"=\u0005\nB3<B\u0001 /<2\u0001 %3:31B7D3\u0001 \u001f=<=/;7<3\u0001 !F72/A3\u0001 \u0014\u0001 \u001b<6707B=@A\u0006\u0001 \u0014\u0002\u0001 \u0016\u001e\u001d\u0002\u0001\n\u000f \u001e#\u0002\u0004\u0001\u0006\u0004\u0005\u0005\u0004\u0001\b\u0007\u0004\u0001\u000e\b\t\u000eP\u000e\b\n\u000e\u0006\u0001\n-\u000e\n.\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001(IH?C3H\u0005$=2@75C3H\u0004\u0001%\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001\n(7L/\u0004\u0001\u0016\u0006\u0001\u001f\u0013!\u00017<6707B=@G\u0001/1B7D7BG\u0001;=2C:/B7=<\u0011\u0001\n\u0005>63<G:1=C;/@7<A\u0001\nD3@ACA\u0001\n\u000503<H=G:1=C;/@7<A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002 \u0004\u0001\u0006\u0004\u0005\u0005\u0004\u0001\u0005\u0004\u0004\u0001\n\u000b\t\t\u000bP\u000b\t\t\u000e\u0006\u0001\n-\u000e\u000b.\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001+IL3H\u0004\u0001\u001f\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0001\n\u0005\n%C0AB7BCB32\u00011=C;/@7<A\u0001/A\u00012C/:\u00017<6707B=@A\u0001=4\u0001\u0013\u00156\u0017\u0001/<2\u0001\u001f\u0013!\u00014=@\u0001B6 3\u0001\nB@3/B;3<B\u0001=4\u0001\u0013:H637;3@NA\u000127A3/A3\u0006\u0001 \u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u000f%##)$\u0002 \u0004\u0001\u0006\u0004\u0005\u0006\u0004\u0001\u0006\u0004\u0001\n\t\b\n\u0005\t\b\u000f\u0006\u0001\n-\u000e\f.\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\u001c/<37@=\u0004\u0001\"\u0006\u0012\u0001\u0014=@53A\u0004\u0001\u0018\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001' @7/@B3\u0004\u0001\n\u0017\u0006\u0001 3E\u00016/:=53</B32\u0001\n\u0005>63<G:1=C;/@7<A\u0001/A\u0001>=B3<B\u0001/<2\u0001A3:31B7D3\u0001\n\u001f\u0013!\u0005\u0014\u00017<6707B=@A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001 \u0016\u001e\u001d\u0002\u0001 \u000f \u001e#\u0002\u0001 \u0015\u001e((\u0002 \u0004\u0001\u0006\u0004\u0005\u0004\u0004\u0001\u0005\u0003\u0004 \u0001\f\b\f\u000e\u0005\n\f\b\r\u0007\u0006\u0001\n-\u000e\r.\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001\u00183@7<=\u0004\u0001\u0019\u0006\u0012\u0001\u0015/2=<7\u0004\u0001\u0017\u0006\u0012\u0001\u001e/5C</\u0004\u0001$\u0006\u0012\u0001\u0014=@ 53A\u0004\u0001\n\u0018\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0001\u000f\u0005%C0AB7BCB32\u0005\n\u0005/@G:1=C;/@7<A\u0001/A\u0001\" =B3<B\u0001\n/<2\u0001 %3:31B7D3\u0001 \u001f\u0013!\u0005\u0014\u0001 \u001b<6707B=@A\u0011\u0001 %G<B63A7A\u0004\u0001 \"6/@;/1=:=571/:\u0001\n\u0017D/:C/B7=<\u0001/<2\u0001\u0016=197<5\u0001%BC273A\u0006\u0001 \u000f \u001e#\u0016\u001e\u001d\u000f \u001e# \u0004\u0001\u0006\u0004\u0005\u0006\u0004\u0001\n\u0004\u0001\u000b\r\u000b\u0005\n\u000b\u000e\u0007\u0006\u0001\n-\u000e\u000e.\u0001%3@@/\u0004\u0001%\u0006\u0012\u0001\u00183@7<=\u0004\u0001\u0019\u0006\u0012\u0001\u001f/B=A\u0004\u0001\u001f\u0006\u0001\u001c\u0006\u0012\u0001(IH?C3H\u0005$=2@K5C3H\u0004\u0001%\u0006\u0012\u0001\u00163: =5C\u0004\u0001\n\u0019\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0012\u0001\u0015/2=<7\u0004\u0001\u0017\u0006\u0012\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0001\u001aG2@=FG1=C;/ @\u0005\n7<A\u0001/A\u0001A3:31B7D3\u0001\u001f\u0013!\u0005\u0014\u00017<6707B=@A\u0006\u0001 \u000e!%%&\u001f\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002\u0001\u0015\u001e((\u0002 \u0004\u0001\u0006\u0004\u0005\u0006\u0004\u0001\n\u0005\u0005\u0004\u0001\t\f\u000f\u0005\t\r\b\u0006\u0001\n-\u000e\u000f.\u0001%3117\u0004\u0001\u0016\u0006\u0012\u0001\u0015/@@/2=@7\u0004\u0001%\u0006\u0012\u0001\u0014=:/A1=\u0004\u0001\u0013\u0006\u0012\u0001\u001567;3<B7\u0004\u0001\"\u0006\u0012\u0001+/<3H\u0004\u0001\u001f\u0006\u0012 \u0001\n!@BCA=\u0004\u0001\u0018\u0006\u0012\u0001\u0013:1/@=\u0004\u0001%\u0006\u0001%G<B63A7A\u0001/<2\u0001A3:31B7D3\u00016C;/<\u0001;=<=/;7<3\u0001=F72/A3\u00017<6707B7=<\u0001=4\u0001\n\u00051/@0=<G:\u0004\u0001\n\u0005/1G:\u0004\u0001/<2\u0001\n\u00051/@0=FG6G2@/H72 =\u0001\n1=C;/@7<\u000123@7D/B7D3A\u0006\u0001 \u0010)&\u0002\u0001\u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0005\u0005\u0004\u0001\u0007\t\u0004\u0001\u000b\u000f\u000b\r\u0005\u000b\u000f\f\t\u0006\u0001\n-\u000e\u0010.\u0001\u00163:=5C\u0004\u0001\u0019\u0006\u0012\u0001\"7117/C\u0004\u0001\u0015\u0006\u0012\u0001\u00183@7<=\u0004\u0001\u0019\u0006\u0012\u0001#C3H/2/\u0004\u0001\u0017\u0006\u0012\u0001\"=22/\u0004\u0001\u0019\u0006\u0012\u0001'@ 7\u0005\n/@B3\u0004\u0001\u0017\u0006\u0012\u0001(7L/\u0004\u0001\u0016\u0006\u0001%G<B63A7A\u0004\u00016C;/<\u0001;=<=/;7<3\u0001=F72/A3\u00017<6707B=@ G\u0001\n/1B7D7BG\u0001/<2\u0001;=:31C:/@\u00012=197<5\u0001ABC273A\u0001=4\u0001\n\u000563B3@=/@G:1=C;/@7<\u0001 23\u0005\n@7D/B7D3A\u0006\u0001 \u0010)&\u0002\u0001\u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0005\u0005\u0004\u0001\u0007\f\u0004\u0001\b\b\u000b\u000e\u0005\b\b\f\t\u0006\u0001\n-\u000f\u0007.\u0001\u001567;3<B7\u0004\u0001\u0018\u0006\u0012\u0001%3117\u0004\u0001\u0016\u0006\u0012\u0001\u0014=:/A1=\u0004\u0001\u0013\u0006\u0012\u0001\u001567;3<B7\u0004\u0001\"\u0006\u0012\u0001\u0019@/<3A3\u0004\u0001\u0013\u0006 \u0012\u0001\n\u001434/<7\u0004\u0001!\u0006\u0012\u0001&C@7<7\u0004\u0001\"\u0006\u0012\u0001\u0013:1/@=\u0004\u0001%\u0006\u0012\u0001!@BCA=\u0004\u0001\u0018\u0006\u0001\u001b<6707B7=<\u0001=4\u0001;= <=\u0005\n/;7<3\u0001=F72/A3A\u00010G\u00011=C;/@7<\u0005\n\u0005/1G:\u000123@7D/B7D3A\u0011\u000107=:=571/:\u0001/1B7D 7BG\u0001\n/<2\u00011=;>CB/B7=</:\u0001ABC2G\u0006\u0001 \u000e!%%&\u001f\u0002\u0001 \u0016\u001e\u001d\u0002\u0001 \u000f \u001e#\u0002\u0001 \u0015\u001e((\u0002 \u0004\u0001\u0006\u0004\u0004\b\u0004\u0001\u0004\u0007\u0004\u0001\n\n\r\u0010\u000e\u0005\n\u000e\u0007\n\u0006\u0001\n-\u000f\b.\u0001\u001567;3<B7\u0004\u0001\u0018\u0006\u0012\u0001%3117\u0004\u0001\u0016\u0006\u0012\u0001\u0014=:/A1=\u0004\u0001\u0013\u0006\u0012\u0001\u001567;3<B7\u0004\u0001\"\u0006\u0012\u0001\u00147H/@@7\u0004\u0001\u0014\u0006 \u0012\u0001\n\u0019@/<3A3\u0004\u0001\u0013\u0006\u0012\u0001\u0015/@@/2=@7\u0004\u0001%\u0006\u0012\u0001+IL3H\u0004\u0001\u001f\u0006\u0012\u0001!@/::=\u0004\u0001\u0018\u0006\u0012\u0001!@BCA=\u0004\u0001\u0018\u0006\u0012\u0001 \u0013:\u0005\n1/@=\u0004\u0001%\u0006\u0001%G<B63A7A\u0004\u0001;=:31C:/@\u0001;=23:7<5\u0004\u0001/<2\u0001A3:31B7D3\u00017<6707B=@ G\u0001/1\u0005\nB7D7BG\u0001/5/7<AB\u00016C;/<\u0001;=<=/;7<3\u0001=F72/A3A\u0001=4\u0001\n\u00051/@0=F/;72=\u0005\u000e\u0005\nAC0AB7BCB32\u00011=C;/@7<A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\f\u0004\u0001\b\u0005\u0004\u0001\b\u0010\n\f\u0005\b\u0010\u000b\t\u0006\u0001\u0001\n-\u000f\t.\u0001\u0014@M6:;/<<\u0004\u0001\u0015\u0006\u0012\u0001!=;A\u0001\u0018\u0006\u0012\u0001\u0015/@@C>B\u0004\u0001\"\u0005\u0013\u0006\u0012\u0001&3AB/\u0004\u0001\u0014\u0006\u0012\u0001\u0015/BB=\u0004\u0001\u001f\u0006\u0012\u0001\u001e3 \u0005\n=<3BB7\u0004\u0001\u0018\u0006\u0012\u0001\u0013:B=;/@3\u0004\u0001\u0015\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0001\u0015=C;/@7<A\u000123@7D/B7D3A\u0001/A\u0001 2C/:\u0001\n7<6707B=@A\u0001=4\u0001/13B6G:1=:7<3AB3@/A3\u0001/<2\u0001;=<=/;7<3\u0001=F72/A3\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\n\u000f \u001e#\u0002\u0004\u0001\u0006\u0004\u0004\u0005\u0004\u0001\u0007\u0007\u0004\n\u0001\n\b\u0010\f\u0005\n\b\u0010\u000f\u0006\u0001\n-\u000f\n.\u0001%/<B/</\u0004\u0001\u001e\u0006\u0012\u0001'@7/@B3\u0004\u0001\u0017\u0006\u0012\u0001\u0019=<HI:3H\u0005\u0016K/H\u0004\u0001\u001a\u0006\u0012\u0001,/5=BB=\u0004\u0001\u0019\u0006\u0012\u0001%=B=\u0005\n!B3@=\u0004\u0001$\u0006\u0012\u0001\u001fJ<23H\u0005Q:D/@3H\u0004\u0001\u0017\u0006\u0001\u0013\u0001#%\u0013$\u0001;=23:\u00014=@\u0001 !$\u0001'!\"!\u001c%\u0001A1@33<\u0005\n7<5\u0001=4\u0001\u001f\u0013!\u0005\u0013\u00017<6707B=@A\u0006\u0001\"@3271B7=<\u0004\u0001AG<B63A7A\u0004\u0001/<2\u000107=:=571/:\u0001 /A\u0005\nA/G\u0001=4\u0001<=D3:\u00011=C;/@7<A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\t\u0004\u0001\u0007\f\u0004\u0001\b\b\u000b\u0010\u0005\b\b\f\r\u0006\u0001\n-\u000f\u000b.\u0001\u00147<2/\u0004\u0001\u0015\u0006\u0012\u0001)/<5\u0004\u0001\u001c\u0006\u0012\u0001\"7A/<7\u0004\u0001\u001e\u0006\u0012\u0001\u0015/117/\u0004\u0001\u0015\u0006\u0012\u0001\u0015/@=BB7\u0004\u0001\u0013\u0006\u0012\u0001%/:D/ B7\u0004\u0001\"\u0006\u0012\u0001\n\u00172;=<2A=<\u0004\u0001\u0016\u0006\u0017\u0006\u0012\u0001\u001f/BB3D7\u0004\u0001\u0013\u0006\u0001%B@C1BC@3A\u0001=4\u00016C;/<\u0001;=<=/;7<3\u0001\n=F72/A3\u0001\u0014\u00011=;>:3F3A\u0001E7B6\u0001A3:31B7D3\u0001<=<1=D/:3<B\u00017<6707B=@A\u0011\u0001A/47 \u0005\n</;723\u0001/<2\u00011=C;/@7<\u0001/</:=5A\u0006\u0001 \u0014\u0002\u0001\u0016\u001e\u001d\u0002\u0001\u000f \u001e#\u0002 \u0004\u0001\u0006\u0004\u0004\n\u0004\u0001\b\u0003\u0004\u0001\f\u000f\u000b\u000f\u0005\n\f\u000f\f\t\u0006\u0001\n\u0018\u001b\u001c145\b\u001a\u0011\u001f\u001d\u0016\u0019\u0014\u0001\u001a\u0019\u0001\u000b\u0013 \u0001\n\u001a\u0019\u001a\u000f\u0018\u0016\u0019\u0013\u0001\f!\u0016\u0012\u000f\u001d\u0013\u0001\t\u0019\u0015\u0016\u0010\u0016\u001e\u001a\u001c\u001d\u0001 \u0007\u001f\u001c\u001c\u0013\u0019\u001e\u0001\r\u001a\u001b\u0016\u0011\u001d\u0001\u0016\u0019\u0001 \n\u0013\u0012\u0016\u0011\u0016\u0019\u000f\u0017\u0001\u0007\u0015\u0013\u0018\u0016\u001d\u001e\u001c\"\u0002\u0001 \u0005\u0003\u0004\u0005\u0002\u0001\u000e\u001a\u0017\u0003\u0001\u0005\u0006\u0002\u0001\u000b\u001a\u0003\u0001\u0006\u0004\u0001\u0001\u0001\u0001 \u0005\u0005\u0006\f\u0001\n.\u0011\u000e/\u0001\u00171=@?C\u0006'?9=9<\u0005\u0001!\u0007\u0014\u0001#B1<<?\u0005\u0001\u001a\u0007\u0014\u0001&1>D1>1\u0005\u0001 \u0007\u0014\u0001(B91BD5\u0005\u0001\u0019\u0007\u0001&I>D85C 9C\u0001\n1>4\u0001F1C?B5<1H1>D\u000113D9F9DI\u0001?6\u0001>5G\u00013?E=1B9>\u00011>4\u00016EB?3?E=1B9>\u000145\u0006\nB9F1D9F5C\u0007\u0001\u0010#'')!\u0004\u0001\u0018 \u001f\u0004\u0001\u0011\" %\u0004\u0001\u0017 ++\u0004\u0001 \u0005\u0003\u0003\u0005\u0005\u0001\u0006\u0007\u0005\u0001\u0010\u0011\f\u0006\u0010\u0011\u000f\u0007\u0001\n.\u0011\u000f/\u0001\u001b1?\u0005\u0001&8E\u0006'\u0007\u0014\u0001 9\u0005\u0001\u0017\u0014\u0001*1>7\u0005\u0001,\u0014\u0001!1\u0005\u0001\u001e9>7\u0006\u001e\u0014\u0001*1>7\u0005\u0001\u0017\u0014\u0001-81>7\u0005\u0001\u001e9>7\u0006\n*\u0007\u0001\"2\u0017<\u000e\u000631D1<IJ54\u0005\u0001C?<F5>D\u00066B55\u0005\u0001?>5\u0006@?D\u0001CI>D85C9C\u0001?6\u00013?E=1B9> C\u0007\u0001\n\u001b.&+\"\u0004\u0001\u0011'%%,&\u0004 \u0001\u0005\u0003\u0004\u0004\u0005\u0001\t\u0006\u0005\u0001\n\r\u0011\u000f\u0006\n\r\u0012\n\u0007\u0001\n.\u0011\u0010/\u0001&EB5C8\u0001\u001fE1B=\u0005\u0001\u0016\u0007\u0014\u0001)5>E\u0001!1481F\u0005\u0001\u001e\u0007\u0014\u0001)9:1I1\u0001 1H=9\u0005\u0001&\u0007\u0014\u0001%1:9D81\u0005\u0001\u0016 \u0007\u0014\u0001\n'89BE@1D89\u0001%544I\u0005\u0001,\u0007\u0014\u0001\"1BC9=81\u0001%544I\u0005\u0001$\u0007\u0014\u0001\u0001\u0015\u0007\u0001\u0017B??;C\u0005\u0001$\u0007\u0001\u0015\u0007\u0001\n\u0019H@549D9?EC\u0001 $538=1>>\u0001 3?>45>C1D9?>\u0001 2I\u0001 EC9>7\u0001 29?457B1412<5\u0001\n35<<E<?C5\u0001CE<6EB93\u00011394\u00011C\u00011\u0001C?<94\u00011394\u000131D1<ICD\u0007 \u0001\u001b.&+\"\u0004\u0001\u0011'%%,&\u0004 \u0005\u0001\n\u0005\u0003\u0004\u0003\u0005\u0001\t\u0005\u0005\u0001\f\f\u000e\u0011\u0006\f\f\u000f\r\u0007\u0001\n.\u0011\u0011/\u0001\u001fE=1B\u0005\u0001)\u0007\u0014\u0001'?=1B\u0005\u0001&\u0007\u0014\u0001$1D5<\u0005\u0001%\u0007\u0014\u0001,?EC16\u0005\u0001\u0015\u0007\u0014\u0001$1B=1B\u0005\u0001)\u0007\u0001&\u0007\u0014\u0001!1< \u0006\n8?DB1\u0005\u0001&\u0007\u0001)\u0007\u0001\u001a5\u0017<\f\u000631D1<IJ54\u0001$538=1>>\u0001CI>D85C9C\u0001?6\u00013?E=1B9>C\u00019> \u0001\n9?>93\u0001<9AE94C\u0007\u0001 \u001b.&+\"\u0004\u0001\u0011'%%,&\u0004 \u0005\u0001\u0005\u0003\u0003\u000b\u0005\u0001\b\r\u0005\u0001\u000b\u000f\r\u000f\u0006\u000b\u000f\u000e\r\u0007\u0001\n.\u0011\u0012/\u0001%544I\u0005\u0001,\u0007\u0001'\u0007\u0014\u0001&?>1B\u0005\u0001)\u0007\u0001\"\u0007\u0014\u0001\u0017B??;C\u0005\u0001$\u0007\u0001\u0015\u0007\u0014\u0001\u00181C1B9\u0005\u0001$\u0007\u0001\u001f\u0007\u0014\u0001%544I \u0005\u0001$\u0007\u0001\n\"\u0007\u0014\u0001%1:9D81\u0005\u0001\u0016\u0007\u0001\u00175B93\u00011==?>9E=\u0001>9DB1D5\u0001\u0003\u0017\u0015\"\u0004\u0013\u0001\u0015>\u00015669395>D\u000131D1 \u0006\n<ICD\u00016?B\u0001D85\u00013?E=1B9>\u0001CI>D85C9C\u0001F91\u0001$538=1>>\u00013?>45>C1D9?>\u0001EC9>7 \u0001\n3?>F5>D9?>1<\u0001851D9>7\u00011>4\u0001=93B?G1F5\u00019BB1491D9?>\u0007\u0001 \u001b.&+\"\u0004\u0001\u0011'%%,&\u0004 \u0005\u0001\n\u0005\u0003\u0003\u000b\u0005\u0001\b\r\u0005\u0001\u000b\t\u0011\u000b\u0006\u000b\t\u0011\u0011\u0007\u0001\n.\u0012\t/\u0001'9=?>5>\u0005\u0001\u001e\u0007\u0001!\u0007\u0014\u0001\"95=9>5>\u0005\u0001%\u0007\u0001 !\u0007\u0014\u0001&1B59<1\u0005\u0001#\u0007\u0014\u0001)19>9?D1<?\u0005\u0001$\u0007\u0014\u0001\n!?9<1>5>\u0005\u0001\u0019\u0007\u0014\u0001\u0015E<1C;1B9\u0005\u0001$\u0007\u0001\u001c\u0007\u0001&I>D85C9C\u00011>4\u00011>D9\u00069>6<1==1D?BI\u0001\n56653DC\u0001?6\u00011\u0001C5B95C\u0001?6\u0001>?F5<\u0001\u0010\u00068I4B?HI3?E=1B9>\u000145B9F1D9F5C\u0007\u0001 \u0012,)\u0004\u0001\u0016\u0004\u0001\n\u0018 \u001f\u0004\u0001\u0011\" %\u0004 \u0005\u0001\u0005\u0003\u0004\u0004\u0005\u0001\t\u000b\u0005\u0001\f\u0011\r\u000e\u0006\f\u0011\u000e\t\u0007 \u0001\n.\u0012\n/\u0001\u00161;8389>91>\u0005\u0001%\u0007\u0014\u0001'5BB95B\u0005\u0001\u001a\u0007\u0014\u0001\u001f9B;91381B91>\u0005\u0001&\u0007\u0014\u0001%5C385\u0006%97?>\u0005\u0001 !\u0007\u0014\u0001\n\u0016?E38?EH\u0005\u0001\u001a\u0007\u0014\u0001\u0017KBL45\u0005\u0001\u0019\u0007\u0001&I>D85C9C\u00011>4\u0001B5<1D9F5\u000129>49>7\u00011669>9D I\u0001D?\u0001\n8E=1>\u0001CD5B?94\u0001B535@D?BC\u0001?6\u0001CE2CD9DED54\u0001\f\u00061BI<?HI3?E=1B9>C\u0007\u0001 \u0015$\u0001\u0013\u001d)\u0003\n%\u001d\u001e'\u0005\u0001\u0005\u0003\u0003\u0006\u0005\u0001\n\r\u0005\u0001\n\u000b\t\n\u0006\n\u000b\t\u0010\u0007\u0001\n.\u0012\u000b/\u0001\u00181BF1D;1B\u0005\u0001\"\u0007\u0001\u0016\u0007\u0014\u0001\u00185?BE;8;1B\u0005\u0001\u0015\u0007\u0001%\u0007\u0014\u0001\u001689<1B5\u0005\u0001&\u0007\u0001)\u0007\u0014\u0001%1ED\u0005\u0001\u0018\u0007\u0001\u001b \u0007\u0014\u0001\n&\n1<E>;85\u0005\u0001!\u0007\u0001!\u0007\u0001\u001d?>93\u0001<9AE94\u0006=5491D54\u0001CI>D85C9C\u0001?6\u00013?E=1B9>\u0006\f\u0006\n31B2?HI<93\u00011394C\u0001F91\u0001\u001f>?5F5>175<\u00013?>45>C1D9?>\u0001?6\u0001!5<4BE=\u0002C\u00011394 \u0001\nG9D8\u0001 ?BD8?\u00068I4B?HI1BI<\u0001 1<458I45C\u0007\u0001 \u001b.&+\"\u0004\u0001 \u0011'%%,&\u0004 \u0005\u0001\u0005\u0003\u0003\u000b\u0005\u0001\b\r\u0002\u0001\n\f\u000e\t\u0011\u0006\f\u000e\n\f\u0007\u0001\n.\u0012\f/\u0001\u001aB5B5\u0005\u0001&\u0007\u0014\u0001'895BI\u0005\u0001)\u0007\u0014\u0001\u00165CC?>\u0005\u0001'\u0007\u0001!93B?G1F5\u00011335<5B1D9?>\u0001?6\u0001D85 \u0001\n$538=1>>\u0001B513D9?>\u0001?>\u00017B1@89D5\b=?>D=?B9<<?>9D5\u0001\u001f\n\t\u0013\u00011@@<931D9?>\u0001 D?\u0001\nD85\u0001@B5@1B1D9?>\u0001?6\u0001\r\u0006CE2CD9DED54\u0001\u0010\u00061=9>?3?E=1B9>C\u0007\u0001 \u001c +)\u001d\" \u001f)'&\u0001\n\u0017 ++\u0004\u0005\u0001\u0005\u0003\u0003\u0004\u0005\u0001\t\u0007\u0005\u0001\u000b\u0010\u0012\n\u0006\u000b\u0010\u0012\r\u0007\u0001\u0001\n.\u0012\r/\u0001 1<\u0001\u001881B\u0005\u0001,\u0007\u0014\u0001&\u0007\u0014\u0001&9>78\u0005\u0001&\u0007\u0014\u0001%19\u0005\u0001)\u0007\u0001\u001f\u0007\u0001\u0015\u0001?>5\u0006@?D\u0001.\u0016=9=/#\u001c\u0006=5491D54\u0001CI>D85C9C\u0001?6\u0001\f\u000625>J1=94?3?E=1B9>C\u0007\u0001 \u001c +)\u001d\" \u001f)'&\u0001\u0017 ++\u0004 \u0005\u0001\n\u0005\u0003\u0003\f\u0005\u0001\n\u0005\u0005\u0001\u000b\u000b\t\u0011\u0006\u000b\u000b\n\u000b\u0007\u0001\n.\u0012\u000e/\u0001!1<9\u0005\u0001 %\u0007\u0001 &\u0007\u0014\u0001 \u001e?C89\u0005\u0001 $\u0007\u0001 $\u0007\u0001 (C56E<\u0001 CI>D85C5C\u0001 ?6\u0001 @B5>I<1D54\u0006\u0001 1>4\u0001\n@IB1>?\u0006\f\u00061BI<3?E=1B9>C\u0007\u0001 \u001b.&+\"\u0001\u0011'%%,&\u0004 \u0005\u0001\u0005\u0003\u0003\u0004\u0005\u0001\b\u0006\u0005\u0001\u000b\u0010\u000e\f\u0006\u000b\u0010\u000f\t\u0007\u0001\n.\u0012\u000f/\u0001)1<9J1458\u0005\u0001\u001c\u0007\u0014\u0001&8?3;B1F9\u0005\u0001\u0015\u0007\u0014\u0001\u001c5B1F9\u0005\u0001!\u0007\u0001!\u0007\u0014\u0001\u001b8149=\u0005\u0001\u001c\u0007\u0001\u0015\u0007\u0001!9\u0006\n3B?G1F5\u00069>4E354\u00019>\u0001C9DE\u0001*9DD97\u0001B 513D9?>\u0001?6\u0001C1<93I<1<458I45C\u0001G9D8\u0001\n5D8I<\u000138<?B?135D1D5\u00011>4\u0001DB9@85>I<@8?C@89>5\u00019>\u0001C?<F5>D<5CC\u0001CICD5=\u0007\u0001 \u0016\u0004\u0001\n\u0011\" %\u0004\u0001\u001a *\u0004\u0001\u001b.&'(\u0004 \u0005\u0001\u0005\u0003\u0003\u0006\u0005\u0001\u0006\u0006\u0005\u0001\u0010\n\u0011\u0006\u0010\u000b\t\u0007\u0001.\u0012\u0010/\u0001!1<9\u0005\u0001%\u0007\u0001&\u0007\u0014\u0001\u001e?C89\u0005\u0001$\u0007\u0001$\u0007\u0001(C56E<\u0001CI>D85C5C\u0001?6\u0001@B5>I<1D54\u00013?E=1B 9>C\u0001\n1>4\u0001 @IB1>?\u0006\f\u00061BI<3?E=1B9>C\u0007 \u0001 \u001b.&+\"\u0004\u0001 \u0011'%%,&\u0004 \u0005\u0001\u0005\u0003\u0003\u0004\u0005\u0001\b\u0006\u0005\u0001 \u000b\u0010\u000e\f\u0006\n\u000b\u0010\u000f\t\u0007\u0001\u0001\n.\u0012\u0011/\u0001(@148I1I\u0005\u0001$\u0007\u0001\u001f\u0007\u0014\u0001\u001fE=1B\u0005\u0001$\u0007\u0001\u0015\u0001>?F5<\u0001CI>D85C9C\u0001?6\u00013?E=1B9>C\u00015=\u0006\n@<?I9>7\u0001DB9@85>I<\u0003 \u0001\u000631B2?HI=5D8I<5>5\u0004@8?C@8?B1>5\u00019=941J?<945\u00011C\u0001\n1\u0001\u0017\u0006\u000b\u0001CI>D8?>\u0007\u0001 \u001c +)\u001d\" \u001f)'&\u0001\u0017 ++\u0004 \u0005\u0001\u0005\u0003\u0003\f\u0005\u0001\n\u0005\u0005\u0001\u000b\f\u000f\u0006\u000b\f\u0011\u0007\u0001\n.\u0012\u0012/\u0001\u001c1B1I1=1\u0005\u0001'\u0007\u0014\u0001\u001f1DCE>?\u0005\u0001\u001f\u0007\u0014\u0001\"9C89?;1\u0005\u0001\u001c\u0007\u0014\u0001\u001aE:99\u0005\u0001!\u0007\u0014\u0001\"9C89D1\u0005\u0001,\u0007 \u0014\u0001\n\u001dC899\u0005\u0001\u001c\u0007\u0014\u0001\u001f1>5;?\u0005\u0001,\u0007 \u0001\u0015\u00013?>F5>95>D\u0001CI>D85C9C\u0001?6\u00011\u0001C9=@<5\u00013?E=1B9>\u0001\n6B?=\u0001 C1<93I3<1<458I45\u0001 1>4\u0001 *9DD97\u0001 B5175>D\u0007\u0001 \u001d\u0007\u0001 \u0015\u0001 CI>D85C9C\u0001 ?6\u0001\n=5D8?HI\u0006\u00011>4\u00018I4B?HI3?E=1B9>C\u0007\u0001 \u0014 + )'\u001e.\u001e$ * \u0005\u0001\u0004\f\f\u0007\u0005\u0001\b\u000e\u0007\u0005\u0001\u000f\n\f\u0006\n\u000f\u000b\u000b\u0007\u0001\u0001\n.\n\t\t/\u0001\u0015E49C9?\u0005\u0001\u0018\u0007\u0014\u0001!5CC1?E49\u0005\u0001&\u0007\u0014\u0001\u0016B9?>\u0005\u0001\u001e\u0007\u0006\u0018\u0007\u0014\u0001\u0015<1=9\u0005\u0001!\u0007\u0001\u0015\u0001C9=@<5\u0001CI >\u0006\nD85C9C\u0001 ?6\u0001 6E>3D9?>1<9J54\u0001 \f\u00062B?=?3?E=1B9>C\u0001 2I\u0001 1\u0001?>5\u0006@?D\u0001 D8B55\u0006\n3?=@?>5>D\u0001B513D9?>\u0007\u0001 \u0012,)\u0004\u0001 \u0016\u0004\u0001 \u0019)!\u0004\u0001 \u0011\" %\u0004 \u0005\u0001\u0005\u0003\u0004\u0003\u0005\u0001\u0003\u000b\u0004\u0005\u0001\n\t\r\u000f\u0006\n\t\u000e\n\u0005\u0001\n&\n\t\r\u000f\b\n\u0006&\n\t\r\u000f\b\n\u0011\u0007\u0001\n.\n\t\n/\u0001\u001f?D1>9\u0005\u0001!\u0007\u0014\u0001,1=1=?D?\u0005\u0001\u001f\u0007\u0014\u0001#I1=141\u0005\u0001\u001e\u0007\u0014\u0001\u001aE:9G1B1\u0005\u0001,\u0007\u0014\u0001\u001f9D1=EB1\u0005\u0001\n'\u0007\u0001\u0015\u00013?>F5>95>D\u0001 \u001d\"\u0019\u001e\u0015\u0013\u001d\u0016\u001d\u0001?6\u00013?E=1B9>C\u00012I\u0001@1<<149E=\u0003\u001d\u001d\u0004 \u000131D1<IJ54\u0001\nB513D9?>\u0001?6\u0001@85>?<C\u0001G9D8\u0001@B?@9?<93\u00011394C\u0007\u0001 \u001b.&+\" *#*\u0005\u0001\u0005\u0003\u0003\u0007\u0005\u0001\u000e\u0005\u0001\n\r\u000f\u000f\u0006\n\n\r\u0010\t\u0007\u0001\n.\n\t\u000b/\u0001 9\u0005\u0001\u001f\u0007\u0014\u0001-5>7\u0005\u0001,\u0007\u0014\u0001\"5E5>CG1>45B\u0005\u0001\u0016\u0007\u0014\u0001'E>75\u0005\u0001\u001e\u0007\u0001\u0015\u0007\u0001&5AE5>D91<\u0001$4\u0001\n\u0003\u001d\u001d\u0004\u0006\u0001$4\u0001\u0003\t\u0004\u000131D1<IC9C\u00016?B\u0001D85\u0001B1@94\u0001CI>D85C9C\u0001?6\u00013?E=1B9>C\u0007\u0001 \u0016\u0004\u0001\u0019)!\u0004\u0001\n\u0011\" %\u0004\u0005\u0001\u0005\u0003\u0003\b\u0005\u0001\f\u0005\u0005\u0001\u000f\u000e\n\u000e\u0006\u000f\u000e\n\u0011\u0007\u0001\n.\n\t\f/\u0001\u001a5B>1>45C\u0005\u0001'\u0007\u0001\u0015\u0007\u0014\u0001\u00171BF1<8?\u0005\u0001%\u0007\u0001\u0017\u0007\u0001\u0017\u0007\u0014\u0001\u001b?>31<F5C\u0005\u0001'\u0007\u0001!\u0007\u0001\u0018\u0007\u0014\u0001\u0017?CD 1\u0005\u0001\n$\u0007%\u0007\u0001%\u0007\u0001\u0015\u0001D1>45=\u0001@1<<149E=\u000631D1<IJ54\u0001\u001c53;\u0006<13D?>9J1D9?>\u0001D8B?E78 \u0001\nD85\u0001B513D9?>\u0001?6\u0001?BD8?\u00069?4?@85>?<C\u0001G9D8\u0001 \u0002\u0006CE2CD9DED54\u000113BI<1D5C\u0013\u0001CI>\u0006\nD85C9C\u0001?6\u0001\r\u0005\u000f\u0006CE2CD9DED54\u00013?E=1B9>C\u0007 \u0001\u001c +)\u001d\" \u001f)'&\u0001\u0017 ++\u0004 \u0005\u0001\u0005\u0003\u0003\u000b\u0005\u0001\t\u000e\u0005\u0001\n\f\f\u000b\u000b\u0006\f\f\u000b\u000e\u0007\u0001\n.\n\t\r/\u0001&389545<\u0005\u0001!\u0006&\u0007\u0014\u0001\u0016B958>\u0005\u0001\u0017\u0007\u0001\u0015\u0007\u0014\u0001\u00161E5B<5\u0005\u0001$\u0007\u0001&9>7<5\u00063?=@?E>4\u0001<92B 1B\u0006\n95C\u0001?6\u0001?B71>93\u0001=1D5B91<C\u0013\u0001@1B1<<5<\u0001CI>D85C9C\u00011>4\u0001C3B55>9>7\u0001?6\u00016 <E?B5C\u0006\n35>D\u00014I5C\u0007\u0001 \u000f&! -\u0004\u0001\u0011\" %\u0004\u0001\u0015&+\u0004\u0001\u0012\u001f#+\u0004 \u0005\u0001\u0005\u0003\u0003\u0004\u0005\u0001\t\u0005\u0005\u0001\r\u000f\u0010\u0010\u0006\r\u000f\u0011\t\u0007\u0001\n.\n\t\u000e/\u0001!1D?C\u0005\u0001!\u0007\u0001\u001e\u0007\u0014\u0001)1JAE5J\u0006%?4B97E5J\u0005\u0001&\u0007\u0014\u0001\u0016?B75C\u0005\u0001\u001a\u0007\u0014\u0001&1>D1>1\u0005\u0001 \u0007\u0014\u0001\n(B91BD5\u0005\u0001\u0019\u0007\u0001&I>D85C9C\u0001?6\u0001\f\u00061BI<3?E=1B9>C\u0001F91\u0001&EJE;9\u00063B?CC\u00063?E@< 9>7\u0001\nB513D9?>C\u0001?6\u0001\f\u000638<?B?3?E=1B9>\u0007\u0001 \u001c +)\u001d\" \u001f)'&\u0001\u0017 ++\u0004 \u0005\u0001\u0005\u0003\u0004\u0004\u0005\u0001\n\u0007\u0005\u0001\n\u000b\u000b\u000e\u0006\n\n\u000b\u000b\u0010\u0007\u0001\n.\n\t\u000f/\u0001%1?\u0005\u0001!\u0007\u0001 \u0007\u0001\"\u0007\u0014\u0001)5>;1D5C8\u0005\u0001)\u0007\u0014\u0001\u001e1481F\u0005\u0001\u0018\u0007\u0001\"\u0007\u0001$1<<149E=\u000631D1<IJ54 \u0001\nCI>D85C9C\u0001?6\u0001\r\u00061BI<3?E=1B9>C\u0001EC9>7\u0001DB91BI<29C=ED8\u00013?=@?E>4C\u00011C\u0001\n1D?=\u00065669395>D\u0001=E<D93?E@<9>7\u0001?B71>?=5D1<<93\u0001>E3<5?@89<5C\u0007\u0001 \u0012,)\u0004\u0001\u0016\u0004\u0001\n\u0019)!\u0004\u0001\u0011\" %\u0004 \u0005\u0001\u0005\u0003\u0004\u0003\u0005\u0001\u0007\u0005\u0005\u0001\f\u0012\r\u000e\u0006\f\u0012\u000e\u000e\u0007\u0001\n.\n\t\u0010/\u0001*E\u0005\u0001\u001e\u0007\u0014\u0001-81>7\u0005\u0001 \u0007\u0014\u0001+91\u0005\u0001\u001c\u0006\u001b\u0007\u0001$1<<149E=\u000631D1<IJ54\u0001&EJE;9\u0006!9I1EB1 \u0001\n3?E@<9>7C\u0001 ?6\u0001 @?D1CC9E=\u0001 1BI<\u0001 DB96<E?B?2?B1D5C\u0001 G9D8\u0001 \r\u0006\nD?CI<?HI3?E=1B9>C\u0001?B\u0001\r\u0006D?CI<?HIAE9>?<9>\u0006\u000b\u0003\n\u001c\u0004\u0006?>5\u0007\u0001 \u001c +)\u001d\" \u001f)'&\u0001\n\u0017 ++\u0004\u0005\u0001\u0005\u0003\u0003\t\u0005\u0001\t\f\u0005\u0001\n\u000e\u000b\u000e\u0006\n\u000e\u000b\u0011\u0007\u0001\u0001\n.\n\t\u0011/\u0001-81>7\u0005\u0001 91>7\u0014\u0001!\u0007\u0001'\u0007\u0014\u0001\u001a1>\u0005\u0001%\u0007\u0001\u0015\u0007\u0014\u0001*E\u0005\u0001\u001e\u0007\u0001\u001b5>5B1<\u00011>4\u00015669395>D\u0001B ?ED5\u0001\n6?B\u0001D85\u0001CI>D85C9C\u0001?6\u0001\f\u0005\r\u000649CE2CD9DED54\u00013?E=1B9>C\u0001F91\u0001$4\u000631D1<IJ 54\u0001\nC9D5\u0006C5<53D9F5\u00013B?CC\u00063?E@<9>7\u0001B513D9?>C\u0007 \u0001 \u0016\u0004\u0019)!\u0004\u0001 \u0011\" %\u0004 \u0005\u0001\u0005\u0003\u0003\n\u0005\u0001\f\u0007\u0005\u0001\n\u0010\u000b\u0010\u0012\u0006\u0010\u000b\u0011\u000f\u0007\u0001\n\u0001\n\u0001\n\u0011\u0015\u0013\u0015\u0017\u001e\u0015\u0014\r\u0001\u0010\u0012\u001a\u0013\u0016\u0001\u0005\u0003\u0002\u0001\u0005\u0003\u0004\u0005\u0001 \u0011\u0015\u001e\u0017\u001b\u0015\u0014\r\u0001\u000f\u001d\u0018\u0015\u0001\u0004\b\u0002\u0001\u0005\u0003\u0004\u0005\u0001 \u000e\u0013\u0013\u0015\u0019\u001c\u0015\u0014\r\u0001\u000f\u001d\u0018\u0015\u0001 \u0004\u000b\u0002\u0001\u0005\u0003\u0004\u0005\u0001\n\u0001\n\u0018\u001b\u001d146MAO inhibitory activity modulation: 3-Phenylcoumarins versus\n3-benzoylcoumarins\nMaria Jo\u00e3o Matosa, Saleta Vazquez-Rodrigueza, Eugenio Uriartea, Lourdes Santanaa, Dolores Vi\u00f1ab,\u21d1\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 5 April 2011Revised 18 May 2011Accepted 20 May 2011\nAvailable online 30 May 2011\nKeywords:\nPerkin reaction\nKnoevenagel reaction\n3-Phenylcoumarins3-BenzoylcoumarinsMAOI activityComparative studyabstract\nWith the aim of \ufb01nding the structural features for the human MAO inhibitory activity and selectivity, in\nthe present communication we report the synthesis, pharmacological evaluation and a comparative\nstudy of a new series of 3-phenylcoumarins (compounds 1\u20134) and 3-benzoylcoumarins (compounds\n5\u20138). A bromo atom and a methoxy/hydroxy substituent were introduced in these scaffolds, at six and\neight positions of the coumarin moiety, respectively. The synthesized compounds 1\u20138 were evaluated\nas MAO-A and B inhibitors using R-( /C0)-deprenyl and iproniazide as reference compounds. The presence\nor absence of a carbonyl group between the coumarin and the phenyl substituent in 3 position remarks,\nrespectively, the MAO-A or MAO-B inhibitory activity. Some of the new compounds showed MAO-B\ninhibitory activities in the low nanomolar range. Compound 2(IC50= 1.35 nM) showed higher inhibitory\nactivity than the R-( /C0)-deprenyl (IC 50= 19.60 nM) and higher MAO-B selectivity, with more than 74,074-\nfold inhibition level, respecting to the MAO-A isoform.\n/C2112011 Elsevier Ltd. All rights reserved.\nCoumarins, chalcone and their natural and/or synthetic deriva-\ntives are biologically interesting compounds because of their struc-\ntural diversity. Due to this variability, these heterocyclic\ncompounds occupy an important role not only in the Organic\nChemistry but also in the Medicinal Chemistry realm.1\u20136They are\ndescribed as anticancer, anti-in\ufb02ammatory, antimicrobial, andantioxidant agents.\n7\u201316A number of studies pay special attention\nto coumarin derivatives as monoamine oxidase (MAO)17\u201323inhibi-\ntors. Recently, chalcone structure has also been identi\ufb01ed as a valid\nscaffold for monoamine oxidase inhibitors (MAOI).24Therefore, re-\ncent \ufb01ndings reveal that MAO-A and MAO-B af\ufb01nity and selectivitycan be ef\ufb01ciently modulated by appropriate substitutions in differ-\nent positions of the coumarin and chalcone moiety (Fig. 1 ).\n19,25\u201327\nMAO is a FAD-containing enzyme (\ufb02avoenzyme) bound to the\nouter mitochondrial membrane in neuronal, glial and many other\ncells.28,29Two isoforms namely as MAO-A and MAO-B have been\nidenti\ufb01ed based on their amino acid sequences, three-dimensionalstructure, substrate preference and inhibitor selectivity.\n30,31These\nisoenzymes are responsible for the oxidative deamination of neu-rotransmitters and dietary amines. Therefore, they are responsible\nfor the regulation of intracellular levels of biogenic amines in the\nbrain and the peripheral tissues.\n32,33MAO-B preferentially deami-\nnates phenylethylamine and benzylamine, while MAO-A has ahigher af\ufb01nity for noradrenaline and serotonin.\n34,35Despite ofthese differences, dopamine and tyramine are common substratesfor both isoforms. These properties determine the pharmacological\ninterest of MAOIs. Selective and irreversible MAO-B inhibitors,\nsuch as selegiline (R-( /C0)-deprenyl) and rasagiline are useful com-\npounds for the treatment of Parkinson\n36,37and Alzheimer\u2019s\ndiseases.38,39Selective MAO-A inhibitors, such as clorgyline\n(irreversible) and moclobemide (reversible), are useful for thetreatment of neurological disorders, such as depression and anxi-\nety.\n40,41All these \ufb01ndings have led us to an intensive search for\nnovel, selective and ef\ufb01cient MAO inhibitors.\nWith the aim of \ufb01nding novel and selective MAO-B inhibitors,\nwe have previously synthesized 3-arylcoumarin derivatives inwhich both the coumarin nucleus and a 3-phenyl ring were differ-\nently substituted. The experimental data show that those com-\npounds are potent and selective MAO-B inhibitors.\n20\u201323In\nparticular, the 6,8-disubstituted coumarins proved to be very inter-esting derivatives.\n22Based on the previous 3-phenylcoumarins\nexperimental results, in this paper we describe a new project witha comparative study between 3-phenylcoumarins (compounds\n1\u20134) and 3-benzoylcoumarins (compounds 5\u20138), which are\nOO\nO\nFigure 1. Chemical structures of coumarin and trans -chalcone.\n0960-894X/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2011.05.074\u21d1Corresponding author.\nE-mail address: mdolores.vina@usc.es (D. Vi\u00f1a).Bioorganic & Medicinal Chemistry Letters 21 (2011) 4224\u20134227\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.el sevier.com/locate/bmcl\n\u0018\u001b\u001e147interesting semi-rigid chalcones with the a,b-unsaturated double\nbond included in the coumarin skeleton (Scheme 1 ).\nThe 6-bromo-8-methoxycoumarins42were ef\ufb01ciently synthe-\nsized by Perkin43\u201345(1and2) and Knoevenagel46,47(5and6) reac-\ntions. The hydroxy derivatives (3 ,4,7and8)42were obtained by\ntwo different hydrolysis reactions,48\u201350according to the synthetic\nprotocol outlined in Scheme 1 . Treatment of the corresponding sal-\nicylaldehyde and the conveniently substituted phenylacetic acid\nwith N,N\u2019-dicyclohexylcarbodiimide (DCC) as dehydrating agent,\nin dimethyl sulfoxide (DMSO) at 110 /C176C during 24 h, afforded the\n3-phenylcoumarins 1and 2. The consequent hydrolysis of 1and\n2in acetic acid and acetic anhydride, with hydriodic acid 57%, for\n4 h, yielded the hydroxy derivatives 3and 4.42The synthesis of\nthe 3-benzoylcoumarins 5and6was performed via condensation\nof the conveniently substituted salicylaldehyde with the corre-\nsponding b-ketoester, in ethanol at re\ufb02ux temperature for 5 or\n2 h respectively, using piperidine as basic catalyst. The resulting\nmethoxy derivatives were treated with boron tribromide at 80 /C176C\nfor 48 h, to give the corresponding hydroxy derivatives 7and 8.Starting from the same salicylaldehyde, we can afford two series,\ndiffering just in the presence (compounds 5\u20138) or absence (com-\npounds 1\u20134) of a carbonyl group between the phenyl substituent\nat the 3 position and the coumarin scaffold.\nThe inhibitory MAO activity of compounds 1\u20138 was evaluated\nin vitro by the measurement of the enzymatic activity of human re-\ncombinant MAO isoforms expressed in BTI insect cells infected\nwith baculovirus.51Subsequently, the IC 50values and MAO-B\nselectivity indexes [IC 50(MAO-A)]/[IC 50(MAO-B)] for inhibitory ef-\nfects of both new types of compounds and reference inhibitors\nwere calculated (Table 1 ).51\u201353\nIn the present communication, the effect of the presence or the\nabsence of a carbonyl group between the coumarin and the 3-phe-\nnyl ring is studied. Substituents and their positions in the 3-phe-\nnylcoumarin nucleus have been selected based on previous\nresults which showed very high MAOI activity for some deriva-\ntives. It was shown that introduction of both bromo and methoxy\nsubstituents at 6 and 8 positions respectively (compounds 1and2)\nenhances the MAO-B inhibitory properties (potency and selectiv-\nity) of the described 3-phenylcoumarins, comparing to some of\nthe other previously described compounds.20\u201322In addition, the\nintroduction of a substituent in the para position of the 3-phenyl\nring might help to improve the activity. Consequently, when this\nsubstituent is a methoxy group (compound 2), the MAO-B inhibi-\ntory activity and selectivity improve in a great extent respecting\nto the other derivatives. However, replacement of the methoxy\ngroups for hydroxyl groups at the indicated positions decreases\nthe activity (compounds 3and4) validating the previous informa-\ntion we already had21and it can even decrease selectivity. On the\nother hand, when we analyze the second series where a 3-benzoyl\ngroup has replaced the 3-phenyl substituent, the introduced car-\nbonyl group decreases the MAOI activity against B isoform. The\n6-bromo-8-hydroxy derivatives 7and8are more active than the\ncorresponding 6-bromo-8-methoxy ones (compounds 5and 6),\nbeing the structure activity relationship just the opposite of the\n3-phenylcoumarins. Compounds 5and6do not present any MAO\ninhibitory activity at the higher tested concentration (100 lM).\nHowever, compounds 7and8increase the af\ufb01nity for the MAO-A\nreceptor, losing the MAO-B selectivity of the \ufb01rst series. A smallchange in the structure causes a big change in the af\ufb01nity of the\nmolecules for the receptor. These preliminary results allow us to\nunderstand slightly better interactions between molecule and\nreceptor and the molecular fragments that are essential to main-\ntain and improve the MAO activity and selectivity.\nAs conclusion, it was veri\ufb01ed an important lost of the MAO-B\ninhibitory activity and selectivity when the 3-phenyl skeleton is\nsubstituted for the 3-benzoyl one. However, in some of the 3-ben-\nzoyl derivatives it was shown not only inactivity against MAO-B\nTable 1\nMAO-A and MAO-B inhibitory activity results for the synthesized compounds 1\u20138 and reference inhibitors\nCompounds MAO-A IC 50(lM) MAO-B IC 50(lM) Selectivity Index\n1*83.48x10/C03\u00b1 5.60x10/C03>1,197b\n2*1.35x10/C03\u00b1 0.09x10/C03>74,074b\n3*30.91 \u00b1 2.09 >3.2b\n4 20.74 \u00b1 1.40 16.87 \u00b1 1.14 1.2\n5** \u2014\n6** \u2014\n7 46.81 \u00b1 3.18a73.92 \u00b1 4.99 0.63\n8 19.17 \u00b1 1.29**0.19c\nR-(/C0)-Deprenyl 67.25 \u00b1 1.02a19.60x10/C03\u00b1 0.86x10/C033,431\nIproniazide 6.56 \u00b1 0.76 7.54 \u00b1 0.36 0.87\n*Inactive at 100 lM (highest concentration tested). At higher concentrations compound precipitate.\n**100lM inhibits enzymatic activity around (by approximately) 45\u201350%. At higher concentrations compound precipitate.\naP< 0.05 versus the corresponding IC 50values obtained against MAO-B, as determined by ANOVA/Dunnett\u2019s.\nbValues obtained under the assumption that the corresponding IC 50against MAO-A is the highest concentration tested (100 lM).\ncValue obtained under the assumption that the corresponding IC 50against MAO-B is the highest tested concentration (100 lM).CHO\nOHR1R1\nO O\nR2(a)\n1: R1 = Br, R2 = OMe, R3 = H\n2: R1 = Br, R2 = R3 = OMe\nR2R3\nCOOHR3\nO\nOEtO\nR3\n(c)R1\nO O\nR2\n5: R1 = Br, R2 = OMe, R3 = H\n6: R1 = Br, R2 = R3 = OMeR3O(b)\n3: R1 = Br, R2 = OH, R3 = H\n4: R1 = Br, R2 = R3 = OH\n7: R1 = Br, R2 = OH, R3 = H\n8: R1 = Br, R2 = R3 = OH(d)\nScheme 1. Reagents and conditions: (a) DCC, DMSO, 110 /C176C, 24 h; (b) HI, AcOH,\nAc2O, 0/C176C to re\ufb02ux, 4 h; (c) ethanol, piperidine, re\ufb02ux, 2\u20135 h; (d) BBr 3, DCM, 80 /C176C,\n48 h.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227 4225\n\u0018\u001b\u001f148isoenzyme, but showed MAO-A inhibitory activity and selectivity.\nTherefore, selectivity seems to depend on the nature of the couma-\nrins\u2019 substituent. In the present study it was shown that 6-bromo-\n8-methoxy-3-phenylcoumarins are an interesting scaffold for\nMAO-B inhibitory studies, whereas the 6-bromo-8-hydroxy-3-\nbenzoylcoumarins are an interesting moiety for MAO-A inhibitory\nones. Compound 2, with a p-methoxy substituent in the 3-phenyl\nring was the most potent and selective molecule of the \ufb01rst seriesagainst MAO-B isoenzyme, with an IC\n50in the low nanomolar\nrange (IC 50= 1.35 nM). This compound is \ufb01fteen times more active\nand several times more selective than the R-( /C0)-deprenyl\n(IC50= 19.6 nM, reference MAO-B inhibitor). The MAO selectivity\nis an important factor to discriminate the different potential ther-\napeutic applications of these molecules. These \ufb01ndings encourage\nus to continue the efforts towards the optimization of the pharma-\ncological pro\ufb01le of these structural types as important scaffolds in\nthe neurodegenerative diseases realm.\nAcknowledgments\nThanks to the Spanish Ministry (PS09/00501) and to Xunta de\nGalicia (PGIDIT09CSA030203PR and 10PXIB203303PR). M.J.M.\nthanks FCT for a PhD grant (SFRH/BD/61262/2009). S.V.R. thanks\nto Ministerio de Educaci\u00f3n y Ciencia for a PhD grant (AP2008-\n04263).\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887.\n2. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front Med. Chem.\n2009 ,4, 23.\n3. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n4. Murray, R. D. H. Prog. Chem. Org. Nat. Prod. 2002 ,83,1 .\n5. Go, M. L.; Wu, X.; Liu, X. L. Curr. Med. Chem. 2005 ,12, 483.\n6. Nowakowska, Z. Eur. J. Med. Chem. 2007 ,42, 125.\n7. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18, 63.\n8. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n9. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543.\n10. Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J.; Hamilakis, S. Bioorg.\nMed. Chem. Lett. 2010 ,20, 3889.\n11. Ostrov, D. A.; Hern\u00e1ndez Prada, J. A.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T.\nC.Antimicrob. Agents Chemother. 2007 ,51, 3688.\n12. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.;\nHong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. J. Med. Chem. 2009 ,52, 1486.\n13. Kostova, I. Curr. HIV Res. 2006 ,4, 347.\n14. Rao, Y. K.; Fang, S.; Tzeng, Y. Bioorg. Med. Chem. 2004 ,12, 2679.\n15. Ni, L.; Meng, C. Q.; Sikorski, J. A. Expert Opin. Ther. Pat. 2004 ,14, 1669.\n16. Nielsen, S. F.; Boesen, T.; Larsen, M.; Schonning, K.; Kromann, H. Bioorg. Med.\nChem. 2004 ,12, 3047.\n17.\nChimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.;\nCarradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52,\n1935.\n18. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.;\nCaccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti,\nA.J. Med. Chem. 2009 ,52, 6685.\n19. Gnerre, C.; Catto, M.; Francesco, L.; Weber, P.; Carrupt, P.-A.; Altomare, C.;\nCarotti, A.; Testa, B. J. Med. Chem. 2000 ,43, 4747.\n20. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n21. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n22. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157.\n23. Delogu, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vi\u00f1a, D.\nEur. J. Med. Chem. 2011 ,49, 1147.\n24. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez,\nM.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52, 2818.\n25. Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 ,49, 1118.\n26. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n27. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.;\nM\u00e9ndez-\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006 ,49, 4912.\n28. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.\nE.; Mattevi, A. J. Med. Chem. 2007 ,50, 5848.29. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.;\nCarrupt, P.; Reist, M. J. Med. Chem. 2006 ,49, 6264.\n30. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n31. Binda, C.; Li, M.; Hub\u00e1lek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl.\nAcad. Sci. U. S. A. 2003 ,100, 9750.\n32. Dostert, P.; Strolin Benedetti, M.; Jafre, M. In Monoamine Oxidase Basic and\nClinical Frontiers ; Kamijo, K., Usdin, E., Nagausu, T., Eds.; Excerpta Medica:\nAmsterdam, 1982; p 197.\n33. Singer, T. P. F. Muller (Ed.) ; CRC Press: London, 1991. p. 437.\n34. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. Mol.\nBiol. 2004 ,338, 103.\n35. Weyler, W.; Hsu, Y. P.; Breake\ufb01eld, X. O. Pharmacol. Ther. 1990 ,47, 391.\n36. Guay, D. R. Am. J. Geriatr. Pharmacother. 2006 ,4, 330.\n37. Riederer, P.; Danielczyk, W.; Grunblatt, E. Neurotoxicology 2004 ,25, 271.\n38. Youdim, M. B. H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111, 1455.\n39. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, 171.\n40. Rudorfer, M. V.; Potter, V. Z. Drugs 1989 ,37, 713.\n41. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R.\nNeurology 2006 ,66, 1200.\n42. General procedure for the preparation of 3-phenylcoumarins ( 1and 2):a\nsolution of the conveniently substituted salicylaldehyde (0.56 mmol) and thecorrespondent phenylacetic acid (0.70 mmol) in DMSO and DCC (0.87 mmol)was heated in an oil-bath at 110 /C176C for 24 h. Triturate ice (20 mL) and acetic\nacid (3.0 mL) were added to the reaction mixture. After keeping it at roomtemperature for 2 h, the mixture was extracted with ether (3 x 25 mL). The\norganic layer was extracted with sodium bicarbonate solution (50 mL, 5%)\nand then with water (20 mL). The solvent was evaporated under vacuum\nand the dry residue was puri\ufb01ed by FC (hexane/ethyl acetate 9:1) to give\nthe desired compound.\n6-Bromo-8-methoxy-3-phenylcoumarin ( 1): it was obtained with a yield of\n50%. Mp 153\u2013154 /C176C.\n1H NMR (CDCl 3)d(ppm), J (Hz): 3.97 (s, 3H, \u2013OCH 3),\n7.16 (d, 1H, H-7, J= 2.0), 7.26 (d, 1H, H-5, J= 2.0), 7.43\u20137.48 (m, 3H, H-3\u2019, H-\n4\u2019, H-5\u2019), 7.68\u20137.73 (m, 3H, H-2\u2019, H-6\u2019, H-4).13C NMR (CDCl 3)d(ppm): 57.2,\n117.0, 117.3, 121.9, 122.1, 129.2, 129.8, 130.3, 134.8, 139.1, 142.8, 148.3,\n160.0. MS m/z(%): 332 (99), 331 (30), 330 (M+, 100), 304 (40), 302 (40), 261\n(25), 259 (26), 194 (16), 165 (12), 153 (14), 152 (88), 151 (23), 102 (19), 76\n(34). Anal. Calcd for C 16H11BrO 3: C, 58.03; H, 3.35. Found: C, 58.01; H, 3.30.\n6-Bromo-8-methoxy-3-(4\u2019-methoxyphenyl)coumarin ( 2): it was obtained with\na yield of 53%. Mp 184\u2013185 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.85 (s, 3H,\n\u2013OCH 3), 3.96 (s, 3H, \u2013OCH 3), 6.93\u20136.96 (m, 2H, H-3\u2019, H-5\u2019), 7.12 (d, 1H, H-7,\nJ= 1.8), 7.23 (d, 1H, H-5, J= 2.0), 7.63\u20137.67 (m, 2H, H-2\u2019, H-6\u2019), 7.69 (s, 1H,\nH-4).13C NMR (CDCl 3)d(ppm): 55.7, 56.8, 114.2, 116.2, 116.8, 121.5, 126.8,\n129.4, 130.2, 130.8, 137.3, 142.2, 147.8, 159.8, 160.6. MS m/z(%): 363 (19),\n362 (M+, 100), 361 (19), 360 (59), 334 (24), 332 (23), 319 (33), 317 (34), 291\n(11), 289 (11), 182 (18), 167 (17), 139 (21), 91 (11). Anal. Calcd for\nC17H13BrO 4: C, 56.53; H 3.63. Found: C, 56.55; H, 3.68.\nGeneral procedure for the preparation of hydroxylated 3-phenylcoumarins ( 3\nand 4). a solution of the corresponding methoxy-3-phenylcoumarin\n(0.50 mmol) in acetic acid (5.0 mL) and acetic anhydride (5.0 mL), at 0 /C176C,\nwas prepared. Hydriodic acid 57% (10.0 mL) was added dropwise. The\nmixture was stirred under re\ufb02ux temperature for 3 h. The solvent was\nevaporated under vacuum and the dry residue was puri\ufb01ed by\nrecrystallization with CH 3CN.\n6-Bromo-8-hydroxy-3-phenylcoumarin ( 3): it was obtained with a yield of\n61%. Mp 160\u2013161 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 7.19 (d, 1H, H-7,\nJ= 2.0), 7.43\u20137.49 (m, 4H, H-5, H-3\u2019, H-4\u2019, H-5\u2019), 7.70 (dd, 2H, H-2\u2019, H-6\u2019,\nJ= 7.6, J= 1.6), 8.13 (s, 1H, H-4), 10.79 (s, 1H, -OH).13C NMR (DMSO- d6)d\n(ppm): 115.5, 119.9, 120.4, 121.8, 127.9, 128.2, 128.5, 128.8, 134.4, 139.7,\n141.1, 145.6, 159.1. MS m/z(%): 319 (16), 318 (99), 317 (17), 316 (M+, 100),\n291 (12), 290 (78), 289 (13), 288 (81), 153 (22), 152 (51), 151 (12), 76 (25).\nAnal. Calcd for C 15H9BrO 3: C, 56.81; H, 2.86. Found: C, 56.78; H, 2.82.\n6-Bromo-8-hydroxy-3-(4\u2019-hydroxyphenyl)coumarin ( 4): It was obtained with a\nyield of 53%. Mp 249\u2013250 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 6.83 (d,\n2H, H-3\u2019, H-5\u2019, J= 8.8), 7.14 (t, 1H, H-7, J= 1.5), 7.36 (d, 1H, H-5, J= 2.0), 7.56\n(d, 2H, H-2\u2019, H-6\u2019, J= 8.5), 8.00 (s, 1H, H-4).13C NMR (DMSO- d6)d(ppm):\n115.6, 116.0, 119.9, 120.6, 122.5, 125.4, 128.2, 130.4, 138.0, 141.2, 146.0,\n158.6, 159.8. MS m/z(%): 335 (35), 334 (99), 333 (45), 332 (M+, 100), 307\n(31), 306 (99), 305 (35), 304 (99), 225 (26), 197 (29), 169 (35), 168 (46), 153(24), 141 (21), 140 (16), 139 (51), 118 (17), 115 (28), 98 (13), 89 (14), 84\n(18), 84 (46), 75 (11), 63 (13). Anal. Calcd for C\n15H9BrO 4: C, 54.08; H, 2.72.\nFound: C, 54.00; H 2.69.\nGeneral procedure for the preparation of 3-benzoylcoumarins ( 5and6).T oa\nsolution of the appropriate b-ketoester and the corresponding\nsalicylaldehyde in ethanol was added piperidine in catalytic amount. The\nreaction mixture was re\ufb02uxed for 2\u20135 h and after completion, the reactionwas cooled and the precipitated was \ufb01ltered and washed with cold ethanol\nand ether to afford the desired compound. Compounds were further\nrecrystallized in methanol/CH\n2Cl2.\n6-Bromo-8-methoxy-3-benzoylcoumarin ( 5): it was obtained with a yield of 49%.\nMp 207\u2013208 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.82 (s, 3H, \u2013OCH 3), 7.09 (s, 1H,\nH-7), 7.14 (s, 1H, H-5), 7.24\u20137.51 (m, 3H, H-3\u2019, H-4\u2019, H-5\u2019), 7.69 (d, 2H, H-2\u2019, H-6\u2019,\nJ= 7.3), 7.78 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 57.2, 116.6, 118.6, 120.5,\n123.0, 128.0, 129.2, 130.0, 134.5, 136.3, 143.3, 144.6, 147.8, 157.8, 191.9. MS m/z\n(%): 360 (18), 359 (M+, 58), 358 (18), 357 (58), 105 (100), 77 (70). Anal. Calcd for\nC17H11BrO 4: C, 56.85; H, 3.09; Found: C, 56.79; H, 3.06.4226 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227\n\u0018\u001b 1496-Bromo-8-methoxy-3-(4 \u00b4-methoxybenzoyl)coumarin ( 6): It was obtained with\na yield of 90%. Mp 224\u2013225 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.71 (s, 3H, \u2013\nOCH 3), 3.82 (s, 3H, \u2013OCH 3), 6.77 (d, 2H, H-3\u2019, H-5\u2019, J= 8.9), 7.14\u20137.16 (m, 2H, H-5,\nH-7), 7.69 (d, 2H, H-2\u2019, H-6\u2019, J= 8.9), 7.72 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm):\n55.5, 56.1, 92.8, 95.2, 103.8, 113.7, 121.2, 129.7, 132.1, 141.5, 157.9, 158.3, 159.2,\n163.8, 165.8, 190.6. MS m/z(%): 389 (87), 388 (17), 387 (M+, 90), 135 (100), 77\n(56). Anal. Calcd for C 18H13BrO 5: C, 55.55; H, 3.37. Found: C, 55.53; H, 3.34.\nGeneral procedure for the preparation of hydroxylated 3-benzoylcoumarins ( 7and\n8). To the corresponding methoxy-3-benzoylcoumarin in DCM (1 mmol), BBr 3in\nDCM (20 mmol) was added in a Schlenk tube. Tube was sealed, and the reactionmixture was heated at 80 /C176C for 48 h. The resulting crude was treated with MeOH\nand rotated to dryness. The obtained precipitated was recrystallized in MeOH to\nafford the desired hydroxy derivative.\n6-Bromo-8-hydroxy-3-benzoylcoumarin ( 7): it was obtained with a yield of 98%.\nMp 240\u2013242 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 7.29 (d, J= 2.2 Hz, 1H, H-7),\n7.61\u20137.39 (m, 3H, H-3\u2019, H-4\u2019, H-5\u2019), 7.76\u20137.67 (m, 1H, H-5), 7.93 (d, 2H, H-2\u2019, H6\u2019,\nJ= 8.0), 8.30 (s, 1H, H-4), 10.92 (s, 1H, -OH).13C NMR (DMSO- d6)d(ppm): 39.3,\n39.5, 39.7, 39.9, 40.1, 40.4, 40.6, 116.2, 120.9, 121.8, 122.0, 127.8, 129.2, 130.0,\n134.5, 136.3, 142.7, 144.8, 146.3, 157.9, 191.9. MS m/z(%): 345 (46), 343 (M+, 45),\n105 (100), 77 (58). Anal. Calcd for C 16H9BrO 4: C, 55.68; H, 2.63. Found: C, 55.63;\nH, 2.59.\n6-Bromo-8-hydroxy-3-(4 \u00b4-hydroxybenzoyl)coumarin ( 8):it was obtained with a\nyield of 40%. Mp 293\u2013295 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 6.86 (d, 2H, H-\n3\u2019, H-5\u2019, J= 8.7), 7.27 (d, 1H, H-7, J= 2.2), 7.46 (d, 1H, H-5 J= 2.2), 7.82 (d, 2H, H-2\u2019,\nH-6\u2019 J= 8.7), 8.18 (s, 1H, H-4), 10.62 (s, 1H, -OH), 10.89 (s, 1H, -OH).13C NMR\n(DMSO- d6)d(ppm): 115.9, 116.2, 121.0, 121.5, 121.6, 127.6, 128.5, 133.0, 142.7,\n143.5, 146.3, 157.9, 163.6, 190.0. MS m/z(%): 362 (29), 360 (M+, 30), 121 (100), 93\n(16), 65 (15). Anal. Calcd for C 16H9BrO 5: C, 53.21; H, 2.51. Found: C, 52.97; H,\n4.41.\n43. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect B 1996 ,35B,\n1159.\n44. Mohanty, S.; Makrandi, J. K.; Grover, S. K. Indian J. Chem., Sect B 1989 ,28B, 766.\n45. Kamat, S. P.; D \u00b4Souza, A. M.; Paknikar, S. K.; Beaucahmp, P. S. J. Chem. Research\n(S)2002 , 242.\n46. Brunet, E.; Alonso, M. T.; Juanes, O.; Velasco, O.; Rodr\u00edguez-Ubis, J. C.\nTetrahedron 2001 ,57, 3105.\n47. Frederick, R.; Robert, S.; Charlier, C.; de Ruyck, J.; Wouters, J.; Pirotte, B.;\nMasereel, B.; Pochet, L. J. Med. Chem. 2005 ,48, 7592.48. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n49. Mart\u00edn-Santamar\u00eda, S.; Rodr\u00edguez, J. J.; de Pascual-Teresa, S.; Gordon, S.;\nBengtsson, M.; Garrido-Laguna, I.; Rubio-Viqueira, B.; L\u00f3pez-Casas, P. P.;Hidalgo, M.; de Pascual-Teresa, B.; Ramos, A. Org. Bio. Chem. 2008 ,6, 3486.\n50. Albrecht, M.; Mirtschin, S.; de Groot, M.; Janser, I.; Runsink, J.; Raabe, G.; Kogej,\nM.; Schalley, C. A.; Fr\u00f6hlich, R. J. Am. Chem. Soc. 2005 ,127, 10371.\n51. Determination of human monoamine oxidase (hMAO) isoform activity. The\neffects of the tested compounds on hMAO isoform enzymatic activity wereevaluated by a \ufb02uorimetric method. Brie\ufb02y, 0.1 mL of sodium phosphate buffer\n(0.05 M, pH 7.4) containing the tested drugs in several concentrations and\nadequate amounts of recombinant hMAO-A or hMAO-B required and adjusted\nto obtain in our experimental conditions the same reaction velocity [165 pmol\nofp-tyramine/min (hMAO-A: 1.1 mg protein; speci\ufb01c activity: 150 nmol of p-\ntyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-\nB: 7.5 mg protein; speci\ufb01c activity: 22 nmol of p-tyramine transformed/min/\nmg protein)] were placed in the dark \ufb02uorimeter chamber and incubated for\n15 min at 37 /C176C. The reaction was started by adding (\ufb01nal concentrations)\n200\nlM Amplex\u00d2 Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-\ntyramine. The production of H 2O2and, consequently, of resoru\ufb01n was\nquanti\ufb01ed at 37 /C176C in a multidetection microplate \ufb02uorescence reader\n(FLX800TM, Bio-Tek\u00d2 Instruments, Inc., Winooski, VT, USA) based on the\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm) over a 15 minperiod, in which the \ufb02uorescence increased linearly. Control experiments were\ncarried out simultaneously by replacing the tested drugs with appropriate\ndilutions of the vehicles. In addition, the possible capacity of the above tested\ndrugs for modifying the \ufb02uorescence generated in the reaction mixture due to\nnon-enzymatic inhibition (e.g., for directly reacting with Amplex\u00d2 Redreagent) was determined by adding these drugs to solutions containing only\nthe Amplex\u00d2 Red reagent in a sodium phosphate buffer. The speci\ufb01c\n\ufb02uorescence emission (used to obtain the \ufb01nal results) was calculated after\nsubtraction of the background activity, which was determined from vials\ncontaining all components except the hMAO isoforms, which were replaced by\na sodium phosphate buffer solution.\n52. All IC\n50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve\nexperiments.\n53. Y\u00e1\u00f1ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Comm. 2006 ,344,\n688.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227 4227\n\u0018\u001c\u0017150Hydroxycoumarins as selective MAO-B inhibitors\nSilvia Serraa,\u21d1, Giulio Ferinob, Maria Jo\u00e3o Matosc, Saleta V\u00e1zquez-Rodr\u00edguezc, Giovanna Delogua,\nDolores Vi\u00f1ad, Enzo Cadonib, Lourdes Santanac, Eugenio Uriartec\naDipartimento Farmaco Chimico Tecnologico, Universit\u00e0 degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy\nbDipartimento di Scienze Chimiche, Universit\u00e0 degli studi di Cagliari, Complesso Universitario di Monserrato, S.S. 554, I-09042 Monserrato (Cagliari), Italy\ncDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\ndDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 12 October 2011Revised 4 November 2011\nAccepted 6 November 2011\nAvailable online 11 November 2011\nKeywords:\n4-Hydroxycoumarin\nMAO inhibitory activitySuzuki reaction\nDocking experimentsabstract\nA series of 3-aryl-4-hydroxycoumarin derivatives was synthesized with the aim to \ufb01nd out the structural\nfeatures for the MAO inhibitory activity and selectivity. Methoxy and/or chloro substituents were intro-\nduced in the 3-phenyl ring, whereas the position 6 in the coumarin moiety was not substituted or substi-\ntuted with a methyl group or a chloro atom due to their different electronic, steric and/or lipophilic\nproperties. Most of the synthesized compounds presented MAO-B inhibitory activity. The presence of\nmethoxy and chloro groups, respectively in the para and meta positions of the 3-phenyl ring, have an\nimportant in\ufb02uence on the inhibitory activity. Moreover, the presence of a chloro atom in the six position\nof the moiety (compound 7) improved the inhibitor activity as well as its selectivity against MAO-B com-\npared with iproniazide, used as reference compound. Docking experiments were carried out to under-\nstand which are the most energetically preferred orientations adopted by compounds 5,6and7inside\nthe MAO-B binding pocket.\n/C2112011 Elsevier Ltd. All rights reserved.\nNeurodegenerative diseases (ND) constitute the third most\nimportant health problem in developed countries. Alzheimer\u2019s dis-\nease (AD) is the most prevalent of the ND followed by Parkinson\u2019s\ndisease (PD). AD is a neurodegenerative and progressive disorder\nassociated, in the most of the cases, with senile dementia. It seems\nto have a multiple etiology although the main cause it is thought\nto be the accumulation of b-amyloid plaques in brain that can\nprovoke a degeneration or atrophy of the cholinergic neurons. PDis also a chronic and progressive neurodegenerative disorder, char-\nacterized by a predominant motor symptomatology, usually accom-\npanied by non motor symptoms such as depression and anxiety. It\nseems to be caused by a decrease in the dopamine levels in neuronal\nsynapses. In the treatment of this disease, dopaminergic agonists are\ngenerally employed. However, other therapeutic alternatives can be\nemployed, such as the use of monoamine oxidase B inhibitors\n(MAOI-B), or the use of antioxidant compounds in order to prevent\nthe oxidative cells damage.\nMAO is an important FAD-containing enzyme (\ufb02avoenzyme)\npresent in the outer mitochondrial membrane of neuronal, glial\nand many other cells.\n1,2It exists in two isoforms namely as\nMAO-A and MAO-B that have been identi\ufb01ed based on their aminoacid sequences, three-dimensional structure, substrate preference\nand inhibitor selectivity.\n3,4MAO-A preferentially deaminates sero-\ntonin and noradrenaline, whereas MAO-B has a higher af\ufb01nity tophenylethylamine and benzylamine.5,6Therefore, these isoen-\nzymes play a vital role in the monoamines degradation and, as con-\nsequence, in the inactivation of neurotransmitters. Their regulation\ndetermines the interest of the MAOI compounds as drugs used in\nthe treatment of neurodegenerative and neurological disorders.\nIn particularly, MAO-A inhibitors are effective in the treatment of\ndepression,7,8while MAO-B inhibitors are useful in the treatment\nof PD.9,10In the last years, it has been proved that in patients\nwho suffer ND the activity of brain MAO-B is increased. This fact\nprovokes an increase of free radicals that are responsible for the\noxidative stress, neuronal cell death and also for the development\nof the b-amyloid plaques.11In this sense, it is an accepted theory\nthat the bene\ufb01cial effects of the MAO-B inhibitors in the preven-tion of the neuronal damage is mostly derived to the decrease of\nhydrogen peroxide generated by the inhibition of this enzyme.\nCoumarins are an important group of organic compounds from\nnatural and/or synthetic origin, that show, due to their structural\ndiversity, numerous biological activity.\n12\u201314There are coumarins\ndescribed as anticancer, anti-in\ufb02ammatory, antimicrobial, cardio-protective, vasorelaxant, and antioxidant agents.\n15\u201320Recently\nstudies pay special attention to the MAO inhibitory properties of\nthe 3-arylcoumarin derivatives.21\u201326\nFlavonoids are naturally occurring polyphenolic compounds\nthat are found in diets and medicinal herbs. The physiological ben-\ne\ufb01ts of dietary \ufb02avonoids (\ufb02avones and iso\ufb02avones) have been\nattributed to their antioxidant and free radical-scavenging\nabilities.27Additionally, \ufb02avonoids have been revealed to exhibit\n0960-894X/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2011.11.020\u21d1Corresponding author.\nE-mail address: silvserra@tiscali.it (S. Serra).Bioorganic & Medicinal Chemistry Letters 22 (2012) 258\u2013261\nContents lists available at SciVerse ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.el sevier.com/locate/bmcl\n\u0018\u001c\u0018151anti-amiloidogenic properties such as inhibitory effects on b-\nsecretase enzimes28,29and also MAO-B inhibitory activity.30\nIn previous works, we reported the synthesis and biological\nevaluation of a series of 3-arylcoumarins as potent and selective\nMAO-B inhibitors.23\u201325These interesting results prompted us to\nsynthesize and evaluate new 3-arylcoumarin derivatives, in whichwe introduce a hydroxyl group in the 4 position of coumarin skel-\neton (Fig. 1 ).\nThis modi\ufb01cation allows us considering the similarity of the\ncore structure of the 4-hydroxycoumarin (B) comparing with the\n2-hydroxyiso\ufb02avone (C). Taking into account these data we could\nestablish a potential therapeutic application of these analogues\n\ufb02avonoids/coumarins as a new interesting scaffold with interest\nagainst age-related neurodegeneration such as PD or AD.\nThe synthesis of 3-aryl-4-hydroxycoumarin derivatives ( 1\u20137)\n31\u201333\nis outlined in Scheme 1 .\nThe key step for the synthesis of the 3-arylcoumarin skeleton\nwas achieved by a palladium-catalyzed coupling Suzuki reactionbetween phenyliodonium zwitterions and aryl conveniently\nsubstituted phenyl boronic acids. Initially we have synthesized\nthe different phenyliodonium coumarinate species (I\u2013III).\n31,32They\nare electrophilic molecules with a positive charge at iodine, com-pensated by a internal negative charge that can be localized for-\nmally at the\na-carbon or delocalized to a neighboring oxygen.\nThen we have carried out the palladium-catalyzed coupling reac-\ntion using Pd(OAc) 2as catalyst and P( t-Bu) 3as ligand to afford\nthe compounds (1\u20137 ) with good yields.\nBy1H and13C NMR spectroscopy studies we have found out that\nthe synthesized compounds ( 1\u20137) were presented in the 4-hydroxy-\ncoumarin tautomeric form. Therefore we have centered on their\nanalysis at the physiologic pH conditions. In the biological inhibitory\nassays it was also used the appropriate solvent that guaranties the\npresence of this structure.\nThe MAO inhibitory activity of compounds 1\u20137 was evaluated\nin vitro by the measurement of the enzymatic activity of human re-\ncombinant MAO isoforms expressed in BTI insect cells infected\nwith baculovirus.34Subsequently, the IC 50values and MAO-B\nselectivity indexes [IC 50(MAO-A)]/[IC 50(MAO-B)] for inhibitory ef-\nfects of both new types of compounds and iproniazide (used as ref-\nerence inhibitor) were calculated (Table 1 ).34,35\nIn the present Letter, we have studied the effect in the MAOI\nactivity of the introduction of alkyl, alkoxy or halogen substituents\nin different positions of the 3-aryl-4-hydroxycoumarin nucleus.\nWe have found that the simple 4-hydroxy-3-phenylcoumarin did\nnot present MAOI activity (compound 1). The introduction of a\nmethoxy substituent in the para position of the 3-phenyl ring led\nto a compound 2with inhibitory activity against MAO-B. So we\ntake this compound as a point of reference for the subsequent\nmodi\ufb01cations. Due to the fact that the 6 position of the coumarin\nskeleton is particularly relevant to the MAO-B inhibitor activity\nand selectivity,36,37we have studied the effect of the introduction\nof a methyl group or a chloro atom in this position. The introduc-tion of a methyl group (compound 3) slightly improved the activ-\nity. However, the replacement for a chloro atom at the sameposition decreases the activity (compound 4). In addition, when\nwe analyze the second series (compounds 5\u20137) where a chloro\natom has been introduced at the meta position of the p-methoxy-\n3-phenyl ring, the MAO-B inhibitory activity, in most of the cases,improves. In this case, if we introduce a methyl group in the 6\nposition (compound 6) the MAOI-B activity did not change,\nwhereas if the substituent is a chloro atom (compound 7) the\nMAO-B inhibitory activity considerably improves. Therefore\ncompound 7is more active against MAO-B isoenzyme than theO OOHO O\nO OHOA\nB C\nFigure 1. Chemical structures of the 3-phenylcoumarin (A), 4-hydroxy-3-phenyl-\ncoumarin (B) and 2-hydroxyiso\ufb02avone (C).R1\nR1\nO O(b)\n1:R1=H ,R2=H ,R3=H\n2:R1=H ,R2=O M e ,R3=H\n3:R1=M e ,R2=O M e ,R3=H\n4:R1=C l ,R2=O M e ,R3=H\n5:R1=H ,R2=O M e ,R3=C l\n6:R1=M e ,R2=O M e ,R3=C l\n7:R1=C l ,R2=O M e ,R3= ClR2OOH\nO\nR2\nB(OH) 2R3\nOHR3R1\nO OI(a)O\nI:R1=H ,\nII:R1=M e\nIII:R1=C l\nScheme 1. Reagents and conditions: (a) PhI(OAc) 2,N a 2CO3,H 2O, rt, 14 h; (b)\nPd(OAc) 2,P(t-Bu) 3, LiOH, DME/H 20, rt, 24\u201348 h.\nTable 1\nMAO-A and MAO-B inhibitory activity results for the synthesized compounds 1\u20137and\nreference inhibitor\nCompounds MAO-A IC 50(lM) MAO-B IC 50(lM) Selectivity index\n1aa\u2014\n2a69.59 \u00b1 4.70 >1.4b\n3a32.04 \u00b1 2.16 >3.1b\n4aa\u2014\n5a9.26 \u00b1 0.63 >10b\n6a42.68 \u00b1 2.88 >2.3b\n7a2.79 \u00b1 0.19 >36b\nIproniazide 6.56 \u00b1 0.76 7.54 \u00b1 0.36 0.87\nR-(/C0)-Deprenyl 68.73 \u00b1 4.21 17x10/C03\u00b1 1.9 /C210/C034.043\nAll IC 50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve experi-\nments. Level of statistical signi\ufb01cance:\naInactive at 100 lM (highest concentration tested).\nbValues obtained under the assumption that the corresponding IC 50against\nMAO-A is the highest concentration tested (100 lM).S. Serra et al. / Bioorg. Med. Chem. Lett. 22 (2012) 258\u2013261 259\n\u0018\u001c\u0019152iproniazide but not than the R-(/C0)Deprenyl, used as reference com-\npounds. None of the described compounds showed MAO-A inhibi-\ntory activity for the highest concentration tested (100 lM).\nA computational approach, through docking calculations, was\nused to better understand which are the most energetically pre-\nferred orientations adopted by compounds 5,6and 7inside the\nMAO-B binding pocket.\nHigh resolution crystal structure of hMAO-B (PDB code 2V60)1\nwas taken as target for docking experiments. Protein PreparationWizard of Maestro 9.1\n38was used to set-up protein before run calcu-\nlations. With this helpful tool co-crystallized ligand was removed,water molecules beyond 5 \u00c5 from the ligand were deleted, hydrogen\natoms were added and then minimized using OPLS_2005 force \ufb01eld.\nCompounds 5,6and 7were prepared with LigPrep\n39tool using\nMMFFs force \ufb01eld. The QM-Polarized Ligand Docking (QPLD)40pro-\ntocol was used for docking calculations. In a \ufb01rst step, ligands weredocked into the known\n26MAO-B binding site using Glide41standard\nprecision (SP); the initial charges were calculated by semiempiricalmethods and 8 best poses for each ligand were retained. In the sec-\nond step the Quantum Mechanical (QM) treatment of charges, calcu-\nlated by Jaguar\n42, allowed to take into consideration the polarization\nof the charges in the ligand by the protein. The \ufb01nal step consisted toredock the ligand, with improved charges, with Glide extra precision\n(XP) mode, retaining the 4 best poses for each ligand. With the aim of\nminimizing the protein\u2013ligand complexes and return the estimate\nbinding free energy for each ligand, the 4 output complexes derived\nfrom QPLD were subjected to MacroModel-eMBrAcE\n43minimiza-\ntion. With this \ufb02exible-receptor tool all residues with a distancenot exceeding 5\u00c5 from the ligand were allowed to move freely, while\nresidues outside this shell were frozen. The complexes were mini-\nmized using OPLS_2005 force \ufb01eld. Results were retrieved using En-\nergy difference mode which calculates separately the energy\nassociated \ufb01rst on the receptor, than on the ligand and \ufb01nally on\nthe complex using the follow equation:\nDE\u00bcEcomplex /C0Eligand/C0Eprotein\nThe most stable binding solution for compounds 5,6and 7\nshows the same pattern (Fig. 2 ).\nThe entrance cavity of binding site is occupied by the hydroxy-\ncoumarin moiety leaving the 3-arylcoumarin rings directed towardFAD cofactor. Cys172 plays a signi\ufb01cant role for the complex stabil-\nization, forming an H-bond with carbonyl oxygen of all the three\ncoumarins. The higher activity showed by 5and7, compared to 6,\ncould be partially due to involvement of another H-bond in the bind-ing mode; in this case only 5and7form an H-bond between the 4-\nhydroxy group and Ile199. Furthermore, 3-arylcoumarin rings of 5,6\nand7share a\np\u2013pstacking interaction with Tyr326. Interestingly,\nthe p-methoxy group occupies the same position in the three\ncoumarins, while the position adopted by the chloro atom in the\n3-phenyl ring appears to be unimportant for the modulation\nof MAO-B inhibitor activity, because it assumes an oppositeorientation in the two most actives compounds 5and7. Good van\nder Waals and electrostatic interactions with Pro102, Ile316 andPhe343 were also observed for all the docked molecules.\nAs conclusion, these preliminary results allow us a better under-\nstanding of the molecular fragments that are essential to maintain\nand/or improve the MAO activity and selectivity. These \ufb01ndings\nencourage us to continue the efforts towards the optimization of\nthe pharmacological pro\ufb01le of this structural moiety as an important\nscaffold for the potential treatment of ND.\nAcknowledgements\nThis work was partially supported by the Ministerio de\nSanidad y Consumo (FIS PS09/00501) and Xunta da Galicia\nFigure 2. Best docking poses retrieved for compounds 5(a),6(b) and 7(c) into the\nMAO-B (PDB code: 2V60). Coumarins are represented in tube with carbon atoms\ncolored in plum for 5, turquoise for 6and purple for 7. Hidden ribbons for a better\nvisualization from residues Glu159 to Glu179 (excluding Cys172). MAO-B binding\nsite displayed as gray mesh style. Interacting residues and FAD cofactor labeled inball and stick, with carbon atom colored in yellow and gray respectively. Watermolecules depicted in wire rendering. H-bonds displayed in yellow dot line.Nonpolar hydrogens are omitted.260 S. Serra et al. / Bioorg. Med. Chem. Lett. 22 (2012) 258\u2013261\n\u0018\u001c\u001a153(PGIDIT09CSA030203PR and 10PXIB203303PR). This work was also\npartially supported by MIUR and Cagliari University (National\nProject \u2018\u2018Stereoselezione in Sintesi Organica metodologie ed\nApplicazioni\u2019\u2019) and by CINMPIS and FIRB. S.S. thanks Regione Sarde-\ngna for the PhD grant (PR-MAB-A2009-613). M.J.M. thanks to Fun-\nda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia for the PhD grant (SFRH/BD/\n61262/2009). S.V.R. thanks to Ministerio de Educaci\u00f3n y Ciencia\nfor a PhD grant (AP2008-04263).\nReferences and notes\n1. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.\nE.; Mattevi, A. J. Med. Chem. 2007 ,50, 5848.\n2. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.;\nCarrupt, P.; Reist, M. J. Med. Chem. 2006 ,49, 6264.\n3. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n4. Binda, C.; Li, M.; Hub\u00e1lek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2003 ,100, 9750.\n5. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. Mol.\nBiol. 2004 ,338, 103.\n6. Weyler, W.; Hsu, Y. P. P.; Breake\ufb01eld, X. O. Pharmacol. Ther. 1990 ,47, 391.\n7. Youdim, M. B. H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111, 1455.\n8. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, 171.\n9. Guay, D. R. Am. J. Geriatr. Pharmacother. 2006 ,4, 330.\n10. Riederer, P.; Danielczyk, W.; Grunblatt, E. Neurotoxicology 2004 ,25, 271.\n11. Saura, J.; Luque, J. M.; Cesura, A. M.; Da Prada, M.; Chan-Palay, V.; Huber, G.;\nLof\ufb02er, J.; Richards, J. G. Neuroscience 1994 ,62, 15.\n12. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. Med. Chem.\n2009 ,4, 23.\n13. Murray, R. D. H. Prog. Chem. Org. Nat. Prod. 2002 ,83,1 .\n14. Nowakowska, Z. Eur. J. Med. Chem. 2007 ,42, 125.\n15. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n16. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543.\n17. Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J.; Hamilakis, S. Bioorg.\nMed. Chem. Lett. 2010 ,20, 3889.\n18. Ostrov, D. A.; Hern\u00e1ndez Prada, J. A.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T.\nC.Antimicrob. Agents Chemother. 2007 ,51, 3688.\n19. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.;\nHong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. J. Med. Chem. 2009 ,52, 1486.\n20. Kostova, I. Curr. HIV Res. 2006 ,4, 347.\n21. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.;\nCarradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52,\n1935.\n22. Secci, D.; Carradori, S.; Bolasco, A.; Chimenti, P.; Y\u00e1\u00f1ez, M.; Ortuso, F.; Alcaro, S.\nEur. J. Med. Chem. 2011 ,46, 4846.\n23. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n24. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n25. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157.\n26. Delogu, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vi\u00f1a, D.\nEur. J. Med. Chem. 2011 ,49, 1147.\n27. Hwang, S. L.; Yen, G. C. J. Agric. Food Chem. 2009 ,57, 2576.\n28. Su, M. Y.; Huang, H. Y.; Li, L.; Lu, Y. H. J. Agric. Food Chem. 2011 ,59, 521.\n29. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini,\nM.; Melchiorre, C. J. Med. Chem. 2008 ,51, 347.\n30. Desideri, N.; Bolasco, A.; Fioravanti, R.; Proietti Monaco, L.; Orallo, F.; Ya\u00f1ez,\nM.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2011 ,54, 2155.\n31. Zhu, Q.; Wu, J.; Fathi, R.; Yang, Z. Org. Lett. 2002 ,4, 3333.\n32. General procedure for the preparation of 3-phenyliodonium coumarinates :\niodobenzene diacetate (10 mmol) was suspended in a solution of Na 2CO3\n(10 mmol) in water (100 mL) and was stirred for 30 min at room temperature.\nTo this solution was added a mixture of the corresponding 4-hydroxycoumarin\n(10 mmol) and Na 2CO3(10 mmol) in water (100 mL). After the mixture was\nstirred at room temperature for 14 h, the precipitate was collected by \ufb01ltration,washed with water (5 /C220 mL) and dried under vacuum. The resulting white\nsolid was used without further puri\ufb01cation.33. General procedure for the preparation of 3-aryl-4-hydroxycoumarins : a degassed\nsolution of appropriated phenyl boronic acid (2.2 equiv) and P( t-But)\n3(27 mL)\nin DME and H 2O (4:1, 12.5 mL) was added to a mixture of iodonium ylide\n(0.55 mmol), LiOH/H 2O (3 equiv) and Pd(OAc) 2(6.2 mg) under argon at room\ntemperature. After being stirred at the same temperature for 24\u201348 h. Theresulting mixture was puri\ufb01ed by FC (hexane/ethyl acetate, 7:3) to give thedesired compound.\n3-(3\n0-Chloro-40-methoxyphenyl)-4-hydroxycoumarin ( 5). It was obtained with\nyield 80%. Mp: 298\u2013300 /C176C.1H NMR (DMSO- d6)d(ppm): 3.94 (s, 3H, OCH 3),\n7.21 (s, 1H, H20), 7.28\u20137.49 (m, 3H, H6, H8, H50), 7.56\u20137.83 (m, 2H, H7, H60),\n7.98 (d, 1H, H5, J= 7.6), 15.7 (s, 1H, OH).13C NMR (DMSO- d6)d(ppm): 56.2,\n105.0, 112.8, 116.6, 116.9, 120.7, 124.2, 124.4, 125.6, 131.5, 132.7, 132.8, 152.7,154.3, 161.0, 162.3. MS m/z(%): 302 (M+, 100), 182 (64), 121 (95). Anal. Calcd\nfor C 16H11ClO 4: C, 63.48; H, 3.66. Found: C, 63.45; H, 3.69.\n3-(30-Chloro-40-methoxyphenyl)-4-hydroxy-6-methylcoumarin ( 6). It was\nobtained with yield 80%. Mp: 301\u2013304 /C176C.1H NMR (DMSO- d6)d(ppm): 2.45\n(s, 3H, CH 3), 3.90 (s, 3H, OCH 3), 7.14\u20137.24 (m, 1H, H8), 7.25\u20137.37 (m, 3H, H7,\nH20,H 50), 7.40\u20137.52 (m, 1H, H60), 7.80 (s, 1H, H5), 15.4 (s, 1H, OH).13C NMR\n(DMSO- d6)d(ppm): 20.9, 56.6, 105.0, 112.8, 116.4, 120.8, 123.8, 125.6, 129.0,\n131.5, 132.7, 133.6, 133.6, 150.8, 154.3, 160.9, 162.4. MS m/z(%): 316 (M+, 59),\n182 (80), 135 (100), 97 (36), 83 (37), 71 (51), 57 (91). Anal. Calcd forC\n17H13ClO 4: C, 64.46; H, 4.14. Found: C, 64.46; H, 4.09.\n6-Chloro-3-(30-chloro-40-methoxyphenyl)-4-hydroxycoumarin ( 7). It was\nobtained with yield 62%. Mp: 321\u2013323 /C176C.1H NMR (DMSO- d6)d(ppm): 3.90\n(s, 3H, OCH 3), 7.0\u20137.57 (m, 3H, H8, H20,H 50), 7.60\u20137.84 (m, 2H, H7, H60), 8.0 (s,\n1H, H5), 15.7 (s, 1H, OH).13C NMR (DMSO- d6)d(ppm): 56.8, 113.0, 119.0,\n121.1, 123.6, 125.5, 128.7, 131.7, 132.6, 132.8, 135.2, 136.1, 151.5, 154.6, 160.2,\n162.2. MS m/z(%): 338 (M+, 59), 336 (100), 182 (75), 155 (88), 142 (26), 57 (31).\nAnal. Calcd for C 16H10Cl2O4: C, 57.0; H, 2.99. Found: C, 57.05; H, 3.05.\n34. Determination of human monoamine oxidase (hMAO) isoform activity. The\neffects of the tested compounds on hMAO isoform enzymatic activity were\nevaluated by a \ufb02uorimetric method. Brie\ufb02y, 0.1 mL of sodium phosphate buffer\n(0.05 M, pH 7.4) containing the tested drugs in several concentrations and\nadequate amounts of recombinant hMAO-A or hMAO-B required and adjusted\nto obtain in our experimental conditions the same reaction velocity [165 pmol\nofp-tyramine/min (hMAO-A: 1.1 lg protein; speci\ufb01c activity: 150 nmol of p-\ntyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-\nB: 7.5 lg protein; speci\ufb01c activity: 22 nmol of p-tyramine transformed/min/mg\nprotein)] were placed in the dark \ufb02uorimeter chamber and incubated for\n15 min at 37 /C176C. The reaction was started by adding (\ufb01nal concentrations)\n200lM Amplex/C210Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-\ntyramine. The production of H 2O2and, consequently, of resoru\ufb01n was\nquanti\ufb01ed at 37 /C176C in a multidetection microplate \ufb02uorescence reader\n(FLX800\u2122, Bio-Tek/C210Instruments, Inc., Winooski, VT, USA) based on the\n\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm) over a 15 min\nperiod, in which the \ufb02uorescence increased linearly. Control experiments were\ncarried out simultaneously by replacing the tested drugs with appropriatedilutions of the vehicles. In addition, the possible capacity of the above tested\ndrugs for modifying the \ufb02uorescence generated in the reaction mixture due to\nnon-enzymatic inhibition (e.g., for directly reacting with Amplex/C210Red reagent)\nwas determined by adding these drugs to solutions containing only the\nAmplex/C210Red reagent in a sodium phosphate buffer. The speci\ufb01c \ufb02uorescence\nemission (used to obtain the \ufb01nal results) was calculated after subtraction of\nthe background activity, which was determined from vials containing all\ncomponents except the hMAO isoforms, which were replaced by a sodium\nphosphate buffer solution.\n35. Y\u00e1\u00f1ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Comm. 2006 ,344,\n688.\n36. Matos, M. J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. J. Med.\nChem. 2011 . doi: 10.1021/jm200716y .\n37. Vi\u00f1a, D.; Matos, M. J.; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. Med. Chem. Comm.\n2011 . doi: 10.1039/C1MD00221J .\n38. Schr\u00f6dinger Suite 2011 Protein Preparation Wizard; Epik version 2.2,\nSchr\u00f6dinger, LLC, New York, NY, 2011 ; Impact version 5.7, Schr\u00f6dinger, LLC,\nNew York, NY, 2011 ; Prime version 3.0, Schr\u00f6dinger, LLC, New York, NY, 2011.\n39. LigPrep, version 2.5, Schr\u00f6dinger, LLC, New York, NY, 2011 .\n40. Schr\u00f6dinger Suite 2011 QM-Polarized Ligand Docking protocol; Glide version\n5.7, Schr\u00f6dinger, LLC, New York, NY, 2011 ; Jaguar version 7.8, Schr\u00f6dinger, LLC,\nNew York, NY, 2011 ; QSite version 5.7, Schr\u00f6dinger, LLC, New York, NY, 2011 .\n41. Glide, version 5.7, Schr\u00f6dinger, LLC, New York, NY, 2011 .\n42. Jaguar, version 7.8, Schr\u00f6dinger, LLC, New York, NY, 2011 .\n43. MacroModel, version 9.9, Schr\u00f6dinger, LLC, New York, NY, 2011 .S. Serra et al. / Bioorg. Med. Chem. Lett. 22 (2012) 258\u2013261 261\n\u0018\u001c\u001b154Synthesis and Electrochemical and Biological Studies of Novel\nCoumarin \u2212Chalcone Hybrid Compounds\nFernanda Pe \u0301rez-Cruz,\u2020Saleta Vazquez-Rodriguez, *,\u2021Maria Joa \u0303o Matos,\u2021Alejandra Herrera-Morales,\u2020\nFrederick A. Villamena,\u00a7Amlan Das,\u00a7Bhavani Gopalakrishnan,\u00a7Claudio Olea-Azar, *,\u2020Lourdes Santana,\u2021\nand Eugenio Uriarte\u2021\n\u2020Free Radical and Antioxidants Laboratory, Inorganic and Analytical Department, Faculty of Chemical and Pharmaceutical Sciences,\nUniversity of Chile, Sergio Livingstone Polhammer 1007, Independencia, Santiago, Chile\n\u2021Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida s/n, 15782, Santiago\nde Compostela, Spain\n\u00a7Department of Pharmacology and Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University,\nColumbus, Ohio 43210, United States\nABSTRACT: A series of novel hydroxy-coumarin \u2212chalcone hybrid compounds 2a\u2212i\nhas been synthesized by employing a simple and e \ufb03cient methodology. An\nelectrochemical characterization using cyclic voltammetry and ESR spectroscopy were\ncarried out to characterize the oxidation mechanism for the target compounds. Theantioxidant capacity and reactivity were determined by ORAC and ESR assays,respectively. Biological assays were assessed to evaluate the cytotoxicity andcytoprotection capacity against ROS/RNS on BAEC. The results revealed that alltested compounds present ORAC values that are much higher than other well-known\nantioxidant compounds such as quercetin and catechin. Compound 2eshowed the\nhighest ORAC value (14.1) and also presented a low oxidation potential, good\nscavenging capacity against hydroxyl radicals, low cytotoxicity, and high cytoprotectiveactivity.\n\u25a0INTRODUCTION\nFree radicals and reactive oxygen and nitrogen species (ROS\nand RNS) are atoms, molecules, or ions possessing at least oneunpaired electron; therefore, they are highly reactive with a\nwide range of other di \ufb00erent molecules. They are constantly\ngenerated and maintained in balance in biological systems\nthrough metabolic processes, and they play important roles in a\nvariety of normal biochemical functions such as cell signaling,\napoptosis, gene expression, ion transport, and pathological\nprocesses.1,2\nIt is accepted that ROS/RNS play di \ufb00erent roles in vivo.\nSome of these roles are positive and are related to their\ninvolvement in energy production, phagocytosis, regulating cell\ngrowth, intercellular signaling, and the synthesis of biologically\nimportant compounds.3However, the overproduction of ROS/\nRNS can have damaging e \ufb00ects on many molecules. ROS/RNS\nare capable of oxidizing cellular proteins, nucleic acids, andlipids because they are very small and highly reactive. Forexample, lipid peroxidation is a free-radical-mediated prop-\nagation of oxidative damage to polyunsaturated fatty acids\ninvolving several types of free radicals, and termination occurs\nthrough enzymatic means or by free-radical scavenging by\nantioxidants.\n4,5Therefore, the excess of ROS/RNS causes a\ndisturbance in the prooxidant \u2212antioxidant balance in favor of\nthe former, leading to potential damage, which is known as\noxidative stress.1,6,7Oxidative stress considerably contributes tothe pathogenesis of in \ufb02ammatory and cardiovascular diseases,\ncancer, diabetes, Alzheimer \u2019s disease, autism, and aging among\nothers.8\u221213\nThe consumption of natural antioxidants, such as \ufb02avonoids,\nsupports the endogenous antioxidant defense system. Both\ndietary and enzymatic antioxidants are components ofinterrelated systems that interact with each other to control\nROS production and thereby ensuring adequate defenses\nagainst oxidative stress.14,15\nIn this sense, many studies concerning the antioxidant\ncapacity of phenolic compounds of di \ufb00erent types (e.g.,\n\ufb02avonoids, coumarins, and tanins) have been established, and\ntheir physicochemical properties have been correlated with\ntheir antioxidant properties.16In general, free-radical scaveng-\ning, redox potential, and the antioxidant activity of these classes\nof compounds mainly depends on the number and position of\nhydrogen-donating hydroxyl groups on the aromatic ring of the\nphenolic molecules, although it is also a \ufb00ected by other\nfactors.17Therefore, low oxidation potentials, the number of\nhydroxyl groups present, and the existence of electron-donating\ngroups and/or the stabilization of a secondary radical via\ndelocalization through conjugated systems play a key role in the\nantioxidant activity.18\u221221\nReceived: April 16, 2013\nPublished: July 16, 2013Article\npubs.acs.org/jmc\n\u00a9 2013 American Chemical Society 6136 dx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145\n\u0018\u001c\u001c155Most of the bene \ufb01cial health e \ufb00ects of \ufb02avonoids are\nattributed to their antioxidant and chelating abilities. Because of\ntheir ability to inhibit low-density lipoprotein (LDL) oxidation,\n\ufb02avonoids have demonstrated unique cardioprotective ef-\nfects.22,23The protective e \ufb00ects of \ufb02avonoids in biological\nsystems are attributed to their capacity for transferring electronsto radicals, chelating metal catalysts,24activating antioxidant\nenzymes,25reducing alpha-tocopherol radicals,26and inhibiting\noxidases.27\nChalcones ( \u03b1-phenyl-\u03b2 -benzoylethylene) are prominent\nsecondary-metabolite precursors of \ufb02avonoids and iso \ufb02avo-\nnoids in plants. Chemically, they consist of two aromatic rings\nlinked by a three-carbon \u03b1,\u03b2-unsaturated system and are known\nto exhibit an impressive array of biological properties.28\u221230\nChalcones have attracted much research attention because of\ntheir pharmaceutical potential resulting from their radical-\nscavenging,31,32antitumor,33,34anti-in \ufb02ammatory,35and neuro-\nprotective properties.36Thus, it is reasonable to explore the\nradical-scavenging properties of the hydroxyl derivatives ofchalcones.\nHowever, coumarins (2 H-chromen-2-one) are a large family\nof compounds of both natural and synthetic origin that are\nimportant because of the pharmacological activities that these\nkind of compounds display,37such as antimicrobial,38mono-\namine oxidase (MAO) inhibition,39\u221241antitumor,42adenosine\nreceptor antagonist,43and antioxidant17among others.\nTherefore, coumarin and chalcones represent promising\nsca\ufb00olds in the medicinal chemistry realm. Taking into account\nthe previously mentioned features18,19and with the aim of\n\ufb01nding new chemical structures with antioxidant activity, we\nhave designed a new sca \ufb00old in which the chalcone fragment is\npartially incorporated in the coumarin moiety. The resulting\ncoumarin \u2212chalcone hybrid \ufb01xes the trans-conformation of the\nchalcone sca \ufb00old by sharing the double bond of the pyrane ring\nof the coumarin nucleus (Scheme 1).\n\u25a0CHEMISTRY\nCoumarin derivatives 2a\u2212iwere e \ufb03ciently synthesized in two\nsteps,40which are brie \ufb02y described as follows: (i) the synthesis\nof methoxy-3-benzoylcoumarins 1a\u2212iand (ii) the synthesis of\nhydroxy-3-benzoylcoumarins 2a\u2212i. These steps are outlined in\nScheme 2.\nOn the basis of the widely used Knoevenagel condensation\nreaction for the preparation of coumarin derivatives,37,44we\nused an e \ufb03cient one-step synthesis to generate methoxy-3-\nbenzoylcoumarin precursors 1a\u2212i. These compounds were\nprepared in good yields (74 \u221298%) using the appropriatelysubstituted salicylaldehyde and the corresponding \u03b2-ketoester\nin the presence of piperidine in ethanol under re \ufb02ux for 2 \u22125h ,\nobtaining the desired compound as a precipitate that wasseparated by \ufb01ltration and further puri\ufb01 ed by recrystallization in\nMeOH/DCM. Final compounds 2a\u2212iwere then synthesized\nby the hydrolysis of the corresponding methoxy precursors 1a\u2212\niby employing an excess of a Lewis acid, BBr\n3, in DCM at 80\n\u00b0C in a Schlenk tube for 48 h followed by treatment with\nMeOH and puri\ufb01 cation by \ufb02ash chromatography of the crude\nproduct (69 \u221298%).\u25a0ELECTROCHEMICAL STUDY\nCyclic Voltammetry. The electrochemical properties of\nhydroxy-coumarin \u2212chalcone derivatives 2a\u2212iwere studied by\ncyclic voltammetry, employing an electrochemical cell withthree electrodes and di \ufb00erent scan rates between 0.050 and\n0.75 V *s\n\u22121. Under these conditions, all derivatives exhibited\none (compounds 2a\u2212g) or two (compounds 2hand2i) anodic\npeaks without the corresponding cathodic peak (Figure 1). Theanodic peak potentials (Epa I and Epa II) obtained at a 0.75 V *\ns\n\u22121scan rate are listed in Table 1.\nCharacterization of Coumarin \u2212Chalcone Radicals by\nESR Spectroscopy. To con \ufb01rm the formation of semiquinone\nradicals from compounds 2a\u2212i, an electron spin resonance\n(ESR) spectroscopy study was performed. For compounds 2a\u2212\ndand2g, the spin trap PBN was used. This nitrone derivative is\na diamagnetic compound that, in the presence of free radicals,produces a spin adduct (paramagnetic species), increasing the\nhalf-life of the radicals species.45The experiment was carried\nout by electrolysis of the derivatives to control the potential in\nsitu using DMSO as the solvent and TBAP as the supportingelectrolyte at room temperature. Next, the PBN spin trap wasadded. In the absence of the PBN spin trap, an ESR spectrum\nwas observed for derivatives 2e,2f,2h, and 2i. Compound 2e,\nwith two hydroxyl groups, evidenced a symmetric ESRScheme 1. Structural Rational Design of Coumarin \u2212\nChalcone Hybrid Compounds\nScheme 2. Synthesis of Methoxylated (1a \u2212i) and\nHydroxylated (2a \u2212i) 3-Benzoylcoumarin Derivativesa\naReagents and conditions: (a) piperidine, EtOH, re \ufb02ux, 2\u22125 h; (b)\nBBr3, DCM, 80 \u00b0C, 48 h.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6137\n\u0018\u001c\u001d156spectrum with \ufb01ve lines (Figure 2a). Compound 2fshowed a\nhyper\ufb01 ne pattern with two lines (Figure 2b) and was simulated\nand characterized by two doublets resulting from two\nnonequivalent hydrogen atoms.ORAC-FL Assay. The capacity for peroxyl radical\nscavenging by coumarin \u2212chalcone hybrids was assessed using\nthe oxygen-radical absorbance capacity (ORAC) assay. This\nmethodology gives an index relative to a standard molecule\n(Trolox), which is a hydrosoluble analog of vitamin E. The\nORAC values obtained for all derivatives are shown in Table 2.All derivatives presented an ORAC index higher than well-known antioxidants quercetin and catechin.\n46Compound 2e\npresented the highest ORAC value of the studied series (14.1).\nAntioxidant Reactivity by ESR Assay. The reactivity\nagainst a mixture of radical species for all of the studiedcoumarin derivatives was carried out by adapting the H\n2O2/\nNaOH/DMSO/DMPO system47using a noncatalytic and\ncompetitive fenton reaction in which the spin trap DMPO andthe antioxidant molecule competes for the hydroxyl, superoxideanion, and methyl radicals.\nFour wide hyper \ufb01ne lines were observed in the control\nmeasure (labeled as \u201cblank \u201d, indicating the absence of the\ntested and antioxidant molecules; Figure 3) because of the\nFigure 1. Cyclic voltammograms of the hydroxy-coumarin \u2212chalcone derivatives 2a\u2212iin phosphate bu\ufb00 er, pH 7.4, at 0.75 V *s\u22121.\nTable 1. Oxidation Potential for Compounds 2a \u2212ia\ncompound Epa I (V) Epa II (V)\n2a 0.77\n2b 0.79\n2c 0.72\n2d 0.77\n2e 0.74\n2f 0.92\n2g 0.30\n2h 0.27 0.69\n2i 0.27 0.77\naValues obtained at a scan rate of 0.75 V *s\u22121.\nFigure 2. Experimental (blue) and simulated (black) ESR spectra for compounds 2e(a) and 2f(b). Simulated hyper \ufb01ne splitting constants (hfscs)\nwere a H= 3.57 and 1.34 G for compound 2eand a H= 2.35, 2.35 (two equivalent hydrogen atom), and 1.75 G for compound 2f.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6138\n\u0018\u001c\u001e157mixture of the DMPO \u2212OH, DMPO \u2212CH 3, and DMPO \u2212O2\u2022\u2212\nadducts that formed.\n\u25a0BIOLOGY\nCytotoxicity Assays. The cytotoxicity of compounds 2a\u2212i\non bovine aortic endothelial cells (BAEC) was assessed and\nevaluated over a concentration range of 0 \u221250\u03bcMb y\nemploying the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-\ntetrazolium bromide (MTT) assay.47The results are shown\nin Table 3 for concentrations of 10, 20, and 50 \u03bcM for each\ncompound studied.Cytoprotection Assays: ROS/RNS Scavenging Activity\nin Cell Systems. Hydrogen Peroxide. To evaluate the\ncytoprotection against H 2O2, derivatives presenting high cell-\nviability values (compounds 2b\u2212g) were selected. These\ncompounds also presented high antioxidant capacity in\nORAC assays and showed notable hydroxyl-radical scavengingactivity.\nBAEC were incubated with two di \ufb00erent concentrations of\neach derivative (10 and 20 \u03bcM) for 24 h in a 24-well plate\nfollowed by treatment with 1 mM H\n2O2for 2 h. Cell viability\nwas then quanti \ufb01ed by the MTT reduction assay (Figure 4a).\nPeroxynitrite. The cytoprotective property of the com-\npounds against peroxynitrite in BAEC was investigated by\nMTT assay. Peroxynitrite was generated in the cells using 3-morpholino-sydnonimine (SIN-1).48Figure 4b shows the\nresults for the cytoprotection assays against peroxynitrite forcompounds 2b\u2212g.\nTheoretical Evaluation of ADME Properties. To\ncorrelate better the druglike properties of the coumarin \u2212\nchalcone hybrid compounds, the lipophilicity, expressed as theoctanol/water partition coe \ufb03cient and herein called log P,a s\nwell as other theoretical calculations such as the topologicalpolar surface area (TPSA), the number of hydrogen-bondacceptors, and the number of hydrogen-bond donors werecalculated using the Molinspiration property program.\n49The\ntheoretical prediction of the absorption, distribution, metabo-lism, and excretion (ADME) properties of all compounds issummarized in table 4.\n\u25a0RESULTS AND DISCUSSION\nTaking into account the importance of the hydroxylsubstituents in the antioxidant properties,17,50we have focused\nthis study on hydroxy-coumarin \u2212chalcone hybrids. All\ncoumarin derivatives described in this Article (compounds1a\u2212iand2a\u2212i) were e \ufb03ciently synthesized according to the\nsimple and generalized experimental procedure outlined inTable 2. ORAC Values and the Percentage of RadicalsScavenging for Compounds 2a \u2212ia\ncompound ORAC value radical scavenging (%)\n2a 9.2\u00b10.4 26\n2b 11.5 \u00b10.4 39\n2c 9.5\u00b10.3 28\n2d 10.9 \u00b10.3 45\n2e 14.1 \u00b10.3 58\n2f 8.3\u00b10.3 65\n2g 13.0 \u00b10.4 100\n2h 8.1\u00b10.6 75\n2i 8.8\u00b10.5 100\nTrolox 1.0\u00b10.2 31\nquercetion 7.3\u00b10.2b\ncatechin 6.8\u00b10.2b\naMeasured by ESR spin trapping in competition with DMPO.bData\nobtained from ref 46.\nFigure 3. ESR spectra for the reactivity assays of compounds 2band\n2i.\nTable 3. Cytotoxicity of Compounds 2a \u2212i tested at Three\nDi\ufb00erent Concentrations on BAECa\ncompound 10 \u03bcM2 0 \u03bcM5 0 \u03bcM\n2a 76\u00b176 0 \u00b164 4 \u00b15\n2b 88\u00b129 5 \u00b128 6 \u00b11\n2c 95\u00b139 3 \u00b19 104 \u00b16\n2d 87\u00b178 2 \u00b15 101 \u00b18\n2e 68\u00b119 4 \u00b159 3 \u00b110\n2f 96\u00b13 101 \u00b119 3 \u00b14\n2g 102\u00b14 100 \u00b159 2 \u00b15\n2h 49\u00b126 8 \u00b126 3 \u00b12\n2i 64\u00b122 3 \u00b127 1 \u00b16\naThe results are expressed as the percentage of cell viability (n = 3).\nFigure 4. Cytoprotection of compounds 2b\u2212gat 10 and 20 \u03bcM\nagainst 1 mM H2O2- (a) and 0.5 mM SIN-1-induced (b) cytotoxicity\nof bovine aortic endothelial cells using MTT assay.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6139\n\u0018\u001c\u001f158Scheme 2. Electrochemical, biological, and theoretical studies\nwere carried out for \ufb01nal tested compounds 2a\u2212i.\nFrom the experimental results obtained by cyclic voltamme-\ntry, we observed that under these conditions all derivatives\nexhibited one (compounds 2a\u2212g) or two (compounds 2hand\n2i) characteristic anodic peaks without the corresponding\ncathodic peak (Figure 1), indicating an irreversible oxidationprocess as a result of the oxidation of one hydroxyl group in anyof the aromatic rings, forming the semiquinone radical.\nThe anodic peak potentials (Epa I and Epa II) obtained at a\n0.75 V *s\n\u22121scan rate are listed in Table 1. Monohydroxyl\nderivatives 2a,2c, and 2d, which contain a hydroxyl substituent\nat the para position of the benzoyl moiety, presented an anodic\npeak potential in the same positive potential range (Epa II =\n0.77, 0.72, and 0.77 V, respectively). The same positive\npotential in derivatives 2aand 2dindicates that the methyl\nsubstituent at position eight of the coumarin core in 2dis not\nrelevant in the oxidation process. In contrast, the bromine\ngroup in derivative 2cseems to provoke a slight decrease in the\nanodic peak potential (Epa II = 0.72 V). The same e \ufb00ect is\nobserved for compound 2e(Epa II = 0.74 V) that, in addition\nto the hydroxyl group present in the benzoyl moiety, also bearsan additional hydroxyl group in the coumarin core.Compounds 2band2f, with a hydroxyl group in the coumarin\nmoiety, presented oxidation potentials that shifted to more\npositive values (0.79 and 0.92 V, respectively), disfavoring the\noxidation process. This e \ufb00ect is more pronounced for\ncompound 2fbecause of the interaction through intramolecular\nhydrogen bonding between the OH group in position eight and\nthe oxygen atom of the pyrone ring as well as the electron-\nwithdrawing properties of this pyrone system.\n51\nCompounds 2g,2h, and 2ishowed a characteristic peak (Epa\nI) attributed to the catechol moiety. This oxidation occurred ata low potential (0.30, 0.27, and 0.27 V, respectively) because of\nthe electron-donating e \ufb00ect of the hydroxyl group at the 3 \u2032\nposition of the benzoyl moiety as well as the favorable quinone\nformation as the \ufb01nal product in these derivatives. In addition\nto this low-potential oxidation peak, compounds 2hand 2i\nshowed an additional second peak that was assigned to the\nhydroxyl group at position eight of the coumarin core.\nThe data obtained for the characterization of the coumarin \u2212\nchalcone radicals by ESR spectroscopy showed that in the\nabsence of the spin trap N-tert-butyl- \u03b1-phenylnitrone (PBN),\nthe oxidation of compounds 2a\u2212dand2ggave no ESR signal.\nHowever, in the presence of PBN, a hyper \ufb01ne pattern with six\nlines was observed, corresponding to the formation of a carbon-centered semiquinone spin adduct (a\nH\u224813.5 and 2.3 G were\nfound for all compounds).52Compound 2e, with two hydroxylgroups, evidenced a symmetric ESR spectrum with \ufb01ve lines\n(Figure 2a), and it was interpreted as a semiquinone radical in\nwhich the hyper \ufb01ne pattern corresponds to one triplet assigned\nto two equivalent hydrogen atoms with a H= 2.37 G and two\ndoublets corresponding to one non equivalent hydrogen atomwith hyper \ufb01ne constants a\nH= 2.35 and 1.75 G.\nCompound 2fshowed a hyper \ufb01ne pattern with two lines\n(Figure 2b) and was simulated and characterized by two\ndoublets resulting from two nonequivalent hydrogen atoms\nwith aH= 1.34 and 3.57 G. For the radical species of compound\n2h, the ESR spectrum (data not shown) was simulated by two\ndoublets attributed to two nonequivalent hydrogen atoms with\naH= 4.35 and 2.37 G. Finally, for the radical species of\ncompound 2i, the hyper\ufb01 ne pattern was interpreted and\nsimulated by four doublets resulting from four nonequivalent\nhydrogen atoms with hyper \ufb01ne coupling constants a H= 2.82,\n2.93, 2.06, and 1.83 G as well as one triplet with a H= 3.37 G\nresulting from two equivalent hydrogen atoms.\nThe antioxidant capacity of compounds 2a\u2212iwas studied by\nORAC-FL assays. From the data obtained, which issummarized in Table 2, we observed that the di \ufb00erence\nbetween the ORAC values could be related to the substituents\npresent in these derivatives. Derivatives 2aand2b, with one\nhydroxyl group at the para position of the benzoyl moiety and\nat the six position of the coumarin sca \ufb00old, respectively,\npresented ORAC values of 9.2 and 11.5, respectively.\nCompounds 2cand 2d, with a hydroxyl group in the same\nposition as in compound 2abut with an additional bromine\nsubstituent in position six of the coumarin or a methyl\nsubstituent at the position eight, respectively, presented ORAC\nvalues of 9.5 and 10.9, respectively. Derivative 2e, which\ncombines the substitution pattern of compounds 2aand2b,\nwas found to be the compound with the highest ORAC value\n(14.1).\nHowever, by structurally comparing compounds 2cand2g,\nwe observed that the only di \ufb00erence is the presence of an\nadditional hydroxyl group at the 3 \u2032position of the benzoyl\nmoiety in compound 2g, forming a catechol function. This\nmodi\ufb01cation increases the antioxidant capacity in compound 2g\n(ORAC = 13.0). ORAC values of around 8 were observed for\ncompounds 2f,2h, and 2i. In addition to the catechol function,\ncompounds 2hand2ipresent an additional hydroxyl group at\nposition eight of the coumarin ring compared to structurally\nrelated compound 2g. This additional hydroxyl group could\nform a hydrogen bond with the oxygen atom of the pyrone\nring, disfavoring the transfer of the hydrogen atom.\nThe antioxidant reactivity of compounds 2a\u2212iwas studied by\nan ESR assay. With this method, it was observed that theTable 4. Theoretical Predictionaof the ADME Properties of Compounds 2a \u2212i\ncompound log P molecular weight TPSA (\u00c52) n\u2212OH acceptors n\u2212OHNH donors volume (\u00c53)\n2a 2.92 266.25 67.51 4 1 227.00\n2b 2.89 266.25 67.51 4 1 227.00\n2c 3.70 345.15 67.51 4 1 244.88\n2d 3.32 280.28 67.51 4 1 243.56\n2e 2.42 282.25 87.74 5 2 235.01\n2f 3.89 345.15 67.51 4 1 244.88\n2g 3.21 361.15 87.74 5 2 252.90\n2h 2.16 298.25 107.97 6 3 243.03\n2i 2.92 377.15 107.97 6 3 260.92\naTPSA, topological polar surface area; n\u2212OH, number of hydrogen acceptors; n\u2212OHNH, number of hydrogen bond donors. The data was\ndetermined with the Molinspiration calculation software.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6140\n\u0018\u001c 159intensity of the spectrum decreased in the presence of the\ntested coumarin \u2212chalcone hybrid compounds that were added\nto the system (red line, Figure 3). This behavior was observed\nin all derivatives 2a\u2212i, and the percent of the radicals (CH3\u2022,\nOH\u2022,O 2\u2022\u2212) scavenging activity is represented in Table 2. The\nscavenging values obtained could be related to the number andposition of the hydroxyl substituents. Compounds 2gand2i\nshowed a di \ufb00erent hyper\ufb01 ne pattern, which was attributed to\nthe formation of carbon-centered spin adducts (Figure 3),\ndemonstrating that the secondary semiquinone radical for eachcompound was trapped by the DMPO spin trap and the radical\nscavenging percentages were close to 100.\nIn general, the MTT assay only provides qualitative trends\nfor the cytotoxicity of the compounds and the cytoprotective\nproperties. The cytotoxicity of compounds 2a\u2212ion BAEC\nusing di \ufb00erent concentrations (10, 20, and 50 \u03bcM) is shown in\nTable 3. Derivatives 2b\u2212gshowed cell viabilities between 86\nand 100% up to the maximum concentration of 50 \u03bcM.\nCompounds 2a,2h, and 2ishowed signi \ufb01cant toxicity at 50\n\u03bcM, whereas compound 2a, which was the most toxic, resulted\nin only a 44% viability. The varying degrees in the toxicity of\nthe compounds can be accounted for by several factors, such as\nthe di \ufb00erences in their compartmentalization properties, the\nnature and concentration of ROS produced, and their ability to\nscavenge radicals and/or initiate pro-apoptotic signaling\npathways.\nBecause compounds 2a, 2i , and 2hdemonstrated signi \ufb01cant\ntoxicity, they were not used for the cytoprotection assays.\nHowever, compounds 2b\u2212g, because of their low toxicity, were\nexamined at lower doses of 10 and 20 \u03bcM to test their\ncytoprotection against hydrogen peroxide (H\n2O2) or peroxyni-\ntrite (ONOO\u2212) generated from SIN-1, and the data are shown\nin Figure 4 panels a and b, respectively. Compounds 2band2d\nshowed the highest cytoprotection against H 2O2compared to\nall compounds, which presented around 40% cytoprotection at10\u03bcM. At 20 \u03bcM, compounds 2c\u22122fwere cytoprotective\nagainst ONOO\n\u2212by\u223c90\u221295%, whereas compound 2b\nimparted no protection at this concentration. Compound 2g\nwas not cytoprotective against both H2O2and ONOO\u2212at any\nof the concentrations tested. All of the studied compounds\nshowed observable cytoprotection, with remarkable results for\ncompounds 2b\u2212f. In our previous work,53it was shown that a\nlypophilic spin trap such as PBN protects BAEC from H 2O2\u2212\ninduced toxicity, whereas more polar DMPO protects the cellsmore e \ufb03ciently from ONOO\n\u2212. The studied compounds show a\nbetter cytoprotective e \ufb00ect against ONOO\u2212. However, because\nof the complexity of the mechanisms that are directly and\nindirectly involved in this assay, it is di \ufb03cult to determine if a\ncorrelation exists between the cytoprotection and partition\ncoe\ufb03cients because these latter values were theoretically\ncalculated. Moreover, the oxidation potentials may not showa direct correlation with the cytotoxicity/cytoprotection databecause of other cellular events that are involved such as\nvariations in the ability of the compounds to redox cycle,\nsubcellular compartmentalization, degradation by cellular\noxido-reductants, and the ability to induce (or suppress)\nnonradical-mediated pro-apoptotic p athways. Therefore,\nalthough we would like to determine if a direct correlation\nexists between the cytotoxicity and physical data, such as the\npartition coe \ufb03cient and redox potentials, the complexity of the\nmechanisms involved in cell viability makes this correlationdi\ufb03cult to realize.\n19,54,55From the data obtained for the theoretical evaluation of the\nADME properties, one can notice that hybrid compounds 2a\u2212i\ndo not break any point of the Lipinski \u2019s rule of \ufb01ve, making\nthem promising leads for drug candidates.56TPSA and log P\nvalues are compatible with those described as a predictive\nindicator of a drug \u2019s capacity for membrane penetration.57\n\u25a0CONCLUSIONS\nIn this Article, we describe the synthesis of coumarin \u2212chalcone\nhybrid compounds by employing the Knoevenagel reaction as akey step for the e \ufb03cient preparation of a selected series. The\nelectrochemical properties of the studied compounds proved to\nbe excellent, presenting low oxidation potentials, very high\nORAC values (all of them were higher than the referencecompounds quercetin and catechin), and a high percentage ofradical scavenging. In most cases, the compounds presentedlow cytotoxicity for BAEC in culture even at the highestconcentration tested as well as good cytoprotective e \ufb00ects\nagainst H\n2O2and ONOO\u2212induced cell death. In addition, the\nwhole series of compounds presented good theoretical ADME\nproperties. Therefore, on the basis of these results, the\nsynthesized coumarin \u2212chalcone hybrid compounds can be\nconsidered to be promising sca \ufb00olds in the studied area.\nIt is worth noting that compound 2epresented the highest\nORAC value (14.1), good scavenging capacity, low cytotoxicity,\nand high cytoprotection values, especially against ONOO\u2212\ninduced cell death (almost 100% cell viability at 20 \u03bcM);\ntherefore, it can be considered to be potential candidate as alead compound for more thorough studies of its antioxidantproperties.\n\u25a0EXPERIMENTAL SECTION\nChemistry. Melting points were determined using a Reichert\nKo\ufb02er thermopan or in capillary tubes on a Bu \u0308chi 510 apparatus and\nare uncorrected.1H and13C NMR spectra were recorded with a\nBruker AMX spectrometer at 300 and 75.47 MHz, respectively, using\nTMS as the internal standard (chemical shifts are given in \u03b4values, Jis\ngiven in Hz). Mass spectra were obtained using a Hewlett-Packard\n5988A spectrometer. Elemental analyses were performed using a\nPerkinElmer 240B microanalyser and were within \u00b10.4% of calculated\nvalues in all cases. Silica gel (Merck 60, 230 \u221200 mesh) was used for\n\ufb02ash chromatography (FC). Analytical thin layer chromatography\n(TLC) was performed on plates precoated with silica gel (Merck 60F254, 0.25 mm). The purity of compounds 1a\u2212iand 2a\u2212iwas\nassessed by HPLC and was found to be higher than 95%. All of thechemical reagents employed in the synthesis process were obtainedfrom Aldrich Chemical Co., Fluka, Across, or Merck (analytical\nreagent grade). All reactions were carried out under a deoxygenated\nand dry argon atmosphere unless otherwise indicated. Argon was driedby\ufb02owing it through CaCl\n2columns, NaOH stones, and P 2O5.\nGeneral Procedure for the Synthesis of Methoxy-3-benzoylcou-\nmarins 1a\u2212i.40To a solution of the appropriate \u03b2-ketoester (1 mmol)\nand the corresponding salicylaldehyde (1 mmol) in ethanol (3 mL)was added piperidine in a catalytic amount. The mixture was re \ufb02uxed\nfor 2\u22125 h. After completion (indicated by TLC), the reaction was\ncooled, and the precipitated was \ufb01ltered and washed with cold ethanol\nand ether to a \ufb00ord the desired compound. The compounds were\nfurther recrystallized from MeOH/CH\n2Cl2.\n6-Bromo-3-(4\u2032 -methoxybenzoyl)coumarin ( 1c).Yellow solid.\nYield: 92%. mp 222 \u2212224 \u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b4\n8.25 (s, 1H, H-4), 8.05 (s, 1H, H-5), 7.92 (d, J= 8.5 Hz, 2H, H-2 \u2032,H -\n6\u2032), 7.84 (d, J= 8.7 Hz, 1H, H-7), 7.44 (d, J= 8.7 Hz, 1H, H-8), 7.05\n(d,J= 8.5 Hz, 2H, H-3 \u2032, H-5 \u2032), 3.85 (s, 3H, OCH3).13C NMR (75\nMHz, DMSO- d6)\u03b4190.1, 164.5, 158.1, 153.5, 143.3, 135.9, 132.7,\n131.9, 129.0, 128.3, 120.6, 119.0, 116.7, 114.6, 56.2. MS (EI) m/z(%):Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6141\n\u0018\u001d\u0017160359/361 (M+, 28), 135 (100), 92 (19), 77 (20). Anal. Calcd for\nC17H11BrO4: C, 56.85; H, 3.09. Found: C, 56.82; H, 3.07.\n8-Methyl-3-(4 \u2032-methoxybenzoyl)coumarin ( 1d).White solid. Yield\n93%. mp 250 \u2212252\u00b0C.1H NMR (300 MHz, DMSO-d6)\u03b48.34 (s, 1H,\nH-4), 7.91 (d, J= 8.7 Hz, 2H, H-2 \u2032, H-4 \u2032), 7.73\u22127.24 (m, 3H, H-5, H-\n6, H-7), 7.06 (d, J=8.7 Hz, 2H, H-3 \u2032, H-5 \u2032), 3.86 (s, 3H, OCH3), 2.41\n(s, 3H, CH3).13C NMR (75 MHz, DMSO- d6)\u03b4190.2, 164.4, 158.4,\n152.9, 152.8, 144.7, 134.7, 132.3, 129.6, 127.7, 125.8, 124.7, 118.5,\n114.6, 56.1, 15.0. MS (EI) m/z(%): 295 ([M + 1]+, 19), 294 (M+,\n100), 135 (88), 77 (31). Anal. Calcd for C18H14O4: C, 73.46; H, 4.79;\nFound: C, 73.39; H, 4.57.\n6-Methoxy-3-(4 \u2032-methoxybenzoyl)coumarin ( 1e).Yellow solid.\nYield 80%. mp 182 \u2212184\u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b47.84\n(s, 1H, H-4), 7.71 (d, J=8.9 Hz, 2H, H-2 \u2032, H-6 \u2032), 7.13\u22126.94 (m, 3H,\nH-5, H-7, H-8), 6.77 (d, J=8.9 Hz, 2H, H-3 \u2032, H-5 \u2032), 3.83 (s, 3H,\nOCH 3), 3.71 (s, 3H, OCH 3).13C NMR (75 MHz, DMSO- d6)\u03b4190.2,\n164.0, 158.3, 155.9, 148.6, 144.2, 132.3, 128.9, 127.3, 121.1, 118.9,\n117.6, 114.2, 111.6, 55.9, 55.8. MS (EI) m/z(%): 311 ([M + 1]+, 29),\n310 (M+, 92), 135 (100), 92 (22), 77 (27). Anal. Calcd for C 18H14O5:\nC, 69.67; H, 4.55. Found: C, 69.45; H, 4.33.\n6-Bromo-3-(3 \u2032,4\u2032-dimethoxybenzoyl)coumarin ( 1g).Yellow solid.\nYield 98%. mp 223 \u2212224\u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b48.23\n(s, 1H, H-4), 8.05 (d, J= 2.4 Hz, 1H, H-5), 7.84 (dd, J= 8.8, 2.4 Hz,\n1H, H-7), 7.56 (dd, J= 8.4, 2.0 Hz, 1H, H-6 \u2032), 7.52\u2212 7.38 (m, 2H, H-8,\nH-2\u2032), 7.05 (d, J= 8.4 Hz, 1H, H-5\u2032 ), 3.86 (s, 3H, 4 \u2032-OCH3), 3.81 (s,\n3H, 3 \u2032-OCH3).13C NMR (75 MHz, DMSO- d6)\u03b4189.8, 157.7, 154.3,\n153.2, 149.0, 142.8, 135.6, 131.6, 128.7, 127.9, 125.8, 120.4, 118.8,\n116.4, 111.3, 111.1, 56.1, 55.9. MS (EI) m/z(%): 389/391 (M+, 59),\n165 (100), 71 (31). Anal. Calcd for C18H13BrO5: C, 55.55; H, 3.37.\nFound: C, 55.54; H, 3.39.\n8-Methoxy-3-(3 \u2032,4\u2032-dimethoxybenzoyl)coumarin ( 1h).Pale-yel-\nlow solid. Yield: 95%. mp 238 \u2212240 \u00b0C.1H NMR (300 MHz,\nDMSO- d6)\u03b48.28 (s, 1H, H-4), 7.54 (dd, J= 8.2, 2.1 Hz, 1H, H-6 \u2032),\n7.46 (d, J= 2.1 Hz, 1H, H-2 \u2032), 7.43 \u22127.27 (m, 3H, H-5, H-6, H-7),\n7.04 (d, J= 8.2 Hz, 1H, H-5 \u2032), 3.93 (s, 3H, OCH3), 3.85 (s, 3H,\nOCH3), 3.81 (s, 3H, OCH3).13C NMR (75 MHz, DMSO- d6)\u03b4190.2,\n157.9, 154.1, 148.9, 146.6, 144.6, 143.5, 128.8, 127.1, 125.7, 124.9,\n120.7, 119.0, 115.5, 111.1, 111.0, 56.3, 56.0, 55.8. MS (EI) m/z(%):\n341 ([M + 1]+, 25), 340 (M+, 97), 165 (100), 137 (9), 77 (10). Anal.\nCalcd for C19H16O6: C, 67.05; H, 4.74. Found: C, 67.06; H, 4.74.\n6-Bromo-8-methoxy-3-(3 \u2032,4\u2032-dimethoxybenzoyl)coumarin ( 1i).\nPale-yellow solid. Yield 90%. mp 276 \u2212277\u00b0C.1H NMR (300 MHz,\nDMSO- d6)\u03b48.21 (s, 1H, H-4), 7.67 \u22127.49 (m, 3H, H-5, H-7, H-6 \u2032),\n7.46 (s, 1H, H-2 \u2032), 7.04 (d, J= 8.5 Hz, 1H, H-5 \u2032), 3.96 (s, 3H, 4 \u2032-\nOCH 3), 3.85 (s, 3H, 8-OCH 3), 3.80 (s, 3H, 3 \u2032-OCH 3).13C NMR (75\nMHz, DMSO- d6)\u03b4195.3, 155.1, 149.9, 149.8, 148.2, 143.6, 138.1,\n129.4, 128.9, 128.7, 126.0, 123.4, 119.0, 116.8, 112.6, 112.0, 59.0, 57.6,\n56.7. MS (EI) m/z(%): 418/420 (M+, 98), 165 (100), 77 (18). Anal.\nCalcd for C19H15BrO6: C, 54.43; H, 3.61. Found: C, 54.43; H, 3.62.\nGeneral Procedure for the Synthesis of Hydroxy-3-benzoylcou-\nmarins ( 2a\u2212i).40To the corresponding methoxy-3-benzoylcoumarin\n(1 mmol), BBr3in DCM (20 mmol, 1M) was added in a Schlenk tube.\nThe tube was sealed, and the reaction mixture was heated at 80 \u00b0C for\n48 h. The resulting crude product was treated with MeOH and rotatedto dryness. The obtained precipitate was recrystallized from MeOH or\npuri\ufb01ed by \ufb02ash chromatography using hexane/ethyl acetate mixtures\nas the eluent to a \ufb00ord the desired hydroxy derivative.\n3-(4\u2032-Hydroxybenzoyl)coumarin ( 2a).White solid. Yield: 78%. mp\n242\u2212243\u00b0C (mp lit. 239 \u00b0C).581H NMR (300 MHz, DMSO- d6)\u03b4\n10.58 (bs, 1H, OH), 8.30 (s, 1H, H-4), 7.89 \u22127.75 (m, 3H, H-5, H-2 \u2032,\nH-6\u2032), 7.78 \u22127.64 (m, 1H, H-7), 7.51 \u22127.37 (m, 2H, H-6, H-8), 6.86\n(d,J= 8.8, 2H, H-3 \u2032,H-5\u2032).13C NMR (75 MHz, DMSO- d6)\u03b4190.1,\n163.4, 158.5, 154.3, 144.2, 133.6, 132.9, 129.9, 127.8, 127.5, 125.3,\n118.7, 116.7, 115.8. MS (EI) m/z(%): 267 ([M + 1]+, 20), 266 (M+,\n93), 237 (25), 121 (100), 93 (22), 65 (25). Anal. Calcd for C16H10O4:\nC, 72.18; H, 3.79. Found: C, 71.83; H, 3.53.\n6-Bromo-3-(4 \u2032-hydroxybenzoyl)coumarin ( 2c).Pale-yellow solid.\nYield: 73%. mp 295 \u2212298\u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b410.61\n(bs, 1H, OH), 8.22 (s, 1H, H-4), 8.05 (d, J= 2.4 Hz, 1H, H-5), 7.93 \u2212\n7.73 (m, 3H, H-7, H-2\u2032 , H-6 \u2032), 7.45 (d, J= 8.8 Hz, 1H, H-8), 6.86 (d, J= 8.7 Hz, 2H, H-3 \u2032, H-5 \u2032).13C NMR (75 MHz, DMSO- d6)\u03b4190.0,\n163.6, 158.1, 153.4, 142.8, 136.2, 133.0, 131.8, 128.5, 127.6, 120.7,\n119.0, 116.7, 115.9. MS (EI) m/z(%): 343/345 (M+, 49), 121 (100).\nAnal. Calcd for C16H9BrO4: C, 55.68; H, 2.63. Found: C, 55.30; H,\n2.45.\n3-(4\u2032-Hydroxybenzoyl)-8-methylcoumarin ( 2d).White solid.\nYield: 56%. mp 252 \u2212253 \u00b0C.1H NMR (300 MHz DMSO- d6)\u03b4\n10.56 (bs, 1H, OH), 8.27 (s, 1H, H-4), 7.80 (d, J= 8.4 Hz, 2H, H-2 \u2032,\nH-6\u2032), 7.63 (d, J= 7.5 Hz, 1H, H-5), 7.57 (d, J= 7.5 Hz, 1H, H-7),\n7.30 (t, J= 7.5 Hz, 1H, H-6), 6.86 (d, J= 8.4 Hz, 2H, H-3 \u2032, H-5 \u2032), 2.40\n(s, 3H, CH3).13C NMR (75 MHz, DMSO- d6)\u03b4190.2, 163.4, 158.6,\n152.6, 144.6, 134.6, 132.9, 127.8, 127.7, 127.2, 125.6, 124.8, 118.5,\n115.9, 15.3. MS (EI) m/z(%): 281 ([M + 1]+, 54), 280 (M+, 96), 252\n(46), 251 (51), 120 (100), 93 (56), 65 (67). Anal. Calcd forC\n17H12O4: C, 72.85; H, 4.32. Found: C, 72.67; H, 4.12.\n6-Hydroxy-3-(4 \u2032-hydroxybenzoyl)coumarin ( 2e).Brown crystals.\nYield: 65%. mp 301\u2212 303\u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b410.58\n(bs, 1H, 4 \u2032\u2212OH), 9.86 (bs, 1H, 8-OH,), 8.21 (s, 1H, H-4), 7.79 (d, J=\n8.8 Hz, 2H, H-2 \u2032, H-6 \u2032), 7.37\u22127.24 (m, 1H, H-5), 7.19 \u22127.01 (m, 2H,\nH-7, H-8), 6.86 (d, J= 8.8 Hz, 2H, H-3 \u2032, H-5 \u2032).13C NMR (75 MHz,\nDMSO- d6)\u03b4190.3, 163.4, 158.8, 154.4, 147.7, 144.0, 132.9, 127.8,\n127.6, 121.6, 119.2, 117.6, 115.9, 113.7. MS (EI) m/z(%): 283 ([M +\n1]+, 9), 282 (M+, 51), 121 (100), 93 (15), 65 (18). Anal. Calcd for\nC16H10O5: C, 68.09; H, 3.57. Found: C, 68.23; H, 3.33.\n3-Benzoyl-6-bromo-8-hydroxycoumarin ( 2f).Pale-yellow solid.\nYield: 98%. mp 293 \u2212295 \u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b4\n10.92 (s, 1H, OH), 8.30 (s, 1H, H-4), 7.93 (dd, J= 8.1, 1.4 Hz, 2H, H-\n2\u2032, H-6 \u2032), 7.79\u22127.63 (m, 1H, H-5), 7.63\u2212 7.44 (m, 3H, H-3 \u2032, H-4 \u2032,H -\n5\u2032), 7.34\u22127.24 (m, 1H, H-8).13C NMR (75 MHz, DMSO- d6)\u03b4191.9,\n157.9, 146.3, 144.8, 142.7, 136.3, 134.5, 130.0, 129.2, 127.8, 121.9,121.8, 120.9, 116.2. MS (EI) m/z(%): 344/346 (M\n+, 46), 105 (100),\n77 (59). Anal. Calcd for C 16H9BrO 5: C, 53.21; H, 2.51. Found: C,\n52.97; H, 2.41.\n6-Bromo-3-(3 \u2032,4\u2032-dihydroxybenzoyl)coumarin ( 2g).Yellow solid.\nYield: 72%. mp 264\u2212 266\u00b0C.1H NMR (300 MHz, DMSO- d6)\u03b410.14\n(s, 1H, OH), 9.47 (s, 1H, OH), 8.19 (s, 1H, H-4), 8.05 (d, J= 2.1 Hz,\n1H, H-5), 7.84 (dd, J= 8.8, 2.2 Hz, 1H, H-7), 7.45 (d, J= 8.8 Hz, 1H,\nH-8), 7.39 \u22127.20 (m, 2H, H-2 \u2032, H-6 \u2032), 6.82 (d, J= 8.1 Hz, 1H, H-5 \u2032).\n13C NMR (75 MHz, DMSO- d6)\u03b4189.6, 157.9, 153.3, 152.5, 145.9,\n142.3, 135.7, 131.7, 128.4, 127.8, 124.5, 120.5, 119.0, 116.7, 116.3,115.7. MS (EI) m/z(%): 360/362 (M\n+, 87), 253 (47), 251 (45), 227\n(14), 225 (18), 137 (100), 109 (44). Anal. Calcd for C16H9BrO5:C ,\n53.21; H, 2.51. Found: C, 53.23; H, 2.52.\n8-Hydroxy-3-(3 \u2032,4\u2032-dihydroxybenzoyl)coumarin ( 2h).Bright-yel-\nlow solid. Yield: 81%. mp 277 \u2212279\u00b0C.1H NMR (300 MHz, DMSO-\nd6)\u03b410.35 (s, 1H, OH), 10.10 (s, 1H, OH), 9.47 (s, 1H, OH), 8.20\n(s, 1H, H-4), 7.36 \u22127.06 (m, 5H, H-5, H-6, H-7, H-2 \u2032, H-6 \u2032), 6.82 (d, J\n= 8.2 Hz, 1H, H-5\u2032 ).13C NMR (75 MHz, DMSO- d6)\u03b4190.2, 158.4,\n152.3, 145.8, 145.0, 144.2, 142.8, 128.0, 127.4, 125.3, 124.2, 119.7,119.5, 116.4, 115.7. MS (EI) m/z(%): 299 ([M + 1]\n+, 8), 298 (M+,\n41), 155 (16), 137 (100), 91 (31). Anal. Calcd for C16H10O6:C ,\n64.43; H, 3.38. Found: 64.43; H, 3.39.\n6-Bromo-8-hydroxy-3-(3\u2032 ,4\u2032-dihydroxybenzoyl)coumarin ( 2i).\nPale-yellow solid. Yield 69%. mp 300 \u2212302\u00b0C.1H NMR (300 MHz,\nDMSO- d6)\u03b410.89 (s, 1H, OH), 10.14 (s, 1H, OH), 9.48 (s, 1H,\nOH), 8.14 (s, 1H, H-4), 7.45 (d, J= 2.2 Hz, 1H, H-5), 7.38 \u22127.12 (m,\n3H, H-7, H-2 \u2032, H-5 \u2032), 6.81 (dd, J= 8.1, 3.0 Hz, 1H, H-6 \u2032).13C NMR\n(75 MHz, DMSO- d6)\u03b4189.3, 157.4, 152.0, 145.8, 145.5, 142.3, 141.9,\n128.0, 127.4, 124.0, 121.1, 121.0, 120.5, 115.9, 115.8, 115.2. MS (EI)\nm/z(%): 376/378 (M+, 100), 269 (30), 267 (24), 137 (80), 109 (74).\nAnal. Calcd for C16H9BrO6: C, 50.95; H, 2.41. Found: C, 50.92; H, 2.\n43.\nCyclic Voltammetry. Cyclic voltammetry was carried out using a\npotentiostat/galvanostat VersaSTAT 3 that was provided with the V3-\nStudio electrochemistry software package in 50 mM sodium phosphatebu\ufb00er (pH 7.4) at room temperature using a three-electrode cell. A\nglassy-carbon electrode was used as the working electrode, a platinum\nwire, the auxiliary electrode, and Ag, AgCl/KCl (ca. 3.5 M), the\nreference electrode. All coumarin\u2212 chalcone hybrids were studied to 1\nmM in 20% methanol as \ufb01nal concentration.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6142\n\u0018\u001d\u0018161Characterization of Coumarin-Chalcone Radicals by ESR Spec-\ntroscopy. ESR measurements were carried out on an ESR\nspectrometer equipped with a high-sensitivity resonator at room\ntemperature. Unless otherwise indicated, the instrument settings used\nfor general spectral acquisition were microwave power, 10 mW,\nmodulation amplitude, 1 G, receiver gain, 1.0 \u00d7104or 1.0 \u00d7105, scan\ntime, 21.5 s, time constant, 40.0 s, and sweep width, 120 G. The\noxidation process was carried out by using 30% H2O2and NaOH (25\nmM) in the presence of chalcone \u2212coumarin hybrids. Scans were\nintegrated using the Bruker WINEPR v.2.11b software. The samplecells used were 50 \u03bcL glass capillary tubes. An automatic \ufb01tting\nprogram carried out the spectrum simulation. The hyper \ufb01ne splitting\nconstants were estimated to be accurate to within 0.05 G.\nRadical-Generating System to Test Coumarin-Chalcone Hybrids.\nTo the corresponding coumarin\u2212 chalcone hybrid compound (1.2\nmmol) in dimethyl sulfoxide (20 \u03bcL), a hydrogen peroxide solution\n(50\u03bcL, 30%) and a sodium hydroxide solution (50 \u03bcL, 25 mM) were\nadded. The total volume of the resulting solution (300 \u03bcL) was\ncompleted with DMSO to achieve a \ufb01nal 4 mM solution of the tested\ncompounds.\nORAC-FL Assay. The ORAC-FL assays were carried out on a\nSynergy HT multidetection microplate reader (Bio-Tek Instruments,\nInc.) using white polystyrene 96-well plates. Fluorescence was read\nfrom the top, with an excitation wavelength of 485/20 nm and an\nemission \ufb01lter of 528/20 nm. The plate reader was controlled by Gen\n5 software. The oxygen radical absorbance capacity was determined as\npreviously described46with slight modi \ufb01cations. The reaction was\ncarried out in 75 mM sodium phosphate bu\ufb00 er (pH 7.4) at a 200 \u03bcL\n\ufb01nal volume. FL (70 nM, \ufb01nal concentration) and coumarin \u2212chalcone\nsolutions in methanol with a range of concentration between 0.3 to 2\n\u03bcM and 0.5 to 7 \u03bcM for the monohydroxy and dihydroxy derivatives,\nrespectively, were placed in each well of the 96-well plate. This rangeof concentration was selected empirically to obtain a good separationbetween the \ufb02uorescence curves. This separation was crucial for more\naccurate data treatment.\n59,60The mixture was preincubated for 15 min\nat 37 \u00b0C before rapidly adding the AAPH solution (18 mM, \ufb01nal\nconcentration). The microplate was immediately placed in the reader\nand automatically shaken prior to each reading. The \ufb02uorescence was\nrecorded every 1 min for 120 min. A blank with FL and AAPH using\nmethanol instead of the antioxidant solution as well as \ufb01ve calibration\nsolutions using Trolox (0.5 to 2.5 \u03bcM) as a standard molecule were\nalso used in each assay. The inhibition capacity was expressed asORAC values, and it was quanti \ufb01ed by employing eq 1. All reaction\nmixtures were prepared in triplicate, and at least three independent\nassays were performed for each sample.\n=\u2212\n\u2212relative ORAC value[AUC AUC ]\n[AUC AUC ][trolox]\n[derivative]0\ntrolox0(1)\nwhere AUC0= area under the curve blank; AUC = area under the\ncurve derivative; AUCtrolox= area under the curve Trolox (standard);\n[trolox] = Trolox concentration, molar; and [Derivative] = derivative\nconcentration, molar\nThe AUC was calculated by integrating the decay of the\n\ufb02uorescence where F0is the initial \ufb02uorescence read at 0 min and F\nis the \ufb02uorescence read at a particular time. The AUCNET\ncorresponding to the sample was calculated by subtracting the AUC\ncorresponding to the blank. Data processing was performed using\nOrigin Pro 8 SR2 (Origin Lab Corporation).\nAntioxidant Reactivity by ESR Assay. The reactivity of all\ncoumarin\u2212 chalcone hybrids against hydroxyl radicals was assessed\nusing the noncatalytic Fenton method that was previously described.56\nIn a typical experiment, 150 \u03bcL of dimethyl sulfoxide was mixed with\n50\u03bcL of NaOH (3 mM) followed by the addition of 50 \u03bcL of DMPO\n(30 mM) spin trap and 50 \u03bcL of hydrogen peroxide (30%). All\nderivatives were studied at a 4 mM \ufb01nal concentration and a 300 \u03bcL\n\ufb01nal volume. The mixture was positioned in the ESR cell, and the\nspectra were recorded after 5 min of the reaction.\nBiological Studies. All chemicals and solvents used were of the\nhighest analytical grade. For cell culture, all reagents or materials werepurchased and used without further puri \ufb01cation. Bovine aortic\nendothelial cells were purchased from Cell Systems (Kirkland, WA)\nand nonessential amino acids and Fetal Bovine Serum (FBS) were\npurchased from Gibco and Invitrogen, respectively.\nCell Culture. Cells were cultured in 75 cm2tissue-culture \ufb02asks\nusing Dulbecco \u2019s modi \ufb01ed Eagle\u2019 s medium with 1 g/L of D-glucose\nand 4 mM L-glutamine and supplemented with 10% fetal bovine\nserum, 2.5 mg/L of endothelial cell growth supplement, and 1%nonessential amino acids in the absence of antibiotics at 37 \u00b0Ci na\nhumidi \ufb01ed atmosphere of 5% CO\n2and 20% O2. The medium was\nchanged every 2 to 3 days, and the cells were subcultured once they\nreached 80 \u221285% con \ufb02uence.51\nCytotoxicity and Cytoprotection. Cytotoxicity assays in BAEC cells\nwere performed for all coumarin \u2212chalcone hybrids using the MTT\nreduction assay. BAEC were seeded in 24-well plates at a density\nranging between 104\u2212105cells/mL per well. After the cells reached\n60\u221270% con \ufb02uence, they were incubated in the presence of 10 to 50\n\u03bcM of the corresponding coumarin \u2212chalcone derivatives for 24 h.\nAfter incubation, the medium was changed (2 mL) and 45 \u03bcLo fa\nsolution of MTT (5 mg/mL in DMEM supplemented with 0.5% FBS)\nwas added to each well. The cells were incubated for another 2 h at 37\n\u00b0C. The medium was then removed, and the wells were rinsed once\nwith PBS. DMSO (0.6 mL) was added to each well at roomtemperature to solubilize the formazan crystals. The dissolved\nformazan was then transferred into 96-well culture plates, and the\nabsorbance was measured at 570 nm using a UV \u2212vis spectropho-\ntometer.57,58\nThe percent of inhibition of cell viability was calculated using eq 2\n=\u2212 AA percent inhibition (1 / )100ts (2)\nwhere Atand Asare the absorbance of the sample solution and the\nsolvent alone, respectively.\nTo assess the cytoprotective properties of the compounds against\nH2O2and SIN-1, BAEC (104\u2212105cells/mL) were grown to 60 \u221270%\ncon\ufb02uence in 24-well plates and each well was incubated with the\nselected derivative at 10 and 20 \u03bcM concentrations for 24 h. After\nincubation, the cells were washed with 1 \u00d7PBS twice to remove the\nresidual drug and exposed to 1 mM of H 2O2and 500 \u03bcM of SIN-1 for\n2 h and 4 h, respectively. These time periods were chosen on the basisof the observed cell death (>50%) using the H\n2O2and SIN-1\nconcetrations mentioned above. Finally, cell viability was evaluated by\nthe MTT reduction assay and calculated using eq 2.\nStatistical Analysis. The experimental results are expressed as the\nmean \u00b1standard error of the mean (SEM) and are accompanied by\nthe number (n) of observations. The di\ufb00 erences between the groups\nwere analyzed by student\u2019 sttest. A pvalue lower than 0.05 was\nconsidered statistically signi \ufb01cant.\nTheoretical Evaluation of ADME Properties. The theoretical\nproperties of log P, TPSA, n\u2212OH, and n\u2212OHNH were calculated\nby the methodology developed by Molinspiration using their software\navailable on http://www.molinspiration.com/services/properties.html.\n\u25a0AUTHOR INFORMATION\nCorresponding Author\n*Phone: +34 981 563100. Fax: +34 981 544912. E-mail:\nsvre77@gmail.com (S.V.-R.); colea@uchile.cl (C.O.-A.).\nNotes\nThe authors declare no competing \ufb01nancial interest.\n\u25a0ACKNOWLEDGMENTS\nThis project was partially supported by CONICYT-Chile\nproject 24110059, Mecesup project UCH-0601, and personal\nfunds of Spanish researchers. F.P.C. thanks CONICYT-Chile\nfor her Ph.D. grant and Fulbright Fellowships for her doctoralstay. S.V.R. thanks the Ministerio de Educacio \u0301n y Ciencia for\nher FPU Ph.D. grant, AP2008-04263 (Spain). M.J.M. thanksJournal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6143\n\u0018\u001d\u0019162Fundac \u0327a \u0303o para a Cie \u0302ncia e Tecnologia for her Ph.D. grant,\nSFRH/BD/61262/2009 (Portugal).\n\u25a0ABBREVIATIONS\nAAPH, 2,2 \u2032-azobis(2-methylpropionamidine)dihydrochloride;\nBAEC, bovine aortic endothelial cells; DCM, dichloromethane;\nDMEM, Dulbecco \u2019s modi \ufb01ed Eagle \u2019s medium; DMPO, 5,5-\ndimethyl-1-pyrroline- N-oxide; DPPH, 2,2-diphenyl-1-picrylhy-\ndrazyl; Epa, anodic peak potential; FL, \ufb02uorescein; MAO,\nmonoamine oxidase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide; ORAC, oxygen radical\nabsorbance capacity; PBN, \u03b1-phenyl- N-tert-butylnitrone; RNS,\nreactive nitrogen species; SIN-1, 3-morpholinosydnonimine;TBAP, tetrabutylammonium perchlorate; TLC, thin layerchromatography; TPSA, topological polar surface area; trolox,\n6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid\n\u25a0REFERENCES\n(1) Forman, H.; Maiorino, M.; Ursini, F. Signaling functions of\nreactive oxygen species. Biochemistry. 2010 ,49, 835\u2212842.\n(2) Lu \u0308, J. M.; Lin, P. H.; Yao, Q.; Chen, C. Chemical and molecular\nmechanisms of antioxidants: experimental approaches and model\nsystems. J. Cell. Mol. Med. 2010 ,14, 840\u2212860.\n(3) Halliwell, B. Antioxidants and human diseases: a general\nintroduction. Nutr. Rev. 1997 ,55,4 4\u221252.\n(4) Korkina, L. G.; Afans \u2019Ev, I. B. Antioxidant and chelating\nproperties of flavonoids. Adv. Pharmacol. 1996 ,38, 151\u2212163.\n(5) Yin, H.; Xu, L.; Porter, N. A. Free radical lipid peroxidation:\nmechanisms and analysis. Chem. Rev. 2011 ,111, 5944\u22125972.\n(6) Sies, H. Oxidative stress: oxidants and antioxidants. Exp. Physiol.\n1997 ,82, 291\u2212295.\n(7) Traykova, M.; Kostova, I. Coumarin derivatives and oxidative\nstress. Int. J. Pharm. 2005 ,1,2 9\u221232.\n(8) Obrenovich, M. E.; Li, Y.; Parvathaneni, K.; Yendluri, B. B.;\nPalacios, H. H.; Leszek, J.; Aliev, G. Antioxidants in health, disease andaging. CNS Neurol. Disord.: Drug Targets 2011 ,10, 192\u2212207.\n(9) Zou, X. Q.; Peng, S. M.; Hu, C. P.; Tan, L. F.; Deng, H. W.; Li, Y,\nJ. Furoxan nitric oxide donor coupled chrysin derivatives: synthesisand vasculoprotection. Bioorg. Med. Chem. Lett. 2011 ,21, 1222\u22121226.\n(10) Liu, R. H.; Hotchkiss, J. H. Potential genotoxicity of chronically\nelevated nitric oxide: a review. Mutat. Res. 1995 ,339,7 3\u221289.\n(11) Geier, D. A.; Kern, J. K.; Garver, C. R.; Adams J. B. Audhya, T.;\nNataf, R.; Geier, M. R. Biomarkers of environmental toxicity andsusceptibility in autism. J. Neurol. Sci. 2009 ,280, 101\u2212108.\n(12)\nPasupathi, P.; Chandrasekar, V.; Kumar, U. S. Evaluation of\noxidative stress, enzymatic and non-enzymatic antioxidants andmetabolic thyroid hormone status in patients with diabetes mellitus.Diabetes Metab. Syndr.: Clin. Res. Rev. 2009 ,3, 160\u2212165.\n(13) Reuter, S.; Gupta, S. C.; Chaturvedi, M. M.; Aggarwal, B. B.\nOxidative stress, inflammation, and cancer: how are they linked? Free\nRadical Biol. Med. 2010 ,49, 1603\u22121616.\n(14) Lodovici, M.; Menichetti, S.; Viglianisi, C.; Giuliani, E.\nPolyhydroxylated 4-thiaflavans as multipotent antioxidants: Protectiveeffect on oxidative DNA damage in vitro. Bioorg. Med. Chem. Lett.\n2006 ,16, 1957\u22121960.\n(15) Heim, K. E.; Tagliaferro, A. R.; Bobilya, D. J. Flavonoid\nantioxidants: chemistry, metabolism and structure-activity relation-ships. J. Nutr. Biochem. 2002 ,13, 572\u2212584.\n(16) Khlebnikov, A. I.; Schepetkin, I. A.; Domina, N. G.; Kirpotina, L.\nN.; Quinn, M. T. Improved quantitative structure-activity relationshipmodels to predict antioxidant activity of flavonoids in chemical,enzymatic, and cellular systems. Bioorg. Med. Chem. 2007 ,15, 1749\u2212\n1770.\n(17) Kostova, I.; Bhatia, S.; Grigorov, P.; Balkansky, S.; Parmar, V. S.;\nPrasad, A. K.; Saso, L. Coumarin as antioxidants. Curr. Med. Chem.\n2011 ,18, 3929\u22123951.(18) Torres de Pinedo, A.; Pen \u0303alver, P.; Morales, J. C. Synthesis and\nevaluation of new phenolic-based antioxidants: structure \u2212activity\nrelationship. Food Chem. 2007 ,103,5 5\u221261.\n(19) Haenen, G. R. M. M.; Arts, M. J. T. J.; Bast, A.; Coleman, M. D.\nStructure and activity in assessing antioxidant activity in vitro and in\nvivo: A critical appraisal illustrated with the flavonoids. Environ.\nToxicol. Pharmacol. 2006 ,21, 191\u2212198.\n(20) Perez-Cruz, F.; Serra, S.; Delogu, G.; Lapier, M.; Maya, J. D.;\nOlea-Azar, C.; Santana, L.; Uriarte, E. Antitrypanosomal andantioxidant properties of 4-hydroxycoumarins derivatives. Bioorg.\nMed. Chem. Lett. 2012 ,22, 5569\u22125573.\n(21) Matos, M. J.; Perez-Cruz, F.; Vazquez-Rodriguez, S.; Uriarte, E.;\nSantana, L.; Borges, F.; Olea-Aza r, C. Remarkable antioxidant\nproperties of a series of hydroxy-3-arylcoumarins. Bioorg. Med. Chem.\n2013 ,21, 3900\u22123906.\n(22)\nKondo, K.; Hirano, R.; Matsumoto, A.; Igarashi, O.; Itakura, H.\nInhibition of LDL oxidation by cocoa. Lancet. 1996 ,348, 1514\u22121518.\n(23) Mazur, A.; Bayle, D.; Lab, C.; Rock, E.; Rayssiguier, Y.\nInhibitory effect of procyanidin-rich extracts on LDL oxidation invitro. Atherosclerosis 1999 ,145, 421\u2212422.\n(24) Ferrali, M.; Signorini, C.; Caciotti, B.; Sugherini, L.; Ciccoli, L.;\nGiachetti, D.; Comporti, M. Protection against oxidative damage of\nerythrocyte membranes by the flavonoid quercetin and its relation to\niron chelating activity. FEBS Lett. 1997 ,416, 123\u2212129.\n(25) Elliott, A. J.; Scheiber, S. A.; Thomas, C.; Pardini, R. S.\nInhibition of glutathione reductase by flavonoids. Biochem. Pharmacol.\n1992 ,44, 1603\u22121608.\n(26) Hirano, R.; Sasamoto, W.; Matsumoto, A.; Itakura, H.; Igarashi,\nO.; Kondo, K. Antioxidant ability of various flavonoids against DPPH\nradicals and LDL oxidation. J. Nutr. Sci. Vitaminol. 2001 ,47, 357\u2212362.\n(27) Cos, P.; Ying, L.; Calomme, M.; Hu, J. P.; Cimanga, K.; Van\nPoel, B.; Pieters, L.; Vlietnck, A. J.; Vanden Berghe, D. Structure-\nactivity relationship and classification of flavonoids as inhibitors ofxanthine oxidase and superoxide scavengers. J. Nat. Prod. 1998 ,61,\n71\u221276.\n(28) Sahu, N. K.; Balbhadra, S. S.; Choudhary, J.; Kohli, D. V.\nExploring pharmacological significance of chalcone scaffold: a review.Curr. Med. Chem. 2012 ,19, 209\u2212225.\n(29) Go, M. L.; Wu, X.; Liu, X. L. Chalcones: an update on cytotoxic\nand chemoprotective properties. Curr. Med. Chem. 2005 ,12, 483\u2212499.\n(30) Bandgar, B. P.; Gawande, S. S.; Bodade, R. G.; Gawande, N. M.;\nKhobragade, C. N. Synthesis and biological evaluation of a novel seriesof pyrazole chalcones as anti-inflammatory, antioxidant and anti-\nmicrobial agents. Bioorg. Med. Chem. 2009 ,17, 8168\u22128173.\n(31) Gaikwad, P.; Priyadarsini, K. I.; Naumov, S.; Rao, B. S. M.\nRadiation and quantum chemical studies of chalcone derivatives. J.\nPhys. Chem. A. 2010 ,114, 7877\u22127885.\n(32) Detsi, A.; Majdalani, M.; Kontogiorgis, C. A.; Hadjipavlou-\nLitina, D.; Kefalas, P. Natural and synthetic 2 \u2019-hydroxy-chalcones and\naurones: synthesis, characterization and evaluation of the antioxidant\nand\nsoybean lipoxygenase inhibitory activity. Bioorg. Med. Chem. 2009 ,\n17, 8073\u22128085.\n(33) Kumar, V.; Kumar, S.; Hassan, M.; Wu, H.; Thimmulappa, R.\nK.; Kumar, A.; Sharma, S. K.; Parmar, V. S.; Biswal, S.; Malhotra, S. V.\nNovel chalcone derivatives as potent Nrf2 activators in mice andhuman lung epithelial cells. J. Med. Chem. 2011 ,54, 4147\u22124159.\n(34) Valdameri, G.; Gauthier, C.; Terreux, R.; Kachadourian, R.; Day,\nB. J.; Winnischofer, S. M. B.; Rocha, M. E. M.; Frachet, V.; Ronot, X.;\nDi Pietro, A.; Boumendjel, A. Investigation of chalcones as selective\ninhibitors of the breast cancer resistance protein: critical role ofmethoxylation in both inhibition potency and cytotoxicity. J. Med.\nChem. 2012 ,55, 3193\u22123200.\n(35) Kachadourian, R.; Day, B. J.; Pugazhenti, S.; Franklin, C. C.;\nGenoux-Bastide, E.; Mahaffey, G.; Gauthier, C.; Di Pietro, A.;Boumendjel, A. A synthetic chalcone as a potent inducer of glutathionebiosynthesis. J. Med. Chem. 2012 ,55, 1382\u22121388.\n(36) Jung, J. C.; Jang, S.; Lee, Y.; Min, D.; Lim, E.; Jung, H.; Oh, M.;\nOh, S.; Jung, M. Efficient synthesis and neuroprotective effect ofJournal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6144\n\u0018\u001d\u001a163substituted 1,3-diphenyl-2-propen-1-ones. J. Med. Chem. 2008 ,51,\n4054\u22124058.\n(37) (a) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E.\nSimple coumarins and analogues in medicinal chemistry: occurrence,\nsynthesis and biological activity. Curr. Med. Chem. 2005 ,12, 887\u2212916.\n(b) Rao, H. S. P.; Tangeti, V. S. Synthesis of 3-aroylcoumarin-flavonehybrids. Lett. Org. Chem. 2012 ,9, 218\u2212220. (c) Rao, H. S. P.;\nSivakumar, S. Condensation of \u03b1-aroylketene dithioacetals and 2-\nhydroxyarylaldehydes results in facile synthesis of a combinatoriallibrary of 3-aroylcoumarins. J. Org. Chem. 2006 ,71, 8715\u22128723.\n(38) Matos, M. J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.;\nFuentes-Edfuf, C.; Santos, Y.; Mun \u0303oz-Crego, A. Looking for new\ntargets: simple coumarins as antibacterial agents. Med. Chem. 2012 ,8,\n1140\u22121145.\n(39) Matos, M. J.; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.;\nUriarte, E.; Santana, L. 8-Substituted 3-arylcoumarins as potent andselective MAO-B inhibitors: synthesis, pharmacological evaluation, anddocking studies. ChemMedChem 2012 ,7, 464\u2212470.\n(40) Matos, M. J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.;\nVin \u0303a, D. MAO inhibitory activity modulation: 3-phenylcoumarins\nversus 3-benzoylcoumarins. Bioorg. Med. Chem. Lett. 2011 ,21, 4224\u2212\n4227.\n(41) Secci, D.; Carradori, S.; Bolasco, A.; Chimenti, P.; Yan \u0303ez, M.;\nOrtuso, F.; Alcaro, S. Synthesis and selective human monoamineoxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazidocoumarin derivatives. Eur. J. Med. Chem. 2011 ,46, 4846\u22124852.\n(42) Serra, S.; Chicca, A.; Delogu, G.; Vazquez-Rodriguez, S.;\nSantana, L.; Uriarte, E.; Casu, L.; Gertsch, J. Synthesis and cytotoxicactivity of non-naturally substituted 4-oxycoumarin derivatives. Bioorg.\nMed. Chem. Lett. 2012 ,22, 5791\u22125794.\n(43) Vazquez-Rodriguez, S.; Matos, M. J.; Santana, L.; Uriarte, E.;\nBorges, F.; Kachler, S.; Klotz, K. N. Chalcone-based derivatives as newscaffolds for hA\n3adenosine receptor antagonists. J. Pharm. Pharmacol.\n2013 ,65, 697\u2212703.\n(44) Brunet, E.; Alonso, M. T.; Juanes, O.; Velasco, O.; Rodr\u00edguez-\nUbis, J. C. Novel polyaminocarboxylate chelates derived from 3-aroylcoumarins. Tetrahedron 2001 ,57, 3105\u22123116.\n(45) Janzen, E. G.; Kotake, Y.; Randall, D. H. Stabilities of hydroxyl\nradical spin adducts of PBN-type spin traps. Free Radical Biol. Med.\n1992 ,12, 169\u2212173.\n(46) Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Development and\nvalidation of an improved oxygen radical absorbance capacity assayusing fluorescein as the fluorescent probe. J. Agric. Food Chem. 2001 ,\n49, 4619\u22124626.\n(47) Clothier, R.; Go \u0301mez-Lecho \u0301n, M. J.; Kinsner-Ovaskainen, A.;\nKopp-Schneider, A.; O \u2019Connor, J. E.; Prieto, P.; Stanzel, S.\nComparative analysis of eight cytotoxicity assays evaluated withinthe ACuteTox Project. Toxicol. In Vitro 2012 ,27, 1347\u22121356.\n(48) Singgh, R. J.; Hogg, N.; Joseph, J.; Konorev, E.; Kalyanaraman,\nB. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor inthe presence of electron acceptors. Arch. Biochem. Biophys. 1999 ,361,\n331\u2212339.\n(49) M cheminformatics . http://www.molinspiration.com/services/\nproperties.html, Bratislava, Slovak Republic.\n(50) Vogel, S.; Barbic, M.; Ju \u0308rgenliemk, G.; Heilmann, J. Synthesis,\ncytotoxicity, anti-oxidative and anti-inflammatory activity of chalconesand influence of A-ring modifications on the pharmacological effect.Eur. J. Med. Chem. 2010 ,45, 2206\u22122213.\n(51) Zhang, H. Y.; Wang, L. F. Theoretical elucidation of structure-\nactivity relationship for coumarins to scavenge peroxyl radical. J. Mol.\nStruct.: THEOCHEM 2004 ,673, 199\u2212202.\n(52) Saprin, A. N.; Piette, L. H. Spin trapping and its application in\nthe study of lipid peroxidation and free radical production with livermicrosomes. Arch. Biochem. Biophys. 1977 ,180, 480\u2212492.\n(53) Durand, G.; Prosak, R. A.; Han, Y.; Ortial, S.; Rockenbauer, A.;\nPucci, B.; Villamena, F. A. Spin trapping and cytoprotective properties\nof fluorinated amphiphilic carrier conjugates of cyclic versus linear\nnitrones. Chem. Res. Toxicol. 2009 ,22,\n1570 \u22121581.(54) Galati, G.; Moridani, M. Y.; Chan, T. S.; O \u2019Brien, P. J.\nPeroxidative metabolism of apigenin and naringenin versus luteolin\nand quercetin: glutathione oxidation and conjugation. Free Radical\nBiol. Med. 2001 ,30, 370\u2212382.\n(55) Bast, A.; Haenen, G. R. M. M. The toxicity of antioxidants and\ntheir metabolites. Environ. Toxicol. Pharmacol. 2002 ,11, 251\u2212258.\n(56) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.\nExperimental and computational approaches to estimate solubility and\npermeability in drug discovery and development settings. Adv. Drug\nDelivery Rev. 1997 ,23,3\u221225.\n(57) Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar\nsurface area as a sum of fragment-based contributions and its\napplication to the prediction of drug transport properties. J. Med.\nChem. 2000 ,43, 3714\u22123717.\n(58) Buu-Hoi, N. P.; Loc, T. B.; Xuong, N. D. 3-( p-Hydroxyaroyl)-\nand -( p-methoxyaroyl)coumarins. Bull. Soc. Chim. Fr. 1958 ,3, 361\u2212\n363.\n(59) Huang, D.; Ou, B.; Hampsch-Woodill, M.; Flanagan, J. A.; Prior,\nR. L. High-throughput assay of oxygen radical absorbance capacity\n(ORAC) using a multichannel liquid handling system coupled with a\nmicroplate fluorescence reader in 96-well format. J. Agric. Food Chem.\n2002 ,50, 4437\u22124444.\n(60) Parker, T. L.; Miller, S. A.; Myers, L. E.; Miguez, F. E.; Engeseth,\nN. J. Evaluation of synergistic antioxidant potential of complex\nmixtures using oxygen radical absorbance capacity (ORAC) and\nelectron paramagnetic resonance (EPR). J. Agric. Food Chem. 2010 ,58,\n209\u2212217.\n( 6 1 )Y o s h i m u r a ,Y . ;I n o m a t a ,T . ;N a k a z a w a ,H . ;K u b o ,H . ;\nYamaguchi, F.; Ariga, T. Evaluation of free radical scavenging activities\nof antioxidants with an H 2O2/NaOH/DMSO system by electron spin\nresonance. J. Agric. Food. Chem. 1999 ,47, 4653\u22124656.\n(62) Das, A.; Chakrabarty, S.; Choudhury, D.; Chakrabarti, G. 1,4-\nBenzoquinone (PBQ) induced toxicity in lung epithelial cells is\nmediated by the disruption of the microtubule network and activation\nof caspase-3. Chem. Res. Toxicol. 2010 ,23, 1054\u22121066.\n(63) Das, A.; Bhattacharya, A.; Chakrabarti, G. Cigarette smoke\nextract induces disruption of structure and function of tubulin-microtubule in lung epithelium cells and in vitro. Chem. Res. Toxicol.\n2009 ,22, 446\u2212459.Journal of Medicinal Chemistry Article\ndx.doi.org/10.1021/jm400546y |J. Med. Chem. 2013, 56, 6136 \u22126145 6145\n\u0018\u001d\u001b164Synthesis of coumarin\u2013 chalcone hybrids and evaluation\nof their antioxidant and trypanocidal properties \u2020\nSaleta Vazquez-Rodriguez, *aRoberto Figueroa-Gu \u00b4\u0131~nez,bMaria Jo ~ao Matos,a\nLourdes Santana,aEugenio Uriarte,aMichel Lapier,bJuan Diego Mayac\nand Claudio Olea-Azar *b\nBased on the observed biological activities of coumarins and chalcones, we have synthesized coumarin \u2013\nchalcone hybrids with the aim of evaluating their antioxidant properties and trypanocidal activity\nagainst Trypanosoma cruzi , the parasite responsible for Chagas disease. All derivatives have been proved\nto be good antioxidants in spite of their moderate trypanocidal activity in the epimastigote stage (cloneDm28c). Based on these results, we can conclude that compounds 4and5are potential candidates for\nin vitro studies of their antioxidant activity. These preliminary \ufb01ndings encourage us to the future\nstructural optimization of these kinds of compounds.\n1 Introduction\nChalcones (1,3-diaryl-2-propen-1-ones) are one of the major\nclasses of naturally occurring compounds with widespreaddistribution in fruits, vegetables, spices, tea and soy basedfoodstu\ufb00 and they have been subject of great interest for their\nremarkable pharmacological activities.\n1,2Chemically, they are\nopen chain precursors of \ue104avonoids and iso \ue104avonoids, in which\nthe two aromatic rings are linked by a three-carbon a,b-unsat-\nurated carbonyl system. Chalcones have been reported to\npossess many useful properties, including antibacterial,3,4\nantimalarial,5\u20137antifungal,8,9antiviral10,11and anti-in \ue104amma-\ntory12\u201314properties.\nOn the other hand, coumarins (2 H-1-benzopyran-2-ones) are\nanother family of naturally occurring compounds widelydistributed in plants. These kinds of molecules of both natural\nand synthetic origin, have also attracted considerable interestdue to their pharmacological activities,\n15for example, their\nenzyme inhibitory16,17antitumor18,19and antiviral20,21activities\nas well as their anti-in \ue104ammatory22,23and antioxidant22,24 \u201326\nproperties.\nChagas disease is caused due to the Trypanosoma cruzi\n(T. cruzi ) parasite and it represents a major health problem inseveral countries of Latin America and in the southern United\nStates. The only two available drugs (nifurtimox and benzni-\ndazole) are limited and su \ufb00er from several drawbacks such as\npoor e\ufb03cacy, toxicity, resistance, and multiple side e \ufb00ects.27,28\nDuring the course of T. cruzi infection and disease development,\nROS can be produced as a consequence of tissue destructioncaused by toxic secretions of the parasite, immune-mediated\ncytotoxic reactions, and secondary damage in the myocardium.\nTherefore, interventions with antioxidant compounds, that\nreduce the generation or the e \ufb00ects of ROS, may exert bene \ue103cial\ne\ufb00ects in preventing or arresting oxidative damage.\n29,30There-\nfore, there is an urgent need for the discovery of new, more\ne\ufb00ective, and safer drugs for human use.\nAntioxidants are a class of substances presenting a wide\nrange of di\ufb00erent chemical structures. They are able to decreaseor prevent the oxidation of other sensitive molecules throughdi\ufb00erent mechanisms like chelation of active metal ions, free\nradicals scavenging or inhibition of pro-oxidant enzymes.\n31Free\nradicals and reactive oxygen species (ROS) are atoms, molecules\nor ions possessing unpaired electrons, which are highly reactive\nwith a wide range of other di\ufb00erent molecules. They areconstantly generated and eliminated in the biological systemthrough metabolic processes and play important roles in avariety of normal biochemical functions, cell signaling\napoptosis, gene expression, ion transport and abnormal path-\nological processes.\n32,33The overproduction of ROS can have\ndamaging e \ufb00ects on many molecules. For example, ROS\nproducing oxidative stress may contribute to Chagas disease\nprogression.34\nIt is also known that the antioxidant properties of chalcones\nare quite dependent on the two aryl structures,25,35that is, the\nsubstituents on the two aryl rings of the chalcone moiety andtheir substitution patterns. Especially, the hydroxyl substituentaDepartamento de Qu \u00b4\u0131mica Org \u00b4anica, Facultad de Farmacia, Universidad de Santiago\nde Compostela, Campus Vida s/n, 15782, Santiago de Compostela, Spain. E-mail:\nsvre77@gmail.com\nbDepartamento de Qu \u00b4\u0131mica Inorg \u00b4anica y Anal \u00b4\u0131tica, Facultad de Ciencias Qu \u00b4\u0131micas y\nFarmac \u00b4euticas, Universidad de Chile, Casilla 233, Santiago, Chile. E-mail: colea@\nuchile.cl\ncDepartamento de Farmacolog \u00b4\u0131a Molecular y Cl \u00b4\u0131nica, Facultad de Medicina,\nUniversidad de Chile, Santiago, Chile\n\u2020Electronic supplementary information (ESI) available. See DOI:\n10.1039/c3md00025gCite this: Med. Chem. Commun. , 2013,\n4, 993\nReceived 18th January 2013\nAccepted 22nd April 2013\nDOI: 10.1039/c3md00025gwww.rsc.org/medchemcomm\nThis journal is \u00aaThe Royal Society of Chemistry 2013 Med. Chem. Commun. , 2013, 4, 993 \u20131000 | 993MedChemComm\nCONCISE ARTICLE\n\u0018\u001d\u001c165is one of the key groups that enhance the antioxidant activity of\nchalcone mainly due to its easy conversion to phenoxy radicalsthrough the hydrogen atom transfer (HAT) mechanism. This\nphenoxy radical formation may be essential for the antioxidant\nproperties, which are assessed primarily as radical scavengingpotential of phenolic chalcones. In fact, the hydroxyl substit-uent is widespread among chalcones from natural sources.\nDue to the potential antioxidant property and trypanocidal\nactivity of the chalcone and coumarin moieties,\n36,37in the\npresent work a series of coumarin\u2013 chalcone hybrids (Fig. 1)\nwere synthesized and their antioxidant capacity and trypanoci-\ndal activity were evaluated. The chalcone moiety in the prepared\nmolecules is included in the coumarin sca \ufb00old so that the\ngeometry of the chalcone remains as a trans isomer due to the\ndouble bond position of the pyrone ring.\n2 Chemistry\nIn order to achieve the \ue103nal products, the synthesis of the\nhydroxy-3-benzoylcoumarins was carried out in two steps,shown in Scheme 1 and brie \ue104y described as follows: (a)\nsynthesis of methoxy-3-benzoylcoumarins and (b) hydrolysis ofthe previous compounds to a\ufb00ord the \ue103nal hydroxyl-3-ben-\nzoylcoumarins ( 1\u20135).\nThe methoxy-3-benzoylcoumarins, with a general structure I\nwere e\ufb03ciently synthesized with 78 \u201394% yield by a Knoevenagelreaction treating the appropriate salicylaldehyde and ethyl 3,4-\ndimethoxybenzoylacetate with piperidine in ethanol at re \ue104ux\nfor 2\u20136 h. The resulting methoxy derivatives were treated with\nboron tribromide in DCM at 80\n/C14C in a Schlenk tube for 48 h to\ngive the corresponding hydroxy derivatives 1\u20135with 69 \u201394%\nyield.\n3 Electrochemical study\nIn order to evaluate the antioxidant behavior of the \ue103ve\ncompounds of this family, cyclic voltammetry, the Oxygen\nRadical Absorbance Capacity (ORAC FL-PGR) and the ElectronSpin Resonance (ESR) studies were carried out.\n3.1 Cyclic voltammetry\nThe electrochemical properties of hydroxyl coumarin \u2013chalcone\nderivatives were studied by cyclic voltammetry. Fig. 2 shows a\ncyclic voltammogram at a glassy carbon electrode (GCE)\nimmersed in DMSO/75 mmol L\n/C01phosphate (pH 7.4) bu \ufb00er\n30/70 media containing 1 mmol L/C01of compound 3for several\nscan rates ( v). Under these experimental conditions, two\noxidation processes (peaks I and II) were observed. In general, ithas been proposed that the charge transfer process at peak Icorresponds to the oxidation of the catechol substituent, whilethe process at peak II comprises oxidation reaction involving\nthe hydroxyl groups present in the coumarinic ring.\nResults of the cyclic voltammetry, reported in Table 1 show\nthat coumarin \u2013chalcone hybrids present low oxidation\npotentials.\nFig. 1 Structural approach employed for the design of new coumarin \u2013chalcone\nhybrid compounds.\nScheme 1 Preparation of coumarin \u2013chalcone hybrids. Reagents and conditions :\n(a) piperidine, EtOH, re \ufb02ux, 2 \u20136 h and (b) BBr 3, DCM, 80/C14C, 48 h.\nFig. 2 Cyclic voltammogram for 1 mmol L/C01compound 3in DMSO/75 mmol L/C01\nphosphate (pH 7.4) bu \ufb00er 30/70 media at a GCE for v\u00bc100, 250, 500, and\n2000 mV s/C01.\nTable 1 Oxidation potential peaks obtained by cyclic voltammetry\nCompounds Epaa(mV)\n1 322\n2 449\n3 312\n4 337\n5 247\naFirst oxidation peak potential at a scan rate of 2000 mV s/C01.\n994 |Med. Chem. Commun. , 2013, 4, 993 \u20131000 This journal is \u00aaThe Royal Society of Chemistry 2013MedChemComm Concise Article\n\u0018\u001d\u001d1663.2 ORAC assays\nThe capacity of scavenging peroxyl radicals was studied\nemploying the ORAC method. In this assay, Trolox and 2,20-azo-\nbis(2-amidinopropane) dihydrochloride (AAPH) were used as a\nreference antioxidant and a peroxyl radical source, respec-\ntively.38This assay evaluates the capacity of antioxidants (or of\ntheir complex mixtures) to inhibit the bleaching of a targetmolecule (probe) induced by peroxyl radicals.\nThe oxidation occurs due to exposition of the target mole-\ncule, \ue104uorescein (FL)\n39or pyrogallol red (PGR),40to the peroxyl\nradical, leading to decay of \ue104uorescence emission or decrease of\nPGR absorbance with time.\nThe consumption of FL is commonly inhibited, even by\nantioxidants of low reactivity, throughout kinetic pro \ue103les\ncharacterized by the presence of induction times. Fig. 3a showsthe results of AAPH mediated \ue104uorescein oxidation in the\nabsence and presence of increasing concentration of compound5in phosphate pH 7.4. Therefore, ORAC-FL values would be\nmore in \ue104uenced by the stoichiometry of the reaction (de \ue103ned as\nthe number of radicals that each additive molecule can remove)than by the reactivity of the additives. Fig. 3b shows that thearea under the curve (AUC\nNET) of the kinetic pro \ue103les for\ncompound 5was linearly related to the concentration of the\nadditive.\nThis behavior was observed for all compounds studied.\nHowever, the consumption of PGR by reactive antioxidants isinhibited without generating induction times.\n41,42This charac-\nteristic pro\ue103 le is observed for all the studied compounds, as well\nas for Trolox (Fig. 4).\nThe absence of induction times in the protective kinetic\npro\ue103 les of PGR would imply that the ORAC-PGR index is more\nrelated to the reactivity of the antioxidants than to stoichio-metric factors. Taking into account the characteristics of the\nORAC-FL and ORAC-PGR assays, it has been recently proposed\nthat both methods could be considered as rendering comple-mentary indexes.\n42Results of this study are expressed as ORAC-\nFL and ORAC-PGR values and are tabulated in Table 2.\nAll experiments were carried out in triplicate, and the data\nrepresent the mean values ( /C6S.D.).\n3.3 ESR assays\nIn order to study the antioxidant reactivity of all the hydroxyl-\nated coumarin\u2013 chalcone hybrids, we have adopted a\nFig. 3 (a) Kinetic pro \ufb01le of \ufb02uorescein consumption, AAPH mediated, in the\npresence of compound 5.F0is the \ufb02uorescence in the absence of the compound\nand Fthe\ufb02uorescence in the presence of compound 5and (b) graph of AUC NET\n(net area under the curve) versus concentration of compound 5.\nFig. 4 Time-course of the consumption of PGR, AAPH mediated, in the presence\nof increasing concentration of Trolox.Table 2 ORAC-FL and ORAC-PGR values and the scavenging hydroxyl radical (%)\nCompound ORAC-FL ORAC-PGR % Scavenging\n1 4.37/C60.22a84.6/C65.3\n2 4.95/C60.14a82.1/C67.1\n3 6.02/C60.12a84.8/C67.3\n4 8.32/C60.27 0.52 /C60.05 84.2 /C66.4\n5 8.51/C60.32 1.17 /C60.10 90.9 /C68.2\nQuercetin 7.28 /C60.22c\u2014\u2014\nCatechin 6.76 /C60.22c\u2014\u2014\nDHMcoumarinb3.3d\nHelichrysetin 4.4e\naInactive compound.b6,7-Dihydroxy-4-methylcoumarin.cData\ncollected from ref. 39.dData collected from ref. 49.eData collected\nfrom ref. 50.\nFig. 5 ESR spectra for adduct DMPO\u2013 OH without an antioxidant molecule\n(black) and in the presence of compound 5(red).\nThis journal is \u00aaThe Royal Society of Chemistry 2013 Med. Chem. Commun. , 2013, 4, 993 \u20131000 | 995Concise Article MedChemComm\n\u0018\u001d\u001e167non-catalytic and competitive Fenton system.23Electron spin\nresonance (ESR) in combination with spin trapping techniques\nwas employed to further verify that the tested compoundspossess the ability to scavenge hydroxyl radicals, measuringthus, the percentage of scavenging of the compounds,summarized in Table 2. DMPO (5,5-dimethyl-1-pyrroline- N-\noxide) reacts with hydroxyl radicals to generate the spin reso-nance signal, and ESR can quantify this spin resonance signal.\nThe ESR spectrum shows four hyper \ue103ne lines due to the DMPO\u2013\nOH adduct formation. The coumarin \u2013chalcone hybrids\ncompete with DMPO for hydroxyl radicals. Thus, the ESR signal\nwill diminish as presented in Fig. 5 for compound 5.\n4 Pharmacology\n4.1 Trypanocidal activity\nStudies on trypanocidal activitywere carried out in order to\ninvestigate a possible relationship between the antioxidantcapacity of the compounds and their antiparasitic activity.Trypanocidal activity was evaluated against the T. cruzi epi-\nmastigote stage (clone Dm28c). It was measured throughthe MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium\nbromide) assay,\n43widely used for in vitro measurement of the\nmetabolic activity or viability of cell cultures. A \ue09der incubation\ntime, we determined the number of viable parasites by\nmeasuring absorbance at 570 nm in a multiwell reader (Asys\nExpert Plus \u00aa, Austria). Untreated parasites were used as\ncontrols (100% of viability). Results are reported as the\npercentage of non-viable epimastigotes regarding the control.\nResults of two di\ufb00erent concentrations of the synthesized\ncompounds (10 and 100 mmol L/C01) are reported in Table 3.\n5 Theoretical evaluation of ADME\nproperties\nTo better correlate the drug-like properties of the coumarin \u2013\nchalcone hybrid compounds the lipophilicity, expressed as the\noctanol/water partition coe \ufb03cient and herein called log P,a s\nwell as other theoretical calculations such as the TPSA, thenumber of hydrogen acceptors and the number of hydrogen\nbond donors were calculated using the Molinspiration property\nprogram. The ADME properties of the studied compounds werecalculated using the Molinspiration property program, and\nresults are summarized in Table 4.\n446 Results and discussion\nTaking into account the importance of the hydroxyl substitu-\nents in the antioxidant properties,26,45we have focused the study\non hydroxylated derivatives of the coumarin \u2013chalcone hybrid\ncompounds, which contain a catechol fragment in the benzoylring at the 3 position of the coumarin.\nAccording to the data obtained in the cyclic voltammetry, all\nderivatives exhibited two anodic peaks without the corre-sponding cathodic peak, indicating an irreversible oxidationprocess as a result of the oxidation of one hydroxyl group in anyof the aromatic rings, forming the semiquinone radical. Wehave thus \ue103rstly investigated the in \ue104uence of the scan rate ( v)i n\norder to access in more detail the characteristics of electro-chemical and chemical reactions that take place at the elec-\ntrode/solution interface. The current ratio I\npc/Ipaprogressively\nincreases as a function of v, corroborating an EC-type mecha-\nnism46associated with peak I. It is known that the antioxidant\ncapacity is conceivably related to the electrochemical behavior,\nbeing indicative that a low oxidation potential corresponds to a\nhigh antioxidant power.47In our case, this fact could be\nexplained as mainly due to the strong electron donating e \ufb00ect of\nthe catechol group, present in all the synthesized derivatives,\nwhich can form stable radicals in which the remaining o-OH\ngroup stabilizes the radical as a result of the intramolecular\nhydrogen bonding.48\nConsidering the ORAC-FL assays, we observed that the\nhighest ORAC-FL values were found for compounds 4and 5\n(8.32 and 8.51 respectively). The results obtained are better thanfor quercetin (7.28) and catechin (6.76), \ue104avonoids currently\nused as reference compounds,\n39as well as other simple\ncoumarins, such as the 6,7-dihydroxy-4-methylcoumarin(DHMcoumarin) studied by our group\n49or chalcones collected\nfrom bibliographic sources such as helichrystein.50It is also\nworth mentioning the activity of compound 3(6.02), compa-\nrable to catechin.\nThe di\ufb00erent ORAC-FL values can be related to the substit-\nuents existing in the coumarin moiety and their pattern ofsubstitution. In addition, the presence of a benzoyl substituent\nimproves the electron delocalization with respect to the\ncoumarin skeleton, in \ue104uencing ORAC values.\nCompound 1is the structurally simplest compound, pre-\nsenting a catechol group in the benzoyl ring, with no substitu-ents on the coumarin skeleton. This feature could explain whyTable 3 Trypanocidal activity results for the coumarin \u2013chalcone hybrids and\nnifurtimox (Nfx)\nCmpd% Trypanocidal\nactivity at 10 mmol L/C01% Trypanocidalactivity at 100 mmol L\n/C01\n1 23.8/C60.4 38.7 /C62.1\n2 27.9/C60.3 47.9 /C61.0\n3 18.9/C60.4 46.4 /C60.8\n4aa\n5 9.5/C60.2 24.1 /C60.7\nNfx 52.5 /C62.2 100 /C63.2\naInactive at concentration tested.Table 4 Theoretical structural properties of the coumarin \u2013chalcone hybridsa\nCompd log P TPSA ( \u02daA2)n-OH\nacceptorsn-OHNHdonors Volume ( \u02daA\n3)\n1 2.43 87.74 5 2 235.01\n2 2.85 87.74 5 2 251.58\n3 1.93 107.97 6 3 243.03\n4 1.63 128.20 7 4 251.05\n5 2.92 107.97 6 3 260.92\naTPSA, topological polar surface area; n-OH, number of hydrogen\nacceptors and n-OHNH, number of hydrogen bond donors. The data\nwere determined with Molinspiration calculation so \ue09dware.\n996 |Med. Chem. Commun. , 2013, 4, 993 \u20131000 This journal is \u00aaThe Royal Society of Chemistry 2013MedChemComm Concise Article\n\u0018\u001d\u001f168compound 1presents the lowest ORAC value (4.37) of all the\nstudied compounds, but still being 4 times more active than the\nemployed reference compound Trolox. If we introduce a methylgroup at position 6 (compound 2), we observe a slight increase\nin the ORAC-FL index (4.95) compared to compound 1. When\nanalyzed the obtained ORAC-FL values of compounds 1\u20133based\non the chemical structure and pattern of substitution, weobserved that, among other features, the higher the electron\ndonating e \ufb00ect of the substituent, the more active the\ncompound. Compound 3containing a hydroxyl at position 6,\nincreases its ORAC value to 6.02 compared to the simplest\nsynthesized compound 1.\nCompounds with the highest activities ( 3\u20135), with ORAC\nvalues 6.02, 8.51 and 8.32 respectively, all present, in addition to\nthe catechol group in the benzoyl ring, at least one hydroxylgroup that increases the electronic density, favoring the\nhydrogen atom transfer (HAT) mechanism. Compound 4, with\ntwo hydroxyl groups in the coumarin moiety, showed a\nconsiderable increase in the ORAC-FL value (8.32) compared tocompound 3, in which only one hydroxyl substituent is present\nin the coumarin ring. In any case, the highest ORAC-FL valuewas found for compound 5, in which one hydroxyl group is\npresent at position 8 and a bromide atom is present at position6 of the coumarin. Therefore, it has been found that the pres-ence, the number and the position of substituents with\ndi\ufb00erent electronic e \ufb00ects on the coumarin skeleton are\nimportant structural factors that contribute to increase the\nantioxidant capacity of these coumarin \u2013chalcone hybrids.\nRegarding the ESR assays, whose results are reported in\nTable 2 we observed accuracy with the obtained ORAC valuesand the radical scavenging activity, as high as 80% for all testedcompounds.\nOn the other hand, results reported in Table 3 have shown\nthat all compounds present moderate trypanocidal activity with\nexception of compound 4that resulted to be inactive at the\nconcentration tested. However, these compounds have less\nactivity than the positive control nifurtimox, the drug currentlyused against T. cruzi in the treatment of Chagas disease.\nFrom the data obtained for the theoretical evaluation of the\nADME properties, one can notice that all the hybrid compounds1\u20135do not break any point of the Lipinski's rule of \ue103ve, making\nthem promising leads for drug candidates.\n51Topological polar\nsurface area (TPSA) and log Pvalues are compatible with those\ndescribed as a predictive indicator of the drug capacity ofmembrane penetration.\n52\nIt is noteworthy that compounds with the higher trypanoci-\ndal activities were those with lower ORAC values. These data canbe taken into account for future studies on the mechanism ofaction of this kind of drug against T. cruzi .\n7 Experimental\n7.1 General methods\nStarting materials and reagents were obtained from commercial\nsuppliers and were used without puri \ue103cation. Melting points\n(mp) are uncorrected and were determined with a Reichert Ko \ue104er\nthermopan or in capillary tubes in a Buchi 510 apparatus.1HNMR (300 MHz) and13C NMR (75.4 MHz) spectra were recorded\nwith a Bruker AMX spectrometer using DMSO-d 6or CDCl 3as\nsolvent. Chemical shi \ue09ds(d) are expressed in parts per million\n(ppm) using TMS as an internal standard. Coupling constantsJare expressed in hertz (Hz). Spin multiplicities are given as s\n(singlet), d (doublet), dd (doublet of doublets) and m (multiplet).\nMass spectrometry was carried out with a Kratos MS-50 ora Varian MAT-711 spectrometer. Elemental analyses were\nperformed by a Perkin-Elmer 240B microanalyzer and were\nwithin /C60.4% of calculated values in all cases. The analytical\nresults were $95% purity for all compounds. Flash Chromatog-\nraphy (FC) was performed on silica gel (Merck 60, 230 \u2013400 mesh)\nand analytical TLC was performed on precoated silica gel plates\n(Merck 60 F254). Organic solutions were dried over anhydrous\nsodium sulfate. Concentration and evaporation of the solventa\ue09der reaction or extraction was carried out on a rotary evaporator\n(B\u00a8uchi Rotavapor) operating at reduced pressure.\n7.2 Synthesis\n7.2.1 General procedure for the synthesis of hydroxy-3-\nbenzoylcoumarins (1 \u20135).To a solution of the appropriate\nb-ketoester (1 mmol) and the corresponding salicylaldehyde\n(1 mmol) in ethanol (5 mL) was added piperidine in a catalyticamount. The reaction mixture was re \ue104uxed for 2 \u20136 h and a\ue09d er\ncompletion (followed by TLC), the reaction mixture was cooled\nand the precipitate was \ue103ltered and washed with cold ethanol\nand ether to a\ufb00ord the corresponding methoxy-3-benzoylcou-\nmarin compounds with a general structure I. The appropriate\nmethoxy derivative compound (1 mmol) was dissolved in DCM(1 mL) and BBr\n3in DCM (20 mmol, 1 M) was added in a Schlenk\ntube. The tube was sealed, and the reaction mixture was heated\nat 80/C14C for 48 h. The resulting crude product was treated with\nMeOH and rotated to dryness. The obtained precipitate wasrecrystallized in MeOH or puri \ue103ed by \ue104ash chromatography\nusing hexane \u2013ethyl acetate mixtures as an eluent, to a\ufb00ord the\ndesired hydroxy derivatives (Scheme 1).\n7.3 Cyclic voltammetry\nCyclic voltammetry was carried out using a potentiostat/galva-\nnostat VersaSTAT 3 provided with a V3-Studio electrochemistry\nso\ue09dware package, in 50 mM sodium phosphate bu \ufb00er (pH 7.4),\nat room temperature, using a three electrode cell, a glassy\ncarbon electrode was used as a working electrode, a platinum\nwire as an auxiliary electrode and Ag, AgCl/KCl ( ca.3.5 M) as a\nreference electrode. All coumarin\u2013 chalcone hybrids were\nstudied to 1 mM in 20% methanol as \ue103nal concentration.\n7.4 Determination of ORAC\nThe ORAC analyses were carried out on a Synergy HT multi\ndetection microplate reader, from Bio-Tek Instruments, Inc.\n(Winooski, USA), using white polystyrene 96-well plates,\npurchased from Nunc (Denmark). The consumption of the\nprobe molecules, FL or PGR, associated with its incubation in\nthe presence of AAPH, was estimated from \ue104uorescence ( F) and\nabsorbance ( A) measurements, respectively. PGR consumption\nwas evaluated from its absorption intensity ( A) decrease at\nThis journal is \u00aaThe Royal Society of Chemistry 2013 Med. Chem. Commun. , 2013, 4, 993 \u20131000 | 997Concise Article MedChemComm\n\u0018\u001d 169540 nm, while FL consumption was evaluated from its decrease\nin the \ue104uorescence intensity ( F, excitation: 485/20 nm; emis-\nsion: 528/20 nm). The plate reader was controlled by Gen 5\nso\ue09dware. The reaction was carried out in 75 mM sodium\nphosphate bu \ufb00er (pH 7.4), and a \ue103nal volume of 200 mL. FL\n(40 nM, \ue103nal concentration) or PGR (70 mM,\ue103nal concentration)\nand coumarin \u2013chalcone hybrid solutions in methanol with a\nrange of concentrations between 0.3 mM and 2 mM were placed\nin each well of 96-well plate. The mixture was preincubated for\n15 min at 37/C14C, before rapidly adding the AAPH solution\n(18 mM and 0.1 M for FL and PGR \ue103nal concentration,\nrespectively). The microplate was immediately placed in the\nreader and automatically shaken prior to each reading. The\ue104uorescence and absorbance were recorded every 1 min for 120\nmin. A blank with FL or PGR and AAPH using methanol instead\nof the antioxidant solution and \ue103ve calibration solutions using\nTrolox (0.5 mM to 2.5 mM for Fl and 50 mM to 250 mM for PGR) as\nantioxidant were also used in each assay. The inhibition\ncapacity was expressed as ORAC-FL and ORAC-PGR values, and\nis quanti \ue103ed by integration of the area under the curve (AUC-\nNET). All reaction mixtures were prepared in triplicate and at\nleast three independent assays were performed for each sample.The area under the \ue104uorescence decay curve (AUC) was calcu-\nlated integrating the decay of the \ue104uorescence where F\n0is the\ninitial \ue104uorescence read at 0 min and Fis the \ue104uorescence read\nat time. The net AUC corresponding to the sample was calcu-lated by subtracting the AUC corresponding to the blank. The\nORAC-PGR values were calculated like we indicated previously.\nData processing was performed using Origin Pro 8 SR2 (OriginLab Corporation, USA).\n7.5 ESR spectroscopy\nTo a solution of 100 mL of NaOH (50 mL, 4 mM), 5,5-dimethyl-1-\npyrroline- N-oxide (DMPO) (50 mL, 30 mM) and hydrogen\nperoxide (50 mL, 30%) was added the antioxidant compound\n(50mL, 3 mM in DMF). The resulting mixture was placed in an\nEPR cell, at room temperature (25\n/C14C) and the spectrum was\nrecorded a\ue09d er\ue103ve minutes of reaction in the X band (9.68 GHz)\nusing a Bruker ECS 106 spectrometer with a rectangular cavity\nand 50 kHz \ue103eld modulation.\n7.6 Determination of trypanocidal activity\nTrypanocidal activity was evaluated against the T. cruzi epi-\nmastigote stage (clone Dm28c) and it was measured through the\nMTT assay,43using 0.22 mg mL/C01phenazine metosulfate (as\nelectron carrier). The T. cruzi epimastigotes Dm28c strain, from\nour own collection ( Programa de Farmacolog \u00b4\u0131a Molecular y Cl \u00b4\u0131nica,\nFacultad de Medicina, Universidad de Chile )w e r eg r o w na t2 8/C14Ci n\nthe Diamond's monophasic medium as reported earlier53but\nreplacing blood by 4 mM hemin and adding fetal calf serum (5%).\nThe coumarin \u2013chalcone hybrids (10 and 100 mM in DMSO) were\nadded to 3 /C2106parasites per mL in the RPMI 1640 culture\nmedium (5% bovine fetal serum) for 24 h at 28/C14C. The DMSO\n\ue103nal concentration was less than 0.1% v/v. The same procedure\nwas followed with nifurtimox as the positive control. The tetra-\nzolium salt was added at a \ue103nal concentration of 0.5 mg mL/C01,incubated at 28/C14C for 4 h and then solubilized with sodium\ndodecyl sulfate (10%) in HCl (0.1 mmol L/C01) and incubated\novernight. A \ue09der incubation time, the number of viable parasites\nwas determined by measuring the absorbance at 570 nm in a\nmultiwell reader (Asys Expert Plus \u00aa, Austria). Untreated parasites\nwere used as controls (100% of viability). Results are reported as\nthe percentage of non-viable epimastigotes regarding the control.Statistical analysis was performed using GraphPad Prism 5 so \ue09d-\nware (GraphPad So \ue09dware, Inc. San Diego, CA). The data are\nexpressed as mean /C6S.D. The experimental data were analyzed\nby one-way analysis of variance (ANOVA), and di \ufb00erences\nbetween groups were assessed using the Tukey's post-test. Thelevel of signi \ue103cance was set at p< 0.05, and all experiments were\nreplicated three times.\n7.7 Theoretical evaluation of ADME properties\nThe ADME properties of the studied compounds were calcu-\nlated using the Molinspiration property program.\n44logPis\ncalculated by the methodology developed by Molinspiration as asum of fragment-based contributions and correction factors.\nTopological Polar Surface Area (TPSA) is calculated based on the\nmethodology published by Ertl et al. as a sum of fragment\ncontributions.\n52Oxygen and nitrogen centered polar fragments\nare considered. PSA has been shown to be a very good descriptor\ncharacterizing drug absorption, including intestinal absorp-\ntion, bioavailability, Caco-2 permeability and blood \u2013brain\nbarrier penetration. The method for calculation of molecular\nvolume developed by Molinspiration is based on group contri-butions. These have been obtained by \ue103tting the sum of frag-\nment contributions to \u201creal\u201d3D volume for a training set of\nabout twelve thousand, mostly drug-like molecules. 3D molec-ular geometries for a training set were fully optimized by thesemiempirical AM1 method.\n8 Conclusions\nIn conclusion, we have con \ue103rmed the good antioxidant activity\nof the hydroxyl coumarin \u2013chalcone hybrids 1\u20135, two of them\n(compounds 4and 5) presenting better ORAC-FL values than\nthe reference compounds quercetin and catechin. The use of acatechol group in the benzoyl ring and the presence of hydroxyland bromine groups in the coumarin moiety make a bigimprovement in the antioxidant activity, compound 5being the\nmost active of the series under study. The results of the anti-oxidant assay using ESR showed signi \ue103cant reactivity against\nthe hydroxyl radical for all tested compounds. A very interesting\ue103nding is that compounds 4and 5resulted to be very reactive\nand present good antioxidant capacity and scavengingpercentage against hydroxyl and peroxyl radicals, as well as lowoxidation potentials. Based on these results, we can concludethat compounds 4and 5are potential candidates for deeper\nstudies of antioxidant activity. On the other hand, it is worth\nmentioning that molecules with higher trypanocidal activities\nshowed a lower ORAC-FL index, which can be a key in theunderstanding of the mechanism of action of the compoundson the T. cruzi parasite.\n998 |Med. Chem. Commun. , 2013, 4, 993 \u20131000 This journal is \u00aaThe Royal Society of Chemistry 2013MedChemComm Concise Article\n\u0018\u001e\u0017170Acknowledgements\nThis work was partially supported by the Ministerio de Sanidad\ny Consumo (PS09/00501), Xunta de Galicia (PGI-DIT09CSA030203PR) (Spain), FONDECYT (projects 1110029 and\n1090078) and Anillo ACT112 (Chile). SVR thanks Ministerio de\nEducaci \u00b4on y Ciencia for her PhD grant FPU (AP2008-04263).\nRFG gratefully acknowledges CONICYT-Chile for his PhD grant\nno. 24121574. MJM thanks Funda\u00e7 ~ao para a Ci \u02c6encia e Tecno-\nlogia for her PhD grant (SFRH/BD/61262/2009).\nNotes and references\n1 G. Di Carlo, Life Sci. , 1999, 65, 337.\n2 N. K. Sahu, S. S. Balbhadra, J. Choudhary and D. V. Kohli,\nCurr. Med. Chem. , 2012, 19, 209.\n3 K. Liaras, A. Geronikaki, J. Glamoclija, A. Ciric and\nM. Sokovic, Bioorg. Med. Chem. Lett. , 2011, 19, 3135.\n4 D. Batovska, S. Parushev, B. Stamboliyska, I. Tsvetkova,\nM. Ninova and H. Najdenski, Eur. J. Med. Chem. , 2009, 44,\n2211.\n5 M. Larsen, H. Kromann, A. Kharazmi and S. F. Nielsen,\nBioorg. Med. Chem. Lett. , 2005, 15, 4858.\n6S .F r \u00a8olich, C. Schubert, U. Bienzle and K. J. Jenett-Siems,\nJ. Antimicrob. Chemother. , 2005, 55, 883.\n7 R. Kumar, D. Mohanakrishnan, A. Sharma, N. K. Kaushik,\nK. Kalia, A. K. Sinha and D. Sahal, Eur. J. Med. Chem. , 2010,\n45, 5292.\n8 P. Boeck, P. C. Leal, R. Yunes, V. C. Filho, S. L \u00b4opez,\nM. Sortino, A. Escalante, R. L. E. Furl \u00b4an and S. Zacchino,\nArch. Pharm. , 2005, 338, 87.\n9 K. L. Lahtchev, D. I. Batovska, S. P. Parushev, V. M. Ubiyvovk\nand A. A. Sibirny, Eur. J. Med. Chem. , 2008, 43, 2220.\n10 S. Cheenpracha, C. Karalai, C. Ponglimanont,\nS. Subhadhirasakul and S. Tewtrakul, Bioorg. Med. Chem. ,\n2006, 14, 1710.\n11 J. Wu, Bioorg. Med. Chem. Lett. , 2003, 13, 1813.\n12 F. Herencia, M. L. Ferrandiz, A. Ubeda, I. G. Guillen,\nJ. N. Dominguez, J. E. Charris, G. M. Lobo and\nM. J. Alcaraz, Free Radical Biol. Med. , 2001, 30, 43.\n13 J. Rojas, Eur. J. Pharmacol., 2003, 465, 183.\n14 Z. Nowakowska, Eur. J. Med. Chem. , 2007, 42, 125.\n15 F. Borges, F. Roleira, N. Milhazes, E. Uriarte and L. Santana,\nFront. Med. Chem. , 2009, 4, 23.\n16 M. J. Matos, D. Vi ~na, C. Picciau, F. Orallo, L. Santana and\nE. Uriarte, Bioorg. Med. Chem. Lett. , 2009, 19, 5053.\n17 Q. Shen, Q. Peng, J. Shao, X. Liu, Z. Huang, X. Pu, L. Ma,\nY. M. Li, A. S. C. Chan and L. Gu, Eur. J. Med. Chem. , 2005,\n40,\n1307.\n18 P. Manojkumar, T. K. Ravi and G. Subbuchettiar, Acta\nPharm. , 2009, 59, 159.\n19 C. Ito, M. Itoigawa, S. Onoda, A. Hosokawa, N. Ruangrungsi,\nT. Okuda, H. Tokuda, H. Nishino and H. Furukawa,\nPhytochemistry , 2005, 66, 567.\n20 I. Kostova, Curr. HIV Res. , 2006, 4, 347.\n21 D. Bhavsar, J. Trivedi, S. Parekh, M. Savant, S. Thakrar,\nA. Bavishi, A. Radadiya, H. Vala, J. Lunagariya, M. Parmar,L. Paresh, R. Loddo and A. Shah, Bioorg. Med. Chem. Lett. ,\n2011, 21, 3443.\n22 G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou, A. Detsi,\nM. Koufaki, C. Kontogiorgis and D. J. Hadjipavlou-Litina,\nEur. J. Med. Chem. , 2009, 44, 3020.\n23 T. Symeonidis, K. C. Fylaktakidou, D. J. Hadjipavlou-Litina\nand K. E. Litinas, Eur. J. Med. Chem. , 2009, 44, 5012.\n24 P. Manojkumar, T. K. Ravi and S. Gopalakrishnan, Eur.\nJ. Med. Chem. , 2009, 44, 4690.\n25 S. A. Rodriguez, M. A. Nazareno and M. T. Baumgartner,\nBioorg. Med. Chem. , 2011, 19, 6233.\n26 I. Kostova, S. Bhatia, P. Grigorov, S. Balkansky, V. S. Parmar,\nA. K. Prasad and L. Saso, Curr. Med. Chem. , 2011, 18, 3929.\n27 J. D. Maya, B. K. Cassels, P. Iturriaga-V \u00b4asquez, J. Ferreira,\nM. Fa \u00b4undez, N. Galanti, A. Ferreira and A. Morello, Comp.\nBiochem. Physiol., Part A: Mol. Integr. Physiol. , 2007, 146, 601.\n28 J. A. Urbina, Acta Trop. , 2010, 115, 55.\n29 C. Bern, N. Engl. J. Med. , 2011, 364, 2527.\n30 X. Ba, S. Gupta, M. Davidson and N. J. Garg, J. Biol. Chem. ,\n2010, 285, 11596.\n31 J. Nordberg and E. S. Arn \u00b4er,Free Radical Biol. Med. , 2001, 31,\n1287.\n32 H. Pelicano, D. Carney and P. Huang, Drug Resist. Updates ,\n2004, 7, 97.\n33 J. M. L \u00a8u, P. H. Lin, Q. Yao and C. Chen, J. Cell. Mol. Med. ,\n2010, 14,\n840.\n34 T. Nishiyama, J. Ohnishi and Y. Hashiguchi, Biosci.,\nBiotechnol., Biochem. , 2001, 65, 1127.\n35 B. P. Bandgar, S. S. Gawande, R. G. Bodade, J. V. Totre and\nC. N. Khobragade, Bioorg. Med. Chem. , 2010, 18, 1364.\n36 J. C. Aponte, M. Ver \u00b4astegui, E. M \u00b4alaga, M. Zimic,\nM. Quiliano, A. J. Vaisberg, R. H. Gilman andG. B. Hammond, J. Med. Chem. , 2008, 51, 6230.\n37 Z. Qiao, Q. Wang, F. Zhang, Z. Wang, T. Bowling, B. Nare,\nR. T. Jacobs, J. Zhang, D. Ding, Y. Liu and H. Zhou, J. Med.\nChem. , 2012, 55, 3553.\n38 Y. Yoshida, N. Itoh, Y. Saito, M. Hayakawa and E. Niki, Free\nRadical Res. , 2004, 38, 375.\n39 B. Ou, M. Hampsch-Woodill and R. L. Prior, J. Agric. Food\nChem. , 2001, 49, 4619.\n40 C. L \u00b4opez-Alarc \u00b4on and E. Lissi, Free Radical Res. , 2005, 39,\n729.\n41 C. L \u00b4opez-Alarc \u00b4on and E. Lissi, Free Radical Res. , 2006, 40,\n979.\n42 E. Alarcon, A. M. Campos, A. M. Edwards, E. Lissi and\nC. Lopez-Alarcon, Food Chem. , 2008, 107, 1114.\n43 S. Muelas-Serrano, J. J. Nogal-Ruiz and A. G \u00b4omez-Barrio,\nParasitol. Res. , 2000, 86, 999.\n44 M cheminformatics, Bratislava, Slovak Republic, http://\nwww.molinspiration.com/services/properties.html, 2009.\n45 S. Vogel, M. Barbic, G. J \u00a8urgenliemk and J. Heilmann, Eur.\nJ. Med. Chem. , 2010, 45, 2206.\n46 A. J. Bard, L. R. Faulkner, E. Swain and C. Robey, Electrochem.\nMeth. Fundamentals Applications , John Wiley, New York,\n1980.\n47 M. Medvidovi \u00b4c-kosanovi \u00b4c, M. \u02c7Seruga, L. Jakobek and\nI. Novak, Croat. Chem. Acta ,\n 2010, 83, 197.\nThis journal is \u00aaThe Royal Society of Chemistry 2013 Med. Chem. Commun. , 2013, 4, 993 \u20131000 | 999Concise Article MedChemComm\n\u0018\u001e\u001817148 M. Musialik, R. Kuzmicz, T. S. Paw 1owski and\nG. Litwinienko, J. Org. Chem. , 2009, 74, 2699.\n49 F. Perez-Cruz, R. Montecinos, F. A. Villamena, A. Das,\nE. Uriarte, C. L \u00b4opez-Alarc \u00b4on and C. Olea-Azar, Free Radical\nBiol. Med. , 2012, 53, S115.\n50 S. Vogel, S. Ohmayer, G. Brunner and J. Heilmann, Bioorg.\nMed. Chem. , 2008, 16, 4286.51 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney,\nAdv. Drug Delivery Rev. , 1997, 23,3 .\n52 P. Ertl, B. Rohde and P. Selzer, J. Med. Chem. , 2000, 43, 3714.\n53 J. D. Maya, A. Morello, Y. Repetto, R. Tellez, A. Rodriguez,\nU. Zelada, P. Puebla, M. Bont \u00b4a, S. Bollo and A. San\nFeliciano, Comp. Biochem. Physiol., Part C: Toxicol.\nPharmacol. , 2000, 125, 103.\n1000 |Med. Chem. Commun. , 2013, 4, 993 \u20131000 This journal is \u00aaThe Royal Society of Chemistry 2013MedChemComm Concise Article\n\u0018\u001e\u0019172\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nCoumarins (2H-1- benzopyran-2-one) are a fam -\nily of natural com pounds profusely distributed \nin the plant kingdom, which can be found in\ndifferent plants, suc h as sweet woo druff, tonka \nbean and vanilla grass [1\u20133]. Deri vatives of this\nwell-known skeleton have been proven to dis play \na wide ran ge of important biolo gical activities \n[1\u20133].Differently substituted coumarins have\nalready proved to be pharmacologically active\nas anticancer, anti-in flammatory, antimicro bial, \nvasorelaxant, cardio protective and antioxidant \nagents [1\u201316 ]. Due to the role that co umarins can\nplay in different areas, the synthesis, character-\nization and study of their derivatives are current \ntopics of interest [17\u201324 ].\nDifferent hydroxyl-substitute d heterocyc lic \ncompounds, in which group hydroxycoumarins\nare included, are bioactive substances present in \nnatural sources. They have been described asnatural antioxidants and their \npresence con -\ntributes to prevent or minimize several oxida -\ntive processes [25]. They can protect ce lls from \nthe oxidative dama ge caused by reactive oxy gen \nspecies (ROS). In fact, the over production of \nfree radicals has been related to cellular mem -\nbrane and DNA dama ge, and indirectly with\naging and oxidative stress-related diseases suchas cancer, car\ndiovascu lar an d neuro degenerative\npatholo gies [26\u201328 ].Antioxidants are ca pable of \ndecreasin g or preventin g oxidation processes\nthrou gh different mechanisms, such as scav -\nenging free radicals, inhibition of pro-oxidant\nenzymes or chelation of transition metal ions [29].\nTherefore , the research and characterization of \nnew bioactive hydroxy-su bstitute d compoun ds has intensified over the last few years, either forthe development of nutraceutics or drugs.\nPro\nduction o f ROS an d the consec utive oxi da-\ntive stress are factors that contrib ute to Chagas \ndisease (Amer ican tr ypanosom iasis) progres-\nsion[30]. This disease has its ori gins in a proto -\nzoan parasite known as Trypanosoma cruz i[31].\nChagas disease is a significant health problem\nin Central and South America , and it is one of \nthe most relevant emerging parasitic diseases in \ndevelo ped countries [32,33 ]. The parasite presents \na complex and multista ge life cycle. In its devel -\nopment and infection it obli gatory involves four \ndifferent stages [34,35 ]. The infection is transmit -tt\nted to humans predominantly by an insect ve c-\ntor, blood trans fusions or between mot her an d\nfetus. Durin g the life cycle o f T.cruzi and its i\ninfection process, ROS can be produced. The\nover production of these s pecies is a conse quence \nof the destruction of different tissues, mainl y \ncaused by the parasite\u2019s toxic secretions, secon d-\nary damage in t he myocar dium an d immune -\nmediated c ytotoxicit y. Therefore, intervention\nwith antioxidant com pounds that are ca pable of \nreducin g the generation, or devastatin g effects, \nof ROS, will exert beneficial effects in protect-\ning the cells from oxidative damage [36,37 ]. Nat -tt\nural products have played an im portant ro le in \nthe thera py of this parasitic disease, but at the \nmoment only nifurtimox and benznidazole dru gs \nare the currently in use. These com pounds are \nvery unspecific, presentin g high toxicity, low \nefficacy , high levels of resistance and multiple \nside effects [38,39 ]. In fact, t his therapy is usua lly \nineffective in chronic sta ges of the disease [32,40 ].$>39/,808\u0001(3+\u0001,;(1:(9043\u00014-\u0001(3904=0+(39\u0001(3+\u0001\n97>5(34*0+(1\u00015745,790, 8\u00014-\u0001(\u00018,1,*9,+\u00018,70,8\u00014-\u0001\n*4:2(703\u0001+,70;(90;,8\n%/08\u0001(790*1,\u0001+,8*70),8\u00019/,\u000157,5(7(9043\u0001(3+\u0001*/(7(*9,70?(9043\u00014-\u0001(\u00018,1,*9,+\u00018,70,8\u00014-\u0001*4:2(703\u0001+,70;(90;,8\u0001<09/\u00019/,\u0001(02\n4-\u0001,;(1:(903.\u00019/,07\u0001(3904=0+(39\u00015745,790,8\u0001(3+\u00019/,07\u0001(*90;09>\u0001( .(0389\u0001\n\u0017\u001d\u0016\u000b\u0014\u0015\u0018\u0015\u0013\u000b\f\u0017\u001a\u001e\u0011\u0007\u00019/,\u00015(7(809,\u00017,854380)1,\u0001-47\u0001\n\u0018/(.(8\u0001+08,(8,\t\u0001\u001711\u00019/,\u0001+,70;(90;,8\u0001+,243897(9,+\u000124+,7(9,\u000197>5(34*0+(1\u0001(*90;09>\u000103\u00019/,\u0001,502(890.49,\u0001(3+\n97>542(890.49,\u000189(.,8\u0001\u0003*143,\u0001\u00192\r\u0013*\u0004\u0007\u0001<09/\u0001\u00184254:3+\u0001\u000e\u000157,8,3903. \u00019/,\u0001/0./,89\u000197>5(34*0+(1\u0001(*90;09>\u00014-\u00019/,\u0001,3907,\u0001\n8,70,8\u0007\u0001+0851(>03.\u0001/0./,7\u0001(*90;09>\u00019/(3\u000130-:79024=\u0007\u0001</0*/\u0001<(8\u0001: 8,+\u0001(8\u0001(\u00017,-,7,3*,\u0001*4254:3+\t\u0001\u001e3\u0001(++09043\u000194\u00019/,\n97>5(34*0+(1\u0001(*90;09>\u0007\u00019/08\u0001*4254:3+\u0001574;,+\u000194\u0001/(;,\u0001(\u0001;,7>\u0001039, 7,8903.\u0001(3904=0+(39\u0001574-01,\u0007\u0001(8\u0001<,11\u0001(8\u000134\u0001*>9494=0*09>\t\n%/,8,\u000157,10203(7>\u0001-03+03.8\u0001,3*4:7(.,+\u00019/,\u0001(:9/478\u000194\u000189:+>\u00019/,\u0001 -:9:7,\u0001897:*9:7(1\u0001459020?(9043\u00014-\u00019/08\u00018*(--41+\t\n\u0018(\u001d +-(\u0001\u0011$\". +(\u001c\u0001\u0012.45 2\b\u0006\n\u0015\u001c+$\u001c\u0001\u0013(3(\u0001\u0015\u001c-(, \u0005\t\u0006\u0001\n\u0019\u001c% -\u001c\u0001\u001b\u001c2 *. 2\u0007\u0018(\u001f+$ \". 2\t\u0006\n\u0014(.+\u001f ,\u0001\u0019\u001c'-\u001c' \u001c\t\u0006\u0001\u0001\n\u0010.\" '$(\u0001\u001a+$\u001c+-  \t\u0006\u0001\n\u000e%\u001c.\u001f$(\u0001\u0016% \u001c\u0007\r2\u001c+\b\u0001\u0001\n\u0002\u0001\u0013.\u001c'\u0001\u000f$ \"(\u0001\u0015\u001c1\u001c\n\f\u0019,5(79(2,394\u0001+,\u0001\":B20*(\u0001\u001e347.@30*(\n>\u0001\u00173(1B90*(\u0007\u0001\u001b(*:19(+\u0001+,\u0001\u00180,3*0(8\n\":B20*(8\u0001>\u0001\u001b(72(*A:90*(8\u0007\u0001&30;,780+(+\n+,\u0001\u0018/01,\u0007\u0001\u0018(8011(\u0001\r\u000e\u000e\u0007\u0001$(390(.4\u0007\u0001\u0018/01,\n\r\u0019,5(79(2,394\u0001+,\u0001\":B20*(\u0001 7.@30*(\u0007\n\u001b(*:19(+\u0001+,\u0001\u001b(72(*0(\u0007\u0001&30;,780+(+\u0001+,\u0001\n$(390(.4\u0001+,\u0001\u0018425489,1(\u0007\u0001\u0018(25:8\u0001'0+(\n8\n3\u0007\u0001\f\u0010\u0012\u0013\r\u0007\u0001$(390(.4\u0001+,\u0001\u0018425489,1(\u0007\n\u001a85(C(\n\u000e\u0019,5(79(2,394\u0001+,\u0001\u001b(72(*414.B(\u0001\n\u001f41,*:1(7\u0001>\u0001\u00181B30*(\u0007\u0001\u001b(*:19(+\u0001+,\u001f,+0*03(\n\u0007\u0001&30;,780+(+\u0001+,\u0001\u0018/01, \u0007\u0001\n$(390(.4\u0007\u0001\u0018/01,\u0001\n\u0005\u0017:9/47\u0001-47\u0001*477,8543+,3*,\u0015\n%,1\t\u0015\u0001\u0006\u000e\u000f\u0001\u0013\u0013\f\u0001\u0013\f\u000f\u0001\u0014\u000e\u0011\u001b(=\u0015\u0001\u0006\u000e\u000f\u0001\u0014\u0013\f\u0001\u0010\u0014\u000f\u0001\u0014\f\r\u001a\b2(01\u0015\u00012(70(*2(948\u0016.2(01\t*42\n1911 ISSN 1756- 8919 10.4155/FMC.1 3.147 \u00a9 2013 Future Science Ltd Future Med. Chem. (2013 ) 5(16), 1911\u2013192 2\n\u0018\u001e\u001a173Therefore, the discovery of new and more effec-\ntive dru gs that are well tolerated and safer, is a \ntopic of ma jor interest.\nSome coumarins proved to be im portant mo l-\necules in the re gression of the described pathol-\nogy. Previous studies described that they act by \ninhibiting GAPDH (enzyme commission num -\nber 1.2.1.12), an im portant protein in the try-\npanosomatids glycolytic pathwa y [41\u201343 ]. In addi -\ntion, antioxidant properties were also attributed\nto the coumarin skeleton [44\u201346 ]. Based on this \nprevious in formation re lated to the pharmaco-\nlogical activities of coumarins, in the present \nwork a selected series of coumarin derivatives \nwere synthesized and studied as antioxidant and \ntrypanocidal agents \u0003\u0010\u0012\u0011\u001a\u0018\u000f\u0001\u0006\u000b\u0001\b7\f\u0004.\n\u00100) +$& '-\u001c%\n\u0003\u0084\u0018/,20897>\n\u001c,3,7(1\u00012,9/4+8\nMelting points were determined using a Reichert \nKofler thermo pan  o r  in  ca pillary tubes on a \nB\u00fcchi 510 a pparatus and are uncorrected.1H\nand 13C NMR s pectra were recorded on a Bruker \nAMX s pectrometer at 300 and 75.4 7 MHz ,\nrespectively, usin g tetramethylsilane as a inter -\nnal standard (chemical shifts in G-values, J in\nHz). Elemental analyses were performed using \na Per kin-Elmer 240B microana lyser an d were \nwithin \u00b10.4% o f calculated values in a ll cases.\nSilica gel (Merck 60, 230\u201300 mesh ) was used for \nflash chromato graphy. Analytical thin layer chro -\nmato graphy was performed on plates precoated \nwith silica gel (Merc k60 F25 4, 0.25 mm ).\n\u001c,3,7(1\u00012,9/4+414.>\u000194\u000157,5(7,\u0001\n\u000e\b(2034*4:2(7038\u0001 \t\u0001\u0002\nThe commercially available 3-nitrocoumarin \n(2.5 mmol ) was dissolved in ethanol and a cata-\nlytic amount of Pd/C was added to the mixture. \nThe solution was stirred, at room tem perature, \nunder a H2 atmos phere, for 5 h. After com ple-\ntion of the reaction , the mixture was filtered\nto eliminate the catalyst. The obtained crude\nwa s  t h e n  p u r i fi e d  b y  fl a s h  c h r o m a t o graphy \n(hexane/ethyl acetate 9:1) to give the desired\n3-am inocoumar in\t or \n.\n\u001c,3,7(1\u0001574*,+:7,\u0001-47\u00019/,\u000157,5(7(9043\u00014-\u0001\n\u000e\b8:)8909:9,+\u0001*4:2(7038\u0001 \u000b\u0001\u0002\f\nThe previously prepared 3-aminocoumarin \u0003\t\u0004\nor 3-amino-4-hydroxycoumarin \u0003\n\u0004 (1 mmol )\nwas dissolved in dichloromethane (9 ml), then \npyridine (1.1 mmol) was added and the mi x-\nture was cooled to 0\u00b0C. 2-chloroacetyl chloride (1.1mmol) was added dro p-wise at this tem -\nperature, and the mixture was stirred overni ght\nat room tem perature. The batch was eva po-\nrated and puri fied by column c hromatograp hy \n(hexane\u2013et hyl acetate 9:1) to give t he desired\n2-chloro-N-(coumarin-3-yl)acetamideNN \u000b or \f,\nrespectively .\n\u0003\u0084 =0+(9043\u0001549,390(1\u0001+,9,7203(9043\u0001)>\u0001\u0018'\nCV was carried out usin g a Metrohm 797 VA \ninstrument with a 797 VA Stand onvertor and a \n797 VA Processor in DMSO/75 mM phosphate \n(pH 7.4) buffer 30/70 DMSO/ (a1.0\u00d710-3 M) \nat room tem perature with KCl ( a0.1 M), usin g \na three-electrode cell. A han ging drop mercury \nelectrode was used as the working electrode, a \nplatinum wire as the auxiliary electrode, and \nsaturate d calomel as the reference e lectro de.\n\u0003\u0084 =>.,3\u00017(+0*(1\u0001()847)(3*,\n*(5(*09>\b-1:47,8*,3*,\nThe oxygen ra dical absorbance capacit y\n(ORAC) studies were carried out on a Synergy\u2122\nHT mu ltidetection micro plate rea der, from Bio -\nTek Instruments, Inc. (VT, USA), usin g white\npolystyrene 96-well plates, purchased from\nNunc (Roskilde, Denmark ). Fluorescence was\nread from the to p,  wi th  an  ex c i ta ti o n  wa v e -\nlength of 485/20 nm and an emission filter o f \n528/20 nm. T he plate rea der was contro lled by \nGen 5 software. The reaction was carried out in\n75 mM sodium phosphate buffer ( pH 7.4), and\n200 \u03bcl final volume. Fluorescence (FL; 40 nM,\nfinal concentration ) and coumarin solutions\nin methanol (range of concentration between0.3 and 2 \u03bcM) were placed in each well of the96-well \nplate. The mixture was preincubated\nfor 15 min at 37\u00b0C, before rapidly addin g the \n2,2\u00b4-azo-bis(2-amidino propane) dihydrochloride\n(AAPH ) solution (18 mM, final concentration ).\nThe micro plate was immediately placed in the\nreader an d automatica lly shaken prior to eac h\nreadin g. The fluorescence was recorded ever y \n1 min for 120 min. A blank with FL and AAPHusin\ng methanol instead of the antioxidant solu -\ntion was used in each assay. Five calibration\nsolutions using Trolo x\u00ae (0.5\u20132.5 \u03bcM) as the\nantioxi dant were a lso use d in eac h assay. T he \ninhibition ca pacity was ex pressed as ORAC-FL \nvalues and it was quantified by inte gration of the \nAUCNET. All reaction mixtures were prepared in\ntriplicate and at least three inde pendent assays \nwere performed for each sam ple. The area under \nthe fluorescence decay curve (AUC) was calcu-lated inte\ngratin g the decay of the fluorescence, Key Term s\nCoumarins (2H-1-\nbenzop yran-2-one) :\u0001\u001b(201>\u0001\n4-\u0001*4254:3+8\u00019/(9\u000157,8,39\u000103\n9/,07\u0001897:*9:7,\u0001(\u0001 ),3?,3,\u0001703.\n(99(*/,+\u000194\u0001(\u00015>743,\u000143,\t\nCha gas disease (American\ntrypanosomiasis): \u0001!(9/414.>\n*(:8,+\u0001)>\u0001(\u000157494?4(3\u00015(7(809,\n*(11,+\u0001\n\u0017\u001d\u0016\u000b\u0014\u0015\u0018\u0015\u0013\u000b\u0001\f\u0017\u001a\u001e\u0011 \t\u0001%/08\n+08,(8,\u0001*(:8,8\u0001\f\u000bF\f\r\u00012011043\u0001\n03-,*90438\u0001(3+\u0001(5574=02(9,1>\n\r\u0010\u0007\u000b\u000b\u000b\u0001+,(9/8\n>,(7\t\nTrypanosoma cruz i:\n\u001b1(.,11(9,+\u000157494?4(3\u00015(7(809,\u0007\u0001\n9/,\u00012(03\u0001038,*9\u0001;,*947\u00014-\u0001</0*/\n08\u00019/,\n\u0017\u0011\u000b\u0019\u0015\u0013\u0011\u0014\r\u0001\u0011\u0014\u000e\r\u0018\u0019\u000b\u0014 \u0018\t\nOxygen ra dical\nabsorbance capacit y:\n\u00173904=0+(398\u0001(7,\u0001(\u0001*1(88\u00014-\u0001\n241,*:1,8\u00017,854380)1,\u0001-47\u0001\n5749,*903.\u0001(\u0001-1:47,8*,39\u0001\n241,*:1,\u0001\u0003-1:47,8*,03\u0004\u0001-742\u00019/,\n4=0+(90;,\u0001+,.,3,7(9043\t\u0001%/,\n1,;,1\u00014-\u0001(3904=0+(39\b2,+0(9,+\u0001\n5749,*9043\u0001*(3\u0001),\u00016:(390-0,+\n:803.\u00019/,\u00017,-,7,3*,\u0001(3904=0+(39\n%7414=D\u0001\u0003(\u0001;09(203\u0001\u001a\u0001(3(14.\u0004\u0001(8\n89(3+(7+\t\nElectron s pin resonance:\n\u0017\u00019,*/306:,\u0001:8,-:1\u0001-47\u00019/,\u000189:+ >\n4-\u0001*4254:3+8\u0001<09/\u0001:35(07,+\n,1,*97438\t\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1912 future science group\n\u0018\u001e\u001b174where F0 is the initial fl uorescence rea d at 0 min\nand F is the fluorescence read at time. The net \nAUC correspondin g to the sample was calcu-\nlated by subtractin g the AUC correspondin g to\nthe blank. Data processing was performed using \nOrigin Pro 8 SR2 (Origin Lab Corporation,MA, USA\n).\n\u0084\u001d>+74=>1\u00017(+0*(1\u00018*(;,3.03.\u0001(88(>\u0001:803.\n,1,*9743\u00018503\u00017,843(3*,\u000185,*9748*45>\nReactivity of all the coumarin derivatives againstt\nhe hydroxyl radical was investigate d using t he \nnon-catalytic Fenton ty pe method. The mixture \nwas put in on electron s pin resonanc e (ESR)\ncell and the authors recorded the s pectrum \nafter five minutes of reaction. ESR s pectra were\nrecor ded in the X band (9.7 GHz) using a Bruker \nECS 106 spectrometer wit h a rectangu lar cavity \nand 50-kHz field modulation, e quipped with a \nhigh-sensitivity resonator at room temperature.\nSpectrometer conditions were: microwave fre-\nquency 9.81 GHz; microwave power 20 mW; \nmodulation amplitude 0.91 G; receiver gain \n59db; time constant 8 1.92 msec; and conver -rr\nsion time 40. 96 msec. The scaven ging activity o f \neach derivative was estimated by comparin g the\nDMPO-OH adduct si gnals in the antioxidant-\nradical reaction mixture and the control rea c-\ntion at the same reaction time, and is ex pressed\nas scavenging percent of hydroxyl radical. T o \nprepare the sam ples, 150 \u03bcl of N,NNN-dimethylNN -\nformamide and 50 \u03bcl of NaOH (3 mM) were \nmix ed,  fo ll o w ed  b y  th e  addi ti o n  o f  5 0 \u03bcl of \nDMPO s pin tra p (30 mM final concentration)\nand finally 50 \u03bcl of hydrogen peroxide 30%. The mixture was \nput in an ESR ce ll and the spectrum\nwas recor ded after 5 min o f reaction. A ll the\ncompounds were studied in concentrations of \n3 mM, 50 \u03bcl. \n\u0084\u0018>9494=0*09>\u0001(88(>\u0001\nThe effect of drug treatments on RAW 264.7 W\ncells was evaluated throu gh the tetrazolium\ndye (MTT; 3[4,5-dimethylthiazol-2-yl]-2,5-di -\nphenyltetrazolium bromide) assay as a viability \ntest [47]. Briefly, 1 0\u03bcl of 5 mg/ml MTT plus\n0.22 mg/ml phenazine metosulfate (electron\ncarrier), were a dded to eac h well containin g \nRAW264.7 cell culture in 10 0\u03bcl RPMI 1 640 \nwithout phenol red. Com pounds under study, \ndissolved in DMSO , were added to the culture\nmedia at the concentrations demonstrated in\nthe figures and tables. DMSO final concentr a-\ntion was less than 0.25% v/v. A fter incu bation \nfor 4 h at 37\u00b0C, the generated water-insoluble formazan dye was dissolved by the addition o f \n100 \u03bcl of 10% w/v so dium dodecyl sulphate\n(SDS) in 0.0 1 M HCl. The plates were further\nincubated overni ght at 37\u00b0C, and optical de n-\nsity of the wells was determined usin g a micr o-\nplate reader (Asys Ex pert Plu s\u00a9, Asys Hitach, \nAustria ) at 57 0 nm. Under these conditions , the \noptical density is directly proportional to the\nviable cell number in each well. All ex periments \nwere performed at least three times and data \nreported as means and their standard deviations \nfrom tri plicate cultures. Results are re ported as\nthe percenta ge of non-viable RAW 264.7 cells\nregarding the control .\n\u0003\u0084\u0019,9,7203(9043\u00014-\u000197>5(34*0+(1\u0001(*90;09>\n\u001a502(890.49,8\u0001;0( )0109>\u000189:+>\nTrypanocidal activity was evaluated a gainst the \nT.c r u z i epimastigote stage (clone Dm28c). It i\nwas measured through the MTT assay [48] using \n0.22mg ml-1 phenazine metosu lfate (as an e lec-\ntron carrier ).T.cruzi epimastigotes (Dm28c i\nstrain ), from the authors own collection (Pro-\ngrama de Farmacolo g\u00eda Molecular y Cl\u00ednica, \nFacultad de Medicina , Universidad de Chile ,\nSantiago, Chile) were grown at 28\u00b0C in Dia -\nmond\u2019s mono phasic me dium, as re ported earlier, \nbut replacin g blood with 4 \u03bcM hemin [49]. Fetal \ncalf ser um was a dded to a final concentration o f \n5%. In this colorimetric assay for testin g the try -\npanocidal activity, the coumarin derivatives were\ndissolved in DMSO and were added to 3 \u00d7106\nparasites ml-1 at 10 \u03bcM final concentrations in\nRPMI 1640 c ulture me dium for 24 h at 28\u00b0C. ONH2\nOR\nOOH\nO\nONH\nClR\nOONO2\nO OR\nR = H or OH\n1\n4: R = H\n5: R = OH2: R = H\n3: R = OHA\nB\nFigure 1. S ynthesis of the described derivatives. Reagents and conditions: \n(A) H2, Pd/C, ethanol, room temperature, 5 h; (B) ClCOC H2Cl, pyridine, \ndichloromet hane, 0\u00b0C to room temperature, overni ght.\u00173904=0+(39\u0001\u0002\u000197>5(34*0+(1\u00015745,790,8\u00014-\u00018,1,*9,+\u0001*4:2(703\u0001+,70 ;(90;,8\u001c\u0001\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nwww.future-science.com 1913 future science group\n\u0018\u001e\u001c175DMSO final concentration was less than 0.1% \nv/v. Likewise, nifurtimox was added as a positive \ncontrol. Tetrazolium salt was added at a final con -\ncentration of 0. 5mg ml-1, incubated at 28\u00b0C for \n4 h and then solubilized with 10% SDS/0.1 mM\nHCl and incubated overnight. After incubation,t\nhe num ber of viable parasites was determine d\nby absorbance measures at 57 0nm in a m ulti-\nwell plate reader (Asys Ex pert Plus). Untreated\nparasites were used as controls (100% of viabil -\nity). Results are reported as the percentage o f \nnon-viable epimastigotes regarding the control.\n%7>542(890.49,\u0001;0( )0109>\u000189:+>\n\b\r\u0012\u0012\u0001\f\u001a\u0012\u0019\u001a\u0017\r\u0001\u0002\u0001\u0011\u0014\u0001\u001b\u0011\u0019\u0017\u0015\u0001\u0011\u0014\u000e\r\f\u0019\u0011\u0015\u0014\u0001\u001c\u0011\u0019\u0010\u0001\n\u0005\u0001\f\u0017\u001a\u001e\u0011\u0001 \u0003\t\u0013\u0006\u0007\f\u0001\n\u0018\u0019\u0017\u000b\u0011\u0014\u0004\u0001\u0019\u0017\u001d\u0016\u0015\u0013\u000b\u0018\u0019\u0011\u000f\u0015\u0019 \r\nVero cells were infected with Dm28c try pomast i-\ngotes at a 1:3 (cell:parasite) ratio. T.cruzi trypoi -\nmastigotes were initially obtained from primary \ncultures of peritoneal macropha ge from cha gasic \nmice. Vero cells were cultured in 5% fetal bovine \nserum su pplemented RPMI 1640 medium in \nhumidified air with 5% CO2 at 37\u00b0C. Vero cell \ncultures were t hen in fected with trypomastigotes \nand incubated at 37\u00b0C in humidified air and 5%\nCO2 for 5\u20137 days. After that time, the culture\nmedium was collected, centrifu ged at 50 0\u00d7 g for \n5min, and the trypomasti gote-containin g pel-\nlet was re-sus pended in free-serum RPMI 1640 \nand penicillin\u2013stre ptomycin at a final density o f \n1\u00d7107 parasites/ml. Trypomasti gote viabilit y \nassays were performed usin g the MTT reduction \nmethod as described previously. 1 \u00d7107 parasites /\nml were incubated in free-serum RPMI 1640 cul-ture medium at 3\n7\u00b0C over 2 4 h with or without \nthe studied com pounds. An ali quot of the para-\nsite sus pension was extracted and incubated in a \n96-well flat-bottom plate and MTT was added at\na final concentration of 0. 5mg/ml usin g 0.22 mg \nml-1 phenazine metosulfate (as an electron carrier),\nincubated at 28\u00b0C during 4 h and then made so l-\nuble with 10% SDS\u20130.1 mM HC l and incubated\noverni ght. Formazan formation was measured at\n570nm, with a reference wavelen gth at 69 0 nm, \nin a multiwell plate reader (Asys Ex pert Plus). \nUntreated parasites were used as controls (100% \nviability). Results are reported as the percentage of \nnon-via ble parasites regar ding the contro l.\n\u00172(890.49,\u0001;0()0109>\u000189:+>\nAmasti gotes were obtained with the same \ntechni que [48] used for trypomastigotes, but \nVero cells were infected with Dm28c try po-\nmastigotes at a 1:10 (cell:parasite) ratio, whichinduces cell rupture and release of amasti\ngotesinto the medium after 5 days. The culture\nmedium was collected, centrifu ged at 500 \u00d7 g \n5 min, and the amasti gote-containin g pellet \nwas resus pended in free-serum RPM I 1640 and\npenicillin\u2013stre ptomycin at a final density o f \n2\u00d7107 amastigotes/m l. Amastigote via bility \nassays were performed usin g the MTT redu c-\ntion method as described previously. 2\u00d7107\nparasites/ml were incubated in free-serum\nRPMI  1640 culture medium at 37\u00b0C durin g \n24h with or without com pound\u0001\u000b. An ali -\nquot o f the parasite sus pension was extracte d\nand incubated in a 96 flat-bottom plate well\nand MTT was added at a final concentration of 0.\n5mg/ml usin g 0.22mg ml-1 phenazine \nmetosulfate (as an electron carrier ), incubated\nat 28\u00b0C during 4 h an d then ma de sol uble \nwith 10% SDS\u20130. 1 mM HCl and incubated\noverni ght. Formazan formation was me a-\nsured at 570 nm, with a reference wavelen gth\nat 690nm, in a multi well plate reader (Asys \nExpert Plus). Untreated parasites were used as\ncontrols (100% viability).\n\u0003\u0084$9(90890*(1\u0001(3(1>80 8\nStatistical analyses were conducted usin g \nGraphPad Prism 5 software (Gra phPad Soft -\nware, Inc., [CA, USA] ). IC50 were analyzed b y \nnonlinear regression. The data are expressed \nas means \u00b1 SD. T he experimenta l data were\nanalyzed b y one-wa y anal ysis of variance, and\ndifferences between groups were assessed usin g \nTukey\u2019s post-test. The level of si gnificance was\nset at p < 0.05. All ex periments were done in\ntriplicate and results corres pond to means \u00b1 SD\nfrom at least three inde pendent ex periments .\n\u000e# &$,-+1\nCom pound \b is commercially available (Si gma-\nAldrich, MO, USA ). Coumarin derivatives \t7\f\nwere efficiently synthesized following the protocol \npresente d in \u0010\u0012\u0011\u001a\u0018\u000f\u0006[50\u201353 ]. Starting from different\nsubstituted commerciall y available 3-nitrocoum a-\nrins, the 3-aminocoumarins \t\u0001\u0002\u0001\n  were afforded.\nThey were prepared in ethanol, with Pd/C as cata -\nlyst, under a H2 atmos phere. The final products\nwere then purified by recrysta llization in et hyl \nacetate to give t he desired 3-aminocoumarins, in \n95% yield. The ac ylation reaction of the 3-ami -\nnocoumarins \t or \n with the conveniently su b-\nstituted acid chloride (2-chloroacetyl chloride),\nin pyridine, afforded the 2-chloro- N-(coumarin-NN\n3-yl)acetamides \u000b\u0001\u0002\u0001\f, in 76 and 83% yields, \nrespectively. The general reaction conditions are \ndetailed in the \u2018Experimenta l\u2019 section.Key Ter m\nCyclic voltammetr y:\n\u0017\u0001549,3904+>3(20*\u0001\n,1,*974*/,20*(1\u00019,*/306:,\n.,3,7(11>\u0001,2514>,+\u0001-47\u00019/,\n2,(8:7,2,39\u0001(3+\u00019/,\u000189:+>\u00014-\u0001\n9/,\u0001,1,*974*/,20*(1\u00015745,790,8\n4-\u0001+0--,7,39\u0001*4254:3+8\u0001\n57,8,39,+\u000103\u0001841:9043\t\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1914 future science group\n\u0018\u001e\u001d176\r'-$(0$\u001f\u001c'-\u0001\u001e\u001c )\u001c\u001e$-1\nThe evaluation of the antioxidant properties o f \nthe studied com pounds \u0003\b7\f\u0004 was performed\ntowards two different ty pes of ROS: peroxyl and\nhydroxyl radicals. Cyclic vo ltammetr y (CV),\nORAC an d ESR were t he techniques em ployed\nto obtain the desired results.\n\u0084\u0018'\nThe electrochemical properties of coumarin\nderivatives were studied by CV. Results of the \nCV for compoun ds\b7\f are reporte d in \u0019\f\r\u0013\u000f\u0019\u0019\u0006\u0005\nand demonstrated that the coumarin deriv a-\ntives present a variety of oxidation potentials\ndependin g on their substitution pattern .\nIn these experimental conditions, a single oxi -\ndation process (peak I) was observed. In general,it \nhas been propose d that the charge trans fer pro -\ncess at peak  I corresponds to the oxidation of thek\nhydroxyl or amine substituent.\nThe cyclic voltammo gram of compoun d\u0001\f is\nillustrate d in \u0010\u0012\u0011\u001a\u0018\u000f\u0007. It was recorded at a glass y \ncarbon electrode immersed in DMSO/75 mM\nphosphate (pH 7.4) buffer 30/70 me dia co n-\ntainin g 1 mM of compound \u0001\f, for several scan \nrates (v).\n\u0003\u0084 #\u0017\u0018\u0001(88(>8\nThe peroxyl radical scavenging activity of the syn -\nthesized coumarins was eva luated by the ORAC \nmethod [54]. This assa y uses a fluorescence-based \ntechnolo gy (ORAC-FL) and allows a relative \nantioxidant index to be obtained by usin g Tro-\nlox, a hydrosoluble vitamin E derivative, as a ref -\nerence. The com pound AAPH was used as the\nperoxy l radical source. T his assay eva luates t he\ncapacity of antioxidants to inhibit the bleachin g \nof a tar get molecule (probe) induced by peroxyl \nradicals. The oxidation occurs due to ex position\nof the tar get molecule, FL, to the peroxyl rad i-\ncal, leading to an oxidation process reflected as a \ndecay o f fluorescence emission t hrough time .\nIn ORAC assays, the loss of fluorescence of F L\ngenerally corresponds to an induction time and \nis reliant on the antioxidant ca pacity of a com -\npound. In fact, it refers to the time in which the \nFL is protected against the oxidative damage o f \nperoxy l radicals, and this behavior is associate d \nto a com petitive reaction between the radical \nand the antioxi dant [48,55 ]. ORAC data takes \ninto account the induction time , the initial rate\nand the ran ge of total antioxidant inhibition in\none value [55].\nResults ex pressed as ORAC-FL values are pre-\nsente d in\u0019\f\r\u0013\u000f\u0019\u0019\u0007. All the obtaine d ESR res ults for the percenta ge scaven ging of the hydroxyl radical\nare also illustrated in \u0019\f\r\u0013\u000f\u0019\u0019\u0007.\nThe consum ption of FL is commonly inhibited, \neven by antioxidants of low reactivity, throu ghout\nkinetic profiles.\u0010\u0012\u0011\u001a\u0018\u000f\b\f illustrates the results \f\nof AAPH-me diated FL oxi dation in the absence\nand presence o f an increasing concentration o f \ncompound \td in phosphate pH7.4, and demo n-\nstrates that the area under the curve (AUCNET) \nof the kinetic profiles for com pound\u0001\t was li n-\nearly related to the concentration of the additive. \n\u0010\u0012\u0011\u001a\u0018\u000f\b\r illustrates the res ults of AAPH-me diated \nFL oxi dation in t he absence an d presence o f an \nincreasing concentration of compound \nd in phos-\nphate pH7.4 and demonstrates that the AUCNET\nof the kinetic profiles for compound \ndwas linearly \nrelated to the concentration of the additive.Table 1. Oxidant potentials obtained by \ncyclic voltammetry for compounds 1\u20135.\nCompoun ds Epa\u2020 (mV)\n\b 1.33\n\t 0.80\n\n 0.50\n\u000b 1.10\n\f 0.64\n\u2020First oxidation peak potential at scan rate o f 2000 mV s-1.\n05\n-51020304050l/(\u03bcA)\nE/V vs Ag/AgCl0.6 0.8 1.0 0.4 0.22.0 V/s\n1.5 V/s\n1.0 V/s\n0.5 V/s\n0.25 V/s\n25\n153545\nFigure 2. C yclic voltammo gram for 1 mM compound 5, in DMSO/75 mM\nphosphate (pH 7.4) bu ffer 30/70 media at a glassy carbon electrode for \nV = 250 , 500, 1000 , 1500 , 2000 mVs-1. \nThis figure can be viewed in full color at: www.future-science.com/doi /\nfull/10.4155/FMC.13.14 7\u00173904=0+(39\u0001\u0002\u000197>5(34*0+(1\u00015745,790,8\u00014-\u00018,1,*9,+\u0001*4:2(703\u0001+,70 ;(90;,8\u001c\u0001\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nwww.future-science.com 1915 future science group\n\u0018\u001e\u001e177Kinetic profiles without induction time \nwere observed for all the studied com pounds. \nIncreasin g the concentration of the coumarin derivatives, the consum ption of FL is inhibited. \nResults of this study are ex pressed as ORAC-FL \nvalues and are tabulated in \u0019\f\r\u0013\u000f\u0019\u0019\u0007.\n\u0003\u0084\u001a$#\u0001(88(>8\nTo stu dy the antioxi dant ca pacity o f all the\nsynthesized coumarins towards h ydroxyl radi-\ncals in de pth, a non-catalytic and com petitive -\ntype Fenton system was performed, employin g \n5,5-dimethyl-1- pyrroline -N-oxide (DMPO) asNN\na spin tra p [56]. In order to test the ability of \nthe new compoun ds to scavenge hydroxyl radi-\ncals, ESR, in combination with spin-trappin g \ntechniques, was employed. The percenta ge of \nscaven ging of the new compounds was me a-\nsured and is summarized in \u0019\f\r\u0013\u000f\u0019\u0019\u0007. DMP O\nreacts with hydroxyl radicals to generate the\nspin resonance signa l, which can be quant i-\nfied by ESR. The ESR s pectrum illustrates four\nhyperfine lines due to the DMPO-OH adduct \nformation. Coumarin derivatives com pete with\n06251250\n1.0 \u00d7 10-6\n2.0 \u00d7 10-6[M]Blk\n0.3 \u03bcM\n0.7 \u03bcM\n1.0 \u03bcM\n1.5 \u03bcM\n2.0 \u03bcM\n0.00.20.40.60.8\n0 2000 4000 6000 8000\nTime (s) Blk\n0.3 \u03bcM\n0.7 \u03bcM\n1.0 \u03bcM\n1.5 \u03bcM\n2.0 \u03bcM\n0.00.20.40.60.8\n0 1000 3000 2000 4000 5000\nTime (s)\n[M]AUCNETAUCNETF/F0F/F0\n010002000\n0.01.0 \u00d7 10-6\n2.0 \u00d7 10-60.01.0\n1.0\nFigure 3. Kinetic profile of fl uorescein consumption 2,2\u00b4-azo -bis(2-amidino propane)\ndihydrochloride mediated in presence o f compound 2 (A) and compound 3 (B). F0 is the\nfluorescence in absence o f the compound (Blk) and F the fluorescence in presence o f the com -\npound; graphic AU CNET (net area under the curve ) versus concentration o f the compound. \nThis figure can be viewed in full color at: www. future-science.com/doi/ full/10.4155/FMC.13.147Table 2. Oxygen radical absorbance capacity, fluorescein values and \npercentage scavenging of hydroxyl radical of the studied and reference compounds.\nCompoun ds ORAC-FL Percentage scaveng ing\u2020\n\b 4.200 \u00b1 0.110 81.2 \u00b1 7.3\n\t 0.820 \u00b1 0.030 20.5 \u00b1 2.0\n\n 4.360 \u00b1 0.120 56.8 \u00b1 4.0\n\u000b 0.065 \u00b1 0.006 35.3 \u00b1 3.2\n\f 1.810 \u00b1 0.040 23.7 \u00b1 2.8\nTrolox 1 31.0 \u00b1 2.5\n6,7-dih ydroxy-4-meth ylcoumarin 3.3\u2021\u2013\nAll the experiments were carried out in triplicate, and the data represent the mean values (\u00b1 standard \ndeviation). The ORAC-FL studies were carried out in 75 mM sodium phosphate bu ffer (pH 7.4) with\ncoumarin solutions in methanol (range o f concentration between 0.3 and2d\u03bcM).\n\u2020The scaven ging activit y of hydroxyl radicals e ffect was calculated as follows: [(A0\u2013Ax)/Axx 0] 00\u00d7 100,\nwhere Ax and A0 are the double-inte gral electron spin resonance for the first line o f samples in the \npresence (3 mM final concentration) and absence o f test compounds, respectivel y.\nORAC -FL: Ox ygen radical absorbance capacit y-fluorescein.\n\u2021Data collected from [62].\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1916 future science group\n\u0018\u001e\u001f178DMPO for hydroxyl radicals, diminishin g the \nESR si gnal, as presented in \u0010\u0012\u0011\u001a\u0018\u000f\t, for com -\npound\u0001\t\u0001\u0002\u0001\n  (red line). ESR s pectrum obtained \nin the control assay (DMPO + N,N-dimethNN -\nylformami de + Na OH + H2O2) presents four\nhyperfine lines, due to the DMPO-OH adduct\nformation , as illustrated in \u0010\u0012\u0011\u001a\u0018\u000f\t (black line ). \nFor each putative antioxidant coumarin com -\npound, ESR s pectra were also ac quired to chec k \ntheir capacity of scavenging hydroxyl radicals .\nThe intensity of the s pectra decreases when\nthe co umarin derivatives were a dded into the\nsystem. This ty pe of res ponse was observed for\nall derivatives, reflectin g different percenta ge \nof the hydroxyl radical scaven ging activit y \n\u0003\u0019\f\r\u0013\u000f\u0019\u0019\u0007\u0004.\n\u0017#\u001c+&\u001c\u001e(%(\"1\nCytotoxicity and try panocidal studies were \ncarried out in order to investi gate a potential\nrelationshi p between the antioxidant ca pac-\nity demonstrated by the new com pounds and\ntheir anti parasitic activity. Cytotoxicity and\ntrypanocidal activities for all the synthesized \ncompounds were evaluated usin g MTT assays \n[57], and the results are re ported in \u0019\f\r\u0013\u000f\u0019\u0019\b. \n\u0003\u0084\u0018>9494=0*09>\u000103\u00012(*745/(.,8\nTo investigate invitro cytotoxicity o f the syn -\nthesized compounds, cultured macropha ges \n(murine RAW 264.7 cells) were ex posed to \nnifurtimox and to the coumarin sus pensions \nat 10 and 10 0\u03bcM for 2 4h. Com pound\u0001\u000b was\nevaluated at different concentrations (0.5, 1, 5, \n10 an d 15 \u03bcM) to determinate t he IC50 values \n\u0003\u0010\u0012\u0011\u001a\u0018\u000f\n\u0004. Results are re ported in \u0019\f\r\u0013\u000f\u0019\u0019\b.\u0003\u0084%7>5(34*0+(1\u0001(*90;09>\n\u001a502(890.49,8\u0001;0( )0109>\nTrypanocidal activity for all synthesized com -\npounds was evaluated against the T.c r u z i epii-\nmastigote (c lone Dm28c) stage. It was measure d \nthrough the MTT assay, a widely used methodol-\nogy for invitro measurement of cellular viabilit y \nand/or metabolic activity. T.c r u z i epimastigote i\nstrain was grown at 28\u00b0C in Diamond\u2019s mon o-\nphasic medium, as re ported previously [57], but\nwith the blood replaced with 4 \u03bcM of hemin.\nFetal calf ser um was a dded to a final concen -\ntration of 5%. After incubation , the number o f \nviable parasites was determined by absorbance\nmeasured at 570nm, with a reference wav e-\nlength at 690 nm, in a multiwell plate reader. As\na contro l, untreate d parasites sam ples were use d\n(100% viability). Results are re ported in \u0019\f\r\u0013\u000f\u0019\u0019\b\nTable 3. In vitro cytotoxicity in murin RAW 264.7 macrophages (IC50) \nand trypanocidal activity re sults in epimastigote and \ntrypomastigote stages (10 \u03bcM) for the coumarin derivatives and \nnifurtimox (reference compound).\nCompound sIC50 (\u03bcM)\u2020Trypanocidal activit y\nin epimast igote\nstage (%)\u2021Trypanocidal activit y \nin trypomast igote \nstage (%)\u2021\n1 >100 48.7 \u00b1 2.8 11.5 \u00b1 0.9\n2 >100 42.1 \u00b1 2.1 8.6 \u00b1 0.6\n3 >100 65.7 \u00b1 3.5 22.2 \u00b1 2. 1\n4 2.70 \u00b1 0.17 53.7 \u00b1 3.2 69.4 \u00b1 4. 4\n5 >100 10.0 \u00b1 0.6 5.8 \u00b1 0.5\nNifurtimox >100 52.5 \u00b1 2.2 36.9 \u00b1 3.4\nAll the ex periments were carried out in tri plicate, and the data re present the mean values (\u00b1 standar d \ndeviation ).\n\u2020IC50C is the concentration that produces 50% o f inhibitor y effect.\n\u2021Results are reported as the percenta ge of non-viable parasites re gardin g the control at 10 \u03bcM .-15,000\n3420 3440 3460 3480 3520 3500 354015,00020,000\n-10,000500010,000\n5000\n0\n3420 3440 3460 3480 3520 3500 3540-15,00015,00020,000\n-10,000500010,000\n5000\n0Intensity\nMagnetic field (G) Magnetic field (G)\nIntensity\nFigure 4. Electron spin resonance spectra obtained for the control (adduct 5,5-dimeth yl-1-p yrroline -N-oxide without\nantioxidant molecule \u2013 black line) and for adduct 5,5-dimeth yl-1-p yrroline- N-oxide. In the presence of (A) compounds \t and \n(B) compoun d\n (3 mM final concentration, li ght line).\u00173904=0+(39\u0001\u0002\u000197>5(34*0+(1\u00015745,790,8\u00014-\u00018,1,*9,+\u0001*4:2(703\u0001+,70 ;(90;,8\u001c\u0001\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nwww.future-science.com 1917 future science group\n\u0018\u001e 179as the percenta ge of nonviable epimasti gotes \nregarding the control. \n%7>542(890.49,\u0001;0( )0109>\nTrypanocidal activity for all synthesized com -\npounds was evaluated a gainst the T.cruzi  tryi-\npomasti gote (clone Dm28c) sta ge. The tryp o-\nmastigote sta ge, in mammals, is the dissemina-\ntor of blood-borne infection. It was measured \nthrough the previous ly described MTT assay. \nTrypomasti gotes were incubated in free-serum \nRPMI 1640 c ulture me dium in h umidified air\nwith 5% CO2 at 37 \u00b0C durin g 24 h with or\nwithout the studied com pounds. After incuba -\ntion time, the number of viable parasites was\ndetermined by absorbance measured at 570 nm,\nwith a reference wavelen gth at 69 0 nm, in a \nmultiwell plate reader. Results are re ported as\nthe percenta ge of non-viable trypomasti gotes \nregarding the control in \u0019\f\r\u0013\u000f\u0019\u0019\b.\n\u000f$,\u001e.,,$('\nThe recent medicinal chemistry paradi gms in \ndrug design, namely the rational discovery of \nmultitar get dru gs, is a promisin g strate gy to \ncombat these ty pes of multifactorial diseases, \nwhich promptedthe authors to look for new \nproperties for the described coumarins. Base d \non this data, a new famil y of derivatives sha r-\ning the same scaffold and type of substituents \nwas desi gned and synthesized lookin g for anti -\noxidant and trypanocidal agents. Evaluation of \nthe antioxidant activity of the described cou -\nmarins was performed towards different ty pes\nof ROS: peroxyl and hydroxyl radicals. The electrochemical behavior of the com pounds was\nalso evaluated. The study of the electrochemical\nanodic behavior of the com pounds was based\nprincipally on previous studies that related lo w \noxidation potentia l to high antioxi dant capa c-\nity [58]. CV, ORAC-FL an d ESR reactivity \nassays were the techni ques used to achieve the \ngoals. In addition, the trypanocidal activity in\nepimasti gote, trypomasti gote and amasti gote\n(Dm28c strain) sta ges was also evaluated.\nAccor ding to t he data obtained in the CV stu dy,\nall the derivatives ex hibited a sing le ano dic pea k \nwithout the correspondin g cathodic peak, indi -\ncating an irreversible oxidation process as a result \nof the oxidation of a hydroxyl or amine group in \nthe coumarin nucleus, forming a semiquinone\nradical. First investigated was the influence of the \nscan rate (v) in order to dee ply assess the char -\nacteristics of the electrochemical an d chemical \nreactions that take place at the electrode/solution \ninterface. Results of the CV, re ported in \u0019\f\r\u0013\u000f\u0019\u0019\u0006,\ndemonstrate d that co umarin derivatives with\nhydroxyl substituents in their structure dis played\nlower oxi dation potentia l than those presentin g \namine groups. In spite of this, 4-hydroxycoum a-\nrin\u0003\b\u0004 reported the hi ghest oxidation potential\n(1.33 mV). This exce ption is due to the fact that \nthe oxidation of this coumarin derivative mi ght\nnot occur at the 4-OH group, but upon oxidationat t\nhe C3\u2013C4 bond [59]. In t he use d experimen -\ntal conditions, sin gle oxidation processes (peak I)\nwere observed for all com pounds. It has been pro-\nposed that the char ge transfer process at peak I\ncorres ponds to the oxidation of the hydroxyl or \nthe amine substituent. \nCompound\u0001\n, presenting a hydroxyl group at\nposition 4 and an amino one at position 3 of its\nskeleton, exhibited the lowest oxidation poten-\ntial (0. 50 m V). In addition, it presented the \nbest ORAC-FL value of the whole series (4.36)\nand a percentage of hydroxyl radical scaveng -\ning o f 56.8%. A ll the coumarin derivatives \nwith a 4-OH s ubstituent on their str ucture\u0003\b\u0006\u0001\n\n\u0001\u0002\f\u0004 presented hi gher ORAC-FL values than \nthe standard trolox, and com pounds\n (4.36) \nand\b (4.20) hi gher than the 6,7-dihydroxy -\n4-met hyl coumarin (3.3), use d as a re ference\ncompound. In com pounds\b\u0001\u0002\u0001\n  the presence \nof a hydroxyl group favored the hydro gen atom \ntransfer mechanism. However, com pound\f,\nwhich presents the same electron-donatin g \ngroup, displayed a minor reactivity to the pe r-\noxyl radical. This could be ex plained due to\nthe fact that the carbonyl substituent can forman intramo\nlecular hydrogen bond with the050100\n-8 -7 -6 -5 -4Survival (%)\nLog[M]\nFigure 5. Dose\u2013response curve o f\nCom pound 4 at different concentrations\n(0.5, 1, 5, 10 and 15 \u03bcM ).Statistica l analyses \nwere conducted usin g GraphPad Prism 5 \nsoftware (GraphPad So ftware, Inc. [CA,\nUSA]). IC50 values were anal yzed b y nonlinear\nregression.\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1918 future science group\n\u0018\u001f\u0017180hydroxyl group at position 4, diminishin g its\nORAC-FL value. Com pounds\t\u0001\u0002\u0001\u000b  (without\nhydroxyl groups at position 4) demonstrated\nlow reactivity towards the peroxyl radical.\n\u0010\u0012\u0011\u001a\u0018\u000f\b\f\u0002\r illustrate the result of the\nkinetic profile when the concentration o f \ncompounds \t\u0001\u0002\u0001\n , in phosphate pH 7.4, was \nincreased. In the same ex perimental condi -\ntions, a kinetic profile was observed without\ninduction times for all the tested com pounds. \nThe absence of induction times in the kinetic \nprofiles of FL would im ply that the ORAC-F L\nindex for these coumarin derivatives is more\nrelated to the antioxidants\u2019 reactivity than\nto stoichiometric factors [60]. The different\nORAC-FL values can , therefore , be related \nto the s ubstituents existent in the co umarin\nscaffold and their pattern o f substitution .\nRegardin g the ESR assays, the results of \nwhich are re ported in \u0019\f\r\u0013\u000f\u0019\u0019\u0007, it was observed\nthat com pound s\b\u0001\u0002\u0001\n , which presented the \nbest ORAC-FL values, also dis played the best\nreactivity towards hydroxyl radicals in the s pin \ntrapping assay (81.2 an d 56.8%, respective ly).\nRegardin g the biolo gical assays, cytotoxicit y \nand try panocidal activity for all the synthe -\nsized com pounds were evaluated and the results \nare re ported in \u0019\f\r\u0013\u000f\u0019\u0019\b. Cytotoxicity assays, in\nmurin R AW 264.7 macrophages, were carriedW\nout, and it was o bserve d that four o f the com -\npounds present cytotoxic effects (I C50) higher \nthan 100\u03bcM. Only compound \u0001\u000b demonstrate d\ncytotoxic effect with an IC50value of 2. 70 \u03bcM. \nIn the study of the effect of the coumarin \nderivatives in the viability of the epimastigote(Dm28c) an\nd trypomastigote (Dm28c) stages\n(10 \u03bcM), carried out usin g MTT assays, all the \ncompounds presented activity.\nIt is known that the activity a gainst one\nform of the parasite life cycle does not ensure \nsimilar activities against the others. Morph o-\nlogic c hanges occur during t he trans formation \nbetween different sta ges of the parasite. In addi -\ntion, im portant metabolic and macromolecular \nmodifications take place alon g the life cycle.\nThe sensibility of the different forms to the drugs is, therefore, modified\n[61]. The assayed\ncompoun ds were signi ficant ly more active \nagainst the epimasti gote form than the trypo-\nmasti gote form o f T.cruzi. These results are si g-\nnificant, since epimasti gotes are present in the\ngut of the insect vector, but trypomasti gotes are \nthe infective forms in the mammalian host. The\ntrypomastigote stage, in mammals, is the dis-\nseminator o f blood-borne in fection. In \u0019\f\r\u0013\u000f\u0019\u0019\bit is re ported that the studied com pounds pres-\nent low try panocidal activity in the try pomasti -\ngote sta ge, with the exception of compound \u000b.\nThis com pound demonstrated better try pano-\ncidal activity in both parasite forms (53.7 and\n69.4%, res pective ly) than ni furtimox, use d as\nreference compoun d. However, compoun d\u000b\npresented the hi ghest cytotoxic effect in murin \nRAW 264.7 macrophages. This means that theW\nexposure to com pound\u000b resulted in a low sele c-\ntivity index in RAW 264.7 cells. In addition , W\ncompound\u000bwas stu died against t he amastigote \n(Dm28c) sta ge, and presented a trypanocidal\nactivity lower than the other parasite forms\n(26.6% at 1 0 \u03bcM). However, compound \u000b was\nactive for all stages o f T.c r u z i. com pound\ndemon strated low cytotoxicity in RAW 264.7\ncells and presente d interesting trypanoci dal \nactivity in epimasti gote and trypomasti gote\nstages (65.7 and 22.2%, respectively). In the \nepimasti gote sta ge, compoun d\nproved to have\nhigher trypanocidal activity than nifurtimox \n(52.5%) and com pound\b presented close try-\npanoci dal activity (48.7%). Base d on the previ-\nously described results, it was concluded that\ncompound\u0001\n is the most interestin g candidate \nfor further studies.\n\u000e('\u001e%.,$('\nIn conclusion , the authors have confirmed the\ngood antioxidant properties of the hydrox y-\ncoumarin derivatives \b\u0006\u0001\n\u0001\u0002\u0001\f, presentin g better \nORAC-FL values than standard Trolox. The \npresence of a 4-hydroxyl group in the coumarin \nscaffold resulted in a high improvement in the \nantioxi dant activity, wit h com pound \n being \nthe best of the series under study. The results of the antioxidant assay usin\ng ESR demon -\nstrated reactivity a gainst hydroxyl radical for all \nthe tested compounds. An interestin g findin g \nis that the compounds with high antioxidant\ncapacity determine d by the ORAC-FL assay a lso\npresented hi gh reactivity a gainst the hydroxyl \nradical. Based on these results , it can be co n-\ncluded that com pound s\b\u0001\u0002\u0001\n  are potential ca n-\ndidates for further antioxidant ca pacity studies. \nIn addition , the coumarin derivatives illustrated\nlow cytotoxicity effect in murin RAW 264.7 W\ncells. In the try panocidal study, com pounds\b\u0006\n\n\u0001\u0002\u0001\u000b  presented hi gh activity in epimasti gotes\nstage and compound s\u0001\n\u0001\u0002\u0001\u000b also dis played the \nhighest trypanocidal activity in trypomasti gote \nstage. Based on these results, it can be concluded \nthat the joint presence o f a hydroxyl group at\nposition 4 and of an amino group at position 3\u00173904=0+(39\u0001\u0002\u000197>5(34*0+(1\u00015745,790,8\u00014-\u00018,1,*9,+\u0001*4:2(703\u0001+,70 ;(90;,8\u001c\u0001\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nwww.future-science.com 1919 future science group\n\u0018\u001f\u0018181(compound\n in relation to com pounds\b\u0001\u0002\u0001\t ) \nincreased the value of ORAC-FL and try pano-\ncidal activity. The formation of the chloroacet -\namide derivative of com pound\n \u0003\f\u0004 drasticall y \ndecreased both properties. This effect was not\nobserved in the same amidation of com pound s\t\n\u0003\u000b\u0004, which drasticall y decreased the ORAC-FL, \nbut was more effective as a try panocidal. The fact\nthat com pound\u000b exhibited such low ORAC-F L\nand presented cytotoxicity led us to discard this \nskeleton in the process of identification of a new \ndrug. Fina lly, compoun d\n prove d to be a goo d\ncandidate for further studies due to the low c yto-\ntoxic effects and hi gh trypanocidal activity, asso-\nciated with an interestin g antioxidative profile .\n\u0011.-.+ \u0001) +,) \u001e-$/  \nChagas disease is a significant health problem \nin Central and South America , and it is one \nof the most si gnificant emer ging parasitic dis -\neases in develo ped countries. Natural products\nhave played a major role in the therapy of this \nparasitic disease, but at the moment only nifur-\ntimox an d benzni dazole are t he current drugs \nin use. These com pounds are very uns pecific, \npresentin g high toxicity, low efficacy, hi gh \nlevel of resistance and multi ple side effects. Therefore, there is an ur gent need for the dis -\ncovery of new, more effective and safer dru gs \nfor human use. Based on the above-described \nresults, com pound\n proved to be a good cand i-\ndate for further studies due to the low cytotoxiceffects and high trypanocidal activity, associ\n-\nated with an interesting antioxi dative pro file. \nThis work is the startin g point for the study o f \nsimple coumarins as try panocidal com pounds .\n\u0011$'\u001c'\u001e$\u001c%\u0001\u0002\u0001\u001e(&) -$'\"\u0001$'- + ,-,\u001f$,\u001e%(,.+  \nThis work was partially supporte d by FONDECYT (pro j-\nects 1110029 an d 1090078) an d Anillo ACT112 (Chile),\nand personal founds of the Spanish researchers. RF Gu\u00ed\u00f1e z F\ngratefully acknowle dges CONICYT-Chile for his PhD \nscholarship (No . 21100132) an d his PhD grant \n(No.24121574). M J Matos gratefully acknowledges J\nFunda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia for her PhD gran t \n(SFRH/BD/61262/2009 ). SVazquez-Ro driguez grat e-\nfully acknowle dges Ministerio de Educaci\u00f3n y Ciencia for \nher FPU PhD grant (AP2008\u201304263). The authors have \nno other relevant affiliations or financial involvement wit h \nany organization or entity with a financial interest in o r \nfinancial conflict with the su bject matter or material s \ndiscusse d in the manuscript apart from those disclose d.\nNo writin g assistance was utilized in the production\nof this manuscript.\n\u0018 ! + '\u001e ,\nPapers o f specia l note have been highlighted as:\n\u0084 of interes t\n\u0084\u0084\u0003of consi derable interes t\n1 Borges F, Ro leira F, Mi lhazes N, Santana L,\nUriarte E. Simp le coumarins an d analogs in\nmedicina l chemistr y: occurrence, s ynthesis \nand biological activity. Curr. Med. Chem. 12, \n887\u2013916 (2005 ).\n\u0084\u0084\u0003Very interestin g review o f coumarins .\n2 Borges F, Ro leira F, Mi lhazes N, Uriarte E, \nSantana L. Simp le coumarins: privi legedscaffolds in me dicina l chemistr y. Front. Me d.\nChem. 4, 23\u201385 (2009) .\n\u0084\u0084 Very interestin g review o f coumarins.\n3 Riveiro ME, De Kimpe N, Moglioni A et Aal.\nCoumarins: old com pounds with novel \npromisin g therapeutic perspectives. Curr. \nMed. Chem. 17, 1325\u20131338 (2010).\n\u0084\u0084 Interestin g review of promisin g therapeuti c \napplications of coumarins.\n4 Zhao H, Donnelly AC, Kusuma BR et Ral.\nEngineerin g an anti biotic to fight cancer:optimization o f the novo biocin sca ffold to \nproduce anti-pro liferative a gents. J. Med. \nChem. 54, 3839\u20133853 (2011) .\n5 Vilar S, Quezada E, Santana L et al. Desi gn,\nsynthesis, an d vasore laxant an d platelet \nantiaggregatory activities o f coumarin-\nresveratro l hybrids. Bioorg. Med. Chem. Lett .\n16, 257\u2013261 (2006 ).\n6 Kostova I, B hatia S, Gri gorov P et al.\nCoumarins as antioxi dants. Curr. Med. Chem.\n18, 3929\u20133951 (2011 ).Executive summary\n\u0003 \u0084Neglected diseases, such as Cha gas disease, are a si gnificant public health problem in Central and South America. Cha gas, caused \nby Trypanosoma cruz i, is also one of the most relevant emer ging parasitic diseases in developed countries. The relationship between \ntrypanocidal activit y and antioxidant capacit y is a novel and innovative approach to the treatment of this patholo gy. \n\u0003 \u0084A selected series o f coumarins were e fficientl y synthesized in ver y good yields. These compounds are a promisin g scaffold a gainst the \ndescribed tar gets. \n\u0003 \u0084Compounds \b and \n, which presented the best ORAC-FL values (4.20 and 4.36, respectivel y), also displa yed the best reactivit y towards \nhydroxyl radical in the spin trappin g assay (81.2 and 56.8%, respectivel y). The y proved to be ver y efficient antioxidants.\n\u0003 \u0084In the trypanoci dal study, compoun ds \b, \n and \u000b presente d high activit y against t he epimasti gotes sta ge and compoun ds \n and \u000b also \ndisplayed the highest tr ypanoci dal activit y against t he trypomasti gote sta ge. \n\u0003 \u0084The joint presence o f a hydroxyl group at position 4 and o f an amino group at position 3 (compound \n in relation to compounds \b\nand \t) increased the value o f ORAC-FL and tr ypanocidal activit y. There fore, compound \n proved to be a good candidate for further \nstudies due to the low c ytotoxic e ffects and the hi gh trypanocidal activit y, associated with an interestin g antioxidative pro file.\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1920 future science group\n\u0018\u001f\u0019182\u0084 Interestin g review of the coumarin scaffold\nas antioxidant moiet y.\n7 Ostrov DA, Hern\u00e1n dez-Pra da JA, Corsino \nPE, Finton KA, Le N, Rowe TC. Discover y of \nnovel DNA gyrase in hibitors by high-\nthroughput virtua l screenin g. Antimicrob.\nAgents C hemother.51, 3688\u20133698 (2007 ).\n8 Hwu JR, Lin S-Y, Tsay S-C, De C lercq E,\nLeyssen P, Neyts J. Coumarin-purine\nribofuranosi de con jugates as new a gents \nagainst hepatitis C virus. J. Med. Chem. 54,\n2114\u20132126 (2011) .\n9 Kostova I. Co umarins as in hibitors o f HIV \nreverse transcriptase. Curr. HI V Res. 4,\n347\u2013363 (2006) .\n10Stefanachi A, Favia AD , Nico lotti O , Leonetti\nF, Hartmann RW, Carotti A. Desi gn, \nsynthesis, an d biological evaluation o f \nimidazolyl derivatives o f 4,7-disubstitute d \ncoumarins as aromatase in hibitors se lective \nover 17-D-hydroxylase/C17\u201320 lyase.J. Med. \nChem. 54, 1613\u20131625 (2011) .\n11 Chilin A, Battistutta R, Bortolato A et Aal.\nCoumarin as attractive casein kinase 2 (CK2) \ninhibitor sca ffold: an inte grate approac h to\nelucidate the putative binding moti f and\nexplain structure-activity re lations hips. \nJ. Med. Chem. 51, 752\u2013759 (2008) .\n12Timonen JM, Nieminen RM, Sarei la O,\nVainiota lo P, Moi lanen E , Aulaskari PH. \nSynthesis an d anti-in flammator y effects o f a \nseries o f nove l 7-hydroxycoumarin derivatives.\nEur. J. Me d. Chem. 46, 38 45\u20133850 (2011).\n13Soto-Orte ga DD, Murp hy BP, Gonza lez-\nVelasquez F J et al. Inhibition o f amyloid-E\naggregation by coumarin ana logs can be\nmani pulated by functiona lization o f the \naromatic center. Bioor g. Med. Chem. 19, \n2596\u20132602 (2011 ).\n14Matos MJ, Vazquez-Ro driguez S, Santana L\netal. Looking for new tar gets: simp le\ncoumarins as anti bacteria l agents. Med.\nChem. 8, 1140\u20131145 (2012 ).\n15Matos M J, Santana L, Uriarte E et al.\nTyrosine- like con densed derivatives as \ntyrosinase in hibitors. J. Pharm. P harmaco l.\n64, 742\u2013746 (2012) .\n16Anan d P, Sin gh B, Sin gh N. A review on \ncoumarins as acet ylcholinesterase in hibitors\nfor Alzheimer\u2019s disease. Bioorg. Med. Chem.\n20, 1175\u20131180 (2012).\n17 Matos MJ, Vi\u00f1a D, Picciau C, Ora llo F,\nSantana L, Uriarte E. S ynthesis an d\nevaluation o f 6-met hyl-3-phenylcoumarins as \npotent an d selective MAO-B in hibitors.\nBioor g. Med. Chem. Lett. 19 , 5053\u20135055\n(2009 ).\n18 Matos MJ, Vi\u00f1a D, Quezada E e tal. A ne w \nseries o f 3-phenylcoumarins as potent an d selective MA O-B in hibitors. Bioor g. Med.\nChem. Lett . 19, 3268\u20133270 (2009 ).\n19Serra S, Ferino G, Matos M J etal.\nHydroxycoumarins as se lective MAO-B\ninhibitors. Bioor g. Med. Chem. Lett . 22,\n258\u2013261 (2012 ).\n20Vi\u00f1a D, Matos M J, Y\u00e1\u00f1ez M, Santana L, \nUriarte E. 3-Su bstitute d coumarins as dual\ninhibitors o f AChE and MAO for the \ntreatment o f Alzheimer\u00b4s disease. Med.\nChem. Commun . 3, 213\u2013218 (2012 ).\n21Matos M J, Ter\u00e1n C, P\u00e9rez-Casti llo Y,\nUriarte E, Santana L, Vi\u00f1a D. Synt hesis an d\nstudy of a series o f 3-ary lcoumarins as potent\nand selective monoamine oxi dase B \ninhibitors. J.Med. Chem. 54, 7127\u20137137\n(2011).\n22Matos MJ, V\u00e1zquez-Ro driguez S, Uriarte E, \nSantana L, Vi\u00f1a D. MAO in hibitory activit y \nmodulation: 3-p henylcoumarins versus\n3-benzo ylcoumarins. Bioorg. Med. Chem. \nLett. 21, 4224\u20134227 (2011).\n23Molina E, So barzo-S\u00e1nc hez E, Spec k-\nPlanche A  etAal. Monoamino oxi dase A: an\ninterestin g pharmaco logical target for the\ndevelopment o f multi-tar get QSAR.  Min i \nRev. Med. Chem.  12, 947\u2013958 (2012 ).\n24Vi\u00f1a D, Matos MJ, Ferino G etal.\n8-Substituted-3-arylcoumarins as potent and\nselective MAO-B in hibitors: s ynthesis, \npharmaco logical evaluation an d docking \nstudies.ChemMe dChem 7, 464\u2013470 (2012) .\n25Guar dado-Yor di E, P\u00e9rez-Mo lina E , Matos\nMJ, Uriarte E. In: Nutrition, Well-Bein g and \nHealth. Boua yed J, Bo hn T (E ds). InTec h,\nRijeka, Croatia, 23\u201348 (2012) .\n26Tyagi YK, Kumar A, Ra j HG etal. Synthesis \nof nove l 4-met hylcoumarins an d evaluation\nof their antioxi dant activity. Eur. J. Med.\nChem. 40, 413\u2013420 (2005) .\n27Ham di N, Puerta C, Va lerga P. Synt hesis, \nstructure an d pharmaco logical investi gations \nof dicoumaro ls and related com pounds. Eur.\nJ.Med. Chem. 43,2541\u201325 48 (2008 ).\n28Panteleon V, Kosta kis IK, Mara kos P, Pou li \nN, An dreado I. S ynthesis an d free ra dical\nscaven ging activity o f some ne w \nspiropyranocoumar ins.Bioorg. Med. Chem. \nLett. 18, 5781\u2013578 4 (2008).\n29Nordberg J, Arn\u00e9r ES. Reactive oxy gen \nspecies, antioxidants, and the mammalian\nthioredoxin s ystem. Free Ra dical Biol. Med.\n31, 1287\u20131312 (2001).\n30 De Oliveira TB, Pe drosa RC, Fi lho DW.\nOxidative stress in c hronic car diopathy \nassociate d with Chagas disease. Int. \nJ.Cardiol. 116, 357\u2013363 (2007 ).\n\u0084 Describes the potential a pplication o f \nantioxidants in Cha gas disease .31 El-Sayed NM, M yler PJ, Bart holomeu D C\netal. The genome sequence o f Trypanosoma \ncruzi, etio logic agent o f Chagas disease. Science\n309, 409\u2013415 (2005) .\n32 Schofield C J, Jannin J, Salvatella R. The \nfuture o f Chagas disease contro l. Tren ds \nParasitol.  22, 583\u2013588 (2006).\n\u0084\u0003Interestin g concepts about Cha gas disease .\n33 Lepesheva GI, Zaitseva NG, Nes WD etal.\nCYP51 from Trypanosoma cruzi: a p hyla-\nspecific resi due in t he B\u2019 helix defines\nsubstrate preferences of sterol 14al pha-\ndemet hylase.J.Biol. Chem. 281, 3 577\u20133 585\n(2006).\n34Bern C, Montgomery SP, Herwaldt BL etLal.\nEvaluation an d treatment o f Chagas disease in\nthe Unite d States: a s ystematic review. J. Am.\nMed. Assoc . 298, 2171\u20132181 (2007).\n35 Castro JA, de Mecca MM, Barte l LC. Toxic\nside effects o f drugs used to treat C hagas\u2019 \ndisease (American try panosomiasis). Hum.  \nExp. Toxico l. 25, 471\u2013479 (2006 ).\n36 Gupta S, Wen JJ, Gar g NJ. Oxi dative stress in\nChagas disease. Interdiscip. Perspect. In fect.\nDis. 190354 (2009 ).\n37 Bern C.Antitry panosoma l therapy for chronic\nChagas\u2019 disease.N. Engl. J. Me d. 364, \n2527\u20132534 (2011) .\n38Maya JD, Cassels BK, Iturria ga-V\u00e1squez P\netal. Mode of action o f natura l and synthetic\ndrugs against Trypanosoma cruzi and their i\ninteraction with the mamma lian host.Comp. \nBiochem. P hysiol. A Mo l. Inte gr. Physiol. 146,\n601\u2013620 (2007 ).\n\u0084\u0003Interestin g concepts related to Cha gas\ndisease .\n39 Urbina JA. Speci fic chemot herapy o f Chagas\ndisease: re levance , current limitations an d new \napproac hes.Acta Trop. 115, 55\u201368 (2010 ).\n40Cerecetto E, Gonza lez M. C hemot herapy of \nChagas\u2019 disease: Status an d new developments.\nCurr. To p. Med. Chem. 2, 1187\u20131213 (2002 ).\n\u0084\u0003Interesting review of Chagas disease .\n41Freitas RF, Prokopczyk IM, Zottis A etAal.\nDisco very of nove lTrypanosoma cruz i\nglycera ldehyde-3-p hosphate dehydrogenase \ninhibitors. Bioorg. Med. Chem. 17, 2476\u20132482\n(2009).\n42Menezes IR, Lopes JCD, Montanari CA etAal.\n3D QSAR stu dies on binding affinities o f \ncoumarin natura l products for glycosoma l\nGAPDH o f Trypanosoma cruz i. J. Com put.\nAided  Mol. Des. 17, 277\u2013290 (2003 ).\n43 Leit\u00e3o A, An dricopu lo, AD, O liva G etal.\nStructure\u2013activity re lations hips of nove l\ninhibitors o f glycera ldehyde-3-p hosphate\ndehydrogenase. Bioorg. Med. Chem. Lett . 14,\n2199\u20132204 (2004).\u00173904=0+(39\u0001\u0002\u000197>5(34*0+(1\u00015745,790,8\u00014-\u00018,1,*9,+\u0001*4:2(703\u0001+,70 ;(90;,8\u001c\u0001\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015\nwww.future-science.com 1921 future science group\n\u0018\u001f\u001a18344 Matos MJ, P\u00e9rez-Cruz F, Vazquez-Ro driguez \nSetal. Remar kable antioxi dant properties o f a \nseries o f hydroxy-3-ary lcoumarins. Bioorg.\nMed. Chem.21, 3900\u20133906 (2013) .\n45Janeiro P, Matos M J, Santana L, Uriarte E, \nOliveira-Brett AM. New hydroxylated\n3-arylcoumarins, s ynthesis an d\nelectroc hemica l study. J.Electroana l. Chem.\n689, 243\u2013251 (2013) .\n46Perez-Cruz F, Serra S, Delo gu G etal.\nAntitry panosoma l and antioxi dant \nproperties o f 4-hydroxycoumarins \nderivatives. Bioorg. Me d. Chem. Lett . 22,\n5569\u20135573 (2012) .\n\u0084\u0084 Antitry panosomal and antioxidant \nproperties of some coumarin derivatives .\n47Mosmann T. Ra pid colorimetric assay for\ncellular growth and surviva l: app lication to\nproliferation an d cytotoxicity assays. \nJ.Immunol. Methods  65, 55\u201363 (1983).s\n48Bisby RH, Broo ke R, Navaratnam S. E ffect o f \nantioxi dant oxi dation potentia l in the oxy gen\nradical absorption capacity (ORAC) assay. \nFood Chem.108, 1002\u20131007 (2008) .\n49Vieites M , Otero L , Santos D  et al.\nPlatinum(II) meta l comp lexes as potentia l\nanti-Trypanosoma cruzi  agents. i J. Inor g. \nBiochem. 102, 1033\u20131043 (2008) .50 Linch FW. 3-Aminocoumarin. J.Chem. Soc.\n101, 1758\u20131765 (1912) .\n51Arndt F, Loewe L, Un R, A yca E.\nCoumarin diol and coumarin\u2013c hromone\ntautomer ism.Chemische Berichte  84, e\n319\u2013329 (1951 ).\n52Okumura K. Novo biocin an d related\ncompoun ds. I. Synt heses o f 3-acy lamino-4-\nhydroxycoumarin derivatives. Yakugaku \nZasshi  80, 525\u2013532 (1960).i\n53Merchant JR, Martyres G. Some\naminocoumarin derivatives possessin g local \nanest hetic activit y.Curr. Scienc e 50, 410\u2013411e\n(1981 ).\n54Ou B, Ham psch-Woo dill M, Prior RL. \nDevelopment an d validation o f an improve d\noxygen ra dical absorbance capacity assa y \nusing fluorescein as the fluorescent probe. \nJ. Agric. Foo d Chem. 49, 4619\u20134626 (2001 ).\n55 Niki E. Assessment o f antioxi dant ca pacity \ninvitro andinvivo. Free Ra dical Bio. Me d. 49,\n503\u2013515 (2010 ).\n56 Yoshimura Y, Inomata T, Na kazawa H, Ku bo\nH, Yama guchi F, Ari ga T. Evaluation o f free \nradical scaven ging activities o f antioxi dants\nwith an H(2)O(2)/NaOH/DMSO s ystem by \nelectron s pin resonance. J. Agric. Food Che m. \n47, 4653\u2013 4656 (1999).57 Muelas-Serrano S, No gal-Ruiz JJ, G\u00f3mez -\nBarrio A. Settin g of a colorimetric met hod to\ndetermine t he viability of Trypanosoma cruzi\nepimast igotes. Parasito l. Res.  86, 999\u20131002\n(2000) .\n58 Medvidovic-Kosanovic M, \u0160eruga M, Ja kobek \nL, Nova k I. Electroc hemica l and antioxi dant\nproperties o f (+)-catec hin, quercetin an d\nrutin. Croat. Chem. Acta  83, 197\u2013207 (2010).a\n59 Hu X-R, He J-B, Wan g Y, Zhu Y-W, Tian \nJ-J. Oxidative s pectroe lectroc hemistry o f two \nrepresentative coumarins. Electrochim.  Acta\n56, 2919\u20132925 (2011 ).\n60 L\u00f3pez-Alarc\u00f3n C, Lissi E. A nove l and simple \nORAC methodolo gy based on the interaction\nof Pyro gallol Red with peroxy l radicals. Free \nRadical  Res. 40, 979\u2013985 (2006) .\n61 Demoro B, Rossi M, Caruso F et al. Potentia l\nmechanism o f the anti-try panosoma l activity \nof organorut henium comp lexes wit h bioactive \nthiosemicar bazones. Biol. Trace E lem. Res .\n153(1\u20133), 371-381 (2013) .\n62 Perez-Cruz F, Montecinos R, Vi llamena F A\netal. Protective e ffect o f synthetic \nhydroxycoumarin derivatives on bovine aortic\nendothelial cells against oxi dative stress\ninduced by 3-mor pholinosydnonimine and \nhydrogen peroxi de.Free Ra dical Biol. Med.\n53, S115 (2012).\u0017\u0018\u000f\u0013\u0012\u0014\u0012\u0015\f\u0018\u001b \u0001\u000e\u0016\u0014\u0014\u001a\u0015\u0012\u000e\f\u0019\u0012\u0016\u0015 \u0001\u001c\u0001\u001c:BC,?\u0007\u0001\u001f(948\u0007\u0001'( ?6:,?\b#4+70.:,?\u0001 \r\u0019\u0001\u000b\u0012\u0005\nFuture Med. Chem.  (2013 ) 5(16) 1922 future science group\n\u0018\u001f\u001b184Remarkable antioxidant properties of a series\nof hydroxy-3-arylcoumarinsq\nMaria Jo\u00e3o Matosa,b,\u21d1, Fernanda P\u00e9rez-Cruzc, Saleta Vazquez-Rodrigueza, Eugenio Uriartea,\nLourdes Santanaa, Fernanda Borgesb, Claudio Olea-Azarc,\u21d1\naDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbCIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal\ncDepartment of Inorganic and Analytical Chemistry, Laboratory of Free Radicals and Antioxidants, Faculty of Chemical and Pharmaceutical Sciences,\nUniversity of Chile, Santiago de Chile, Chile\narticle info\nArticle history:\nReceived 13 December 2012Revised 26 March 2013\nAccepted 3 April 2013\nAvailable online 19 April 2013\nKeywords:\n3-ArylcoumarinsHydroxyl derivativesORAC-FL assaysESR assaysCV assays\nAntioxidant capacityabstract\nIn the present work we synthesized a series of hydroxy-3-arylcoumarins (compounds 1\u20139), some of them\npreviously described as MAO-B selective inhibitors, with the aim of evaluating their antioxidant proper-\nties. Theoretical evaluation of ADME properties of all the derivatives was also carried out. From the\nORAC-FL, ESR and CV data it was concluded that these derivatives are very good antioxidants, with a very\ninteresting hydroxyl, DPPH and superoxide radicals scavenging pro\ufb01les. In particular compound 9is the\nmost active and effective antioxidant of the series (ORAC-FL = 13.5, capacity of scavenging hydroxyl\nradicals = 100%, capacity of scavenging DPPH radicals = 65.9% and capacity of scavenging superoxide\nradicals = 71.5%). Kinetics pro\ufb01le for protection \ufb02uorescein probe against peroxyl radicals by addition\nof antioxidant molecule 9was also performed. Therefore, it can operate as a potential candidate for pre-\nventing or minimizing the free radicals overproduction in oxidative-stress related diseases.\n/C2112013 The Authors. Published by Elsevier Ltd. All rights reserved.\n1. Introduction\nPhenolic compounds are bioactive substances widely distrib-\nuted in the vegetable kingdom. Generally, this group of compounds\nhas one or more aromatic rings in their structure and one or more\nhydroxyl groups. They have been described to act as natural anti-\noxidants and their presence contributes to prevent or minimize\nseveral types of oxidative processes.1Due to their antioxidant\nactivity their ingestion is correlated with interesting bene\ufb01ts tohealth. Therefore, the research and characterization of new bioac-\ntive phenolic substances from diet has been intensi\ufb01ed in the last\nyears, either for the development of nutraceutics or medicines.\n1\nDue to their antioxidant properties they can protect cells fromthe oxidative damage of the reactive oxygen species (ROS). In fact,\nthe overproduction of free radicals have been related to cellular\nmembrane and DNA damage, and indirectly with aging and\noxidative-stress related diseases like cancer, cardiovascular andneurodegenerative pathologies.\n2Therefore, antioxidants are very\nimportant for protecting the organisms from oxidative disorders,in which ROS are also involved.\n3,4Antioxidants are capable of\ndecrease or prevent oxidation processes through different mecha-\nnisms, such as scavenging free radicals, inhibition of pro-oxidant\nenzymes or chelation of transition metal ions.5\nAn increasing number of reports suggested the involvement of\noxidative stress in neurodegenerative diseases (ND), where the in-\ncreased formation of ROS can contribute to neuronal damage and\ncell death.3,4\nSuggestion has been made that the etiology of Parkinson\u2019s (PD)\nand Alzheimer\u2019s (AD) diseases may be closely linked to biochemi-\ncal changes resultant from this oxidative stress.6\u20138Dopamine (DA)\nauto-oxidation naturally produces oxidative species and may\ncontribute to ND such as PD and ischemia/reperfusion-induced\ndamage. Monoamine oxidase (MAO) enzyme (particularly\nMAO-B) is responsible for metabolizing DA and plays an important\nrole in oxidative stress through altering the redox state of neuronal\nand glial cells, leading to neuronal death.9Consequences are an\nover-production of MAO and non-MAO initiated hydrogen perox-ide (H\n2O2) by proliferated reactive microglia and inability of\nneurons to dispose of H 2O2and other recative species like peroxyl\nradicals.10H2O2produces highly toxic ROS, namely hydroxyl\n0968-0896/$ - see front matter /C2112013 The Authors. Published by Elsevier Ltd. All rights reserved.\nhttp://dx.doi.org/10.1016/j.bmc.2013.04.015qThis is an open-access article distributed under the terms of the Creative\nCommons Attribution License, which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original author and source are credited.\n\u21d1Corresponding authors. Tel.: +34 981594912; fax: +34 981528070.\nE-mail addresses: mariacmatos@gmail.com (M.J. Matos), colea@uchile.cl\n(C. Olea-Azar).Bioorganic & Medicinal Chemistry 21 (2013) 3900\u20133906\nContents lists available at SciVerse ScienceDirect\nBioorganic & Medicinal Chemistry\njournal homepage: www.elsevier.com/locate/bmc\n\u0018\u001f\u001c185radical, by Fenton reaction that is catalyzed by iron and neuro-\nmelanin.11Concerning the mechanism of the clinical ef\ufb01cacy of\nMAO-B inhibitors in PD, the inhibition of DA degradation (asymptomatic effect) and also the prevention of the formation of\nneurotoxic DA degradation products, that is, ROS and DA derived\naldehydes have been speculated.\n12The neuroprotective effect of\nrasagiline, a well-known MAO-B inhibitor, might be explained\nthrough multiple mechanisms, possibly due to reduction of DA\ncatabolism with a subsequent increased activity on dopaminergic\nD2receptors and suppressing the action of ROS as well.13So, the\npossible mechanism of neuroprotection of MAO-B inhibitors maybe related not only to MAO-B inhibition but also to induction and\nactivation of multiple factors related with oxidative stress and\napoptosis.\n14\nCoumarins are a family of compounds widely distributed in the\nnature.15Due to their structural features, and biological properties,\nnamely anticancer, anti-in\ufb02ammatory, antioxidant, antithrom-\nbotic, vasorelaxant, antiviral and enzymatic inhibition agents, they\nhave been ascribed as important building blocks in Organic\nChemistry and Medicinal Chemistry.16\u201323\nRecently, it was shown by our group that 3-substituted aryl\ncoumarins are potent and selective MAO-B inhibitors.24\u201330In addi-\ntion, it has been found that hydroxycoumarins are antioxidantsscavenging ROS and/or chelating transition metals, exhibiting\ntissue-protective properties.\n6,31\u201333The complementarity of these\nactivities for 3-arylcoumarins was not previously studied anddescribed. The versatility of the used reactions allowed obtaining\na family of compounds with hydroxyl and/or methyl substituents\nin different positions of the molecule. The election of these deriva-\ntives has considered the previously MAO-B inhibitory pharmaco-\nlogical evaluation and the low cost of the commercial reagents to\nbegin with. Also, the in\ufb02uence of the substituents in the desired\nactivity was taken into account.\n2. Materials and methods\n2.1. Chemistry\nMelting points were determined using a Reichert Ko\ufb02er ther-\nmopan or in capillary tubes on a B\u00fcchi 510 apparatus and are\nuncorrected.\n1H and13C NMR spectra were recorded on a Bruker\nAMX spectrometer at 300 and 75.47 MHz, respectively, usingTMS as internal standard (chemical shifts in dvalues, Jin Hz). Mass\nspectra were obtained using a Hewlett\u2013Packard 5988A spectrome-ter. Elemental analyses were performed using a Perkin\u2013Elmer 240B\nmicroanalyser and were within \u00b10.4% of calculated values in all\ncases. Silica gel (Merck 60, 230-00 mesh) was used for \ufb02ash chro-\nmatography (FC). Analytical thin layer chromatography (TLC) was\nperformed on plates precoated with silica gel (Merck 60 F254,\n0.25 mm).\n2.1.1. General procedure for the preparation of methoxy-3-\narylcoumarins\nTo a solution of the conveniently substituted ortho -hydroxy-\nbenzaldehyde (7.34 mmol) and the corresponding phenylaceticacid (9.18 mmol) in dimethyl sulfoxide (15 mL), N,N\n0-dicyclohexyl-\ncarbodiimide (11.46 mmol) was added. The mixture was heated at110/C176C for 24 h. Then, ice (100 mL) and acetic acid (10 mL) were\nadded to the reaction mixture. After keeping it at room tempera-ture for 2 h, the mixture was extracted with ether (3 /C225 mL).\nThe organic layers were combined and washed with sodium bicar-\nbonate solution (50 mL, 5%) and water (20 mL). Subsequently, the\nsolvent was evaporated under vacuum and the dry residue was\npuri\ufb01ed by \ufb02ash chromatography (hexane/ethyl acetate 9:1), togive the desired methoxy-3-arylcoumarins.\n23,282.1.2. General procedure for the preparation of hydroxy-3-\narylcoumarins\nTo a solution of a methoxy-3-arylcoumarin (0.50 mmol) in ace-\ntic acid (5 mL) and acetic anhydride (5 mL), at 0 /C176C, hydriodic acid\n57% (10 mL) was added dropwise. The mixture was stirred under\nre\ufb02ux, for 3 h. The solvent was evaporated under vacuum and\nthe dry residue was puri\ufb01ed by crystallization (CH 3CN).23,28,34\n2.1.2.1. 3-(30,40-Dihydroxyphenyl)-6-methylcoumarin (4).\nYield: 92%; mp 199\u2013200 /C176C;1H NMR (300 MHz, DMSO- d6):d2.43\n(s, 3H, \u2013CH 3), 6.43 (s, 1H, H-20), 7.01 (d, J= 7.1 Hz, 1H, H-50), 7.14\n(d,J= 7.0 Hz, 1H, H-60), 7.28\u20137.32 (m, 2H, H-7, H-8), 7.57 (d,\nJ= 2.2 Hz, 1H, H-5), 7.83 (s, 1H, H-4), 10.40 (s, 2H, \u2013OH);13C\nNMR (75 MHz, DMSO- d6):d20.7, 100.1, 110.7, 111.6, 115.7,\n119.4, 120.1, 127.3, 127.4, 132.1, 133.7, 138.8, 146.5, 146.8,151.3, 161.6; EI MS m/z: 269 (13), 268 (M\n+, 100), 241 (31), 240\n(70), 239 (22), 165 (30), 125 (12), 111 (10); Anal. Calcd for\nC16H12O4: C, 71.64; H, 4.51. Found: C, 71.60; H, 4.49.\n2.1.2.2. 3-(30,40-Dihydroxyphenyl)-8-methylcoumarin (5).\nYield: 85%; mp 205\u2013206 /C176C;1H NMR (300 MHz, DMSO- d6):d\n2.50 (s, 3H, \u2013CH 3), 6.80 (d, J= 8.3 Hz, 1H, H-50), 7.05 (dd,\nJ=8 . 2 , J= 2.2 Hz, 1H, H-60), 7.22 (d, J= 2.2 Hz, 1H, H-20), 7.25\n(d,J= 7.6 Hz, 1H, H-6), 7.44 (dd, J=7 . 4 , J=1 . 0H z , 1 H , H - 7 ) ,\n7.57 (dd, J=7 . 6 , J= 1.1 Hz, 1H, H-5), 8.09 (s, 1H, H-4), 9.09\n(s, 1H, \u2013OH), 9.24 (s, 1H, \u2013OH);13C NMR (75 MHz, DMSO-\nd6):d14.9, 115.4, 116.0, 119.5, 119.9, 124.1, 124.6, 125.7,\n126.1, 126.5, 132.2, 138.7, 144.8, 146.2, 150.9, 159.9; EI MS\nm/z: 270 (12), 269 (76), 268 (M+, 82), 241 (47), 240 (100)\n239 (57), 211 (23), 166 (19), 165 (58), 152 (18), 139 (14),125 (30), 111 (28), 82 (19); Anal. Calcd for C\n16H12O4:C ,\n71.64; H, 4.51. Found: C, 71.63; H, 4.49.\n2.1.2.3. 3-(30,50-Dihydroxyphenyl)-8-methylcoumarin (6).\nYield: 90%; mp 180\u2013181 /C176C;1H NMR (300 MHz, DMSO- d6):d\n2.49 (s, 3H, \u2013CH 3), 6.70 (s, 3H, H-20,H - 40,H - 60), 7.26 (t,\nJ= 7.6 Hz, 1H, H-6), 7.48 (d, J= 7.8 Hz, 1H, H-7), 7.62 (d,\nJ= 7.7 Hz, 1H, H-5), 8.11 (s, 1H, H-4), 10.27 (s, 2H, OH);13C\nNMR (75 MHz, DMSO- d6):d15.3, 103.3, 107.2, 119.6, 124.5,\n125.1, 126.8, 127.2, 133.1, 136.6, 140.9, 151.6, 158.5, 160.0;\nEI MS m/z: 269 (21), 268 (M+, 100), 241 (12), 240 (63), 239\n(26); Anal. Calcd for C 16H12O4: C, 71.64; H, 4.51. Found: C,\n71.60; H, 4.50.\n2.1.2.4. 3-(30,40,50-Trihydroxyphenyl)-8-methylcoumarin (7).\nYield: 82%; mp 189\u2013190 /C176C.1H NMR (300 MHz, DMSO- d6):d2.49\n(s, 3H, \u2013CH 3), 6.95 (s, 2H, H-20,H - 60), 7.20 (t, J= 7.4 Hz, 2H, H-6,\nH-7), 7.38 (d, J= 7.4 Hz, 1H, H-5), 7.79 (s, 1H, H-4), 10.55 (s, 2H,\n\u2013OH), 10.60 (s, 1H, \u2013OH);13CN M R( 7 5 M H z ,D M S O - d6DMSO- d6):\nd15.6, 106.1, 119.4, 124.2, 125.4, 125.7, 127.7, 130.4, 132.7,\n135.6, 139.8, 146.7, 146.9, 160.6; EI MS m/z: 285 (16), 284 (M+,\n100), 283 (84), 256 (32), 181 (10) 141 (10); Anal. Calcd for\nC16H12O5: C, 67.60; H, 4.25. Found: C, 67.61; H, 4.28.\n2.2. Antioxidant assays\n2.2.1. Oxygen radical antioxidant capacity-\ufb02uorescein (ORAC-FL)\nThe ORAC analyses were carried out on a Synergy HT multi\ndetection microplate reader, from Bio-Tek Instruments, Inc.\n(Winooski, USA), using white polystyrene 96-well plates, pur-\nchased from Nunc (Denmark). Fluorescence was read from the\ntop, with an excitation wavelength of 485/20 nm and an emission\n\ufb01lter of 528/20 nm. The plate reader was controlled by Gen 5 soft-\nware. The reaction was carried out in 75 mM sodium phosphate\nbuffer (pH 7.4), and 200 lL \ufb01nal volume. FL (70 nM, \ufb01nal concen-\ntration) and hydroxy-3-arylcoumarin solutions in methanol withM. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3901\n\u0018\u001f\u001d186a range of concentration between 0.3 and 2 lM were placed in\neach well of 96-well plate. The mixture was pre-incubated for\n15 min at 37 /C176C, before rapidly adding the AAPH solution\n(18 mM, \ufb01nal concentration). The microplate was immediately\nplaced in the reader and automatically shaken prior to each read-\ning. The \ufb02uorescence was recorded every 1 min for 120 min. A\nblank with FL and 2,20-azobis(2-methylpropionamidine)dihydro-\nchloride (AAPH) using methanol instead of the antioxidant solution\nwere used in each assay. Five calibration solutions using Trolox\n(0.5\u20132.5 lM) as antioxidant were also done. The inhibition capac-\nity was expressed as ORAC values and is quanti\ufb01ed by integrationof the area under the curve (AUC\nNET). All reaction mixtures were\nprepared in triplicate and at least three independent assays wereperformed for each sample. The area under the \ufb02uorescence decay\ncurve (AUC) was calculated integrating the decay of the \ufb02uores-\ncence where F\n0is the initial \ufb02uorescence read at 0 min and Fis\nthe \ufb02uorescence read at time. The net AUC corresponding to thesample was calculated by subtracting the AUC corresponding to\nthe blank. Data processing was performed using Origin Pro 8 SR2\n(Origin Lab Corporation, USA).\n2.2.2. Hydroxyl radical scavenging assay using electron spin\nresonance (ESR)\nReactivity of all the hydroxy-3-arylcoumarin derivatives against\nthe hydroxyl radical was investigated using the non-catalytic Fen-ton type method. ESR spectra were recorded in the X band\n(9.7 GHz) using a Bruker ECS 106 spectrometer with a rectangular\ncavity and 50 kHz \ufb01eld modulation, equipped with a high-sensitiv-\nity resonator at room temperature. Spectrometer conditions were:\nmicrowave frequency 9.81 GHz, microwave power 20 mW, modu-\nlation amplitude 0.91 G, receiver gain 59 db, time constant\n81.92 ms and conversion time 40.96 ms. The scavenging activity\nof each derivative was estimated by comparing the DMPO-OH ad-\nduct signals in the antioxidant\u2013radical reaction mixture and the\ncontrol reaction at the same reaction time, and is expressed as\nscavenging percent of hydroxyl radical.\nTo prepare the samples, 150\nlLo fN,N-dimethylformamide (DMF)\nand 50 lL of NaOH (3 mM) were mixed, followed by the addition of\n50lL of 5,5-dimethyl-1-pyrroline- N-oxide (DMPO) spin trap (30 mM\n\ufb01nal concentration) and \ufb01nally 50 lL of hydrogen peroxide 30%. The\nmixture was put in an ESR cell and the spectrum was recorded after\n\ufb01ve minutes of reaction. All the compounds were studied to 4 mM\n\ufb01nal concentration (300 lL \ufb01nal volume).\n2.2.3. DPPH radical scavenging assay using ESR\nThe 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging\ncapacity35\u201338of the hydroxy-3-arylcoumarin derivatives was\ndetermined by an ESR spectrometry method.39\u201343Each hydroxy-\n3-arylcoumarin solution was mixed with DPPH stock solution toinitiate the antioxidant\u2013radical reaction. All the reaction mixtures\ncontained 1.0 mM of DPPH and 1.0 mM of the studied compound.\nThe control solution was prepared in absence of the studied com-\npounds. Both DPPH and compounds solutions were prepared in\nacetonitrile. ESR signals were recorded after \ufb01ve minutes of reac-\ntion. Spectrometer conditions were: microwave frequency\n9.81 GHz, microwave power 20 mW, modulation amplitude 0.95\nG, receiver gain 59 db, time constant 81.92 ms and conversion time\n40.96 ms. The scavenging activity of each compound was esti-\nmated by comparing the DPPH signals in the antioxidant\u2013radical\nreaction mixture and the control reaction at the same reaction\ntime, and was expressed as scavenging percent of DPPH.\n2.2.4. Superoxide antioxidant assay using cyclic voltammetry\n(CV)\nCyclic voltammetry (CV) measurements were performed in a\nMetrohm 693VA instrument with a 694VA stand convertor and a693VA processor, at room temperature, using a three-electrode\ncell. A glassy carbon (GC) electrode presenting an area of\n0.03 cm\n2was used as the working electrode. The electrode surface\nwas polished to a mirror \ufb01nish with alumina powder (0.3 and0.05\nlM) before use and after each measurement. Platinum wire\nwas used as auxiliary electrode and silver-silver chloride (Ag/AgCl,3 M KCl) of Metrohm Company with a plastic tip was used as a ref-\nerence electrode. The CV experiments were carried out in dimethyl\nsulfoxide (DMSO) of analytical grade (Sigma\u2013Aldrich) with 0.1 M of\ntetrabutylammonium perchlorate (TBAP) as supporting electrolyte.\nSuperoxide anion radical was generated in DMSO containing TBAP\n0.1 M. The scan rate was kept 30 mV/s and potential window was\n/C01.0 to /C00.0 V. The atmospheric solubility of oxygen in DMSO was\n2.1 mM.\n44The \ufb01nal concentration of each derivative (30 lM) was\nachieved by additions of the corresponding aliquot of stock solu-tion (10 mL \ufb01nal volume). Finally, the antioxidant activity was as-\nsessed from the change in the cathodic current of the\nvoltammograms in absence and present of the derivatives, using\npertinent mathematical formulations.\n2.2.5. Data statistical analysis\nStatistical analyses were conducted using GraphPad Prism 5\nsoftware (GraphPad Software, Inc., San Diego, CA). The data are ex-\npressed as means \u00b1 SD. The experimental data were analyzed by\none-way analysis of variance (ANOVA), and differences between\ngroups were assessed using Tukey\u2019s post-test. The level of signi\ufb01-\ncance was set at p<0.05, and all experiments were replicated\n3 times.\n3. Results\n3.1. Chemical synthesis\nCoumarin derivatives 1\u20139were ef\ufb01ciently synthesized accord-\ning to the protocol outlined in Scheme 1 . The general reaction con-\nditions and the characterization data of the new compounds were\ndescribed in the experimental section. Perkin condensation of dif-\nferent ortho -hydroxybenzaldehydes with the adequate arylacetic\nacid, using N,N\n0-dicyclohexylcarbodiimide (DCC) as dehydrating\nagent,28afforded the methoxy-3-arylcoumarins. Hydroxyl deriva-\ntives were obtained from the above-mentioned methoxy substi-tuted precursors by acidic hydrolysis, using hydriodic acid 57% in\nthe presence of acetic acid and acetic anhydride.\n28\n3.2. Antioxidant capacity assays\nThe evaluation of the antioxidant activity of the studied com-\npounds was performed towards different types of reactive oxygenor nitrogen species\u2014peroxyl, hydroxyl, superoxide and DPPH rad-\nicals. ORAC-FL, ESR and CV assays were the techniques used to ob-\ntain the desired results.\nThe peroxyl radical scavenging activity of the synthesized\nhydroxy-3-arylcoumarins was evaluated by the oxygen radical\nabsorbance capacity (ORAC) method\n45This assay use a \ufb02uores-\ncence-based technology (ORAC-FL) and allow obtaining a relative\nantioxidant index by using as reference trolox, a hydrosoluble vita-\nmin E derivative. The exposition of the \ufb02uorophore, in this case\n\ufb02uorescein (FL) to the peroxyl radical lead to an oxidation process\nre\ufb02ected as a decay of \ufb02uorescence emission through time. In\nORAC assays, the loss of \ufb02uorescence of FL generally corresponds\nto an induction time and is reliant on antioxidant capacity of a\ncompound. In fact, it refers to the time in which the FL is protected\nagainst the oxidative damage of peroxyl radicals and this behavior\nis associated to a competitive reaction between the radical and the\nantioxidant.46,47ORAC data take into account the induction time,3902 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n\u0018\u001f\u001e187initial rate and the range of total antioxidant inhibition in one\nvalue.46\nResults expressed as ORAC-FL values are presented in Table 1 .\nAll the obtained ESR results for the% scavenging of the hydroxyl\nand DPPH radicals are also illustrated in Table 1 . In addition, % of\nsuperoxide radical scavenging, performed by CV, are also repre-sented in Table 1 .\nThe ORAC-FL pro\ufb01le, intensity of \ufb02uorescence at 528 nm versus\nthe incubation time was obtained for all derivatives. Compounds 3\nand9(8.4 and 13.5, respectively) display the highest ORAC-FL in-\ndexes, comparing with the \ufb02avonoids quercetin and catechin that\nare very well known natural antioxidant compounds. Figure 1\nshows the kinetic pro\ufb01le for protection of FL probe against peroxyl\nradicals obtained in presence of increasing concentrations of com-\npound 9. It was obtained a pro\ufb01le of \ufb02uorescence measure at\n528 nm versus the incubation time at different concentration, forall derivatives.In order to study the antioxidant reactivity of all the synthe-\nsized hydroxy-3-arylcoumarin derivatives towards hydroxyl radi-\ncals, a non-catalytic and competitive type Fenton system in\nwhich the DMPO spin trap was performed.\n48The ESR spin-trapping\nspectrum obtained in the control assay (DMPO+ N,N-dimethylform-\namide + NaOH + H 2O2) presents four hyper\ufb01ne lines, due to the\nDMPO-OH adduct formation, as it is shown in Figure 2 (red line).\nFor each putative antioxidant coumarin compounds ESR spectra\nwere also acquired to check their capacity of scavenging hydroxyl\nradicals. The data obtained with compound 2is depicted in Figure 2\n(black line).\nThe intensity of the spectra decreases when the hydroxy-3-aryl-\ncoumarin derivatives were added into the system. For compound 9,\n100% of scavenging of hydroxyl radicals was obtained (Fig. 3 \u2014black\nline). This type of response was observed for all derivatives, re\ufb02ect-ing different percentage of the hydroxyl radical scavenging activity(Table 1 ).\nThe stable free radical DPPH assay has been used for detecting\nthe antioxidant activity in several chemical analyses.\n35\u201338Cur-\nrently, DPPH assay is considered an easy and accurate method,appropriate for measuring the antioxidant capacity of fruits, vege-\ntables, juices or extracts.\n39This is due to the electronic properties\nshared by DPPH and peroxyl radicals (the unpaired electron isdelocalized through the pair of nitrogen or oxygen atoms, respec-CHO\nOHRCOOH\nR1\nOORR1\nOORR11:R=6 - C H 3;R1=4 ' - O H\n2:R=6 - C H 3;R1=3 ' - O H\n3:R=6 - C H 3;R1=2 ' - O H\n4:R=6 - C H 3;R1=3 ' , 4 ' - O H\n5:R=8 - C H 3;R1=3 ' , 4 ' - O H\n6:R=8 - C H 3;R1=3 ' , 5 ' - O H\n7:R=8 - C H 3;R1=3 ' , 4 ' , 5 ' - O H\n8:R=8 - O H;R 1=4 ' - C H 3\n9:R=8 - O H;R 1=4 ' - O HR or R 1= OCH 3i\nii\nScheme 1. Reagents and conditions: (i) DCC, DMSO, 110 /C176C, 24 h; (ii) HI 57%, AcOH, Ac 2O, re\ufb02ux, 3 h.\nTable 1\nORAC-FL index and hydroxyl, DPPH and superoxide radical scavenging data obtained\nfor compounds 1-9\nCompd ORAC-\nFL\nindex% Scavenging\nhydroxyl\nradicalsa% Scavenging\nDPPH radicalsa% Scavengingsuperoxide\nradicals\nb\n1 6.1 100 27.7 17.4\n2 6.7 5.2 3.4 17.5\n3 8.4 100 10.6 25\n4 5.3 6.05 28.3 28.9\n5 5.7 100 66.7 77.3\n6 5.5 75 11.2 22.6\n7 5.3 100 100 76.5\n8 6.3 16 28.6 17.4\n9 13.5 100 65.9 71.5\nTrolox 1.0 \u2014 \u2014 \u2014\nQuercetin 7.28c\u2014 20.0d\u2014\nCatechin 6.76c\u2014 44.5d\u2014\naThe scavenging activity of hydroxyl and DPPH radicals effect was calculated as\nfollows: [( A0/C0Ax)/A0]/C2100, where Axand A0are the double-integral ESR for the\n\ufb01rst line of samples in the presence and absence of test compounds, respectively.\nbThe scavenging activity of superoxide radical effect was calculated as follows:\n[(Ipc blank /C0Ipc aox)/ Ipc blank] /C2100, where Ipc blank is cathodic current in the\nabsence of the studied compounds and Ipc aox is the cathodic current in the\npresence of the studied compounds.\ncData collected from Ref. 45.\ndData collected from Ref. 49.\nFigure 1. ORAC-FL pro\ufb01le (kinetic pro\ufb01le for protection FL probe against peroxyl\nradicals) for compound 9.M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3903\n\u0018\u001f\u001f188tively), in such way that the reaction rate between DPPH and sev-\neral antioxidants provides a good approximation for scavenging\nactivities with lipid peroxyl radicals.40,41ESR spectra of DPPH in\nabsence and presence of compounds 4,7and 9are showed in\nFigure 4 .Superoxide anion radical was generated by one electron reduc-\ntion of the atmospheric molecular oxygen dissolved in DMSO atroom temperature (25 /C176C). Then, the voltammetric performance\nof the nine compounds was studied, one by one, in DMSO and TBAP0.1 M. The resultant CV responses for derivative 5,7and9, and in\nabsence of any derivative (blank) are represented in Figure 5 .\n3.3. Theoretical evaluation of ADME properties\nIn order to better understand the overall properties of the de-\nscribed compounds, the lipophilicity (expressed as the octanol/water partition coef\ufb01cient and herein called log P), was calculated\nusing the Molinspiration property calculation program.\n50The the-\noretical prediction of ADME properties (molecular weight, log P,\nnumber of hydrogen donors and acceptors) of all the compoundswas carried out and is presented in Table 2 .\n51,52\n4. Discussion\nIn previous works, 3-arylcoumarin derivatives were described\nas potent and selective MAO-B inhibitors.28This family of com-\npounds and their remarkable data on the selective inhibition ofMAO-B isoenzyme and putative application for ND therapy were\nthe inspiration for this work. In particular, compounds 1\u20133were\npreviously described as potent and selective MAO-B inhibitors,with IC\n50values between 120 and 650 nM.28On the other hand\nthe recent medicinal chemistry paradigms in the drug design,\nnamely the rational discovery of multi-target drugs, as a promising\nstrategy to combat this type of multifactorial diseases prompted us\nto look for other properties for this type of coumarins. Based on\nthis data, a new family of derivatives sharing the same scaffold\nand type of substituents was designed and synthesized.\nThe evaluation of the antioxidant activity of the hydroxy-3-\narylcoumarin compounds was performed towards different types\nof reactive oxygen or nitrogen species\u2014peroxyl, hydroxyl, superox-\nide and DPPH radicals. ORAC-FL, ESR reactivity and CV assays were\nthe techniques used to achieve the goals. From the obtained data, it\nwas concluded that the antioxidant scavenging activity is related\nwith the type of substituents presented in the 3-arylcoumarin\nskeleton.\nCompound 9was found to be the most interesting coumarin of\nthe series. This compound has two hydroxyl groups in its structure,\none at position 8 and another at position 40of the 3-arylcoumarin\nscaffold. The other compounds have structural combinations oftwo types of substituents (methyl and one, two or three hydroxyl\ngroups). Compounds 1,3,5and 7have ORAC-FL values between\nFigure 2. ESR spectra obtained for the control (adduct DMPO-OH without\nantioxidant molecule\u2014red line) and for adduct DMPO-OH in the presence of\ncompound 2(black line).\nFigure 3. ESR spectra obtained for the control (adduct DMPO-OH without\nantioxidant molecule\u2014red line) and for adduct DMPO-OH in the presence ofcompound 9(black line).\nFigure 4. ESR signal from DPPH radical in absence (blank) and presence of\ncompounds 4,7and9.\nFigure 5. Cyclic voltammograms of superoxide radical in absence (blank) and\npresence of compounds 5,7and 9in DMSO + TBAP 0.1 M, on GC (working\nelectrode) versus. Ag/AgCl, at room temperature, with scan rate of 30 mV/s.3904 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n\u0018\u001f 1895.3 and 8.4 and the higher scavenging activity towards hydroxyl\nradicals (100% /C0total scavenging). From these derivatives, com-\npound 7presented the best DPPH and superoxide radicals scaveng-\ning (100 and 76.5%, respectively). Compounds 1and3have on their\nstructure a methyl group at position 6 of the coumarin moiety and\na hydroxyl group in the 3-aryl ring. The ORAC-FL indexes are 6.1\nand 8.4, respectively, but the position of the hydroxyl group in\nthe exocyclic aromatic ring seems to have no in\ufb02uence on the hy-\ndroxyl radical scavenging capacity (100%, in both cases). The DPPH\nradical scavenging values of these compounds are, respectively,\n27.7% and 10.6% and superoxide radical scavenging values are,\nrespectively, 17.4% and 25%. Their pro\ufb01les are, therefore, very sim-\nilar. Compounds 5and7have a methyl group at position 8 of the\ncoumarin moiety, and two or three hydroxyl groups, respectively,in the 3-aryl ring. Both ORAC-FL values (5.7 and 5.3, respectively),\nhydroxyl radical scavenging capacity (100%) and superoxide radi-\ncal scavenging capacity (77.3% and 76.5%, respectively) are similar,\nproving that the presence of the extra hydroxyl group does not\nseem to signi\ufb01cantly affect the peroxyl, hydroxyl and superoxide\nradicals scavenging activities. One the other hand, DPPH radical\nscavenging capacity is 66.7% for compound 5and 100% for com-\npound 7. Compounds 2,4and 8, with ORAC-FL values between\n5.3 and 6.7, presented the lowest hydroxyl scavenging capacity(between 5.2% and 16%). Compound 2presented also the lowest\nDPPH radical scavenging capacity (3.4%) and compounds 1and8\nthe lowest superoxide radical scavenging capacities (17.4%). Com-\nparing the data obtained for compound 4(3\n0,40-dihydroxy substi-\ntuted) and for compound 1(40-hydroxy substituted), it can be\nconcluded that the presence of two hydroxyl groups led to the\ndecline in the ORAC-FL index (6.1\u20135.3) and the hydroxyl radical\nscavenging capacity (100%\u20136.05%). Comparing compound 4with\n2(30-hydroxy substituted), it is also noted a decrease in the\nORAC-FL index (from 6.7 to 5.3), caused by the presence of two hy-\ndroxyl groups in the molecule. However, the hydroxyl radical scav-\nenging capacity is almost the same (6.05% and 5.2%, respectively).\nSuperoxide radical scavenging capacity is also similar (28.9 and\n17.5, respectively). Compounds 4and5have the same substitution\npattern, changing only the position of the methyl group from 6 to\n8. This modi\ufb01cation strongly affects the hydroxyl radical scaveng-\ning capacity (from 6.05% to 100%), the DPPH radical scavenging\ncapacity (from 28.3% to 66.7%) and superoxide radical scavenging\ncapacity (from 28.9% to 77.3%). Compound 6, with a methyl group\nat position 8 of the coumarin moiety and two hydroxyl groups at\npositions 30and 50of the 3-aryl ring, in spite of presenting an\nORAC-FL value of 5.5 and low DPPH and superoxide radicals scav-\nenging (11.2 and 22.6, respectively), evidence a signi\ufb01cant ten-\ndency to scavenge hydroxyl radicals (75%).\nAs said before, the highest ORAC-FL values were found for com-\npounds 3and 9(8.4 and 13.5, respectively). The results are very\ninteresting comparing with the ORAC-FL values of catechin (6.76)\nand quercetin (7.28), very well known natural antioxidants. Com-paring with trolox (ORAC-FL = 1.0), the interesting ORAC-FL values\nof compounds 3and 9make them promising antioxidant mole-\ncules. It is important to notice that compound 5,7and9presented\ngood trends against all the studied radicals.\nFrom the obtained data, it is also remarkable that all the couma-\nrin derivatives possess log Pvalues compatible with those required\nto cross membranes. TPSA, described to be a predictive indicator ofmembrane penetration, is also found to be positive. In addition, it\ncan be observed that no violations of Lipinski\u2019s rule (molecular\nweight, log P, number of hydrogen donors and acceptors) were\nfound. This is important information about the promising potential\nof these derivatives.\nAll the synthesized compounds, in spite of presenting different\nchemical substituents, disclose interesting ORAC-FL values, in most\ncases accompanied by a remarkable ability to scavenge hydroxyl,\nDPPH and superoxide radicals. Therefore, the data acquired so far\nare relevant allowing proposing hydroxy-3-arylcoumarins as a va-\nlid scaffold for the design of novel antioxidants.\n5. Concluding remarks\nIn conclusion, in the current work coumarins presenting very\npromising antioxidant pro\ufb01les were described. Compound 9\nproved to be the most interesting molecule of the whole series,\nwith an ORAC-FL of 13.5, 100% of scavenging of hydroxyl radicals,\n65.9% of scavenging of DPPH radicals and 71.5% of scavenging of\nsuperoxide radicals. This derivative has presented good antioxi-\ndant capacity towards different types of reactive oxygen or nitro-\ngen species\u2014peroxyl, hydroxyl, superoxide and DPPH radicals.\nCompound 3, previously describe as very good selective MAO-B\ninhibitor, presented also a very interesting antioxidative pro\ufb01le.It is important to notice that compound 5and 7also presented\ngood trends against all the studied radicals. In addition, it can be\nobserved that no theoretical violations of Lipinski\u2019s rule were ob-\nserved for all the studied derivatives. Therefore, the described\ncompounds seem to present desirable ADME properties. Based on\nthese results, it can be concluded that especially compounds 3\nand9are potential candidates for a further optimization process\nand could be successfully employed in the prevention or minimiza-tion of the oxidative damage caused by overproduction of oxygen\nfree radicals.\nAcknowledgments\nThe current work was supported by Mecesup (Project\nUCH-0601), CONICYT-Chile (Project N 24110059), Funda\u00e7\u00e3o paraa Ci\u00eancia e Tecnologia (Project PTDC/QUI-QUI/113687/2009) and\npersonal funds from the researchers. M.J. Matos thanks Funda\u00e7\u00e3o\npara a Ci\u00eancia e Tecnologia (SFRH/BD/61262/2009) Ph.D. Grant, F.\nP\u00e9rez-Cruz thanks CONICYT-Chile PhD. grant, Becas-Chile andTable 2\nTheoretical structural properties of the hydroxy-3-arylcoumarins derivatives 1\u20139a\nCompd logP Molecular weight TPSA n-OH acceptors n-OHNH donors Volume\n1 3.68 252.27 50.44 3 1 224.57\n2 3.66 252.27 50.44 3 1 224.57\n3 3.89 252.27 50.44 3 1 224.57\n4 3.19 268.27 70.67 4 2 232.59\n5 3.17 268.27 70.67 4 2 232.59\n6 3.11 268.27 70.67 4 2 232.59\n7 2.88 284.27 90.90 5 3 240.61\n8 3.92 252.27 50.44 3 1 224.57\n9 2.99 254.24 70.67 4 2 216.03\nalogP\u2014octanol/water partition coef\ufb01cient; TPSA\u2013topological polar surface area; n-OH\u2014number of hydrogen acceptors; n-OHNH\u2014number of hydrogen bond donors. The\ndata was determined with Molinspiration calculation software.50M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3905\n\u0018 \u0017190Fulbright doctoral stay fellowships and S. Vazquez-Rodriguez\nthanks Ministerio de Educaci\u00f3n y Ciencia (AP2008-04263) PhD.\nGrant.\nReferences and notes\n1.Guardado-Yordi, E.; P\u00e9rez-Molina, E.; Matos, M. J.; Uriarte, E. In Nutrition, Well-\nBeing and Health ; Bouayed, J., Bohn, T., Eds.; InTech, 2012. Chapter 2 .\n2.Tyagi, Y. K.; Kumar, A.; Raj, H. G.; Vohra, P.; Gupta, G.; Kumari, R.; Kumar, P.;\nGupta, R. K. Eur. J. Med. Chem. 2005 ,40, 413.\n3.Hamdi, N.; Puerta, C.; Valerga, P. Eur. J. Med. Chem. 2008 ,43, 2541 .\n4.Panteleon, V.; Kostakis, I. K.; Marakos, P.; Pouli, N.; Andreado, I. Bioorg. Med.\nChem. Lett. 2008 ,18, 5781 .\n5.Nordberg, J.; Arn\u00e9r, E. S. Free Radic. Biol. Med. 2001 ,31, 1287 .\n6.Jenner, P. Ann. Neurol. 2003 ,53, S26. discussion S36\u2013S38 .\n7.Berg, D.; Gerlach, M.; Youdim, M. B.; Double, K. L.; Zecca, L.; Riederer, P.; Becker,G.J. Neurochem. 2001 ,79, 225.\n8.Riederer, P.; So\ufb01c, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.;Youdim, M. B. J. Neurochem. 1989 ,52, 515.\n9.Gerlach, M.; Ben-Shachar, D.; Riederer, P.; Youdim, M. B. H. J. Neurochem. 1994 ,\n63, 793.\n10. Shoham, S.; Youdim, M. B. Cell Mol. Biol. 2000 ,46, 743.\n11. Youdim, M. B.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111, 1455 .\n12. Nagatsu, T.; Sawada, M. J. Neural Transm. Suppl. 2006 ,71,5 3.\n13. Seif-El-Nasr, M.; Atia, A. S.; Abdelsalam, R. M. Arzneimittelforschung 2008 ,58,\n160.\n14. Betard,\nR.; Sherer, T. B.; Greenamyre, J. T. Bioassays 2002 ,24, 308 .\n15. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. Med. Chem.\n2009 ,4,2 3.\n16. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543 .\n17. Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.; Nicolaides, D. N. Curr.\nPharm. Des. 2004 ,10, 3813 .\n18. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n19. Kostova, I. Curr. HIV Res. 2006 ,4, 347.\n20. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S.\nK.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. J. Med. Chem. 2009, 52,\n1486.\n21. Vi\u00f1a, D.; Matos, M. J.; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. Med. Chem. Commun.\n2012 ,3, 213.\n22. Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R. J. Med. Chem. 2006 ,\n49, 4275 .\n23. Matos, M. J.; Santana, L.; Uriarte, E.; Delogu, G.; Corda, M.; Fadda, M. B.; Era, B.;\nFais, A. Bioorg. Med. Chem. Lett. 2011 ,21, 3342 .24. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;Uriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268 .\n25. Matos,\n M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n26. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157 .\n27. Matos, M. J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. Bioorg.\nMed. Chem. Lett. 2011 ,21, 4224 .\n28. Matos, M. J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. J. Med.\nChem. 2011 ,54, 7127 .\n29. Serra, S.; Ferino, G.; Matos, M. J.; Vazquez-Rodriguez, S.; Delogu, G.; Vi\u00f1a, D.;Cadoni, E.; Santana, L.; Uriarte, E. Bioorg. Med. Chem. Lett. 2012 ,22, 258.\n30. Vi\u00f1a, D.; Matos, M. J.; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, E.;Santana, L. ChemMedChem 2012 ,7, 464.\n31. Symeonidis, T.; Chamilos, M.; Hadjipavlou-Litina, D. J.; Kallitsakis, M.; Litinas,\nK. E. Bioorg. Med. Chem. Lett. 2009 ,19, 1139 .\n32. Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K.; Nicolaides, D. N. Curr.\nPharm. Des. 2004 ,10, 3813 .\n33. Kostova, I. Mini-Rev. Med. Chem. 2006 ,6, 365.\n34. Buu-Hoi, N. P.; Eckert, B.; Royer, R. J. Org. Chem. 1954 ,19, 1548 .\n35. Espinoza, M.; Olea-Azar, C.; Speisky, H.; Rodr\u00edguez, J. Spectrochim. Acta Part A:\nMol. Biomol. Spectrosc. 2009 ,71, 1638 .\n36. Guo, Q.; Zhao, B.; Shen, S.; Hou, J.; Hu, J.; Xin, W. Biochime. Biophys. Acta (BBA) \u2013\nGen. Subjects 1999 ,1427,1\n 3.\n37. Jin, Z.-Q.; Chen, X. J. Pharmacol. Toxicol. Methods 1998 ,39,6 3.\n38. Suvarna, A. M.; Sunandana, C. S. Phys. C: Supercond. 1997 ,276,6 5.\n39. S\u00e1nchez-Moreno, C. Food Sci. Technol. Int. 2002 ,8, 121.\n40. Brand-Williams, W.; Cuvelier, M. E.; Berset, C. Food Sci. Technol. 1995 ,28,2 5.\n41. Valgimigli, L.; Banks, J. T.; Ingold, K. U.; Lusztyk, J. J. Am. Chem. Soc. 1995 ,117,\n9966 .\n42. Rodr\u00edguez, J.; Olea-Azar, C.; Cavieres, C.; Norambuena, E.; Delgado-Castro, T.;\nSoto-Delgado, J.; Araya-Maturana, R. Bioorg. Med. Chem. 2007 ,15, 7058 .\n43. Yu, L.; Haley, S.; Perret, J.; Harris, M.; Wilson, J.; Qian, M. J. Agric. Food Chem.\n2002 ,50, 1619 .\n44. Ahmed, S.; Shakeel, F. Pak. J. Pharm. Sci. 2012 ,25, 501 .\n45. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. J. Agric. Food Chem. 2001 ,49, 4619 .\n46. Niki, E. Free Radic. Biol. Med. 2010 ,49, 503 .\n47. Bisby, R. H.; Brooke, R.; Navaratnam, S. Food Chem. 2008 ,108, 1002 .\n48. Yoshimura, Y.; Inomata, T.; Nakazawa, H.; Kubo, H.; Yamaguchi, F.; Ariga, T. J.\nAgric. Food Chem. 1999 ,47, 4653 .\n49. Jullian, C.; Moyano, L.; Ya\u00f1ez, C.; Olea-Azar, C. Spectrochim. Acta, Part A Mol.\nBiomol. Spectrosc. 2007 ,67, 230 .\n50. M cheminformatics, Bratislava, Slovak Republic, http://www.molinspiration.\ncom/services/properties.html (2012).\n51. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev.\n1997 ,23,3.\n52. Ertl, P.; Rohde, B.; Selzer, P. J. Med. Chem. 2000 ,43, 3714 .3906 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n\u0018 \u0018191 Chalcone-based derivatives as new sca ffolds forhA3\nadenosine receptor anta gonists\nSaleta Vazquez-Rodrigue za,Maria Jo\u00e3o Matosa,b,Lourdes Santan aa, Eugenio Uriart ea,\nFernanda Bor gesb, Son ja Kachle rcandKarl-N orbertKlotzc\naDepartamento de Qu\u00edmica Or g\u00e1nica, Facultad de Farmacia, Universidad de Santia go de Compostela, Santia go de Compostela, Spain ,\nbCIQUP/Departmento de Qu\u00edmica e Bioqu\u00edmica, Facu ldadede Ci\u00eancias, Universi dadedo Porto, Porto, Portuga landcInstitut f\u00fcr Pharmakologie un d\nT oxi kologie, Universit\u00e4t W\u00fcrz burg, W\u00fcrz burg, Germany\nKeywor ds\nadenosine rece ptor; chalcone ;\ncoumarin-c halcone hyb rids; structure\u2013activit y\nrelations hip\nCorres pondenc e\nSaleta Vazquez-Rodri guez, Departamento d e\nQu\u00edmica Or g\u00e1nica, Facu ltadd e Farmacia,\nUniversi dadd e Santiago de Composte la,\n15782 Santia go de Compostela, Spain.\nE-mai l: svre77@gmai l.com\nReceive dNovem ber 9, 201 2\nAccepte dDecem ber 19, 2012\ndoi: 10.1111/ jphp.1202 8Abst ract\nObjectives With the aim of \ufb01ndin gnew adenosine receptor (AR) li gands base d\nonthechalcone sca ffold, we report t he synt hesis o fa new series o fcoumarin\u2013\nchalcone hybrids and the pharmacological characterization of their actions at four\nsubt ypes of AR .\nMethodsThe synt hesize dcompoun ds 5\u201310 were c haracterize din ra dioligan d\nbinding ( A1,A 2AandA3)andadeny lylcyc lase activity assays (A 2B)todetermine t he\naf\ufb01nity of the compounds for the four human AR ( hAR) subtypes.\nKey \ufb01ndings Coumarin\u2013c halcone hybridsw e r e foun dtobeligan dsw i t han o v e l\nstructure, not reporte dthusfar, t hat s howe dvarying a f\ufb01nity an dselectivity for AR\nsubtypes.\nConc lusions The coumarin\u2013c halcone hybridsi nw hichr i n gBo fthechalcone\nscaffold was a thio phene (com pound s5and9) were found to be the most poten t\ncom pounds of the series. Com pound 9,in which rin gA of the chalcone moiet y\nwas t hepheny lring o fthe coumarin, s howe dsimi lar activity agains thA1,hA2Aand\nhA3ARs, w hilec o m poun d5,in w hichring A o fthechalcone was su bstitute d\nby the benzopyrone ring of the coumarin moiety, showed similar activity onl y\nat t hehA3AR and, therefore, was deemed to be selective (K i(dissociatio n\nconstant )=5160nm).\nIntroduction\nAdenosine is a purine nuc leosi dep r o duce db ya llmeta-\nbolically active cells. It a cts as an endogenous modulato r\ncontrollin ga wide ran geo fp h ysiolo gical processes due to\nits interaction with four s peci\ufb01c cell membrane G- protein-\ncou pled rece ptors (GPCRs) classi\ufb01ed as A 1,A 2A,A2BandA 3\nadenosine rece ptors (ARs) .[1\u20133 ]Because of their ubi quitou s\npresence in ce lls, ARs have been seen as promising target s\nin the \ufb01eld of medicinal chemistry. ARs are distribute d\nalon gdifferent tissues in mammalian s ystems and re gulat e\ndiverse p hysio logica lfunctions bym o dulating ce llsigna l-\nling, being activated by endogenous adenosine and blocked\nby antagonists .[4,5]In the last two decades, a large number\nofligan dshave been synt hesize din t he searc hfor poten t\nand selective agonists and antagonists for each AR subtype ;\nselectiveA 2BAR agonists are among the most recentl y\nreported .[6]T argeting ARs has opene dan e ww i n dow for\npotential drug treatment of a variety of pathologies suc h\nas asthma, neurode generative disorders, cancer and in\ufb02am -matory an dischaemic con ditions .[7\u201312 ]More speci \ufb01cally,\nAR antagonists are involved in several pathological proc -\nesses such as in\ufb02ammation (A 2A),[13,14 ]heart an drenal\nfailure (A 1)[15]or neuro logica ldisor ders likeP a r kinson \u2019s[16]\nand Alzheimer\u2019s disease (A 2Aand /orA1).[17]\nAR anta gonists developed re centl ypresent a chemica l\ndiversity, w hilethe 1,3- dialkylxant hines are consi deredas\nderivatives of the classical scaffol d.[18,19 ]Among the non -\nclassical anta gonists, the \ufb02avone and iso\ufb02avone derivatives\nhave p laye da remar kabler o le, name ly genistein, w hichh as\nbeen described as a competitive antagonist at the A 1AR in\nFRTL (th yroid) cell s[20]or galangin, which was found t o\nbindthree su btypes o fARs, an dithasbeen s hown t hat t his\ntype of compound presents micromolar af\ufb01nity for the A3\nAR .[21](Figure 1 )\nCoumarins (chromone isosteres )and chalcones (\ufb02avon e\nwith an opened pyrone ring) are another class of\nbenzop yran-related compounds of natural ori gin tha tbs_bs_banner\nJournal of Pharmac yResearch Paper\n\u00a92013 T he Autho rs.JPP\u00a9201 3\nRoyalPharmaceutica lSociet y2013 Journal of Pharmac yand Pharmacolo gy,65,pp. 697\u2013703 697\n\u0018 \u001a193present a wide range of pharmacological actions.[22\u201324]\nCoumarins have health value mainly due to their antimi-\ncrobial,[25]enzyme-inhibitory,[26\u201328]anticancer[29]and anti-\noxidant[30]activity.\nOn the other hand, chalcones also present related bio-\nlogical activity as antimicrobial and anti-in\ufb02ammatory,[24]\nanti-tumour,[29]antioxidant[31]or enzyme-inhibitory\neffects.[32]Thus, due to structural similarities between \ufb02a-\nvones, coumarins and chalcones, we decided to synthesizehybrid compounds bearing both scaffolds in the same mol-\necule, and to evaluate their activity towards the four sub-\ntypes of human AR expressed in Chinese hamster ovary\n(CHO) cells. The designed compounds have the chalconescaffold as the main structural core, and the different\nderivatives are mainly based on the substitution of one or\nboth of the chalcone phenyl rings (A and/or B) for a cou-marin and/or thiophene with different substituents\n(Figure 1). In addition, the drug-like properties of the\nhybrids were also evaluated.\nMaterials and Methods\nSynthetic methodologies\nMelting points were determined using a Reichert Ko\ufb02erthermopan or in capillary tubes on a B\u00fcchi 510 apparatus\nand are uncorrected.\n1H and13C NMR spectra were\nrecorded on a Bruker AMX spectrometer at 300 and75.47 MHz, respectively, using tetramethylsilane as internalstandard (chemical shifts in dvalues, J in Hz). Mass spectra\nwere obtained using a Hewlett-Packard 5988A spectrom-\neter. Elemental analyses were performed using a Perkin-\nElmer 240B microanalyser and were within /H110060.4% of\ncalculated values in all cases. Silica gel (Merck 60, 230\u201300mesh) was used for \ufb02ash chromatography. Analytical thin-\nlayer chromatography (TLC) was performed on plates pre-coated with silica gel (Merck 60 F254, 0.25 mm). The purity\nof compounds was assessed by high-performance liquid\nchromatography (HPLC) coupled at diode array detector(DAD) on a Thermo Quest Spectrasystem (Thermo Fisher\nScienti\ufb01c, W altham, MA, USA) equipped with a P4000\npump, a UV6000 UV-Vis diode array detector and anSN4000 interface for operation via a personal computer.\nInstrument software ChromQuest 5.0 (Thermo Fisher Sci-\nenti\ufb01c) was used for data acquisition. Different analyticalcolumns and mobile phases (all solvents were HPLC grade)\nwere tested. The mobile phase was H\n2O\u2013CH 3CN (70:30)\nand an Eclipse xdb C18 column (5 mm particle size,\n0.46 mm i.d., 25 cm length; Agilent T echnologies) was used.\nThe purity of the compounds was found to be higher than\n95%.\nChemistry\nThe chalcone-based derivatives 5\u201310 were ef\ufb01ciently\nsynthesized according to the protocol outlined in Figure 2.O OOO\nCoumarinO\nChalconeFlavone\nO\nO\nCoumarin\u2013chalcone hybridO\nA\nBPhenyl/ThiophenylOO OH\nHOOH\nGalangin\nFigure 1 Rational design of the synthesized compounds based on \ufb02avonoid scaffolds.Saleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 698\n\u0018 \u001b194Different starting materials were used in accordance with\nthe substitution pattern of the \ufb01nal compounds. T osynthesize compounds 5and 6,\n[33]we \ufb01rst prepared the\n3-acetylcoumarin ( 1) by a Knoevenagel reaction using\nsalicylaldehyde and ethyl acetoacetate without solvent\nand employing piperidine in a catalytic amount at room\ntemperature.[34]T o prepare compounds 7 and 8,[35]\n4-hydroxycoumarin (2) was used as the starting material.\nAcylation at the 3 position of compound 2, using POCl 3in\nglacial acetic acid under re\ufb02ux, afforded precursor 3\n(93%).[35]Compounds 9and 10 were prepared from the\ncommercially available 8-acetyl-7-hydroxycoumarin ( 4).\nStarting from precursors 1, 3and 4, a Claisen-Schmidt\ncondensation in EtOH, using piperidine as base, and under\nre\ufb02ux mixed with the corresponding aromatic aldehydes,\nafforded the desired \ufb01nal compounds 5\u201310 in good yields\n(47\u201387%).\nSynthesis of 3-(3-aryl)acryloylcoumarin (5\u20138) and\n8-(3-aryl)acryloylcoumarin (9, 10) derivatives\nThe corresponding 3-acetylcoumarin ( 1or 3, 1 mmol) or\n8-acetylcoumarin ( 4) and the conveniently substituted\naromatic aldehyde (1.1 mmol) were dissolved in EtOH\n(3 ml) and a catalytic amount of piperidine (0.05 ml) wasadded. The reaction mixtures were stirred for 2\u20136 h under\nre\ufb02ux. After completion of reaction (followed by TLC), the\nsolvent was evaporated under vacuum and the dry residuewas puri\ufb01ed by \ufb02ash chromatography (hexane\u2013ethyl\nacetate, 85:15) to give the desired products 5\u201310.Biological assays\nThe binding af\ufb01nity of the compounds for the human AR\nsubtypes hA 1,hA 2Aand hA 3was determined using radiolig-\nand competition experiments in CHO cells that had been\nstably transfected with the individual receptor subtypes.[36,37]\nThe radioligands used were 1 n m [3H]2-chloro-N6-\ncyclopentyladenosine (CCPA) for hA 1,1 0 n m [3H]\nN-ethylcarboxamidoadenosine (NECA) for hA 2Aand 1 nm\n[3H]2-(1-Hexynyl)-N-methyladenosine (HEMADO) for\nhA 3receptors. Due to the lack of a suitable radioligand for\nhA 2Breceptors the potency of antagonists at hA 2Breceptor\n(expressed on CHO cells) was determined by inhibition\nof NECA-stimulated adenylyl cyclase activity.[36]The 50%\ninhibitory concentration (IC50) for inhibition of cAMP\n(cyclic adenosine monophosphate) production was deter-\nmined and converted to a K ivalue (dissociation constants)\nusing the Cheng and Prusoff equation.[38]For all the tested\ncompounds no measurable activity for the hA 2B AR\n(K i>10 000 nm) was detected.\nStatistical methods\nKivalues (dissociation constants) were determined in radio-\nligand competition experiment with seven or eight different\nconcentrations of test compound and each concentrationwas tested in duplicate. K\nivalues are given as geometric\nmeans of three independent experiments with 95% con\ufb01-\ndence intervals. For analysis of the competition curves the\nprogramme SCTFIT was used.[39]O OR1 O\n1 R1 = H\n3 R1 = OH\nO OOH(a)\nO OR1O\nR2\n5 R1 = H, R 2 = 3-thiophenyl\n6 R1 = H, R 2 = p-methoxyphenyl\n7 R1 = OH, R 2 = 3-thiophenyl\nR1 = OH, R 2 = p-methoxyphenyl 8 (c)\nO\nOOH O\nO\nOOH O\n 9R2 = 3-thiophenyl\n10 R2 = p-methoxyphenyl2\n4EtO 2CO CHO\nOH\n(b)\nR2 (c)\nFigure 2 Protocol for synthesis of chalcone-based derivatives 5\u201310. Reagents and conditions: (a) solvent-free, piperidine, rt, 10 min; (b) POCl 3,\nglacial acetic acid, re\ufb02ux, 30 min; (c) appropriate aldehyde, EtOH, piperidine, re\ufb02ux, 2\u20136 h.Saleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 699\n\u0018 \u001c195Theoretical evaluation of absorption,\ndistribution, metabolism and\nexcretion properties\nThe absorption, distribution, metabolism and excretion\n(ADME) properties of the studied compounds were calcu-\nlated using the Molinspiration property programme.[40]\nLogP was calculated using the methodology developed by\nMolinspiration as a sum of fragment-based contributions\nand correction factors. T opological polar surface area\n(TPSA) was calculated based on the methodology published\nby Ertl et al . as a sum of fragment contributions.[42]Oxygen-\nand nitrogen-centred polar fragments were considered.\nPolar surface area (PSA) has been shown to be a very good\ndescriptor characterizing drug absorption, including intesti-nal absorption, bioavailability, Caco-2 permeability and\nblood\u2013brain barrier penetration. The method for calcula-\ntion of molecule volume developed at Molinspiration isbased on group contributions. These have been obtained by\n\ufb01tting the sum of fragment contributions to \u2018real\u2019 three-\ndimensional (3D) volume for a training set of about 12 000,mostly drug-like molecules. 3D molecular geometries for\na training set were fully optimized by the semi-empirical\nAM1 method.\nResults\nStructural identi\ufb01cation\n(E)-3-(3-(Thiophen-3-yl)acryloyl)coumarin ( 5): Yield 61%.\nMp 146\u2013148\u00b0C1H NMR (300 MHz, CDCl 3)dppm 8.57 (s,\n1H, H-4), 7.87 (d, J=15.6 Hz, 1H, H b), 7.74 (d, J=15.7 Hz,\n1H, H a), 7.69\u20137.60 (m, 3H, H-2\u2019, H-4\u2019, H-5\u2019), 7.43 -7.29\n(m, 4H, H-5, H-6, H-7, H-8).13C NMR (75 MHz, CDCl 3)\ndppm 186.5, 155.1, 148.1, 141.8, 138.4, 138.3, 134.2, 132.6,\n130.7, 129.9, 126.9, 125.7, 124.9, 123.6, 118.6, 116.5. MS m/z\n(%) (ESI): 283 ([M +1]+, 8), 282 ([M]+, 35), 254 (100), 226\n(73), 137 (88), 109 (93). Anal. Calcd. for C 16H 10O 3S: C,\n68.07; H, 3.57. Found: C, 68.11; H, 3.59(E)-4-Hydroxy-3-(3-(thiophen-3-yl)acryloyl)coumarin\n(7): Yield 87%. Mp 192\u2013194\u00b0C1H NMR (300 MHz, CDCl 3)\ndppm 8.25 (d, J=15.6 Hz, 1H, H b), 8.15\u20137.99 (m, 2H, H a,\nH-5), 7.77\u20137.61 (m, 2H, H-2\u2019, H-5\u2019), 7.52 (dd, J=5.2,\n1.3 Hz, 1H, H-4\u2019), 7.43\u20137.23 (m, 3H, H-6, H-7, H-8).13C\nNMR (75 MHz, CDCl 3)dppm 192.5, 181.5, 160.1, 154.6,\n140.5, 138.3, 135.9, 131.1, 127.1, 125.9, 125.6, 124.2, 122.1,116.9, 116.2. MS m/z (%) (ESI): 299 ([M +1]\n+, 13), 298\n([M]+, 68), 280 (38), 270 (46), 137 (100), 121 (99), 109 (86).\nAnal. Calcd. for C 16H 10O 4S: C, 64.42; H, 3.38. Found: C,\n64.39; H, 3.32\n(E)-7-Hydroxy-8-( 3-(thiophen -3-yl)acryloyl)c oumarin (9):\nYield 47%. Mp 169\u2013171\u00b0C.1H NMR (300 MHz, CDCl 3)\ndppm 14.10 (bs, 1H, OH), 8.16 (d, J=15.3 Hz, 1H, H b),\n7.98 (d, J=15.1 Hz, 1H, H a), 7.80\u20137.59 (m, 2H, H-4, H-5),\n7.59\u20137.44 (m, 2H, H-6, H-2\u2019), 7.39 (dd, J=5.0, 2.8 Hz, 1H,\nH-4\u2019), 6.93 (d, J=8.7 Hz, 1H, H-5\u2019), 6.30 (d, J=9.6 Hz, 1H,\nH-3).13C NMR (75 MHz, CDCl 3)dppm 193.2, 167.8, 159.4,\n144.3, 139.6, 138.3, 134.4, 130.4, 127.3, 125.9, 125.7, 115.8,111.9, 111.0, 109.6. MS m/z (%) (ESI): 299 ([M +1]\n+, 11),\n298 ([M]+, 28), 203 (25), 189 (100), 84 (89). Anal. Calcd. for\nC16H 10O 4S: C, 64.42; H, 3.38. Found: C, 64.44; H, 3.40.\n(E)-7-Hydroxy-8-(3-(4-methoxyphenyl)acryloyl)c oumarin\n(10): Yield: 68%. Mp 187\u2013188\u00b0C.1H NMR (300 MHz,\nCDCl 3)dppm 14.00 (s, 1H, OH), 8.03 (d, J=15.4 Hz, 1H,\nHb), 7.82 (d, J=15.5 Hz, 1H, H a), 7.62\u20137.42 (m, 3H, H-4,\nH2\u2019, H6\u2019), 7.34 (d, J=8.8 Hz, 1H, H-5), 6.86\u20136.66 (m, 3H,\nH-6, H3\u2019, H-5\u2019), 6.12 (d, J=9.5 Hz, 1H, H-3), 3.70 (s, 3H,\n-OMe).13C NMR (75 MHz, CDCl 3)dppm 192.85, 167.84,\n162.22, 159.47, 155.44, 146.39, 144.28, 134.17, 131.05,127.55, 123.42, 115.71, 114.59, 111.88, 111.01, 109.70, 55.41.\nMS m/z (%) (ESI): 323 ([M +1]\n+, 24), 322 ([M]+, 47), 321\n(100), 293 (10), 134 (44). Anal. Calcd. for C 19H 14O 5:C ,\n70.80; H, 4.38. Found: C, 70.77; H, 4.35.\nBinding af\ufb01nity assays\nThe data obtained for the binding af\ufb01nity assays from\nradioligand binding experiments for compounds 5\u201310 are\nT able 1 The binding af\ufb01nity of compounds 5\u201310 for the human adenosine receptor subtypes hA 1,hA 2Aand hA 3\nCompoundKi(nM)\nhA 1 hA 2A hA 3\n5 >30 000 >30 000 5 160 (3 000\u20138 900)\n6 >10 000 >10 000 >10 000\n7 >30 000 >30 000 31 500 (21 600\u201346 000)\n8 >10 000 >10 000 >10 000\n9 8 330 (7 510\u20139 230) 11 900 (7 790\u201318 300) 5 020 (3 260\u20137 730)\n10 >10 000 >10 000 20 200 (14 600\u201328 100)\nThe binding af\ufb01nity (K i) for the human AR subtypes hA 1,hA 2Aand hA 3of compounds 5\u201310 was determined using radioligand competition experi-\nments in Chinese hamster ovary (CHO) cells. Highest concentrations tested were different depending on the solubility of compounds under the\nrespective assay conditions. Values are geometric means of three experiments and given with 95% con\ufb01dence intervals in parentheses.Saleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 700\n\u0018 \u001d196summarized in T able 1. Compound 9showed binding af\ufb01n-\nity to hA 1and hA 2AARs in the micromolar range, compara-\nble with the prototypical antagonist theophylline.[4,36]\nCompounds 5and 9bound with af\ufb01nity in the low micro-\nmolar range to hA 3AR, with compound 5being the one that\nshowed selectivity for this subtype.\nTheoretical evaluation of ADME properties\nT o better correlate the drug-like properties of the\ncoumarin\u2013chalcone hybrid compounds, the lipophilicity,expressed as the octanol/water partition coef\ufb01cient and\nherein called logP , as well as other theoretical calculations\nsuch as the TPSA, the number of hydrogen acceptors and\nthe number of hydrogen bond donors were calculated using\nthe Molinspiration property programme.\n[40]From the data\nobtained, it was noticed that all the hybrid compounds,5\u201310, not only had logP values compatible with those\nrequired to cross membranes but also they did not break\nany point of the Lipinski\u2019s rule of \ufb01ve. Theoretical predic-tion of ADME properties of all compounds is summarized\nin T able 2.\nDiscussion\nWith the aim of \ufb01nding novel and selective AR ligands, wehave synthesized chalcone- and coumarin-containing\nhybrids in which one or both phenyl groups of the chalconescaffold either retains the two phenyl groups corresponding\nto an original chalcone structure (rings A and B, Figure 1),\nor is isosterically substituted by heteroaromatic rings(pyrone ring of the coumarin and/or thiophene).\nThe data obtained in the binding af\ufb01nity assays are\nshown in T able 1. From all the synthesized derivatives, com-\npounds 5,7and 9exhibit signi\ufb01cant binding af\ufb01nity in the\nlow micromolar range for one or more AR. The commonfeature of compounds 5,7and 9is the presentation of a thi-\nophenyl substituent as the key isosterical change in ring B ofthe chalcone. However, only compound 5displays a note-\nworthy selectivity for the hA\n3AR (K i=5160 nm). It is inter-\nesting to note that compound 9, when compared with\ncompound 5, shows similar A 3af\ufb01nity; however, it alsoexhibits similar af\ufb01nity for A 1and A 2AARs whereas com-\npound 5is devoid of measurable af\ufb01nity for these subtypes.\nThe con\ufb01guration with both A and B rings replaced seems\nto be favourable for high A 3af\ufb01nity and selectivity. Compar-\ning compounds 5, 7and 9suggests that the 4-hydroxyl\ngroup in compound 7and the corresponding 7-hydroxyl\ngroup in compound 9, respectively, might abolish subtype\nselectivity. Compound 9presents a binding af\ufb01nity for the\nhA 3AR (K i=5020 nm) and also for hA 1AR (K i=8330 nm)\nand hA 2AAR (K i=11 900 nm). The A 1and A 2Aaf\ufb01nities are\nthus comparable to the af\ufb01nity of the classical naturally\noccurring antagonist theophylline.[36]\nComparison of the structurally related compounds 5and\n7, reveals that the only difference between them is theabsence or presence of a hydroxyl group at position 4,\nrespectively. One can conclude that the presence of the\nhydroxyl group seems to cause a marked decrease in thebinding af\ufb01nity for the hA\n3AR (K i=5160 and 31 500 nm,\nrespectively).\nComparing another pair of 8-substituted derivatives,\ncompounds 9and 10, that differ in the substitution of ring\nB of the chalcone (compound 10 has the original phenyl\nring of the chalcone while compound 9presents a thiophe-\nnyl ring as a result of an isosteric change), one can observethat compound 9shows af\ufb01nity with no selectivity and\ncompound 10 is less potent at all three receptor subtypes.\nDue to the limited af\ufb01nity close to the detection limit the\ndegree of selectivity cannot be determined. From these pre-\nliminary structure\u2013activity relationships, one can concludethat substitution of ring B of the chalcone (Figure 1) by a\nthiophenyl ring (compounds 5,7and 9) favoured binding\naf\ufb01nity towards the AR. However, hA\n3AR selectivity is\nattained when ring B of the chalcone is substituted by a thi-\nophene ring and when ring A is substituted for the pyronering contained in the coumarin moiety (compound 5).\nOn the other hand, looking at the theoretical evaluation\nof ADME properties (T able 2), it can be observed that no\nviolations of Lipinski\u2019s rule of \ufb01ve (molecular weight, logP ,\nnumber of hydrogen donors and acceptors) were found,\nmaking these hybrid compounds promising leads for\ndrug candidates.\n[41]TPSA, described as being a predictiveT able 2 Theoretical structural properties of the coumarin\u2013chalcone hybrids\nCompound logP Molecular weight TPSA (\u00c52) n-OH acceptors n-OHNH donors Volume (\u00c53)\n5 3.22 282.32 47.28 3 0 237.11\n6 3.87 306.32 56.52 4 0 271.94\n7 2.93 298.32 67.51 4 1 245.12\n8 3.58 322.32 76.54 5 1 279.96\n9 3.19 298.32 67.51 4 1 245.12\n10 3.84 322.32 76.74 5 1 279.96\nn-OH, number of hydrogen acceptors; n-OHNH, number of hydrogen bond donors; TPSA, topological polar surface area. The data was determined\nwith Molinspiration calculation software.Saleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 701\n\u0018 \u001e197indicator of the drug capacity of membrane penetration,\nwas also found to be positive.[42]\nThe remarkable results found for compounds 5and 9\nencourage us to continue our research looking for the opti-mization of these lead compounds with the aim of obtain-\ning potent and selective chalcone-based hA\n3AR ligands.\nConclusions\nIsosteric substitution of the phenyl rings of the chalcone\nmoiety for one or two heteroaromatic rings (benzopyrone\nand/or thiophenyl) results in compounds ( 5and 9) with\nbinding af\ufb01nity towards particular subtypes of ARs. A pre-\nliminary structure\u2013activity relationship study of the synthe-\nsized derivatives allowed veri\ufb01cation that hA 3AR selectivity\nwas achieved only when ring B of the chalcone was substi-\ntuted for a thiophene and ring A was substituted for thepyrone ring included in the coumarin scaffold (compound\n5). Replacing ring B by a thiophenyl group but keeping a\nphenyl group in place of ring A, namely the benzene ring of\ncoumarin (compound 9), resulted in an increase of hA\n1and\nhA 2AAR af\ufb01nity. As binding af\ufb01nity remained similar for\nhA 3AR, selectivity was, therefore, lost.These \ufb01ndings encourage us to continue the efforts\ntowards the optimization of the pharmacological pro\ufb01le for\nthis type of hybrid as potent and selective ligands for thehA\n3ARs.\nDeclarations\nCon\ufb02ict of interest\nThe Author(s) declare(s) that they have no con\ufb02icts of\ninterest to disclose.\nFunding\nThis work was partially supported by the Ministerio de\nSanidad y Consumo (PS09/00501) and Xunta de Galicia\n(PGIDIT09CSA030203PR) (Spain) and by the Foundationfor Science and T echnology (FCT) project PTDC/QUI-\nQUI/113687/2009 (Portugal). S. V azquez-Rodriguez thanks\nthe Ministerio de Educaci\u00f3n y Ciencia for the PhD FPU\ngrant (AP2008-04263). M. J. Matos thanks Funda\u00e7\u00e3o para a\nCi\u00eancia e T ecnologia for the PhD grant (SFRH/BD/61262/2009).\nReferences\n1. Poulsen SA, Quinn RJ. Adenosine\nreceptors: new opportunities for\nfuture drugs. Bioorg Med Chem 1998;\n6: 619\u2013641.\n2. Fredholm BB et al . International\nunion of pharmacology. XXV . Nomen-\nclature and classi\ufb01cation of adenosinereceptors. J Pharmacol Rev 2001; 53:\n527\u2013552.\n3. Fredholm BB et al . Structure and\nfunction of adenosine receptors andtheir genes. Arch Pharmacol 2000; 362:\n364\u2013374.\n4. Klotz K-N. Adenosine receptors and\ntheir ligands. Naunyn Schmiedebergs\nArch Pharmacol 2000; 362: 382\u2013391.\n5. Baraldi PG et al . A3 adenosine recep-\ntor ligands: history and perspectives.Med Res Rev 2000; 20: 103\u2013128.\n6. Baraldi PG. Recent improvements in\nthe development of A2B adenosinereceptor agonists. Purinergic Signal\n2009; 5: 3\u201319.\n7. Jacobson KA et al . Preparation of\nN6-benzyladenosine-5\u2019-uronamides,modi\ufb01ed xanthine ribosides, andrelated compounds as adenosine A3receptor agonists. WO 9502604 A119950126. Patent 1995.\n8. Feoktistov I et al . Adenosine A2B\nreceptors as therapeutic targets. Drug\nDev Res 1998; 45: 198\u2013206.\n9. Jacobson KA. Adenosine A3 receptors:\nnovel ligands and paradoxical effects.Trends Pharmacol Sci 1998; 19: 184\u2013\n195.\n10. Gessi S et al . Elevated expression of A3\nadenosine receptors in human color-ectal cancer is re\ufb02ected in peripheralblood cells. Clin Cancer Res 2004; 10:\n5895\u20135901.\n11. Jacobson KA, Gao ZG. Adenosine\nreceptors as therapeutic targets. Nat\nR e vD r u gD i s c o v2006; 49: 247\u2013264.\n12. Kim Y et al . Novel 2- and\n4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as\nallosteric modulators of the A3 adeno-\nsine receptor. J Med Chem 2009; 52:\n2098\u20132108.\n13. Sitkovsky MV et al . Physiological\ncontrol of immune response andin\ufb02ammatory tissue damage byhypoxia-inducible factors and adenos-ine A2A receptors. Annu Rev Immunol\n2004; 22: 657\u2013682.14. Lappas CM et al . Adenosine A2A ago-\nnists in development for the treatmentof in\ufb02ammation. Expert Opin Investig\nDrugs 2005; 14: 797\u2013806.\n15. Shah R, Frishman WH. Adenosine1\nreceptor antagonism: a new therapeu-tic approach for the treatment ofdecompensated heart failure. Cardiol\nRev 2009; 17: 125\u2013131.\n16. Shook BC et al . Design and characteri-\nzation of optimized adenosine\nA2A/A1 receptor antagonists for\nthe\ntreatment of Parkinson\u2019s disease.\nJ Med Chem 2012; 55: 1402\u20131417.\n17. Stone TW et al . Adenosine receptors\nand neurological disease: neuroprotec-tion and neurodegeneration. Handb\nExp Pharmacol 2009; 193: 535\u2013597.\n18. Baraldi PG et al . Adenosine receptor\nantagonists: translating medicinal\nchemistry and pharmacology into\nclinical utility. Chem Rev 2008; 108:\n238\u2013263.\n19. Moro S et al . Progress in the pursuit of\ntherapeutic adenosine receptor\nantagonists. Med Res Rev 2006; 26:\n131\u2013159.\n20. Okajima F et al . Genistein, an inhibi-\ntor of protein tyrosine kinase, isSaleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 702\n\u0018 \u001f198also a competitive antagonist for\nP1-purinergic (adenosine) receptor in\nFRTL-5 thyroid cells. Biochem Biophys\nRes Commun 1994; 203: 1488\u20131495.\n21. Jacobson KA et al . Interactions of \ufb02a-\nvones and other phytochemicals with\nadenosine receptors. Adv Exp Med Biol\n2002; 505: 163\u2013171.\n22. Borges F et al . Simple coumarins and\nanalogues in medicinal chemistry:occurrence, synthesis and biologicalactivity. Curr Med Chem 2005; 12:\n887\u2013916.\n23. Go ML et al . Chalcones: an update on\ncytotoxic and chemoprotective prop-erties. Curr Med Chem 2005; 12: 483\u2013\n495.\n24. Nowakowska Z. A review of anti-\ninfective and anti-in\ufb02ammatory chal-cones. Eur J Med Chem 2007; 42: 125\u2013\n137.\n25. Bryskier A, Klich M. Coumarin antibi-\notics: novobiocin, coumermycin, and\nclorobiocin. In: Bryskier A, ed. Antimi-\ncrob Agents Washington, DC, USA:\nAmerican Society for Microbiology Press2005: 816\u2013825.\n26. Vi\u00f1a D et al . 3-Substituted coumarins\nas dual inhibitors of AChE and MAOfor the treatment of Alzheimer\u2019sdisease. Med Chem Comm 2012; 3:\n213\u2013218.\n27. Matos MJ et al . Synthesis and study of\na SEries of 3-arylcoumarins as Potent\nand selective monoamine oxidase B\ninhibitors. J Med Chem 2011; 54:\n7127\u20137137.\n28. Matos MJ et al . New halogenated phe-\nnylcoumarins as tyrosinase inhibitors.Bioorg Med Chem Lett 2011; 21: 3342\u2013\n3345.\n29. Sashidhara KV et al . Synthesis and\nin vitro evaluation of novel coumarin-\nchalcone hybrids as potential antican-\ncer agents. Bioorg Med Chem Lett\n2010; 20: 7205\u20137211.\n30. Vukovic N et al . An ef\ufb01cient synthesis\nand antioxidant properties of novelimino and amino derivatives of4-hydroxycoumarins. Arch Pharm Res\n2010; 33: 5\u201315.\n31. V ogel S et al . Natural and non-narural\nprenylated chalcones: synthesis, cyto-toxicity and anti-oxidative activity.\nBioorg Med Chem 2008; 16: 4286\u2013\n4293.\n32. Chimenti F et al . Chalcones: a valid\nscaffold for monoamine oxidases\ninhibitors. J Med Chem 2009; 52:\n28218\u201322824.\n33. Liu XH et al . Synthesis and molecular\ndocking study of novel coumarinderivatives containing 4,5-dihydropyrazole moiety as potentialantitumor agents. Biorg Med Chem\nLett 2010; 20: 5705\u20135708.\n34. Sugino T, T anaka K. Solvent-free cou-\nmarin synthesis. Chem Lett 2001;\n 30:\n110\u2013111.\n35. Hamdi N et al . A rapid access to new\ncoumarinyl chalcone and substitutedchromeno[4,3-c]pyrazol-4(1 H)-ones\nand their antibacterial and DPPHradical scavenging activities. Med\nChem Res 2011; 20: 522\u2013530.\n36. Klotz KN et al . Comparative pharma-\ncology of human adenosine receptor\nsubtypes \u2013 characterization of stablytransfected receptors in CHO cells.\nNaunyn Schmiedebergs Arch Pharma-col 1998; 357: 1\u20139.\n37. Klotz KN et al .[\n3H]HEMADO- a\nnovel tritiated agonist selective for thehuman adenosine A\n3receptor. Eur J\nPharmacol 2007; 556: 14\u201318.\n38. Cheng YC et al . Relation between the\ninhibition constant (K i) and the con-\ncentration of inhibitor which causes\ufb01fty per cent inhibition (I50) of anenzymic reaction. Biochem Pharmacol\n1973; 22: 3099\u20133108.\n39. De Lean A et al . V alidation and\nstatistical analysis of a computer\nmodeling method for quantitative\nanalysis of radioligand binding datafor mixtures of pharmacologicalreceptor subtypes. Mol Pharmacol\n1982; 21: 5\u201316.\n40. M Cheminformatics, Bratislava, Slovak\nRepublic. 2009. http://www.molinspiration.com/services/properties.\nhtml\n41. Lipinski CA et al . Experimental and\ncomputational approaches to estimatesolubility and permeability in drug\ndiscovery and development settings.A d vD r u gD e l i vR e v 1997; 23: 3\u201325.\n42. Ertl P et al . Fast calculation of\nmolecular polar surface area as a sumof fragment-based contributions andits application to the prediction of\ndrug transport properties. JM e d\nChem 2000; 43: 3714\u20133717.Saleta Vazquez-Rodriguez et al. Chalcone derivatives as hA 3receptors\n\u00a9 2013 The Authors. JPP \u00a9 2013\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 697\u2013703 703\n\u0018  199 \u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0006\u0001\u000b\r\u0013\u000e\u0007\u000b\u000e\n\u000e\u0015\u0001:E?\u0014\u000b\n\b\r\r\u0013\n\tCEB;9KB;I\u000b\u0012\n\f\u000b\r\u0013\u000e\u0001\n\u0001\n\n\u000b\t\u0007\u0006\u000e\t\u0007\r\u0001\n\u001a##\u001f\u0001\n\r\u000b\t\u0006\f\t\r\u0012\u0001\nMMM\bC:F?\b9EC\t@EKHD7B\tCEB;9KB;I\u0001\n\u001446-'/)\u0001\n#?4:/,909\u0001(4+\u0001#:8;*:;8,\u0006\u0014*:0<0:?\u0001\",2(:0549/069\u00015-\u0001\u0001\n\u001f5<,2\u0001\u00143045\b\u001f0:85\u0001#;)9:0:;:,+\u0001\f\u0006\u00148?2*5;3(8049\u0001(9\u0001\u0001\u00144:0)(*:,80(2\u0001\u0014.,4:9\u0001\n\u001e(80(\u0001\u001b\u0007\u0001\u001e(:59\u0001\n\u0005\u0004\u0005\u0001#(2,:(\u0001&(@7;,@\u0006\"5+80.;,@\u0001\n\u0005\u0001\u001d5;8+,9\u0001#(4:(4(\u0001\n\u0005\u0001\u0018;.,405\u0001%80(8:,\u0001\n\u0005\u0001\u0001\n\u0016809:04(\u0001\u0019;,4:,9\u0006\u0018+-;-\u0001\u000b\u0005\u0001'9(),2\u0001#(4:59\u0001\u000b\u0001(4+\u0001\u00144.,2,9\u0001\u001e;A5@\u0006\u00168,.5\u0001\u000b\u0001\n\u000b\u0001 \u001e;F7HJ7C;DJE\u0001:;\u0001+KYC?97\u0001)H=SD?97\u0006\u0001 79KBJ7:\u0001:;\u0001 7HC79?7\u0006\u0001/D?L;H I?:7:\u0001:;\u0001-7DJ?7=E\u0001:;\u0001\u001dECFEIJ;B7\u0006\u0001\n\u000b\u000f\u0011\u0012\f\u0001-7DJ?7=E\u0001:;\u0001\u001dECFEIJ;B7\u0006\u0001-F7?D\u0015\u0001\u001f\u0007'7?BI\u0014\u0001ILH;\u0011\u0011\u001a=C7?B\b9EC\u0001 \u0003-\b0\b\u0007,\b\u0004\u0015\u0001\nBEKH:;I\bI7DJ7D7\u001aKI9\b;I\u0001\u0003&\b-\b\u0004\u0015\u0001;K=;D?E\bKH?7HJ;\u001aKI9\b;I\u0001\u0003\u001f\b/\b\u0004\u0001\n\f\u0001 \u001e;F7HJ7C;DJE\u0001:;\u0001'?9HE8?EBE=Y7\u0001O\u0001*7H7I?JEBE=Y7\u0006\u0001 79KBJ7:\u0001:;\u0001\u001c?E BE=Y7\u0006\u0001\u0001\n/D?L;HI?:7:\u0001:;\u0001-7DJ?7=E\u0001:;\u0001\u001dECFEIJ;B7\u0006\u0001\u000b\u000f\u0011\u0012\f\u0001-7DJ?7=E\u0001:;\u0001\u001dECFEI J;B7\u0006\u0001-F7?D\u0015\u0001\u0001\n\u001f\u0007'7?BI\u0014\u00019H?IJ?D7\b<K;DJ;I;:<K<\u001a=C7?B\b9EC\u0001\u0003\u001d\b \b\u0007\u001f\b\u0004\u0015\u0001OI78;B\bI7DJ EI\u001aKI9\b;I\u0001\u00033\b-\b\u0004\u0015\u0001\n7\bCKDEP\b9H;=E\u001aKI9\b;I \u0001\u0003\u001b\b'\b\u0007\u001d\b\u0004\u0001\n\u0004\u0001 \u001bKJ>EH\u0001JE\u0001M>EC\u00019EHH;IFED:;D9;\u0001I>EKB:\u00018;\u00017::H;II;:\u0015\u0001\u001f\u0007'7?B\u0014\u0001C7H?79C7JEI\u001a=C7?B\b9EC\u0015\u0001\u0001\n.;B\b\u0014\u0001\u0005\r\u000e\u0007\u0013\u0012\u000b\u0007\u000f\f\u0012\u0007\n\u0011\n\u0015\u0001 7N\u0014\u0001\u0005\r\u000e\u0007\u0013\u0012\u000b\u0007\u000f\u0013\u000e\u0007\u0013\u000b\f\b \u0001\n\")')-8)(\u0012\u0001\n\f\u0001\u0017)')0&)4\u0001\n\b\t\n\u0013\u0001-1\u00014)8-5)(\u0001*240\u0012\u0001\t\r\u0001\u001c%17%4;\u0001\n\b\t\u000b\u0001\u0007\u0001\u0014'')36)(\u0012\u0001\t\u000f\u0001\u001c%17%4;\u0001\n\b\t\u000b\u0001\u0007\u0001\n!7&/-5,)(\u0012\u0001\n\f\u0001\u001c%17%4;\u0001\n\b\t\u000b\u0001\n\u0001\n\u0014)9:8(*:\u0013\u0001\u001b\u0001D;M\u0001I;H?;I\u0001E<\u00017C?DE\tD?JHE\u0007IK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\u0001M;H;\u0001I ODJ>;I?P;:\u00017D:\u0001\nJ>;?H\u00017DJ?879J;H?7B\u000179J?L?JO\u00017=7?DIJ\u00019B?D?97B\u0001?IEB7J;I\u0001E<\u0001 #6%3,;/2'2''75\u0001%74)75\u0001\u0003!H7C\u0007FEI?J?L;\u0004\u0001\n7D:\u0001\u00185',)4-',-%\u0001'2/- \u0001\u0003!H7C\u0007D;=7J?L;\u0004\u0001M7I\u0001;L7BK7J;:\b\u0001-EC;\u0001E<\u0001J>;I;\u0001CEB;9KB;I\u0001;N>?8?J;:\u0001\n7DJ?879J;H?7B\u000179J?L?JO\u00017=7?DIJ\u0001 #\u0006\u0001%74)75\u00019ECF7H78B;\u0001JE\u0001J>;\u0001IJ7D:7H:I\u0001KI;:\u0001\u0003ENEB?D?9\u000179?:\u00017D:\u0001\n7CF?9?BB?D\u0004\b\u0001 .>;\u0001 FH;B?C?D7HO\u0001 IJHK9JKH;\u000779J?L?JO\u0001 H;B7J?EDI>?F\u0001 \u0003- \u001b,\u0004\u0001 IJK:O\u0001 I>EM;:\u0001 J>7J\u0001 J>;\u0001\n7DJ?879J;H?7B\u000179J?L?JO\u00017=7?DIJ\u0001 #\u0006\u0001%74)75\u0001:;F;D:I\u0001ED\u0001J>;\u0001FEI?J?ED\u0001E<\u0001J>;\u0001\r\u00077HOB9EKC7H?D\u0001\nIK8IJ?JKJ?ED\u0001F7JJ;HD\b\u00011?J>\u0001J>;\u00017?C\u0001E<\u0001<?D:?D=\u0001J>;\u0001IJHK9JKH7B\u0001<; 7JKH;I\u0001<EH\u0001J>;\u00017DJ?879J;H?7B\u0001\n79J?L?JO\u00017D:\u0001I;B;9J?L?JO\u0006\u0001?D\u0001J>;\u0001FH;I;DJ\u0001C7DKI9H?FJ\u0001:?<<;H;DJ\u0001FEI?J?EDI\u0001E<\u0001D?JHE\u0006\u0001C;J>OB\u0006\u0001C;J>ENO\u0006\u00017C?DE\u00017D:\u00018HECE\u0001IK8IJ?JK;DJI\u0001ED\u0001J>;\u0001\r\u00077HOB9EKC7H?D\u0001I97 <<EB:\u0001M;H;\u0001H;FEHJ;:\b\u0001\n\u001c,?=58+9\u0013 \u00017C?DE\tD?JHE\u0001IK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\u0015\u0001*;HA?D\u0001H;79J?ED\u0015\u00017DJ?879J;H?7B\u00017II7OI\u0015\u0001\n#\u0006\u0001%74)75\u0015\u0001\u0018\u0006\u0001'2/-\u0001\n\u0001 !\u0018\u001f\u0001\u0014\u0016\u0016\u0018##\n\u0019\u0017\u0018201\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\f\u0012\u000e\u0001\n\u0001\n\u0001\n\u0007\u0001\u001a4:85+;*:054\u0001\n\u001eHK=\u0001 :?I9EL;HO\u0001 ?I\u0001 9EDI?:;H;:\u0001 7\u0001 9ECFB;N\u0001 7D:\u0001 IBEM\u0001 79J?L?JO\b\u0001 \"EM;L;H\u0006\u0001 M?J>\u0001 J>;\u0001 ?DJ;DJ?ED\u0001 E<\u0001\n:?I9EL;H?D=\u0001D;M\u00019>;C?97B\u0001;DJ?J?;I\u0001?D\u00017\u0001D;M\u00017D:\u0001CEH;\u0001;<<?9?;DJ\u0001M 7O\u0006\u0001C;:?9?D7B\u00019>;C?IJHO\u0001H;I;7H9>;HI\u0001\n>7L;\u0001:;L;BEF;:\u0001D;M\u00017FFHE79>;I\u00017D:\u0001C;J>E:I\b\u0001-EC;\u0001E<\u0001J>;\u0001D;M\u0001FHE: K9JI\u00017H;\u000187I;:\u0001ED\u0001:?L;HI?JO\u0001\nCEB;9KB;I\u0001<EKD:\u00017D:\u0001;NJH79J;:\u0001<HEC\u0001D7JKH7B\u0001IEKH9;I\b\u0001\u001dEKC7H?DI\u00017 H;\u00017\u0001B7H=;\u0001<7C?BO\u0001E<\u00019ECFEKD:I\u0001E<\u0001\nD7JKH7B\u0001EH\u0001IODJ>;J?9\u0001EH?=?D\u0006\u00017IIE9?7J;:\u0001M?J>\u0001H;C7HA78B;\u0001F>7HC79EBE=?97B\u000179J?L?J?;I\u00015\u000b\u0006\f6\b\u0001.>;O\u0001E99KH\u0001\nD7JKH7BBO\u0001?D\u0001FB7DJI\u00017D:\u0001C?9HEEH=7D?ICI\u00017D:\u00017FFHEN?C7J;BO\u0001\u000b\u0006\n\n\n\u0001 9EKC7H?D\u0001:;H?L7J?L;I\u0001>7L;\u00018;;D\u0001\n?IEB7J;:\u0001<HEC\u0001EL;H\u0001\u0012\n\n\u0001IF;9?;I\u00015\f6\b\u0001.>;\u0001<KI;:\u0001>;J;HE9O9B?9\u0001<H7C ;MEHA\u0001E<\u00019EKC7H?DI\u0001>7I\u00018;;D\u0001KI;:\u00017I\u00017\u0001\nFHEJEJOF;\u0001I97<<EB:\u0001<EH\u0001J>;\u0001IODJ>;I?I\u0001E<\u00017\u0001M?:;\u0001L7H?;JO\u0001E<\u00017D7BE =K;I\u0001?D\u0001EH:;H\u0001JE\u0001IJK:O\u00017D:\u0001?CFHEL;\u0001J>;?H\u0001\n8?EBE=?97B\u0001FHEF;HJ?;I\b\u0001#JI\u0001IJHK9JKH7B\u0001L7H?;JO\u0001?I\u0001H;IFEDI?8B;\u0001<EH\u0001J>;\u0001?CFEHJ7DJ\u0001FB79;\u0001J>;O\u0001E99KFO\u0001?D\u0001J>;\u0001H;7BC\u0001E<\u0001D7JKH7B\u0001FHE:K9JI\u00017D:\u0001IODJ>;J?9\u0001EH=7D?9\u00019>;C?IJHO\u00015\f\u0006\r6 \b\u0001-EC;\u00019EKC7H?DI\u0001>7L;\u00018;;D\u0001IJK:?;:\u0001<EH\u0001\nJ>;?H\u00017DJ?C?9HE8?7B\u00015\u000ec\u00116\u0006\u000197H:?EFHEJ;9J?L;\u00015\u00126\u0006\u00017DJ?97D9;H\u00015\u0013\u0006\u000b\n6\u0006\u00017DJ?EN?:7J?L;\u00015\u000b\u000b6\u00017D:\u0001;DPOC7J?9\u0001?D>?8?J?ED\u0001FHEF;HJ?;I\u00015\u000b\fc\u000b\u00116\b\u0001!EJ>\u0001:;I9H?8;:\u0001J>;\u00017DJ?879J;H?7B\u0001FHEF;HJ?;I\u0001E<\u00019EKC7H?DI\u0001<EH\u0001J>;\u0001<?HIJ\u0001J?C;\u0001\n?D\u0001\u000b\u0013\u000e\u000f\u0001M>;D\u0001>;\u0001IJK:?;:\u0001J>;\u0001:?9EKC7HEB\u0001\u0003 ?=KH;\u0001\u000b\u0004\u00015\u000b\u00126\b\u0001-EC;\u0001EJ >;H\u00019EKC7H?D\u0001:;H?L7J?L;I\u0001>7L;\u0001FHEL;D\u0001\nJE\u0001:?IFB7O\u00017DJ?879J;H?7B\u00017D:\u00017DJ?<KD=7B\u000179J?L?J?;I\u00015\u000b\u0013c\f\f6\b\u0001\u001b\u0001I JK:O\u0001E<\u00019EKC7H?D\u0001:;H?L7J?L;I\u0001IK8IJ?JKJ;:\u0001\nED\u0001J>;\u0001FOHED;\u0001H?D=\u0001?D:?97J;:\u0001J>7J\u0001\r\u000797H8ENOB\u0001:;H?L7J?L;I\u0001I>EM\u0001I ?=D?<?97DJ\u000179J?L?J?;I\u00015\f\r6\b\u0001\u001e?<<;H;DJ\u0001\u0001\n\u000e\u0007IK8IJ?JKJ;:\u0001 9EKC7H?DI\u0006\u0001 IK9>\u0001 7I\u0001 \u000e\u00079>BEHE9EKC7H?DI\u0006\u0001 ;N>?8?J\u0001 7BIE\u0001 7D\u0001 ?DJ;H;IJ?D=\u0001 7DJ?C?9HE8?7B\u0001\u0001\nFHE<?B;\u0001 5\f\u000e\u0006\f\u000f6\b\u0001 (ELE8?E9?D\u0001 \u0003 ?=KH;\u0001 \u000b\u0004\u0006\u0001 9>BEHE8?E9?D\u0001 7D:\u0001 9EKC;H CO9?D\u0001 \u001b\n\u000b\u0001 7H;\u0001 ?CFEHJ7DJ\u0001 D7JKH7B\u0001\nE99KHH?D=\u00017DJ?8?EJ?9I\u0001?D\u0001M>?9>\u0001J>;\u00019EKC7H?D\u0001DK9B;KI\u0001?I\u0001FH;I;DJ\u0001 ?D\u0001J>;?H\u0001IA;B;JED\u00015\f\u00106\b\u0001\n\u00190.;8,\u0001\n\u0007\u0001\u001d>;C?97B\u0001IJHK9JKH;I\u0001E<\u0001:?9EKC7HEB\u00017D:\u0001DELE8?E9?D\b\u0001\n\u0001\n.>;\u0001CEIJ\u000179J?L;\u0001E<\u0001J>;C\u0001?I\u0001DELE8?E9?D\u0006\u0001?IEB7J;:\u0001<HEC\u0001 #64)3620;')5 \u00011-8)75\u00017D:\u0001M>?9>\u0001?I\u0001C7?DBO\u0001\n79J?L;\u00017=7?DIJ\u0001!H7C\u0007FEI?J?L;\u0001879J;H?7\b\u0001\u001bBJ>EK=>\u0001J>;O\u00017DJ7=ED?P; \u0001J>;\u0001\u001c\u0001IK8KD?J\u0001E<\u0001J>;\u0001;II;DJ?7B\u0001 \u0018\u0006\u0001'2/-\u0001\n\u001e(\u001b\u0001=OH7I;\u0001IKF;HJM?IJ?D=\u000179J?L?JO\u0001 -1\u00018-642\u00017D:\u0001J>;\u0001879J;H?7B\u0001CKBJ?FB?97J?ED\u0006\u0001J>;O\u00017H;\u0001DEJ\u0001KI;:\u0001?D\u0001J>;\u0001\n9B?D?9\u0001:K;\u0001JE\u0001J>;?H\u0001H;B7J?L;BO\u0001M;7A\u000179J?L?JO\u00017=7?DIJ\u0001!H7C\u0007D;=7J ?L;\u0001879J;H?7\u0006\u0001I?:;\u0001;<<;9JI\u00017D:\u0001FEEH\u0001M7J;H\u0001\nIEBK8?B?JO\u00015\u000e\u0006\f\u00106\b\u0001)D\u0001J>;\u0001EJ>;H\u0001>7D:\u0006\u0001J>;I;\u0001J>H;;\u0001;N7CFB;I\u00017H;\u0001 7DJ?8?EJ?9I\u0006\u0001M>?9>\u0001FH;I;DJ\u000179J?L?JO\u0001\u0001\n7=7?DIJ\u0001 C;J>?9?BB?D\u0007H;I?IJ7DJ\u0001 #\u0006\u0001%74)75\u0001 \u0003',-\u001b\u0004\u0001 5\f\u00106\b\u0001 .>;\u0001 DKC8;H\u0001 E<\u0001 CKBJ?:HK=\u0007H;I?IJ7DJ\u0001 \u0003'\u001e,\u0004\u0001\n879J;H?7\u0001?I\u0001?D9H;7I?D=\u00017D:\u0001J>;\u0001!H7C\u0007FEI?J?L;\u0001',-\u001b\u00017H;\u0001E<\u0001F7HJ?9 KB7H\u0001?CFEHJ7D9;\b\u0001.>;\u000178?B?JO\u0001E<\u0001\u0001\n\u0019\u0017\u0019202\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\f\u0012\u000f\u0001\n\u0001\n\u0001#\u0006\u0001%74)75\u0001IF;9?;I\u0001JE\u0001:;L;BEF\u0001H;I?IJ7D9;\u0001JE\u0001L?HJK7BBO\u00017BB\u00017DJ?8?EJ?9I\u0001?I\u00017 \u0001C7@EH\u00019ED9;HD\u00017D:\u0001J>;\u0001:?I9EL;HO\u0001\nE<\u0001D;M\u00017DJ?C?9HE8?7B\u00017=;DJI\u0001?I\u0001;II;DJ?7B\u0001JE\u00019EC87J\u0001J>?I\u0001FHE8B;C \u00015\f\u00116\b\u0001',-\u001b\u00017H;\u0001E<J;D\u00017D\u0001?CFEHJ7DJ\u0001\nFHE8B;C\u0001<EH\u0001I;L;H;\u0001?D<;9J?EDI\u0001?D\u0001F7J?;DJI\u0006\u0001;IF;9?7BBO\u0001?<\u0001J>;O\u00017 H;\u0001?CCKDEIKFFH;II;:\u0006\u0001:KH?D=\u0001BED=\u0001IJ7OI\u0001?D\u0001\n>EIF?J7BI\u00015\f\u00116\b\u0001.>;\u0001:H7C7J?9\u0001MEHB:M?:;\u0001?D9H;7I;\u0001E<\u0001:7D=;HEKI\u0001?D<;9J?EDI\u00018O\u0001H;I?IJ7DJ\u00017D:\u0001CKBJ?\u0007H;I?IJ7DJ\u0001\nC?9HE8;I\u0001C7A;I\u0006\u0001J>;H;<EH;\u0006\u0001J>;\u0001I;7H9>\u0001E<\u0001D;M\u0001CEB;9KB;I\u00017D:\u0001D;M\u0001 9>;C?97B\u0001;DJ?J?;I\u00017D\u0001?CFEHJ7DJ\u0001JEF?9\u0001\n?D\u0001C;:?9?D7B\u00019>;C?IJHO\u00015\f\u0012\u0006\f\u00136\b\u0001\u001bI\u0001J>;\u0001?:;7B\u0001:HK=\u000197D:?:7J;\u0001>7I \u0001DEJ\u00018;;D\u00017JJ7?D;:\u0006\u00017D\u0001?DJ;DI?L;\u0001I;7H9>\u0001\n<EH\u0001 D;M\u0001 7D:\u0001 ?DDEL7J?L;\u0001 7DJ?C?9HE8?7BI\u0001 ?I\u0001 IJ?BB\u0001 D;;:;:\b\u0001 /D<EHJKD 7J;BO\u0006\u0001 :K;\u0001 JE\u0001 ;9EDEC?9\u0001 H;7IEDI\u0006\u0001\nF>7HC79;KJ?97B\u00019ECF7D?;I\u0001>7L;\u00019EDI?:;H78BO\u0001:;9H;7I;:\u0001J>?I\u0001;<<EH J\u0001?D\u0001H;9;DJ\u0001O;7HI\u00015\r\n6\b\u0001\n\u000b\u0007\u0001\",9;2:9\u0001(4+\u0001\u001709*;99054\u0001\n\u001c7I;:\u0001 ED\u0001 FH;L?EKI\u0001 <?D:?D=I\u0001 ?D\u0001 J>;\u0001 7H;7\u0001 5\f\u000e\u0006\f\u000f6\u0006\u0001 7D:\u0001 ?D\u0001 EKH\u0001 ;NF; H?;D9;\u0001 M?J>\u0001 IK8IJ?JKJ;:\u0001\u0001\n\r\u00077HOB9EKC7H?DI\u00015\u000b\u000f\u0006\r\u000b\u0006\r\f6\u0006\u0001?D\u0001J>;\u0001FH;I;DJ\u0001MEHA\u0001M;\u0001FHEFEI;:\u0001J>; \u0001IODJ>;I?I\u00017D:\u00017DJ?879J;H?7B\u0001;L7BK7J?ED\u0001\nE<\u00017\u0001I;H?;I\u0001E<\u0001:?<<;H;DJ\u0001IK8IJ?JKJ;:\u00017C?DE\tD?JHE\u0001\r\u00077HOB9EKC7H?D I\u0001\u0003-9>;C;\u0001\u000b\u0004\b\u00011?J>\u0001J>;\u00017?C\u0001E<\u0001<?D:?D=\u0001\nJ>;\u0001 IJHK9JKH7B\u0001 <;7JKH;I\u0001 <EH\u0001 J>;\u0001 7DJ?879J;H?7B\u0001 79J?L?JO\u0001 7D:\u0001 I;B;9J?L?JO\u0006\u0001 M;\u0001 :;9?:;:\u0001 JE\u0001 ;NFBEH;\u0001 J>;\u0001\n?CFEHJ7D9;\u0001E<\u0001J>;\u0001D7JKH;\u00017D:\u0001FEI?J?ED\u0001E<\u0001IC7BB\u0001=HEKFI\u0001\u0003C;J>ENO\u0006\u00018HECE\u0006\u0001D?JHE\u0006\u00017C?DE\u00017D:\u0001C;J>OB\u0001\nIK8IJ?JK;DJI\u0004\u0001?DJE\u00018EJ>\u00019EKC7H?D\u0001DK9B;KI\u00017D:\u0001\r\u00077HOB\u0001H?D=\u0001\u0003-9>;C;\u0001\u000b\u0004\b\u0001\n#*/,3,\u0001\n\u0007\u0001-ODJ>;I?I\u0001E<\u0001\r\u00077HOB9EKC7H?DI\u0001\u0003 \nc\n\n\u0004\b\u0001\n\u0001\n\")%+)165\u0001%1(\u0001'21(-6-215 \u0014\u0001\u00037\u0004\u0001(7\"\u0006\u000179;J?9\u00017D>O:H?:;\u0006\u0001H\bJ\b\u0006\u0001\r\u0001>\u0015\u0001\u00038\u0004\u0001\" \f\u0006\u0001*:\t\u001d\u0006\u0001;J>7DEB\u0006\u0001H\bJ\b\u0006\u0001\r\u0001>\b\u0001\n(;M\u0001:;H?L7J?L;I\u0001 \u000b\u0006\u0001\rc\u0010\u00017D:\u0001\u0012c\n\n\u0006\u00017I\u0001M;BB\u00017I\u0001J>;\u00017BH;7:O\u0001:;I9H?8;:\u00019ECFEKD:I\u0001 \n\u0006\u0001\f\u00017D:\u0001\u0011\u00015\r\rc\r\u00106\u0006\u0001\nM;H;\u0001 ;<<?9?;DJBO\u0001 IODJ>;I?P;:\u0001 799EH:?D=\u0001 JE\u0001 J>;\u0001 IODJ>;J?9\u0001 FHEJE9E B\u0001 EKJB?D;:\u0001 ?D\u0001 -9>;C;\u0001 \u000b\b\u0001\u0001\n\r\u0007\u001bHOB9EKC7H?DI\u0001 \nc\n\t\u0001M;H;\u0001IODJ>;I?P;:\u0001?D\u00017\u0001:HO\u0001-9>B;DA\u0001JK8;\u0006\u0001?D\u0001FH;I;D9;\u0001E<\u0001IE:?KC\u0001>O:H?:;\u00017D:\u0001M?J>\u0001\n79;J?9\u00017D>O:H?:;\u00017I\u0001IEBL;DJ\u0006\u00017J\u0001HEEC\u0001J;CF;H7JKH;\u0001<EH\u0001J>H;;\u0001>EKH I\b\u0001.>;\u0001H;79J?ED\u0001C?NJKH;\u0001M7I\u0001FKH?<?;:\u00018O\u0001\n<B7I>\u00019>HEC7JE=H7F>O\u0006\u0001KI?D=\u0001>;N7D;\t;J>OB\u000179;J7J;\u00017I\u0001;BK;DJ\u0001?D\u00017 \u0001FHEFEHJ?ED\u0001E<\u0001\u0013\u0014\u000b\b\u0001-J7HJ?D=\u0001<HEC\u0001\n:?<<;H;DJ\u0001 9ECC;H9?7BBO\u0001 7L7?B78B;\u0001 IK8IJ?JKJ;:\u0001 I7B?9OB7B:;>O:;I\u0001 7 D:\u0001 J>;\u0001 H;IF;9J?L;BO\u0001 IK8IJ?JKJ;:\u0001\nF>;DOB79;J?9\u000179?:I\u0006\u0001M;\u0001E8J7?D;:\u0001J;D\u0001:;H?L7J;I\u0001?D\u0001=EE:\u0001O?;B:I\u0001\u0003\u0010\nc\u0011\u000f\u0002\u0004\b\u0001.>;\u0001:;H?L7J?L;\u0001 \n\n\u0001M7I\u0001E8J7?D;:\u0001\n\u0019\u0017\u001a203\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\f\u0012\u0010\u0001\n\u0001\n\u0001<HEC\u0001\r\u0006\u0001?D\u0001;J>7DEB\u0006\u0001M?J>\u0001F7BB7:?KC\t97H8ED\u00017I\u000197J7BOIJ\u00017D:\u0001KD:;H\u0001>O:HE =;D\u00017JCEIF>;H;\u0001<EH\u0001J>H;;\u0001>EKHI\b\u0001\n.>;\u0001H;79J?ED\u0001C?NJKH;\u0001M7I\u0001FKH?<?;:\u00018O\u0001<B7I>\u00019>HEC7JE=H7F>O\u0006\u0001KI?D =\u0001>;N7D;\t;J>OB\u000179;J7J;\u00017I\u0001;BK;DJ\u0006\u0001?D\u00017\u0001\nFHEFEHJ?ED\u0001 E<\u0001 \u0013\u0014\u000b\b\u0001 1;\u0001 E8J7?D;:\u0001 J>;\u0001 :;I?H;:\u0001 :;H?L7J;\u0001 ?D\u0001 =EE:\u0001 O?; B:\u0001 \u0003\u0012\n\u0002\u0004\b\u0001 .>;D\u0006\u0001 JME\u0001 :?<<;H;DJ\u0001\nC;J>E:EBE=?;I\u0001M;H;\u0001;CFBEO;:\u0001<EH\u0001J>;\u00017DJ?879J;H?7B\u0001;L7BK7J?ED\u0001E< \u0001J>;I;\u00019ECFEKD:I\u0014\u0001:?IA\u0001:?<<KI?ED\u0001J;IJ\u0001\n7D:\u0001C?9HE:?BKJ?ED\u0001C;J>E:\b\u0001\u001dB?D?97B\u00017DJ?C?9HE8?7B\u0001:HK=IcENEB?D?9 \u000179?:\u00017D:\u00017CF?9?BB?DcM;H;\u0001KI;:\u00017I\u0001\nFEI?J?L;\u00019EDJHEBI\b\u0001.>;\u0001?D>?8?J?ED\u0001PED;I\u0001<EH\u0001=HEMJ>\u0001?D>?8?JEHO\u0001; <<;9JI\u0001E<\u0001J>;\u0001D;M\u00019ECFEKD:I\u00017D:\u0001\n9EDJHEBI\u0001M;H;\u0001C;7IKH;:\u0001?D\u0001C?BB?C;JH;I\u0001\u0003.78B;\u0001\u000b\u0006\u0001C;J>E:\u0001\u001b\u0004\b\u0001.>;\u0001 C?D?CKC\u0001?D>?8?JEHO\u00019ED9;DJH7J?EDI\u0001\n\u0003'#\u001dI\u0004\u0001E<\u0001J>;\u0001D;M\u00019ECFEKD:I\u00017D:\u00019EDJHEBI\u0001M;H;\u0001C;7IKH;:\u0001?D\u0001C?9HE=H7C\tC?BB?B?JH;\u0001\u0003.78B;\u0001\u000b\u0006\u0001C;J>E:\u0001\u001c\u0004\b\u0001\n$()2,\u0001\n\u0007\u0001\u001b1\u00018-642\u00017DJ?879J;H?7B\u000179J?L?JO\u00017\u0001E<\u00017C?DE\tD?JHE\u0001IK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\u0001 \nc\n\n\u0001\n\u0003\u0014\u0004\u0001;NFH;II;:\u00017I\u0001?D>?8?J?ED\u0001PED;I\u0001\u0003CC\u0004\u00018\u00017D:\u0001\u0003\u0015\u0004\u0001;NFH;II;:\u00017I\u0001'#\u001dI\u0001\u0003b=\tC&\u0004\b\u0001\n\u00165365;4+9\u0001\u001e,:/5+\u0001\u0014\u0001\u000233\u0003\u0001 \u001e,:/5+\u0001\u0015\u0001\u0002B.\b3\u001d\u0003\u0001\n\u0004\u0002\u0001\u0005\u000e\f\u0007\u000e\r\u0001 \u0003\u0002\u0001\u0006\u000b\t\b\u0001 \u0004\u0002\u0001\u0005\u000e\f\u0007\u000e\r\u0001 \u0003\u0002\u0001\u0006\u000b\t\b\u0001\n\u000b\u0001 \u000b\u0013\u0001 (\u001b\u0001 \u000b\f\u0012\u0001 \u0007\u0001\n\f\u0001 \f\u000f\u0001 (\u001b\u0001 \u0010\u000e\u0001 \u0007\u0001\n\r\u0001 \f\f\u0001 (\u001b\u0001 \r\f\u0001 \u0007\u0001\n\u000e\u0001 \f\f\u0001 (\u001b\u0001 \r\f\u0001 \u0007\u0001\n\u000f\u0001 \f\u000f\u0001 (\u001b\u0001 \u0010\u000e\u0001 \u0007\u0001\n\u0010\u0001 \r\f\u0001 (\u001b\u0001 \u0012\u0001 \u0007\u0001\n\u0011\u0001 \u000b\u000e\u0001 (\u001b\u0001 \f\u000f\u0010\u0001 \u0007\u0001\n\u0012\u0001 (\u001b\u0001 (\u001b\u0001 \u0018\u000f\u000b\f\u0001 \u0007\u0001\n\u0013\u0001 (\u001b\u0001 (\u001b\u0001 \u0018\u000f\u000b\f\u0001 \u0007\u0001\n\u000b\n\u0001 (\u001b\u0001 (\u001b\u0001 \u0018\u000f\u000b\f\u0001 \u0007\u0001\n\u000b\u000b\u0001 \u000b\u0012\u0001 (\u001b\u0001 \u000b\f\u0012\u0001 \u0007\u0001\n)NEB?D?9\u000179?:\u0001 \f\u0010\u0001 \r\u000b\u0001 \f\u0001 \u0016\u000b\u0001\n\u001bCF?9?BB?D\u0001 \r\f\u0001 \f\r\u0001 \f\u0001 \u0012\u0001\n7\u0001.>;I;\u0001H;IKBJI\u00017H;\u00017L;H7=;\u0001H;IKBJI\u0001E<\u0001J>H;;\u0001;NF;H?C;DJI\u0015\u00018\u0001.>;\u00019ECFEKD:I\u0001M;H;\u0001KI;:\u0001 7J\u0001J>;\u00019ED9;DJH7J?ED\u0001E<\u0001\n\u000b\n\n\u0001b=\t:?IA\u00017D:\u0001J>;\u0001?D>?8?J?ED\u0001PE D;I\u00017H;\u0001IJ7J;:\u0001?D\u0001CC\u0015\u0001(\u001b\u0001\u0017\u0001DEJ \u000179J?L;\u0015\u0001:?7C;J;H\u0001E<\u0001?D>?8?J?ED\u0001PED;\u0001 \u0094\u0001\u000f\u0001CC\b\u0001\n.>;\u0001E8J7?D;:\u0001?D>?8?J?ED\u0001PED;I\u0001H;L;7B;:\u0001J>7J\u00017BB\u0001J>;\u0001\u0010\u0007D?JHE\u0001:;H ?L7J?L;I\u0001\u00039ECFEKD:I\u0001 \nc\u0010\u0004\u0001FH;I;DJ;:\u0001\n7DJ?879J;H?7B\u000179J?L?JO\u00017=7?DIJ\u0001 #\u0006\u0001%74)75\u0006\u0001I>EM?D=\u0001?D>?8?J?ED\u0001PED;I\u0001H7D=?D=\u00018;JM;;D\u0001\u000b\u000e\u00017D:\u0001\r\f\u0001CC\b\u0001.>;\u0001\n7C?DE\u0001:;H?L7J?L;\u0001 \n\n\u0001FH;I;DJ;:\u000179J?L?JO\u00017=7?DIJ\u0001J>;\u0001I7C;\u0001879J;H?7B\u0001IJH7?D\b\u0001.>;\u0001\r\u00077H OB9EKC7H?DI\u0001D?JHE\u0001\nIK8IJ?JKJ;:\u0001EDBO\u0001?D\u0001J>;\u0001\r\u00077HOB\u0001H?D=\u0001\u00039ECFEKD:I\u0001 \u0011c\n\t\u0004\u0001M;H;\u0001?D79J?L;\u00017=7?DIJ\u0001 #\u0006\u0001%74)75\u0001 ?D\u0001J>;\u0001-1\u00018-642\u0001\n:?IA\u0001:?<<KI?ED\u0001J;IJ\u00017II7OI\u0006\u0001?D:;F;D:;DJBO\u0001E<\u0001J>;\u0001H;B7J?L;\u0001FEI?J ?ED\u0001E<\u0001J>?I\u0001D?JHE\u0001=HEKF\u0001\u0003 3%4%\u0001EH\u00010)6%\u0001\nFEI?J?EDI\u0004\b\u0001 HEC\u0001J>;\u0001:7J7\u0006\u0001?J\u0001?I\u0001I>EMD\u0001J>7J\u00019ECFEKD:\u0001 \u000f\u00017D:\u00017CF?9?BB?D\u0001FH;I;DJ;:\u0001J>;\u0001I7C;\u0001?D>?8?J?ED\u0001\nPED;\u00017=7?DIJ\u0001#\u0006\u0001%74)75\u0001\u0003\r\f\u0001CC\u0004\u00017D:\u00017\u0001>?=>;H\u0001?D>?8?J?ED\u0001PED;\u0001J>7D\u0001J>;\u0001ENEB?D?9\u000179?:\u0001\u0003\f \u0010\u0001CC\u0004\b\u0001\";D9;\u0006\u0001\nJ>;\u0001 FH;B?C?D7HO\u0001 ;NF;H?C;DJ7B\u0001 :7J7\u0001 H;L;7B;:\u0001 J>7J\u0001 IEC;\u0001 E<\u0001 J>;\u0001 J;I J;:\u0001 9ECFEKD:I\u0001 I>EM;:\u0001 7\u0001 L;HO\u0001\n?DJ;H;IJ?D=\u000179J?L?JO\u0001FHE<?B;\u00017=7?DIJ\u0001 #\u0006\u0001%74)75\u0001M>;D\u00019ECF7H;:\u0001M?J>\u0001J>;\u0001IJ7D:7H:I\u00017CF?9?BB?D\u00017D:\u0001ENEB?D?9\u0001\n79?:\b\u0001#D\u00017::?J?ED\u0006\u0001J>;\u0001:?<<;H;DJ\u0001D7JKH;\u00017D:\u0001FEI?J?ED\u0001E<\u0001J>;\u0001IK8IJ?JK;DJ\u0001?D\u0001J>;\u00019EKC7H?D\u0001I97<<EB:\u0001I;;CI\u0001JE\u0001\n?D<BK;D9;\u0001J>;\u00017DJ?879J;H?7B\u000179J?L?JO\b\u0001\u0001\n#D\u0001 EH:;H\u0001 JE\u0001 :;;FBO\u0001 IJK:O\u0001 J>;\u0001 7DJ?879J;H?7B\u0001 79J?L?J?;I\u0001 7D:\u0001 GK7DJ ?<O\u0001 J>;\u0001 FH;L?EKIBO\u0001 C;DJ?ED;:\u0001\n?D<EHC7J?ED\u0006\u0001 '#\u001dI\u0001 E<\u0001 9ECFEKD:I\u0001 \nc\n\n\u0001 7=7?DIJ\u0001 #\u0006\u0001 %74)75\u0001 M;H;\u0001 7BIE\u0001 :;J;HC?D;:\b\u0001.>?I\u0001 I;9ED:\u0001\nC;J>E:EBE=O\u0001\u0003C;J>E:\u0001\u001c\u0004\u0001?I\u0001KI;:\u0001JE\u00019B7H?<O\u00017D:\u0001H;<?D;\u0001J>;\u0001FH;L?E KIBO\u0001H;IKBJI\u0001E8J7?D;:\u00018O\u0001C;J>E:\u0001\u001b\u0006\u0001\nM>?9>\u00019EKB:\u00018;\u0001?D<BK;D9;:\u00018O\u0001:?<<;H;D9;I\u0001?D\u0001J>;\u0001:?<<KI?ED\u0001E<\u0001J>;\u00019ECFEKD:I\b\u0001.>?I\u0001IJK:O\u0001M7I\u0001F;H<EHC;:\u0001\n\u0019\u0017\u001b204\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\f\u0012\u0011\u0001\n\u0001\n\u00017=7?DIJ\u0001J>;\u0001I7C;\u0001879J;H?7\u0001IJH7?D\u0006\u00018O\u00017\u0001C?9HE:?BKJ?ED\u00017II7O\u0001M?J> \u0001I;H?7B\u0001:?BKJ?EDI\u0001\u0003<HEC\u0001\u000f\u000b\f\u0001JE\u0001\u000b\u0001 \u021d=\tC&\u0004\u0001\nE<\u0001J>;\u0001IODJ>;I?P;:\u00017D:\u0001J>;\u0001H;<;H;D9;\u00019ECFEKD:I\b\u0001'#\u001dI\u0001E<\u00019ECFEKD :I\u0001\nc\n\n\u00017=7?DIJ\u0001 \u0018\u0006\u0001'2/-\u0001M;H;\u0001DEJ\u0001\n;L7BK7J;:\u0006\u0001 J7A?D=\u0001 ?DJE\u0001 799EKDJ\u0001 J>;\u0001 B79A\u0001 E<\u0001 ?D>?8?J?ED\u0001 PED;I\u0001 ?D\u0001 J>;\u0001 FH;L?EKI\u0001 :?IA\u0001 :?<<KI?ED\u0001 J;IJ\u0001\u0001\n\u0003?D>?8?J?ED\u0001PED;I\u0001 \u0094\u0001\u000f\u0001CC\u0004\b\u0001\u001bD7BOI?D=\u0001J>;\u0001'#\u001dI\u0001H;IKBJI\u0001<EH\u0001 #\u0006\u0001%74)75\u0006\u0001?J\u0001?I\u00019B;7H\u0001J>7J\u0001J>;\u0001FH;I;D9;\u0001E<\u00017\u0001\nD?JHE\u0001IK8IJ?JK;DJ\u00017J\u0001J>;\u0001I?N\u0001FEI?J?ED\u0001E<\u00019EKC7H?D\u0001CE?;JO\u0001\u00039ECFE KD:I\u0001\nc\u0010\u0004\u0001?I\u0001CEH;\u00018;D;<?9?7B\u0001J>7D\u0001?JI\u0001\nFH;I;D9;\u0001EDBO\u00017J\u00010)6% \u0001EH\u00013%4%\u0001FEI?J?EDI\u0001E<\u0001J>;\u0001\r\u00077HOB\u0001H?D=\u0001\u00039ECFEKD:I\u0001 \u0011c\n\t\u0004\b\u0001\u0001\n\u001dECFEKD:I\u0001M?J>\u0001D?JHE\u0001IK8IJ?JK;DJI\u0001;?J>;H\u0001?D\u0001J>;\u00019EKC7H?D\u0001CE?;JO \u00017D:\u0001?D\u0001J>;\u00017HOB\u0001=HEKF\u0001\u00039ECFEKD:I\u0001\n\n\u00017D:\u0001\r\u0004\u00017H;\u0001DEJ\u00018;JJ;H\u0001J>7D\u00019ECFEKD:I\u0001M>;H;\u0001J>;\u0001D?JHE\u0001?D\u0001J>;\u00017HOB\u0001H?D =\u0001?I\u0001IK8IJ?JKJ;:\u0001<EH\u00017\u0001C;J>OB\u0001EH\u00017\u0001\nC;J>ENO\u0001=HEKF\u0001\u00039ECFEKD:I\u0001 \u000b\u00017D:\u0001\f\u00019ECF7H;:\u0001JE\u00019ECFEKD:\u0001 \n\u0006\u00017D:\u00019ECFEKD:I\u0001 \u000e\u00017D:\u0001\u000f\u00019ECF7H;:\u0001JE\u0001\n9ECFEKD:\u0001\r\u0004\b\u0001\"EM;L;H\u0006\u00019ECFEKD:\u0001 \r\u0001\u0003'#\u001d\u0001\u0017\u0001\r\f\u0001b=\tC&\u0004\u0006\u0001M?J>\u0001J>;\u0001D?JHE\u0001IK8IJ?JK;DJ\u0001?D\u0001 0)6%\u0001FEI?J?ED\u0001E<\u0001\nJ>;\u0001\r\u00077HOB\u0001H?D=\u0006\u0001?I\u00018;JJ;H\u0001J>7D\u00019ECFEKD:\u0001 \n\u0001\u0003'#\u001d\u0001\u0017\u0001\u000b\f\u0012\u0001b=\tC&\u0004\u0006\u0001M?J>\u0001J>;\u0001I7C;\u0001IK8IJ?JK;DJ\u0001?D\u0001 3%4%\u0001\nFEI?J?ED\b\u0001.>;\u0001FH;I;D9;\u0001E<\u00017\u0001C;J>OB\u0001=HEKF\u0001?D\u0001J>;\u0001 0)6%\u0001FEI?J?ED\u0001?I\u0001J>;\u00018;IJ\u0001IK8IJ?JKJ?ED\u0001M>;D\u0001ED;\u0001D?JHE\u0001\nIK8IJ?JK;DJ\u0001?I\u0001FH;I;DJ\u00017J\u0001I?N\u0001FEI?J?ED\u0001E<\u0001J>;\u00019EKC7H?D\u0001CE?;JO\u0001\u0003 9ECFEKD:\u0001\u000f\u0006\u0001'#\u001d\u0001\u0017\u0001\u0012\u0001b=\tC&\u0004\b\u0001#D\u0001\n=;D;H7B\u0006\u00010)6%\u0001IK8IJ?JKJ?EDI\u00017H;\u0001CEH;\u0001<7LEKH78B;\u0001J>7D\u0001 3%4%\u0006\u00018;?D=\u0001J>;\u0001 0)6%\u0007C;J>OB\u0001IK8IJ?JK;DJ\u0001J>;\u0001CEIJ\u0001\n79J?L;\u0006\u0001<EBBEM;:\u00018O\u0001 0)6%\u0007D?JHE\u00017D:\u0001<?D7BBO\u0001 0)6%\u0007C;J>ENO\b\u0001.>;H;\u0001?I\u0001ED;\u0001;N9;FJ?ED\u0001JE\u0001J>?I\u00019ED9BKI?ED\b\u0001\n.>;\u0001?DJHE:K9J?ED\u0001E<\u00017\u00018HECE\u00017JEC\u00017J\u0001J>;\u0001I7C;\u0001FEI?J?ED\u0001M7I\u0001J>;\u0001M EHIJ\u0001IK8IJ?JKJ?ED\u0001E<\u0001J>;\u0001IJK:?;:\u0001\u0001\n\r\u00077HOB\u0007\u0010\u0007D?JHE9EKC7H?DI\u0001\u00039ECFEKD:\u0001 \u0010\u0006\u0001'#\u001d\u0001\u0017\u0001\f\u000f\u0010\u0001b=\tC&\u0004\b\u0001\u001b\u0001 3%4%\u0007C;J>OB\u0001IK8IJ?JK;DJ\u0001?D\u0001J>;\u0001\r\u00077HOB\u0001\nH?D=\u0001\u00039ECFEKD:\u0001 \f\u0006\u0001'#\u001d\u0001\u0017\u0001\r\f\u0001b=\tC&\u0004\u0001?I\u0001J>;\u00018;IJ\u0001IK8IJ?JKJ?ED\u0001?D\u0001J>?I\u0001 3%4%\u0001 FEI?J?ED\b\u0001.>;H;<EH;\u0006\u0001J>;\u0001 \u0001\n3%4%\u0007C;J>OB\u0001IK8IJ?JKJ?ED\u0001?I\u00018;JJ;H\u0001J>7D\u0001J>;\u0001 3%4%\u0007D?JHE\u00017D:\u0001 3%4%\u0007C;J>ENO\u0001IK8IJ?JKJ?EDI\b\u0001\u001dECF7H?D=\u0001J>;\u0001\nJME\u0001FEI?J?EDI\u0001?D\u0001J>;\u0001\r\u00077HOB\u0001H?D=\u0006\u0001J>;\u0001IK8IJ?JKJ?EDI\u00018O\u0001C;J>OB\u0001= HEKFI\u00017H;\u0001CEH;\u0001<7LEKH78B;\u0001<EH\u0001J>;\u0001:;I?H;:\u0001\n79J?L?JO\b\u0001.>;\u0001IK8IJ?JKJ?ED\u0001E<\u0001D?JHE\u00018O\u00017C?DE\u0001=HEKFI\u0001I?=D?<?97DJBO\u0001:;9H;7I;I\u0001J>;\u000179J?L?JO\u0001E<\u0001J>;\u0001:;I9H?8;:\u0001\n9ECFEKD:I\u0001\u00039ECF7H?D=\u00019ECFEKD:I\u0001 \r\u00017D:\u0001\n\n\u0004\b\u0001\n#D\u0001EH:;H\u0001JE\u0001;L7BK7J;\u0001?<\u0001J>;H;\u0001M7I\u00017\u00019EHH;B7J?ED\u00018;JM;;D\u0001J>;\u000179J ?L?JO\u00017D:\u0001J>;\u0001B?FEF>?B?9?JO\u0006\u00017D:\u0001JE\u00018;JJ;H\u0001\nKD:;HIJ7D:\u0001 J>;\u0001 EL;H7BB\u0001 FHEF;HJ?;I\u0001 E<\u0001 J>;\u0001 :;I9H?8;:\u0001 9ECFEKD:I\u0006\u0001 B E=*\u0001 \u0003E9J7DEB\tM7J;H\u0001 F7HJ?J?ED\u0001\n9E;<<?9?;DJ\u0004\u0001L7BK;I\u0001M;H;\u000197B9KB7J;:\u0001KI?D=\u0001J>;\u0001'EB?DIF?H7J?ED\u0001FHEF;HJO\u000197B9KB7J?ED\u0001FHE=H7C\u00015\r\u00116\b\u0001.>;\u0001H;IKBJI\u00017H;\u0001FH;I;DJ;:\u0001?D\u0001.78B;\u0001\f\b\u0001\n$()2,\u0001\u000b\u0007\u0001&E=*\u0001\u0003E9J7DEB\tM7J;H\u0001F7HJ?J?ED\u00019E;<<?9?;DJ\u0004\u0001L7BK;I\u000197B9KB7J;:\u0001< EH\u0001J>;\u00017C?DE\tD?JHE\u0001\nIK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\u0001\nc\n\n\u0001\n7\b\u0001\n\u00165365;4+9\u0001 \u001d5.!\u0001\n\u000b\u0001 \r\u0006\u0010\r\u000b\u0001\n\f\u0001 \r\u0006\u0011\f\u0013\u0001\n\r\u0001 \u000e\u0006\u000b\f\n\u0001\n\u000e\u0001 \r\u0006\u0010\n\u0011\u0001\n\u000f\u0001 \r\u0006\u0011\n\u000f\u0001\n\u0010\u0001 \u000e\u0006\n\u0013\u0010\u0001\n\u0011\u0001 \u000e\u0006\u000e\u000f\u0011\u0001\n\u0012\u0001 \r\u0006\u0011\f\u0013\u0001\n\u0013\u0001 \r\u0006\u0011\n\u000f\u0001\n\u000b\n\u0001 \u000e\u0006\u000b\f\n\u0001\n\u000b\u000b\u0001 \u000b\u0006\u0012\u000e\u000b\u0001\n7\u0001.>;\u0001:7J7\u0001M7I\u0001:;J;HC?D;:\u0001M?J>\u0001'EB?DIF?H7J?ED\u000197B9KB7J?ED\u0001IE<JM7H;\u00015\r\u00116\b\u0001\n\u0019\u0017\u001c205\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\f\u0012\u0012\u0001\n\u0001\n\u0001\u001bD7BOI?D=\u0001J>;\u0001E8J7?D;:\u0001:7J7\u0006\u0001?J\u000197D\u00018;\u00019ED9BK:;:\u0001J>7J\u0001J>;H;\u00017H; \u0001DE\u0001B?D;7H\u00019EHH;B7J?EDI\u00018;JM;;D\u0001J>;\u0001\nB?FEF>?B?9?JO\u00017D:\u0001J>;\u000179J?L?JO\u0001E<\u0001J>;\u00019ECFEKD:I\b\u0001\u001dECFEKD:I\u0001 \u000e\u00017D:\u0001\u000f\u00017H;\u0001JME\u0001E<\u0001J>;\u00018;IJ\u00019ECFEKD:I\u0001\n7=7?DIJ\u0001#\u0006\u0001%74)75\u0006\u0001FH;I;DJ?D=\u0001?DJ;HC;:?7J;\u0006\u00018KJ\u0001:?<<;H;DJ\u0006\u0001BE=*\u0001L7BK;I\u0001\u0003\r\b\u0011\n\u000f\u00017D:\u0001\u000e\b\n\u0013\u0010\u0001H;IF;9J?L;BO\u0004\b\u0001\n.>;\u00019ECFEKD:I\u0001M?J>\u0001J>;\u0001BEM;IJ\u0001\u00039ECFEKD:\u0001 \n\n\u0006\u0001\u000b\b\u0012\u000e\u000b\u0004\u00017D:\u0001J>;\u0001>?=>;IJ\u0001\u00039ECFEKD:\u0001 \u0010\u0006\u0001\u000e\b\u000e\u000f\u0011\u0004\u0001BE=*\u0001\nFH;I;DJ;:\u000179J?L?JO\b\u0001\u001dECFEKD:\u0001 \u0012\u0006\u0001M?J>\u0001J>;\u0001I7C;\u0001BE=*\u00017I\u00019ECFEKD:\u0001 \u000e\u0006\u0001H;IKBJ;:\u0001JE\u00018;\u0001?D79J?L;\b\u0001\u001bBIE\u0006\u0001\n9ECFEKD:\u0001\n\t\u0006\u0001M?J>\u0001J>;\u0001I7C;\u0001B?FEF>?B?9?JO\u0001FHE<?B;\u00017I\u00019ECFEKD:\u0001 \f\u0001\u0003BE=*\u0001\u0017\u0001\u000e\b\u000b\f\u0004\u0006\u0001H;IKBJ;:\u0001JE\u00018;\u0001?D79J?L;\b\u0001\n.>;H;<EH;\u0006\u0001J>;H;\u00017H;\u0001DE\u00019B;7H\u00019EHH;B7J?ED\u00018;JM;;D\u000179J?L?JO\u00017D:\u0001BE=*\u0001L7BK;I\b\u0001#J\u0001?I\u0001?CFEHJ7DJ\u0001JE\u0001>?=>B?=>J\u0001\nJ>7J\u0001J>;\u000197B9KB7J;:\u0001BE=*\u0001L7BK;I\u0001<EH\u00017BB\u0001J>;\u0001:;I9H?8;:\u00019ECFEKD:I \u00017H;\u0001BEM;H\u0001J>7D\u0001\u000f\b\u0001\n\f\u0007\u0001\u0018>6,803,4:(2\u0001\n\u000b\u0006\t\u0006\u0001\u0016,)0-564;\u0001\n';H9A\u0001IKFFB?;:\u0001J>;\u0001;DJ?H;\u00019>;C?97BI\u0001KI;:\u0001?D\u0001J>;\u0001IODJ>;I?I\b\u0001';BJ ?D=\u0001FE?DJI\u0001\u0003CF\u0004\u00017H;\u0001KD9EHH;9J;:\u0001\nM;H;\u0001:;J;HC?D;:\u0001KI?D=\u00017\u0001,;?9>;HJ\u0001%E<B;H\u0001J>;HCEF7D\u0001EH\u0001?D\u000197F?BB7 HO\u0001JK8;I\u0001ED\u00017\u0001\u001c\\9>?\u0001\u000f\u000b\n\u00017FF7H7JKI\u00017D:\u0001\n7H;\u0001KD9EHH;9J;:\b\u0001\u000b\"\u0007(',\u0001\u0003\r\n\n\u0001'\"P\u0004\u00017D:\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u0011\u000f\b\u000e\u0001'\"P\u0004\u0001IF;9JH7\u0001M;H;\u0001H;9EH:;:\u0001M?J>\u00017\u0001\u001cHKA;H\u0001\n\u001b'2\u0001IF;9JHEC;J;H\b\u0001\u001d>;C?97B\u0001I>?<JI\u0001\u0003 \u012f\u0004\u00017H;\u0001;NFH;II;:\u0001?D\u0001F7HJI\u0001F;H\u0001C?BB?ED\u0001\u0003FFC\u0004\u0001KI?D=\u0001.'-\u00017I\u00017D\u0001\n?DJ;HD7B\u0001IJ7D:7H:\b\u0001-F?D\u0001CKBJ?FB?9?J?;I\u00017H;\u0001=?L;D\u00017I\u0001I\u0001\u0003I?D=B;J\u0004 \u0006\u0001:\u0001\u0003:EK8B;J\u0004\u0006\u0001::\u0001\u0003:EK8B;J\u0001E<\u0001:EK8B;JI\u0004\u00017D:\u0001\nC\u0001\u0003CKBJ?FB;J\u0004\b\u0001'7II\u0001IF;9JHEC;JHO\u0001M7I\u000197HH?;:\u0001EKJ\u0001 M?J>\u0001 7\u0001 %H7JEI\u0001 '-\u0007\u000f\n\u0001 EH\u0001 7\u0001 07H?7D\u0001 '\u001b.\u0007\u0011\u000b\u000b\u0001\nIF;9JHEC;J;H\b\u0001\u001fB;C;DJ7B\u00017D7BOI;I\u0001M;H;\u0001F;H<EHC;:\u00018O\u00017\u0001*;HA?D\u0007\u001fBC;H\u0001\f\u000e\n\u001c\u0001C?9HE7D7BOP;H\u00017D:\u0001M;H;\u0001\nM?J>?D\u0001 a\n\b\u000e\u0002\u0001 E<\u0001 97B9KB7J;:\u0001 L7BK;I\u0001 ?D\u0001 7BB\u0001 97I;I\b\u0001  B7I>\u0001 \u001d>HEC7JE= H7F>O\u0001 \u0003 \u001d\u0004\u0001 M7I\u0001 F;H<EHC;:\u0001 ED\u0001\u0001\nI?B?97\u0001=;B\u0001\u0003';H9A\u0001\u0010\n\u0006\u0001\f\r\nc\u000e\n\n\u0001C;I>\u0004\u0015\u00017D7BOJ?97B\u0001.&\u001d\u0001M7I\u0001F;H<EHC ;:\u0001ED\u0001FH;9E7J;:\u0001I?B?97\u0001=;B\u0001FB7J;I\u0001\n\u0003';H9A\u0001\u0010\n\u0001 \f\u000f\u000e\u0004\b\u0001\n!;D;H7B\u0001*HE9;:KH;\u0001<EH\u0001J>;\u0001FH;F7H7J?ED\u0001E<\u0001\r\u00077HOB9EKC7H?DI\u0001 \nc\n\t\b\u0001#D\u00017\u0001\f\n\u0001C&\u0001:HO\u0001-9>B;DA\u0001JK8;\u0006\u0001JE\u00017\u0001\nIEBKJ?ED\u0001E<\u0001J>;\u00019EDL;D?;DJBO\u0001IK8IJ?JKJ;:\u0001I7B?9OB7B:;>O:;\u0001\u0003\f\b\u000e\u0010\u0001 CCEB\u0004\u00017D:\u0001J>;\u00017HOB79;J?9\u000179?:\u0001\u0003\f\b\u000e\u0010\u0001CCEB\u0004\u0006\u0001\n?D\u000179;J?9\u00017D>O:H?:;\u0001\u0003\u0010\u0001C&\u0004\u0006\u0001(7\"\u0001\u0003\f\b\u000e\u0010\u0001CCEB\u0004\u0001M7I\u00017::;:\u0001?D\u0001IC7BB\u0001FEHJ?EDI\u0006\u00017D:\u0001J>;\u0001H;79J?ED\u0001C?NJKH;\u0001\nM7I\u0001IJ?HH;:\u0001<EH\u0001\r\u0001>EKHI\u0006\u00017J\u0001HEEC\u0001J;CF;H7JKH;\b\u0001.>;\u0001E8J7?D;:\u00019HK:;\u0001M7I\u0001<?BJ;H;:\u00017D:\u0001M7I>;:\u0001M?J>\u0001:?;J>OB\u0001\n;J>;H\b\u0001.>;\u0001IEB?:\u0001M7I\u0001J>;D\u0001FKH?<?;:\u00018O\u0001<B7I>\u00019>HEC7JE=H7F>O\u0001\u0003>;N7D;\t;J>OB\u000179;J7J;\u0001\u0013\u0014\u000b\u0004\u0001JE\u0001=?L;\u0001J>;\u0001\n:;I?H;:\u00019EKC7H?DI\u0001 \nc\n\t\b\u0001\u0001\n\u000b\u0005\u0002\f\u018d\u0005\u001e)6,2:;3,)1;/\u0003\u0005\u000e\u00051-642'270%4-1 \u0001\u0003\u000b\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0011\u000f\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\u0010\fc\u0010\r\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\r\b\u0012\n\u0001\u0003I\u0006\u0001\r\"\u0006\u0001)\u001d\" \r\u0004\u0006\u0001\u0011\b\n\u000f\u0001\u0003:\u0006\u0001\f\"\u0006\u0001\"\u0007\r \u018d\u0006\u0001\"\u0007\u000f\u018d\u0006\u0001\u001c\u0001\u0017\u0001\u0013\b\u000e\u000f\u0001\"P\u0004\u0006\u0001\u0011\b\u0010\fc\u0011\b\u0010\u0013\u0001\u0003C\u0006\u0001\r\"\u0006\u0001\"\u0007\f \u018d\u0006\u0001\"\u0007\u0010\u018d\u0006\u0001\n\"\u0007\u0012\u0004\u0006\u0001\u0012\b\r\u0010\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\u0006\u0001\u0012\b\u0011\r\u0001\u0003:\u0006\u0001\f\"\u0006\u0001\"\u0007\u000f\u0006\u0001\"\u0007\u0011\u0006\u0001 \u001c\u0001\u0017\u0001\f\b\u0013\r\u0001\"P\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000f\u000f\b\u0013\u0006\u0001\u000b\u000b\u0010\b\u000e\u0006\u0001\n\u000b\u000b\u0013\b\u0011\u0006\u0001\u000b\f\u0011\b\u0013\u0006\u0001\u000b\f\u0012\b\u000e\u0006\u0001\u000b\f\u0012\b\u0010\u0006\u0001\u000b\f\u0013\b\f\u0006\u0001\u000b\r\f\b\f\u0006\u0001\u000b\r\f\b\u000f\u0006\u0001\u000b\r\u000e\b\r\u0006\u0001\u000b\r\u0013\b\u000b\u0006\u0001\u000b\r\u0013\b\u000e\u0006\u0001\u000b\u000f\u000b\b\u000f\u0006\u0001\u000b\u000f\u000f\b\u0012\u0006\u0001\u000b\u0010\u000b\b\f\b\u0001\u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001\n\f\u0013\u0011\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u0010\"\u000b\u000b()\u000f\u0014\u0001\u001d\u0006\u0001\u0010\u000e\b\u0010\u000f\u0015\u0001\"\u0006\u0001\r\b\u0011\r\u0015\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u0010\u000e\b\u0010\u0011\u0015\u0001\"\u0006\u0001\r\b\u0011\u0010\b\u0001\n\u000b\u0005\u0002\u000b\u018d\u0005\u001f-6423,)1;/\u0003\u0005\u000e\u00051-642'270%4-1 \u0001\u0003\r\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0010\u0013\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\u0012\u0011c\u0012\u0012\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\n\u0003FFC\u0004\u0014\u0001\u0011\b\u000f\u0011c\u0011\b\u0010\r\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\u0012\u0006\u0001\"\u0007\u0010 \u018d\u0004\u0006\u0001\u0011\b\u0011\u000bc\u0011\b\u0011\u0011\u0001\u0003C\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000f \u018d\u0004\u0006\u0001\u0012\b\u000b\u000f\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\u0006\u0001\u0012\b\u000e\f\u0007\u0012\b\u0010\r\u0001\u0003C\u0006\u0001\u000e\"\u0006\u0001\u0001\n\"\u0007\u000e\u018d\u0006\u0001\"\u0007\f\u0006\u0001\"\u0007\u000f\u0006\u0001\"\u0007\u0011\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000b\u000b\u0012\b\u000b\u0006\u0001\u000b\f\n\b\f\u0006\u0001\u000b\f\r\b\u000b\u0006\u0001\u000b\f\r\b\r\u0006\u0001\u000b\f\u000e\b\r\b\u0001\u000b\f\u000e\b\u000f\u0006\u0001\u000b\f\u000e\b\u0011\u0006\u0001\n\u000b\f\u0013\b\u000e\u0006\u0001\u000b\r\r\b\u0010\u0006\u0001\u000b\r\u000f\b\u000b\u0006\u0001\u000b\u000e\u000b\b\f\u0006\u0001\u000b\u000e\u000e\b\u0010\u0006\u0001\u000b\u000e\u0011\b\u0013\u0006\u0001\u000b\u000f\u0013\b\f\u0006\u0001\u000b\u0010\n\b\u000f\b\u0001\u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001\r\u000b\f\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\n\u001d\u000b\u000f\"\u0012(\f)\u0010\u0014\u0001\u001d\u0006\u0001\u000f\n\b\u0011\n\u0015\u0001\"\u0006\u0001\f\b\u000f\u0012\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u000f\n\b\u0011\f\u0015\u0001\"\u0006\u0001\f\b\u0010\n\b\u0001\n\u0019\u0017\u001d206\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\r\t\t\u0001\n\u0001\n\u0001\u000b\u0005\u0002\u000b\u018d\u0005\u001e)6,2:;3,)1;/\u0003\u0005\u000e\u00051-642'270%4-1 \u0001\u0003\u000e\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0011\u000b\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\u000f\rc\u000f\u000e\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\r\b\u0011\u000b\u0001\u0003I\u0006\u0001\r\"\u0006\u0001)\u001d\" \r\u0004\u0006\u0001\u0010\b\u0012\n\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\f \u018d\u0004\u0006\u0001\u0011\b\u000b\u0011c\u0011\b\f\f\u0001\u0003C\u0006\u0001\r\"\u0006\u0001\"\u0007\u000e \u018d\u0006\u0001\"\u0007\u000f\u018d\u0006\u0001\"\u0007\u0010\u018d\u0004\u0006\u0001\u0011\b\u000f\u0011\u0001\u0003:\u0006\u0001\n\u000b\"\u0006\u0001\"\u0007\u0012\u0006\u0001\u001c\u0001\u0017\u0001\u0010\b\u000f\u0001\"P\u0004\u0006\u0001\u0011\b\u0011\u0011\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000f\u0004\u0006\u0001\u0012\b\u000b\u0013\u0001\u0003:\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u0011\u0006\u0001 \u001c\u0001\u0017\u0001\u0010\b\u000f\u0001\"P\u0004\u0006\u0001\u0012\b\r\u0013\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000f\u000f\b\u000e\u0006\u0001\u0012\u000e\b\u000f\u0006\u0001\u000b\u000b\f\b\u000e\u0006\u0001\u000b\u000b\u000f\b\u000f\u0006\u0001\u000b\f\f\b\n\u0006\u0001\u000b\f\r\b\u000f\u0006\u0001\u000b\f\u000f\b\u0012\u0006\u0001\u000b\f\u0010\b\u0012\u0006\u0001\u000b\f\u0013\b\u000f\u0006\u0001\u000b\f\u0013\b\u0011\u0006\u0001\u000b\r\u0010\b\u0013\u0006\u0001\u000b\u000e\u000f\b\u0011\u0006\u0001\n\u000b\u000f\r\b\f\u0006\u0001\u000b\u000f\u0013\b\u0010\u0006\u0001\u000b\u0010\u0012\b\u0011\u0006\u0001\u000b\u0011\r\b\n\b\u0001\u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001\f\u0013\u0011\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u0010\"\u000b\u000b()\u000f\u0014\u0001\u001d\u0006\u0001\u0010\u000e\b\u0010\u000f\u0015\u0001\"\u0006\u0001\n\r\b\u0011\r\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u0010\u000e\b\u0010\r\u0015\u0001\"\u0006\u0001\r\b\u0011\n\b\u0001\n\u000b\u0005\u0002\u000b\u018d\u0005\u001e)6,;/3,)1;/\u0003\u0005\u000e\u00051-642'270%4-1 \u0001\u0003\u000f\u0004\b\u0001 *7B;\u0001 O;BBEM\u0001 IEB?:\u0006\u0001 \u0010\u0013\u0002\u0001 O?;B:\b\u0001 'F\u0014\u0001 \u000f\u000fc\u000f\u0010\u0001 ]\u001d\b\u0001\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\f\b\f\u000f\u0001\u0003I\u0006\u0001\r\"\u0006\u0001\u001d\" \r\u0004\u0006\u0001\u0010\b\u0013\nc\u0011\b\r\n\u0001\u0003C\u0006\u0001\u000f\"\u0006\u0001\"\u0007\f \u018d\u0006\u0001\"\u0007\u000e\u018d\u0006\u0001\"\u0007\u000f\u018d\u0006\u0001\"\u0007\u0010\u018d\u0006\u0001\"\u0007\u0012\u0004\u0006\u0001\u0011\b\u0011\u000f\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\u0006\u0001\n\u0012\b\u000e\u000e\u0001\u0003:\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u0011\u0006\u0001 \u001c\u0001\u0017\u0001\f\b\u0012\u0001\"P\u0004\u0006\u0001\u0012\b\u0010\f\u0001\u0003:\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000f\u0006\u0001 \u001c\u0001\u0017\u0001\f\b\u0012\u0001\"P\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\f\u000b\b\u000f\u0006\u0001\u000b\u000b\u0012\b\u000e\u0006\u0001\n\u000b\f\r\b\r\u0006\u0001\u000b\f\u000e\b\u000f\u0006\u0001\u000b\f\u000e\b\u0010\u0006\u0001\u000b\f\u000e\b\u0012\u0006\u0001\u000b\f\u000f\b\u0013\u0006\u0001\u000b\f\u0010\b\u0010\u0006\u0001\u000b\f\u0012\b\r\u0006\u0001\u000b\f\u0012\b\u000f\u0006\u0001\u000b\r\f\b\u0011\u0006\u0001 \u000b\r\u0012\b\u000e\u0006\u0001\u000b\u000e\u000b\b\u000b\u0006\u0001\u000b\u000e\u000e\b\u0010\u0006\u0001\u000b\u000f\u0013\b\r\u0006\u0001\u000b\u0010\n\b\u0013\b\u0001\u0001\n\u001f-#\u0007'-\u00010\u0007<\u0014\u0001\f\u0012\u000b\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u0010\"\u000b\u000b()\u000e\u0014\u0001\u001d\u0006\u0001\u0010\u0012\b\r\f\u0015\u0001\"\u0006\u0001\r\b\u0013\u000e\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u0010\u0012\b\r\u000b\u0015\u0001\"\u0006\u0001\r\b\u0013\f\b\u0001\n\u000b\u0005\u0002\u000b\u018d\u0005\u001542023,)1;/\u0003\u0005\u000e\u00051-642'270%4-1 \u0001\u0003\u0010\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0010\n\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\f\u000e\nc\f\u000e\u000b\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u0011\b\u000b\fc\u0011\b\f\u0010\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\u000e \u018d\u0006\u0001\"\u0007\u000f\u018d\u0004\u0006\u0001\u0011\b\u000e\u0010c\u0011\b\u0011\u000b\u0001\u0003C\u0006\u0001\u000f\"\u0006\u0001\"\u0007\f \u018d\u0006\u0001\"\u0007\u0010\u018d\u0006\u0001\"\u0007\u000f\u0006\u0001\"\u0007\u0011\u0006\u0001\"\u0007\u0012\u0004\u0006\u0001\u0011\b\u0011\u0012\u0001\u0001\n\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000b\u000b\u0011\b\u0013\u0006\u0001\u000b\f\f\b\u0011\u0006\u0001 \u000b\f\r\b\u000b\u0006\u0001\u000b\f\u000e\b\u000f\u0006\u0001\u000b\f\u000e\b\u0010\u0006\u0001\u000b\f\u000e\b\u0012\u0006\u0001\u000b\f\u0011\b\u0013\u0006\u0001\u000b\f\u0013\b\u000f\u0006 \u0001\u000b\f\u0013\b\u0011\u0006\u0001\n\u000b\r\n\b\u0012\u0006\u0001\u000b\r\u000e\b\u0010\u0006\u0001\u000b\u000e\n\b\u0011\u0006\u0001\u000b\u000e\u000e\b\u0010\u0006\u0001\u000b\u000f\u0013\b\u000b\u0006\u0001\u000b\u0010\u000b\b\u000b\b\u0001\u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001\r\u000e\u000f\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u000f\"\u0012\u001cH()\u000e\u0014\u0001\n\u001d\u0006\u0001\u000f\f\b\n\u000f\u0015\u0001\"\u0006\u0001\f\b\r\r\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u000f\f\b\n\u000b\u0015\u0001\"\u0006\u0001\f\b\r\n\b\u0001\u0001\u000e\u0005\u001e)6,2:;\u0005\u000b\u0005\u0002\u000b \u018d\u00051-6423,)1;/\u0003'270%4-1 \u0001\u0003\u0012\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0011\r\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\u0012\u000ec\u0012\u000f\u0001]\u001d\b\u0001\n\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\r\b\u0011\u0011\u0001\u0003I\u0006\u0001\r\"\u0006\u0001)\u001d\" \r\u0004\u0006\u0001\u0011\b\n\u000bc\u0011\b\u000b\n\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\u000f\u0006\u0001\"\u0007\u0011\u0004\u0006\u0001\u0011\b\u000f\u000ec\u0011\b\u000f\u0013\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\u000f \u018d\u0006\u0001\"\u0007\u0010\u018d\u0004\u0006\u0001\n\u0011\b\u0011\u000b\u0001\u0003:\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u0012\u0006\u0001 \u001c\u0001\u0017\u0001\u0011\b\u0010\u0001\"P\u0004\u0006\u0001\u0012\b\n\u0010c\u0012\b\n\u0013\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\f \u018d\u0006\u0001\"\u0007\u000e\u018d\u0004\u0006\u0001\u0012\b\u000b\u000f\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\n\u0003FFC\u0004\u0014\u0001\u000f\u0010\b\u0011\u0006\u0001\u000b\u000b\u000f\b\n\u0006\u0001\u000b\u000b\u0010\b\u0012\u0006\u0001\u000b\f\f\b\r\u0006\u0001\u000b\f\u000e\b\u0013\u0006\u0001\u000b\f\u0012\b\u0011\u0006\u0001\u000b\r\n\b\f\u0006\u0001\u000b\r\u000e\b\f\u0006\u0001\u000b\r\u000f\b\u000f\u0006\u0001\u000b\r\u0011\b\f\u0006\u0001\u000b\r\u0012\b\n\u0006\u0001\u000b\u000e\r\b\r\u0006\u0001\u000b\u000e\u0012\b\r\u0006\u0001\u000b\u000f\u0010\b\u0012\u0006\u0001\n\u000b\u0010\u0011\b\u0011\u0006\u0001\u000b\u0011\f\b\u0011\b\u0001\u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001\f\u0013\u0011\u0001\u0003'\u0005\u0006\u0001\u000b\n\n\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u0010\"\u000b\u000b()\u000f\u0014\u0001\u001d\u0006\u0001\u0010\u000e\b\u0010\u000f\u0015\u0001\"\u0006\u0001\r\b\u0011\r\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\n\u0010\u000e\b\u0010\r\u0015\u0001\"\u0006\u0001\r\b\u0011\n\b\u0001\n\u000e\u0005\u001e)6,;/\u0005\u000b\u0005\u0002\f \u018d\u00051-6423,)1;/\u0003'270%4-1 \u0001\u0003\n\t\u0004\b\u0001*7B;\u0001O;BBEM\u0001IEB?:\u0006\u0001\u0011\u000f\u0002\u0001O?;B:\b\u0001'F\u0014\u0001\u000b\n\nc\u000b\n\u000b\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\n\u0003\u001d\u001e\u001dB\r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\f\b\r\u0010\u0001\u0003I\u0006\u0001\r\"\u0006\u0001\u001d\" \r\u0004\u0006\u0001\u0011\b\f\u000b\u0001\u0003:\u0006\u0001\f\"\u0006\u0001\"\u0007\u0011\u0006\u0001\"\u0007\u0012\u0006\u0001 \u001c\u0001\u0017\u0001\u0012\b\f\u0001\"P\u0004\u0006\u0001\u0011\b\r\u0012\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000f\u0004\u0006\u0001\u0011\b\u0010\rc\u0011\b\u0011\n\u0001\u0001\n\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\f \u018d\u0006\u0001\"\u0007\u0010\u018d\u0004\u0006\u0001\u0011\b\u0013\u0013c\u0012\b\f\n\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\r \u018d\u0006\u0001\"\u0007\u000f\u018d\u0004\u0006\u0001\u0012\b\r\u0012\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\n\f\n\b\u0010\u0006\u0001\u000b\f\f\b\u0010\u0006\u0001\u000b\f\r\b\u0013\u0006\u0001\u000b\f\u000f\b\u000b\u0006\u0001\u000b\f\u0011\b\u0013\u0006\u0001\u000b\r\n\b\f\u0006\u0001\u000b\r\u000b\b\u000e\u0006\u0001\u000b\r\u0010\b\u000e\u0006\u0001\u000b\r\u0010\b\u0010\u0006\u0001\u000b\r\u0010\b\u0012\u0006\u0001\u000b\r\u0011\b\f\u0006\u0001\u000b\u000e\u0012\b\u000b\u0006\u0001\u000b\u000e\u0013\b\r\u0006\u0001\u000b\u0011\n\b\f\u0006\u0001\u000b\u0013\n\b\u0010\b\u0001\n\u001f-#\u0007'-\u00010\u0007<\u0014\u0001\f\u0012\u000b\u0001\u0003'\u0005\u0006\u0001\u0013\u0012\u0004\b\u0001\u001bD7B\b\u0001\u001d7B9:\b\u0001<EH\u0001\u001d \u000b\u0010\"\u000b\u000b()\u000e\u0014\u0001\u001d\u0006\u0001\u0010\u0012\b\r\f\u0015\u0001\"\u0006\u0001\r\b\u0013\u000e\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u0010\u0012\b\r\u0012\u0015\u0001\"\u0006\u0001\r\b\u0013\u0013\b\u0001\u0001\n*HE9;:KH;\u0001<EH\u0001J>;\u0001*H;F7H7J?ED\u0001E<\u0001\r\u0007\u0003\r \u018d\u0007\u001bC?DEF>;DOB\u0004\u0007\u0010\u0007\u001bC?DE9EKC7H?D\u0001\u0003 \n\n\u0004\u0001\n.>;\u0001 FH;L?EKIBO\u0001 FH;F7H;:\u0001 \r\u0007\u0003\r \u018d\u0007D?JHEF>;DOB\u0004\u0007\u0010\u0007D?JHE9EKC7H?D\u0001 \u0003 \r\u0006\u0001 \f\b\u000e\u0010\u0001 CCEB\u0004\u0001 M7I\u0001 :?IIEBL;:\u0001 ?D\u0001\n;J>7DEB\u0001\u0003\u000f\u0001C&\u0004\u00017D:\u00017\u000197J7BOJ?9\u00017CEKDJ\u0001E<\u0001*:\t\u001d\u0001M7I\u00017::;:\u0001JE\u0001J>;\u0001 C?NJKH;\b\u0001.>;\u0001IEBKJ?ED\u0001M7I\u0001IJ?HH;:\u0006\u00017J\u0001\nHEEC\u0001J;CF;H7JKH;\u0006\u0001KD:;H\u00017\u0001\" \f\u00017JCEIF>;H;\u0006\u0001<EH\u0001\r\u0001>\b\u0001\u001b<J;H\u00019ECFB;J?ED\u0001E<\u0001J>;\u0001H;79J?ED\u0006\u0001J>;\u0001C?NJKH;\u0001M7I\u0001\n<?BJ;H;:\u0001JE\u0001;B?C?D7J;\u0001J>;\u000197J7BOIJ\b\u0001.>;\u0001E8J7?D;:\u00019HK:;\u0001M7I\u0001J>;D \u0001FKH?<?;:\u00018O\u0001<B7I>\u00019>HEC7JE=H7F>O\u0001\n\u0003>;N7D;\t;J>OB\u0001 79;J7J;\u0001 \u0013\u0014\u000b\u0004\u0001 JE\u0001 =?L;\u0001 J>;\u0001 :;I?H;:\u0001 9EKC7H?D\u0001 \n\n\u0001 7I\u0001 7\u0001 M>?J;\u0001 IEB?:\u0001 ?D\u0001 \u0012\n\u0002\u0001 O?;B:\b\u0001 'F\u0014\u0001\u0001\n\u000b\n\u000fc\u000b\n\u0010\u0001]\u001d\b\u0001\u000b\"\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000e\b\n\f\u0001\u0003I\u0006\u0001\f\"\u0006\u0001(\" \f\u0004\u0006\u0001\u0010\b\u000f\nc\u0010\b\u000f\u000f\u0001\u0003C\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e \u018d\u0004\u0001\u0010\b\u000f\u0010\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\f \u018d\u0004\u0006\u0001\u0001\n\u0010\b\u0010\u0013c\u0010\b\u0011\r\u0001\u0003C\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u0010\u018d \u0004\u0001\u0010\b\u0012\n\u0001\u0003::\u0006\u0001\f\"\u0006\u0001\"\u0007\u000f\u0006\u0001\"\u0007\u0011\u0006\u0001 \u001c\u0001\u0017\u0001\u0011\b\u0012\u0006\u0001\u001c\u0001\u0017\u0001\f\b\u000e\u0001\"P\u0004\u0006\u0001\u0011\b\r\nc\u0011\b\r\u0012\u0001\u0003C\u0006\u0001\f\"\u0006\u0001\"\u0007\u000f \u018d\u0006\u0001\"\u0007\u0012\u0004\u0006\u0001\n\u0012\b\u000e\u0001\u0003I\u0006\u0001\u000b\"\u0006\u0001\"\u0007\u000e\u0004\b\u0001\u000b\r\u001d\u0007(',\u0001\u0003\u001d\u001e\u001dB \r\u0004\u0001\u012f\u0001\u0003FFC\u0004\u0014\u0001\u000b\u000b\u000e\b\u0013\u0006\u0001\u000b\u000b\u000f\b\u0011\u0006\u0001\u000b\u000b\u0010\b\u0011\u0006\u0001\u000b\f\n\b\u0013\u0006\u0001\u000b\f\r\b\u0010\u0006\u0001\u000b\f\u000f\b\u000e\u0006\u0001\u000b\f\u0011\b\f\u0006\u0001\u000b\f\u0012\b\u0010\u0006\u0001\n\u0019\u0017\u001e207\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\r\t\n\u0001\n\u0001\n\u0001\u000b\r\r\b\u0011\u0006\u0001 \u000b\r\u000f\b\u0012\u0006\u0001 \u000b\r\u0010\b\f\u0006\u0001 \u000b\u000e\r\b\r\u0006\u0001 \u000b\u000e\u000f\b\u000f\u0006\u0001 \u000b\u000e\u0013\b\u0011\u0006\u0001 \u000b\u0010\u000b\b\u0013\b\u0001 \u001f-#\u0007'-\u0001 0\u0007<\u0014\u0001 \f\u000f\f\u0001 \u0003'\u0005\u0006\u0001 \u000b\n\n\u0004\b\u0001 \u001bD7B\b\u0001 \u001d7B9:\b\u0001 <EH\u0001\n\u001d\u000b\u000f\"\u000b\f(\f)\f\u0014\u0001\u001d\u0006\u0001\u0011\u000b\b\u000e\f\u0015\u0001\"\u0006\u0001\u000e\b\u0011\u0013\b\u0001 EKD:\u0014\u0001\u001d\u0006\u0001\u0011\u000b\b\u000e\u000f\u0015\u0001\"\u0006\u0001\u000e\b\u0012\f\b \u0001\n\u000b\u0006\n\u0006\u0001\u0015-2/2+-'%/\u0001\u001455%;5\u0001\n\u0017-5.\u0001\u0017-**75-21\u0001$)56\u0012 \u0001.>;\u00017DJ?C?9HE8?7B\u000179J?L?JO\u0001E<\u0001J>;\u00019ECFEKD:I\u0001M7I\u00017II7O;:\u00018O\u0001J>; \u0001:?IA\u0001:?<<KI?ED\u0001\nC;J>E:\u0006\u0001<EBBEM?D=\u0001J>;\u0001FHE9;:KH;I\u0001E<\u0001J>;\u0001\u001dB?D?97B\u00017D:\u0001&78EH7JEHO \u0001-J7D:7H:I\u0001#DIJ?JKJ;\u0001\u0003\u001d&-#\u0006\u0001\f\n\n\u0010\u0004\b\u0001.>;\u0001\n?DE9KBKC\u0001M7I\u0001FH;F7H;:\u00017I\u00017\u0001I7B?D;\u0001IKIF;DI?ED\u0001E<\u00019EBED?;I\u0001<HEC\u00017 \u0001\f\u000e\u0001>\u0001'K;BB;H\u0001\"?DJED\u0001\u001b=7H\u0001\u0003'\"\u001b\u0004\u0001\n\u0003\u001dKBJ?C;:\u0006\u0001\u001c7H9;BED7\u0006\u0001-F7?D\u0004\u0001FB7J;\u00019KBJKH;\u0001E<\u0001J>;\u0001C?9HEEH=7D?IC I\u0006\u00019EDJ7?D?D=\u00017FFHEN?C7J;BO\u0001\u000b\u0001h\u0001\u000b\n\u0012\u0001\n9EBEDO\u0001<EHC?D=\u0001KD?JI\u0001\u0003\u001d /\u0004\tC&\u0001\u0003)\u001e \u0010\f\n\u0001E<\u0001\n\u0006\n\u0013\u0004\b\u0001\u001dEBEDO\u00019EKDJI\u0001ED\u0001?DE9KBKC\u0001IKIF;DI?ED\u0001M;H;\u0001L;H?<?;:\u0001\n8O\u0001J>;\u0001FB7J;\u0001:?BKJ?ED\u0001C;J>E:\u0001KI?D=\u0001'\"\u001b\u0001FB7J;I\u00017D:\u00019EKDJ?D=\u0001J>;\u0001 879J;H?7B\u00019EBED?;I\u0001FHE:K9;:\b\u0001.>;\u0001\n;DJ?H;\u0001IKH<79;\u0001E<\u0001J>;\u0001'\"\u001b\u0001FB7J;\u0001M7I\u0001?DE9KB7J;:\u00018O\u0001IJH;7A?D=\u0001M?J >\u0001J>;\u0001IM78\u00019EDJ7?D?D=\u0001J>;\u0001?DE9KBKC\b\u0001\n\u001bDJ?C?9HE8?7B\u0001IEBKJ?ED\u0001\u00039ED9;DJH7J?ED\u0001E<\u0001\u000b\n\n\n\n\u0001b=\tC&\u0004\u0001M7I\u0001FH;F7 H;:\u0001KI?D=\u0001\u001e'-)\u00017I\u0001IEBL;DJ\b\u0001-J;H?B;\u0001\n:?IAI\u0001E<\u0001\u0010\u0001CC\u0001:?7C;J;H\u0001\u0003&?E<?B9>;C\u0006\u0001 ,EI;JE\u0001:;=B?\u0001\u001b8HKPP? \u0006\u0001#J7BO\u0004\u0001;C8;::;:\u0001?D\u0001J>;\u0001:HK=\u00017J\u00017\u0001<?D7B\u0001\n9ED9;DJH7J?ED\u0001E<\u0001\u000b\n\n\u0001b=\t:?IA\u0001M;H;\u0001A;FJ\u0001ED\u00017=7H\u0001IKH< 79;\b\u0001-J;H?B;\u0001:?IAI\u0001;C8;::;:\u0001M?J>\u0001\u001e'-)\u0001M;H;\u0001KI;:\u0001\n7I\u00017\u0001D;=7J?L;\u00019EDJHEB\b\u0001.>;\u0001FB7J;I\u0001M;H;\u0001?D9K87J;:\u00017J\u0001\r\u0011\u0001]\u001d\u0001<EH\u0001\f \u000e\u0001>\b\u00014ED;I\u0001E<\u0001?D>?8?J?ED\u0001M;H;\u0001C;7IKH;:\u0001\n?D\u0001C?BB?C;J;H\b\u0001\u0001\n\u0017-5.\u0001\u001e-1-070\u0001\u001b1,-&-624;\u0001\u001621')164%6-215 \u0001\u0003\u001e\u001b\u0016I\u0004\u0014\u0001 .>;\u0001 '#\u001dI\u0001 M;H;\u0001 ;L7BK7J;:\u0001 KI?D=\u0001 J>;\u0001 8HEJ>\u0001\nC?9HE:?BKJ?ED\u0001C;J>E:\u0006\u0001<EBBEM?D=\u0001J>;\u0001FHE9;:KH;I\u0001E<\u0001J>;\u0001\u001dB?D?97B\u00017D:\u0001&78EH7JEHO\u0001-J7D:7H:I\u0001#DIJ?JKJ;\u0001\n\u0003\u001d&-#\u0006\u0001\f\n\n\u0010\u0004\b\u0001\u001cHEJ>\u0001C?9HE:?BKJ?ED\u0001J;IJI\u0001M;H;\u0001F;H<EHC;:\u0001M?J>\u0001\u0013\u0010\u0001IJ;H?B;\u0001<B7J\u00078EJJEC\u0001C?9HEJ?J;H\u0001FB7J;I\u0001\n\u0003\u001c;9JED\u0001\u001e?9A?DIED\u0001&78M7H;\u0001\u001fKHEF;\u0006\u0001'7:H?:\u0006\u0001-F7?D\u0004\b\u0001\u001bDJ?C?9HE8?7B I\u0001M;H;\u0001I;H?7BBO\u0001:?BKJ;:\u0001\u0003\u000f\u000b\f\u0001JE\u0001\u0001\n\u000b\u0001\u021d=\tC&\u0004\u0001?D\u0001'K;BB;H\u0007\"?DJED\u0001\u001cHEJ>\u0001\u0003'\"\u001c\u0004\u0001\u0003\u001dKBJ?C;:\u0004\u00017D:\u0001J>;D\u0001ED;\u0001>KD:H;:\u0001C?9HEB?J;HI\u0001E<\u0001;79>\u0001\n:?BKJ?ED\u0001M;H;\u0001:;FEI?J;:\u0001?DJE\u0001;79>\u0001M;BB\b\u0001.>;\u0001?DE9KBKC\u0001M7I\u0001FH;F7H ;:\u00018O\u0001C7A?D=\u00017\u0001'\"\u001c\u0001IKIF;DI?ED\u0001E<\u0001\n9EBED?;I\u0001<HEC\u00017\u0001\f\u000e\u0001>\u0001'\"\u001b\u0001\u0003\u001dKBJ?C;:\u0004\u0001FB7J;\u00019KBJKH;\u0001E<\u0001J>;\u0001C?9HEE H=7D?ICI\u0006\u00019EDJ7?D?D=\u00017FFHEN?C7J;BO\u0001\u0001\n\u000b\u0001h\u0001\u000b\n\u0012\u00019EBEDO\u0001<EHC?D=\u0001KD?JI\u0001\u0003\u001d /\u0004\tC&\u0001\u0003)\u001e \u0010\f\n\u0001E<\u0001\n\u0006\n\u0013\u0004\b\u0001.>;\u0001?DE9KBKC\u0001M7I\u0001:?BKJ;:\u0001\u000b\u0014\u000b\n\n\u0001?D\u0001'\"\u001c\u0001JE\u0001\nO?;B:\u0001\u000b\u0001h\u0001\u000b\n\u0010\u0001\u001d /\tC&\b\u0001.;D\u0001C?9HEB?J;HI\u0001E<\u0001J>?I\u0001IKIF;DI?ED\u0001M7I\u0001?DE9KB7J;:\u0001?DJE\u0001 J>;\u0001;79>\u0001M;BB\b\u0001\u001dEBEDO\u0001\n9EKDJI\u0001ED\u0001?DE9KBKC\u0001IKIF;DI?ED\u0001M;H;\u0001L;H?<?;:\u00018O\u0001J>;\u0001FB7J;\u0001:?BKJ?ED\u0001C;J>E:\u0001KI?D=\u0001'\"\u001b\u0001FB7J;I\u00017D:\u0001\n9EKDJ?D=\u0001J>;\u0001879J;H?7B\u00019EBED?;I\u0001FHE:K9;:\b\u0001'\"\u001c\u0001M?J>\u00017D:\u0001M?J>EKJ\u0001 ?DE9KBKC\u0001M7I\u0001KI;:\u00017I\u0001=HEMJ>\u00079EDJHEB\u0001\n7D:\u0001D;=7J?L;\u00019EDJHEB\u0006\u0001H;IF;9J?L;BO\b\u0001.>;\u0001FB7J;I\u0001M;H;\u0001?D9K87J;:\u00017 J\u0001\r\u0011\u0001]\u001d\u0001<EH\u0001\f\u000e\u0001>\b\u0001.>;\u0001'#\u001d\u0001M7I\u0001\n;IJ78B?I>;:\u00019ECF7H?D=\u0001J>;\u00017CEKDJ\u0001E<\u0001=HEMJ>\u0001?D\u0001J>;\u0001M;BBI\u00019EDJ7?D ?D=\u0001J>;\u00017DJ?C?9HE8?7B\u00017=;DJI\u0001M?J>\u0001J>;\u0001\n7CEKDJ\u0001E<\u0001=HEMJ>\u0001?D\u0001J>;\u0001=HEMJ>\u00079EDJHEB\u0001M;BBI\u00018EJ>\u0001M?J>\u0001J>;\u0001KD7? :;:\u0001;O;\u00017D:\u00018O\u0001KI?D=\u00017\u0001F>EJEC;JH?9\u0001\n:;L?9;\u0001\u0003)\u001e \u0010\f\n\u0004\b\u0001\n\r\u0007\u0001\u001654*2;90549\u0001\u0001\n#D\u0001 9ED9BKI?ED\u0006\u0001 ?D\u0001 J>;\u0001 FH;I;DJ\u0001 IJK:O\u0001 ?J\u0001 M7I\u0001 I>EMD\u0001 J>7J\u0001 ;?=>J\u0001 EKJ\u0001 E<\u0001 J>;\u0001 ;B;L;D\u0001 IODJ>;I?P;:\u0001\n7C?DE\tD?JHE\u0007IK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\u0001>7L;\u0001?D>?8?JEHO\u000179J?L?J O\u00017=7?DIJ\u0001#\u0006\u0001%74)75\b\u0001'#\u001d\u0001:;J;HC?D7J?EDI\u0001\nFHEL;:\u0001 J>7J\u0001 J>;\u0001 J;IJ;:\u0001 9ECFEKD:I\u0001 FH;I;DJ;:\u0001 :?<<;H;DJ\u0001 FHE<?B;I\u0001 7 =7?DIJ\u0001#\u0006\u0001 %74)75\u0001 :K;\u0001 JE\u0001 J>;?H\u0001\nIK8IJ?JK;DJI\u0006\u00018;?D=\u0001\r\u0007\u0003\r \u018d\u0007C;J>OBF>;DOB\u0004\u0007\u0010\u0007D?JHE9EKC7H?D\u0001\u0003 \u000f\u0004\u0001J>;\u00018;IJ\u0001ED;\b\u0001\u001b\u0001D?JHE\u0001IK8IJ?JK;DJ\u00017J\u0001J>;\u0001\u0001\n\u0010\u0007FEI?J?ED\u0001E<\u0001J>;\u00019EKC7H?D\u0001CE?;JO\u0001I;;CI\u0001JE\u00018;\u0001;II;DJ?7B\u0001<EH\u0001J>; \u00017DJ?879J;H?7B\u000179J?L?JO\u0001E<\u0001J>?I\u0001A?D:\u0001E<\u0001\n9ECFEKD:I\b\u0001.>;\u0001?DJHE:K9J?ED\u0001E<\u00017D\u00017C?DE\u0001IK8IJ?JK;DJ\u0001I;;CI\u0001JE\u0001:; 9H;7I;\u0001J>;\u0001:;I9H?8;:\u000179J?L?JO\b\u0001.>;\u0001\nF>7HC79EBE=?97B\u0001FEJ;DJ?7B\u0001E<\u0001J>;I;\u00017C?DE\tD?JHE\u0007IK8IJ?JKJ;:\u0001\r\u00077H OB9EKC7H?DI\u00019ED<?HCI\u0001J>7J\u0001J>?I\u0001I97<<EB:\u0001\n97D\u00018;\u0001;<<;9J?L;BO\u0001EFJ?C?P;:\u0001?DJE\u00017\u000197D:?:7J;\u0001<EH\u0001J>;\u0001JH;7JC;DJ \u0001E<\u0001IEC;\u0001879J;H?7B\u0001?D<;9J?EKI\u0001:?I;7I;I\b\u0001\n\u0019\u0017\u001f208\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\r\t\u000b\u0001\n\u0001\n\u0001\u0014*145=2,+.3,4:9\u0001\n.>7DAI\u0001 7H;\u0001 :K;\u0001 JE\u0001 J>;\u0001 '?D?IJ;H?E\u0001 \u001fIF7ZEB\u0001 \u0003*-\n\u0013\t\n\n\u000f\n\u000b\u0004\u0006\u0001 2KDJ7\u0001 :7 \u0001 !7B?9?7\u0001\n\u0003*!#\u001e#.\n\u0013\u001d-\u001b\n\r\n\f\n\r*,\u00017D:\u0001*!#\u001e.\n\u0012''\u001b\n\u000b\u000b\f\n\n*,\u0004\u00017D:\u0001#(\u0012\u000e\u000f\u001c\u0007\f\n\u000b\n\t\n\u0012 \u0013\u0001<EH\u0001J>;\u0001<?D7D9?7B\u0001\nIKFFEHJ\b\u0001 '\b$\b'\b\u0001 J>7DAI\u0001 JE\u0001  KD:7VUE\u0001 F7H7\u0001 7\u0001 \u001d?XD9?7\u0001 ;\u0001 .;9DEBE=?7\u0001 <EH\u0001 7\u0001 *>\u001e\u0001 =H7DJ\u0001\n\u0003- ,\"\t\u001c\u001e\t\u0010\u000b\f\u0010\f\t\f\n\n\u0013\u0004\b\u0001 -\b0\b,\b\u0001 J>7DAI\u0001 J>;\u0001 '?D?IJ;H?E\u0001 :;\u0001 \u001f:K979?[D \u0001 O\u0001 \u001d?;D9?7\u0001 <EH\u0001 7\u0001 *>\u001e\u0001 =H7DJ\u0001\n\u0003\u001b*\f\n\n\u0012\u0007\n\u000e\f\u0010\r\u0004\b\u0001\n\",-,8,4*,9\u0001\n\u000b\b\u0001\u001cEH=;I\u0006\u0001 \b\u0015\u0001,EB;?H7\u0006\u0001 \b\u0015\u0001'?B>7P;I\u0006\u0001(\b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0001-?CFB;\u00019EKC7H?DI\u00017D:\u00017D7BE=K;I\u0001?D\u0001\nC;:?9?D7B\u00019>;C?IJHO\u0014\u0001)99KHH;D9;\u0006\u0001IODJ>;I?I\u00017D:\u00018?EBE=?97B\u000179J?L ?JO\b\u0001\u0016744\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\t\u000e\u0006\u0001\t\n\u0006\u0001\n\u0012\u0012\u0011c\u0013\u000b\u0010\b\u0001\n\f\b\u0001\u001cEH=;I\u0006\u0001 \b\u0015\u0001,EB;?H7\u0006\u0001 \b\u0015\u0001'?B>7P;I\u0006\u0001(\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0001-?CFB;\u00019EKC7H?DI\u0014\u0001*H?L?B;=;:\u0001\nI97<<EB:I\u0001?D\u0001C;:?9?D7B\u00019>;C?IJHO\b\u0001 \u00194216\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u000b\t\t\u0012\u0006\u0001\f\u0006\u0001\f\rc\u0012\u000f\b\u0001\u0001\n\r\b\u0001\u001d>?B?D\u0006\u0001\u001b\b\u0015\u0001\u001c7JJ?IJKJJ7\u0006\u0001,\b\u0015\u0001\u001cEHJEB7JE\u0006\u0001\u001b\b\u0015\u0001\u001dEPP7\u0006\u0001!\b\u0015\u000147D7JJ7\u0006 \u0001-\b\u0015\u0001*EB;JJE\u0006\u0001!\b\u0015\u0001'7PPEH7D7\u0006\u0001'\b\u0015\u0001\n47=EJJE\u0006\u0001!\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u0001!K?EJJE\u0006\u0001\u001b\b\u0015\u0001 )6\u0001%/\u0006\u0001\u001dEKC7H?D\u00017I\u0001\u001bJJH79J?L;\u0001\u001d7I;?D\u0001%?D7I;\u0001\f\u0001\u0003\u001d%\f\u0004\u0001\n#D>?8?JEH\u0001I97<<EB:\u0014\u0001\u001bD\u0001?DJ;=H7J;\u00017FFHE79>\u0001JE\u0001;BK9?:7J;\u0001J>;\u0001FKJ7 J?L;\u00018?D:?D=\u0001CEJ?<\u00017D:\u0001;NFB7?D\u0001\nIJHK9JKH;c79J?L?JO\u0001H;B7J?EDI>?FI\b\u0001 \u001c\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\t\u0011\u0006\u0001\r\t\u0006\u0001\u0011\u000f\fc\u0011\u000f\u0013\b\u0001\n\u000e\b\u0001\"EEF;H\u0006\u0001\u001e\b\u001d\b\u0015\u00011?B<IED\u0006\u0001$\b-\b\u0015\u0001'9\"K=>\u0006\u0001!\b&\b\u0015\u00011?DJ;HI\u0006\u0001'\b\u001c\b\u0015\u0001-M7HJP\u0006\u0001'\b(\b\u0001 \u001b1\u00018-642\u000179J?L?JO\u0001E<\u0001\n\u001e(\u001b\u0001 =OH7I;\u0001 ?D>?8?JEHI\u0006\u0001 I?D=BO\u0001 7D:\u0001 ?D\u0001 9EC8?D7J?ED\u0006\u0001 7=7?DIJ\u0001 \u001e;'2&%'6)4-70\u0001%8-70 \u0001 9ECFB;N\b\u0001\n\u001416-0-'42&\u0006\u0001\u0014+)165\u0001\u0016,)026,)4\u0006 \u0001\n\u0012\u0011\u000b\u0006\u0001\n\n\u0006\u0001\u0010\u0010\fc\u0010\u0011\u000b\b\u0001\n\u000f\b\u0001)IJHEL\u0006\u0001\u001e\b\u001b\b\u0015\u0001\";HDSD:;P\u0001*H7:7\u0006\u0001$\b\u001b\b\u0015\u0001\u001dEHI?DE\u0006\u0001*\b\u001f\b\u0015\u0001 ?DJED\u0006\u0001%\b\u001b \b\u0015\u0001&;\u0006\u0001(\b\u0015\u0001,EM;\u0006\u0001.\b\u001d\b\u0001\u001e?I9EL;HO\u0001E<\u0001\nDEL;B\u0001\u001e(\u001b\u0001=OH7I;\u0001?D>?8?JEHI\u00018O\u0001>?=>\u0007J>HEK=>FKJ\u0001L?HJK7B\u0001I9H;;D?D =\b\u0001\u001416-0-'42&\u0006\u0001\u0014+)165\u0001\u0016,)026,)4\u0006 \u0001\n\u000b\t\t\u0010\u0006\u0001\r\t\u0006\u0001\r\u0010\u0012\u0012c\r\u0010\u0013\u0012\b\u0001\u0001\n\u0010\b\u0001\u001d>?C;DJ?\u0006\u0001 \b\u0015\u0001\u001c?PP7HH?\u0006\u0001\u001c\b\u0015\u0001\u001cEB7I9E\u0006\u0001\u001b\b\u0015\u0001-;99?\u0006\u0001\u001e\b\u0015\u0001\u001d>?C;DJ?\u0006\u0001* \b\u0015\u0001!H7D;I;\u0006\u0001\u001b\b\u0015\u0001\u001d7HH7:EH?\u0006\u0001-\b\u0015\u0001\n,?L7D;H7\u0006\u0001\u001e\b\u0015\u00014?97H?\u0006\u0001\u001b\b\u0015\u0001-97BJH?JE\u0006\u0001'\b'\b\u0015\u0001 )6\u0001%/\u0006\u0001-ODJ>;I?I\u0006\u0001-;B;9J?L;\u00017DJ?\u0007 \u001a)/-'2&%'6)4\u00013;/24- \u0001\n79J?L?JO\u0006\u0001 \u001bD:\u0001 9OJEJEN?9?JO\u0001 E<\u0001 DEL;B\u0001 \u001f\u0007IK8IJ?JKJ;:\u0007\f\u0007ENE\u0007\f \u001a\u0007\u000b\u00078;DPEFOH7D\u0007\r\u000797H8EN7C?:;I\b\u0001\n\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006\u0001 \u000b\t\n\t\u0006\u0001\n\b\u0006\u0001\u000e\u0013\f\fc\u000e\u0013\f\u0010\b\u0001\u0001\n\u0011\b\u0001'7JEI\u0006\u0001'\b$\b\u0015\u000107PGK;P\u0007,E:H?=K;P\u0006\u0001-\b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u0001 K;DJ;I\u0007\u001f:<K<\u0006\u0001\u001d\b\u0015\u0001-7DJEI\u0006\u00013\b\u0015\u0001\n'KZEP\u0007\u001dH;=E\u0006\u0001\u001b\b\u0001&EEA?D=\u0001<EH\u0001D;M\u0001J7H=;JI\u0014\u0001-?CFB;\u00019EKC7H?DI\u00017I\u00017DJ?879J;H?7B\u00017=;DJI\b\u0001 \u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\n\u000b\t\n\u000b\u0006\u0001\u0010\u0006\u0001\u000b\u000b\u000e\nc\u000b\u000b\u000e\u000f\b\u0001\n\u0012\b\u00010?B7H\u0006\u0001-\b\u0015\u0001+K;P7:7\u0006\u0001\u001f\b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u000137D;P\u0006\u0001'\b\u0015\u0001 H 7?P\u0006\u0001(\b\u0015\u0001\u001bB97?:;\u0006\u0001\u001d\b\u0015\u0001\u001d7DE\u0006\u0001\u001f\b\u0015\u0001)H7BBE\u0006\u0001 \b\u0001\n\u001e;I?=D\u0006\u0001-ODJ>;I?I\u0006\u00017D:\u000107IEH;B7N7DJ\u00017D:\u0001FB7J;B;J\u00017DJ?7==H;=7JEH O\u000179J?L?J?;I\u0001E<\u00019EKC7H?D\u0007H;IL;H7JHEB\u0001\n>O8H?:I\b\u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\u000b\t\t\u000f\u0006\u0001\t\u000e\u0006\u0001\f\u000f\u0011c\f\u0010\u000b\b\u0001\n\u0013\b\u0001,?L;?HE\u0006\u0001'\b\u001f\b\u0015\u0001'E=B?ED?\u0006\u0001\u001b\b\u0015\u000107PGK;P\u0006\u0001,\b\u0015\u0001!EC;P\u0006\u0001(\b\u0015\u0001 79EHHE\u0006\u0001! \b\u0015\u0001*?;>B\u0006\u0001&\b\u0015\u0001:;\u0001\u001d;B?I\u0006\u0001\u001f\b,\b\u0015\u0001\n->7OE\u0006\u0001\u001d\b\u0015\u0001\u001e7L?E\u0006\u0001\u001d\b\u0001-JHK9JKH7B\u0001?DI?=>JI\u0001?DJE\u0001>O:HENO9EKC7H?D\u0007? D:K9;:\u00017FEFJEI?I\u0001?D\u0001/\u0007\u0013\r\u0011\u00019;BBI\b\u0001\n\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u000b\t\t\u0011 \u0006\u0001\t\u000e\u0006\u0001\f\u0010\u0010\u000fc\f\u0010\u0011\u000f\b\u0001\n\u000b\n\b\u0001\u001c;BBKJ?\u0006\u0001 \b\u0015\u0001 EDJ7D7\u0006\u0001!\b\u0015\u0001\u001cE\u0006\u0001&\b\u0015\u0001\u001d7H;D?D?\u0006\u0001(\b\u0015\u0001!?ECC7H;BB?\u0006\u0001\u001d\b \u0015\u00014KD?DE\u0006\u0001 \b\u0001\u001e;I?=D\u0006\u0001-ODJ>;I?I\u00017D:\u0001\n7DJ?97D9;H\u000179J?L?J?;I\u0001E<\u0001IJ?B8;D;\u00079EKC7H?D\u0001>O8H?:\u00019ECFEKD:I\u0014\u0001#: ;DJ?<?97J?ED\u0001E<\u0001DEL;B\u0001FHE7FEFJEJ?9\u0001\n7=;DJI\b\u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u000b\t\n\t\u0006\u0001\t\u0010\u0006\u0001\r\u000f\u000e\rc\r\u000f\u000f\n\b\u0001\n\u0019\u0017 209\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\r\t\f\u0001\n\u0001\n\u0001\u000b\u000b\b\u0001,EKII7A?\u0006\u0001'\b\u0015\u0001%EDJE=?EH=?I\u0006\u0001\u001d\b\u0015\u0001\"7:@?F7LBEK\u0007&?J?D7\u0006\u0001\u001e\b$\b\u0015\u0001\"7C?B 7A?I\u0006\u0001-\b\u0001\u001b\u0001DEL;B\u0001IODJ>;I?I\u0001E<\u0001\u0001\n\r\u00077HOB\u0001 9EKC7H?DI\u0001 7D:\u0001 ;L7BK7J?ED\u0001 E<\u0001 J>;?H\u0001 7DJ?EN?:7DJ\u0001 7D:\u0001 B?FENO =;D7I;\u0001 ?D>?8?JEHO\u0001 79J?L?JO\b\u0001 \u0001\n\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\u000b\t\n\t\u0006\u0001\n\b\u0006\u0001\r\u0012\u0012\u0013c\r\u0012\u0013\f\b\u0001\n\u000b\f\b\u0001 7?I\u0006\u0001\u001b\b\u0015\u0001\u001dEH:7\u0006\u0001'\b\u0015\u0001\u001fH7\u0006\u0001\u001c\b\u0015\u0001 7::7\u0006\u0001'\b\u001c\b\u0015\u0001'7JEI\u0006\u0001'\b$\b\u0015\u0001+K;P7:7 \u0006\u0001\u001f\b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001*?99?7K\u0006\u0001\u001d\b\u0015\u0001\n*E::7\u0006\u0001!\b\u0015\u0001\u001e;BE=K\u0006\u0001!\b\u0001.OHEI?D7I;\u0001?D>?8?JEH\u000179J?L?JO\u0001E<\u00019EKC7H?D \u0007H;IL;H7JHEB\u0001>O8H?:I\b \u0001\u001e2/)'7/)5 \u0001\n\u000b\t\t\u0012\u0006\u0001\t\f\u0006\u0001\f\u000f\u000b\u000ec\f\u000f\f\n\b\u0001\n\u000b\r\b\u0001'7JEI\u0006\u0001'\b$\b\u0015\u00010?Z7\u0006\u0001\u001e\b\u0015\u0001+K;P7:7\u0006\u0001\u001f\b\u0015\u0001*?99?7K\u0006\u0001\u001d\b\u0015\u0001\u001e;BE=K\u0006\u0001!\b\u0015\u0001)H7BBE\u0006\u0001 \b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0001\u0001\n\u001b\u0001(;M\u0001I;H?;I\u0001E<\u0001\r\u0007F>;DOB9EKC7H?DI\u00017I\u0001FEJ;DJ\u00017D:\u0001I;B;9J?L;\u0001'\u001b)\u0007\u001c \u0001?D>?8?JEHI\b\u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\n\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\u000b\t\t\u0012\u0006\u0001\t\u0011\u0006\u0001\r\f\u0010\u0012c\r\f\u0011\n\b\u0001\n\u000b\u000e\b\u0001'7JEI\u0006\u0001 '\b$\b\u0015\u0001 0?Z7\u0006\u0001 \u001e\b\u0015\u0001 $7D;?HE\u0006\u0001 *\b\u0015\u0001 \u001cEH=;I\u0006\u0001  \b\u0015\u0001 -7DJ7D7\u0006\u0001 &\b\u0015\u0001 /H ?7HJ;\u0006\u0001 \u001f\b\u0001 (;M\u0001 >7BE=;D7J;:\u0001\u0001\n\r\u0007F>;DOB9EKC7H?DI\u00017I\u0001FEJ;DJ\u00017D:\u0001I;B;9J?L;\u0001'\u001b)\u0007\u001c\u0001?D>?8?JEHI\b \u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\u000b\t\n\t\u0006\u0001\u0001\n\n\b\u0006\u0001\u000f\u000b\u000f\u0011c\u000f\u000b\u0010\n\b\u0001\n\u000b\u000f\b\u0001'7JEI\u0006\u0001'\b$\b\u0015\u0001.;HSD\u0006\u0001\u001d\b\u0015\u0001*WH;P\u0007\u001d7IJ?BBE\u0006\u00013\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u0001-7DJ7D 7\u0006\u0001&\b\u0015\u00010?Z7\u0006\u0001\u001e\b\u0001-ODJ>;I?I\u00017D:\u0001IJK:O\u0001\nE<\u0001 7\u0001 I;H?;I\u0001 E<\u0001 \r\u00077HOB9EKC7H?DI\u0001 7I\u0001 FEJ;DJ\u0001 7D:\u0001 I;B;9J?L;\u0001 CEDE7C?D ;\u0001 EN?:7I;\u0001 \u001c\u0001 ?D>?8?JEHI\b\u0001\u0001\n\u001c\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001 \u000b\t\n\n\u0006\u0001\r\f\u0006\u0001\u0011\u000b\f\u0011c\u0011\u000b\r\u0011\b\u0001\n\u000b\u0010\b\u0001'7JEI\u0006\u0001'\b$\b\u0015\u00010?Z7\u0006\u0001\u001e\b\u0015\u0001*?99?7K\u0006\u0001\u001d\b\u0015\u0001)H7BBE\u0006\u0001 \b\u0015\u0001-7DJ7D7\u0006\u0001&\b\u0015\u0001/H ?7HJ;\u0006\u0001\u001f\b\u0001-ODJ>;I?I\u00017D:\u0001;L7BK7J?ED\u0001E<\u0001\n\u0010\u0007C;J>OB\u0007\r\u0007F>;DOB9EKC7H?DI\u00017I\u0001FEJ;DJ\u00017D:\u0001I;B;9J?L;\u0001'\u001b)\u0007\u001c\u0001?D>?8? JEHI\b\u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\n\u000b\t\t\u0012\u0006\u0001\t\u0011\u0006\u0001\u000f\n\u000f\rc\u000f\n\u000f\u000f\b\u0001\n\u000b\u0011\b\u0001\u001e;BE=K\u0006\u0001!\b\u0015\u0001*?99?7K\u0006\u0001\u001d\b\u0015\u0001 ;H?DE\u0006\u0001!\b\u0015\u0001+K;P7:7\u0006\u0001\u001f\b\u0015\u0001*E::7\u0006\u0001!\b\u0015\u0001/H?7HJ;\u0006\u0001\u001f\b\u0015\u00010?Z7\u0006\u0001\u001e\b\u0001-ODJ>;I?I\u0006\u0001\n\"KC7D\u0001 CEDE7C?D;\u0001 EN?:7I;\u0001 ?D>?8?JEHO\u0001 79J?L?JO\u0001 7D:\u0001 CEB;9KB7H\u0001 :E9A? D=\u0001 IJK:?;I\u0001 E<\u0001\u0001\n\r\u0007>;J;HE7HOB9EKC7H?D\u0001:;H?L7J?L;I\b\u0001 \u001874\u0006\u0001\u001c\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\n\n\u0006\u0001\f\u0011\u0006\u0001\u000b\u000b\u000e\u0011c\u000b\u000b\u000f\f\b\u0001\n\u000b\u0012\b\u0001!EJ>\u0006\u0001\u001b\b\u0001.>;\u00017DJ?879J;H?7B\u0001FHEF;HJ?;I\u0001E<\u0001:?9KC7HEB\b\u0001 #'-)1')\u0001\n\u0012\r\u000e\u0006\u0001\t\b\t\u0006\u0001\r\u0012\r\b\u0001\n\u000b\u0013\b\u0001\"E;JJ;9A;\u0006\u0001 (\b\u0015\u0001 ,EJPEBB\u0006\u0001 -\b\u0015\u0001 \u001bB8H;9>J\u0006\u0001 /\b\u0015\u0001 &7BA\u0006\u0001 '\b\u0015\u0001  ?I9>;H\u0006\u0001 \u001d\b \u0015\u0001 &7D=;H\u0006\u0001 *\b\u0001 -ODJ>;I?I\u0001\u0001\n7D:\u0001 7DJ?C?9HE8?7B\u0001 79J?L?JO\u0001 E<\u0001 \f\u00077BA;DOB9>HEC7D\u0007\u000e\u0007ED;I\u0006\u0001 \f\u00077BA;DO BJ>?E9>HEC7D\u0007\u000e\u0007ED;I\u0001 7D:\u0001\u0001\n\f\u00077BA;DOBGK?DEB\u0007\u000e\u0007ED;I\b\u0001 \u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u000b\t\t\u0011 \u0006\u0001\t\u000e\u0006\u0001\u000b\n\r\u000b\u0013c\u000b\n\r\f\u000f\b\u0001\n\f\n\b\u0001->?\u0006\u00013\b\u0015\u00014>EK\u0006\u0001\u001d\b\u0001-ODJ>;I?I\u00017D:\u0001;L7BK7J?ED\u0001E<\u00017\u00019B7II\u0001E<\u0001D;M\u00019EKC7H?D\u0001JH?7PEB;\u0001:;H?L7J?L;I\u00017I\u0001\nFEJ;DJ?7B\u00017DJ?C?9HE8?7B\u00017=;DJI\b\u0001 \u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\u000b\t\n\n\u0006\u0001\n\t\u0006\u0001\u0013\u000f\u0010c\u0013\u0010\n\b\u0001\n\f\u000b\b\u0001*7J?B\u0006\u0001-\b\u001b\b\u0015\u0001/DA?\u0006\u0001-\b(\b\u0015\u0001%KBA7HD?\u0006\u0001\u001b\b\u001e\b\u0015\u0001(7?A\u0006\u00010\b\"\b\u0015\u0001\u001c7:7C?\u0006\u0001*\b -\b\u0001-ODJ>;I?I\u0006\u0001\u001d>7H79J;H?P7J?ED\u0006\u0001\u0001\n\u001b1\u00018-642\u00017DJ?C?9HE8?7B\u00017D:\u0001\u001e(\u001b\u00019B;7L7=;\u0001IJK:?;I\u0001E<\u0001\u001dE\u0003##\u0004\u0006\u0001(?\u0003##\u0004\u00017D:\u0001\u001dK\u0003##\u0004\u00019ECFB;N;I\u0001M?J>\u0001\n)())\u0001:EDEH\u00019EKC7H?D\u0001-9>?<<\u000187I;I\b\u0001 \u001c\u0006\u0001\u001e2/\u0006\u0001#647'6\u0006 \u0001\u000b\t\n\n\u0006\u0001\u0011\u0010\r \u0006\u0001\r\r\nc\r\r\u0012\b\u0001\n\f\f\b\u0001-78HO\u0006\u0001(\b'\b\u0015\u0001'E>7C;:\u0006\u0001\"\b'\b\u0015\u0001%>7JJ78\u0006\u0001\u001f\b-\b\u001b\b\u001f\b\"\b\u0015\u0001'EJB7G\u0006\u0001-\b-\b\u0015\u0001\u001fB\u0007\u001b=HE:O\u0006\u0001\u001b\b'\b\u0001-ODJ>;I?I\u0001E<\u0001\n\u000e\u001a\u00079>HEC;D;\u0006\u0001 \u001dEKC7H?D\u0006\u0001 \u000b\f \u001a\u00079>HEC;DE5\f\u0006\r\u0007 (6FOH?C?:?D;\u0001 :;H?L7J?L;I\u0001 7D:\u0001 IEC;\u0001 E<\u0001 J>;?H\u0001\n7DJ?C?9HE8?7B\u00017D:\u00019OJEJEN?9?JO\u000179J?L?J?;I\b\u0001 \u001874\u0006\u0001\u001c\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\n\n\u0006\u0001\f\u000e\u0006\u0001\u0011\u0010\u000fc\u0011\u0011\f\b\u0001\n\f\r\b\u0001%7M7I;\u0006\u0001'\b\u0015\u000107HK\u0006\u0001\u001c\b\u0015\u0001->7>\u0006\u0001\u001b\b\u0015\u0001'EJE>7I>?\u0006\u0001'\b\u0015\u0001.7D?\u0006\u0001-\b\u0015\u0001-7?JE\u0006\u0001-\b\u0001\u001bDJ?C?9HE8?7B\u000179J?L?JO\u0001E<\u0001D;M\u0001\n9EKC7H?D\u0001:;H?L7J?L;I\b\u0001 \u00144<1)-0-66)/*245',71+ \u0001\u000b\t\t\n\u0006\u0001\r\t\u0006\u0001\u0010\u0011c\u0011\u000b\b\u0001\n\f\u000e\b\u0001*7J;B\u0006\u0001\u001e\b\u0015\u0001%KC7H?\u0006\u0001*\b\u0015\u0001*7J;B\u0006\u0001(\b\u0001-ODJ>;I?I\u0006\u00019>7H79J;H?P7J?ED\u00017D :\u00018?EBE=?97B\u0001;L7BK7J?ED\u0001E<\u0001IEC;\u0001\nJ>?7PEB?:?DED;\u0001:;H?L7J?L;I\u00017I\u00017DJ?C?9HE8?7B\u00017=;DJI\b\u0001 \u001c\u0006\u0001\u0016,)0\u0006\u0001!,%40\u0006\u0001\")5\u0006 \u0001\u000b\t\n\t\u0006\u0001\n\u0006\u0001\u0012\u000ec\u0013\u000b\b\u0001\n\f\u000f\b\u0001*7J;B\u0006\u0001\u001e\b\u0015\u0001%KC7H?\u0006\u0001*\b\u0015\u0001*7J;B\u0006\u0001(\b\u0001-ODJ>;I?I\u00017D:\u00019>7H79J;H?P7J?ED \u0001E<\u0001IEC;\u0001D;M\u0001J>?7PEB?:?DED;I\u0001\n9EDJ7?D?D=\u00019EKC7H?D\u0001CE?;JO\u00017D:\u0001J>;?H\u00017DJ?C?9HE8?7B\u0001IJK:O\b\u0001 \u00144',\u0006\u0001\u001433/\u0006\u0001#'-\u0006\u0001\")5\u0006 \u0001\u000b\t\n\t\u0006\u0001\n\u0006\u0001\u0010\u0012c\u0011\u000f\b\u0001\n\f\u0010\b\u0001&7KH?D\u0006\u0001*\b\u0015\u0001 ;HHEK:\u0006\u0001\u001e\b\u0015\u0001%B?9>\u0006\u0001'\b\u0015\u0001\u001eKFK?I\u0007\"7C;B?D\u0006\u0001\u001d\b\u0015\u0001'7KL7?I\u0006\u0001*\b\u0015\u0001&7II7?=D;\u0006\u0001*\b\u0015\u0001\u001cEDD;<EO\u0006\u0001\u001b\b\u0015\u0001\n'KI?9A?\u0006\u0001\u001c\b\u0001-ODJ>;I?I\u00017D:\u0001 -1\u00018-642\u0001;L7BK7J?ED\u0001E<\u0001DEL;B\u0001>?=>BO\u0001FEJ;DJ\u00019EKC7H?D\u0001?D>?8?JEHI\u0001E<\u0001=OH7I ;\u0001\n\u001c\b\u0001\u0015-224+\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006\u0001\u001d)66\u0006 \u0001\n\u0012\u0012\u0012\u0006\u0001\u0011\u0006\u0001\f\n\u0011\u0013c\f\n\u0012\u000e\b\u0001\n\u0019\u0018\u0017210\u001e2/)'7/)5\u0001\u000b\t\n\f\u0006\u0001\t\u0010\u0001 \n\r\t\r\u0001\n\u0001\n\u0001\f\u0011\b\u0001(7J>7D\u0006\u0001\u001d\b\u0001\u001bDJ?8?EJ?9I\u00017J\u0001J>;\u00019HEIIHE7:I\b\u0001\u001f%674) \u0001\u000b\t\t\r\u0006\u0001\f\u000b\t\u0006\u0001\u0012\u0013\u0013c\u0013\n\f\b\u0001\n\f\u0012\b\u0001,79>7AED:7\u0006\u0001-\b\u0015\u0001\u001d7HJ;;\u0006\u0001&\b\u0001\u001d>7BB;D=;I\u0001?D\u00017DJ?C?9HE8?7B\u0001:HK=\u0001:?I 9EL;HO\u00017D:\u0001J>;\u0001FEJ;DJ?7B\u0001E<\u0001\nDK9B;EI?:;\u00017DJ?8?EJ?9I\b\u0001 \u0016744\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\t\r\u0006\u0001\t\t\u0006\u0001\u0011\u0011\u000fc\u0011\u0013\r\b\u0001\n\f\u0013\b\u000117BI>\u0006\u0001\u001d\b\u0001\u001416-&-26-'5\u0004\u0001\u0014'6-215\u0004\u0001 4-+-15\u0004\u0001\")5-56%1') \u0015\u0001\u001b-'\u0014\u000117I>?D=JED\u0006\u0001\u001e\u001d\u0006\u0001/-\u001b\u0006\u0001\f\n\n\r\b\u0001\n\r\n\b\u00010ED\u0001(KII87KC\u0006\u0001 \b\u0015\u0001\u001cH7D:I\u0006\u0001'\b\u0015\u0001\"?DP;D\u0006\u0001\u001c\b\u0015\u00011;?=7D:\u0006\u0001-\b\u0015\u0001\"T8?9>\u0006\u0001 \u001e\b\u0001\u001bDJ?879J;H?7B\u0001D7JKH7B\u0001\nFHE:K9JI\u0001?D\u0001C;:?9?D7B\u00019>;C?IJHO\u0001\u0007\u0001;NE:KI\u0001EH\u0001H;L?L7B\u0019\u0001 \u00141+)9\u0006\u0001\u0016,)0\u0006\u0001\u001b16\u0006\u0001\u0018(\u0006\u0001\u000b\t\t\u000f\u0006\u0001\f\r\u0006\u0001\u000f\n\u0011\fc\u000f\u000b\f\u0013\b\u0001\n\r\u000b\b\u0001'7JEI\u0006\u0001 '\b$\b\u0015\u0001 \u001e;BE=K\u0006\u0001 !\b\u0015\u0001 *E::7\u0006\u0001 !\b\u0015\u0001 -7DJ7D7\u0006\u0001 &\b\u0015\u0001 /H?7HJ;\u0006\u0001 \u001f\b\u0001 ,; =?EI;B;9J?L;\u0001 IODJ>;I?I\u0001 E<\u0001\u0001\n8HECE\u0007IK8IJ?JKJ;:\u0001\r\u00077HOB9EKC7H?DI\b \u0001#;16,)5-5\u0001\u000b\t\n\t\u0006\u0001\t\u000e\u0006\u0001\f\u0011\u0010\rc\f\u0011\u0010\u0010\b\u0001\n\r\f\b\u0001'7JEI\u0006\u0001 '\b$\b\u0015\u0001 07PGK;P\u0007,E:H?=K;P\u0006\u0001 -\b\u0015\u0001 \u001cEH=;I\u0006\u0001  \b\u0015\u0001 -7DJ7D7\u0006\u0001 &\b\u0015\u0001 /H?7HJ;\u0006\u0001 \u001f\b\u0001 -ODJ>;I?I\u0001 E<\u0001\u0001\n\r\u00077HOB9EKC7H?DI\u0001 L?7\u0001 -KPKA?\u00079HEII\u00079EKFB?D=\u0001 H;79J?EDI\u0001 E<\u0001 \r\u00079>BEHE 9EKC7H?D\b\u0001$)64%,)(421\u0001\u001d)66\u0006 \u0001\n\u000b\t\n\n\u0006\u0001\u000f\n\u0006\u0001\u000b\f\f\u000fc\u000b\f\f\u0011\b\u0001\n\r\r\b\u0001%H?I>D7IM7CO\u0006\u0001 (\b,\b\u0015\u0001 -;I>7:H?\u0006\u0001 .\b,\b\u0015\u0001 ->7HC7\u0006\u0001 \u001c\b,\b\u0001 (?JHE\u0001 :;H?L7J?L;I\u0001 E<\u0001 \r\u0007F>;DOB9EKC7H?DI\b\u0001 \u0001\n\u001b1(\u0006\u0001\u001c\u0006\u0001\u0016,)0\u0006\u0001\n\u0012\u000f\u0012\u0006\u0001\u000f\u0006\u0001\u000e\u0013c\u000f\u000f\b\u0001\u0001\n\r\u000e\b\u0001,7E\u0006\u0001\u001e\b0\b\u0015\u0001-7O?=>\u0006\u0001\u001b\b,\b\u0015\u0001/BH?9>\u0006\u0001\"\b\u0001\u001bC?DEF>;DOB\u00017BAENO\u00019EKC7H?DI\b\u0001/-\u0001\r\u0010\u0011\u0010\u000e\r\u0010\u0001\u001b\u0006\u0001\u000b\u000b\u0001$KBO\u0001\u000b\u0013\u0011\f\b\u0001\n\r\u000f\b\u0001%H;CAO\u0006\u0001\u001f\b\u0001\u001d>HEC7JE=H7F>?9\u0001C;J>E:\u0001<EH\u0001J>;\u0001I;F7H7J?ED\u00017D:\u0001?:;DJ? <?97J?ED\u0001E<\u0001IEC;\u00019EKC7H?D\u0001\n:;H?L7J?L;I\b\u0001 4+%1-.%\u0001\n\u0012\u0010\u0012\u0006\u0001\u000b\u000f\u0013c\u000b\u0010\r\b\u0001\n\r\u0010\b\u0001*?7PP?\u0006\u0001&\b\u0015\u0001\u001d7L7BB?\u0006\u0001\u001b\b\u0015\u0001\u001c;BBKJ?\u0006\u0001 \b\u0015\u0001\u001c?I?\u0006\u0001\u001b\b\u0015\u0001!E88?\u0006\u0001-\b\u0015\u0001,?PP E\u0006\u0001-\b\u0015\u0001\u001c7HJEB?D?\u0006\u0001'\b\u0015\u0001\u001bD:H?I7DE\u0006\u00010\b\u0015\u0001\n,;97D7J?D?\u0006\u0001 '\b\u0015\u0001 ,7CF7\u0006\u0001 \u001b\b\u0001 \u001fNJ;DI?L;\u0001 -\u001b,\u0001 7D:\u0001 9ECFKJ7J?ED7B\u0001 IJK:? ;I\u0001 E<\u0001\u0001\n\r\u0007Q\u000e\u00075\u00038;DPOBC;J>OB7C?DE\u0004C;J>OB6F>;DOBR\u0007\u0010\u0006\u0011\u0007:?C;J>ENO\u0007\f \u001a\u0007\f\u00079>HEC;DED;\u0001 \u0003\u001b*\f\f\r\u0012\u0004\u0001\n\u001e;H?L7J?L;I\b\u0001\u001c\u0006\u0001\u001e)(\u0006\u0001\u0016,)0\u0006 \u0001\u000b\t\t\u0010\u0006\u0001\r\b\u0006\u0001\u000e\f\u000f\nc\u000e\f\u000f\u000e\b\u0001\n\r\u0011\b\u0001'\u0001 9>;C?D<EHC7J?9I\u0006\u0001 \u001cH7J?IB7L7\u0006\u0001 -BEL7A\u0001 ,;FK8B?9\b\u0001 \u001bL7?B78B;\u0001 EDB?D ;\u0014\u0001\n>JJF\u0014\t\tMMM\bCEB?DIF?H7J?ED\b9EC\tI;HL?9;I\tFHEF;HJ?;I\b>JCB\u0001\u0003799;II; :\u0001ED\u0001\u000b\u000e\u0001\u001e;9;C8;H\u0001\f\n\n\u0013\u0004\b\u0001\n#%03/)\u0001\u00148%-/%&-/-6; \u0014\u0001-7CFB;I\u0001E<\u0001J>;\u00019ECFEKD:I\u00017H;\u00017L7?B78B;\u0001<HEC\u0001J>;\u00017KJ>EHI\b\u0001\n^\u0001\f\n\u000b\r\u00018O\u0001J>;\u00017KJ>EHI\u0015\u0001B?9;DI;;\u0001'\u001e*#\u0006\u0001\u001c7I;B\u0006\u0001-M?JP;HB7D:\b\u0001.>?I\u0001 7HJ?9B;\u0001?I\u00017D\u0001EF;D\u0001799;II\u00017HJ?9B;\u0001\n:?IJH?8KJ;:\u0001 KD:;H\u0001 J>;\u0001 J;HCI\u0001 7D:\u0001 9ED:?J?EDI\u0001 E<\u0001 J>;\u0001 \u001dH;7J?L;\u0001 \u001dECC EDI\u0001 \u001bJJH?8KJ?ED\u0001 B?9;DI;\u0001\n\u0003>JJF\u0014\t\t9H;7J?L;9ECCEDI\bEH=\tB?9;DI;I\t8O\t\r\b\n\t\u0004\b\u0001\n\u0019\u0018\u0018211 \u0019\u0018\u001a213\u0019\u0018\u001b214\u0019\u0018\u001c215\u0019\u0018\u001d216\u0019\u0018\u001e217\u0019\u0018\u001f218\u0001\n\u0001\n\u0015 !)\u0001\u001c%\u001b+#\u001d$*\u0001!)\u0001\u001b%$\u001e!\u001c\u001d$*!\u0019\"\u0001\u0019$\u001c\u0001!)\u0001&(%&(!\u001d*\u0019(.\u0001*%\u0001* \u001d\u0001\b#\u001d(!\u001b\u0019 $\u0001\t \u001d#!\u001b\u0019\"\u0001\u0014%\u001b!\u001d*.\u0001\u0019$\u001c\u0001!*)\u0001\u0019+* %()\u0004\u0001\n%\u0001$%*\u0001\n\u001b%&.\u0001%(\u0001\u001c!)\u001b\"%)\u001d\u0001-!* %+*\u0001-(!**\u001d$\u0001&\u001d(#!))!%$\u0004\u0001\r\u001e\u0001.%+\u0001 \u0019,\u001d\u0001(\u001d\u001b\u001d!, \u001d\u001c\u0001* !)\u0001!*\u001d#\u0001!$\u0001\u001d((%(\u0002\u0001$%*!\u001e.\u0001* \u001d\u0001)\u001d$\u001c\u001d(\u0001\u0019$\u001c\u0001\n\u001c\u001d\"\u001d*\u001d\u0001\u0019\"\"\u0001\u001b%&!\u001d)\u0004\u0001\n\u0001\n\u0001\u0001\n\t\u001e\u0016\u001a\u0012\u000f\u0019\u0013\u0019\u0001\u000b\u0016\u000e\u0001\u0003\u0016\u001a\u0013\f\u000b\r\u001a\u000f\u0018\u0013\u000b\u0014\u0001\u0005\u001c\u000b\u0014\u001b\u000b\u001a\u0013\u0017\u0016\u0001\u0017\u0010\u0001\u0004\u0017\u001b\u0015\u000b\u0018\u0013\u0016\u0002\n\u0004\u0012\u000b\u0014\r\u0017\u0016\u000f\u0001\u0006\u001e\f\u0018\u0013\u000e\u0019\u0001\u000b\u0019\u0001\u0007\u000f\u001d\u0001\u000b\u0016\u000e\u0001\b\u0017\u001a\u000f\u0016\u001a\u0001\u0003\u0011\u000f\u0016\u001a\u0019\u0001\u0010\u0017\u0018\u0001\n\n\u000f\u0016\u000b\r\u0013\f\u000b\r\u001b\u0014\u0017\u0019\u0013\u0019\u0001\n\u0001\u0001\n\u000e%+($\u0019\"\u0006\u0001 \u0005\u0011\u0015\u0012\u0010\u0006\u000e\u0001\u0011\n\u0001\u0002\u000b\u0012\r\u0007\u0015\u000e\u0014\u0015\u0012\u0006\u000e\u0001\u0006\u0010\b\u0001\u0004\u0011\u0011\b\u0001\u0003\f\t\u000f\r\u0013\u0014\u0012\u0016 \u0001\n\u0010\u0019$+)\u001b(!&*\u0001\r\n\u0006\u0001 \n(\u0019\u001e*\u0001\n\u0010\u0019$+)\u001b(!&*\u0001\u0015.&\u001d\u0006\u0001 \b(*!\u001b\"\u001d\u0001\n\n\u0019*\u001d\u0001\u0014+\u001a#!**\u001d\u001c\u0001\u001a.\u0001* \u001d\u0001\b+* %(\u0006\u0001 $\u0005\u0019\u0001\n\t%#&\"\u001d*\u001d\u0001\u000f!)*\u0001%\u001e\u0001\b+* %()\u0006\u0001 \u0017\u0019/'+\u001d/\u0003\u0013%\u001c(!\u001f+\u001d/\u0002\u0001\u0014\u0019\"\u001d*\u0019\u0007\u0001\u0016$!,\u001d()!*.\u0001%\u001e\u0001\u0014\u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019 \u0002\u0001\n\n\u001d&\u0019(*#\u001d$*\u0001%\u001e\u0001\u0011(\u001f\u0019$!\u001b\u0001\t \u001d#!)*(.\u0002\u0001\f\u0019\u001b+\"*.\u0001%\u001e\u0001\u0012 \u0019(#\u0019\u001b.\u0001\n\n0\u0019/\u0002\u0001\b\"\u001a\u0019\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d\u0001\u0014\u0019$*! \u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\n\u001d&\u0019(*\u0019#\u001d$*\u0001 %\u001e\u0001\u001c\u001d\u0001\n\u0010!\u001b(%\u001a!%\"%\u001f.\u0001\u0019$\u001c\u0001\u0012\u0019(\u0019)!*%\"%\u001f.\u0001\n\u0010\u0019*%)\u0002\u0001\u0010\u0019(!\u0019\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d\u0001\u0014\u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\u0011(\u001f\u0019$!\u001b\u0001\t \u001d#!)*(.\u0001\n\u0014\u001d((\u0019\u0002\u0001\u0014!\",!\u0019\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d\u0001\u0014\u0019$ *!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\u0011(\u001f\u0019$!\u001b\u0001\t  \u001d#!)*(.\u0001\n\u0016(!\u0019(*\u001d\u0002\u0001\u000b+\u001f\u001d$!%\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d \u0001\u0014\u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\u0011(\u001f\u0019$! \u001b\u0001\n\t \u001d#!)*(.\u0001\n\u0014\u0019$*\u0019$\u0019\u0002\u0001\u000f%+(\u001c\u001d)\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d \u0001\u0014\u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\u0011(\u001f\u0019$! \u001b\u0001\n\t \u001d#!)*(.\u0001\n\u0010+1%/\u0003\t(\u001d\u001f%\u0002\u0001\b$\u001f\u001d\"\u001d)\u0007\u0001\u0016$!,\u001d()! \u001c\u0019\u001c\u0001\u001c\u001d\u0001\u0014\u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\n\n\u001d&\u0019(*\u0019#\u001d$*\u0001%\u001e\u0001\u001c\u001d\u0001\u0010!\u001b(%\u001a !%\"%\u001f.\u0001\u0019$\u001c\u0001\u0012\u0019(\u0019)!*%\"%\u001f.\u0001\n\u0014\u0019$*%)\u0002\u0001\u0018)\u0019\u001a\u001d\"\u0007\u0001\u0016$!,\u001d()!\u001c\u0019\u001c\u0001\u001c\u001d\u0001\u0014 \u0019$*!\u0019\u001f%\u0001\u001c\u001d\u0001\t%#&%)*\u001d\"\u0019\u0002\u0001\n\u001d&\u0019(*\u0019# \u001d$*\u0001%\u001e\u0001\n\u001c\u001d\u0001\u0010!\u001b(%\u001a!%\"%\u001f.\u0001\u0019$\u001c\u0001\u0012\u0019(\u0019)!*%\"%\u001f.\u0001\n\u0001\u0001\n\u0001\n\u0001\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0018 219\u0001 \f\u0001\u001c4*/%\".&.\u0001\u001e*!\u0001\u0010*/&\u001f\u001e /\"-&\u001e(\u0001\u00121\u001e(0\u001e/&+*\u0001+#\u0001\u0011+0)\u001e-&*\u0003\n\u0011%\u001e( +*\"\u0001\u00144\u001f-&!.\u0001\u001e.\u0001\u0018\"2\u0001\u001e*!\u0001\u001a+/\"*/\u0001\u0010$\"*/.\u0001#+-\u0001\n\u001d\"*\u001e &\u001f\u001e 0(+.&. \u0001\n\u0001\n\u0001\n+5@9H5\u0001.5NEI9N\b*C8F=;I9N\f\u0007\u0005\u0007\u0001\u0019@65\u0001\u001cS5N\r\u0007\u0001%5F=5\u0001\"CPC\u0001%5HCG\f\u0007\u0001+=@J=5\u0001+9FF5\f\u0007\u0001\u001dI;9B=C\u0001\n-F=5FH9\f\u0007\u0001$CIF89G\u0001+5BH5B5\f\u0007\u0001\u0019B;9@9G\u0001%ITCN\b\u001bF9;C\r\u0007\u00011G569@\u0001+5BHCG\r\t\u0001\n\u0001\n\f\u001c9D5FHA9BH\u0001C:\u0001'F;5B=7\u0001\u001b<9A=GHFM\u0007\u0001\u001e57I@HM\u0001C:\u0001(<5FA57M\u0007\u0001-B=J9FG=H M\u0001C:\u0001+5BH=5;C\u000189\u0001\n\u001bCADCGH9@5\u0007\u0001\u001b5ADIG\u0001.=85\u0001G\nB\u0007\u0001\f\u0010\u0012\u0013\r\u0007\u0001+5BH=5;C\u000189\u0001\u001bCADCGH9@5\u0007\u0001\u0019\u0001\u001b CFIT5\u0007\u0001+D5=B\t\u0001\n\r\u0001\u001c9D5FH5A9BH\u0001C:\u000189\u0001%=7FC6=C@C;M\u00015B8\u0001(5F5G=HC@C;M\u0007\u0001\u001e57I@HM\u0001C:\u0001\u001a= C@C;M\u0007\u0001-B=J9FG=HM\u0001C:\u0001\n+5BH=5;C\u000189\u0001\u001bCADCGH9@5\u0007\u0001\f\u0010\u0012\u0013\r\u0001+5BH=5;C\u000189\u0001\u001bCADCGH9@5\u0007\u0001+D5=B\t\u0001\n\u0005\u001bCFF9GDCB8=B;\u00015IH<CF\u0015\u0001,C\u0001K<CA\u00017CFF9GDCB89B79\u0001G<CI@8\u000169\u0001588F9GG 98\t\u0001\u001988F9GG\u0015\u0001+5@9H5\u0001\n.5NEI9N\b*C8F=;I9N\u0007\u0001 \u001c9D5FHA9BH\u0001 C:\u0001 'F;5B=7\u0001 \u001b<9A=GHFM\u0007\u0001 \u001e57I@HM\u0001 C:\u0001 (<5FA57M\u0007\u0001\n-B=J9FG=HM\u0001C:\u0001+5BH=5;C\u000189\u0001\u001bCADCGH9@5\u0007\u0001\f\u0010\u0012\u0013\r\u0001+5BH=5;C\u000189\u0001\u001bCADCGH 9@5\u0007\u0001+D5=B\u0016\u0001(<CB9\u0015\u0001\n\u0006\u000e\u000f\u0001\u0014\u0013\f\u0001\u0010\u0011\u000e\f\u000b\u000b\t\u0001\u001e5L\u0015\u0001\u0006\u000e\u000f\u0001\u0014\u0013\f\u0001\u0010\u000f\u000f\u0014\f\r\t\u0001\u001d\bA5=@\u0015\u0001 GJF9\u0012\u0012\u0018;A5=@\t7CA \u0001\u0001\n\u0001Page 1 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u0017220\u0001 \r\u0001\u0010\u001f./-\u001e /\u0001\f\u0001\n/=H<\u0001H<9\u00015=A\u0001C:\u0001:=B8=B;\u0001H<9\u0001GHFI7HIF5@\u0001:95HIF9G\u0001:CF\u0001H<9\u00015BH=657 H9F=5@\u000157H=J=HM\u00015B8\u0001 \r\u0001\nG9@97H=J=HM\u0001C:\u0001B9K\u00015BH=657H9F=5@\u00015;9BHG\u0007\u00015\u0001G9F=9G\u0001C:\u00017CIA5F=B\b7 <5@7CB9\u0001<M6F=8\u00017CADCIB8G\u0001 \u000e\u0001\n695F=B;\u00015A=BC\u0007\u0001A9H<CLM\u0007\u00019H<CLM\u00015B8\u00016FCAC\u0001GI6GH=HI9BHG\u00015H\u00018=::9F 9BH\u0001DCG=H=CBG\u0001K9F9\u0001 \u000f\u0001\n89G=;B98\u00015B8\u0001GMBH<9G=N98\t\u0001,<9=F\u00015BH=657H9F=5@\u000157H=J=HM\u0001K5G\u00019J5@ I5H98\u00015;5=BGH\u0001H<F99\u0001 \u0010\u0001\n=ADCFH5BH\u0001HMD9G\u0001C:\u0001<IA5B\u0001657H9F=5\u0001GHF5=BG\u0001\u0003 \u0018\u0006\u0001)30/\u0007\u0001$\u0006\u0001'96+97\u00015B8\u0001\"\u0006\u0001'+69-/237'\u0003 \u00015G\u0001K9@@\u0001 \u0011\u0001\n5G\u00015;5=BGH\u0001H<F99\u00018=::9F9BH\u0001GHF5=BG\u0001C:\u0001H<9\u0001 %+2')/(')9091\u00011'6/8/191 \u0001\u0003%\u0006\u00011'6/8/191 \u0004\u0001 \u0012\u0001\n657H9F=5\u0007\u0001F9GDCBG=6@9\u0001:CF\u0001H9B57=657I@CG=G\u0001=B\u0001A5F=B9\u0001:=G<\u0007\u00015B\u0001=A DCFH5BH\u00018=G95G9\u0001H<5H\u000175IG9G\u0001 \u0013\u0001\n;F95H\u000197CBCA=75@\u0001@CGG\u0001=B\u0001H<9\u00015EI57I@HIF9\u0001=B8IGHFM\t\u0001\u0019@@\u0001H<9\u00015A=BC\u000189F=J5H=J9G\u0001 \n\u0003\u0006\u0007\u0001 \u0014\u0001\nDF9G9BH98\u0001<=;<\u000157H=J=HM\u00015;5=BGH\u0001 %\u0006\u00011'6/8/191 \u00015B8\u0001BC\u000157H=J=HM\u00015;5=BGH\u00015BM\u0001C:\u0001H<9\u0001H<F99\u0001 \f\u000b\u0001\nD5H<C;9B=7\u0001<IA5B\u0001657H9F=5\u0001GHF5=BG\u0007\u000169=B;\u0001H<9F9:CF9\u0001;CC8\u000175B8=85 H9G\u0001:CF\u00015EI57I@HIF9\u0001 \f\f\u0001\nHF95HA9BHG\t\u0001\f\r\u0001\n\u0001\f\u000e\u0001\n\u0016\"42+-!.\u000f\u0001\u001bCIA5F=B\u0007\u00017<5@7CB9\u0007\u00015BH=657H9F=5@\u0007\u0001 %+2')/(')9091\u00011'6/8/191 \u0007\u0001\u0019EI=7I@HIF9\u0001\u0001 \f\u000f\u0001\n\u0001\f\u0010\u0001\n\u0001\f\u0011\u0001\n\u0001\f\u0012\u0001\n\u0001\f\u0013\u0001\n\u0001\f\u0014\u0001\n\u0001\r\u000b\u0001\n\u0001\r\f\u0001\n\u0001\r\r\u0001\n\u0001\r\u000e\u0001\n\u0001\r\u000f\u0001\n\u0001\r\u0010\u0001\n\u0001\r\u0011\u0001Page 2 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u0018221\u0001 \u000e\u0001\u0015*/-+!0 /&+*\u0001\r\u0012\u0001\n%+2')/(')9091\u00011'6/8/191 \u0001\u0003%\u0006\u00011'6/8/191 \u0004\u0007\u0001:CFA9F@M\u0001?BCKB\u00015G\u0001 \u00190+;/(')8+6\u00011'6/8/197\u0001 \r\u0013\u0001\n3\f4\u0007\u0001=G\u00015\u0001\u001fF5A\bB9;5H=J9\u00015B8\u0001:=@5A9BHCIG\u0001657H9F=IA\u0007\u0001F9GDCBG=6@9\u0001 :CF\u0001H9B57=657I@CG=G\u0001=B\u0001 \r\u0014\u0001\nA5F=B9\u0001:=G<\t\u0001,<9\u0001D5H<C@C;M\u0001C:\u0001H<9\u00018=G95G9\u000175IG98\u00016M\u0001H<=G\u0001A5F=B9 \u0001CF;5B=GA\u0001<5G\u0001A5=B@M\u0001 \u000e\u000b\u0001\n699B\u00015GGC7=5H98\u0001K=H<\u00017<5F57H9F=GH=7\u0001;FCGG\u0001@9G=CBG\u0001CB\u0001H<9\u00016C8M\u0001G IF:579\u0001C:\u0001:=G<\u0001GI7<\u00015G\u0001 \u000e\f\u0001\nI@79FG\u0007\u0001B97FCG=G\u0007\u00019FC898\u0001ACIH<\u0007\u0001:F5M98\u0001:=BG\u00015B8\u0001H5=@\u0001FCHG\u0007\u00015B8\u0001 GCA9H=A9G\u0001B97FCG=G\u0001CB\u0001H<9\u0001 \u000e\r\u0001\n;=@@G\u00015B8\u00019M9G\u00013\r\b\u00114\t\u0001\u0001\u000e\u000e\u0001\n\u001dJ9B\u0001H<CI;<\u0001H9B57=657I@CG=G\u0001<5G\u0001@CB;\u0001699B\u0001F97C;B=N98\u00015G\u00015\u00018=G95 G9\u0001C:\u0001:=G<\u0001=B\u0001\"5D5B\u0007\u0001H<9\u0001 \u000e\u000f\u0001\n=B:97H=CB\u0001 K5G\u0001 BCH\u0001 7CBG=89F98\u0001 C:\u0001 97CBCA=75@\u0001 =ADCFH5B79\u0001 IBH=@\u0001 G9F =CIG\u0001 ACFH5@=H=9G\u0001 \u000e\u0010\u0001\n5::97H=B;\u0001 \u001cCJ9F\u0001 GC@9\u0001 $30+'\u0001 730+'\u0001 =B\u0001 +7CH@5B8\u0001 K9F9\u0001 F9DCFH98\u0001 3\r\u0007\u00124\t\u0001 ,C\u0001 85H9\u0007\u0001 \u000e\u0011\u0001\nH9B57=657I@CG=G\u0001=G\u0001CB9\u0001C:\u0001H<9\u0001ACGH\u0001H<F95H9B=B;\u0001657H9F=5@\u0001=B:97H =CBG\u0001@=A=H=B;\u0001H<9\u00017I@HIF9\u0001C:\u0001 \u000e\u0012\u0001\nA5BM\u0001GD97=9G\u0001C:\u00017CAA9F7=5@\u0001J5@I9\u0001=B\u00018=GH=B7H\u0001;9C;F5D<=75@\u00015F95G \u0001C:\u0001H<9\u0001KCF@8\u00013\u00134\t\u0001\u0001 \u000e\u0013\u0001\n\u001c9GD=H9\u0001H<9\u0001G=;B=:=75B79\u0001C:\u0001 %\u0006\u00011'6/8/191 \u0001=B\u0001H<9\u00015EI57I@HIF9\u0001=B8IGHFM\u0007\u0001F9@5H=J9@M\u0001@=HH@9\u0001=G\u0001 \u000e\u0014\u0001\n?BCKB\u000156CIH\u0001H<9\u0001D5H<C;9B=7=HM\u0001C:\u0001H<=G\u0001657H9F=IA\t\u0001 \u001c2\u0001:/863\u0001GHI8=9G\u0001CB\u0001H<9\u0001GIG79DH=6=@=HM\u0001C:\u0001 \u000f\u000b\u0001\n%\u0006\u00011'6/8/191 \u0001HC\u0001J5F=CIG\u00017<9ACH<9F5D9IH=7\u00015;9BHG\u0001=B8=75H9\u0001H<5H\u0001657H9F=5@\u0001GHF 5=BG\u0001=GC@5H98\u0001 \u000f\f\u0001\n:FCA\u00018=::9F9BH\u0001<CGH\u0001GD97=9G\u00015B8\u0001;9C;F5D<=75@\u0001F9;=CBG\u00019L<=6=H\u00015\u0001 G=A=@5F\u0001D5HH9FB\u0007\u0001K=H<\u0001 \u000f\r\u0001\nF9GD97H\u0001 HC\u0001 GIG79DH=6=@=HM\u0001 HC\u0001 B=HFC:IF5BG\u0007\u0001 D9B=7=@@=BG\u0007\u0001 9FMH<FCA M7=B\u0007\u0001 H9HF57M7@=B9G\u0007\u0001 \u000f\u000e\u0001\n7<@CF5AD<9B=7C@\u0007\u0001HF=A9H<CDF=A\u0007\u0001DCH9BH=5H98\u0001GI@:CB5A=89G\u00015B8\u0001:@I CFCEI=BC@CB9G\u0007\u00015B8\u0001 \u000f\u000f\u0001\nF9G=GH5B79\u0001HC\u00017C@=GH=B\u0007\u0001?5B5A=7MB\u0007\u0001B9CA=7MB\u00015B8\u0001H<9\u0001EI=BC@CB9G\u0007 \u0001CLC@=B=7\u000157=8\u00015B8\u0001 \u000f\u0010\u0001\n:@IA9EI=B9\u00013\u00144\t\u0001\u0001\u000f\u0011\u0001\n\u0019ACB;\u0001H<9\u00018FI;G\u0001IG98\u0001=B\u0001H<9\u0001D5GH\u0001:9K\u0001M95FG\u0001=B\u0001HIF6CH\u00015B8\u0001GC@9\u00017 I@HIF9G\u0001\u0003H9HF57M7@=B9\u0007\u0001 \u000f\u0012\u0001\n9BFC:@CL57=B\u0007\u0001:@IA9EI=B9\u00015B8\u0001DCH9BH=5H98\u0001GI@:CB5A=89G\u0004\u0007\u00019BFC:@C L57=B\u0001DFCJ98\u0001HC\u000169\u0001H<9\u0001 \u000f\u0013\u0001\nACGH\u0001IG9:I@\u00017CADCIB8\u0001:CF\u00017CBHFC@@=B;\u0001 %\u0006\u00011'6/8/191 \u0001CIH6F95?G\u0007\u00015@H<CI;<\u0001H<9\u0001F5D=8\u0001 \u000f\u0014\u0001\n5DD95F5B79\u0001C:\u0001F9G=GH5BH\u0001GHF5=BG\u0001<5G\u00015@F958M\u0001699B\u000189G7F=698\u0001\u0003\u001e=; IF9\u0001\f\u0004\u00013\f\u000b4\t\u0001 CK9J9F\u0007\u0001 \u0010\u000b\u0001\n8IF=B;\u0001H<9\u0001@5GH\u0001:9K\u0001M95FG\u0007\u00019BFC:@CL57=B\u0007\u00015\u0001A9A69F\u0001C:\u0001H<9\u0001\u000f\bEI=B C@CB9\u0001;FCID\u0001K=H<\u00016FC58\u0001 \u0010\f\u0001Page 3 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u0019222\u0001 \u000f\u0001GD97HFIA\u000157H=J=HM\u0007\u0001<5G\u0001F979=J98\u0001;FCK=B;\u00015HH9BH=CB\u0001:CF\u0001=HG\u0001DCH9BH=5@\u0001=B\u0001:=G<\u0001H<9F5DM\u00015;5=BGH\u0001\u0010\r\u0001\n=B:97H=CBG\u000175IG98\u00016M\u0001657H9F=5@\u0001D5H<C;9BG\u00013\f\f\u0007\f\r4\t\u0001\u0001\u0010\u000e\u0001\n\u0019ACB;\u0001CH<9F\u00018=::9F9BH\u0001<9H9FC7M7@=7\u00017CADCIB8G\u0007\u00017CIA5F=BG\u00015F9\u00015\u0001@ 5F;9\u00015B8\u0001K9@@\b?BCKB\u0001 \u0010\u000f\u0001\n:5A=@M\u0001C:\u00017CADCIB8G\u0001C:\u0001B5HIF5@\u00015B8\u0001GMBH<9H=7\u0001CF=;=B\u0001K=H<\u0001;F95H\u0001 GHFI7HIF5@\u0001J5F=9HM\u0001 \u0010\u0010\u0001\nF9GDCBG=6@9\u0001:CF\u00015\u0001K=89\u0001F5B;9\u0001C:\u0001D<5FA57C@C;=75@\u000157H=J=H=9G\u00013\f\u000e\u0007 \f\u000f4\t\u0001*979BH\u0001GHI8=9G\u0001D5M\u0001 \u0010\u0011\u0001\nGD97=5@\u0001 5HH9BH=CB\u0001 HC\u0001 H<9=F\u0001 5BH=\b=B:@5AA5HCFM\u0001 3\f\u0010\u0007\f\u00114\u0007\u0001 5BH=CL=85 H=J9\u0001 3\f\u0012\u0007\f\u00134\u0007\u0001 \u0010\u0012\u0001\n75F8=CDFCH97H=J9\u00013\f\u00144\u0007\u00015BH=HIACF\u00013\r\u000b\u0007\r\f4\u0007\u00015BH=A=7FC6=5@\u00013\r\r\b\r\u000f4 \u00015B8\u00019BNMA5H=7\u0001=B<=6=H=CB\u0001 \u0010\u0013\u0001\n3\r\u0010\u0007\r\u00114\u0001 DFCD9FH=9G\t\u0001 \u0019G\u0001 K9@@\u0001 5G\u0001 7CIA5F=BG\u0007\u0001 H<9F9\u0001 5F9\u0001 =ADCFH5BH\u0001 B5HIF5@\u0001 C77IFF=B;\u0001\u0010\u0014\u0001\n5BH=6=CH=7G\u00017CBH5=B=B;\u0001H<9\u000169BNCDMFCB9\u0001AC=9HM\u0007\u0001GI7<\u00015G\u0001BCJC6=C7 =B\u0007\u00017<@CFC6=C7=B\u00015B8\u0001 \u0011\u000b\u0001\n7CIA9FAM7=B\u0001\u0019 \f\u0001\u0003\u001e=;IF9\u0001\r\u0004\t\u0001\u0001+D97=5@\u00015HH9BH=CB\u000175B\u000169\u0001D5=8\u0001HC\u00015A=BC7CIA5F=BG\u0007\u0001 K<=7<\u0001 \u0011\f\u0001\nF9DF9G9BHG\u00015\u00017@5GG\u0001C:\u00015BH=6=CH=7G\u0001H<5H\u000157H\u00016M\u0001H<9\u0001=B<=6=H=CB\u0001C: \u0001H<9\u0001\u001c&\u0019\u0001;MF5G9\u00019BNMA9\u0001 \u0011\r\u0001\n=BJC@J98\u0001=B\u0001H<9\u000179@@\u00018=J=G=CB\u0001=B\u0001657H9F=5\u00016M\u00016=B8=B;\u0001H=;<H@M\u0001HC \u0001=HG\u0001\u001a\u0001GI6IB=H\u0007\u0001H<9F96M\u0001 \u0011\u000e\u0001\n=B<=6=H=B;\u0001H<=G\u00019GG9BH=5@\u00019BNMA9\u00013\r\u00124\t\u0001\u0001\u0011\u000f\u0001\n\u0001 \u0011\u0010\u0001\n\u0003\u001e=;IF9\u0001\f\u0004\u0001 \u0011\u0011\u0001\n\u0001\u0011\u0012\u0001\n\u001bCIA5F=B\u000189F=J5H=J9G\u00017CI@8\u000169\u00017CBG=89F98\u00015G\u0001GHFI7HIF5@@M\u0001G=A=@5 F\u0001EI=BC@CB9\u00018FI;G\u0001 \u0011\u0013\u0001\n\u000369BNCDMF=8CB9\u0001AC=9HM\u0004\u0007\u0001K=89@M\u0001IG98\u0001=B\u00017@=B=7\u00015B8\u0001K=H<\u00015\u00016FC58\u0001 5BH=A=7FC6=5@\u0001GD97HFIA\u0007\u0001 \u0011\u0014\u0001\n=B7@I8=B;\u0001A5BM\u00019B7CIBH9F98\u0001D5H<C; 9BG\u0001\u0003\u001e=;IF9\u0001\r\u0004\u00013\r\u00134\t\u0001,<=G\u0001:57H \u0001A5?9G\u0001H<9\u0001GHI8M\u0001C:\u0001 \u0012\u000b\u0001\nEI=BC@CB9\b@=?9\u00017CADCIB8G\u00015B\u0001=BH9F9GH=B;\u0001HCD=7\u0001CB\u0001H<=G\u0001F9G95F7<\u0001 5F95\t\u0001\u0001 \u0012\f\u0001\n'B\u0001H<9\u0001CH<9F\u0001<5B8\u0007\u00017<5@7CB9G\u00015F9\u0001DFCA=B9BH\u0001G97CB85FM\u0001A9H56C@=H9G\u0001DF97IFGCFG\u0001C:\u0001\u0012\r\u0001\n:@5JCBC=8G\u00015B8\u0001=GC:@5JCBC=8G\u0001=B\u0001D@5BHG\t\u0001\u001b<9A=75@@M\u0007\u0001H<9M\u00017CBG=G H\u0001C:\u0001HKC\u00015FCA5H=7\u0001F=B;G\u0001 \u0012\u000e\u0001\n@=B?98\u00016M\u00015\u0001H<F99\b75F6CB\u0001 \u0001\u0007\u0002\bIBG5HIF98\u0001GMGH9AG\u0001H<5H\u00015F9\u0001?BCK\u0001HC\u00019L<=6=H\u00015B\u0001=ADF9GG=J9\u0001 \u0012\u000f\u0001\n5FF5M\u0001C:\u00016=C@C;=75@\u0001DFCD9FH=9G\u00013\r\u00144\t\u0001\u0019ACB;\u0001H<9A\u0007\u0001=H\u0001=G\u0001F9A5F?56 @9\u0001HC\u0001A9BH=CB\u0001H<9=F\u0001 \u0012\u0010\u0001Page 4 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001a223\u0001 \u0010\u00015BH=657H9F=5@\u00013\u000e\u000b\u0007\u000e\f4\u0007\u00015BH=A5@5F=5@\u00013\u000e\r\u0007\u000e\u000e4\u0007\u00015BH=:IB;5@\u00013\u000e\u000f4\u0007\u00015 BH=J=F5@\u00013\u000e\u0010\u0007\u000e\u00114\u00015B8\u00015BH=\b \u0012\u0011\u0001\n=B:@5AA5HCFM\u00013\u000e\u0012\u0007\u000e\u00134\u0001DFCD9FH=9G\t\u0001\u0012\u0012\u0001\n\u0001\u0012\u0013\u0001\n\u0003\u001e=;IF9\u0001\r\u0004\u0001 \u0012\u0014\u0001\n\u0001\u0013\u000b\u0001\n,5?=B;\u0001=BHC\u0001577CIBH\u0001H<9\u000197CBCA=75@\u0001=ADCFH5B79\u0001C:\u0001H<9\u0001A5F=B9\u0001:=G <\u00018=G95G9G\u0001=B\u0001H<9\u0001 \u0013\f\u0001\n5EI57I@HIF9\u0001=B8IGHFM\u00015B8\u0001H<9\u0001=B7F95G=B;\u0001B998\u0001C:\u0001:=B8=B;\u0001B9K\u00018FI ;\u000175B8=85H9G\u0001:CF\u0001H<9\u0001 \u0013\r\u0001\nHF95HA9BH\u0001C:\u0001 H9B57=657I@CG=G\u0007\u0001K9\u0001<5J9\u000189G=;B98\u00015B8\u0001GMBH<9G=N98\u0001 BCJ9@\u00017CIA5F=B\b \u0013\u000e\u0001\n7<5@7CB9\u0001<M6F=8\u00017CADCIB8G\u00015B8\u0001H9GH98\u0001H<9=F\u0001 /2\u0001:/863\u00015BH=657H9F=5@\u000157H=J=HM\u0001\u0003\u001e=;IF9\u0001\u000e\u0004\t\u0001/9\u0001 \u0013\u000f\u0001\n<5J9\u0001G9@97H98\u0001H<F99\u0001<IA5B\u0001D5H<C;9B=7\u0001657H9F=5\u0001GHF5=BG\u0001\u0003 \u0018\u0006\u0001)30/\u0007\u0001$\u0006\u0001'96+97\u00015B8\u0001\"\u0006\u0001 \u0013\u0010\u0001\n'+69-/237'\u0004\u00015B8\u0001H<F99\u00018=::9F9BH\u0001 %\u0006\u00011'6/8/191\u0001786'/27 \u0001\u0003,%\u0001$\u001b\u000b\u0012\u0001\f\u000b\t\f\t\r\u0007\u0001,%\u0001\u001b<=@9\u00015B8\u0001 \u0013\u0011\u0001\n,%\u0001$$\u000b\f\u0001\u0013\t\u000e\t\u0013\u0004\u0001K=H<\u0001H<9\u00015=A\u0001C:\u0001:=B8=B;\u0001B9K\u00018FI;\u000175B8=85H9\u0007\u000157H= J9\u00015;5=BGH\u0001H<=G\u0001A5F=B9\u0001 \u0013\u0012\u0001\nD5H<C;9B\u00016IH\u0001BCH\u000157H=J9\u0001K=H<\u0001D5H<C;9B=7\u0001<IA5B\u0001657H9F=5\u0001=B\u0001CF89F \u0001HC\u00015JC=8\u00018FI;\u0001 \u0013\u0013\u0001\nF9G=GH5B79\u0001 DFC6@9AG\u0001 =B\u0001 <IA5BG\t\u0001 \u001a5G98\u0001 CB\u0001 DF9J=CIG\u0001 :=B8=B;G\u0007\u0001 =B\u0001 5 A=BC7CIA5F=B\u0001 \u0013\u0014\u0001\n89F=J5H=J9G\u0007\u0001=B\u0001H<9\u0001EI=BC@CB9\b@=?9\u00015BH=657H9F=5@\u00018FI;G\u00015B8\u0001=B\u0001CIF\u00019LD9F=9B79\u0001K=H<\u0001\u000e\b\u0014\u000b\u0001\nGI6GH=HIH98\u00017CIA5F=BG\u00013\u000e\u0014\b\u000f\f4\u0001K9\u0001<5J9\u000189G=;B98\u00015B8\u0001GMBH<9G=N98\u0001 7CIA5F=B\b7<5@7CB9\u0001 \u0014\f\u0001\n<M6F=8\u00017CADCIB8G\u00015B8\u0001H9GH98\u0001H<9=F\u00015BH=657H9F=5@\u00015;5=BGH\u0001H<9\u0001DF9 J=CIG\u0001A9BH=CB98\u0001GHF5=BG\t\u0001 \u0014\r\u0001\n\u0003\u001e=;IF9\u0001\u000e\u0004\u0001 \u0014\u000e\u0001\n\u0001\u0014\u000f\u0001\n\u0017\u001e/\"-&\u001e(.\u0001\u001e*!\u0001)\"/%+!. \u0001 \u0014\u0010\u0001\n%9@H=B;\u0001DC=BHG\u0001\u0003AD\u0004\u00015F9\u0001IB7CFF97H98\u00015B8\u0001K9F9\u000189H9FA=B98\u0001K=H<\u00015\u0001 *9=7<9FH\u0001#C:@9F\u0001 \u0014\u0011\u0001\nH<9FACD5B\u0001CF\u0001=B\u000175D=@@5FM\u0001HI69G\u0001=B\u00015\u0001\u001aI7<=\u0001\u0010\f\u000b\u00015DD5F5HIG\t\u0001\f \u0001&%*\u0001\u0003\u000e\u000b\u000b\u0001% N\u0004\u00015B8\u0001\f\u000e\u001b\u0001 \u0014\u0012\u0001\n&%*\u0001\u0003\u0012\u0010\t\u000f\u0001% N\u0004\u0001GD97HF5\u0001K9F9\u0001F97CF89F\u0001K=H<\u00015\u0001\u001aFI?9F\u0001\u0019%0\u0001GD97HFCA 9H9F\t\u0001\u001b<9A=75@\u0001 \u0014\u0013\u0001\nG<=:HG\u0001\u0003b\u0004\u00015F9\u00019LDF9GG98\u0001=B\u0001D5FHG\u0001D9F\u0001A=@@=CB\u0001\u0003DDA\u0004\u0001IG=B;\u0001,%+\u00015 G\u00015B\u0001=BH9FB5@\u0001GH5B85F8\t\u0001 \u0014\u0014\u0001\n+D=B\u0001AI@H=D@=7=H=9G\u00015F9\u0001;=J9B\u00015G\u0001G\u0001\u0003G=B;@9H\u0004\u0007\u00018\u0001\u00038CI6@9H\u0004\u0007\u000188\u0001\u0003 8CI6@9H\u0001C:\u00018CI6@9HG\u0004\u00015B8\u0001A\u0001 \f\u000b\u000b\u0001Page 5 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001b224\u0001 \u0011\u0001\u0003AI@H=D@9H\u0004\t\u0001%5GG\u0001GD97HFCA9HFM\u0001K5G\u000175FF=98\u0001CIH\u0001K=H<\u00015\u0001#F5HCG\u0001%+ \b\u0010\u000b\u0001CF\u00015\u0001.5F=5B\u0001%\u0019,\b \f\u000b\f\u0001\n\u0012\f\f\u0001 GD97HFCA9H9F\t\u0001 \u001d@9A9BH5@\u0001 5B5@MG 9G\u0001 K9F9\u0001 D9F:CFA98\u0001 6M\u0001 5\u0001 (9F?=B \b\u001d@A9F\u0001 \r\u000f\u000b\u001a\u0001 \f\u000b\r\u0001\nA=7FC5B5@MN9F\u0001 5B8\u0001 K9F9\u0001 K=H<=B\u0001 X\u000b\t\u000f\u0002\u0001 C:\u0001 75@7I@5H98\u0001 J5@I9G\u0001 =B\u0001 5@@ \u0001 75G9G\t\u0001 \u001e@5G<\u0001 \f\u000b\u000e\u0001\n\u001b<FCA5HC;F5D<M\u0001 \u0003\u001e\u001b\u0004\u0001 K5G\u0001 D9F:CFA98\u0001 CB\u0001 G=@=75\u0001 ;9@\u0001 \u0003%9F7?\u0001 \u0011\u000b\u0007\u0001 \r\u000e\u000b\b \u000f\u000b\u000b\u0001 A9G<\u0004\u0016\u0001 \f\u000b\u000f\u0001\n5B5@MH=75@\u0001,$\u001b\u0001K5G\u0001D9F:CFA98\u0001CB\u0001DF97C5H98\u0001G=@=75\u0001;9@\u0001D@5H9G\u0001\u0003%9 F7?\u0001\u0011\u000b\u0001\u001e\r\u0010\u000f\u0004\t\u0001 \f\u000b\u0010\u0001\n\u0001\f\u000b\u0011\u0001\n\u001a+2+6'0\u0001463)+*96+\u0001,36\u00018.+\u00017<28.+7/7\u00013,\u0001\u000b\u0005(+2=3<0)391'6/27 \u0001\u0006\u0003\t\u0015\u0001 \f\u000b\u0012\u0001\n, C \u00015 \u0001G C @ I H = C B \u0001C : \u0001H < 9 \u00015 D D F C D F = 5 H 9 \u0001 \u0002\b?9HC9GH9F\u0001 \u0003\f\u0001 AAC@\u0004\u0001 5B8\u0001 H<9\u0001 7CFF9GDCB8=B;\u0001 \f\u000b\u0013\u0001\nG5@=7M@5@89<M89\u0001\u0003\f\u0001AAC@\u0004\u0001=B\u00019H<5BC@\u0001\u0003\u000e\u0001A$\u0004\u0001K5G\u000158898\u0001D=D9F=8=B9 \u0001=B\u000175H5@MH=7\u00015ACIBH\t\u0001 \f\u000b\u0014\u0001\n,<9\u0001A=LHIF9\u0001K5G\u0001F9:@IL98\u0001:CF\u0001\r\\\u0010\u0001<\u00015B8\u00015:H9F\u00017CAD@9H=CB\u0001\u0003:C@@CK 98\u00016M\u0001,$\u001b\u0004\u0007\u0001H<9\u0001 \f\f\u000b\u0001\nF957H=CB\u0001K5G\u00017CC@98\u00015B8\u0001H<9\u0001DF97=D=H5H98\u0001K5G\u0001:=@H9F98\u00015B8\u0001K5G<9 8\u0001K=H<\u00017C@8\u00019H<5BC@\u00015B8\u0001 \f\f\f\u0001\n9H<9F\u0001HC\u00015::CF8\u0001H<9\u000189G=F98\u00017CADCIB8\t\u0001\u001bCADCIB8G\u0001K9F9\u0001:IFH<9F\u0001F9 7FMGH5@@=N98\u0001:FCA\u0001 \f\f\r\u0001\n%9' \n\u001b \r\u001b@\r\t\u0001 \f\f\u000e\u0001\n\u000b\u0005\u0015+2=3<0\u0005\u0010\u0005+8.3;<)391'6/2 \u0001\u0003\b\u0004\u0015\u00011=9@8\u0001\u0003\u0011\u000b\u0002\u0004\u0007\u0001AD\u0001\f\u000f\f\b\f\u000f\u000e\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001 \f\f\u000f\u0001\n\u001b\u001c\u001b@\u000e\u0004\u0001?\u0001DDA\u0001\u0012\t\u0013\u0014\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0012\f\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u000e\u0001 N\u0007\u0001\r \u0007\u0001 \b\r]\u0007\u0001 \b\u0011]\u0004\u0007\u0001\u0012\t\u000f\u000f\u0001\u0003H\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\f\u0001 \f\f\u0010\u0001\n N\u0007\u0001\f \u0007\u0001 \b\u000f]\u0004\u0007\u0001\u0012\t\u000e\u0011\b\u0012\t\r\u000e\u0001\u0003A\u0007\u0001\r \u0007\u0001 \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0012\t\f\u000f\b\u0011\t\u0014\f\u0001\u0003A\u0007\u0001\u000e \u0007 \u0001 \b\u0010\u0007\u0001 \b\u0011\u0007\u0001 \b\u0012\u0004\u0007\u0001\u000f\t\u000b\u0010\u0001 \f\f\u0011\u0001\n\u0003E\u0007\u0001\u001d\u0001\u0017\u0001\u0012\t\u000b\u0001 N\u0007\u0001\r \u0007\u0001\u001b \r\u0004\u0007\u0001\f\t\u000e\u0010\u0001\u0003H\u0007\u0001\u001d\u0001\u0017\u0001\u0012\t\u000b\u0001 N\u0007\u0001\u000e \u0007\u0001\u001b \u000e\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001b\u001c\u001b@ \u000e\u0004\u0001?\u0001 \f\f\u0012\u0001\nDDA\u0001\f\u0014\r\t\f\u0010\u0007\u0001\f\u0010\u0013\t\u000f\u0012\u0007\u0001\f\u000f\u0012\t\u000b\u000b\u0007\u0001\f\u000f\u0011\t\u000b\u0011\u0007\u0001\f\u000f\u0010\t\u000b\u0011\u0007\u0001\f\u000e\u0011\t\u0010\u0012\u0007\u0001\f\u000e\u000f\t\f\u0011\u0007\u0001\f\u000e\u000b \t\u000b\u000b\u0007\u0001\f\r\u0013\t\u0014\u000e\u0007\u0001\f\r\u0012\t\u0011\f\u0007\u0001 \f\f\u0013\u0001\n\f\r\u0010\t\f\u0013\u0007\u0001\f\r\u000b\t\u0011\u0013\u0007\u0001\f\f\u0014\t\r\u0012\u0007\u0001\f\f\u0011\t\u0013\r\u0007\u0001\u0011\u0010\t\u0010\u000b\u0007\u0001\f\u0010\t\f\r\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\r\u0014\u0010\u0001\u00033%\u0006\f4\u0006\u0007\u0001\r\u0013\u0004\u0007\u0001\r\u0014\u000f\u0001 \f\f\u0014\u0001\n\u00033%4\u0006\u0007\u0001\u0012\u0013\u0004\u0007\u0001\r\u0011\u0011\u0001\u0003\u000f\u000e\u0004\u0007\u0001\r\u000e\u0012\u0001\u0003\u000e\u0010\u0004\u0007\u0001\f\u000b\u0010\u0001\u0003\f\u000b\u000b\u0004 \u0007\u0001\u0012\u0012\u0001\u0003\u0012\u0012\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF \u0001\u001b\f\u0013 \f\u000f'\u000f\u0015\u0001\u001b\u0007\u0001\u0012\u000e\t\u000f\u0011\u0016\u0001 \f\r\u000b\u0001\n \u0007\u0001\u000f\t\u0012\u0014\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0012\u000e\t\u000b\u0011\u0016\u0001 \u0007\u0001\u000f\t\u000f\u0010\t\u0001\f\r\f\u0001\n\u000e\u0005\u00156313\u0005\u000b\u0005(+2=3<0)391'6/2 \u0001\u0003\t\u0004\u0015\u00011=9@8\u0001\u0003\u0010\u0013\u0002\u0004\u0007\u0001AD\u0001\f\u0012\u000e\b\f\u0012\u0010\u0001[\u001b\u0016\u0001\f \b&%*\u0001\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001 \f\r\r\u0001\n\u001b\u001c\u001b@\u000e\u0004\u0001?\u0001DDA\u0001\u0013\t\u000b\f\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0014\f\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0012\t\u0010\u0001 N\u0007\u0001\r \u0007\u0001 \b\r]\u0007\u0001 \b\u0011]\u0004\u0007\u0001\u0012\t\u0013\f\b\u0012\t\u0012\r\u0001\u0003A\u0007\u0001\r \u0007\u0001 \f\r\u000e\u0001\n \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0012\t\u0011\u0011\u0001\u0003H\u0007\u0001 \u001d\u0001\u0013\u0001\u0012\t\u000e\u0001 N\u0007\u0001\f \u0007\u0001 \b\u000f]\u0004\u0007\u0001\u0012\t\u0010\u0010\u0001\u00038\u0007\u0001 \u001d\u0001\u0013\u0001\u0013\t\u000e\u0001 N\u0007\u0001\r \u0007\u0001 \b\u0012\u0007\u0001 \b\u0013\u0004\u0007\u0001\u0012\t\u000e\u000e\u0001\u00038\u0007\u0001 \f\r\u000f\u0001\n\u001d\u0001\u0013\u0001\u0014\t\u000e\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0010\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0011\u000e\u0001% N\u0007\u0001\u001b\u001c\u001b@ \u000e\u0004\u0001b\u0001\f\u0014\f\t\u000f\u0013\u0007\u0001\f\u0010\u0013\t\u000b\u0014\u0007\u0001\f\u0010\u000e\t\u0014\f\u0007\u0001\f\u000f\u000f\t\f\u000b\u0007\u0001 \f\r\u0010\u0001Page 6 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001c225\u0001 \u0012\u0001\f\u000e\u0011\t\u0011\u000f\u0007\u0001 \f\u000e\u0011\t\r\u0012\u0007\u0001\f\u000e\u000f\t\u000f\u000e\u0007\u0001 \f\u000e\f\t\u0011\u000f\u0007\u0001\f\r\u0014\t\u0014\u0013\u0007\u0001\f\r\u0014\t\u000b\u0012\u0007\u0001\f\r\u0013\t\u0010\f\u0007\u0001\f\r\f\t\u0011\u0012\u0007 \u0001 \f\r\u000b\t\u000b\u000e\u0007\u0001\f\f\u0014\t\u000b\u000f\u0007\u0001 \f\r\u0011\u0001\n\f\f\u0012\t\u0014\f\u0007\u0001\f\u000b\u0013\t\r\u0011\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\u000e\u000e\f\u0001\u00033%\u0006\r4\u0006\u0007\u0001\r\u0011\u0004\u0007\u0001\u000e\u000e\u000b\u0001\u00033%\u0006\f4\u0006\u0007\u0001\u0011\u0004\u0007\u0001\u000e\r\u0014\u0001\u00033%4\u0006\u0007\u0001\r\u0012\u0004\u0007\u0001\f\u000b\u0010\u0001 \f\r\u0012\u0001\n\u0003\f\u000b\u000b\u0004\u0007\u0001\u0012\u0012\u0001\u0003\u0013\u0012\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0012 \f\f\u001aF'\u000f\u0015\u0001\u001b\u0007\u0001\u0010\u0011\t\u0013\u0010\u0016\u0001 \u0007\u0001\u000e\t\u000b\u0014\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0010\u0011\t\u0010\f\u0016\u0001 \u0007\u0001 \f\r\u0013\u0001\n\u000e\t\u000b\r\t\u0001\f\r\u0014\u0001\n\u0001\f\u000e\u000b\u0001\n\u001a+2+6'0\u0001463)+*96+\u0001,36\u00018.+\u00017<28.+7/7\u00013,\u0001'1/23\u0001\u000b\u0005(+2=3<0)391'6/27 \u0001\n\u0003\u0006\u0007\u0015\u0001\u001eC@@CK=B;\u0001H<9\u0001 \f\u000e\f\u0001\nG5A9\u0001 DFC798IF9\u0001 89G7F=698\u0001 :CF\u0001 H<9\u0001 GMBH<9G=G\u0001 C:\u0001 89F=J5H=J9G\u0001 \u0006\u0003\t\u0007\u0001 H<9\u0001 B=HFC\u0001 \u000e\b \f\u000e\r\u0001\n69BNCM@7CIA5F=B\u000189F=J5H=J9G\u0001K9F 9\u0001DF9D5F98\u00015B8\u0001K9F9\u0001IG98\u0001K=H<CIH \u0001:IFH<9F\u0001DIF=:=75H=CB\t\u0001 \f\u000e\u000e\u0001\n,C\u00015\u0001GC@IH=CB\u0001C:\u0001H<9\u00017CFF9GDCB8=B;\u0001B=HFC\u0001\u000e\b69BNCM@7CIA5F=B\u0001\u0003\f\u0001AAC@\u0004\u0001=B\u0001DIF9\u00019H<5BC@\u0001\u0003\u0010\u0001\f\u000e\u000f\u0001\nA$\u0004\u0001K5G\u0001HF95H98\u0001K=H<\u0001+B\u001b@ \r\t\r \r'\u00015B8\u0001H<9\u0001F9GI@H=B;\u0001A=LHIF9\u0001K5G\u0001@9:H\u0001IB89F\u0001F9:@IL\u0001:CF\u0001\u000e\b \f\u000e\u0010\u0001\n\u0012<\t\u0001\u0019:H9F\u00017CAD@9H=CB\u0001C:\u0001F957H=CB\u0001ACB=HCF98\u00016M\u0001,$\u001b\u0007\u0001K5H9F\u0001K5G\u0001DCIF98\u0001CJ9F\u0001H<9\u0001F957H=CB\u0001\f\u000e\u0011\u0001\nA=LHIF9\u0001\u0003\f\u0010\u0001A$\u0004\u0007\u00015B8\u0001H<9\u0001GC@IH=CB\u0001K5G\u0001:IFH<9F\u0001B9IHF5@=N98\u0001K=H<\u0001 5\u0001\u0010\u0002\u0001&5 \u001b' \u000e\u0001GC@IH=CB\t\u0001\u0001 \f\u000e\u0012\u0001\n\u001dLHF57H=CB\u0001K5G\u000175FF=98\u0001CIH\u0001K=H<\u0001\u001dH'\u00197\u0001\u0003\u000eL\u0001\r\u000b\u0001A$\u0004\u0007\u0001H<9\u00017CA6=B98\u0001 CF;5B=7\u0001@5M9FG\u0001K9F9\u0001 \f\u000e\u0013\u0001\n8F=98\u0001CJ9F\u00015B<M8F=89\u0001&5 \r+'\u000f\u00015B8\u0001GC@J9BH\u0001K5G\u00017CAD@9H9@M\u0001F9ACJ98\t\u0001,<9\u00017FI89\u0001K5G\u0001 \f\u000e\u0014\u0001\nDIF=:=98\u00016M\u0001:@5G<\u00017<FCA5HC;F5D<M\u0001\u0003\u0012\u0015\u000e\u0001 9L5B9\n\u001dH'\u00197\u0004\u0001HC\u00015::CF8\u0001H <9\u000189G=F98\u00015A=BC\u0001 \f\u000f\u000b\u0001\n89F=J5H=J9G\t\u0001\f\u000f\f\u0001\n\u000b\u0005\u0002\f>\u0005'1/23(+2=3<0\u0003)391'6/2 \u0001\u0003\n\u0004\u0015\u00011=9@8\u0001\u0003\u0011\u0012\u0002\u0004\u0007\u0001AD\u0001\r\u000b\f\b\r\u000b\u000e\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001 \f\u000f\r\u0001\n\u001c%+'\b*\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\f\u0011\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0012\u0013\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0012\t\u0010\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0010\u0004\u0007\u0001\u0012\t\u0012\f\b\u0012\t\u0010\u0011\u0001\u0003A\u0007\u0001\u000e \u0007\u0001 \b \f\u000f\u000e\u0001\n\u0012\u0007\u0001 \r]\u0007\u0001 \b\u0011]\u0004\u0007\u0001\u0012\t\u000f\u0014\b\u0012\t\u000e\r\u0001\u0003A\u0007\u0001\r \u0007\u0001 \b\u0011\u0007\u0001 \b\u0013\u0004\u0007\u0001\u0011\t\u0010\u0014\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\r\u0001 N\u0007\u0001\r \u0007\u0001 \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0011\t\r\u0012\u0001 \f\u000f\u000f\u0001\n\u00036G\u0007\u0001\r \u0007\u0001\b& \r\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\f\u0013\u0013\t\u000e\u0014\u0007\u0001\f\u0010\u0013\t\u000f\f\u0007\u0001\f\u0010\u000f\t\u0014\u000e\u0007\u0001\f\u0010\u000e\t\u0013\u000e\u0007\u0001 \f\u000f\u0010\u0001\n\f\u000f\r\t\u0012\u000e\u0007\u0001\f\u000e\r\t\u0014\u0010\u0007\u0001\f\u000e\r\t\u0011\u0010\u0007\u0001\f\r\u0014\t\u000e\u0014\u0007\u0001\f\r\u0012\t\u0014\f\u0007\u0001\f\r\u000f\t\u0014\u000e\u0007\u0001\f\r\u000e\t\r\u0012\u0007\u0001\f\f\u0013\t\u0010\f\u0007 \u0001\f\f\u0011\t\u000e\u0014\u0007\u0001\f\f\r\t\u0012\u0014\t\u0001%+\u0001\u001d!\u0001 \f\u000f\u0011\u0001\n1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\r\u0011\u0011\u0001\u00033%\u0006\f4\u0006\u0007\u0001\u000f\u000b\u0004\u0007\u0001\r\u0011\u0010\u0001\u00033%4\u0006\u0007\u0001\u0013\u0014\u0004\u0007\u0001\r\u000e\u0012\u0001\u0003\f\u0013\u0004\u0007\u0001\r\u000e\u0011\u0001\u0003\f\u0012\u0004\u0007\u0001\f\r\f\u0001\u0003\u000e\f\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004\u0007\u0001\u0013\u0014\u0001 \f\u000f\u0012\u0001\n\u0003\f\u0011\u0004\u0007\u0001\u0011\u0010\u0001\u0003\u0011\u000e\u0004\u0007\u0001\u0011\u000e\u0001\u0003\f\u0013\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0011 \f\f&'\u000e\u0001\u001b\u0007\u0001\u0012\r\t\u000f\u0010\u0016\u0001 \u0007\u0001\u000f\t\f\u0013\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0012\r\t\r\u0012\u0016\u0001 \f\u000f\u0013\u0001\n \u0007\u0001\u000f\t\u000b\r\t\u0001\f\u000f\u0014\u0001Page 7 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001d226\u0001 \u0013\u0001\u000b\u0005\u0002\f>\u0005'1/23(+2=3<0\u0003\u0005\u0010 \u00051+8.3;<)391'6/2 \u0001\u0003\u000b\u0004\u0015\u00011=9@8\u0001\u0003\u0013\r\u0002\u0004\u0007\u0001AD\u0001\f\u0011\u0010\b\f\u0011\u0012\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0010\u000b\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\f\u0011\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0011\r\u0001\u000388\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0013\u0007\u0001\r\t\u000e\u0001 N\u0007\u0001\r \u0007\u0001 \b\r]\u0007\u0001 \b \f\u0010\f\u0001\n\u0011]\u0004\u0007\u0001\u0012\t\u000f\u000e\b\u0012\t\f\u0014\u0001\u0003A\u0007\u0001\u000e \u0007\u0001 \b\u0010\u0007\u0001 \b\u0011\u0007\u0001 \b\u0012\u0004\u0007\u0001\u0011\t\u0010\u0011\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0013\u0001 N\u0007\u0001\r \u0007\u0001 \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0011\t\u000e\u000e\u0001\u00036G\u0007\u0001 \f\u0010\r\u0001\n\r \u0007\u0001& \r\u0004\u0007\u0001\u000e\t\u0014\r\u0001\u0003G\u0007\u0001\u000e \u0007\u0001'\u001b \u000e\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\f\u0013\u0013\t\u000e\u0013\u0007\u0001\f\u0010\u000f\t\u0014\u000e\u0007\u0001 \f\u0010\u000e\u0001\n\f\u000f\u0011\t\u0010\u0010\u0007\u0001\f\u000f\r\t\u0014\u000f\u0007\u0001\f\u000e\r\t\u0011\u000e\u0007\u0001\f\r\u0013\t\f\u000b\u0007\u0001\f\r\u000f\t\u0013\u000f\u0007\u0001\f\r\u000e\t\r\u0010\u0007\u0001\f\r\u000b\t\u000f\u000f\u0007\u0001\f\f\u0014\t\u000b\u0012\u0007 \u0001\f\f\u0010\t\u000b\u0012\u0007\u0001\f\f\r\t\u0012\u0011\u0007\u0001\u0010\u0011\t\u000e\u000b\t\u0001 \f\u0010\u000f\u0001\n%+\u0001\u001d!\u00011\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\r\u0014\u0011\u0001\u00033%\u0006\f4\u0006\u0007\u0001\r\u000e\u0004\u0007\u0001\r\u0014\u0010\u0001\u00033%4\u0006\u0007\u0001\u0011\u0014\u0004\u0007\u0001\f\r\f\u0001\u0003\f\u0010\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004 \u0007\u0001\u0014\r\u0001\u0003\r\u0013\u0004\u0007\u0001\u0011\u0010\u0001\u0003\f\u0012\u0004\t\u0001 \f\u0010\u0010\u0001\n\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0012 \f\u000e&'\u000f\u0001\u001b\u0007\u0001\u0011\u0014\t\f\u0010\u0016\u0001 \u0007\u0001\u000f\t\u000f\u000f\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\f\r\u0016\u0001 \u0007\u0001\u000f\t\u000f\u000e\t\u0001 \f\u0010\u0011\u0001\n\u000b\u0005\u0002\f>\u0005'1/23(+2=3<0\u0003 \u0005\u0010\u0005+8.3;<)391'6/2 \u0001\u0003\f\u0004\u0015\u00011=9@8\u0001\u0003\u0011\r\u0002\u0004\u0007\u0001AD\u0001\r\r\f\b\r\r\r\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0010\u0012\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\f\u0011\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0011\f\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0012\u0001 N\u0007\u0001\r \u0007\u0001 \b\r]\u0007\u0001 \b\u0011]\u0004\u0007\u0001 \f\u0010\u0013\u0001\n\u0012\t\u000f\r\b\u0012\t\r\r\u0001\u0003A\u0007\u0001\u000e \u0007\u0001 \b\u0010\u0007\u0001 \b\u0011\u0007\u0001 \b\u0012\u0004\u0007\u0001\u0011\t\u0010\u0011\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0012\u0001 N\u0007\u0001\r \u0007\u0001 \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0011\t\u000e\u000e\u0001\u00036G\u0007\u0001\r \u0007\u0001 \f\u0010\u0014\u0001\n& \r\u0004\u0007\u0001\u000f\t\f\u0013\u0001\u0003E\u0007\u0001\u001d\u0001\u0017\u0001\u0011\t\u0014\u0001 N\u0007\u0001\r \u0007\u0001\u001b \r\u0004\u0007\u0001\f\t\u000f\u000b\u0001\u0003H\u0007\u0001\u001d\u0001\u0017\u0001\u0011\t\u0014\u0001 N\u0007\u0001\u000e \u0007\u0001\u001b \u000e\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001 \f\u0011\u000b\u0001\n\u001c%+'\b*\u000e\u0004\u0001b\u0001DDA\u0001\f\u0013\u0013\t\u000e\u0013\u0007\u0001\f\u0010\u0013\t\r\r\u0007\u0001\f\u0010\u000f\t\u0014\r\u0007\u0001\f\u000f\u0010\t\u0012\u0013\u0007\u0001\f\u000f\u000e\t\u000b\r\u0007\u0001\f\u000e\r\t\u0011\r\u0007\u0001\f\r\u0013\t\f\f\u0007 \u0001\f\r\u000f\t\u0013\u000f\u0007\u0001 \f\u0011\f\u0001\n\f\r\u000e\t\r\u0011\u0007\u0001\f\r\u000b\t\u000e\u0014\u0007\u0001\f\f\u0014\t\f\u0011\u0007\u0001\f\f\u0010\t\u0014\r\u0007\u0001\f\f\r\t\u0012\u000f\u0007\u0001\u0011\u000f\t\u0010\u0013\u0007\u0001\f\u000f\t\u0012\u0011\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\u000e\f\u000b\u0001\u00033%\u0006\f4\u0006\u0007\u0001 \f\u0011\r\u0001\n\r\u000f\u0004\u0007\u0001\u000e\u000b\u0014\u0001\u00033%4\u0006\u0007\u0001\u0011\u0012\u0004\u0007\u0001\r\u0013\f\u0001\u0003\f\r\u0004\u0007\u0001\r\u0013\u000b\u0001\u0003\f\f\u0004\u0007\u0001\f\r\f\u0001\u0003\f\u0013\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004\u0007\u0001\u0014\r\u0001\u0003\r\u0014\u0004\u0007\u0001\u0011\u0010\u0001\u0003\r\u000b \u0004\t\u0001\u0019B5@\t\u0001 \f\u0011\u000e\u0001\n\u001b5@78\t\u0001:CF\u0001\u001b \f\u0013 \f\u0010&'\u000f\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\u0013\u0014\u0016\u0001 \u0007\u0001\u000f\t\u0013\u0014\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\u0011\u0013\u0016\u0001 \u0007\u0001\u000f\t\u0012\u0010\t\u0001\u0001 \f\u0011\u000f\u0001\n\u000b\u0005\u0002\f>\u0005'1/23(+2=3<0\u0003\u0005\u000e\u0005(6313)391'6/2 \u0001\u0003\r\u0002\u0015\u00011=9@8\u0001\u0003\u000f\r\u0002\u0004\u0007\u0001AD\u0001\r\u000f\u000e\b\r\u000f\u0010\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0011\u0010\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\f\f\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0013\t\u000b\u000e\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\r\t\u0010\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0010\u0004\u0007\u0001\u0012\t\u0013\f\u0001\u000388\u0007\u0001 \f\u0011\u0011\u0001\n\u001d\u0001\u0017\u0001\u0013\t\u0014\u0007\u0001\r\t\u0010\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0012\u0004\u0007\u0001\u0012\t\u0011\u000e\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0011\u0001 N\u0007\u0001\r \u0007\u0001 \b\r]\u0007\u0001 \b\u0011]\u0004\u0007\u0001\u0012\t\u000f\u000e\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0014\u0001 N\u0007\u0001\f \u0007\u0001 \f\u0011\u0012\u0001\n \b\u0013\u0004\u0007\u0001\u0011\t\u0010\u0012\u0001\u00038\u0007\u0001\u001d\u0001\u0017\u0001\u0013\t\u000e\u0001 N\u0007\u0001\r \u0007\u0001 \b\u000e]\u0007\u0001 \b\u0010]\u0004\u0007\u0001\u0011\t\u000e\r\u0001\u00036G\u0007\u0001\r \u0007\u0001& \r\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001 \f\u0011\u0013\u0001\n\u001c%+'\b*\u000e\u0004\u0001b\u0001DDA\u0001\f\u0013\u0012\t\u0014\u000e\u0007\u0001\f\u0010\u0012\t\u0014\r\u0007\u0001\f\u0010\u0010\t\u000b\u0012\u0007\u0001\f\u0010\r\t\u0014\r\u0007\u0001\f\u000f\f\t\r\u0014\u0007\u0001\f\u000e\u0010\t\f\u000e\u0007\u0001\f\u000e\r\t\u0012\u000e\u0007 \u0001\f\u000e\f\t\r\u0013\u0007\u0001 \f\u0011\u0014\u0001\n\f\r\u0013\t\u0013\u0013\u0007\u0001\f\r\u000e\t\u000b\u000e\u0007\u0001\f\r\u000b\t\u000f\u0013\u0007\u0001\f\f\u0013\t\u0011\u0014\u0007\u0001\f\f\u0011\t\u000e\u0010\u0007\u0001\f\f\r\t\u0012\u0011\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\u000e\u000f\u0010\u0001\u00033%\u0006\r4\u0006\u0007\u0001\u000f\u000f\u0004\u0007\u0001\u000e\u000f\u000e\u0001 \f\u0012\u000b\u0001\n\u00033%4\u0006\u0007\u0001\u000f\u000f\u0004\u0007\u0001\f\r\f\u0001\u0003\f\u000f\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004\u0007\u0001\u0014\r\u0001\u0003\r\u0013\u0004\u0007\u0001\u0011\u0010\u0001\u0003\r\u000b\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001 \u001b\f\u0011 \f\u000b\u001aF&'\u000e\u0015\u0001\u001b\u0007\u0001 \f\u0012\f\u0001\n\u0010\u0010\t\u0013\u000f\u0016\u0001 \u0007\u0001\r\t\u0014\u000e\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0010\u0010\t\u0013\u0012\u0016\u0001 \u0007\u0001\r\t\u0013\u0013\t\u0001\f\u0012\r\u0001\n\u000b\u0005\u0002\u000b>\u0005'1/23(+2=3<0\u0003)391'6/2 \u0001\u0003\u000e\u0004\u0015\u00011=9@8\u0001\u0003\u0014\u000f\u0002\u0004\u0007\u0001AD\u0001\f\u000f\u0012\b\f\u000f\u0013\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001 \f\u0012\u000e\u0001\n\u001b\u001c\u001b@\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\u000b\u000b\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u0012\r\b\u0012\t\u0010\u000b\u0001\u0003A\u0007\u0001\r \u0007\u0001 \b\u0010\u0007\u0001 \b\u0012\u0004\u0007\u0001\u0012\t\u000f\u0010\b\u0012\t \r\u0012\u0001\u0003A\u0007\u0001\r \u0007\u0001 \b\u0011\u0007\u0001 \f\u0012\u000f\u0001Page 8 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001e227\u0001 \u0014\u0001 \b\u0013\u0004\u0007\u0001\u0012\t\r\u0012\b\u0012\t\f\r\u0001\u0003A\u0007\u0001\u000e \u0007\u0001 \b\r]\u0007\u0001 \b\u0010]\u0007\u0001 \b\u0011]\u0004\u0007\u0001\u0011\t\u0014\u0012\b\u0011\t\u0013\u000e\u0001\u0003A\u0007\u0001\f \u0007\u0001 \b \u000f]\u0004\u0007\u0001\u000e\t\u0013\u0010\u0001\u00036G\u0007\u0001\r \u0007\u0001& \r\u0004\t\u0001 \f\u0012\u0010\u0001\n\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001b\u001c\u001b@ \u000e\u0004\u0001b\u0001DDA\u0001\f\u0014\f\t\u0011\u000f\u0007\u0001\f\u0010\u0013\t\r\u000e\u0007\u0001\f\u0010\u000f\t\u0010\u000b\u0007\u0001\f\u000f\u0011\t\u0012\u0012\u0007\u0001\f\u000f\u000f\t\u0012\u0010\u0007\u0001\f\u000e\u0012\t\u000b\u0010\u0007\u0001 \f\u0012\u0011\u0001\n\f\u000e\u000e\t\u000e\u0012\u0007\u0001\f\r\u0014\t\u000e\r\u0007\u0001\f\r\u0014\t\u000b\f\u0007\u0001\f\r\u0011\t\u0014\u0012\u0007\u0001\f\r\u000f\t\u0013\f\u0007\u0001\f\r\u000b\t\u000e\u0010\u0007\u0001\f\r\u000b\t\u000b\u0011\u0007\u0001\f\f\u0012\t\u0014\u0013\u0007 \u0001\f\f\u0011\t\u0012\u0012\u0007\u0001\f\f\u000f\t\u0014\u0012\t\u0001%+\u0001\u001d!\u0001 \f\u0012\u0012\u0001\n1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\r\u0011\u0011\u0001\u00033%\u0006\f4\u0006\u0007\u0001\u000e\u000b\u0004\u0007\u0001\r\u0011\u0010\u0001\u00033%4\u0006\u0007\u0001\f\u000b\u000b\u0004\u0007\u0001\r\u000e\u0011\u0001\u0003\r\u0013\u0004\u0007\u0001\f\u0012\r\u0001\u0003\r\r\u0004 \u0007\u0001\f\r\u000b\u0001\u0003\u0013\u000f\u0004\u0007\u0001\u0013\u0014\u0001\u0003\f\u0010\u0004\u0007\u0001\u0011\u0010\u0001 \f\u0012\u0013\u0001\n\u0003\u000f\u000f\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0011 \f\f&'\u000e\u0015\u0001\u001b\u0007\u0001\u0012\r\t\u000f\u0010\u0016\u0001 \u0007\u0001\u000f\t\f\u0013\u0016\u0001\u001e CIB8\u0015\u0001\u001b\u0007\u0001\u0012\r\t\u000e\f\u0016\u0001 \u0007\u0001\u000f\t\f\r\t\u0001 \f\u0012\u0014\u0001\n\u000b\u0005\u0002\u000b>\u0005'1/23(+2=3<0\u0003\u0005\u0010 \u00051+8.3;<)391'6/2 \u0001\u0003\u0006\u0005\u0004\u0015\u00011=9@8\u0001\u0003\u0012\u000f\u0002\u0004\u0007\u0001AD\u0001\f\u000e\u0013\b\f\u000f\f\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0013\u000b\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\u000e\u000b\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u000f\u0012\b\u0012\t\r\u0012\u0001\u0003A\u0007\u0001\u000e \u0007\u0001\u000eL\u0019F\b \u0004\u0007\u0001\u0012\t\f\u0011\u0001\u0003H\u0007\u0001 \u001d\u0001\u0017\u0001 \f\u0013\f\u0001\n\u0012\t\u0013\u0001 N\u0007\u0001\f \u0007\u0001\u0019F\b \u0004\u0007\u0001\u0012\t\f\r\b\u0011\t\u0014\u0011\u0001\u0003A\u0007\u0001\r \u0007\u0001\rL\u0019F\b \u0004\u0007\u0001\u0011\t\u0013\u0010\u0001\u000388\u0007\u0001 \u001d\u0001\u0017\u0001\u0012\t\u0013\u0007\u0001\r\t\u000e\u0001 N\u0007\u0001\f \u0007\u0001\u0019F\b \u0004\u0007\u0001 \f\u0013\r\u0001\n\u0010\t\u000e\u0013\u0001\u00036G\u0007\u0001\r \u0007\u0001& \r\u0004\u0007\u0001\u000e\t\u0014\u000e\u0001\u0003G\u0007\u0001\u000e \u0007\u0001'\u001b \u000e\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\f\u0014\r\t\f\u000e\u0007\u0001 \f\u0013\u000e\u0001\n\f\u0010\u0012\t\u0012\u0012\u0007\u0001 \f\u000f\u0014\t\r\u0014\u0007\u0001\f\u000f\u0011\t\u0010\u0012\u0007\u0001 \f\u000f\u000f\t\u000f\u0010\u0007\u0001\f\u000f\u000e\t\u000e\u000e\u0007\u0001\f\u000e\u0011\t\u0011\u0014\u0007\u0001\f\r\u0014\t\u000f\u000b\u0007\u0001\f\r\u0012\t\f\r\u0007 \u0001 \f\r\u0010\t\u000b\u000f\u0007\u0001\f\r\u000b\t\u0012\u0010\u0007\u0001 \f\u0013\u000f\u0001\n\f\f\u0014\t\u000f\u000e\u0007\u0001\f\f\u0013\t\u0013\f\u0007\u0001\f\f\u0012\t\r\r\u0007\u0001\f\f\u0010\t\u0011\u000b\u0007\u0001\f\f\u000f\t\r\f\u0007\u0001\u0010\u0011\t\u000e\u000f\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\r\u0014\u0011\u0001\u00033%\u0006\f4\u0006\u0007\u0001\u000e\f\u0004\u0007\u0001\r\u0014\u0010\u0001 \f\u0013\u0010\u0001\n\u00033%4\u0006\u0007\u0001\f\u000b\u000b\u0004\u0007\u0001\r\u0011\u0011\u0001\u0003\f\u0011\u0004\u0007\u0001\f\r\u000b\u0001\u0003\u0013\r\u0004\t\u0001\u0014\r\u0001\u0003\u0010\u0013\u0004\u0007\u0001\u0011\u0010\u0001\u0003\r\u0011\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001 \u001b\f\u0012 \f\u000e&'\u000f\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\f\u0010\u0016\u0001 \f\u0013\u0011\u0001\n \u0007\u0001\u000f\t\u000f\u000f\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\u000b\f\u0016\u0001 \u0007\u0001\u000f\t\u000f\u0010\t\u0001\f\u0013\u0012\u0001\n\u000b\u0005\u0002\u000b>\u0005'1/23(+2=3<0\u0003 \u0005\u0010\u0005+8.3;<)391'6/2 \u0001\u0003\u0006\u0006\u0004\u0015\u00011=9@8\u0001\u0003\u0011\u0014\u0002\u0004\u0007\u0001AD\u0001\r\r\u0014\b\r\u000e\u000b\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0013\u0013\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\r\u0011\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0012\t\u000e\r\b\u0012\t\f\u0013\u0001\u0003A\u0007\u0001\u000e \u0007\u0001\u000eL\u0019F\b \u0004\u0007\u0001\u0012\t\u000b\u0014\u0001\u0003H\u0007\u0001 \u001d\u0001\u0017\u0001 \f\u0013\u0014\u0001\n\u0012\t\u0013\u0001 N\u0007\u0001\f \u0007\u0001\u0019F\b \u0004\u0007\u0001\u0012\t\u000b\f\b\u0011\t\u0013\u000f\u0001\u0003A\u0007\u0001\r \u0007\u0001\rL\u0001\u0019F\b \u0004\u0007\u0001\u0011\t\u0012\u0010\u0001\u000388\u0007\u0001 \u001d\u0001\u0017\u0001\u0012\t\u0013\u0007\u0001\r\t\u000e\u0001 N\u0007\u0001\f \u0007\u0001\u0019F\b \u0004\u0007\u0001 \f\u0014\u000b\u0001\n\u0010\t\u000e\r\u0001\u00036G\u0007\u0001\r \u0007\u0001& \r\u0004\u0007\u0001\u000f\t\u000b\u0010\u0001\u0003E\u0007\u0001\u001d\u0001\u0017\u0001\u0012\t\u000b\u0001 N\u0007\u0001\r \u0007\u0001\u001b \r\u0004\u0007\u0001\f\t\u000e\u0010\u0001\u0003H\u0007\u0001\u001d\u0001\u0017\u0001\u0012\t\u000b\u0001 N\u0007\u0001\u000e \u0007\u0001\u001b \u000e\u0004\t\u0001\f\u000e\u001b\u0001 \f\u0014\f\u0001\n&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\f\u0014\r\t\f\u0010\u0007\u0001\f\u0010\u0013\t\r\u0011\u0007\u0001\f\u000f\u0013\t\u0010\r\u0007\u0001\f\u000f\u0011\t\r\u0012\u0007\u0001\f\u000f\u000f\t\u000f\u0010\u0007\u0001\f\u000f\u000e\t\u000e\u000e\u0007\u0001 \f\u0014\r\u0001\n\f\u000e\u0011\t\u0010\u0014\u0007\u0001\f\r\u0014\t\u000f\u000f\u0007\u0001\f\r\u0012\t\u0012\u0012\u0007\u0001\f\r\u0010\t\f\u000f\u0007\u0001\f\r\u000b\t\u0011\u0012\u0007\u0001\f\f\u0014\t\u000e\u000e\u0007\u0001\f\f\u0013\t\u0013\f\u0007\u0001\f\f\u0012\t\r\r\u0007 \u0001\f\f\u0010\t\u0011\u000b\u0007\u0001\f\f\u000f\t\r\f\u0007\u0001\u0011\u0010\t\u0010\u000b\u0007\u0001 \f\u0014\u000e\u0001\n\f\u0010\t\f\r\t\u0001%+\u0001\u001d!\u00011\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\u000e\f\u000b\u0001\u00033%\u0006\f4\u0006\u0007\u0001\r\u000b\u0004\u0007\u0001\u000e\u000b\u0014\u0001\u00033%4\u0006\u0007\u0001\u0011\r\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004\u0007\u0001\u0014\r\u0001\u0003\r\u0013\u0004\u0007\u0001\u0011\u0010\u0001\u0003\f\u0013\u0004\t\u0001 \f\u0014\u000f\u0001\n\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0013 \f\u0010&'\u000f\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\u0013\u0014\u0016\u0001 \u0007\u0001\u000f\t\u0013\u0014\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0011\u0014\t\u0012\u0010\u0016\u0001 \u0007\u0001\u000f\t\u0013\f\t\u0001 \f\u0014\u0010\u0001\n\u000b\u0005\u0002\u000b>\u0005'1/23(+2=3<0\u0003\u0005\u000e\u0005(6313<)391'6/2 \u0001\u0003\u0006\u0007\u0004\u0015\u00011=9@8\u0001\u0003\u0011\f\u0002\u0004\u0007\u0001AD\u0001\r\u000b\u0010\b\r\u000b\u0012\u0001[\u001b\u0016\u0001\f \u0001&%*\u0001 \f\u0014\u0011\u0001\n\u0003\u000e\u000b\u000b\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001b\u0001DDA\u0001\u0013\t\r\u0011\u0001\u0003G\u0007\u0001\f \u0007\u0001 \b\u000f\u0004\u0007\u0001\u0013\t\u000b\u0012\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\r\t\u0014\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0010\u0004\u0007\u0001\u0012\t\u0013\u0010\u0001\u000388\u0007\u0001 \f\u0014\u0012\u0001\n\u001d\u0001\u0017\u0001\u0013\t\u0014\u0007\u0001\r\t\u0014\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0012\u0004\u0007\u0001\u0012\t\u000f\u0010\u0001\u00038\u0007\u0001 \u001d\u0001\u0017\u0001\u0013\t\u0014\u0001 N\u0007\u0001\f \u0007\u0001 \b\u0013\u0004\u0007\u0001\u0012\t\r\u0010\b\u0011\t\u0014\u0011\u0001\u0003A\u0007\u0001\u000e \u0007\u0001 \b\r]\u0007\u0001 \b\u0010]\u0007\u0001 \f\u0014\u0013\u0001\n \b\u0011]\u0004\u0007\u0001\u0011\t\u0013\u0011\u0001\u00038\u0007\u0001\u001d\u0001\u0017\u0001\u0012\t\u000e\u0001 N\u0007\u0001\f \u0007\u0001 \b\u000f]\u0004\u0007\u0001\u0010\t\u000e\u0013\u0001\u0003G\u0007\u0001\r \u0007\u0001& \r\u0004\t\u0001\f\u000e\u001b\u0001&%*\u0001\u0003\u0012\u0010\u0001% N\u0007\u0001\u001c%+'\b *\u000e\u0004\u0001 \f\u0014\u0014\u0001Page 9 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019\u001f228\u0001 \f\u000b\u0001b\u0001DDA\u0001\f\u0014\f\t\u0012\u000f\u0007\u0001\f\u0010\u0012\t\u0010\u0014\u0007\u0001\f\u0010\u000e\t\f\f\u0007\u0001\f\u000f\u0014\t\u000e\u000f\u0007\u0001\f\u000f\r\t\u0013\u0011\u0007\u0001\f\u000e\u0011\t\u0010\f\u0007\u0001\f\u000e\u0010\t\u0012\u000e\u0007\u0001\f \u000e\f\t\u0011\u0010\u0007\u0001\f\r\u0014\t\u000f\u000f\u0007\u0001\f\r\u0012\t\u0013\u0010\u0007\u0001 \r\u000b\u000b\u0001\n\f\r\u000b\t\f\u0014\u0007\u0001\f\f\u0014\t\u0011\u000e\u0007\u0001\f\f\u0013\t\u0012\u0014\u0007\u0001\f\f\u0012\t\u0010\f\u0007\u0001\f\f\u0011\t\u0010\u000f\u0007\u0001\f\f\u000f\t\u000b\u0010\t\u0001%+\u0001\u001d!\u0001 1\u0007=\u0001\u0003\u0002\u0004\u0015\u0001\u000e\u000f\u0010\u0001\u00033%\u0006\r4\u0006\u0007\u0001\u0012\u000b\u0004\u0007\u0001\u000e\u000f\u000e\u0001 \r\u000b\f\u0001\n\u00033%4\u0006\u0007\u0001\u0012\u000b\u0004\u0007\u0001\f\r\u000b\u0001\u0003\f\u000b\u000b\u0004\u0007\u0001\u0014\r\u0001\u0003\u0013\u0010\u0004\u0007\u0001\u0011\u0010\u0001\u0003\u0010\r\u0004\t\u0001\u0019B5@\t\u0001\u001b5@78\t\u0001:CF\u0001\u001b \f\u0011 \f\u000b\u001aF&'\u000e\u0015\u0001\u001b\u0007\u0001\u0010\u0010\t\u0013\u000f\u0016\u0001 \u0007\u0001 \r\u000b\r\u0001\n\r\t\u0014\u000e\u0016\u0001\u001eCIB8\u0015\u0001\u001b\u0007\u0001\u0010\u0010\t\u0012\u0012\u0016\u0001 \u0007\u0001\r\t\u0013\u0014\t\u0001\r\u000b\u000e\u0001\n\u0001\r\u000b\u000f\u0001\n\u0010*/&\u001f\u001e /\"-&\u001e(\u0001\u001e /&1&/4\u0001\r\u000b\u0010\u0001\n,<9\u00015BH=A=7FC6=5@\u000157H=J=HM\u0001C:\u0001H<9\u00017CADCIB8G\u0001K5G\u00015GG5M98\u00016M\u0001H<9\u0001 8=G?\u00018=::IG=CB\u0001A9H<C8\u0007\u0001 \r\u000b\u0011\u0001\n:C@@CK=B;\u0001H<9\u0001DFC798IF9G\u0001C:\u0001H<9\u0001\u001b@=B=75@\u00015B8\u0001$56CF5HCFM\u0001+H5B85F 8G\u0001!BGH=HIH9\u0001\u0003\u001b$+!\u0007\u0001 \r\u000b\u0012\u0001\n\r\u000b\u000b\u0011\u0004\t\u0001,<9\u00015GG5M\u0001K5G\u000175FF=98\u0001CIH\u0001K=H<\u0001H<9\u0001F9:9F9B79\u0001GHF5=BG\u0001C:\u0001 \u00187).+6/)./'\u0001)30/ \u0001 \r\u000b\u0013\u0001\n\u0019,\u001b\u001b\r\u0010\u0014\r\r\u0007\u0001$8'4.<03)3))97\u0001 '96+97 \u0001 \u0019,\u001b\u001b\r\u0010\u0014\r\u000e\u0001 5B8\u0001 \"7+9*3132'7\u0001 '+69-/237'\u0001 \r\u000b\u0014\u0001\n\u0019,\u001b\u001b\r\u0012\u0013\u0010\u000e\u0001 5B8\u0001 H<F99\u0001 8=::9F9BH\u0001 GHF5=BG\u0001 C:\u0001 H<9\u0001 \u001fF5A\bB9;5H=J9\u0001 A5F=B9\u0001 657H9F=IA\u0001\r\f\u000b\u0001\n%+2')/(')9091\u00011'6/8/191 \u0001\u0003,%\u0001$\u001b\u000b\u0012\u0001\f\u000b\t\f\t\f\u0007\u0001,%\u0001\u001b<=@9\u00015B8\u0001,%\u0001$$\u000b\f\u0001\u0013\t\u000e\t\u0013\u0004\t\u0001,<9\u0001 \r\f\f\u0001\n=BC7I@IA\u0001K5G\u0001DF9D5F98\u0001=B\u0001GH9F=@9\u0001G5@=B9\u0001:FCA\u00015\u0001\r\u000f\u0001<\u0001%I9@@9F\u0001 =B HCB\u0001\u0019;5F\u0001\u0003% \u0019\u0004\u0001 \r\f\r\u0001\n\u0003\u001bI@H=A98\u0007\u0001+D5=B\u0004\u0001D@5H9\u00017I@HIF9\u0001C:\u0001F9:9F9B79\u0001GHF5=BG\u0001C:\u0001 \u0018\u0006\u0001)30/\u0007\u0001\"\u0006\u0001'+69-/237' \u0001M\u0001$\u0006\u0001'96+97\u0001 \r\f\u000e\u0001\n5B8\u0001:FCA\u00015\u0001\u000f\u0013\u0001<\u0001 \u00190+;/(')8+6\u00011'6/8/191 \u0001A98=IA\u0001\u0003\u001e%%\u0004\u00013\u000f\r4\u0001D@5H9\u00017I@HIF9\u0001C:\u0001 %\u0006\u0001 \r\f\u000f\u0001\n1'6/8/191\u0001GHF5=BG\u0007\u00017CBH5=B=B;\u00015DDFCL=A5H9@M\u0001\fL\f\u000b\u0013\u00017C@CBM\u0001:CFA=B;\u0001IB=HG\u0001\u0003\u001b\u001e-\u0004\nA$\u0001 \r\f\u0010\u0001\n\u0003'\u001c\u0011\r\u000b\u0001C:\u0001\u000b\u0007\u000b\u0014\u0004\t\u0001\u001bC@CBM\u00017CIBHG\u0001CB\u0001=BC7I@IA\u0001GIGD9BG=CB\u0001K9F9\u0001J9F=:=98\u00016M \u0001H<9\u0001D@5H9\u0001 \r\f\u0011\u0001\n8=@IH=CB\u0001A9H<C8\u0001IG=B;\u0001H<9\u00015DDFCDF=5H9\u0001GC@=8\u0001A98=IA\u00015B8\u00017CIBH=B; \u0001H<9\u0001657H9F=5@\u00017C@CB=9G\u0001 \r\f\u0012\u0001\nDFC8I798\t\u0001\u0019BH=A=7FC6=5@\u0001GC@IH=CB\u0001\u00037CB79BHF5H=CB\u0001C:\u0001\f\u000b\u000b\u000b\u000b\u0001Z;\nA$\u0004 \u0001K5G\u0001DF9D5F98\u00016M\u0001 \r\f\u0013\u0001\nIG=B;\u0001\u001c%+'\u00015G\u0001GC@J9BH\t\u0001+H9F=@9\u00018=G?G\u0001C:\u0001\u0011\u0001AA\u00018=5A9H9F\u0001\u0003$=C:=@7< 9A\u0007\u0001!H5@M\u0004\u00019A698898\u0001 \r\f\u0014\u0001\n=B\u0001H<9\u00018FI;\u00015H\u00015\u0001:=B5@\u00017CB79BHF5H=CB\u0001C:\u0001\f\u000b\u000b\u0001Z;\n8=G?\u0001K9F9\u0001?9DH\u0001C B\u00015;5F\u0001GIF:579\t\u0001+H9F=@9\u0001 \r\r\u000b\u0001\n8=G?G\u00019A698898\u0001K=H<\u0001\u001c%+'\u0001K9F9\u0001IG98\u00015G\u00015\u0001B9;5H=J9\u00017CBHFC@\t\u0001,<9\u0001D @5H9G\u0001K9F9\u0001=B7I65H98\u0001 \r\r\f\u0001\n5H\u0001\u000e\u0012\u0001[\u001b\u0001:CF\u0001\r\u000f\u0001<\u0001\u0003F9:9F9B79\u0001GHF5=BG\u0004\u00015B8\u00015H\u0001\r\u0010\u0001[\u001b\u0001:CF\u0001\u000f\u0013\u0001<\u0001 %\u0006\u00011'6/8/191 \u0001=GC@5H9G\t\u0001\u00012CB9G\u0001 \r\r\r\u0001\nC:\u0001=B<=6=H=CB\u0001K9F9\u0001A95GIF98\u0001=B\u0001A=@@=A9H9F\t\u0001\r\r\u000e\u0001\n\u0001\r\r\u000f\u0001Page 10 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u0019 229\u0001 \f\f\u0001\u0001\r\r\u0010\u0001\n\u0001\r\r\u0011\u0001\n\u001b\".0(/.\u0001\u001e*!\u0001!&. 0..&+*\u0001\r\r\u0012\u0001\n\u0011%\")&./-4\u0001\r\r\u0013\u0001\n,<9\u0001GMBH<9G=G\u0001C:\u0001H<9\u0001GHI8=98\u00017CADCIB8G\u0001 \u0006\u0003\u0006\u0007\u0001K5G\u0001D9F:CFA98 \u0001:C@@CK=B;\u0001H<9\u0001GMBH<9H=7\u0001 \r\r\u0014\u0001\nFCIH9\u0001CIH@=B98\u0001=B\u0001+7<9A9\u0001\f\t\u0001\u0001\r\u000e\u000b\u0001\n\u0001\r\u000e\f\u0001\n\u0003+7<9A9\u0001\f\u0004\u0001 \r\u000e\r\u0001\n\u0001\r\u000e\u000e\u0001\n\u001bCADCIB8G\u0001 \u0006\u0003\t\u0001K9F9\u00019::=7=9BH@M\u0001GMBH<9G=N98\u0001K=H<\u0001\u0010\u0013\b\u0012\u000b\u0002\u0001M=9@8\u0001J=5\u0001#BC9J9B5;9@ \u0001 \r\u000e\u000f\u0001\nF957H=CB\u0001HF95H=B;\u0001H<9\u00015DDFCDF=5H9\u0001G5@=7M@5@89<M89\u00015B8\u0001H<9\u00017CFF9 GDCB8=B;\u00019H<M@\u0001GI6GH=HIH98\u0001 \r\u000e\u0010\u0001\n69BNCM@579H5H9\u0001K=H<\u0001D=D9F=8=B9\u0001=B\u00019H<5BC@\u00015H\u0001F9:@IL\u0001:CF\u0001\r\\\u0010\u0001<\t\u0001 \u001eCF\u0001H<9\u0001DF9D5F5H=CB\u0001C:\u0001H<9\u0001 \r\u000e\u0011\u0001\n5A=BC\u0001GI6GH=HIH98\u000189F=J5H=J9G\u0001 \n\u0003\u0006\u0007\u0007\u0001H<9\u0001G5A9\u0001GHF5H9;M\u0001K5G\u00019AD@CM98\u0001HC\u000157<=9J9\u0001H<9\u0001B=HFC\u0001 \r\u000e\u0012\u0001\nGI6GH=HIH98\u0001 \u000e\b69BNCM@7CIA5F=BG\u0001 DF97IFGCFG\u0007\u0001 K<=7<\u0001 K9F9\u0001 HF95H98\u0001 K =H<CIH\u0001 :IFH<9F\u0001 \r\u000e\u0013\u0001\nDIF=:=75H=CB\u0001K=H<\u0001+B\u001b@ \r\t\r \r'\u0001=B\u00019H<5BC@\u00015H\u0001F9:@IL\u0001:CF\u0001\u000e\b\u0012\u0001<\u0001HC\u000157<=9J9\u0001H<9\u0001:=B5@\u00015A=BC\u0001 \r\u000e\u0014\u0001\nGI6GH=HIH98\u0001 7CADCIB8G\u0001 \n\u0003\u0006\u0007\u0001=B\u0001 \u000f\r\b\u0014\u000f\u0002\u0001 CJ9F5@@\u0001 M=9@8\u0001 5:H9F\u0001 DIF=:=75H=CB\u0001 6M\u0001 :@5G<\u0001 \r\u000f\u000b\u0001\n7<FCA5HC;F5D<M\u0001=B\u0001\u0012\u0015\u000e\u0001 9L5B9\n\u00197'\u001dH\t\u0001\u0001\r\u000f\f\u0001\n\u0001\r\u000f\r\u0001\n\u0010*/&\u001f\u001e /\"-&\u001e(\u0001\u001e /&1&/4\u0001\r\u000f\u000e\u0001\n!B\u0001CF89F\u0001HC\u0001H9GH\u0001H<9\u00015BH=657H9F=5@\u000157H=J=HM\u0001C:\u0001H<9\u0001H5F;9H\u00017CADC IB8G\u0007\u0001H<9\u00018=G?\u00018=::IG=CB\u0001H9GH\u0001 \r\u000f\u000f\u0001\nK5G\u00019AD@CM98\t\u0001,<9\u00015BH=A=7FC6=5@\u00018FI;G\u0007\u0001CLC@=B=7\u000157=8\u00015B8\u00019BFC:@ CL57=B\u0001\u0003EI=BC@CB9\u0001 \r\u000f\u0010\u0001\n5BH=6=CH=7\u0007\u0001\u001e=;IF9\u0001\f\u0004\u00015B8\u00015AD=7=@@=B\u0001\u0003 \u0002\b@57H5A=7\u00015BH=6=CH=7\u0004\u0007\u0001K9F9\u0001IG98\u00015G\u0001DCG=H=J9\u0001 \r\u000f\u0011\u0001\n7CBHFC@G\t\u0001,<9\u00015BH=657H9F=5@\u000157H=J=HM\u0001C:\u00017CADCIB8G\u0001 \u0006\u0003\u0006\u0007\u0001K5G\u00019J5@I5H98\u0001 /2\u0001:/863\u00016M\u0001 \r\u000f\u0012\u0001\nA95GIF=B;\u0001H<9\u0001=B<=6=H=CB\u0001NCB9\u0001\u0003=B\u0001A=@@=A9H9FG\u0004\u0001:CF\u0001;FCKH<\u0001=B<=6 =HCFM\u00019::97HG\u0001CJ9F\u0001CB9\u0001 \r\u000f\u0013\u0001\n\u001fF5A\bDCG=H=J9\u0001657H9F=IA\u0001 $\u0006\u0001'96+97\u00015B8\u0001HKC\u0001\u001fF5A\bB9;5H=J9\u0001657H9F=5\u0001\u0003 \u0018\u0006\u0001)30/\u00015B8\u0001\"\u0006\u0001 \r\u000f\u0014\u0001Page 11 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u0017230\u0001 \f\r\u0001'+69-/237'\u0004\u0001 5B8\u0001 H<F99\u0001 8=::9F9BH\u0001 GHF5=BG\u0001 C:\u0001 H<9\u0001 \u001fF5A\bB9;5H=J9\u0001 A5F=B9\u0001 657H9 F=5\u0001%\u0006\u0001 \r\u0010\u000b\u0001\n1'6/8/191\u0001\u0003,%\u0001$\u001b\u000b\u0012\u0001\f\u000b\t\f\t\f\u0007\u0001,%\u0001\u001b<=@9\u00015B8\u0001,%\u0001$$\u000b\f\u0001\u0013\t\u000e\t\u0013\u0004\t\u0001,<9\u00015BH=657H9F=5 @\u0001 \r\u0010\f\u0001\n57H=J=H=9G\u0001K9F9\u0001H9GH98\u00015H\u00017CB79BHF5H=CBG\u0001C:\u0001\f\u000b\u000b\u0001 \u0003;\n8=G?\u0001=B\u0001\u001c%+'\t\u0001,<9\u0001657H9F=5@\u00017I@HIF9G\u0001 \r\u0010\r\u0001\nK9F9\u0001=BC7I@5H98\u00015B8\u0001=B7I65H98\u0001577CF8=B;\u0001HC\u0001H<9\u000189G7F=698\u0001DFCHC7 C@\u0001C:\u0001H<9\u00019LD9F=A9BH5@\u0001 \r\u0010\u000e\u0001\nG97H=CB\t\u0001,<9\u00019LD9F=A9BH5@\u0001F9GI@HG\u0001C:\u0001H<=G\u0001 /2\u0001:/863\u00015BH=657H9F=5@\u00019J5@I5H=CB\u00015F9\u0001GIAA5F=N98\u0001 \r\u0010\u000f\u0001\n=B\u0001,56@9\u0001\f\t\u0001\r\u0010\u0010\u0001\n\u0001\r\u0010\u0011\u0001\n\u0003,56@9\u0001\f\u0004\u0001 \r\u0010\u0012\u0001\n\u0001\r\u0010\u0013\u0001\n,<9\u0001C6H5=B98\u0001F9GI@HG\u0001F9J95@98\u0001H<5H\u00015@@\u0001H9GH98\u00017CADCIB8G\u0001 \u0006\u0003\u0006\u0007\u0001K9F9\u0001=B57H=J9\u00015;5=BGH\u0001H<9\u0001 \r\u0010\u0014\u0001\n<IA5B\u0001D5H<C;9B=7\u0001657H9F=5\u0001GHF5=BG\u0001C:\u0001 \u0018\u0006)30/\u0007\u0001$\u0006\u0001'96+97\u00015B8\u0001\"\u0006\u0001'+69-/237' \t\u0001 CK9J9F\u0001 \r\u0011\u000b\u0001\nACGH\u0001C:\u0001H<9\u0001GMBH<9G=N98\u00017CADCIB8G\u0001\u0003 \n\u0003\f\u00015B8\u0001\u000e\u0003\u0006\u0007\u0004\u0001DF9G9BH98\u00015BH=657H9F=5@\u000157H=J=HM\u0001 \r\u0011\f\u0001\n5;5=BGH\u0001H<9\u0001H<F99\u0001 %\u0006\u00011'6/8/191\u0001A5F=B9\u0001657H9F=5\u0001GHF5=BG\u0007\u0001G<CK=B;\u0001=B<=6=H=CBG\u0001NCB9G\u0001 \r\u0011\r\u0001\nF5B;=B;\u000169HK99B\u0001\f\f\u0001HC\u0001\u000e\u0010\u0001AA\t\u0001\u001bCADCIB8G\u0001K=H<CIH\u00015B\u00015A=BC\u0001GI6GH=H I9BH\u0001\u0003\u0006\b\t\u0004\u0001K9F9\u0001 \r\u0011\u000e\u0001\n=B57H=J9\u00015;5=BGH\u00015BM\u0001C:\u0001H<9\u0001 %\u0006\u00011'6/8/191 \u0001GHF5=BG\u0007\u0001K=H<\u00019L79DH=CB\u0001C:\u00017CADCIB8\u0001 \u0006\u0007\u0001K<=7<\u0001 \r\u0011\u000f\u0001\nF9GI@H98\u0001HC\u000169\u0001G@=;<H@M\u0001G9BG=H=J9\u0001HC\u0001CB9\u0001C:\u0001H<9\u0001 %\u0006\u00011'6/8/191\u0001GHF5=BG\u0001\u0003,%\u0001$\u001b\u000b\u0012\u0001\f\u000b\t\f\t\r\u0004\u0007\u0001 \r\u0011\u0010\u0001\nDF9G9BH=B;\u0001 5B8\u0001 =B<=6=H=CB\u0001 NCB9\u0001 C:\u0001 \f\r\u0001 AA\t\u0001 ,<9F9:CF9\u0007\u0001 =BHFC8I7H=C B\u0001 C:\u0001 5B\u0001 5A=BC\u0001 \r\u0011\u0011\u0001\nGI6GH=HI9BH\u0001CB\u0001H<9\u0001\u000e\b69BNCM@\u0001AC=9HM\u0001=B\u00019=H<9F\u0001\u000e]\u0001CF\u0001\u000f]\u0001DCG=H=CBG\u0007\u0001F9GI@H98\u0001HC\u000169\u00015\u0001?9M\u0001\r\u0011\u0012\u0001\nGI6GH=HIH=CB\u0001:CF\u0001H<9\u000157H=J=HM\u0001C:\u0001H<9G9\u00017CADCIB8G\u0001CJ9F\u0001 %\u0006\u00011'6/8/191 \u0001GHF5=BG\t\u0001\u0001 \r\u0011\u0013\u0001\n\u001bCAD5F=B;\u0001 7CADCIB8G\u0001 C:\u0001 H<9\u0001 \u000f]\b5A=BC\u0001 GI6GH=HIH98\u0001 G9F=9G\u0001 \u0003 \n\u0003\r\u0004\u0007\u0001 H<9\u0001 \u000e\b\u0003\u000f]\b \r\u0011\u0014\u0001\n5A=BC69BNCM@\u00047CIA5F=B\u0001 \n\u0001\u0001G<CK98\u000157H=J=HM\u0001CB@M\u00015;5=BGH\u0001HKC\u0001C:\u0001H<9\u0001H<F99\u0001 %\u0006\u00011'6/8/191 \u0001 \r\u0012\u000b\u0001\nGHF5=BG\u0007\u0001\u0001,%\u0001\u001b<=@9\u00015B8\u0001,%\u0001$\u001b\u000b\f\u0001\u0013\t\u000e\t\u0013\u0007\u0001K=H<\u0001=B<=6=H=CB\u0001NCB9G\u0001C:\u0001 \f\u000b\u00015B8\u0001\f\r\u0001AA\u0007\u0001 \r\u0012\f\u0001\nF9GD97H=J9@M\t\u0001/<9B\u00015\u0001A9H<CLM\u0001CF\u00019H<CLM\u0001GI6GH=HI9BH\u00015H\u0001DCG=H=CB\u0001 \u0013\u0001C:\u0001H<9\u00017CIA5F=B\u00017CF9\u0001 \r\u0012\r\u0001\n\u00037CADCIB8G\u0001 \u000b\u00015B8\u0001\f\u0007\u0001F9GD97H=J9@M\u0004\u0001K5G\u0001=BHFC8I798\u0007\u0001H<9\u000157H=J=HM\u0001C:\u0001H<=G\u0001G9F=9G\u0001BCH 56@M\u0001 \r\u0012\u000e\u0001\n=\nB7F95G98\u0001F9GD97H\u0001HC\u0001H<9\u0001G=AD@9GH\u000189F=J5H=J9\u0001C:\u0001H<9\u0001G9F=9G\u0001 \n\u0007\u0001DF9G9BH=B;\u0001=B<=6=H=CB\u0001NCB9G\u0001 \r\u0012\u000f\u0001Page 12 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u0018231\u0001 \f\u000e\u0001F5B;=B;\u0001:FCA\u0001\r\u0013\u0001HC\u0001\u000e\u000f\u0001AA\u0001:CF\u0001H<9\u0001H<F99\u0001 %\u0006\u00011'6/8/191 \u0001GHF5=BG\u0007\u0001F957<=B;\u0001=B<=6=H=CB\u0001NCB9\u0001 \r\u0012\u0010\u0001\nJ5@I9G\u0001 <=;<9F\u0001 H<5B\u0001 9BFC:@CL57=B\u0007\u0001 H<9\u0001 7IFF9BH@M\u0001 IG98\u0001 8FI;\u0001 :CF\u0001 H< 9\u0001 HF95HA9BH\u0001 C:\u0001 \r\u0012\u0011\u0001\nH9B57=657I@CG=G\t\u0001 CK9J9F\u0007\u0001K<9B\u00015\u0001GI6GH=HI9BH\u0001K5G\u0001=BHFC8I798\u00015H\u0001 DCG=H=CB\u0001\u0011\u0001C:\u0001H<9\u0001 \r\u0012\u0012\u0001\n7CIA5F=B\u0001\u00037CADCIB8\u0001 \r\u0004\u0007\u0001H<9\u000157H=J=HM\u0001K5G\u00017CAD@9H9@M\u0001@CGH\t\u0001\u0001 \r\u0012\u0013\u0001\n\u001eCF\u0001H<9\u0001\u000e]\b5A=BC\u0001GI6GH=HIH98\u0001G9F=9G\u0001\u0003 \u000e\u0003\u0006\u0007\u0004\u0007\u0001BC\u0001G=;B=:=75BH\u00018=::9F9B79G\u0001=B\u0001H<9\u000157H=J=HM\u0001K9F9\u0001 \r\u0012\u0014\u0001\n:CIB8\u000169HK99B\u0001H<9\u0001G=AD@9GH\u00017CADCIB8\u0001C:\u0001H<9\u0001G9F=9G\u0001 \u000e\u0007\u0001K=H<\u0001CB@M\u00015B\u00015A=BC\u0001;FCID\u00015H\u0001 \r\u0013\u000b\u0001\nDCG=H=CB\u0001\u000e]\u0007\u00015B8\u00017CADCIB8G\u0001=B\u0001K<=7<\u00015B\u0001588=H=CB5@\u0001A9H<CLM\u0001CF\u00019H <CLM\u0001GI6GH=HI9BH\u0001 \r\u0013\f\u0001\n\u00037CADCIB8G\u0001 \u0006\u0005\u00015B8\u0001\u0006\u0006\u0007\u0001F9GD97H=J9@M\u0004\u0001K9F9\u0001=BHFC8I798\u00015H\u0001DCG=H=CB\u0001\u0013\u0007\u0001DF9G9BH98\u0001=B<=6= H=CB\u0001 \r\u0013\r\u0001\nNCB9\u0001J5@I9G\u0001<=;<9F\u0001H<5B\u0001H<9\u0001F9:9F9B798\u00017CADCIB8G\u0001CLC@=B=7\u000157=8\u0001 5B8\u00019BFC:@CL57=B\u0007\u0001 \r\u0013\u000e\u0001\nF5B;=B;\u0001:FCA\u0001\f\u0014\u0001HC\u0001\u000e\u0010\u0001AA\t\u0001!B\u00015BM\u000175G9\u0007\u0001H<9\u0001ACGH\u0001G9BG=H=J9\u0001 %\u0006\u00011'6/8/191 \u0001GHF5=B\u0001K5G\u0001,%\u0001 \r\u0013\u000f\u0001\n\u001b<=@9\t\u0001\u0019G\u0001:CF\u0001H<9\u0001\u000f]\b5A=BC\u0001GI6GH=HIH98\u0001G9F=9G\u0007\u0001H<9\u0001\u0011\b6FCAC\u0001GI6GH=HIH98\u00017CADCIB8\u0001 \u0006\u0007\u0007\u0001 \r\u0013\u0010\u0001\nK5G\u0001H<9\u0001@9GG\u000157H=J9\u00017CADCIB8\u0001C:\u0001H<9\u0001G9F=9G\u00016IH\u0001DF9G9BH=B;\u0001H<9\u0001G5A9\u000157H=J=HM\u0001F5B;9\u0001H<5B\u0001\r\u0013\u0011\u0001\nH<9\u0001F9:9F9B79\u00017CADCIB8\u0001CLC@=B=7\u000157=8\t\u0001\r\u0013\u0012\u0001\n!B\u00017CB7@IG=CB\u0007\u00015\u0001G9F=9G\u0001C:\u00017CIA5F=B\b7<5@7CB9\u0001<M6F=8\u00017CADCIB8G\u0001< 5J9\u0001699B\u000189G=;B98\u00015B8\u0001 \r\u0013\u0013\u0001\nGMBH<9G=N98\u00015B8\u0001H<9=F\u00015BH=657H9F=5@\u000157H=J=HM\u00015;5=BGH\u0001<IA5B\u0001D5H< C;9B=7\u0001657H9F=5\u0001\u0003 \u0018\u0006)30/\u0007\u0001$\u0006\u0001 \r\u0013\u0014\u0001\n'96+97\u00015B8\u0001\"\u0006\u0001'+69-/237' \u0004\u00015B8\u0001H<F99\u00018=::9F9BH\u0001GHF5=BG\u0001C:\u0001H<9\u0001A5F=B9\u0001D5H<C;9B=7\u0001657H9F=5 \u0001 \r\u0014\u000b\u0001\n%\u0006\u00011'6/8/191\u0001 K9F9\u0001H9GH98\t\u0001\u001bCADCIB8G\u0001K9F9\u0001BCB\b57H=J9\u00015;5=BGH\u00015BM\u0001<IA5B\u0001D5H<C; 9B=7\u0001 \r\u0014\f\u0001\n657H9F=5\u0007\u0001 6IH\u0001 ACGH\u0001 C:\u0001 H<9A\u0001 G<CK98\u0001 <=;<\u0001 =B<=6=H=CB\u0001 ;FCKH<\u0001 5;5=BGH\u0001 H<9\u0001 H<F99\u0001 %\u0006\u0001 \r\u0014\r\u0001\n1'6/8/191\u0001GHF5=BG\u0007\u0001K=H<\u0001=B<=6=H=CB\u0001NCB9G\u0001=B\u0001H<9\u0001G5A9\u0001F5B;9\u0001CF\u0001<=;<9F\u0001H<5 B\u0001H<9\u00017IFF9BH@M\u0001 \r\u0014\u000e\u0001\n8FI;\u0001IG98\u0001:CF\u0001H<9\u0001HF95HA9BH\u0001C:\u0001H9B57=657I@CG=G\u0007\u00019BFC:@CL57=B\u0007\u0001K <=7<\u0001=G\u0001BCH\u0001G9@97H=J9\u0001 \r\u0014\u000f\u0001\n5;5=BGH\u0001%\u0006\u00011'6/8/191 \u0001G=B79\u0001=H\u0001=G\u00015@GC\u0001<=;<@M\u000157H=J9\u00015;5=BGH\u0001H<9\u0001H9GH98\u0001<IA5B\u0001D5H<C; 9B=7\u0001 \r\u0014\u0010\u0001\n657H9F=5\t\u0001(F9G9B79\u0001C:\u00015B\u00015A=BC\u0001;FCID\u0001=B\u0001H<9\u000169BNCM@\u0001AC=9HM\u0001\u00037CA DCIB8G\u0001\n\u0003\u0006\u0007\u0004\u0001F9GI@H98\u0001 \r\u0014\u0011\u0001\nHC\u000169\u00015\u0001?9M\u0001GI6GH=HIH=CB\u0001:CF\u0001H<9\u000157H=J=HM\u0001C:\u00017CADCIB8G\u00015;5=BGH\u0001 %\u0006\u00011'6/8/191 \t\u0001\u001988=H=CB5@\u0001 \r\u0014\u0012\u0001\nGI6GH=HIH=CBG\u0001CB\u0001H<9\u00017CIA5F=B\u00017CF9\u00015H\u0001DCG=H=CB\u0001\u0013\u0001CF\u0001\u0011\u00015@GC\u0001D@5M 98\u00015\u0001?9M\u0001FC@9\u0001=B\u0001H<9=F\u0001 \r\u0014\u0013\u0001\n57H=J=HM\u00015;5=BGH\u0001 %\u0006\u00011'6/8/191 \u0007\u0001=B8=75H=B;\u0001H<5H\u0001GI6GH=HIH=CBG\u00015H\u0001DCG=H=CB\u0001\u0013\u0001\u00037CADCIB8G\u0001 \u000b\u0007\u0001 \r\u0014\u0014\u0001Page 13 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u0019232\u0001 \f\u000f\u0001\f\u0007\u0001\u0006\u0005\u00015B8\u0001\u0006\u0006\u0004\u0001=B7F95G9G\u0001H<9=F\u000157H=J=HM\u0007\u0001K<9F95G\u0001GI6GH=HIH=CB\u00015H\u0001DCG=H=CB\u0001\u0011\u0001 \u00037CADCIB8G\u0001 \r\u0001 \u000e\u000b\u000b\u0001\n5B8\u0001\u0006\u0007\u0004\u0001897F95G9G\u0001%\u0006\u00011'6/8/191 \u00015BH=657H9F=5@\u000157H=J=HM\t\u0001,<9F9:CF9\u0007\u0001H<9\u0001<=;<\u000157H=J=HM\u0001C:\u0001 \u000e\u000b\f\u0001\n7CADCIB8G\u00015B8\u0001H<9=F\u0001G9@97H=J=HM\u0001CB@M\u00015;5=BGH\u0001H<9\u0001A5F=B9\u0001657H9F= 5\u000175B\u00015JC=8\u00018FI;\u0001 \u000e\u000b\r\u0001\nF9G=GH5B79\u0001DFC6@9AG\u0001=B\u0001<IA5BG\u0007\u0001A5?=B;\u0001H<9G9\u00017CADCIB8G\u0001;CC8\u000175B8 =85H9G\u0001:CF\u0001H<9\u0001 \u000e\u000b\u000e\u0001\nHF95HA9BH\u0001C:\u0001H9B57=657I@CG=G\t\u0001\u000e\u000b\u000f\u0001\n\u0001\u000e\u000b\u0010\u0001\n\u0010 '*+2(\"!$\")\"*/.\u0001\u000e\u000b\u0011\u0001\n,<=G\u0001(FC>97H\u0001<5G\u0001699B\u0001D5FH=5@@M\u0001GIDDCFH98\u00016M\u0001D9FGCB5@\u0001:CIB8G\u0001C: \u0001+D5B=G<\u0001F9G95F7<9FG\u00015B8\u0001 \u000e\u000b\u0012\u0001\nH<9\u0001-B=J9FG=HM\u0001C:\u0001+5BH=5;C\u000189\u0001\u001bCADCGH9@5\t\u0001+.*\u0001H<5B?G\u0001HC\u0001%=B=GH9 F=C\u000189\u0001\u001d8I757=UB\u0001M\u0001 \u000e\u000b\u0013\u0001\n\u001b=9B7=5\u0001:CF\u0001<9F\u0001\u001e(-\u0001(<\u001c\u0001;F5BH\u0001\u0019(\r\u000b\u000b\u0013\b\u000b\u000f\r\u0011\u000e\u0001\u0003+D5=B\u0004\t\u0001%\"%\u0001H<5B?G\u0001 \u001eIB85QPC\u0001D5F5\u00015\u0001 \u000e\u000b\u0014\u0001\n\u001b=RB7=5\u00019\u0001,97BC@C;=5\u0001:CF\u0001<9F\u0001( <\u001c\u0001;F5BH\u0001+\u001e* \n\u001a\u001c\n\u0011\f\r\u0011\r\n\r\u000b\u000b\u0014\u0001\u0003(CFH I;5@\u0004\t\u0001 \u000e\f\u000b\u0001\n\u0001\u000e\f\f\u0001\n\u0011+*#(& /\u0001+#\u0001&*/\"-\"./\u0001\u000e\f\r\u0001\n,<9\u00015IH<CFG\u0001<5J9\u0001897@5F98\u0001BC\u00017CB:@=7H\u0001C:\u0001=BH9F9GH\t\u0001\u000e\f\u000e\u0001\n\u0001\u000e\f\u000f\u0001\n\u001b\"#\"-\"* \".\u0001\u000e\f\u0010\u0001\n\u0003\f\u0004\u0001+INI?=\u0007\u0001%\t\u0016\u0001&5?5;5K5\u0007\u00011\t\u0016\u0001 5F5M5A5\u0007\u0001+\t\u0016\u000115A5ACHC\u0007\u0001+\t\u0001(<M@C; 9B9H=7\u00015B5@MG=G\u00015B8\u0001 \u000e\f\u0011\u0001\nH5LCBCA=7\u0001GHI8M\u0001C:\u0001A5F=B9\u0001\u001bMHCD<5;5\b@=?9\u0001657H9F=5\u0015\u0001DFCDCG5@\u0001:CF \u0001,9B57=657I@IA\u0001;9B\t\u0001 \u000e\f\u0012\u0001\nBCJ\t\u0001K=H<\u0001,9B57=657I@IA\u0001A5F=H=AIA\u00017CA6\t\u0001BCJ\t\u00015B8\u0001,9B57=657I@IA\u0001 CJC@MH=7IA\u00017CA6\t\u0001 \u000e\f\u0013\u0001\nBCJ\t\u0007\u00015B8\u000189G7F=DH=CB\u0001C:\u0001,9B57=657I@IA\u0001A9GCD<=@IA\u0001GD\t\u0001BCJ\t\u00015B8\u0001 ,9B57=657I@IA\u0001 \u000e\f\u0014\u0001\n5AM@C@MH=7IA\u0001GD\t\u0001BCJ\t\u0001 \u001c28\u0006\u0001\u001d\u0006\u0001$<78\u0006\u0001\u0018:30\u0006\u0001 /)63(/30\u0006 \u0001\u0007\u0005\u0005\u0006\u0007\u0001\r\t\u0004\u0001\f\u0011\u000e\u0014\\\f\u0011\u0010\r\t\u0001 \u000e\r\u000b\u0001\n\u0003\r\u0004\u0001%7.=75F\u0007\u0001\u0019\t\u0001 \t\u0016\u0001/<=H9\u0007\u0001(\t\u0001\u001f\t\u0001\u001e=B\u00015B8\u0001G?=B\u0001B97FCG=G\u0001C:\u00017I@H= J5H98\u0001\u001cCJ9F\u0001GC@9\u0007\u0001+C@95\u0001 \u000e\r\f\u0001\nGC@95\t\u0001\u001d\u0006\u0001\u0019/7.\u0001\u0017/7\u0006\u0001 \u0006\u000e\f\u000e\u0007\u0001\n\u0007\u0001\u0010\u0010\u0012\\\u0010\u0011\r\t\u0001 \u000e\r\r\u0001\n\u0003\u000e\u0004\u0001\u0019@G=B5\u0007\u0001%\t\u0016\u0001\u001a@5B7<\u0007\u0001\u0019\t\u0001*\t\u0001\u001e=FGH\u0001=GC@5H=CB\u0001C:\u0001\u001e@9L=657H9F\u0001A5 F=H=AIG\u0001:FCA\u00017I@H=J5H98\u0001 \u000e\r\u000e\u0001\nHIF6CH\u0001\u0003+7CD<H<5@AIG\u0001A5L=AIG\u0004\t\u0001 \u0015900\u0006\u0001\u001896\u0006\u0001\u0014773)\u0006\u0001\u0019/7.\u0001\"'8.30\u0006 \u0001\u0006\u000e\u000e\b\u0007\u0001\t\u000b\u0007\u0001\f\u0010\u0012\\\f\u0011\u000b\t\u0001 \u000e\r\u000f\u0001Page 14 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001a233\u0001 \f\u0010\u0001\u0003\u000f\u0004\u0001'GH@5B8\u0007\u0001.\t\u0001\u001d\t\u0016\u0001$5,F579\u0007\u0001\u001b\t\u0016\u0001%CFF=GCB\u0007\u0001\u001c\t\u0016\u0001\u001e9F;IGCB\u0007\u0001 \t\u0001/\t\u0001 \u001e@9L=657H9F\u0001A5F=H=AIG\u0001 \u000e\r\u0010\u0001\n5GGC7=5H98\u0001K=H<\u00015\u0001657H9F=5@\u0001GHCA5H=H=G\u0001=B\u0001\u0019H@5BH=7\u0001G5@ACB\u0001GAC@H G\u0001F95F98\u0001=B\u0001B9H\bD9BG\u0001=B\u0001 \u000e\r\u0011\u0001\n\u001aF=H=G<\u0001\u001bC@IA6=5\t\u0001 \u001d\u0006\u0001\u001459'8\u0006\u0001\u00142/1\u0006\u0001\u001b+'08. \u0001\u0006\u000e\u000e\u000e\u0007\u0001\t\t\u0007\u0001\u000e\u0010\\\u000f\u000f\t\u0001 \u000e\r\u0012\u0001\n\u0003\u0010\u0004\u0001\u001b9D985\u0007\u0001\u001b\t\u0016\u0001+5BHCG\u0007\u00011\t\u0001\u001e=FGH\u0001=GC@5H=CB\u0001C:\u0001 \u00190+;/(')8+6\u00011'6/8/197\u0001 :FCA\u0001:5FA98\u0001 \u000e\r\u0013\u0001\n+9B9;5@9G9\u0001GC@9\u0001\u0003 $30+'\u00017+2+-'0+27/7 \u0007\u0001#5ID\u0004\u0001=B\u0001+D5=B\t\u0001 \u0015900\u0006\u0001\u001896\u0006\u0001\u0014773)\u0006\u0001\u0019/7.\u0001\"'8.30\u0006 \u0001 \u000e\r\u0014\u0001\n\u0007\u0005\u0005\u0007\u0007\u0001\n\n\u0007\u0001\u000e\u0013\u0013\\\u000e\u0014\r\t\u0001 \u000e\u000e\u000b\u0001\n\u0003\u0011\u0004\u0001\u001a5L5\u0007\u0001\u001c\t\u0001.\t\u0016\u0001#5K5=\u0007\u0001#\t\u0016\u0001#IGI85\u0007\u0001*\t\u0001\u001b<5F57H9F=GH=7G\u0001C:\u0001;@=;= B;\u0001657H9F=5\u0001=GC@5H98\u0001:FCA\u0001 \u000e\u000e\f\u0001\n8=G95G9G\u00017I@HIF98\u0001:@CIB89F\u0001 \"'6'0/).8.<7\u000130/:')+397 \t\u0001\u0019/7.\u0001\"'8.30\u0006\u0001\u0006\u000e\r\u000b\u0007\u0001\n\t\u0004\u0001\r\u0010\f\\\r\u0010\u0013\t\u0001 \u000e\u000e\r\u0001\n\u0003\u0012\u0004\u0001%7.=75F\u0007\u0001\u0019\t\u0001 \t\u0016\u0001/<=H9\u0007\u0001(\t\u0001\u001f\t\u0001,<9\u0001DF9J9BH=CB\u00015B8\u00017IF9\u0001C:\u00015B\u0001 =B:97H=CIG\u00018=G95G9\u0001=B\u0001 \u000e\u000e\u000e\u0001\n7I@H=J5H98\u0001>IJ9B=@9\u0001\u001cCJ9F\u0001GC@9\u0007\u0001+C@95\u0001GC@95\u0001\u0003$\t\u0004\t\u0001\u0001 \u001459')90896+\u0001 \u0006\u000e\r\u0007\u0007\u0001\n\u000e\u0007\u0001\r\f\u000e\\\r\r\r\t\u0001 \u000e\u000e\u000f\u0001\n\u0003\u0013\u0004\u0001,CF5BNC\u0007\u0001\u0019\t\u0001\u001d\t\u0016\u0001%5;5F=TCG\u0007\u0001\u001a\t\u0016\u0001*CA5@89\u0007\u0001\"\t\u0001$\t\u0001\u0019\u0001F9J=9K\u0001C:\u0001H <9\u0001A5=B\u0001657H9F=5@\u0001:=G<\u0001 \u000e\u000e\u0010\u0001\n8=G95G9G\u0001=B\u0001A5F=7I@HIF9\u0001GMGH9AG\t\u0001 \u001459')90896+\t\u0001\u0007\u0005\u0005\n\u0007\u0001\n\f\u000e\u0007\u0001\u000e\u0012\\\u0011\f\t\u0001 \u000e\u000e\u0011\u0001\n\u0003\u0014\u0004\u0001\u001a5L5\u0007\u0001\u001c\t\u0001.\t\u0016\u0001#5K5=\u0007\u0001#\t\u0016\u0001#IGI85\u0007\u0001*\t\u0001\u001b<9ACH<9F5DM\u0001C:\u0001\u001e@9L=657 H9F\u0001A5F=H=AIG\u0001 \u000e\u000e\u0012\u0001\n=B:97H=CB\t\u0001\u0001#+4\u0006\u0001&$\u0014\u0001 '6\u0006\u0001\u0015/30\u0006\u0001\u001c278\u0006\u0001\u001e3)./\u0001&2/:\u0006\u0001 \u0006\u000e\r\r\u0007\u0001\t\b\u0007\u0001\u0014\\\f\u000f\t\u0001 \u000e\u000e\u0013\u0001\n\u0003\f\u000b\u0004\u0001 \u0019J9B85TC\b 9FF9F5\u0007\u0001 *\t\u0001 \u0019J5B79G\u0001 9B\u0001 9@\u0001 7CBC7=A=9BHC\u0001 89@\u0001 D5HU;9 BC\u0001 89\u0001 D979G\u0001 \u000e\u000e\u0014\u0001\n,9B57=657I@IA\u0001 A5F=H=AIA\u0015\u0001 =AD@=757=CB9G\u0001 9B\u0001 9@\u0001 8=5;BUGH=7C\u0001 M\u0001 DF9J 9B7=UB\u0001 89\u0001 @5\u0001 \u000e\u000f\u000b\u0001\n9B:9FA9858\t\u0001\".\u0006\u0001\u0017\u0006\u0001%.+7/7\u0007\u0001-B=J9FG=858\u000189\u0001+5BH=5;C\u000189\u0001\u001bCADCGH9@5\u0007\u0001 \u0007\u0005\u0005\n\t\u0001\u0001 \u000e\u000f\f\u0001\n\u0003\f\f\u0004\u0001/=@@=5AG\u0007\u0001(\t\u0001\"\t\u0016\u0001\u001bCIFH9B5M\u0007\u0001+\t\u0001\u001b\t\u0016\u0001.5F8M\u0007\u0001\u001b\t\u0001-G9\u0001C:\u00019BFC:@ CL57=B\u0001HC\u00017CBHFC@\u00015HMD=75@\u0001 \u000e\u000f\r\u0001\n\u0014+63132'7\u00017'0132/)/*' \u0001=B\u00015H@5BH=7\u0001HCA\u00017C8\t\u0001 \u001d\u0006\u0001\u001459'8\u0006\u0001\u00142/1\u0006\u0001\u001b+'08. \u0001\u0006\u000e\u000e\f\u0007\u0001\u0011\u0007\u0001\r\f\u0011\\\r\r\r\t\u0001 \u000e\u000f\u000e\u0001\n\u0003\f\r\u0004\u0001 GI\u0007\u0001 \t\u0001%\t\u0016\u0001/CCGH9F\u0007\u0001\u001f\t\u0001\u0019\t\u0016\u0001\u001aCKG9F\u0007\u0001(\t\u0001*\t\u0001\u001d::=757M\u0001C:\u0001\u001dBFC :@CL 57=B\u0001:CF\u0001H<9\u0001 \u000e\u000f\u000f\u0001\n,F95HA9BH\u0001C:\u0001+5@ACB=8G\u0001K=H<\u0001\u001a57H9F=5@\u0001#=8B9M\u0001\u001c=G95G9\u0007\u0001\u001b5IG98\u00016M \u0001#+2/(')8+6/91\u0001 \u000e\u000f\u0010\u0001\n7'0132/2'691 \t\u0001\u001d\u0006\u0001\u001459'8\u0006\u0001\u00142/1\u0006\u0001\u001b+'08. \u0001\u0006\u000e\u000e\t\u0007\u0001\u000e\u0007\u0001\r\r\u000b\\\r\r\u000e\t\u0001 \u000e\u000f\u0011\u0001\n\u0003\f\u000e\u0004\u0001\u001aCF;9G\u0007\u0001\u001e\t\u0016\u0001*C@9=F5\u0007\u0001\u001e\t\u0016\u0001%=@<5N9G\u0007\u0001&\t\u0016\u0001+5BH5B5\u0007\u0001$\t\u0016\u0001-F=5FH 9\u0007\u0001\u001d\t\u0001+=AD@9\u00017CIA5F=BG\u0001 \u000e\u000f\u0012\u0001\n5B8\u00015B5@C;I9G\u0001=B\u0001A98=7=B5@\u00017<9A=GHFM\u0015\u0001C77IFF9B79\u0007\u0001GMBH<9G=G\u00015B8 \u00016=C@C;=75@\u000157H=J=HM\t\u0001 \u000e\u000f\u0013\u0001\n\u0016966\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0005\n\u0007\u0001\t\n\u0007\u0001\u0013\u0013\u0012\\\u0014\f\u0011\t \u0001 \u000e\u000f\u0014\u0001Page 15 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001b234\u0001 \f\u0011\u0001\u0003\f\u000f\u0004\u0001\u001aCF;9G\u0007\u0001\u001e\t\u0016\u0001*C@9=F5\u0007\u0001\u001e\t\u0016\u0001%=@<5N9G\u0007\u0001&\t\u0016\u0001-F=5FH9\u0007\u0001\u001d\t\u0016\u0001+5BH5B 5\u0007\u0001$\t\u0001+=AD@9\u00017CIA5F=BG\u0015\u0001 \u000e\u0010\u000b\u0001\n(F=J=@9;98\u0001G75::C@8G\u0001=B\u0001A98=7=B5@\u00017<9A=GHFM\t\u0001\u00196328\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0005\u000e\u0007\u0001\f\u0007\u0001\r\u000e\\\u0013\u0010\t\u0001 \u000e\u0010\f\u0001\n\u0003\f\u0010\u0004\u0001%9@5;F5?=\u0007\u0001\u001f\t\u0016\u0001\u0019:5BH=H=G\u0007\u0001\u0019\t\u0016\u0001!;;@9GG=\b%5F?CDCI@CI\u0007\u0001'\t\u0016\u0001\u001c9 HG=\u0007\u0001\u0019\t\u0016\u0001#CI:5?=\u0007\u0001%\t\u0016\u0001 \u000e\u0010\r\u0001\n#CBHC;=CF;=G\u0007\u0001\u001b\t\u0016\u0001 58>=D5J@CI\b$=H=B5\u0007\u0001\u001c\t\u0001\"\t\u0001+MBH<9G=G\u00015B8\u00019J5@I 5H=CB\u0001C:\u0001H<9\u00015BH=CL=85BH\u0001 \u000e\u0010\u000e\u0001\n5B8\u00015BH=\b=B:@5AA5HCFM\u000157H=J=HM\u0001C:\u0001BCJ9@\u00017CIA5F=B\b\u000e\b5A=BC5A=89G\u0001 5B8\u0001H<9=F\u00015@D<5\b@=DC=7\u0001 \u000e\u0010\u000f\u0001\n57=8\u0001588I7HG\t\u0001\u001896\u0006\u0001\u001d\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001 \u0007\u0005\u0005\u000e\u0007\u0001\f\f\u0007\u0001\u000e\u000b\r\u000b\\\u000e\u000b\r\u0011\t\u0001 \u000e\u0010\u0010\u0001\n\u0003\f\u0011\u0004\u0001+MA9CB=8=G\u0007\u0001,\t\u0016\u0001\u001eM@5?H5?=8CI\u0007\u0001#\t\u0001\u001b\t\u0016\u0001 58>=D5J@CI\b$=H=B5\u0007\u0001\u001c \t\u0001\"\t\u0016\u0001$=H=B5G\u0007\u0001#\t\u0001\u001d\t\u0001 \u000e\u0010\u0011\u0001\n+MBH<9G=G\u0001 5B8\u0001 5BH=\b=B:@5AA5HCFM\u0001 9J5@I5H=CB\u0001 C:\u0001 BCJ9@\u0001 5B;I@5F@M\u0001 C F\u0001 @=B95F@M\u0001 :IG98\u0001 \u000e\u0010\u0012\u0001\n7CIA5F=BG\t\u0001\u001896\u0006\u0001\u001d\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0005\u000e\u0007\u0001\f\f\u0007\u0001\u0010\u000b\f\r\\\u0010\u000b\f\u0012\t\u0001 \u000e\u0010\u0013\u0001\n\u0003\f\u0012\u0004\u0001#CGHCJ5\u0007\u0001!\t\u0016\u0001\u001a<5H=5\u0007\u0001+\t\u0016\u0001\u001fF=;CFCJ\u0007\u0001(\t\u0016\u0001\u001a5@?5BG?M\u0007\u0001+\t\u0016\u0001(5FA 5F\u0007\u0001.\t\u0001+\t\u0016\u0001(F5G58\u0007\u0001\u0019\t\u0001#\t\u0016\u0001 \u000e\u0010\u0014\u0001\n+5GC\u0007\u0001$\t\u0001\u001bCIA5F=BG\u00015G\u00015BH=CL=85BHG\t\u0001 \u0016966\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001 \u0007\u0005\u0006\u0006\u0007\u0001\t\u0010\u0007\u0001\u000e\u0014\r\u0014\\\u000e\u0014\u0010\f\t\u0001 \u000e\u0011\u000b\u0001\n\u0003\f\u0013\u0004\u0001*C8F=;I9N\u0007\u0001+\t\u0001\u0019\t\u0016\u0001&5N5F9BC\u0007\u0001%\t\u0001\u0019\t\u0016\u0001\u001a5IA;5FHB9F\u0007\u0001%\t\u0001,\t\u0001\u001d::9 7H\u0001C:\u00018=::9F9BH\u0001\u001b\u000e\b5FM@\u0001 \u000e\u0011\f\u0001\nGI6GH=HI9BHG\u0001CB\u0001H<9\u00015BH=CL=85BH\u000157H=J=HM\u0001C:\u0001\u000f\b<M8FCLM7CIA5F=B\u000189F=J5H=J9G\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001 \u000e\u0011\r\u0001\n\u0016.+1\u0006\u0001\u0007\u0005\u0006\u0006\u0007\u0001\t\u0011\u0007\u0001\u0011\r\u000e\u000e\\\u0011\r\u000e\u0013\t\u0001 \u000e\u0011\u000e\u0001\n\u0003\f\u0014\u0004\u0001.=@5F\u0007\u0001+\t\u0016\u0001)I9N585\u0007\u0001\u001d\t\u0016\u0001+5BH5B5\u0007\u0001$\t\u0016\u0001-F=5FH9\u0007\u0001\u001d\t\u0016\u000115B9N\u0007\u0001% \t\u0016\u0001\u001eF5=N\u0007\u0001&\t\u0016\u0001\u0019@75=89\u0007\u0001\u001b\t\u0016\u0001 \u000e\u0011\u000f\u0001\n\u001b5BC\u0007\u0001\u001d\t\u0016\u0001'F5@@C\u0007\u0001\u001e\t\u0001\u001c9G=;B\u0007\u0001GMBH<9G=G\u0007\u00015B8\u0001J5GCF9@5L5BH\u00015B8\u0001D@ 5H9@9H\u00015BH=5;;F9;5HCFM\u0001 \u000e\u0011\u0010\u0001\n57H=J=H=9G\u0001C:\u00017CIA5F=B\bF9GJ9F5HFC@\u0001<M6F=8G\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0005\u000b\u0007\u0001\t\u000e\u0007\u0001\r\u0010\u0012\\\r\u0011\f\t\u0001 \u000e\u0011\u0011\u0001\n\u0003\r\u000b\u0004\u0001\u001a9@@IH=\u0007\u0001\u001e\t\u0016\u0001\u001eCBH5B5\u0007\u0001\u001f\t\u0016\u0001\u001aC\u0007\u0001$\t\u0016\u0001\u001b5F9B=B=\u0007\u0001&\t\u0016\u0001\u001f=CAA5F9@@ =\u0007\u0001\u001b\t\u0016\u00012IB=BC\u0007\u0001\u001e\t\u0001\u001c9G=;B\u0007\u0001 \u000e\u0011\u0012\u0001\nGMBH<9G=G\u0001 5B8\u0001 5BH=75B79F\u0001 57H=J=H=9G\u0001 C:\u0001 GH=@69B9\b7CIA5F=B\u0001 <M6F=8\u0001 7CADCIB8G\u0015\u0001\u000e\u0011\u0013\u0001\n!89BH=:=75H=CB\u0001C:\u0001BCJ9@\u0001DFC5DCDHCH=7\u00015;9BHG\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0006\u0005\u0007\u0001\t\u0010\u0007\u0001\u000e\u0010\u000f\u000e\\\u000e\u0010\u0010\u000b\t\u0001 \u000e\u0011\u0014\u0001\n\u0003\r\f\u0004\u0001*=J9=FC\u0007\u0001%\t\u0001\u001d\t\u0016\u0001%C;@=CB=\u0007\u0001\u0019\t\u0016\u0001.5NEI9N\u0007\u0001*\t\u0016\u0001\u001fCA9N\u0007\u0001&\t\u0016\u0001\u001e57C FFC\u0007\u0001\u001f\t\u0016\u0001(=9<@\u0007\u0001$\t\u0016\u000189\u0001 \u000e\u0012\u000b\u0001\n\u001b9@=G\u0007\u0001\u001d\t\u0001*\t\u0016\u0001+<5MC\u0007\u0001\u001b\t\u0016\u0001\u001c5J=C\u0007\u0001\u001b\t\u0001+HFI7HIF5@\u0001=BG=;<HG\u0001=BHC\u0001<M8 FCLM7CIA5F=B\b=B8I798\u0001 \u000e\u0012\f\u0001\n5\nDCDHCG=G\u0001=B\u0001-\b\u0014\u000e\u0012\u000179@@G\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0005\r\u0007\u0001\t\u000e\u0007\u0001\r\u0011\u0011\u0010\\\r\u0011\u0012\u0010\t\u0001 \u000e\u0012\r\u0001Page 16 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001c235\u0001 \f\u0012\u0001\u0003\r\r\u0004\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001.5NEI9N\b*C8F=; I9N\u0007\u0001+\t\u0016\u0001+5BH5B5\u0007\u0001$\t\u0016\u0001-F=5FH9\u0007 \u0001\u001d\t\u0016\u0001\u001eI9BH9G\b\u001d8:I:\u0007\u0001\u001b\t\u0016\u0001 \u000e\u0012\u000e\u0001\n+5BHCG\u0007\u0001 1\t\u0016\u0001 %IBCN\b\u001bF9;C\u0007\u0001 \u0019\t\u0001 $CC?=B;\u0001 :CF\u0001 B9K\u0001 H5F;9HG\u0015\u0001 G=AD@9\u0001 7CI A5F=BG\u0001 5G\u0001 \u000e\u0012\u000f\u0001\n5BH=657H9F=5@\u00015;9BHG\t\u0001  +*\u0006\u0001\u0016.+1\u0006\u0001 \u0007\u0005\u0006\u0007\u0007\u0001\u0010\u0007\u0001\f\f\u000f\u000b\\\f\f\u000f\u0010\t\u0001 \u000e\u0012\u0010\u0001\n\u0003\r\u000e\u0004\u0001\u001b<=A9BH=\u0007\u0001\u001e\t\u0016\u0001\u001a=NN5FF=\u0007\u0001\u001a\t\u0016\u0001\u001aC@5G7C\u0007\u0001\u0019\t\u0016\u0001+977=\u0007\u0001\u001c\t\u0016\u0001\u001b<=A9B H=\u0007\u0001(\t\u0016\u0001\u001fF5B9G9\u0007\u0001\u0019\t\u0016\u0001 \u000e\u0012\u0011\u0001\n\u001b5FF58CF=\u0007\u0001+\t\u0016\u0001*=J5B9F5\u0007\u0001\u001c\t\u0016\u00012=75F=\u0007\u0001\u0019\t\u0016\u0001+75@HF=HC\u0007\u0001%\t\u0001%\t\u0016\u0001+=GH C\u0007\u0001\u001e\t\u0001+MBH<9G=G\u0007\u0001G9@97H=J9\u0001 \u000e\u0012\u0012\u0001\n5BH=\b 9@=7C657H9F\u0001DM@CF=\u000157H=J=HM\u0007\u00015B8\u00017MHCHCL=7=HM\u0001C:\u0001BCJ9@\u0001&\bGI6GH=HIH98\b\r\bCLC\b\r \b\f\b\u000e\u0012\u0013\u0001\n69BNCDMF5B\b\u000e\b75F6CL5A=89G\t\u0001\u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006\u0001 \u0007\u0005\u0006\u0005\u0007\u0001\n\b\u0007\u0001\u000f\u0014\r\r\\\u000f\u0014\r\u0011\t\u0001 \u000e\u0012\u0014\u0001\n\u0003\r\u000f\u0004\u0001+<=\u0007\u00011\t\u0016\u00012<CI\u0007\u0001\u001b\t\u0001+MBH<9G=G\u00015B8\u00019J5@I5H=CB\u0001C:\u00015\u00017@5GG\u0001C:\u0001B 9K\u00017CIA5F=B\u0001HF=5NC@9\u0001 \u000e\u0013\u000b\u0001\n89F=J5H=J9G\u00015G\u0001DCH9BH=5@\u00015BH=A=7FC6=5@\u00015;9BHG\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0006\u0006\u0007\u0001\n\t\u0007\u0001\u0014\u0010\u0011\\ \u000e\u0013\f\u0001\n\u0014\u0011\u000b\t\u0001\u000e\u0013\r\u0001\n\u0003\r\u0010\u0004\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001.=T5\u0007\u0001\u001c\t\u0016\u0001(=77=5I\u0007\u0001\u001b\t\u0016\u0001'F5@@C\u0007\u0001\u001e\t\u0016\u0001+5BH5B5\u0007\u0001 $\t\u0016\u0001-F=5FH9\u0007\u0001\u001d\t\u0001+MBH<9G=G\u0001 \u000e\u0013\u000e\u0001\n5B8\u0001 9J5@I5H=CB\u0001 C:\u0001 \u0011\bA9H<M@\b\u000e\bD<9BM@7CIA5F=BG\u0001 5G\u0001 DCH9BH\u0001 5B8\u0001 G9@9 7H=J9\u0001 %\u0019'\b\u001a\u0001 \u000e\u0013\u000f\u0001\n=B<=6=HCFG\t\u0001\u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0005\u000e\u0007\u0001\t\u0011\u0007\u0001\u0010\u000b\u0010\u000e\b\u0010\u000b\u0010\u0010\t\u0001 \u000e\u0013\u0010\u0001\n\u0003\r\u0011\u0004\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001.5NEI9N\b*C8F=;I9N\u0007\u0001+\t\u0016\u0001-F=5FH9\u0007\u0001\u001d\t\u0016\u0001+5BH5B5\u0007 \u0001$\t\u0016\u0001.=T5\u0007\u0001\u001c\t\u0001%\u0019'\u0001 \u000e\u0013\u0011\u0001\n=B<=6=HCFM\u000157H=J=HM\u0001AC8I@5H=CB\u0015\u0001\u000e\b(<9BM@7CIA5F=BG\u0001J9FGIG\u0001\u000e\b69BN CM@7CIA5F=BG\t\u0001\u0015/336-\u0006\u0001 \u000e\u0013\u0012\u0001\n +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0006\u0006\u0007\u0001\n\t\u0007\u0001\u000f\r\r\u000f\\\u000f\r\r\u0012\t\u0001 \u000e\u0013\u0013\u0001\n\u0003\r\u0012\u0004\u0001\u001f5@A\u0007\u0001-\t\u0016\u0001 9@@9F\u0007\u0001+\t\u0016\u0001+<5D=FC\u0007\u0001+\t\u0016\u0001(5;9\u0007\u0001%\t\u0016\u0001$=\u0007\u0001+\t\u0001%\t\u0016\u0001 9 =89\u0007\u0001$\t\u0001\u0019BH=A=7FC6=5@\u00015B8\u0001 \u000e\u0013\u0014\u0001\n\u001c&\u0019\u0001 ;MF5G9\b=B<=6=HCFM\u0001 57H=J=H=9G\u0001 C:\u0001 BCJ9@\u0001 7@CFC6=C7=B\u0001 89F=J5H=J 9 G \u0001D F C 8 I 7 9 8 \u00016 M \u0001 \u000e\u0014\u000b\u0001\nAIH5GMBH<9G=G\t\u0001\u0014-+287\u0001\u0016.+138.+6 \t\u0001\u0007\u0005\u0005\t\u0007\u0001\f\u0010\u0007\u0001\f\u000e\u000b\u0012\\\f\u000e\f\r\t\u0001 \u000e\u0014\f\u0001\n\u0003\r\u0013\u0004\u0001\u001aF586IFM\u0007\u0001\u001a\t\u0001\"\t\u0016\u0001(I77=\u0007\u0001%\t\u0001\"\t\u0001*979BH\u000158J5B79G\u0001=B\u0001657H9F=5@ \u0001HCDC=GCA9F5G9\u0001=B<=6=HCFG\t\u0001 \u000e\u0014\r\u0001\n\u0016966\u0006\u0001!4/2\u0006\u0001\".'61')30\u0006 \u0001\u0007\u0005\u0005\r\u0007\u0001\u0010\u0007\u0001\u0010\u0012\u000f\\\u0010\u0013\f\t\u0001 \u000e\u0014\u000e\u0001\n\u0003\r\u0014\u0004\u0001 +5<I\u0007\u0001 &\t\u0001 #\t\u0016\u0001 \u001a5@6<58F5\u0007\u0001 +\t\u0001 +\t\u0016\u0001 \u001b<CI8<5FM\u0007\u0001 \"\t\u0016\u0001 #C<@=\u0007\u0001 \u001c\t\u0001 .\t \u0001 \u001dLD@CF=B;\u0001 \u000e\u0014\u000f\u0001\n(<5FA57C@C;=75@\u0001+=;B=:=75B79\u0001C:\u0001\u001b<5@7CB9\u0001+75::C@8\u0015\u0001\u0019\u0001*9J=9K\t\u0001 \u0016966 \u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001 \u000e\u0014\u0010\u0001\n\u0007\u0005\u0006\u0007\u0007\u0001\t\u0011\u0007\u0001\r\u000b\u0014\\\r\r\u0010\t\u0001 \u000e\u0014\u0011\u0001Page 17 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001d236\u0001 \f\u0013\u0001\u0003\u000e\u000b\u0004\u0001$=5F5G\u0007\u0001#\t\u0016\u0001\u001f9FCB=?5?=\u0007\u0001\u0019\t\u0016\u0001\u001f@5AC7@=>5\u0007\u0001\"\t\u0016\u0001\u001b=F=7\u0007\u0001\u0019\t\u0016\u0001+C? CJ=7\u0007\u0001%\t\u0001,<=5NC@9\b65G98\u0001 \u000e\u0014\u0012\u0001\n7<5@7CB9G\u00015G\u0001DCH9BH\u00015BH=A=7FC6=5@\u00015;9BHG\t\u0001+MBH<9G=G\u00015B8\u00016=C@C;= 75@\u00019J5@I5H=CB\t\u0001 \u0015/336-\u0006\u0001 \u000e\u0014\u0013\u0001\n +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0006\u0006\u0007\u0001\t\u0011\u0007\u0001\u000e\f\u000e\u0010\\\u000e\f\u000f\u000b\t\u0001 \u000e\u0014\u0014\u0001\n\u0003\u000e\f\u0004\u0001 \u001a5HCJG?5\u0007\u0001 \u001c\t\u0016\u0001 (5FIG<9J\u0007\u0001 +\t\u0016\u0001 +H5A6C@=MG?5\u0007\u0001 \u001a\t\u0016\u0001 ,GJ9H?CJ5\u0007\u0001 ! \t\u0016\u0001 &=BCJ5\u0007\u0001 %\t\u0016\u0001 \u000f\u000b\u000b\u0001\n&5>89BG?=\u0007\u0001 \t\u0001\u001dL5A=B5H=CB\u0001C:\u0001;FCKH<\u0001=B<=6=HCFM\u0001DFCD9FH=9G\u0001C:\u0001GM BH<9H=7\u00017<5@7CB9G\u0001:CF\u0001 \u000f\u000b\f\u0001\nK<=7<\u00015BH=657H9F=5@\u000157H=J=HM\u0001K5G\u0001DF98=7H98\t\u0001 \u001896\u0006\u0001\u001d\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006 \u0001\u0007\u0005\u0005\u000e\u0007\u0001\f\f\u0007\u0001\r\r\f\f\\\r\r\f\u0013\t\u0001 \u000f\u000b\r\u0001\n\u0003\u000e\r\u0004\u0001$5FG9B\u0007\u0001%\t\u0016\u0001#FCA5BB\u0007\u0001 \t\u0016\u0001#<5F5NA=\u0007\u0001\u0019\t\u0016\u0001&=9@G9B\u0007\u0001+\t\u0001\u001e\t\u0001\u001bCB: CFA5H=CB5@@M\u0001F9GHF=7H98\u0001 \u000f\u000b\u000e\u0001\n5BH=\bD@5GAC8=5@\u00017<5@7CB9G\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88 \t\u0001\u0007\u0005\u0005\n\u0007\u0001\t\r\u0007\u0001\u000f\u0013\u0010\u0013\\\u000f\u0013\u0011\f\t\u0001 \u000f\u000b\u000f\u0001\n\u0003\u000e\u000e\u0004\u0001#IA5F\u0007\u0001*\t\u0016\u0001%C<5B5?F=G<B5B\u0007\u0001\u001c\t\u0016\u0001+<5FA5\u0007\u0001\u0019\t\u0016\u0001#5IG<=?\u0007\u0001&\t\u0001#\t\u0016 \u0001#5@=5\u0007\u0001#\t\u0016\u0001+=B<5\u0007\u0001\u0019\t\u0001 \u000f\u000b\u0010\u0001\n#\t\u0016\u0001 +5<5@\u0007\u0001 \u001c\t\u0001 *9=BJ9GH=;5H=CB\u0001 C:\u0001 GHFI7HIF9\b57H=J=HM\u0001 F9@5H=CBG<= D\u0001 C:\u0001 A9H<CLM@5H98\u0001 \u000f\u000b\u0011\u0001\n7<5@7CB9G\u00015G\u00015BH=A5@5F=5@G\u0015\u0001GMBH<9G=G\u00015B8\u00019J5@I5H=CB\u0001C:\u0001\r\u0007\u000f\u0007\u0010\bH F=A9H<CLM\u0001GI6GH=HIH98\u0001 \u000f\u000b\u0012\u0001\nD5HH9FBG\u00015G\u0001@958\u000175B8=85H9G\u000189F=J98\u0001:FCA\u000156IB85BH@M\u00015J5=@56@9\u0001B 5HIF5@\u0001c\b5G5FCB9\t\u0001 \u001896\u0006\u0001\u001d\u0006\u0001 \u000f\u000b\u0013\u0001\n +*\u0006\u0001\u0016.+1\u0006\u0001\u0007\u0005\u0006\u0005\u0007\u0001\f\r\u0007\u0001\u0010\r\u0014\r\\\u0010\u000e\u000b\f\t\u0001 \u000f\u000b\u0014\u0001\n\u0003\u000e\u000f\u0004\u0001$5<H7<9J\u0007\u0001#\t\u0001$\t\u0016\u0001\u001a5HCJG?5\u0007\u0001\u001c\t\u0001!\t\u0016\u0001(5FIG<9J\u0007\u0001+\t\u0001(\t\u0016\u0001-6=MJCJ ?\u0007\u0001.\t\u0001%\t\u0016\u0001+=6=FBM\u0007\u0001\u0019\t\u0001\u0019\t\u0001 \u000f\f\u000b\u0001\n\u0019BH=:IB;5@\u000157H=J=HM\u0001C:\u00017<5@7CB9G\u0015\u00015\u0001A97<5B=GH=7\u0001GHI8M\u0001IG=B;\u0001J5F =CIG\u0001M95GH\u0001GHF5=BG\t\u0001 \u001896\u0006\u0001\u001d\u0006\u0001 \u000f\f\f\u0001\n +*\u0006\u0001\u0016.+1\u0006\u0001\u0007\u0005\u0005\r\u0007\u0001\f\u000b\u0007\u0001\r\r\r\u000b\\\r\r\r\u0013\t\u0001 \u000f\f\r\u0001\n\u0003\u000e\u0010\u0004\u0001\u001b<99BDF57<5\u0007\u0001+\t\u0016\u0001#5F5@5=\u0007\u0001\u001b\t\u0016\u0001(CB;@=A5BCBH\u0007\u0001\u001b\t\u0016\u0001+I6<58<=F5 G5?I@\u0007\u0001+\t\u0016\u0001,9KHF5?I@\u0007\u0001+\t\u0001 \u000f\f\u000e\u0001\n\u0019BH=\b !.\b\f\u0001DFCH95G9\u000157H=J=HM\u0001C:\u00017CADCIB8G\u0001:FCA\u0001\u001aC9G9B69F;=5\u0001D5B 8IF5H5\t\u0001\u0015/336-\u0006\u0001 +*\u0006\u0001 \u000f\f\u000f\u0001\n\u0016.+1\u0006\u0001\u0007\u0005\u0005\u000b\u0007\u0001\t\f\u0007\u0001\f\u0012\f\u000b\\\f\u0012\f\u000f\t\u0001 \u000f\f\u0010\u0001\n\u0003\u000e\u0011\u0004\u0001/I\u0007\u0001\"\t\u0001 \t\u0016\u0001/5B;\u0007\u00010\t\u0001 \t\u0016\u00011=\u0007\u00011\t\u0001 \t\u0016\u0001$99\u0007\u0001#\t\u0001 \t\u0001\u0019BH=\b\u0019!\u001c+\u00015; 9BHG\u0001\u0010\u000f\t\u0001\u0019\u0001DCH9BH\u00015BH=\b \u000f\f\u0011\u0001\n !.\u00017<5@7CB9\u00015B8\u0001:@5JCBC=8G\u0001:FCA\u0001;9BIG\u0001\u001c9GACG\t\u0001 \u0015/336-\u0006\u0001 +*\u0006\u0001\u0016.+1\u0006\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0005\b\u0007\u0001\t\u000b\u0007\u0001 \u000f\f\u0012\u0001\n\f\u0013\f\u000e\\\f\u0013\f\u0010\t\u0001\u000f\f\u0013\u0001\n\u0003\n\u000e\u0012\u0004\u0001*C>5G\u0007\u0001\"\t\u0016\u0001(5MO\u0007\u0001%\t\u0016\u0001\u001cCASB;I9N\u0007\u0001\"\t\u0001&\t\u0016\u0001\u001e9FFOB8=N\u0007\u0001%\t\u0001$\t\u0001HH \u001b \u0007\u00015\u0001G9@97H=J9\u0001=B<=6=HCF\u0001 \u000f\f\u0014\u0001\nC:\u0001=B8I7=6@9\u0001B=HF=7\u0001CL=89\u0001GMBH<5G9\u00019LDF9GG=CB\u0001K=H<\u00015BH=5FH<F=H= 7\u0001DFCD9FH=9G\t\u0001\u001896\u0006\u0001\u001d\u0006\u0001 \u000f\r\u000b\u0001\n\".'61')30\u0006\u0001\u0007\u0005\u0005\b\u0007\u0001\f\u000e\r\u0007\u0001\f\u0013\u000e\\\f\u0013\u0014\t\u0001 \u000f\r\f\u0001Page 18 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001e237\u0001 \f\u0014\u0001\u0003\u000e\u0013\u0004\u0001&CK5?CKG?5\u0007\u00012\t\u0001\u0019\u0001F9J=9K\u0001C:\u00015BH=\b=B:97H=J9\u00015B8\u00015BH=\b=B:@5AA 5HCFM\u00017<5@7CB9G\t \u0001\u001896\u0006\u0001 \u000f\r\r\u0001\n\u001d\u0006\u0001 +*\u0006\u0001\u0016.+1 \t\u0001\u0007\u0005\u0005\f\u0007\u0001\f\n\u0007\u0001\f\r\u0010\\\f\u000e\u0012\t\u0001 \u000f\r\u000e\u0001\n\u0003\u000e\u0014\u0004\u0001.5NEI9N\b*C8F=;I9N\u0007\u0001+\t\u0016\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001+5BH5B5\u0007\u0001$\t\u0016\u0001-F=5FH9\u0007 \u0001\u001d\t\u0016\u0001\u001aCF;9G\u0007\u0001\u001e\t\u0016\u0001#57<@9F\u0007\u0001 \u000f\r\u000f\u0001\n+\t\u0016\u0001#@CHN\u0007\u0001#\t\u0001&\t\u0001\u001b<5@7CB9\b65G98\u000189F=J5H=J9G\u00015G\u0001B9K\u0001G75::C@8G\u0001:C F\u0001<\u0019\u000e\u0001589BCG=B9\u0001 \u000f\r\u0010\u0001\nF979DHCF\u00015BH5;CB=GHG\t\u0001 \u001d\u0006\u0001\".'61\u0006\u0001\"'61')30\u0006 \u0001\u0007\u0005\u0006\b\u0007\u0001\u000e\r\u0007\u0001\u0011\u0014\u0012\\\u0012\u000b\u000e\t\u0001 \u000f\r\u0011\u0001\n\u0003\u000f\u000b\u0004\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001.5NEI9N\b*C8F=;I9N\u0007\u0001+\t\u0016\u0001\u001aCF;9G\u0007\u0001\u001e\t\u0016\u0001+5BH5B5\u0007\u0001 $\t\u0016\u0001-F=5FH9\u0007\u0001\u001d\t\u0001+MBH<9G=G\u0001 \u000f\r\u0012\u0001\nC:\u0001 \u000e\b5FM@7CIA5F=BG\u0001 J=5\u0001 +INI?=\b7FCGG\b7CID@=B;\u0001 F957H=CBG\u0001 C:\u0001 \u000e\b7<@ CFC7CIA5F=B\t\u0001 \u000f\r\u0013\u0001\n%+86'.+*632\u0001\u001f+88\u0006 \u0001\u0007\u0005\u0006\u0006\u0007\u0001\u000f\n\u0007\u0001\f\r\r\u0010\\\f\r\r\u0012\t\u0001 \u000f\r\u0014\u0001\n\u0003\u000f\f\u0004\u0001.5NEI9N\b*C8F=;I9N\u0007\u0001+\t\u0016\u0001\u001e=;I9FC5\b\u001fIST9N\u0007\u0001*\t\u0016\u0001%5HCG\u0007\u0001%\t\u0001\"\t\u0016\u0001 +5BH5B5\u0007\u0001$\t\u0016\u0001-F=5FH9\u0007\u0001 \u000f\u000e\u000b\u0001\n\u001d\t\u0016\u0001$5D=9F\u0007\u0001%\t\u0016\u0001%5M5\u0007\u0001\"\t\u0001\u001c\t\u0016\u0001'@95\b\u0019N5F\u0007\u0001\u001b\t\u0001+MBH<9G=G\u0001C:\u00017CIA5F= B\\7<5@7CB9\u0001<M6F=8G\u00015B8\u0001 \u000f\u000e\f\u0001\n9J5@I5H=CB\u0001C:\u0001H<9=F\u00015BH=CL=85BH\u00015B8\u0001HFMD5BC7=85@\u0001DFCD9FH=9G\t\u0001  +*\u0016.+1\u0016311\u0006 \u0001\u0007\u0005\u0006\b\u0007\u0001\f\u0007\u0001 \u000f\u000e\r\u0001\n\u0014\u0014\u000e\\\f\u000b\u000b\u000b\t\u0001\u000f\u000e\u000e\u0001\n\u0003\u000f\r\u0004\u0001(5NCG\u0007\u0001\u001e\t\u0016\u0001+5BHCG\u0007\u00011\t\u0016\u0001%57S5G\u0007\u0001\u0019\t\u0001*\t\u0016\u0001&VT9N\u0007\u0001+\t\u0016\u0001,CF5BNC\u0007\u0001 \u0019\t\u0001\u001d\t\u0001\u001dJ5@I5H=CB\u0001C:\u0001 \u000f\u000e\u000f\u0001\nA98=5\u0001:CF\u0001H<9\u0001GI779GG:I@\u00017I@HIF9\u0001C:\u0001 \u00190+;/(')8+6\u00011'6/8/191\u0006 \u0001\u001d\u0006\u0001\u0019/7.\u0001\u0017/7\u0006\u0001\u0006\u000e\u000e\u000b\u0007\u0001\t\u0011\u0007\u0001\f\u0014\u000e\b \u000f\u000e\u0010\u0001\n\f\u0014\u0012\t\u0001\u000f\u000e\u0011\u0001\n\u0001\u000f\u000e\u0012\u0001Page 19 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a\u001f238\u0001 \r\u000b\u0001\u0001\n\u0001\n\u0001\n\u0001\u0001\u0001\n\u0013&$0-\"\u0001\u0006\u0004\u0001)I=BC@CB9\u000189F=J5H=J9G\u00015G\u00015BH=657H9F=5@\u00018FI;G\t\u0001\n\u0001\u0001\u0001Page 20 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001a 239\u0001 \r\f\u0001\u0001\n\u0001\n\u0013&$0-\"\u0001\u0007\u0004\u0001\u001a9BNCDMFCB9\u000189F=J5H=J9G\u00017IFF9BH @M\u0001IG98\u00015G\u0001DCH9BH\u00015BH=657H9F=5@ \u00015;9BHG\t\u0001\n\u0001\n\u0001Page 21 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001b\u0017240\u0001 \r\r\u0001\u0001\n\u0001\n\u0001\n\u0001\u0001\n\u0001\n\u0013&$0-\"\u0001\b\t\u0001*5H=CB5@\u000189G=;B\u0001C:\u0001H<9\u00017CIA5F=B\b7<5@7CB9\u0001<M6F=8\u00017CADCIB8G\u0001\n\u0001\n\u0001\u0007\u0007\u0007\n\n\u0013\u0017\u0011\b\u0015\u000f\u0012 \n\u000e\b\u0010\n\u0013\u0012\f\n\u0007\n\u0007\u0007\n\n\u0013\u0017\u0011\b\u0015\u000f\u0012\u0004\n\u000e\b\u0010\n\u0013\u0012\f\u0001\u000e\u0018\t\u0015\u000f\u000b\nPage 22 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001b\u0018241\u0001 \r\u000e\u0001\u0001\n\u0001\n\u001c %\")\"\u0001\u0006\u0004\u0001+MBH<9G=G\u0001C:\u0001H<9\u0001H5F;9H\u0001AC@97I@9G\u0001 \u0006\u0003\u0006\u0007\t\u0001#+'-+287\u0001'2*\u0001)32*/8/327\u0012 \u0001=\u0004\u0001\u001dH' \u0007\u0001\nD=D9F=8=B9\u0007\u0001F9:@IL\u0007\u0001\r\b\u0010\u0001<\u0016\u0001==\u0004\u0001+B\u001b@ \r\t\r \r'\u0007\u0001\u001dH' \u0007\u0001F9:@IL\u0007\u0001\u000e\b\u0012\u0001<\t\u0001\n\u0001Page 23 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001b\u0019242\u0001 \r\u000f\u0001\u001d\u001e\u001f(\"\u0001\u0006\u0004\u0001\u001c2\u0001:/863\u00015BH=657H9F=5@\u000157H=J=HM5\u0001C:\u0001H5F;9H\u00017CADCIB8G\u0001 \u0006\u0003\u0006\u0007\u00019LDF9GG98\u00015G\u0001=B<=6=H=CB\u0001\nNCB9G\u0001\u0003AA\u0004\t6\u0001\n\u0001\n\u0011+),+0*!\u0001 \u0018\u0006\u0001)30/\u0001 $\u0006\u0001'96+97\u0001 \"\u0006\u0001'+69-/237'\u0001,%\u0001$\u001b\u000b\u0012\u0001\n\f\u000b\t\f\t\r\u0001,%\u0001\u001b<=@9\u0001,%\u0001$\u001b\u000b\f\u0001\n\u0013\t\u000e\t\u0013\u0001\n\u0006\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \f\r\u0001 &\u0019\u0001 &\u0019\u0001\n\u0007\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001\n\b\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001\n\t\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001\n\n\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \f\u000b\u0001 \f\r\u0001\n\u000b\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \u000e\u000b\u0001 \u000e\u000e\u0001 \u000e\r\u0001\n\f\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \u000e\f\u0001 \r\u0013\u0001 \u000e\u000f\u0001\n\r\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001\n\u000e\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \r\u0013\u0001 \u000e\u0010\u0001 \u000e\u000e\u0001\n\u0006\u0005\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \f\u0014\u0001 \r\u0011\u0001 \r\u000e\u0001\n\u0006\u0006\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \r\u0013\u0001 \u000e\u0010\u0001 \u000e\u0010\u0001\n\u0006\u0007\u0001 &\u0019\u0001 &\u0019\u0001 &\u0019\u0001 \f\f\u0001 \f\u0011\u0001 \f\u000f\u0001\n\u00193+(&*& \u0001\u001e &!\u0001 \u000e\f\u0001 \r\u0010\u0001 &\u0019\u0001 \f\r\u0001 \f\u0011\u0001 \f\u000f\u0001\n\u0012*-+#(+3\u001e &*\u0001 \u000f\r\u0001 \u000e\r\u0001 \f\u0013\u0001 \r\u000f\u0001 \r\u0014\u0001 \r\u0014\u0001\n\u0010),& &((&*\u0001 \r\f\u0001 \u000e\u000b\u0001 &\u0019\u0001 \u000e\f\u0001 \u000e\u000b\u0001 \u000e\u000f\u0001\n\u0001\n5\u0001,<9G9\u0001F9GI@HG\u00015F9\u00015J9F5;9\u0001F9GI@HG\u0001C:\u0001H<F99\u00019LD9F=A9BHG\t\u00016\u0001,<9\u00017CADCIB8G\u0001K9F9\u0001IG98\u00015H\u0001H<9\u00017CB79BHF5H=CB\u0001C:\u0001\n\f\u000b\u000b\u0001d;\n8=G?\u00015B8\u0001H<9\u0001=B<=6=H=CB\u0001NCB9G\u00015F9\u0001GH5H98\u0001=B\u0001AA\u0016\u0001&\u0019\u0001\u0017\u0001BCH \u000157H=J9\u0016\u00018=5A9H9F\u0001C:\u0001=B<=6=H=CB\u0001NCB9\u0001Y\u0001\u0010\u0001AA\t\u0001\n\u0001Page 24 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001b\u001a243\u0001 \r\u0010\u0001\u001d\u001e\u001f(\"\u0001+#\u0001 +*/\"*/.\u0001\n\u0001\n\u0019\u0001G9F=9G\u0001C:\u00017CIA5F=B\b7<5@7CB9\u0001<M6F=8\u00017CADCIB8G\u0001<5G\u0001699B\u0001GMBH<9G =N98\u00015B8\u0001H<9=F\u0001\n5BH=657H9F=5@\u00019J5@I5H=CB\u00015;5=BGH\u0001<IA5B\u0001D5H<C;9B=7\u0001657H9F=5\u00015B8\u0001 H<F99\u00018=::9F9BH\u0001GHF5=BG\u0001C:\u0001\n,\t\u0001A5F=H=AIA\u0001<5G\u0001699B\u00015GG9GG98\t\u0001\u001bCADCIB8G\u0001G<CK98\u0001<=;<\u000157H=J=HM\u0001 5B8\u0001G9@97H=J=HM\u0001\n5;5=BGH\u0001H<9\u0001H<F99\u0001GHF5=BG\u0001:=G<\u0001D5H<C;9B\u00015B8\u0001DF9G9BH98\u0001=B<=6=H=C B\u0001;FCKH<\u0001NCB9G\u0001=B\u0001H<9\u0001G5A9\u0001\nF5B;9\u0001CF\u0001<=;<9F\u0001H<5B\u0001H<9\u00017IFF9BH@M\u0001IG98\u00015BH=657H9F=5@\u00018FI;\u00019BFC :@CL57=B\u0007\u0001A5?=B;\u0001H<9G9\u0001\n7CADCIB8G\u0001;CC8\u000175B8=85H9G\u0001:CF\u0001H<9\u0001HF95HA9BH\u0001C:\u0001H9B57=657I@CG=G\t \u0001\n\u0001\n\u0001\u0001\u0001\u0001\n\u0001\n\u0001\n\u0001\u0001\u0001\n\u0001\n\u0001\n\u0001\n\u0001\u0001\n\u0002\t\f\u0007\u0004\u0003\u0005\f\u0006\u000b\u0007\u0003\u0001\u0006\u000e\u0003\b\r\u0003\f\u0007\n\t\n\u0004\u0001\u0005\u0017\u0011\b\u0012\u0001\u0014\b\u0016\u000e\u0013\r\f\u0012\u000f\n\u0001\t\b\n\u0016\f\u0015\u000f\b\n\u0004\u0001\u0006\b\u0015\u000f\u0012\f\u0001\u0014\b\u0016\u000e\u0013\r\f\u0012\u0001\u0002 \u0003\u0002\u0001\u0006\u0004\u0007\u0005\b\u0005\u0006\t\u0006 \u0003\nPage 25 of 25\nACS Paragon Plus EnvironmentJournal of Agricultural and Food Chemistry\n\u0019\u001b\u001b244Journa l Name \nCite this: DOI: 10.1039/c0xx00000x \nwww.rsc.org/xxxxxx Dynam ic Article Links \u25ba\nARTICLE TYPE\n\u0001\nThis journal is \u00a9 The Royal Society of Chemistry [year] 3-Benzoylcoumarins as new selective scaffolds for \nmodulation of the hA1 and h A3 binding affinity. \nSynthesis, biological assays and docking studies. \n \nSaleta Vazquez-Rodriguez,a,* Santiago Vilar,a Silvia Serra,a Eugenio Uriarte,a 5 \nLourdes Santana,a Sonja Kachler,b Karl-Norbert Klotz.b  \nReceived (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX \nDOI: 10.1039/b000000x \nWith the aim of finding new and selective adenosine receptor ligands, in \nthe present communication we report the synthesis and the 10 \npharmacological characterization for the four subtypes of adenosine receptors of a new series of coumarin-chalcone hybrids.  The synthesized \ncompounds 1-8 were characterized in radioligand binding (A\n1, A 2A and \nA3) and adenylyl cyclase activity assays (A 2B) in order to determine the \naffinity of the compounds for the four human adenosine receptors 15 \nsubtypes ( hARs).  Coumarin-chalcone hybrids resulted to be ligands with \na novel structure never reported before that showed varying affinity and selectivity for the hA\n1 or h A3 subtypes depending on the methoxylate or \nhydroxylated nature of the substituents. Hydroxy-substituted hybrids were \nselective for the hA1, while methoxy substituted hybrids resulted to be 20 \nselective for the hA3. The most active compound selective for the h A1 \nresulted to be compound 7, whereas compound 4 was the most active \nselective for hA3.. In addition, homology models for the hA1 and h A3 \nwere developed to analyze the structure-activity relationship through molecular docking calculations. Results showed that different residues \n25 \ncan play an important role in ligand selectivity.  \n\u0019\u001b\u001c245Journa l Name \nCite this: DOI: 10.1039/c0xx00000x \nwww.rsc.org/xxxxxx Dynam ic Article Links \u25ba \nARTICLE TYPE  \n\u0001\nThis journal is \u00a9 The Royal Society of Chemistry [year] 1. Introduction \nAdenosine is a purine nucleoside comprised of \nfour distinct receptor subtypes designated as A 1, \nA2A, A 2B, and A 3 belonging to the G protein-\ncoupled receptor superfamily (GPCRs).1 It acts as 5 \nan endogenous modulator controlling a wide \nrange of physiological processes due to its \ninteraction with this four specific cell membrane \nGPCRs.2,3,4 Extracellular adenosine activates \nreceptors of the A 1 and A 2A subtypes, which 10 \ndepresses the action of the heart, brain, kidneys, and the immune system, as well as other \nsystems.\n5 Recent studies have allowed to clone \nthe A 3 subtype of adenosine receptors, 6,7 and \nestablish its pharmacological8,9,10,11 and 15 \nregulatory characteristics12. The A 2A and A 2B \nadenosine receptor (AR) subtypes are primarily coupled to Gs and thereby increase intracellular \ncAMP levels, whereas the A\n1 and A 3ARs inhibit \ncAMP production via activation of Gi. \n20 \nBecause of their ubiquitous presence in cells, ARs have been seen as promising targets in the \nmedicinal chemistry field. During the last years, \nthe search for agonist and antagonist ligands \nbinding to individual AR subtypes has been \n25 \nintensified, and therefore the role of these receptors in drug discovery is continuously expanding.\n13,14,15 Most of the AR antagonists are \npromising new drug candidates for a number of pathological processes such as inflammation \n30 \n(A3),14 heart and renal failure (A 1),16 or \nneurological disorders like Parkinson17,18 and \nAlzheimer\u2019s diseases (A 2A and/or A 1).19 For this \nreason, targeting the different ARs can open a new window for potential drug treatment of a \n35 \nvariety of pathologies.  From the large number of compounds exerting high potency and selectivity towards ARs, the \nxanthine and adenine scaffolds have been used to \ndevelop the so-called classical AR \n40 \nantagonists.20,21 In the search for nonclassical AR ligands, novel structures have recently been \ndiscovered. For example, flavone and isoflavone \nderivatives have play a remarkable role, namely \ngenistein, which has been described to be a 45 \ncompetitive antagonist at A 1AR in FRTL \n(thyroid) cells22 or galangin, which was found to \nbind three subtypes of adenosine receptors \npresenting micromolar affinity for the A 3AR.23 \nThe affinity of flavonoids and other 50 \nphytochemicals to adenosine receptors suggests that a wide range of natural substances in the diet \nmay potentially block the effects of endogenous \nadenosine. \nCoumarins (chromone isosteres) and chalcones \n55 \n(flavone with an opened pyrone ring) are another \nclass of benzopyran related compounds of natural \norigin that present a wide range of \npharmacological activities.24,25,26 Taking into \nconsideration that the coumarin and chalcone 60 \nnucleus are structurally related flavonoids, it was found to be relevant to explore them for the \ndesign of novel AR antagonists. Our interest in \nthis new scaffold was also motivated by the \nstructure similarity between coumarin skeleton \n65 \nand chromone scaffolds previously described as AR antagonists that present a particular \nselectivity for the A\n3 and A 2A AR subtypes.27,28,29 \nAmong them, our attention was focused on the 3-\nbenzoylcoumarin ring system, which can be 70 \nconsidered as hybrid compounds in which the chalcone moiety is fixed in a trans  conformation \nthrough the double bond of the pyrone ring of the \ncoumarin scaffold (Figure 1), which has never been proposed as a scaffold for AR ligands. \n75 \nThus, due to structural similarities between flavones, coumarins and chalcones, we decided to \nsynthesize hybrid compounds bearing in the same molecule both scaffolds, and evaluate their \nactivity towards the four subtypes of human AR \n80 \nexpressed in Chinese Hamster Ovary (CHO) cells. \n\u0019\u001b\u001d246 \nThis journal is \u00a9 The Royal Society of Chemistry [year]   \n \n Figure 1.  Rational design of coumarin-chalcone \nhybrid compounds based on flavonoids. \n5 \n \n2. Chemistry \nTwo groups of coumarin-chalcone hybrid \ncompounds have been synthesized: methoxy \nsubstituted hybrids ( 1-4) and hydroxyl substituted 10 \nderivatives ( 5-8). In order to achieve the final \nproducts, the synthesis of the methoxy-3-\nbenzoylcoumarins 1-4 was carried out employing \na Knoevenagel reaction as the key step. Synthesis \nof the corresponding hydroxy-3-15 \nbenzoylcoumarins 5-8 was performed via \nhydrolysis of the previously synthesized methoxy \ndeivatives employing BBr 3 as deprotection \nreagent. The synthetic approach is highlighted in \nScheme 1.  20 \nThe methoxy-3-benzoylcoumarins 1-4 were \nefficiently synthesized with 85-97% yield by a \nKnoevenagel reaction treating the appropriate \nsalicylaldehyde and the corresponding \nmethoxylated ethyl benzoylacetate with 25 \npiperidine in ethanol at reflux for 2-6 h. The \nresulting methoxy derivatives were treated with \nboron tribromide in DCM at 80 \u00baC in a Schlenk \ntube for 48 h to afford the corresponding hydroxy \nderivatives 5-8 with 75-94 % yield. Reaction 30 \nconditions and compounds characterization are \ndescribed in the experimental section.  \n \nScheme 1.  Preparation of coumarin-chalcone 35 \nhybrids. Reagents and conditions:  (a) piperidine, \nEtOH, reflux, 2-6 h; (b) BBr 3, DCM, 80 \u00baC, 48 h. \n \n3. Pharmacology \n3.1. Adenosine receptor binding 40 \naffinity assays \nThe adenosine binding affinity of compounds 1-8 \nfor the human AR subtypes hA1, hA2A, hA2B and \nhA3, expressed in Chinese Hamster Ovary (CHO) \ncells, was determined in radioligand competition 45 \nexperiments.30,31,32,33 In the binding affinity assay, \nit is measured the competition of ligands for \nspecific binding of [3H]CCPA binding at \nhA1ARs; specific binding of [3H]NECA binding \nat hA2A ARs; and specific binding of 50 \n[3H]HEMADO at hA3 ARs. The results were \nexpressed as Ki (dissociation constants), which \nwere calculated with the program SCTFIT, and \ngiven as geometric means of at least three \nexperiments, including 95 % confidence 55 \nintervals.32 Due to the lack of a suitable \nradioligand for hA2B receptor in binding assay, \nthe potency of antagonists at hA2B receptor was \ndetermined instead by inhibition of NECA- \nstimulated adenylyl cyclase activity with 60 \nincreasing concentrations of antagonist.30,31 As a \nresult, cAMP (cyclic adenosine monophosphate) \nproduction was inhibited in a concentration EtO2CO\nCHO\nOHR1\nR2\nR3 OMe\nR4OO\nO\nR4OMeR1\nR2\nR3(a)\nOO\nO\nR4OHR1\nR2\nR3(b)R1, R2, R3, R4  = H, OMe+\n1  R1 = R 2 = R 3 = H; R 4 =  OMe\n2  R1 = R 3 = H; R 2 = R 4 = OMe \n3  R2 = H; R 1 = R 3 = R 4 =  OMe\n4  R2 = R 4 = H; R 1 = R 3 =  OMe\n5  R1 = R 2 = R 3 = H; R 4 =  OH\n6  R1 = R 3 = H; R 2 = R 4 = OH \n7  R2 = H; R 1 = R 3 = R 4 =  OH\n8  R2 = R 4 = H; R 1 = R 3 =  OH5-81-4OOOHOH\nHO\nGenisteinOO OH\nOHHO\nGalanginOO OH\nOHHO\nOHHO\nQuercetin\nO\nChalconeO O\nCoumarinFlavonols with the chalcone scaffold embeded\nchromone isoster\nOO\ncoumarin-chalcone hybridO\n\u0019\u001b\u001e247 \n4  |  Journal Name , [year], [vol] , 00\u201300  dependent fashion, and IC50 and Ki values, \nrespectively, were determined \nThe data obtained for the binding affinity assays \nfrom radioligand binding experiments for \ncompounds 1-8 are summarized in Table 1. Data 5 \nobtained from the binding affinity assays showed \nthe that methoxylated derivative compounds \nshowed either non binding affity for any of the \nhAR (compounds 1  and 2) or good binding \naffinity and selectivity for the hA3AR 10 \n(compounds 3 and 4). On the contrary, all \nhydroxylated compounds 6-8 presented \nmoderated but selective affinity for the hA1, \nexcept compounds 5, which presented the same \nbinding affinity for both hA1 and hA3 ARs.  15 \n  \nTable 1.  The binding affinity (K\ni) for the human \nAR subtypes hA1, hA2A and h A3 of compounds 1-\n8 was determined using radioligand competition 20 \nexperiments in chinese hamster ovary (CHO) \ncells. Highest concentrations tested were different \ndepending on the solubility of compounds under \nthe respective assay conditions.   \n 25 \nCompound hA1 \n (Ki nM) hA3  \n(Ki nM) \n1 >100,000 >100,000 \n2 >100,000 >30,000 \n3 >30,000 9,030 \n(6,280-13,000) \n4 >100,000 2,490 \n(2,330-2,660) \n5 39,500 \n(25,300-61,500) 34,500 \n(29,700-40,100) \n6 54,000 \n(49,800-58,500) >30,000 \n7 17,700 \n(16,000-19,500) >30,000 \n8 29,100 \n(20,400-41-500) >30,000 \nThese results are geometric means of 3 experiments and \ngiven with 95% confidence intervals in parentheses. \n \n4. Theoretical e valuation of ADME \nproperties 30 To better correlate the drug-like properties of the \ncoumarin-chalcone hybrid compounds, their \ntheoretical ADME properties were calculated \nusing the Molinspiration property program.34  \n 35 \nTable 2.  Theoretical evaluation of the ADME \nproperties of the tested compoundsa \nComp\nd. log\nP TPS\nA \n(\u00c52) n-OH \naccepto\nrs n-\nOHN\nH \ndonor\ns Volu\nme \n(\u00c53) \n1 3.0\n4 65.75 5 0 270.07 \n2 3.0\n8 74.98 6 0 295.62 \n3 3.0\n6 84.22 7 0 321.16 \n4 3.4\n7 74.98 6 0 295.16 \n5 2.4\n3 87.74 5 2 235.01 \n6 1.9\n3 107.9\n7 6 3 243.03 \n7 1.6\n3 128.2\n0 7 4 251.05 \n8 2.1\n2 107.9\n7 6 3 243.03 \na TPSA, topological polar surface area; n-OH, number \nof hydrogen acceptors; n-OHNH, number of hydrogen \nbond donors. The data was determined with 40 \nMolinspiration calculation software. \n \n \n5. Molecular modeling \nWe successfully constructed homology models of 45 \nthe hA1 and hA3 (see Methods section). A \nselection of protein models extracted from Induce \nFit calculations were tested according to their \ncapability to discriminate between known ligands and decoys and between sub-type selective \n50 \ncompounds. The final models selected to run docking calculations with the synthesized ligands showed excellent results in both tests. A set of \n200 decoys randomly selected from ZINC \ndatabase\n35 were mixed up with 22 known ligands 55 \n\u0019\u001b\u001f248 \nThis journal is \u00a9 The Royal Society of Chemistry [year]  of each adenosine sub-type receptor.36 The \ndatabase was docked to the hA1 and hA3 models \nusing Glide SP precision.37 Table 3 shows the \narea under the ROC curve (AUROC) for both \nsystems. We carried out a second and more 5 \nchallenging test to differentiate between subtype-selective ligands. In a similar way as a previous study,\n36 we docked 66 sub-type selective \ncompounds (22 hA1, 22 hA2A and 22 hA3 \ncompounds) to the hA1 model (22 true positives 10 \nvs 44 false positives) and to the hA3 (22 true \npositives vs 44 false positives). Results are \nsimilar to the article published by Katritch et al.36 \nand have shown that the developed homology \nmodels can discriminate between sub-type 15 \nselective compounds (see Table 3).  \nTable 3.  Area under the ROC curve (AUROC) \nfor both homology models. In test 1 we \nconsidered 22 hA\n1 or 22 h A3 ligands as true 20 \npositives (TP) and 200 random decoys as false \npositives (FP). In test 2 for hA1, we considered 22 \nhA1 selective compounds as TP and 22 hA2A + 22 \nhA3 compounds as FP. In test 2 for hA3, we \nconsidered 22 hA3 compounds as TP and 22 hA2A 25 \n+ 22 h A1 compounds as FP. \n \n hA1 hA3  \nAUROC test 1 0.91 0.95 \nAUROC test 2 0.86 0.82 \n \nWe run Glide SP molecular docking simulations37 \nwith our data using as the protein structure the 30 \nhA1 and hA3 selected homology models to detect \nthe hypothetical binding mode of the new \nsynthesized compounds. We optimized the \nprotein structure for each binding mode with \nPrime module.38 The calculations showed great 35 \nvariability since all the compounds yielded \ndifferent possible binding modes inside the \nproteins. Selection of the hypothetical binding \npose was carried out considering number of \nsimilar poses extracted from the calculations and 40 \ngeometrical correspondence to crystallized ligands in the hA\n2A (see Figure 2a). \n \n6. Results and discussion \nCompounds 1-8 were efficently synthesized and 45 their in vitro binding affinity against human AR \nsubtypes hA1, hA2A, hA2B and h A3, expressed in \nCHO cells, was tested. In the present \ncommunication, studies of the effect on the \nbinding affinity by the presence of methoxy or 50 \nhydroxy substituents in different number and \npositions of the 3-benzoylcoumarin scaffold, \nwere performed.  The experimental data show that none of the \ncoumarin-chalcone hybrid compounds have \n55 \ndetectable binding affinity for the  hA2A and hA2B \nARs (K i > 30,000 \u2013 100,000 nM). Compounds 1 \nand 3, presenting no substituents on the coumarin \nring system or with a methoxy group at the 6 position, respectively, were the only tested \n60 \ncompounds that showed no binding affinity for \nany of the four evaluated receptors (Ki > 30,000-\n100,000). Introduction of two methoxy groups at \npositions 5 and 7 of the coumarin moiety \n(compounds 3 and 4 ) resulted in an increase of 65 \npotency and selectivity of the compounds. \nCompound 3, containing three methoxy groups at \npositions 5, 7 and 4\u2019 showed selectivity for hA3, \nwith Ki = 9,030 nM, whereas compound 4, with \nfour methoxy groups at positions 5, 7, 3\u2019 and 4\u2019, 70 \nshowed a slight increase in its activity comparing \nto compound 3, and resulted to be selective for \nhA3 too, with a Ki value of 2,490 nM. Docking \nresults showed that the compounds orientated the oxygens in the benzopyrone ring towards the \n75 \nresidue Asn250 and the benzoyl fragment buried in the h A\n3 pocket. This hypothetical binding \nmode is in agreement with the conformations \nshown by the co-crystallized ligands in the hA2A \n(PDB: 3EML and 3UZC)39,40 (see Figure 2a and 80 \n2b). The pose of compound 3 yielded hydrogen \nbonds with the residues Gln167, Asn250 and \nHis272. \n \n\u0019\u001b 249 \n6  |  Journal Name , [year], [vol] , 00\u201300   \n \nFigure 2. a) Comparison of the co-crystallized ligands (green carbons) in the hA\n2A (3EML (left) \nand 3UZC (right)) with the pose of compound 3 5 \nextracted from the hA3 docking calculations (grey \ncarbons). Protein pockets in hA2A and h A3 were \nsuperimposed. b) Pose extracted for compound 3 \ninside the hA3 after docking. Hydrogen bonds are \nrepresented in yellow color. c) Hypothetical 10 \nbinding mode for compound 5 (pink carbons) in \nthe hA3. d) Pose obtained through docking \nsimulations for compound 7 (green carbons) in \nthe hA1 protein pocket. \n 15 \nTransformation of methoxy into hydroxy \nsubstituents resulted in a completely different \nselectivity, showing affinity for the hA1 instead of \naffinity for the hA3. The only compound of the \nhydroxylated series ( 5-8) that showed putative 20 \naffinity for both receptors was compound 5 (hA1 \nKi  = 39,500 and hA3 Ki = 34,500 nM), which \nbears a catechol group at positions 3\u2019 and 4\u2019 and no substituents in the coumarin moiety. The \nhypothetical binding mode for compound 5 in the \n25 \nhA3 according to docking calculations is shown in \nFigure 2c. The compound can establish hydrogen bonds with residues Asn250, Ala69 and His272. \nAs it was shown in the h A\n2A crystallized structure \nand previous  molecular modeling studies,41,42 the 30 \ncorresponding residue Asn250 seems to play an \nimportant role in ligand recognition. The pose \nshown by compound 5 inside the hA1 is similar to \nthe described pose in the hA3. However, the pose \nwas slightly shifted and calculations were not 35 \nable to retrieve a hydrogen bond with the residue \nAsn250.  Introduction of an additional hydroxyl group at position 6 of the coumarin (compound 6), resulted in an increase of the binding affinity \nand selectivity for the hA\n1AR (Ki = 54,000 nM).  40 \nAs well as in the case of the methoxy derivatives, \nthe best binding affinities were found for compounds with hydroxyl substituents at \npositions 5 and 7 of the coumarin. Thereby, \ncompound 7, with the same pattern of substitution \n45 \nthan quercetin, that is, hydroxyl groups at positions 5, 7, 3\u2019 and 4\u2019, presented selectivity for the hA\n1, and the best binding affinity, with a Ki \nvalue of 17,700 nM. Compound 8, with the same \npattern of substitution than genistein (hydroxyl 50 \nsubstituents at positions 5, 7 and 4\u2019) presented also selectivity for the hA\n1, with a Ki value of \n29,100 nM. The pose obtained through docking \nfor compound 7  in the hA1 protein pocket showed \nhydrogen bonds with residues Glu172, Asn254 55 \nand Thr277 (see Figure 2d).  \nFrom these preliminary results, one can conclude that the nature and position of the substituents \nplay a key role in both potency and selectivity for \nthe hA\n1 or hA3 ARs. Positions 5 and 7 of the 60 \ncoumarin moiety resulted to be important for the selectivity and potency. In the case of the \nmethoxylated derivatives 1-4, only compounds \npresenting substituents at these positions \n(compounds 3 and 4) showed not only activity, \n65 \nbut also selectivity for the hA3AR. For the \nhydroxylated series ( 5-8), compounds with higher \npotency and selectivity for the hA1 were also \nthose which bear the hydroxyl groups at positions 5 and 7 (compounds 7 and 8). There are different \n70 \nresidues in both hA1 and h A3 that can be \nimportant to explain selectivity. Hydrophobic \nresidues in the hA3, such as the residues Val169 \nand Leu264 can contribute to ligand stabilization when the compounds bear hydrophobic \n75 \nsubstituents like methoxy groups (compounds 3 \nand 4) (see Fi gure 3). However, the \ncorresponding residues in the hA1, the Glu172 \nand Thr270 with hydrophilic characteristics, \ncontribute to the binding of compounds with 80 \npolar substituents, such as hydroxyl groups (compounds 6-8). Nevertheless, compound 5 does \nnot present substitutions in the coumarin ring and could adapt to the pocket in both proteins. Figure \n3 shows the molecular surface originated by the \n85 \n\u0019\u001c\u0017250 \nThis journal is \u00a9 The Royal Society of Chemistry [year]  combination of both different residues that could \nbe responsible for protein selectivity.  \nFinally, analyzing the obtained theoretical results of the ADME properties, it can be observed that \nno violations of Lipinski\u2019s rule (molecular \n5 \nweight, logP, number of hydrogen donors and \nacceptors) were found for the described \ncoumarins. Also, TPSA, described to be a \npredictive indicator of membrane penetration, \nwas also found to be positive for these drug 10 \ncandidates. \n \n \n \n 15 \n \n \nFigure 3. Molecular surface showing favoured \ninteraction areas generated in the hA1(a) and h A3 \n(b). Red color represents hydrogen-bond areas, 20 \ngreen color shows hydrophobic areas and blue \nrepresents mild polar. Protein structures are \nviewed from the extracellular side. \n \n 25 \n  7. Experimental  \n7.1. General methods \n 30 \nStarting materials and reagents were obtained \nfrom commercial suppliers and were used without purification. Melting points (mp) are uncorrected and were determined with a Reichert Kofler thermopan or \n35 \nin capillary tubes in a Buchi 510 apparatus. 1H \nNMR (300 MHz) and 13C NMR (75.4 MHz) \nspectra were recorder with a Bruker AMX \nspectrometer using DMSO-d 6 or CDCl 3 as \nsolvent. Chemical shifts ( \u03b4) are expressed in parts 40 \nper million (ppm) using TMS as an internal \nstandard. Coupling constants J are expressed in \nhertz (Hz). Spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets) and \nm (multiplet). Mass spectrometry was carried out \n45 \nwith a Kratos MS-50 or a Varian MAT-711 \nspectrometer. Elemental analyses were performed \nby a Perkin-Elmer 240B microanalyzer and were \nwithin \u00b10.4 % of calculated values in all cases. The analytical results were \u2265 95% purity for all \n50 \ncompounds Flash Chromatography (FC) was performed on silica gel (Merck 60, 230-400 mesh); analytical TLC was performed on precoated silica gel plates (Merck 60 F254). Organic solutions were dried over anhydrous \n55 \nsodium sulfate. Concentration and evaporation of the solvent after reaction or extraction was carried out on a rotary evaporator (B\u00fcchi Rotavapor) operating at reduced pressure.  \n60 \n7.2. Synthesis \n7.2.1. General procedure for the synthesis of \nmethoxy-3-benzoylcoumarins 1-4. To a solution \nof the appropriate \u03b2-ketoester (1 mmol) and the \ncorresponding salicylaldehyde (1 mmol) in 65 \nethanol (5 mL) was added piperidine in catalytic \namount (0.10 mL). The reaction mixture was \nrefluxed for 2\u20136 h and after completion (followed by TLC), the reaction was cooled and the \nprecipitated was filtered and washed with cold \n70 \nethanol and ether. The obtained solid was recrystallized in DCM to afford the \ncorresponding methoxy-3-benzoylcoumarin \ncompounds. \n \n75 \n5.2.2. General procedure for the synthesis of hydroxy-3-benzoylcoumarins 5-8. The \nappropriate methoxy derivative compound 1-4 (1 \n\u0019\u001c\u0018251 \n8  |  Journal Name , [year], [vol] , 00\u201300  mmol) was dissolved in DCM (1 mL) and BBr 3 in \nDCM (20 mmol, 1M) was added dropwise in a \nSchlenk tube. Tube was sealed, and the reaction \nmixture was heated at 80 \u00baC for 48 h. The \nresulting crude was treated with MeOH and 5 \nrotated to dryness. The obtained crude was \nrecrystallized in MeOH or purified by flash \nchromatography using hexane/ethyl acetate \nmixtures as eluent, to afford the desired hydroxy \nderivatives.  10 \n \n3-(3\u2019,4\u2019-Dimethoxybenzoyl)coumarin (1) \n85% yield; white solid; mp 190-191 \u00baC; 1H NMR \n(300 MHz, CDCl 3) \u03b4 ppm 8.01 (s, 1H, H-4), 7.71 \n\u2013 7.52 (m, 3H, 3xAr-H), 7.50 \u2013 7.29 (m, 3H, 15 \n3xAr-H), 6.87 (d, J = 8.4 Hz, 1H, H-5\u2019), 3.95 (s, \n6H, 2xOCH 3); 13C NMR (75 MHz, CDCl 3) \u03b4 ppm \n190.27, 154.83, 154.42, 149.53, 144.62, 133.55, 129.34, 129.20, 127.76, 125.71, 125.15, 118.46, \n117.15, 111.24, 110.19, 56.38, 56.32; EI-MS m/z \n20 \n(%): 311 ([M+1]+, 59), 310 (M+, 100), 173 (41), \n166 (25), 165 (99), 79 (22), 77 (22); Ana. Calcd. \nFor C 18H14O5: C 69.67, H 4.55. Found: C 69.69, \nH 4.58.  \n25 \n6-Methoxy-3-(3\u2019,4\u2019-\ndimethoxybenzoyl)coumarin (2) 97% yield; beige solid; mp 202-203 \u00baC; \n1H NMR \n(300 MHz, CDCl 3) \u03b4 ppm 7.78 (s, 1H, H-4), 7.38 \n(d, J = 1.9 Hz, 1H, H-2\u2019), 7.26 (dd, J = 8.4, 2.0 30 \nHz, 1H, H-6\u2019), 7.16 (d, J = 9.1 Hz, 1H, H-8), 7.04 \n(dd, J = 9.1, 2.9 Hz, 1H, H-7), 6.82 (d, J = 2.9 \nHz, 1H, H-5), 6.70 (d, J = 8.4 Hz, 1H, H-5\u2019), 3.78 \n(s, 6H, 2xOCH 3), 3.69 (s, 3H, OCH 3); 13C NMR \n(75 MHz, CDCl 3) \u03b4 ppm 190.41, 156.60, 154.40, 35 \n149.51, 149.31, 144.43, 129.36, 128.02, 125.73, 121.56, 118.77, 118.18, 111.24, 110.75, 110.18, 56.39, 56.32, 56.14; EI-MS  m/z (%): 341 \n([M+1]\n+, 58), 340 ([M]+, 94), 165 (100), 77 (22); \nAna. Calcd. For C 19H16O6: C 67.05, H 4.74. 40 \nFound: C 67.09, H 4.75.  \n5,7-Dimethoxy-3-(3\u2019,4\u2019-\nDimethoxybenzoyl)coumarin (3) \n91% yield; pale yellow solid; mp 210-211 \u00baC; \n1H 45 \nNMR (300 MHz, CDCl 3) \u03b4 ppm 8.19 (s, 1H, H-\n4), 7.34 (d, J = 1.9 Hz, 1H, H-2\u2019), 7.26 (dd, J = \n8.4, 2.0 Hz, 1H, H-6\u2019), 6.70 (d, J = 8.4 Hz, 1H, H-5\u2019), 6.29 (d, J = 1.9 Hz, 1H, H-6), 6.14 (d, J = \n2.1 Hz, 1H, H-8), 3.77 (bs, 6H, 2x OCH 3), 3.72 50 \n(bs, 6H, 2x OCH 3); 13C NMR (75 MHz, CDCl 3) \u03b4 \nppm 190.91, 165.76, 159. 37, 158.37, 157.97, \n153.89, 149.28, 141.54, 130.03, 125.35, 121.28, 111.54, 110.11, 103.91, 95. 37, 93.01, 56.32; EI-\nMS m/z (%): 371 ([M+1]\n+, 24), 370 (M+, 100), 55 \n339 (21), 233 (30), 165 (63); Anal. Calcd. For \nC20H18O7: C 64.86, H 4.90. Found: C 64.88, H \n4.93. \n \n5,7-Dimethoxy-3-(4\u2019-60 \nDimethoxybenzoyl)coumarin (4) 97% yield; pale yellow solid; mp 174-175 \u00baC; \n1H \nNMR (300 MHz, CDCl 3) \u03b4 ppm 8.21 (s, 1H, H-\n4), 7.69 (d, J  = 8.8 Hz, 2H, H-2\u2019, H-6\u2019), 6.77 (d, J \n= 8.9 Hz, 2H, H-3\u2019, H-5\u2019), 6.29 (d, J = 2.1 Hz, 65 \n1H, H-6), 6.13 (d, J = 2.2 Hz, 1H, H-8), 3.76-3.67 \n(m, 9H, 3x OCH 3); 13C NMR (75 MHz, CDCl 3) \u03b4 \nppm 190.69, 165.61, 163. 80, 159.14, 158.21, \n157.81, 141.54, 132.08, 129.79, 121.16, 113.73, 103.81, 95.17, 92.81, 56. 13, 56.05, 55.54; EI-MS \n70 \nm/z (%): 341 ([M+1]+, 33), 340 (M+, 88), 325 \n(28) 312 (30), 309 (45), 297 (20), 233 (48), 135 \n(100), 92 (27), 77 (38). Anal. Calcd. For \nC19H16O6: C 67.05, H 4.74. Found: C 67.08, H \n4.76. 75 \n 5,7-Dihydroxy-3-(4\u2019-\ndihydroxybenzoyl)coumarin (8)  \n \n \n80 \n \n7.3. Binding affinity assays \nThe binding affinity for the human AR subtypes \nhA1, hA2A, hA3 of the compounds was \ndetermined using radioligand competition 85 \nexperiments in Chinese hamster ovary (CHO) \ncells that were stably transfected with the \nindividual receptor subtypes.30,31 \nThe radioligands used were 1 nM [3H]CCPA for \nhA1, 10 nM [3H]NECA for hA2A, and 1 nM 90 \n[3H]HEMADO for hA3 receptors. Due to the lack \nof a suitable radioligand for hA2B receptors the \npotency of antagonists at hA2B receptor \n(expressed on CHO cells) was determined by inhibition of NECA-stimulated adenylyl cyclase \n95 \nactivity.30 The IC50 for inhibition of cAMP \n\u0019\u001c\u0019252 \nThis journal is \u00a9 The Royal Society of Chemistry [year]  (cyclic adenosine monophosphate) production \nwas determined and converted to Ki values using \nthe Cheng and Prusoff equation.30 For all the \ntested compounds no measurable activity for the hA\n2B or hA2A (Ki > 30,000 nM) was detected. 5 \n \n7.4. Statistical methods \nKi values (dissociation constants) were \ndetermined in radioligand competition experiments with 7-8 different concentrations of \n10 \ntest compound and each concentration was tested \nin duplicate.  K i values are given as geometric \nmeans of three independent experiments with 95% confidence intervals.  For analysis of the \ncompetition curves the program SCTFIT was \n15 \nused.33  \n \n7.5. Theoretical e valuation of the \nADME properties.  \nLogP was calculated by the methodology 20 \ndeveloped by Molinspiration as a sum of \nfragment-based contributions and correction \nfactors. Topological Polar Surface Area (TPSA) was calculated based on the methodology \npublished by Ertl et al.  as a sum of fragment \n25 \ncontributions.43 Oxygen and nitrogen centered \npolar fragments are considered. PSA has been shown to be a very good descriptor characterizing \ndrug absorption, including intestinal absorption, \nbioavailability, Caco-2 permeability and blood-\n30 \nbrain barrier penetration. Method for calculation of molecule volume developed at Molinspiration is based on group contributions. These have been \nobtained by fitting sum of fragment contributions \nto \"real\" 3D volume for a training set of about \n35 \ntwelve thousand, mostly drug-like molecules. 3D molecular geometries for a training set were fully optimized by the semiempirical AM1 method.\n \n \n7.6. Molecular modeling  40 \nHomology modeling was carried out using the Molecular Operating Environment (MOE) suite.\n44 \nMolecular docking simulations were performed \nwith the Schrodinger package.37,38  \n 45 \n7.6.1. Homology models of hA1 and hA3 \nARs. We constructed homology models of the hA1 and \nhA3 adenosine receptors. As a template we used \nthe crystallized structure of the hA2A receptor 50 \n(PDB: 3EML).39 Protein sequence alignment of \nthe 3 receptors ( hA1, hA2A and hA3) used to \ngenerate the homology models was performed as \ndescribed by Katritch et al .36 The alignment was \nmade considering the highly conserved residues 55 \nin the different TM helices. Homology models were generated using the MOE software.\n44 \nProtein geometry was evaluated for the models \ntaking into account Phi-Psi plots, bond lengths, \nbond angles, dihedrals, rotamers, atom clashes 60 \nand contact energies. Presence of different conserved disulfide bridges was manually \nchecked in the models, such as the bridge \nbetween the corresponding residues Cys166 and Cys77 in the hA\n2A. The final models were 65 \noptimized using Induce Fit Docking Workflow in the Schrodinger package.\n45 We used selective \nhigh affinity ligands (compounds coll_11 and \njaco_mre3008_f20 of a previous publication)36 to \nadapt the protein pocket for the hA1 and hA3 70 \nrespectively. This procedure involved three steps: 1) Glide-based docking of the ligands using SP \nmode (standard-precision); 2) Protein pocket optimization using Prime and considering the \nresidues within 5\u00c5 from the ligand poses; 3) \n75 \nGlide-based docking of the ligands in the refined \npocket using XP mode (Extra-precision). As \ndescribed previously,36 homology models were \ntested for their capability to discriminate ligands from decoys and between known subtype-\n80 \nselective compounds. ROC curves were \nperformed and the best models were selected for \nfurther molecular docking studies.  7.6.2. Molecular docking of hA1 and hA3 ARs. \n85 \nWe carried out molecular docking studies using \nthe hA1 and h A3 homology models selected in \nthe previous step. Compounds were docked using \nGlide SP mode.37 Ten poses for each ligand were \ncollected and optimized using MM-GBSA in 90 \nPrime38 taking into account a flexible protein \nregion defined by 5 \u00c5 from the ligand. Final \nbinding modes were selected taking into account \nnumber of similar poses extracted from the \ncalculations and geometrical correspondence to 95 \nco-crystallized ligands in the hA2A. \n \n\u0019\u001c\u001a253 \n10  |  Journal Name , [year], [vol] , 00\u201300  Conclusions \nA series of methoxy and hydroxy-coumarin-\nchalcone hybrid compounds were synthesized and \ntheir binding affinity towards the four subtypes of \nadenosine receptors was studied. A preliminary 5 \nstructure-activity relationship (SAR) of the \nsynthesized derivatives showed that in general, methoxy substituted derivatives ( 1-4) presented \ngood binding affinity and selectivity for the hA\n3AR, whereas hydroxy substituted derivatives 10 \n(5-8) presented moderate but selective binding \naffinity for the hA1AR. Positions 5 and 7 of the \ncoumarin ring were crucial for the potency and \nselectivity in both series of compounds. Methoxy \nderivative 4 and hydroxy derivative 7 were the 15 \nmost active compounds, being selective for hA3 \n(Ki = 2,490 nM) and hA1 (Ki = 17,700 nM) \nrespectively. We also performed molecular \ndocking simulations to study the binding mode of \nthe compounds. 20 \nIn addition, from the data obtained for the \ntheoretical evaluation of the ADME properties, \none can notice that all the hybrid compounds 1-8 \ndo not break any point of the Lipinski\u2019s rule of five, making them promising leads for drug \n25 \ncandidates. Therefore, according to our findings, coumarin-\nchalcone hybrid compounds proved to be \ninteresting scaffolds as ARs ligands worth to \ndeepen study. \n30 \n  Acknowledgements This work was partially supported by the \nMinisterio de Sanida d y Consumo (PS09/00501) \nand Xunta de Galicia (PGIDIT09CSA030203PR \n35 \nand 10PXIB203303PR). SVR thanks to \nMinisterio de Educaci\u00f3n y Ciencia for her PhD grant FPU (AP2008-04263). \n  \n40 \nNotes and references \na Departamento de Qu\u00edmica Org\u00e1nica, Facultad de \nFarmacia, Universidad de Santiago de Compostela, \n15782 Santiago de Compostela, Spain. Fax: +34 981 \n544912; Tel: +34 981 563100; E-mail: 45 \nsvre77@gmail.com   \nb Institut f\u00fcr Pharmakologie und Toxikologie, \nUniversit\u00e4t W\u00fcrzburg, 97078, W\u00fcrzburg, Germany \u0001\n\u0001\n1 G.L. Stiles, J. Biol. Chem. , 1992, 267, 6451. \n2 S.A. Poulsen and R.J. Quinn, Bioorg. Med. Chem. , \n1998, 6, 619. \n3 B.B. Fredholm, A.P. IJzer man, K.A. Jacobson, K.N. \nKlotz and J. Linden, J. Pharmacol. Rev. , 2001, 53, 527. \n4 B.B. Fredholm, G. Arslan, L. Halldner, B. Kull, G. \nSchulte and W. Wasserman, Arch. Pharmacol.  2000, \n362, 364. \n5 K.A Jacobson, P.J.M. Van Galen, M. Williams, J. \nMed. Chem. 1992, 35, 407. \n6 Q.Y. Zhou,; C.Y. Li, M.E. Olah, R.A. Johnson, G.L. \nStiles and O. Civelli, Proc. Natl. Acad. Sci.  U.S.A. , \n1992, 89, 7432. \n7 C.A. Salvatore, M.A. Jac obson, H.E. Taylor, J. Linden \nand R-G- Johnson, Proc. Natl. Acad. Sci.  U.S.A. , 90, \n10365. \n8 V. Ramkumar, G.L. Stiles, M.A. Beaven and H. Ali, J. \nBiol. Chem., 1993, 268, 16887. \n9 J. Linden, Trends Pharmacol. Sci. , 1994, 15, 298. \n10 J.P. Hannon, H.J. Pfannkuche and J.R. Fozard, J. \nPharmacol.  1995, 115, 945. \n11 K.A. Jacobson, O. Nikodijevic, D. Shi, C. Gallo-\nRodriguez, M.E. Olah, G.L. Stiles and J.W. Daly, FEBS \nLett., 1993, 336,57. \n12 T.M. Palmer, T.W. Gettys and G.L. Stiles, J. Biol. \nChem. , 1995, 270, 16895. \n13 Y. Kim, S. De Castro, Z.G. Gao, A.P. IJzerman and \nK.A. Jacobson. J. Med. Chem. , 2009, 52, 2098. \n14 L.V. Lopes, A.M. Sebastia o and J.A. Ribeiro, Curr. \nTop. Med. Chem., 2011, 11, 1087.  \n15 A. El-Tayeb, S. Michael, A. Abdelrahaman, A. \nBehrenswerth, S. Gollos, K. Nieber and C.E. M\u00fcller, \nACS Med. Chem.  Lett., 2011, 2, 890. \n16 R.H. Shah and W.H. Frishmanet, Cardiol. Rev. , 2009, \n17, 125. \n17 B.C. Shook, S. Rassnick, N. Wallace, J. Crooke, M. \nAult, D. Chakravarty, J.K.  Barbay, A. Wang, M.T. \nPowell, K. Leonard, V. Alford, R.H. Scannevin, K. Carroll, L. Lampron, L. Westover, H.K. Lim, R. \nRussell, S. Branum, K.M. Wells, S. Damon, S. Youells, \nX. Li, D.A. Beauchamp, K. Rhodes, and Paul F. \nJackson, J. Med. Chem. , 2012, 55, 1402. \n18 T. Armentero, A. Pinna, S. Ferr\u00e9, J.L. Lanciego and \nC.E. M\u00fcller Pharmacol. Ther ., 2011, 132, 280.  \n19 T.W. Stone, S. Ceruti and M.P. Abbracchio, Handb. \nExp. Pharmacol. 2009, 193, 535. \n20 P.G. Baraldi, M.A. Tabrizi, S. Gessi and P.A. Borea, \nChem. Rev. , 2008, 108, 238. \n21 S. Moro, Z.G. Gao, K.A. Jacobson and G. Spalluto, \nMed. Res. Rev. 2006, 26, 131. \n22 F. Okajima, M. Akbar, M.A. Majid, K. Sho, H. \nTamura and Y. Kondo Biochem. Biophys. Res. \nCommun. , 1994, 203, 1488. \n\u0001\n\u0001\n\u0019\u001c\u001b254 \nThis journal is \u00a9 The Royal Society of Chemistry [year]  \u0001\n\u0001\n23 K.A. Jacobson, S. Moro, J.A. Manthey, P.L. West and \nX.D. Ji, Adv. Exp. Med. Biol. , 2002, 505, 163. \n24 F. Borges, F. Roleira, N. Milhazes, L. Santana and E. \nUriarte, Curr. Med. Chem. , 2005, 12, 887. \n25 M.L. Go, Z. Wu and X.L. Liu, Curr. Med. Chem. , \n2005, 12, 483. \n26 Z. Nowakowska, Eur. J. Med. Chem. , 2007, 42, 125. \n27 C.J. Langmead, S.P. Andrews, M. Congreve, J.C. \nErrey, E. Hurrell, F.H. Marshall, J.S. Mason, C.M. \nRichardson, N. Robertson, A. Zhukov and M. Weir, J. \nMed. Chem. , 2012, 55, 1904. \n28 A. Gaspar, J. Reis, S. Kachler, S. Paoletta, E. Uriarte, \nK.N. Klotz, S. Moro and F. Borges, Bioch. Pharm. \n2012, 84, 21. \n29 A.Gaspar, J. Reis, M.J. Matos, E. Uriarte and F. \nBorges, Eur. J. Med. Chem. , 2012, 54, 914. \n30 K.N. Klotz, J. Hessling,  J. Hegler, C. Owman, B. \nKull, B.B. Fredholm and M.J. Lohse, N-S Arch. \nPharmacol. 1997, 357, 1. \n31 K.N. Klotz, N. Falgner, S. Kachler, C. Lambertucci, \nS. Vittori, R. Volpini and G. Cristalli, Eur. J. \nPharmacol. , 2007, 556, 14. \n32 Y.C. Cheng and W.H. Prusoff, Biochem. Pharmacol. \n1973, 22, 3099. \n33 A. De Lean, A.A. Hancock and R.J. Lefkowitz, Mol. \nPharmacol. , 1982, 21, 5. \n34 M cheminformatics, Bratislava, Slovak Republic, \nhttp://www.molinspiration.com/services/properties.html  \n2009. \n35 J.J. Irwin and B.K. Shoichet, J. Chem. Inf. Model. \n2005, 45, 177. \n36 V. Katritch, I. Kufareva and R. Abagyan, \nNeuropharmacology.  2011, 60, 108. \n37 Glide, version 5.7, Schr\u00f6dinger, LLC, New York, \nNY, 2011. \n38 Prime, version 3.0, Schr\u00f6dinger, LLC, New York, \nNY, 2011. \n39 V.P. Jaakola, M.T. Gr iffith, M.A. Hanson, V. \nCherezov, E.Y. Chien, J.R. Lane, A.P. Ijzerman and R.C. Stevens, Science, 2008, 322, 1211. \n40 M. Congreve, S.P. A ndrews, A.S. Dor\u00e9, K. \nHollenstein, E. Hurrell, C.J. Langmead, J.S. Mason, I.W. Ng, B. Tehan, A. Zhukov, M. Weir and F.H. \nMarshall, J. Med. Chem., 2012, 55, 1898. \n41 O. Lenzi, V. Colotta, D. Catarzi, F. Varano, D. Poli, \nG. Filacchioni, K. Varani, F. Vincenzi, P.A. Borea, S. \nPaoletta, E. Morizzo and S.  Moro, J. Med. Chem., 2009, \n52, 7640 \n42 A. Gaspar, J. Reis, S. Kachler, S. Paoletta, E. Uriarte, \nK.N. Klotz, S. Moro and F. Borges, Biochem. \nPharmacol. 2012, 84, 21. \n43 P. Ertl, B. Rohde and P. Selzer, J. Med. Chem. , 2000, \n43, 3714. \n\u0001\n\u0001\u0001\n\u0001\n44 MOE, version 2011.10; Ch emical Computing Group, \nInc.: www.chemcomp.com . \n45 W. Sherman, T. Day, M.P.  Jacobson, R.A. Friesner \nand R. Farid, J. Med. Chem.  2006, 49, 534. \n\u0019\u001c\u001c255 Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 257 \n2. Compuestos preparados bajo estudio y pendientes de \npublicaci\u00f3n.  \nPara los compuestos que no se encuentr an descritos en publicaciones en el \nmomento de la presentaci\u00f3n de esta Memori a, pero que est\u00e1n bajo estudio y cuyos \nresultados est\u00e1n pendientes de ser publicados, se describir\u00e1 de forma breve su \ncaracterizaci\u00f3n estructural as\u00ed como los rendimientos obtenidos en la s\u00edntesis de los \nmismos. Al igual que anteriormente (apartad o 2.5. de Resultados y discusi\u00f3n), se \npresentan los datos de: 3-benzoilcumarinas (Tabla 7), 3-benzoil-4-hidroxicumarinas \n(Tabla 8), 3-cinamoilcumarinas (Tabla 9), 3-cinamoil-4-hidrox icumarinas (Tabla 10), 3-(3-\naril-3-oxo-propenil)-4-clorocum arinas (Tabla 11) y 8-cinam oilcumarinas (Tabla 12).  \n \nTabla 7. 3-Benzoilcumarinas no publicadas. \n \nCCompuesto NMR MS Rdto. (%) \n77 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.87 \n(s, 1H, H-4), 7.71 (d, J = 7.0 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.45 (t, J = 7.4 Hz, 1H, H-4\u2019), \n7.39-7.12 (m, 5H, H-5, H-7, H-8, H-3\u2019, H-\n5\u2019), 2.27 (s, 3H, CH3). m/z (%): 265 ([M+1]+, \n18), 264 ([M]+, 75), 235 \n(52), 221 (39), 105 (85), \n77 (100) 82 \n8 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.07 \n(s, 1H, H-4), 7.94-7.85 (m, 2H, H-2\u2019, H-\n6\u2019), 7.67-7.38 (m, 5H, H-3\u2019, H-4\u2019, H-5\u2019, H-5, H-6), 7.27 (d, J = 7.50 Hz,  1H, H-7 ), \n2.51 (s, 3H, CH\n3). m/z (%): 265 ([M+1]+\n+, \n39), 264 ([M]+\n+, 98), 235 \n(67), 221 (48), 105 (100), 77 (95). 94 \n9 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.35 \n(d, J = 9.3 Hz, 2H, H-7, H-8), 7.94 (s, 1H, \nH-4), 7.71 (d, J = 7.7 Hz, 2H, H-2\u2019, H-6\u2019), \n7.60-7.24 (m, 3H, H-3\u2019, H-4\u2019, H-5\u2019), 7.09 (s, 1H, H-5). m/z (%): 296 ([M+1]\n+\n+, \n22), 295 ([M]+\n+, 100), \n288 (31), 190 (21), 105 (55), 77 (81). 57 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n257Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 258 \nCompuesto NMR MS Rdto. (%) \n10 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.44 \n(s, 1H, H-4), 7.91-7. 77 (m, 2H, Ar), 7.67-\n7.52 (m, 1H, Ar), 7. 52-7.37 (m, 2H, \naromatic0), 6.45 (d, J = 2.2 Hz, 1H, H-6), \n6.30 (d, J  = 2.2 Hz, 1H, H-8), 3.89 (m, \n6H). m/z (%): 311 ([M+1]+\n+,  \n28), 310 ([M]+\n+, 100), \n282 (37), 281 (31), 233 \n(84), 105 (53), 77 (54). 88 \n11 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.35 (s, 1H), 7.99-7.89 (m, 3H), 7.80-7.63 \n(m, 2H), 7.60-7.46 (m, 3H). m/z (%): 285 ([M+1]+\n+, 4), \n284 ([M]+, 24), 256 (10), \n255 (19), 221 (11), 105 \n(97), 77 (100), 69 (16). 69 \n12 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.08 \n(s, 1H), 7.84 (d, J = 7.8 Hz, 2H), 7.67-\n7.37 (m, 4H), 7.00-6. 78 (m, 2H), 3.90 (s, \n3H). m/z (%): 281 ([M+1]+\n+, \n18), 280 ([M]+\n+, 100), \n252 (22), 251 (46), 221 (16), 203 (53), 119 (20), 105 (62), 77 (69). 82 \n20 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.80 \n(s, 1H, H-4), 7.71 (d, J = 8.8 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.34-7.05 (m, 3H, H-5, H-7, H-8), 6.77 (d, J = 10.2 Hz, 2H, H-3\u2019, H-5\u2019), \n3.69 (s, 3H, OCH\n3), 2.24 (s, 3H, CH3).  m/z (%): 295 ([M+1]+\n+, \n18), 294 ([M]+\n+, 74), 250 \n(16), 135 (100), 77 (26). 97 \n21 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.83 \n(s, 1H, H-4), 7.71 (d, J = 9.0 Hz, 2H, H-2\u2019, H-6\u2019), 7.13-6.92 (m, 3H, H-5, H-6, H-7), 6.77 (d, J = 9.0 Hz, 2H, H-3\u2019, H-5\u2019) \n4.04 (q, J = 6.99 Hz, 2H, CH\n32, \n(OCH2CH3)), 3.68 (s, 3H, OCH3) 1.35 (t, J \n= 6.99 Hz, 3H, CH3 (-OCH2CH3).  m/z (%): 325 ([M+1]+\n+, \n31), 324 ([M]+\n+, 88), 188 \n(34), 135 (100), 92 (30), 77 (40). 98 \n22 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.81 \n(s, 1H, H-4), 7.72 (d, J = 8.78 Hz, 2H, H-\n2\u2019, H-6\u2019) 7.22-6.99 (m, 2H, H-3\u2019, H-5\u2019) \n6.86-6.72 (m, 3H, H-5, H-6, H-7) 3.71 (s, \n3H, 4\u2019-OCH3) 3.69 (s, 3H, 8-OCH3). m/z (%): 311 ([M+1]+\n+, \n23), 310 ([M]+\n+, 87), 135 \n(100), 92 (27), 77 (63). 93 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n258Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 259 \nCompuesto NMR MS Rdto. (%) \n23 1H-NMR (300 MHz, DMSO- d6) \u03b4 ppm \n8.25 (s, 1H, H-4), 8.05 (s, 1H, H-5), 7.92 \n(d, J = 8.5 Hz, 2H, H-2\u2019, H-6\u2019), 7.84 (d, J \n= 8.8 Hz, 1H, H-7), 7.44 (d, J = 8.8 Hz, \n1H, H-8), 7.05 (d, J = 8.6 Hz, 2H, H-3\u2019, \nH-5\u2019), 3.85 (s, 3H, OCH3). m/z (%): 316 ([M+2]+\n+, \n23), 314 ([M]+\n+, 66), 135 \n(100), 77 (26). 83 \n24 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.28 (s, 1H, H-4), 7.86 (d, J = 8.8 Hz, 2H, \nH-2\u2019, H-6\u2019), 7.75 (dd, J = 8.8, 1.8 Hz, 1H, \nH-6), 7.14-6.94 (m, 4H), 3.88 (s, 3H, \nOCH3), 3.84 (s, 3H, OCH3). m/z (%): 311 ([M+1]+\n+, \n47), 330 ([M]+\n+, 80), 295 \n(23), 282 (29), 281 (26), \n251 (35), 203 (41), 135 (100), 119 (19), 107 (28), 92 (54), 77 (74), 76 (23). 96 \n31 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.78 \n(s, 1H), 7.38 (d, J = 1.8 Hz, 1H), 7.33-\n7.03 (m, 4H), 6.70 (d, J = 8.4 Hz, 1H), \n3.78 (d, J = 0.8 Hz, 6H), 2.26 (s, 3H). \n m/z (%): 325 ([M+1]+\n+, \n36), 324 ([M]+\n+, 99), 165 \n(100), 77 (20). 96 \n32 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.30 (s, 1H, H-4), 7.73-7.40 (m, 4H, \narom\u00e1tico), 7.30 (t, J = 7.6 Hz, 1H, H-6\u2019), \n7.04 (d, J = 7.6 Hz, 1H, H-5\u2019), 3.85 (s, \n3H, OCH3), 3.81 (s, 3H, OCH3), 2.40 (s, \n3H, CH3). m/z (%): 325 ([M+1]+\n+, \n16), 324 ([M]+\n+, 73), 187 \n(13), 165 (100), 77 (23). 98 \n33 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.80 (d, J = 2.6 Hz, 1H, H-4), 8.55-8.37 \n(m, 2H, ), 7.70 (d, J = 9.1 Hz, 1H, H-5), \n7.62 (dd, J = 8.4, 1.7 Hz, 1H, H-6\u2019), 7.49 \n(d, J = 1.7 Hz, 1H, H-2\u2019), 7.06 (d, J = 8.5 \nHz, 1H, H-5\u2019), 3.86 (s, 3H, OCH3), 3.81 (s, \n3H, OCH3). m/z (%): 356 ([M+1]+\n+, \n31), 355 ([M]+\n+, 97), 218 \n(18), 165 (100). 99 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n259Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 260 \nCompuesto NMR MS Rdto. (%) \n34 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.81 \n(s, 1H, H-4), 7.37 (d, J = 1.8 Hz, 1H, H-\n2\u2019), 7.26 (dd, J = 8.4, 1.9 Hz, 1H, H-6\u2019), \n7.14-6.88 (m, 3H, Ar), 6.69 (d, J = 8.4 Hz, \n1H, H-5\u2019), 4.04 (q, J = 7.0 Hz, 2H, OCH2-\n), 3.86 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), \n1.35 (t, J = 7.0 Hz, 3H, CH3). m/z (%): 355 ([M+1]+\n+, \n22), 356 ([M]+\n+, 89), 188 \n(12), 165 (100), 77 (12) 91 \n35 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.74 \n(s, 1H, H-4), 7.47-7.34 (m, 3H, Ar), 7.30-\n7.14 (m, 2H, Ar), 6.70 (d, J = 8.4 Hz, 1H, \nH-5\u2019), 3.79 (m, 6H, 2x OCH3). m/z (%): 420 ([M+2]+\n+, \n95), 418 ([M]+\n+, 98), 165 \n(100), 77 (18). 73 \n36 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.01 \n(s, 1H, H-4), 7.59-7. 37 (m, 3H, H-5, H-2\u2019, \nH-6\u2019), 6.96-6.79 (m, 3H, H-6, H-8, H-5\u2019), \n4.02-3.93 (m, 6H, 2x OCH3), 3.91 (s, 3H, \nOCH3). m/z (%): 341 ([M+1]+\n+, \n30), 340 ([M]+\n+, 100), \n309 (22) 165  (99), 119 \n(21), 79 (21), 77 (27). 60 \n38 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.51 (s, 1H, H-4), 8.33 (d, J = 8.9 Hz, 2H, \nH-2\u2019, H-6\u2019), 8.14 (d, J = 8.9 Hz, 2H, H-3\u2019, \nH-5\u2019) 7.52-7.28 (m, 3H, H-5, H-7, H-8), \n3.81 (s, 3H, OCH3).  m/z (%): 326 ([M+1]+\n+, \n20), 325 ([M]+\n+, 100), \n150 (31), 77 (20). 91 \n39 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.50 (s, 1H, H-4), 8.33 (d, J = 8.8 Hz, 2H, \nH-2\u2019, H-6\u2019), 8.21-8.11 (m, 3H, Ar) 7.91 \n(dd, J = 8.8, 2.39 Hz, 1H, H-7), 7.49 (d, J \n= 8.8 Hz, 1H, H-8).  m/z (%): 376 ([M+1]+\n+, \n98), 375 ([M]+\n+, 19), 374 \n([M]+, 100), 347 (32), 150 \n(85), 77 (48). 95 \n40 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.17 \n(s,1H, H-4), 8.12 (d, J = 3.9 Hz, 2H, H-2\u2019, \nH-6\u2019), 7.82 (d, J = 8.4 Hz, 2H, H-3\u2019, H-5\u2019), \n7.22-7.01 (m, 3H, H-5, H-6, H-7) 3.84 (s, \n3H, OCH3).  m/z (%): 326 ([M+1]+\n+, \n33), 325 ([M]+\n+, 100), \n296 (44), 202 (35), 174 \n(51), 150 (62), 104 (65), 76 (60). 59 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n260Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 261 \nCompuesto NMR MS Rdto. (%) \n41 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.63 \n(s, 1H, H-4), 8.44 (dt, J = 8.0, 1.5 Hz, 1H, \nH-5), 8.24 (s, 1H), 8.16 (d, J = 7.3 Hz, \n1H), 7.68 (t, J  = 8.0 Hz, 1H, H-6), 7.41-\n7.21 (m, 2H, Ar), 7.05 (d, J = 2.8 Hz, 1H), \n3.88 (s, 3H, OCH3). m/z (%): 326 ([M+1]+\n+, \n45), 325 ([M]+\n+, 100), \n297 (18), 296 (35), 203 \n(51), 175 (41), 150 (73), 119 (32), 104 (48), 76 (46). 94 \n42 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.48 (s, 1H, H-4), 8.33 (d, J = 8.8 Hz, 2H, \nH-2\u2019, H-6\u2019), 8.16 (d, J = 8.8 Hz, 2H, H-3\u2019, \nH-5\u2019), 7.65 (dd, J = 2.8, 1.9 Hz, 2H, H-5, \nH-7), 3.96 (s, 3H, OCH3).  m/z (%): 388 ([M+2]+\n+, \n97), 387 ([M+1]+\n+, 18), \n386 ([M]+\n+, 100), 150 \n(24), 104 (19), 77 (27).   59 \n43 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.17 \n(s, 1H, H-4), 8.11 (d, J = 8.6 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.81 (d, J = 8.6 Hz, 2H, H-3\u2019, H-\n5\u2019), 7.39-7.12 (m, 3H, H-5, H-7, H-8) 2.29 \n(s, 3H, CH33).  m/z (%): 310 ([M+1]+\n+, \n19), 309 ([M]+\n+, 100), \n280 (59), 187 (38), 150 \n(25), 76 (19). 79 \n44 1H-NMR (250 MHz, CDCl36) \u03b4 ppm 8.17 \n(s, 1H, H-4), 8.13 (d, J = 3.8 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.83 (d, J = 8.7 Hz, 2H, H-3\u2019, H-\n5\u2019), 7.36 (dd, J = 12.4, 7.5 Hz, 2H, H-6, \nH-7), 7.14 (d, J = 7.5 Hz, 1H, H-5) 2.34 \n(s, 3H, CH3).  m/z (%): 310 ([M+1]+\n+, \n21), 309 ([M]+\n+, 100),  \n280 (64), 187 (48), \n159(30), 150 (32), 76 \n(25). 89 \n45 1H-NMR (400 MHz, DMSO- d6) \u03b4 ppm \n8.84 (d, J = 2.7 Hz, 1H, H-5), 8.67 (s, 1H, \nH-4), 8.51 (dd, J = 9.1, 2.8 Hz, 1H, H-7), \n8.33 \u2013 8.27 (m, 2H, Ar), 8.19 \u2013 8.14 (m, 2H), 7.70 (d, J = 9.1 Hz, 1H, H-8). m/z (%): 341 ([M+1]\n+\n+, \n12), 340 ([M]+\n+, 100), \n323 (68), 311 (36), 295 (56), 294 (25), 265 (31), 218 (46), 150 (100), 104 (78), 76 (55). 52 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n261Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 262 \nCompuesto NMR MS Rdto. (%) \n46 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.39 (s, 1H, H-4), 8.29 (d, J = 8.8 Hz, 2H, \nH-3\u2019, H-5\u2019), 8.01 (d, J = 8.8 Hz, 2H, H-2\u2019, \nH-6\u2019), 6.68 (s, 1H, H-6), 6.55 (s, 1H, H-8), \n3.92 (s, 3H, OCH3), 3.90 (s, 3H, OCH3). m/z (%): 356 ([M+1]+\n+, \n28), 355 ([M]+\n+, 100), \n327 (42), 326 (31), 233 \n(280). 61 \n47 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.70 \n(s, 1H, H-4), 8.51 (dt, J  = 8.0, 1.5 Hz, 1H, \nH-5), 8.19 (s, 1H), 8.07 (d, J = 7.3 Hz, \n1H), 7.88 (t, J  = 8.0 Hz, 1H, H-6), 7.41-\n7.21 (m, 2H, Ar), 7.27 (d, J = 2.8 Hz, 1H), \n3.88 (s, 3H, OCH3). m/z (%): 331 ([M+2]+\n+, \n35), 329 ([M]+\n+, 100), \n302 (15), 300 (37), 207 (38), 179 (32), 150 (99), 123 (29), 120 (24), 76 (50)  53 \n48 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.53 (s, 1H, H-4), 8.30 (d, J = 8.8 Hz, 2H, \nH-2\u2019, H-6\u2019), 8.07 (d, J  = 8.8 Hz, 2H, H-3\u2019, \nH-4\u2019), 7.83 (d, J  = 8.6 Hz, 1H, H-5), 7.18-\n6.95 (m, 2H, Ar), 3.90 (s, 3H, OCH3). m/z (%): 326 ([M+1]+\n+, \n41), 325 ([M]+\n+, 100), \n297 (40), 296 (58), 203 (93), 175 (33), 150 (30), 120 (24), 119 (53), 104 (52), 76 (55). 95 \n49 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.91 \n(s, 1H, H-4), 7.65 (d, J = 8.5 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.29 (d, J = 8.5 Hz, 2H, H-3\u2019, H-\n5\u2019), 7.20-7.02 (m, 2H, Ar), 6.84 (d, J = 2.8 \nHz, 1H, H-5), 3.70 (s, 3H, OCH3). m/z (%): 316 ([M+2]+\n+, \n36), 314 ([M]+\n+, 90), 285 \n(23), 279 (15), 251 (23), 175 (22), 141 (39), 139 (100), 119 (16), 111 (52), 76 (13), 75 (15). 93 \n50 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.37 (s, 1H, H-4), 8.09 (s, 1H, H-5), 7.96 (d, J = 8.2 Hz, 2H, H-2\u2019, H-6\u2019), 7.87 (dd, J \n= 8.9, 2.6 Hz, 1H, H-7), 7.60 (d, J = 8.2 \nHz, 2H, H-3\u2019, H-5\u2019), 7.46 (d, J = 8.9 Hz, \n1H, H-8). m/z (%): 365 ([M+2]\n+\n+,  \n6), 363 ([M]+\n+, 38), 361 \n(30), 141 (43), 139 (100), 113 (17), 111 (52).  99 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n262Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 263 \nCompuesto NMR MS Rdto. (%) \n51 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.93 \n(s, 1H, H-4), 7.64 (d, J = 8.6 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.27 (d, J = 8.6 Hz, 2H, H-3\u2019, H-\n5\u2019), 7.15-6.96 (m, 3H, Ar), 3.82 (s, 3H, \nOCH3). m/z (%): 316 ([M+2]+\n+, \n27), 314 ([M]+\n+, 77), 285 \n(20), 279 (16), 251 (11), \n175 (20), 141 (34), 139 (100), 111 (43), 75 (13). 95 \n52 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.81 \n(s, 1H, H-4), 7.63 (d, J = 8.4 Hz, 2H, H-\n2\u2019, H-4\u2019), 7.28 (d, J = 8.4 Hz, 2H, H-3\u2019, H-\n5\u2019), 7.14 (s, 1H, H-6), 7.10 (s, 1H, H-8), \n3.82 (s, 3H, OCH3). m/z (%): 394 ([M+2]+\n+, \n17), 392 ([M]+\n+, 48), 356 \n(62), 252 (32), 139 \n(100), 111 (31), 77 (18). 98 \n53 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.90 \n(s, 1H, H-4), 7.64 (d, J = 8.6 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.35-6.99 (m, 6H, Ar), 2.27 (s, \n3H, CH3). m/z (%): 300 ([M+2]+\n+, \n33), 298 ([M]+\n+, 81), 271 \n(16), 269 (38), 187 (30), \n159 (29), 141 (42), 139 (100), 113 (24), 111 (66) 98 \n54 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.42-\n8.30 (m, 2H, Ar), 7.98 (s, 1H, H-4), 7.65 (d, J = 8.7 Hz, 2H, H-2\u2019, H-6\u2019), 7.39 (d, J \n= 9.0 Hz, 1H, H-8), 7.31 (d, J = 8.7 Hz, \n2H, H-3\u2019, H-5\u2019). m/z (%): 331 ([M+2]\n+\n+, \n12), 329 ([M]+\n+, 35), 141 \n(36), 139 (100), 113 (15), 111 (45) 41 \n55 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.29 \n(d, J = 10.2 Hz, 1H), 7.61 (d, J = 8.5 Hz, \n2H), 7.26 (d, J = 8.4 Hz, 2H), 6.29 (d, J = \n2.0 Hz, 1H), 6.14 (d, J = 2.0 Hz, 1H), 3.73 \n(d, J = 2.5 Hz, 6H, 2x OCH3). m/z (%): 346 ([M+2]+\n+, \n15), 342 ([M]+\n+, 42), 205 \n(31), 139 (100), 105 (27). 98 \n56 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.86 \n(s, 1H, H-4), 7.64 (d, J = 8.7 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.48-7.39 (m, 2H, Ar), 7.30 (d, J \n= 8.7 Hz, 2H, H-3\u2019, H-5\u2019), 7.20 (d, J = 9.8 \nHz, 1H, H-8). m/z (%): 322 ([M+4]+\n+, \n15), 320 ([M+2]+\n+, 82), \n318 ([M]+\n+, 82), 285 (21), \n283 (59), 257 (28), 255 (81), 141 (94), 139 (84), 113 (46), 111 (100), 75 (52). 90 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n263Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 264 \nCompuesto NMR MS Rdto. (%) \n57 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.05 \n(s, 1H, H-4), 7.79 (d, J = 8.3 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.71-7.54 (m, 2H, Ar), 7.46-7.20 \n(m, 4H, Ar), 2.43 (s, 3H, CH3). m/z (%): 265 ([M+1]+\n+, \n30), 264 ([M]+\n+, 86), 249 \n(27), 136 (26), 235 (24), \n221 (37), 173 (21), 120 (19), 119 (100), 91 (60), 89 (26), 65 (31). 91 \n58 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.99 \n(s, 1H, H-4), 7.77 (d, J = 8.3 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.38-7.14 (m, 4H, Ar), 6.98 (d, J \n= 2.9 Hz, 1H, H-8), 3.84 (s, 3H, OCH3), \n2.41 (s, 3H, CH3). m/z (%): 295 ([M+1]+\n+, \n18), 194 ([M]+\n+, 73), 266 \n(17), 265 (16), 251 (31), 120 (17), 119 (100), 65 (17). 98 \n59 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.93 \n(s, 1H, H-4), 7.82-7.63 (m, 4H, Ar), 7.36-\n7.21 (m, 3H, Ar), 2.43 (s, 3H, CH3). m/z (%): 344 ([M+2]+\n+, \n43), 342 ([M]+\n+, 43), 301 \n(23), 299 (23), 119 \n(100), 91 (57), 65 (28).  87 \n60 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.52 \n(d, J = 7.1 Hz, 2H, H-2\u2019, H-6\u2019), 8.08 (s, \n1H, H-4), 7.78 (d, J = 7.1 Hz, 2H, H-3\u2019, \nH-5\u2019), 7.54 (dt, J = 8.6, 3.5 Hz, 1H, H-5), \n7.41-7.19 (m, 2H, Ar), 2.45 (s, 3H, CH3). m/z (%): 310 ([M+1]+\n+, \n14), 309 ([M]+\n+, 68), 294 \n(17), 119 (100), 91 (78), 65 (22). 42 \n61 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.41 \n(s, 1H, H-4), 7.75 (d, J = 7.5 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.26 (d, J = 7.5 Hz, 2H, H-3\u2019, H-\n5\u2019), 6.45 (d, J = 2.7 Hz, 1H, H-6), 6.30 (d, \nJ = 2.7 Hz, 1H, H-8), 3.88 (d, J = 3.3 Hz, \n6H, 2x OCH3), 2.42 (s, 3H, CH3). m/z (%): 341 ([M+1]+\n+, \n33), 340 ([M]+\n+, 88), 325 \n(28) 312 (30), 309 (45), 297 (20), 233 (48), 119 \n(100), 92 (27), 77 (38). 90 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n264Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 265 \nCompuesto NMR MS Rdto. (%) \n62 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.06 \n(s, 1H, H-4), 7.77 (d, J = 8.1 Hz, 2H, H-\n2\u2019, H-6\u2019), 7.49 (d, J = 8.5 Hz, 1H, H-5), \n7.27 (d, J  = 8.0 Hz, 2H, H-3\u2019, H-5\u2019), 6.97-\n6.80 (m, 2H, H-6, H-8\u2019), 3.91 (s, 3H, \nOCH3), 2.42 (s, 3H, CH3). m/z (%): 295 ([M+1]+\n+, \n30), 294 ([M]+\n+, 100), \n279 (38), 266 (26), 265 \n(34), 251 (36), 203 (42), 119 (86), 91 (55), 65 (19). 63 \n63 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.05 \n(s, 1H, H-4), 7.71-7. 55 (m, 2H, H-5, H-7), \n7.46-7.30 (m, 2H, H-6, H-8), 7.13 (s, 2H, \nH-2\u2019, H-6\u2019), 3.93 (s, 3H, OCH3), 3.87 (s, \n6H, 2x OCH3). m/z (%): 341 ([M+1]+\n+, \n23), 340 ([M]+\n+, 100), \n325 (42), 269 (46), 195 \n(27), 173 (33), 134 (18).  99 \n64 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.00 \n(s, 1H, H-4), 7.33 (d, J = 9.0 Hz, 1H, H-8), \n7.27-7.16 (m, 1H, H-7), 7.12 (s, 2H, H-2\u2019, H-6\u2019), 7.00 (d, J = 2.9 Hz, 1H, H-5), 3.93 \n(s, 3H, OCH\n3), 3.87 (s, 6H, 2x OCH3), \n3.85 (s, 3H, OCH3). m/z (%): 371 ([M+1]+\n+, \n23), 370 ([M]+\n+, 100), \n355 (28), 203 (19), 195 (62), 134 (34). 95 \n65 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.99 \n(s, 1H, H-4), 7.52-7.23 (m, 3H, H-5, H-7, H-8), 7.12 (s, 2H, H-2\u2019, H-6\u2019), 3.93 (s, 3H, \nOCH\n3), 3.87 (s, 6H, 2x OCH3), 2.43 (s, \n3H, CH3). m/z (%): 355 ([M+1]+\n+, \n37), 354 ([M]+\n+, 100), \n339 (36), 283 (13), 195 \n(47), 187 (34). 95 \n66 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.04 \n(s, 1H, H-4), 7.27 (d, J = 8.4 Hz, 1H, H-5), \n7.22-7.14 (m, 2H, H-6. H-7), 7.12 (s, 2H, \nH-2\u2019, H-6\u2019), 3.99 (s, 3H, OCH3), 3.92 (s, \n3H, 8- OCH3), 3.86 (s, 6H, 2x OCH3). m/z (%): 371 ([M+1]+\n+, \n37), 370 ([M]+\n+, 100), \n355 (31), 203 (26), 195 \n(65). 96 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n265Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 266 \nCompuesto NMR MS Rdto. (%) \n67 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.02 \n(s, 1H, H-4), 7.29-7.12 (m, 3H, H-5, H-6, \nH-7), 7.11 (s, 2H, H-2\u2019, H-6\u2019), 4.19 (q, J = \n6.9 Hz, 2H, -CH\n2), 3.91 (s, 3H, OCH3), \n3.85 (s, 6H, 2x OCH3), 1.47 (s, J = 6.9 \nHz, 3H, CH3). m/z (%): 385 ([M+1]+\n+, \n36), 384 ([M]+\n+, 100), \n369 (31), 195 (69).  99 \n68 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.29 (s, 1H, H-4), 7.66 (d, J = 2.2 Hz, 1H, \nH-5), 7.58 (d, J = 2.2 Hz, 1H, H-7), 7.26 \n(s, 2H, H2\u2019, H-6\u2019), 3.99 (s, 3H, OCH3), \n3.84 (s, 6H, 2x OCH3), 3.80 (s, 3H, \nOCH3). m/z (%): 450 ([M+2]+\n+, \n84), 448 ([M]+\n+, 84), 283 \n(11), 281 (11), 196 (15), 195 (100).  92 \n69 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.99 \n(s, 1H, H-4), 7.52-7.23 (m, 3H, H-5, H-7, H-8), 7.12 (s, 2H, H-2\u2019, H-6\u2019), 3.93 (s, 3H, \nOCH\n3), 3.87 (s, 6H, 2x OCH3), 2.43 (s, \n3H, CH3). m/z (%): 355 ([M+1]+\n+, \n37), 354 ([M]+\n+, 100), \n339 (36), 283 (13), 195 \n(47), 187 (34). 95 \n70 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.03 \n(s, 1H, H-4), 7.50 (d, J = 7.4 Hz, 1H, H-5), \n7.43 (dd, J = 7.4, 1.5 Hz, 1H, H-7), 7.30-\n7.18 (m, 1H, H-6), 7.14 (s, 2H, H-2\u2019, H-\n6\u2019), 3.93 (s, 3H, OCH3), 3.87 (s, 6H, 2x \nOCH3), 2.50 (s, 3H, CH3). m/z (%): 355 ([M+1]+\n+, \n31), 354 ([M]+\n+, 100), \n339 (42), 283 (14), 195 \n(39), 187 (31). 96 \n71 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.82 (s, 1H, H-4), 8.67-8.38 (m, 2H, H-5, H-7), 7.70 (d, J = 9.2 Hz, 1H, H-8), 7.27 \n(s, 2H, H-2\u2019, H-6\u2019), 4.07-3.60 (m, 9H, 3x \nOCH\n3). m/z (%): 386 ([M+1]+\n+, \n34), 385 ([M]+\n+, 100), \n370 (31), 314 (17), 218 \n(30), 195 (32). 51 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n266Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 267 \nCompuesto NMR MS Rdto. (%) \n72 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.97 \n(s, 1H, H-4), 7.02 (s, 2H, H-2\u2019, H-6\u2019), 6.31 \n(d, J = 2.7 Hz, 1H, H-6), 6.26 (d, J = 2.7 \nHz, 1H, H-8), 3.93 (s, 3H, OCH3), 3.91 (s, \n3H, OCH3), 3.87 (s, 6H, 2x OCH3). m/z (%): 401 ([M+1]+\n+, \n10), 400 ([M]+\n+, 45), 191 \n(18), 135 (13), 134 (100). 95 \n73 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 7.94 \n(s, 1H, H-4), 7.66-7. 53 (m, 2H, H-5, H-7), \n7.36 (d, J = 7.4 Hz, 1H, H-8), 7.11 (s, 2H, \nH-2\u2019, H-6\u2019), 3.93 (s, 3H, OCH3), 3.87 (s, \n6H, 2x OCH3). m/z (%): 376 ([M+2]+\n+, \n34), 374 ([M]+\n+, 100), \n359 (32), 207 (25), 195 (40). 94 \n74 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.06 \n(s, 1H, H-4), 7.50 (d, J = 8.5 Hz, 1H, H-5), \n7.11 (s, 2H, H-2\u2019, H-6\u2019), 6.95-6.83 (m, \n2H, H-6, H-8), 3.93 (s, 3H, OCH3), 3.91 \n(s, 3H, OCH3), 3.87 (s, 6H, 2x OCH3). m/z (%): 371 ([M+1]+\n+, \n22), 370 ([M]+\n+, 100), \n355 (23), 327 (16), 203 \n(28), 195 (28). 97 \n75 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.65 (s, 1H, H-4), 8.57 (s, 1H), 8.49 (dd, J  \n= 8.2, 2.2 Hz, 1H, H-2\u2019), 8.35 (d, J  = 6.9 \nHz, 1H, H-4\u2019), 7.95-7.69 (m, 3H, Ar), 7.56-7.38 (m, 2H, Ar). m/z (%): 296 ([M+1]\n+\n+, \n19), 295 ([M]+\n+, 100), \n278 (24), 266 (47), 250 (23), 248 (25), 220 (21), 173 (74), 150 (44), 145 (36), 104 (32), 89 (25), 76 (28). 89 \n76 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.63 \n(s, 1H, H-4), 8.44 (dt, J = 8.0, 1.5 Hz, 1H, \nH-6\u2019), 8.24 (s, 1H, H-5), 8.16 (d, J = 7.3 \nHz, 1H, H-4\u2019), 7.68 (t, J = 8.0 Hz, 1H, H-\n5\u2019), 7.41-7.21 (m, 2H, Ar), 7.05 (d, J = 2.8 \nHz, 1H, H-7), 3.88 (s, 3H, OCH3). m/z (%): 326 ([M+1]+\n+, \n45), 325 ([M]+\n+, 100), \n297 (18), 296 (35), 203 (51), 175 (41), 150 (73), 119 (32), 104 (48), 76 (46). 94 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n267Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 268 \nCompuesto NMR MS Rdto. (%) \n77 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.65 (s, 1H, H-4), 8.55-8.42 (m, 2H, H-2\u2019, \nH-4\u2019), 8.35 (d, J = 7.1 Hz, 1H, H-6\u2019), 8.14 \n(dd, J = 4.9, 2.5 Hz, 1H, H-5\u2019), 7.97-7.75 \n(m, 2H, H-5, H-6), 7.47 (d, J = 8.8 Hz, \n1H, H-8). m/z (%): 375 ([M+2]+\n+, \n99), 373 ([M]+\n+, 100), \n346 (26), 344 (25), 253 (36), 251 (37), 225 (23), 223 (23), 150 (89), 104 (46), 76 (40) 90 \n78 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.64 (s, 1H, H-4), 8.58-8.39 (m, 2H, Ar), 8.34 (d, J = 7.8 Hz, 1H), 7.82 (t, J = 7.8 \nHz, 1H), 7.57-7.24 (m, 3H, Ar), 3.94 (s, \n3H, OCH\n3). m/z (%): 326 ([M+1]+\n+, \n21), 325 ([M]+\n+, 100), \n296 (24), 203 (27), 175 \n(30), 150 (43), 104 (28), 76 (26).  82 \n79 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.64 \n(td, J = 4.5, 3.9, 1.9 Hz, 1H), 8.43 (d, J = \n8.1 Hz, 1H, Ar), 8.34-8.22 (m, 1H, Ar), 8.15 (d, J = 9.2 Hz, 1H, Ar), 7.68 (qd, J = \n7.8, 3.9 Hz, 1H, Ar), 7.42-7.06 (m, 3H, \nAr), 4.21 (q, J = 6.9 Hz, 2H, CH\n2), 1.57-\n1.45 (t, 3H, CH3). m/z (%): 340 ([M+1]+\n+, \n29), 339 ([M]+\n+, 100), \n312 (21), 311 (88), 283 \n(23),, 282 (42), 266 (27), 264 (25), 188 (45), 160 (40), 150 (98), 120 (19), 105 (18), 104 (56), 92 (17), 76 (42). 91 \n80 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.70-8.56 (m, 1H, Ar),  8.56-8.39 (m, 2H, \nAr), 8.34 (d, J  = 7.8 Hz, 1H), 7.83 (t, J = \n7.8 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.59 \n(d, J = 2.0 Hz, 1H), 3.97 (s, 3H, OCH3). m/z (%): 405 ([M+2]+\n+, \n97), 403 ([M]+\n+, 97), 253 \n(23), 150 (100), 104 (50), 76 (43). 77 \n81 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.68-8.56 (m, 1H), 8.49 (d, J = 5.8 Hz, \n2H), 8.33 (d, J = 7.7 Hz, 1H), 7.82 (t, J = \n8.0 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H), 7.58 \n(dd, J = 8.5, 2.2 Hz, 1H), 7.39 (d, J = 8.4 \nHz, 1H), 2.38 (s, 3H). m/z (%): 310 ([M+1]+\n+, \n27), 309 ([M]+\n+, 100), \n281 (21), 280 (56), 264 (22), 262 (30), 234 (22), 187 (74), 159 (50), 150 (52), 104 (45), 103 (27), \n77 (20), 76 (40). 88 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n268Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 269 \nCompuesto NMR MS Rdto. (%) \n82 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.64 \n(d, J = 2.0 Hz, 1H, H-4), 8.44 (d, J = 7.7 \nHz, 1H, H-4\u2019), 8.28 (s, 1H, H-2\u2019), 8.22-\n8.06 (m, 1H), 7.68 (t, J = 8.0 Hz, 1H), \n7.61-7.39 (m, 2H), 7.40 -7.18 (m, 1H), \n2.51 (s, 3H, CH3). m/z (%): 310 ([M+1]+\n+, \n55), 309 ([M]+\n+, 100), \n281 (36), 280 (70), 263 (26), 262 (44), 235 (28), 234 (36), 187 (85),  159 (51), 150 (64), 104 (51), 76 (50). 79 \n84 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.53 (t, J  = 2.1 Hz, 1H), 8.48-8.30 (m, \n2H), 8.22 (dt, J  = 7.1, 1.2 Hz, 1H), 7.78 (t, \nJ = 8.0 Hz, 1H), 6.68 (d, J  = 2.2 Hz, 1H), \n6.56 (d, J = 2.2 Hz, 1H), 3.92 (s, 4H), \n3.90 (s, 3H). m/z (%): 356 ([M+1]+\n+, \n32), 355 ([M]+\n+, 100), \n327 (36), 326 (25), 325 (26), 234 (20), 233 (93), 150 (21), 104 (16), 76 (17). 89 \n85 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.71 (s, 1H, H-4), 8.63-8.51 (m, 2H, H-2\u2019, \nH-4\u2019), 8.42 (d, J = 7.1 Hz, 1H, H-6\u2019), 8.14 \n(dd, J = 4.9, 2.5 Hz, 1H, H-5\u2019), 7.98-7.77 \n(m, 2H, H-5, H-6), 7.57 (d, J = 8.8 Hz, \n1H, H-8). m/z (%): 331 ([M+2]+\n+, \n50), 329 ([M]+\n+, 100), \n302 (20), 301 (22), 300 \n(47), 284 (39), 282 (32), 255 (22), 254 (25), 209 (27), 207 (65), 181 (18), 151 (17), 150 (99), 123 (39), 104 (65), 76 (57), 75 (23). 80 \n86 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.57 (s, 1H, H-4), 8.52 (s, 1H, H-2\u2019), 8.45 (dd, J = 8.0, 2.6 Hz, 1H, H-4\u2019), 8.27 (d, J \n= 7.7 Hz, 1H, H-6\u2019), 7.89-7.70 (m, 2H, H-5, H-5\u2019), 7.16-6.93 (m, 2H, H-6, H-8), \n3.89 (s, 3H, OCH\n3). m/z (%): 326 ([M+1]+\n+, \n37), 325 ([M]+\n+, 100), \n297 (34), 296 (36), 203 \n(85), 150 (23), 104 (21), 76 (24). 85 \n89 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.38 (s, 1H), 8.36 (s, 1H), 7.96-7.81 (m, \n2H), 7.69 (t, J = 7.4 Hz, 1H), 7.61-7.47 \n(m, 2H), 7.33-7.09 (m, 3H). m/z (%): 267 ([M+1]+\n+, 7), \n266 ([M]+\n+, 42), 105 \n(100),  77 (60)  82 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n269Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 270 \nCompuesto NMR MS Rdto. (%) \n90 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n11.11 (s, 1H), 10.86 (s, 1H), 8.25 (s, 1H), \n7.77 (d, J  = 7.7 Hz, 2H), 7.71-7.33 (m, \n3H), 6.28 (s, 1H), 6.24 (s, 1H). m/z (%): 283 ([M+1]+\n+, \n29), 282 ([M]+\n+, 100), \n254 (30), 253 (69), 205 (72), 105 (88), 77 (72). 75 \n91 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.95 (s, 1H), 8.32 (s, 1H), 7.84 (d, J = \n7.4 Hz, 2H), 7.75-7.58 (m, 2H), 7.50 (t, J \n= 7.5 Hz, 2H), 6.92-6.66 (m, 2H). m/z (%): 267 ([M+1]+\n+, \n31), 266 ([M]+\n+, 100), \n238 (35), 237 (68), 189 (63), 161 (22), 105 (97), 77 (79). 79 \n98 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.58 (sa, 1H, OH), 8.23 (s, 1H, H-4), 7.80 (d, J = 8.7 Hz, 2H, H-2\u2019, H-6\u2019), 7.64 \n\u2013 7.46 (m, 2H, H-5, H-7), 7.38 (d, J = 8.5 \nHz, 1H, H-8), 6.86 (d, J = 8.7 Hz, 2H, H-\n3\u2019, H-5\u2019). m/z (%): 280 ([M]\n+\n+, 65), \n251 (21), 237 (14), 93 (19), 76 (15), 65 (24). 89 \n99 1H-NMR (300 MHz, DMSO- d6) \u03b4 ppm \n10.56 (sa, 1H, -OH, 4\u2019-OH), 10.33 (sa, \n1H, -OH, 8-OH), 8.22 (s, 1H, H-4), 7.79 (d, J = 8.7 Hz, 2H, H-2\u2019, H-6\u2019), 7.29-7.06 \n(m, 3H, H-5, H-6, H-7), 6.86 (d, J = 8.7 \nHz, 2H, H-3\u2019, H-5\u2019). m/z (%): 283 ([M+1]\n+\n+, 9), \n282 ([M]+\n+, 49), 252 (46), \n120 (100). 71 \n100 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.80 (s, 1H), 10.41 (s, 1H), 8.18 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 \nHz, 1H), 6.85 (d, J  = 9.0 Hz, 3H), 6.77 (s, \n1H). m/z (%): 283 ([M+1]\n+\n+, \n22), 282 ([M]+\n+, 92), 254 \n(18), 253 (30), 237 (19), 189 (22), 121 (100), 98 (26), 93 (25), 73 (19), 71 (19), 55 (30). 68 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n270Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 271 \nCompuesto NMR MS Rdto. (%) \n108 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.06 (s, 1H), 9.43 (s, 1H), 8.24 (d, J = \n1.5 Hz, 1H), 7.71-7.49 (m, 2H), 7.42-7.19 \n(m, 3H), 6.82 (d, J = 8.1 Hz, 1H), 2.40 (s, \n3H). m/z (%): 297 ([M+1]+\n+, \n28), 296 ([M]+\n+, 93), 268 \n(15), 267 (21), 187 (63), 137 (100), 109 (28), 81 (18), 77 (15). 77 \n109 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.85 (s, 1H), 10.00 (s, 1H), 9.42 (s, 1H), 8.16 (s, 1H), 7.63 (d, J = 8.2 Hz, 1H), \n7.35-7.15 (m, 2H), 6.90-6.68 (m, 3H). m/z (%): 299 ([M+1]\n+\n+, \n16), 298 ([M]+\n+, 85), 269 \n(15), 189 (69), 161 (19), 137 (100), 109 (25). 74 \n111 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n9.85 (s, 1H, -OH), 9.29 (d, J = 19.0 Hz, \n3H, 3X -OH), 8.17 (s, 1H, H-4), 7.33 (d, J \n= 9.6 Hz, 1H, H-8), 7.18-7.06 (m, 2H, H-5, H-7), 6.87 (s, 2H, H-2\u2019, H-6\u2019). m/z (%): 315 ([M+1]\n+\n+, \n31), 314 ([M]+\n+, 92), 189 \n(73), 161 (39), 153 (100), 125 (21), 79 (16). 81 \n112 1H-NMR (250 MHz DMSO-d6) \u03b4 ppm \n9.33 (bs, 3H, 3x OH), 8.19 (s, 1H, H-4), \n8.06 (s, 1H, H-5), 7.84 (d, J = 8.3 Hz, 1H, \nH-7), 7.45 (d, J = 8.3 Hz, 1H, H-8), 6.90 \n(s, 2H, H-2\u2019, H-6\u2019). m/z (%): 377 ([M+2]+\n+, \n27), 375 ([M]+\n+, 32), 297 \n(41), 251 (59), 249 (63), \n153 (100), 125 (25), 79 (18). 70 \n113 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n9.34 (bs, 3H, 3x-OH), 8.18 (s, 1H, H-4), 7.59 (s, 1H, H-5), 7.52 (d, J = 8.4 Hz, 1H, \nH-7), 7.37 (d, J = 8.8 Hz, 1H, H-8), 6.88 \n(s, 2H, H-2\u2019, H-6\u2019), 2.37 (s, 3H, CH\n3). m/z (%): 313 ([M+1]+\n+, \n29), 312 ([M]+\n+, 100), \n283 (15), 187 (85), 153 (94), 125 (24), 79 (15). 57 \n114 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n9.32 (bs, 3H, 3x OH), 8.20 (s, 1H, H-4), 7.93 (d, J = 3.1 Hz, 1H, H-5), 7.73 (d, J  = \n9.2, 2.9 Hz, 1H, H-7), 7.52 (d, J = 9.0 Hz, \n1H, H-8), 6.90 (s, 2H, H-2\u2019, H-6\u2019). m/z (%): 334 ([M+2]\n+\n+, \n24), 332 ([M]+\n+, 70), 266 \n(18), 207 (48), 153 (100), 125 (21), 79 (15). 58 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n271Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 272 \nCompuesto NMR MS Rdto. (%) \n115 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.88 (s, 1H, OH), 9.29 (s, 3H, 3x OH), \n8.14 (s, 1H, H-4), 7.46 (s, 1H, H-5), 7.27 \n(s, 1H, H-7), 6.88 (s, 2H, H-2\u2019, H-6\u2019). m/z (%): 394 ([M+2]+\n+, \n54), 392 ([M]+\n+, 47), 378 \n(13), 348 (12), 269 (12), 153 (100), 125 (18), 79 (13). 82 \n116 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.34 (s, 1H, OH), 9.31 (s, 3H, 3x OH), 8.20 (s, 1H, H-4), 7.35-7.04 (m, 3H, H-5, \nH-6, H-7), 6.88 (s, 2H, H-2\u2019, H-6\u2019). m/z (%): 315 ([M+1]\n+\n+, \n19), 314 ([M]+\n+, 88), 299 \n(21), 298 (95), 288 (42), \n270 (63), 253 (21), 189 (27), 153 (100), 139 (18), 125 (20), 79 (14). 54 \n117 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n9.31 (bs, 3H, 2x-OH ), 8.24 (s, 1H, H-4), 7.72-7.48 (m, 2H, H-5, H-6), 7.44-7.15 (m, 1H, H-7), 6.89 (s, 2H, H-2\u2019, H-6\u2019), 2.45-2.13 (m, 3H). m/z (%): 313 ([M+1]\n+\n+, \n22), 312 ([M]+\n+, 97), 187 \n(92), 153 (100), 125 (27), 77 (13). 70 \n118 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n11.15 (s, 1H, OH), 11.01 (s, 1H, OH), 10.74 (s, 1H, OH), 9.30 (s, 2H, 2xOH), 8.05 (s, 1H, H-4 ), 6.80 (s, 2H, H-2\u2019, H-6\u2019), 6.29 (d, J = 2.3 Hz, 1H, H-6), 6.24 (d, \nJ = 2.2 Hz, 1H, H-8). m/z (%): 331 ([M+1]\n+\n+, \n12), 330 ([M]+\n+, 18), 223 \n(47), 211 (41), 181 (100), 180 (39), 152 (18), 115 (19), 103 (51), 91 (24), 77 (17), 69 (15). 62 \n120 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n9.88 (s, 1H, -OH), 8.28 (s, 1H, H-4), 7.79 (d, J = 8.2 Hz, 2H, H-2\u2019, H-6\u2019), 7.39-7.24 \n(m, 3H, H-8, H-3\u2019, H-5\u2019), 7.20-7.04 (m, \n2H, H-5, H-7), 2.38 (s, 3H, CH\n3). m/z (%): 281 ([M+1]+\n+, \n20), 280 ([M]+\n+, 80), 279 \n(15), 265 (17), 252 (17), \n251 (18), 237 (28), 119 (100), 91 (56), 65 (16). 72 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n272Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 273 \nCompuesto NMR MS Rdto. (%) \n121 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n10.96 (s, 1H, OH), 8.29 (s, 1H, H-4), 7.74 \n(d, J = 8.1 Hz, 2H, H-2\u2019, H-6\u2019), 7.68 (d, J \n= 8.4 Hz, 1H, H-5), 7.31 (d, J  = 7.9 Hz, \n2H, H-3\u2019, H-5\u2019), 6.84 (dd, J = 8.4, 2.3 Hz, \n1H, H-6), 6.77 (d, J = 2.2 Hz, 1H, H-8), \n2.37 (s, 3H, CH3). \n m/z (%): 281 ([M+1]+\n+, \n20), 280 ([M]+\n+, 100), \n265 (26), 252 (28), 189 (26), 119 (99), 105 (16), 91 (61), 65 (18). 74 \n122 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n11.03 (s, 1H), 10.79 (s, 1H), 8.22 (s, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.30 (d, J = 7.8 \nHz, 2H), 6.27 (dd, J = 12.6, 2.0 Hz, 2H). m/z (%): 297 ([M+1]\n+\n+, \n12), 296 ([M]+\n+, 63), 281 \n(22), 267 (19), 205 (25), 204 (18), 119 (100), 91 (63), 65 (18). 68 \n125 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.11 (s, 1H), 7.61 (d, J = 8.7 Hz, 2H), \n7.44-7.18 (m, 3H), 6.57 (d, J = 8.7 Hz, \n2H), 6.34 (s, 2H), 3.79 (s, 3H).  m/z (%): 296 ([M+1]\n+\n+, \n21), 295 ([M]+\n+, 71), 121 \n(15), 120 (100), 92 (28), 65 (20). 62 \n126 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.10 (s, 1H), 7.69-7.53 (m, 3H), 7.49 (dd, \nJ = 8.5, 2.2 Hz, 1H), 7.35 (d, J = 8.6 Hz, \n1H), 6.57 (d, J = 8.3 Hz, 2H), 6.31 (s, 2H), \n2.36 (s, 3H). m/z (%): 280 ([M+1]+\n+, \n26), 279 ([M]+\n+, 55), 187 \n(16), 120 (100), 92 (31), \n65 (20). 55 \n127 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n7.99 (s, 1H), 7.58 (d, J = 8.8 Hz, 2H), \n7.16 (d, J  = 8.7 Hz, 1H), 6.91 (dd, J = \n8.8, 2.7 Hz, 1H), 6.80 (d, J = 2.7 Hz, 1H), \n6.56 (d, J = 8.3 Hz, 2H), 6.27 (s, 2H), \n5.29 (s, 2H). m/z (%): 281 ([M+1]+\n+, \n19), 280 ([M]+\n+, 57), 120 \n(100), 92 (26), 65 (15). 92 \n128 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.11 (s, 1H), 7.88 (d, J = 2.6 Hz, 1H), \n7.77-7.58 (m, 3H), 7.48 (d, J = 8.9 Hz, \n1H), 6.58 (d, J = 8.3 Hz, 2H), 6.31 (s, 2H). m/z (%): 301 ([M+2]+\n+, \n31), 299 ([M]+\n+, 59), 121 \n(19), 120 (100), 92 (33), 65 (25). 34 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n273Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 274 \nCompuesto NMR MS Rdto. (%) \n129 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.16 (s, 1H), 7.71-7.45 (m, 4H), 7.28 (t, J \n= 7.6 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), \n6.31 (s, 2H), 2.39 (s, 3H). m/z (%): 280 ([M+1]+\n+, \n19), 279 ([M]+\n+, 79), 120 \n(100), 92 (26), 65 (17). 42 \n133 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.12 (s, 1H), 7.70 (dd, J  = 8.4, 2.2 Hz, \n1H), 7.60 (dd, J = 8.9, 2.4 Hz, 2H), 7.12-\n6.86 (m, 2H), 6.57 (d, J = 8.8 Hz, 2H), \n6.24 (s, 2H), 3.87 (s, 3H). m/z (%): 296 ([M+1]+\n+, \n52), 295 ([M]+\n+, 87), 267 \n(23), 266 (24), 203 (26), \n121 (27), 120 (100), 92 (56), 65 (44). 57 \n134 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.00 (s, 1H), 7.56 (d, J = 8.3 Hz, 2H), \n6.65 (s, 1H), 6.55 (d, J = 8.6 Hz, 3H), \n6.23 (s, 2H), 3.88 (s, 6H). m/z (%): 326 ([M+1]+, \n28), 325 ([M]+, 93), 310 \n(25), 233 (46), 120 (100), 92 (28). 71 \n137 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.25 (s, 1H), 7.48-7.35 (m, 2H), 7.29 (dd, J = 9.0, 3.1 Hz, 1H), 7.16 (t, J = 7.7 Hz, \n1H), 7.09-6.92 (m, 2H), 6.84 (dd, J = 7.9, \n2.4 Hz, 1H), 5.41 (s, 2H), 3.79 (s, 3H). m/z (%): 296 ([M+1]\n+\n+, \n32), 295 ([M]+\n+, 100), \n266 (22), 251 (17), 120 (74), 92 (52), 65 (29). 65 \n138 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.24 (s, 1H), 7.60 (s, 1H), 7.52 (dd, J = \n7.4, 2.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), \n7.16 (t, J  = 7.7 Hz, 1H), 7.09-6.94 (m, \n2H), 6.85 (dd, J = 7.7, 2.6 Hz, 1H), 5.38 \n(s, 2H), 2.36 (s, 3H). m/z (%): 280 ([M+1]+\n+, \n31), 279 ([M]+\n+, 100), \n250 (26)187 (21), 120 (68), 92 (51), 65 (29). 87 \n139 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.27 (s, 1H), 7.94 (d, J = 2.6 Hz, 1H), \n7.74 (dd, J = 8.9, 2.6 Hz, 1H), 7.52 (d, J \n= 8.8 Hz, 1H), 7.23-6.98 (m, 3H), 6.86 (d, J = 6.4 Hz, 1H), 5.41 (s, 2H). m/z (%): 301 ([M+1]\n+\n+, \n68), 299 ([M]+\n+, 100), \n270 (21), 121 (23), 120 (99), 92 (95, 65 (68).). 59 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n274Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 275 \nCompuesto NMR MS Rdto. (%) \n140 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.30 (s, 1H), 7.65 (dd, J  = 7.8, 1.6 Hz, \n1H), 7.58 (d, J = 7.3 Hz, 1H), 7.30 (t, J = \n7.6 Hz, 1H), 7.24-6.97 (m, 3H), 6.85 (dd, \nJ = 7.7, 2.5 Hz, 1H), 5.36 (s, 2H), 2.40 (s, \n3H). m/z (%): 280 ([M+1]+\n+, \n60), 279 ([M]+\n+, 100), \n250 (48), 223 (28), 187 (42), 120 (95), 92 (96), 65 (66). 64 \n143 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.23 (s, 1H), 7.58 (d, J = 15.8 Hz, 2H), \n7.16 (t, J  = 7.8 Hz, 1H), 7.10-6.94 (m, \n2H), 6.85 (d, J = 7.9 Hz, 1H), 5.38 (s, 2H), \n3.95 (s, 3H). m/z (%): 375 ([M+1]+\n+, \n77), 373 ([M]+\n+, 77), 121 \n(16), 120 (100), 92 (66), 65 (37). 61 \n144 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.28 (s, 1H), 7.75 (d, J = 8.6 Hz, 1H), \n7.23-6.92 (m, 6H), 6.83 (d, J = 7.9 Hz, \n1H), 5.39 (s, 2H), 3.88 (s, 3H). m/z (%): 296 ([M+1]+\n+, \n32), 295 ([M]+\n+, 100), \n266 (28), 203 (55), 187 (42), 120 (75), 92 (68), 65 (39). 60 \n145 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.13 (s, 1H), 7.14 (t, J = 7.8 Hz, 1H), 7.00 \n(t, J = 2.0 Hz, 1H), 6.93 (dt, J  = 7.5, 1.3 \nHz, 1H), 6.81 (dd, J = 7.4, 2.3 Hz, 1H), \n6.66 (d, J = 2.1 Hz, 1H), 6.54 (d, J = 2.1 \nHz, 1H), 5.36 (s, 2H), 3.89 (s, 6H). m/z (%): 326 ([M+1]+\n+, \n29), 325 ([M]+\n+, 100), \n310 (16), 297 (18), 296 (17), 233 (55), 120 (32), 92 (35), 65 (20).  59 \n146 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.23 (s, 1H), 7.87 (d, J = 7.2 Hz, 2H), \n7.67 (t, J  = 7.2 Hz, 1H), 7.61-7.45 (m, \n2H), 7.19 (d, J = 8.8 Hz, 1H), 6.96 (dd, J \n= 8.8, 2.7 Hz, 1H), 6.85 (d, J = 2.8 Hz, \n1H), 5.35 (s, 2H). m/z (%): 266 ([M+1]+\n+, \n25), 265 ([M]+\n+, 94), 237 \n(18), 236 (32), 105 (100), 77 (67). 72 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\n275Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 276 \nCompuesto NMR MS Rdto. (%) \n147 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.15 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), \n7.18 (d, J = 8.7 Hz, 1H), 7.04 (d, J = 8.2 \nHz, 2H), 6.94 (dd, J = 8.8, 2.6 Hz, 1H), \n6.83 (d, J = 2.8 Hz, 1H), 5.33 (s, 2H), \n3.84 (s, 3H). m/z (%): 296 ([M+1]+\n+, \n34), 295 ([M]+\n+, 100), \n136 (26), 135 (79), 107 \n(19), 92 (25), 77 (35). 92 \n148 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.12 (s, 1H), 7.55-7.38 (m, 2H), 7.17 (d, J \n= 8.7 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), \n6.94 (d, J = 8.9 Hz, 1H), 6.83 (s, 1H), \n5.30 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H). m/z (%): 326 ([M+1]+\n+, \n27), 325 ([M]+\n+, 83), 166 \n(19), 165 (100), 77 (18). 81 \n \nTabla 8. 3-Benzoil-4-hidroxicum arinas no publicadas.  \n \nCompuesto NMR MS Rdto. (%) \n149 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm (dd, \nJ = 7.8, 1.6 Hz, 1H, H-5), 7.87 (dd, J = \n8.1, 1.4 Hz, 2H, H-2\u2019, H-6\u2019), 7.74 (ddd, J \n= 8.5, 7.1, 1.7 Hz, 1H, H-7), 7.64 (t, J = \n7.3 Hz, 1H, H-4\u2019), 7.56-7.37 (m, 4H, H-6, H-8, H-3\u2019, H-5\u2019). m/z (%): 267 \n([M+1]\n+\n+, 55), 266 \n([M]+\n+, 94), 120 (26), \n105 (100), 77 (99). 87 \n152 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.31 \n(dd, J = 8.8, 2.3 Hz, 2H, H-2\u2019, H-6\u2019), 8.15 \n(dd, J = 9.7, 2.2 Hz, 1H, H-5), 7.89-7.64 \n(m, 3H, H-7, H-3\u2019, H-5\u2019), 7.49-7.20 (m, 2H, H-6, H-8). m/z (%): 311 \n([M+1]\n+\n+, 54), 310 \n([M]+\n+, 100), 294 (41), \n264 (30), 150 (77), 120 (42), 105 (34), 76 (32). 69 O OO\nR4'\nR3'R5\nR6\nR7\nR8R5'\nOOOOH\nRR6\nR7\n276Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 277 \nCompuesto NMR MS Rdto. (%) \n153 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.10 \n(dd, J = 7.8, 1.6 Hz, 1H, H-5), 7.71 (ddt, J \n= 8.8, 7.4, 1.8 Hz, 1H, H-7), 7.64 (d, J = \n8.2 Hz, 2H, H-2\u2019, H-6\u2019), 7.41-7.21 (m, 4H, \nH-6, H-8, H-3\u2019, H-5\u2019), 2.43 (d, J = 1.6 Hz, \n3H, -CH3). m/z (%): 281 \n([M+1]+\n+, 75), 280 \n([M]+\n+, 100), 265 (17), \n119 (75), 91 (34). 81 \n154 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 8.12 \n(dd, J = 7.9, 1.7 Hz, 1H, H-5), 7.79-7.70 \n(m, 2H, 2xAr-H), 7.55-7 -48 (m, 2H, 2x Ar-\nH), 7.43-7.30 (m, 2H, 2x Ar-H). m/z (%): 337 \n([M+4]+\n+, 16), 335 \n([M+2]+\n+, 74), 333 \n([M]+\n+, 100), 175 (49), \n173 (77), 147 (18), 145 (28), 92 (17), 69 (21). 71 \n156 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.15-\n8.02 (m, 2H, H-3\u2019, H-5\u2019), 7.81-7.63 (m, 2H, H-5, H-7), 7.41-7.23 (m, 2H, H-6, H-8), 6.64 (dd, J = 3.7, 1.7 Hz, 1H, H-4\u2019). m/z (%): 257 \n([M+1]\n+\n+, 21), 256 \n([M]+\n+, 76), 229 (25), \n228 (92), 121 (100), 120 (57), 95 (70), 65 (21). 52 \n159 1H-NMR (250 MHz, CDCl33) \u03b4 ppm 7.82 \n(s, 1H, H-5), 7.74-7.63 (m, 2H, H-2\u2019, H-6\u2019), 7.62-7.51 (m, 1H, H-4\u2019), 7.51-7.38 (m, 2H, H3\u2019, H-5\u2019), 7.10 (s, 1H, H-8), 2.39 (s, \n3H, 7-CH\n3), 2.35 (s, 3H, 6-CH3). m/z (%): 294 \n([M+1]+\n+, 70), 293 \n([M]+\n+, 100), 149 (25), \n148 (30), 105 (99), \n91 (23), 77 (65). 68 \n \n   \n OOOOH\nRR6\nR7\n277Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 278Tabla 9. 3-Cinamoilcumarinas no publicadas.  \n  \nCompuesto NMR MS Rdto. (%) \n163 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.57 \n(s, 1H), 7.88 (d, J = 15.5 Hz 1H), 7.87 \n(s, J = 15.5 Hz, 1H), 7.70-7.61 (m, 2H), \n7.57 (d, J = 8.1 Hz, 2H), 7.43-7.33 (m, \n2H), 7.21 (d, J = 7.8 Hz, 2H), 2.39 (s, \n3H). m/z (%): 291 ([M+1]+\n+, 20), \n290 ([M]+\n+, 100), 289 (31), \n276 (18), 275 (92), 262 \n(33), 261 (28), 145 (68), 117 (47), 116 (20), 115 \n(62), 91 (40), 77 (45), 89 \n(27). 72 \n164 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.37 \n(s, 1H), 8.00 (d, J = 15.8 Hz, 1H), 7.72 \n(d, J = 15.7 Hz, 1H), 7.55-7.39 (m, 3H), \n7.27-7.11 (m, 2H), 6.36 (dd, J = 8.6, \n2.4 Hz, 1H), 6.29 (d, J = 2.4 Hz, 1H), \n3.73 (s, 3H), 3.69 (s, 3H). m/z (%): 337 ([M+1]+\n+,  \n24), 336 ([M]+\n+, 100), 305 \n(42), 191 (53), 145 (41), 137 (29), 92 (18), 77 (15). 94 \n165 1H-NMR (250 MHz,\n CDCl3) \u03b4 ppm 8.38 \n(s, 1H), 8.05 (d, J = 15.8 Hz, 1H), 7.65 \n(d, J = 15.7 Hz, 1H), 7.56-7.39 (m, 2H), \n7.27-7.12 (m, 2H), 7.01 (s, 1H), 6.33 (s, 1H), 3.78 (s, 3H), 3.74 (d, J = 1.7 \nHz, 6H). m/z (%): 337 ([M+1]\n+\n+, 28), \n336 ([M]+\n+, 100), 308 (32), \n293 (42), 161 (91), 133 (19), 89 (17). 96 \n166 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.48 \n(s, 1H), 8.33 (d, J = 16.1 Hz, 1H), 8.15 \n(d, J = 15.9 Hz, 1H), 7.72-7.53 (m, 2H), \n7.43-7.22 (m, 2H), 6.09 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H). m/z (%): 367 ([M+1]\n+\n+, 14), \n366 ([M]+\n+, 46), 336 (34), \n335 (100), 221 (18), 178 (21), 168 (18). 98 \n169 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.57 \n(s, 1H), 7.89 (d, J = 15.7 Hz, 1H), 7.77 \n(d, J = 15.7 Hz, 1H), 7.72-7.58 (m, 2H), \n7.44-7.30 (m, 2H), 6.80 (d, J = 2.3 Hz, \n2H), 6.52 (t, J = 2.3 Hz, 1H), 3.83 (s, \n6H). m/z (%): 336 ([M]+\n+, 81), \n307 (42), 292 (53), 291 \n(100), 148 (17), 89 (30), \n69 (18). 91 O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\n278Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 279  \nCompuesto NMR MS Rdto. (%) \n170 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.65 (s, 1H), 8.03-7.82 (m, 2H), 7.82-\n7.63 (m, 2H), 7.56-7.24 (m, 3H), 7.24-7.08 (m, 2H), 3.81 (s, 3H), 3.76 (s, 3H). m/z (%): 336 ([M+1]\n+\n+, 81), \n337 ([M]+\n+, 42), 292 (53), \n291 (100), 148 (17), 89 (30), 69 (18). 87 \n171 1H-NMR (250 MHz,  CDCl3) \u03b4 ppm \n8.54 (s, 1H), 8.18 (d, J = 15.8 Hz, 1H), \n7.93 (d, J = 15.8 Hz, 1H), 7.73-7.57 \n(m, 2H), 7.44-7.28 (m, 2H), 7.21 (d, J = \n3.0 Hz, 1H), 7.00-6.79 (m, 2H), 3.87 (s, \n3H), 3.81 (s, 3H). m/z (%):  337 ([M+1]+\n+, 10), \n336 ([M]+\n+, 29), 306 (34), \n305 (100), 173 (23), 89 \n(26). 83 \n173 1H-NMR (250 MHz, CDCl33) \u03b4 ppm \n8.47 (s, 1H), 7.85 (s, 2H), 7.70-7.46 (m, 4H), 7.34 (d, J = 8.9 Hz, 1H), 7.22 \n(d, J = 7.9 Hz, 2H), 2.39 (s, 3H). m/z (%): 326 ([M+2]\n+\n+, 40), \n324 ([M]+\n+, 83), 311 (49), \n310 (29), 309 (91), 145 (100), 117 (66), 116 (27), 115 (75), 91 (50). 53 \n174 1H-NMR (250 MHz, CDCl3)  \u03b4 ppm \n8.43 (s, 1H), 8.16 (d, J = 15.8 Hz, 1H), \n7.83 (d, J = 15.8 Hz, 1H), 7.69-7.50 \n(m, 3H), 7.34 (s, 1H), 6.52 (dd, J = 8.6, \n2.3 Hz, 1H), 6.45 (d, J = 2.4 Hz, 1H), \n3.89 (s, 3H), 3.85 (s, 3H). m/z (%): 372 ([M+2]+\n+, 35), \n370 ([M]+\n+, 81), 341 (48), \n430 (28), 339 (100), 191 (60), 148 (39), 133 (26). 56 \n175 1H-NMR (250 MHz, CDCl3)  \u03b4 ppm \n8.43 (s, 1H), 8.20 (d, J = 15.7 Hz, 1H), \n7.75 (d, J = 15.9 Hz, 1H), 7.66-7.48 \n(m, 2H), 7.34 (s, 1H), 7.15 (s, 1H), 6.49 (s, 1H), 3.94 (s, 3H), 3.89 (d, J = 2.4 \nHz, 6H). m/z (%): 402 ([M+2]\n+\n+, 40), \n400 ([M]+\n+, 81), 371 (69), \n370 (49), 369 (100), 207 (52). 42 O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\n279Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 280  \nCompuesto NMR MS Rdto. (%) \n177 1H-NMR (250 MHz, CDCl3)  \u03b4 ppm \n8.45 (s, 1H), 8.19 (d, J = 15.9 Hz, 1H), \n7.88 (d, J = 15.8 Hz, 1H), 7.72-7.52 \n(m, 2H), 7.34 (d, J = 8.8 Hz, 1H), 7.20 \n(d, J = 3.0 Hz, 1H), 6.96 (dd, J = 9.0, \n3.1 Hz, 1H), 6.86 (d, J = 9.0 Hz, 1H), \n3.87 (s, 3H), 3.81 (s, 3H). m/z (%): 372 ([M+2]+\n+, 18), \n370 ([M]+\n+, 45), 341 (68), \n339 (100), 207 (37), 176 \n(28), 148 (18), 123 (14). 41 \n178 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.54 (s, 1H), 8.03 (d, J = 2.5 Hz, 1H), \n7.83-7.66 (m, 1H), 7.64 (s, 1H), 7.58-7.45 (m, 2H), 6.91 (d, J = 2.3 Hz, 2H), \n6.59 (t, J = 2.2 Hz, 1H), 3.77 (s, 6H). m/z (%): 372 ([M+2]\n+\n+, 34), \n370 ([M]+\n+, 84), 342 (31), \n341 (62), 327 (61), 326 (63), 325 (100), 230 (33), 191 (63), 148 (60). 40 \n179 1H-NMR (250 MHz, CDCl3)  \u03b4 ppm \n8.51 (s, 1H, H-4), 7.80 (s, 2H, H \u03b1, H\u03b2), \n7.60 (d, J = 8.8 Hz, 2H, H-2\u2019, H-6\u2019), \n7.31-7.04 (m, 3H, H-5, H-6, H-7), 6.89 (d, J = 8.8 Hz, 2H, H-3\u2019, H-5\u2019), 3.96 (s, \n3H, 8-OCH\n3), 3.82 (s, 3H, 4\u2019-OCH3). m/z (%): 337 ([M+1]+\n+, 37), \n336 ([M]+\n+, 100), 308 (26), \n293 (19), 161 (87), 133 \n(47), 89 (21). 37 \n180 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.47 \n(s, 1H, H-4), 8.12 (d, J = 15.8 Hz, 1H, \nH\u03b2 ), 7.85 (d, J = 15.8 Hz, 1H, H \u03b1), \n7.60 (d, J = 8.6 Hz, 1H, H-6\u2019), 7.27-\n7.06 (m, 2H, H-5, H-6, H-7), 6.49 (dd, \nJ = 8.6, 2.4 Hz, 1H, H.5\u2019), 6.41 (d, J = \n2.3 Hz, 1H, H-3\u2019), 3.95 (s, 3H, OCH3), \n3.86 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). m/z (%): 367 ([M+1]+\n+, 33), \n366 ([M]+\n+, 95), 336 (35), \n335 (100), 203 (27), 191 (75), 148 (40), 133 (26), 89 (19), 77 (17). 68 \n181 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.46 \n(s, 1H, H-4), 8.16 (d, J = 15.8 Hz, 1H, \nH\u03b2), 7.78 (d, J = 15.8 Hz, 1H, H \u03b1), \n7.29-7.04 (m, 4H, H-5, H-6, H-7, H-6\u2019), \n6.46 (s, 1H, H-3\u2019), 3.95 (s, 3H, OCH3), \n3.90 (s, 3H, OCH3), 3.86 (s, 6H, 2x \nOCH3). m/z (%): 397 ([M+1]+\n+, 26), \n396 ([M]+\n+, 71), 366 (45), \n365 (100), 221 (20), 203 \n(33). 71 O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\n280Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 281  \nCompuesto NMR MS Rdto. (%) \n182 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.51 \n(s, 1H, H-4), 8.18 (d, J = 15.8 Hz, 1H, \nH\u03b2), 7.93 (d, J = 15.9 Hz, 1H, H \u03b1), \n7.28-7.14 (m, 4H, H-5, H-6, H-7, H-6\u2019), \n6.95 (dd, J = 9.0, 2.9 Hz, 1H, H-4\u2019), \n6.86 (d, J  = 9.0 Hz, 1H, H-3\u2019), 3.99 (s, \n3H, OCH3), 3.87 (s, 3H, OCH3), 3.81 (s, \n3H, OCH3). m/z (%): 397 ([M+1]+\n+, 16), \n396 ([M]+\n+, 55), 336 (57), \n335 (100), 176 (39), 161 (18), 133 (20). 59 \n183 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 8.53 \n(s, 1H, H-4), 7.88 (d, J = 15.7 Hz, 1H, \nH\u03b2), 7.75 (d, J = 15.7 Hz, 1H, H \u03b1), \n7.33-7.09 (m, 3H, H-5, H-6, H-7), 6.79 \n(d, J = 2.3 Hz, 2H, H-2\u2019, H-6\u2019), 6.51 (t, \nJ = 2.3 Hz, 1H, H-4\u2019), 3.98 (s, 3H, 8-\nOCH3), 3.82 (s, 6H, 2x OCH3). m/z (%): 367 ([M+1]+\n+, 19), \n366 ([M]+\n+, 83), 338 (29), \n337 (60), 323 (29), 322 \n(65), 321 (100), 203 (30), 148 (53), 89 (23), 77 (18). 37 \n185 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.71 (s, 1H), 8.68 (dd, J = 4.9, 1.7 Hz, \n1H), 8.06 (d, J = 15.7 Hz, 1H), 7.96 \n(dd, J = 7.7, 1.6 Hz, 1H), 7.88 (td, J = \n7.5, 1.7 Hz, 1H), 7.81-7.68 (m, 3H), 7.53-7.38 (m, 3H). m/z (%): 278 ([M+1]\n+\n+, 26), \n277 ([M]+\n+, 77), 249 (21), \n248 (48), 221 (54), 220 \n(100), 173 (29), 132 (65), \n104 (53), 89 (30), 78 (50), 63 (21). 72 \n186 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n8.52 (s, 1H), 8.13-7.93 (m, 2H), 7.85-7.57 (m, 3H), 7.50 (t, J = 6.3 Hz, 2H), \n7.36 (d, J = 15.8 Hz, 1H). m/z (%): 318 ([M+2]\n+\n+, 16), \n316 ([M]+\n+, 36), 288 (79), \n287 (52), 260 (67), 137 (100), 109 (82), 65 (42). 65 \n \n   O OO\nR6\nR8R2' R4'\nR3'R5'R6'\nOHet\nOO\nR6\nR8\n281Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 282Tabla 10. Caracterizaci\u00f3n de 3-ci namoil-4-hidroxicumarinas no publicadas. \n  \nCompuesto NMR MS Rdto. (%) \n187 1H-NMR (250 MHz, DMSO- d6) \u03b4 \nppm 8.23 (d, J = 14.5 Hz, 1H), \n8.07-7.91 (m, 2H ), 7.85-7.66 (m, \n3H), 7.53-7.33 (m, 5H).  m/z (%): 293 ([M+1]+\n+, 20), \n292 ([M]+\n+, 89), 291 (72), 290 \n(21), 289 (34), 272 (20), 247 \n(30), 215 (100), 171 (42), 144 (32), 121 (55), 103 (67), 77 (43). 75 \n189 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.41 (d, J  = 15.8 Hz, 1H), 8.09 (dd, \nJ = 7.9, 1.7 Hz, 1H), 7.98 (d, J  = \n15.7 Hz, 1H), 7.74-7.58 (m, 3H), 7.44-7.24 (m, 4H). m/z (%): 328 ([M+2]\n+\n+, 53), \n326 ([M]+\n+, 97), 281 (20), 216 \n(100), 205 (36), 178 (30), 167 (34), 165 (92), 139 (21), 138 (21), 137 (50), 121 (93), 102 (42), 101 (46), 92 (22), 57 (25). 83 \n190 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.41 (d, J  = 15.7 Hz, 1H), 8.15-\n7.96 (m, 2H), 7.75 -7.54 (m, 3H), \n7.40-7.16 (m, 4H), 2.40 (s, 3H). m/z (%): 307 ([M+1]+\n+, 22), \n306 ([M]+\n+, 100), 305 (50), 215 \n(43), 189 (20), 185 (37), 158 (31), 145 (43), 121 (34), 117 (26), 115 (23). 79 \n191 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.43 (s, 2H), 8.09 (dd, J  = 7.7, 1.7 \nHz, 1H), 7.80-7.59 (m, 2H), 7.39-7.21 (m, 3H), 6.56 (dd, J = 8.7, 2.3 \nHz, 1H), 6.45 (d, J = 2.3 Hz, 1H), \n3.93 (s, 3H), 3.87 (s, 3H). m/z (%): 353 ([M+1]\n+\n+, 20), \n352 ([M]+\n+, 100), 321 (31), 191 \n(33), 149 (41), 121 (50), 92 (21), 77 (16). 82 \n192 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.49 (d, J = 15.7 Hz, 1H), 8.34 (d, J \n= 15.7 Hz, 1H), 8.08 (dd, J = 7.9, \n1.7 Hz, 1H), 7.66 (ddd, J = 8.8, \n7.4, 1.7 Hz, 1H), 7.38-7.14 (m, 3H), \n6.48 (s, 1H), 3.95 (s, 3H), 3.94 (s, \n3H), 3.92 (s, 3H). m/z (%): 382 ([M]+\n+, 34), 351 \n(16), 61 (100). \n87 O OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\n282Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 283  \nCompuesto NMR MS Rdto. (%) \n193 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.75 (d, J = 15.8 Hz, 1H), 8.59 (d, J \n= 15.9 Hz, 1H), 8.07 (dd, J = 7.8, \n1.7 Hz, 1H), 7.62 (ddd, J = 8.7, \n7.3, 1.7 Hz, 1H), 7.35-7.19 (m, 2H), \n6.09 (s, 2H), 3.95 (s, 6H), 3.84 (s, 3H). m/z (%): 383 ([M]\n+\n+, 12), 382 \n([M]+\n+, 57), 380 (22), 351 (48), \n350 (69), 349 (100), 192 (21), 179 (63), 178 (34), 121 (31), 92 (21), 91 (29), 69 (27). 84 \n196 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.07 (d, J = 8.6 Hz, 1H), 7.66 (d, J \n= 15.5 Hz, 1H), 7.49 (d, J = 6.7 Hz, \n1H), 7.35-7.11 (m, 3H), 7.03 (d, J = \n3.1 Hz, 1H), 6.99-6.74 (m, 2H), 3.77 (s, 6H).  m/z (%): 352 ([M]\n+\n+, 39), 321 \n(50), 268 (21), 267 (26), 239 (30), 134 (30), 121 (26), 112 (25), 111 (21), 99 (21), 98 (58), 97 (26), 85 (54), 84 (57), 74 (33), 71 (65), 69 (33), 57 (100), 56 (25), 55 (55). \n70 \n197 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.44 (d, J = 15.7 Hz, 1H), 8.42 (d, J \n= 15.7 Hz, 1H), 8.08 (dd, J = 7.8, \n1.7 Hz, 1H), 7.67 (ddd, J = 8.7, \n7.4, 1.7 Hz, 1H), 7.41 (dd, J = 7.9, \n1.5 Hz, 1H), 7.36-7.23 (m, 2H), 7.11 (t, J  = 8.0 Hz, 1H), 6.99 (dd, J \n= 8.1, 1.5 Hz, 1H), 3.93 (d, J = 1.2 \nHz, 3H), 3.89 (s, 3H). m/z (%): 352 ([M]\n+\n+, 24), 322 \n(28), 321 (100), 319 (23), 121 (24).  \n68 \n199 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.52 (d, J = 15.9 Hz, 1H), 8.44 (d, J \n= 15.9 Hz, 1H), 8.09 (dd, J = 7.9, \n1.7 Hz, 1H), 7.76 (dd, J = 7.7, 1.7 \nHz, 1H), 7.67 (ddd, J = 8.3, 7.4, \n1.7 Hz, 1H), 7.45-7.23 (m, 3H), 7.07-6.89 (m, 2H), 3.94 (s, 3H). m/z (%): 323 ([M+1]\n+\n+, 15), \n322 ([M]+\n+, 100), 291 (75), 215 \n(33), 204 (19), 189 (26), 161 (49), 121 (50), 105 (24), 96 (28), 95 (24), 77 (30), 69 (52).  64 O OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\n283Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 284  \nCompuesto NMR MS Rdto. (%) \n200 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.43 (d, J = 16.3 Hz, 1H), 8.10 (d, J \n= 7.9 Hz, 1H), 8.03 (d, J = 16.1 Hz, \n1H), 7.69 (t, J  = 8.0 Hz, 1H), 7.43-\n7.18 (m, 5H), 7.05 -6.94 (m, 1H), \n3.87 (s, 3H). m/z (%): 323 ([M+1]+\n+, 19), \n322 ([M]+\n+, 97), 321 (40), 304 \n(26), 278 (49), 277 (82),  215 \n(80), 204 (25), 202 (70),  201 (94), 200 (33), 189 (29), 174 (77), 162 (22), 161 (100), 133 (43), 121 (93), 120 (30), 118 (41), 92 (38), 90 (26), 89 (20), 77 (40), 65 (22). 55 \n202 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.39 (d, J  = 15.6 Hz, 1H), 8.09 (dd, \nJ = 7.9, 1.7 Hz, 1H), 7.97 (d, J  = \n15.7 Hz, 1H), 7.69 (td, J = 8.5, 7.9, \n1.7 Hz, 1H), 7.39-7.27 (m, 2H), 6.84 (d, J  = 2.3 Hz, 2H), 6.55 (t, J = \n2.2 Hz, 1H), 3.84 (s, 6H). m/z (%): 353 ([M+1]\n+\n+, 19), \n352 ([M]+\n+, 92), 308 (43), 307 \n(78), 232 (44), 231 (62), 230 (21), 215 (32), 205 (100), 191 (34), 189 (44), 176 (25), 165 (27), 148 (34), 121 (79), 120 (39), 77 (22).  79 \n204 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.81-8.66 (m, 2H), 8.10 (dd, J = \n8.1, 1.7 Hz, 1H), 8.03 (d, J = 15.6 \nHz, 1H), 7.83-7.62 (m, 3H), 7.41-7.21 (m, 3H). m/z (%): 294 ([M+1]\n+\n+, 18), \n293 ([M]+\n+, 100), 291 (38), 264 \n(27), 215 (33), 145 (55), 132 (39), 121 (26), 120 (37), 117 (26), 104 (42), 92 (31), 78 (34). 63 \n206 1H-NMR (250 MHz, DMSO- d6) \u03b4 \nppm 8.31 (s, 1H), 8.08-7.93 (m, 3H), 7.88-7.73 (m, 2H), 7.48-7.35 (m, 2H), 6.88 (d, J  = 2.0 Hz, 1H). m/z (%): 283 ([M+1]\n+\n+, 13) 282 \n([M]+\n+, 48), 254 (65), 239 (27), \n134 (23), 121 (100), 120 (20), 97 (27), 93 (33), 92 (21), 85 (33), 71 (42), 65 (31). 56 \n \n \n O OO\nR2' R4'\nR3'R5'R6' OH\nOHet\nOO OH\n284Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 285Tabla 11. Caracterizaci\u00f3n de 3-(3-ari l-3-oxo-propenil)-4-clorocum arinas no publicadas. \n \n \nCompuesto NMR MS Rendimiento \n(%) \n207 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.60 (d, J  = 15.5 Hz, 1H), 8.20-7.97 \n(m, 4H), 7.72-7.23 (m, 7H). \n m/z (%):  312 ([M+2]+\n+, \n12) 310 ([M]+\n+, 30), 207 \n(34), 205 (100), 187 (15), 105 (41), 77 (30). 62 \n208 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.59 (d, J  = 15.4 Hz, 1H), 8.17-8.04 \n(m, 3H), 8.00 (d, J = 9.5 Hz, 1H), \n7.65 (ddd, J = 8.9, 7.3, 1.6 Hz, 1H), \n7.40 (td, J  = 7.6, 1.1 Hz, 2H), 6.98 \n(d, J = 9.0 Hz, 2H), 3.89 (s, 3H). m/z (%):  326 ([M+2]+\n+, \n10) 324 ([M]+\n+, 29), 289 \n(51), 207 (41), 205 (100), 119 (28), 91 (26). 68 \n209 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.58 (d, J = 15.4 Hz, 1H), 8.10 (d, J \n= 15.4 Hz, 1H), 8.00 (d, J = 8.3 Hz, \n3H), 7.65 (ddd, J = 8.8, 7.3, 1.5 Hz, \n1H), 7.45-7.24 (m, 4H), 2.43 (s, 3H). m/z (%): 342 ([M+2]+\n+, 7) \n340 ([M]+\n+, 18), 305 (57), \n207 (36), 205 (100), 135 (74), 77 (14). 71 \n210 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.59 (dd, J = 15.7, 1.8 Hz, 1H), 8.37 \n(dd, J = 8.8, 2.0 Hz, 2H), 8.29-8.11 \n(m, 3H), 8.04 (dd, J = 8.0, 1.7 Hz, \n1H), 7.70 (td, J = 7.8, 1.6 Hz, 1H), \n7.43 (t, J = 8.3 Hz, 2H). m/z (%): 357 ([M+2]+\n+, 9) \n355 ([M]+\n+, 23), 321 (25), \n320 (93), 274 (28), 207 (96), 205 (100), 149 (27), \n76 (22). 54 \n211 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.57 (d, J = 15.4 Hz, 1H, H \u03b2), 8.12 \n(d, J = 15.4 Hz, 1H \u03b1), 8.01 (d, J = \n7.2 Hz, 1H, H-5), 7.77-7.54 (m, 3H), \n7.48-7.33 (m, 3H), 7.15 (dd, J = 8.2, \n2.7 Hz, 1H), 3.89 (s, 3H, OCH3). m/z (%): 342 ([M+2]+\n+, 5), \n340 ([M]+\n+, 15), 306 (20), \n305 (56), 207 (47), 205 (100), 135 (42), 77 (17) 47 O OCl O\nR2' R4'R5'\nR3'\n285Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 286 \nCompuesto NMR MS Rendimiento \n(%) \n213 1H-NMR (250 MHz, CDCl3) \u03b4 ppm \n8.44 (d, J  = 15.5 Hz, 1H), 8.09-7.90 \n(m, 2H), 7.63 (ddd, J  = 7.2, 5.5, 3.3 \nHz, 1H), 7.49-7.31 (m, 2H), 7.31-\n7.19 (m, 1H), 7.13 -7.00 (m, 1H), \n7.00-6.88 (m, 1H), 3.91 (s, 3H), 3.82 (s, 3H). m/z (%): 372 ([M+2]\n+\n+, 9) \n375 ([M]+\n+, 23), 335 (21), \n207 (16), 205 (48), 165 (100). 62 \n \nTabla 12. Caracterizaci\u00f3n de 8-cinamoil cumarinas no publicadas.  \n \n \nCompuesto NMR MS Rdto.(%) \n215 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 14.30 \n(s, 1H), 8.25 (d, J = 15.5 Hz, 1H), 8.08 (d, \nJ = 15.5 Hz, 1H), 7.58 -7.39 (m, 2H), 7.32 \n(d, J = 8.7 Hz, 1H), 6.75 (d, J  = 8.7 Hz, \n1H), 6.40 (dd, J = 8.6, 2.4 Hz, 1H), 6.32 \n(d, J = 2.4 Hz, 1H), 6.11 (d, J  = 9.5 Hz, \n1H), 3.82 (s, 3H), 3.70 (s, 3H). m/z (%): 353 ([M+1]+\n+, \n14), 352 ([M]+\n+, 100), \n321 (45), 191 (52), 149 (29), 121 (63), 92 (19), 77 (12). 95 \n217 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm \n11.54 (s, 1H), 7.98 (d, J = 9.6 Hz, 1H), \n7.81 (d, J = 16.1 Hz, 1H), 7.63 (d, J = 8.6 \nHz, 1H), 7.43 (d, J = 16.0 Hz, 1H), 6.91 (d, \nJ = 8.6 Hz, 1H), 6.36-6.16 (m, 3H), 3.81 \n(s, 9H). m/z (%): 383 ([M+1]+\n+, \n24), 382 ([M+1]+\n+, 84), \n352 (30), 351 (100), 349 (39), 194 (31), 191 (15), 189 (15), 181 (27), 179 (56), 168 (16). 93 O OCl O\nR2' R4'R5'\nR3'\nO HO O\nO\nR2'\nR3'R4'R5'R6'\nO HO O\nO Het\n286Parte Experimental                                                               2. Compuestos bajo estudio  \n \n 287 \n \nCompuesto NMR MS Rdto.(%) \n218 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 14.30 \n(s, 1H, OH), 8.29 (d, J  = 15.3 Hz, 1H, H \u03b2), \n7.92 (d, J = 15.3 Hz, 1H, H \u03b1), 7.65 (d, J  = \n9.5 Hz, 1H, H-4), 7.50 (d, J = 8.7 Hz, 1H, \nH-5), 7.38 (d, J = 2.0 Hz, 1H, H-6\u2019), 7.22 \n(d, J = 2.0 Hz, 1H, H-2), 6.90 (m, 2H, H-\n5\u2019, H-6), 6.26 (d, J = 9.6 Hz, 1H, H-3), \n4.00 (s, 3H, 4\u2019-OCH3), 3.93 (s, 3H, 3\u2019-\nOCH3). m/z (%): 353 ([M+1]+\n+, \n81), 352 ([M]+\n+, 100), \n292 (53), 291 (100), \n191 (27), 161 (32), 148 (17), 89 (30), 69 (18). 81 \n221 1H-NMR (250 MHz, DMSO- d6) \u03b4 ppm 8.53 \n(s, 1H), 8.30-8.14 (m, 2H), 7.97 (d, J = 9.3 \nHz, 1H), 7.78-7.49 (m, 3H), 7.35 (d, J = \n16.4 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), \n6.22 (d, J = 9.7 Hz, 1H). m/z (%): 338 ([M+1]+\n+, \n17), 337 ([M]+\n+, 49), \n291 (100), 274 (62), 176 (34) 161 (23). 63 \n222 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 13.94 \n(s, 1H), 8.34 (d, J = 15.8 Hz, 1H), 8.25 (d, \nJ = 15.7 Hz, 1H), 7.65 (dd, J = 9.6, 2.6 \nHz, 1H), 7.56-7.36 (m , 2H), 7.22-7.05 (m, \n1H), 7.05-6.83 (m, 2H), 6.28 (dd, J = 9.5, \n2.6 Hz, 1H), 3.93 (s, 3H), 3.89 (s, 3H). m/z (%): 352 ([M+1]+\n+, \n18), 322 ([M]+\n+, 100), \n321 (35), 319 (21), 121 (42) 92 (25), 77 (18). 85 \n223 1H-NMR (250 MHz, CDCl3) \u03b4 ppm 14.04 \n(s, 1H), 8.32 (d, J = 15.3 Hz, 1H), 7.84 (d, \nJ = 15.4 Hz, 1H), 7.65 (d, J = 9.5 Hz, 1H), \n7.51 (d, J = 8.7 Hz, 1H), 6.99-6.74 (m, \n3H), 6.52 (t, J = 2.2 Hz, 1H), 6.27 (d, J = \n9.6 Hz, 1H), 3.86 (s, 6H). m/z (%): 353 ([M+1]+\n+, \n27), 352 ([M]+\n+, 100), \n351 (33), 350 (16), 335 (19), 334 (51), 321 (33), 319 (24), 164 (53), 98 (17). 90 O HO O\nO\nR2'\nR3'R4'R5'R6'\nO HO O\nO Het\n287 \n \n  Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n 289\u0004\u001a\u0019\u000f\u0017\u001f\u001d\u0014\u001a\u0019\u0011\u001d \u0001\n \n \u2022 Se han desarrollado y puesto a punto m\u00faltiples metodolog\u00edas sint\u00e9ticas \npara la preparaci\u00f3n de forma sencilla, r\u00e1pida y vers\u00e1til de las series de \ncompuestos h\u00edbridos seleccionadas. Todos los compuestos h\u00edbridos contienen \ncomo n\u00facleo principal el es queleto de cumari na, al que se le incorporan los \nfarmac\u00f3foros derivados de estilbenos (3-a rilcumarinas) o de chalconas (\u201cendo\u201d \ncumarina-chalcona y \u201cexo\u201d cumarina-chalconas), obteni\u00e9ndose una amplia \nquimioteca que ha sido comple tamente caracterizada.  \n\u2022 Se han obtenido series de compuestos  con sustituyentes de distinta \nnaturaleza, en diferente n\u00fam ero y en distintas posiciones de los esqueletos que \nnos han permitido realizar estudios de la relaci\u00f3n estructura-actividad sobre \naquellas dianas estudiadas. \n\u2022 Las 3-arilcumarinas estudiadas resultaron ser excelentes inhibidores \nselectivos de la MAO-B (en co ncreto, 6-bromo- 8-metoxi-3-(4\u2019-\nmetoxifenil)cumarina, IC\n50 = 1.35 nM), mientras que las 3-benzoilcumarinas \npresentaban una moderada pero select iva actividad frente a MAO-A (en \nconcreto, 6-bromo-8- hidroxi-3-(4\u2019-hidroxibenzoil)cumarina, IC50 =19.17 \u03bcM). \n\u2022 Los compuestos h\u00edbridos hidroxilados mostraron una muy buena actividad \nantioxidante, con excelentes valores de ORAC, buena capacidad para atrapar \nradicales, bajos poten ciales de oxidaci\u00f3n, baja cito toxicidad y elevados valores \nde citoprotecci\u00f3n. En part icular, la 6-hidroxi-3-(4 \u2019-hidroxibenzoil)cumarina \nresult\u00f3 ser el compuesto m\u00e1s prometedor  de la serie estudiada con un ORAC \nde 14.1 y un 100% de viabilidad celular en BAEC.  \n\u2022 Los h\u00edbridos \u201cexo\u201d cumarina-chalcona presentaron buena afinidad como \nligandos de uno o varios receptores de adenosina. En concreto, el compuesto \n(E)-3-(3-(tiofen-3-il)acriloil)cumarina presen t\u00f3 la mejor actividad y selectividad \n(hA3 = 5.16 \u03bcM) siendo clave la sustituci\u00f3n de l anillo B de la chalcona por un \ngrupo tiofeno. \n\u2022 Los compuestos estudiados presentaron moderadas actividades \nantibacterianas frente a un gran n\u00famero de pat\u00f3genos humanos y excelentes \n289Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n290 frente a otros de origen marino. En particular, los derivados aminados de las 3-\nbenzoilcumarinas resultaron ser tan activos frente al pat\u00f3geno marino \nTenacibaculum maritimum  como los actuales f\u00e1rmaco s empleados, sin afectar \na las cepas bacterianas humanas estudiadas. \n\u2022 Se ha desarrollado una nueva metodolog\u00eda sint\u00e9tica que permite llevar a \ncabo la reacci\u00f3n de ciclaci\u00f3n de Nazarov de dienonas completamente \nsustituidas de forma diastereoespec\u00edfi ca, generando estereocentros vecinales \ncon todos los \u00e1tomos de carbono cuater narios. Dicha metodolog\u00eda sint\u00e9tica \npresenta una gran aplicaci\u00f3n pa ra la s\u00edntesis total de compuestos derivados de \nproductos naturales de estructura oxac\u00edclica. \u2022 El car\u00e1cter multidisciplinar de este tra bajo deja patente la importancia y la \nnecesidad de la colaboraci\u00f3n entre grupos de distintas \u00e1reas. Sin estas \ncolaboraciones, los resultados y conclusio nes de este trabajo no hubiesen sido \nposibles. \n  \n  \n290Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n 291\u0004\u001a\u0019\u000f\u0017\u001f\u001d\u0014\u001a\u0019\u001d\u0001\n \n \u2022 Multiple synthetic methodologies have been developed and tuned up in \norder to prepare hybrid compounds series  in a simple, fast and versatile way. \nAll the hybrid compounds contain the coumarin scaffold as the main nucleus. \nStilbene (3-arylcoumarin) and chalcone (\u201c endo\u201d and \u201cexo\u201d coumarin-chalcones) \npharmacophores have been i ncorporated into the coum arin core, obtaining a \nbroad compound library  fully characterized.  \n\u2022 Series of compounds with a wide vari ety of substituents of different nature \nnumber and in various positions of the scaffolds have been obtained. This \nallowed us to conduct a study of t he structure-activity relationship on the \nconsidered targets. \n\u2022 The studied 3-arylcoumarins were found  to be excellent selective MAO-B \ninhibitors (in particular, 6-bromo-8- methoxy-3-(4\u2019-methoxyphenyl)coumarin, IC\n50 \n= 1.35 nM), while the 3-benzoulcoumarins showed a moderated but selective \nMAO-A inhibitory activity (in particular, 6-bromo-8-hydroxy-3-(4\u2019-hydroxybenzoyl)coumarin, IC\n50 =19.17 \u03bcM). \n\u2022 The hydroxylated hybrid compounds s howed very good antioxidant activity, \npresenting excellent ORAC values, good scavenging capacity, low oxidation potential, low cytotoxicity and high cito protective properties. In particular, 6-\nhydroxy-3-(4\u2019-hydroxybenzoyl)coumarin  was the most promising compound, \nwith an ORAC value of 14.1 an d 100% of cell viability in BAEC. \n\u2022 The \"exo\" coumarin-chalcone hybrids showed good affinity as ligands for \none or more adenosine receptors. Specifically, compound ( E)-3-(3-(thiophen-3-\nyl)acryloyl)coumarin presented the best activity and selectivity (h A\n3 = 5.16 mM) \nbeing essential the substitution of  the chalcone ring B by a thiophene. \n\u2022 Some of the studied compounds showed  moderated antibacterial activities \nagainst human pathogens pathogens and some others excellent activities \nagainst marine origin pathogens. In particular, amino-3-benzoylcoumarin derivatives proved to be as active as the current drugs used against the marine \npathogen Tenacibaculum maritimum , with no effect on human bacteria strains. \n291Tesis Doctoral 2014                                                                Saleta V\u00e1zquez Rodr\u00edguez  \n \n292 \u2022 A new synthetic methodology to carry out the diastereospecific Nazarov \ncyclization of fully substituted dienones has been developed, generating vicinal \nall-carbon-atom quaternary stereocentres.  This synthetic methodology has a \nbroad application for the total synt hesis of oxacyclic natural products \nderivatives. \n\u2022 The multidisciplinary nature of this work makes clear the importance and \nnecessity of collaboration between groups from different areas. Without these \ncontributions, the result s and conclusions of this work would not have been \npossible.    \n292Bibliograf\u00eda \n \n 293\u0003\u0014\u000e\u0017\u0014\u001a\u0013\u001c\r\u0012$\r\u0001\n\n\u0011\u0012\u0011\u001c\u0011\u0019\u000f\u0011\u001d\u0001\n \n  \n293 \n \n \n Bibliograf\u00eda \n \n295  \n                                                \n1Hamilton, G.R.; Baskett, T.F. Can. J. Anaesth.  22000, 47, 367. \n2 Somberg, J.C. The Evolvi ng Drug Discovery Process, The Drug Discovery Process: \nIncreasing Efficiency and Cost  Effectiveness. In: Wellington, P.G.; Lasagna, L.; Banakar, \nU.V.; Dekker, M. (E ds), New York, 1 1996. \n3 Pizzi, R. Salving with Science. The Pharmaceut ical Century: Ten Decades of Drug \nDiscovery Supplement to Am erican Chemical Society 2 2000. \n4 Tsinopoulos, C.; McCarthy, I. An Evolutionary Classification of the Strategies for Drug \nDiscovery. Manufacturing Complexity Network C onference; Cambridge, 2 2002. \n5 Li, J.W.H.; Vederas, J.C. Science 2 2009, 325, 161.  \n6 Harvey, A.L. Drug Discov. Today  22008, 13, 894. \n7 Mishra, B.B.; Tiwari, V.K. Eur. J. Med. Chem.  22011, 46, 4769. \n8 Hedge, S.; Carter, J. Ann. Rep. Med. Chem.  22006, 41, 473. \n9 Ribeiro, N.; Thuaud, F.; Nebigil, C.; Desaubry, L. Bioorg. Med. Chem.  22012, 20, 1857 \n10 Polier, G.; Neumann, J.; Thuaud, F.; Ribeiro, N.; Gelhaus,  C.; Schmidt, H.; Giaisi, M.; \nKoehler, R.; Mueller, W.W.; Proksch, P. Chem. Biol. 2 2012, 19, 1093.  \n11 IUPAC, Nomenclature of Organi c Chemistry, Pergamon Press 1 1979. \n12 Soine, T.O. J. Pharm. Sci.  11964, 53, 231. \n13 Vogel, A. Annalen Der Physik , 11820, 64, 161. \n14 Murray, R.D.H.; Mendez, J.; Brown, S. A. The natural coum arins. Occurrence, \nchemistry and biochemistry, John Wiley and Sons: Chichester, 1 1982. \n15 Accame, M. Panorama Actual Med.  22000, 24, 432. \n16 Borges, F.; Roleira, F.; Milhaz es, N.; Uriarte, E.; Santana, L. Front. Med. Chem.  \n2009 , 4, 23. \n17 Santana, L.; Uriarte, E.; Roleira,  F.; Milhazes, N.; Borges, F. Curr. Med. Chem.  22004, \n11, 3239. \n18 Riveiro, M.E.; De Kimpe, N.; Moglioni, A .; V\u00e1zquez, R.; Monczor, F.; Shayo, C.; Davio, \nC. Curr. Med. Chem. 2010 , 17, 1325. \n19 Marchi, A.; Castilho, M.; Nascimento, P.; Archanjo, F.; Del Ponte, G.; Oliva, G.; Pupo, \nM. Bioorg. Med. Chem. Lett. 2004 , 12, 4823. \n20 Moskvina, V.S.; Khilya, V.P. Chem. Nat. Comp. 2 2008, 44, 16. \n21 Singh, P.R.; Singh, De V.U.; Samant, S.D. Synlett 22004, 11, 1909. \n22 Quezada, E.; Delogu, G.; Vi\u00f1a, D.; Santan a, L.; Podda, G.; Matos, M.J.; Picciau, C. \nHelvetica Chimica Acta  22009, 92, 1309. \n23 Brady, W.T.; Shieh, C.H. J. Heterocycl. Chem. 1 1984, 21, 1337. \n24 Sabitha, G.; Rao, A.V. Syn. Commun.  11987, 17, 341. \n295Bibliograf\u00eda \n \n296                                                                                                                            \n25 Johnson, J.R. Org. React.  11942, 1, 210. \n26 Von Pechmann H.; Duisberg, C. Ber. Dtsch. Chem. Ges.  11884, 17, 929. \n27 Brufola, G.; Fringuelli, F .; Piermatti O.; Pizzo, F. Heterocycles  11996, 43, 1257. \n28 Yavari, I.; Hekmat-S hoar R.; Zonouzi, A. Tetrahedron Lett.  11998, 39, 2391. \n29 Shirner, R.L. Org. React.  11942, 1, 1. \n30 Roman, J.; Kozhkov, V.; Larock, R.C. J. Org. Chem.  22003, 68, 6314. \n31 Pankajkumar, R.S.; Devendraprat ap, U.S.; Shriniwas, D.S. Synlett 2004 , 11, 1909. \n32 Li, T.S.; Zhang, Z.H.; Yang F.; Fu, C.G. J. Chem. Res. (S) , 11998, 38. \n33 Sethna, S.M.; Shah, N.M. Chem. Rev.  11945, 36,1. \n34 Dong, F.; Jian, C.; Kai, G.; Qunrong, S.; Zuliang, L. Catal. Lett.  22008, 121, 255. \n35 John, E.; Israelstam, S. J. Org. Chem.  11961, 26, 240. \n36 Bose, D.S.; Rudradas, A.; Babu, M. H. Tetrahedron Lett.  22002, 43, 9195. \n37 Robertson, A.; Waters, R.B.; Jones, E.T. J. Chem. Soc. 1932 , 1681. \n38 Tyagi, B.; Mishra, M.K.; Jasra, R.V. J. Mol. Catal.  A 22007, 276, 47. \n39 Woods, L.L.; Sapp, J.A. J. Org. Chem.  11962, 27, 3703. \n40 Torviso, R.; Mansillo, D.; Beliz \u00e1n, A.; Alesso, E.; Moltrasio, G.; V\u00e1zquez, P.; Pizzio, L.; \nBlanco, M.; Cres, C. Appl. Catal. A  22008, 339, 53. \n41 Calvino-Casilda, V.; B anares, M.; Lozano-Diz, E. Catal. Today  22010, 155, 279. \n42 Guo, X.; Yu, R.; Li, H.; Li, Z. J. Am. Chem. Soc.  22009, 131, 17387. \n43 Laue, T.; Plagens, A. Named Organic Chemis try, John Wiley &Sons Ltd., Wolfsburg, \nGermany, 2 2005. \n44 Knoevenagel, E. Ber. Dtsch. Chem. Ges.  11894, 27, 2345. \n45 Jones, G. Org. React.  11967, 15, 204. \n46 Smith, B.; March, J. Mar ch\u2019s Advanced Organic Chemistr y, John Wiley & Sons Ltd, \nNew York, USA, 2 2001.  \n47 Valizadeh, H.; Mamaghani , M.; Badrian, A. Synth. Commun.  22005, 35, 785. \n48 Valizadeh, H.; Shockravi, A. Heterocyclic Commun. 2 2004, 10, 475. \n49 Sheng, S.R.; Huang, P.G.; Wang, Q.; Huang , R.; Liu, X.L. Synth. Commun. 2 2006, \n36, 3175. \n50 Doebner, O. Ber. Dtsch. Chem. Ges.  11900, 33, 2140. \n51 Mundy, B.P.; Ellerd, M. G.; Favarolo Jr., F.G. Name Reactions and Reagents in \nOrganic Synthesis, 2nd Ed, Wiley-Interscience, New Jersey, 2 2005, 212. \n52 Henry, L. Compt. Rend.  11895, 120, 1265. \n53 Luzzio, F.A. Tetrahedron  22001, 57, 915. \n54 Kamlet, J. US Patent 2.151.171 , 11931. \n55 Trkovnik, M.; Ivezi\u00e9, Z. J. Heterocyclic Chem. 2 2000, 37, 137. \n296Bibliograf\u00eda \n \n297                                                                                                                            \n56 Xiang Z.; Xiao-Bing W.; Tao W.; Ling-Yi K. Bioorg. Med. Chem. , 22008, 16, 8011. \n57 Robert, S.; Bertolla, C.; Masereel, B.; D ogne, J-M.; Pochet, L. J. Med.Chem.  22008, \n51, 3077. \n58 Pochet, L.; Doucet, C.; Dive, G.; Wouter s, J.; Massereel, B.; Reboud-Ravaux, M.; \nPirotte, B. Bioorg. Med. Chem.  22000, 8, 1489. \n59 Sugino T, Tanaka K. Chem. Lett.  22001, 30, 110. \n60 Chizhov, D.L.; Sosnovskikh, V.Y.; Pryade ina, M.V.; Burgart, Y.V.; Saloutin, V.I.; \nCharushin, V.N.; Postovsky, I.Y. Synlett  22008, 2, 281. \n61 Seema; Kumar, S .; Makrandi, J.K. Indian J. Chem., Section B:  Org. Chem. Incl. Med. \nChem.  22005, 44B , 1307. \n62 Reddy, N.S.; Mallireddigari, M.R.; Cosenza, S.; Gumireddy, K. Bioorg. Med. Chem. \nLett. 2 2004, 14, 4093. \n63 Hill, B.; Liu, Y.; Taylor, S.D. Org. Lett.  22004, 6, 4285. \n64 Alonso, M.T.; Brunet, E.; Hernand ez, C.; Rodr\u00edguez-Ubis, J.C. Tetrahedron Lett.  \n1993 , 34, 7465. \n65 Zakehi, A.; Ito, S.; Suga, H .; Yasuraoka, K. Ho, J.Z. Heterocycles  22001, 54, 185. \n66 Stanchev, S.; Momekov, G .; Jensen, F.; Manolov, I. Eur. J. Med. Chem.  22008, 43, \n694. \n67 Kudale, A.A.; Kendall, J.; Warford, C.C.; Wilkins, N.D.; Bodwell, G.J. Tetrahedron \nLett. 2 2007, 48, 5077.  \n68 Reddy, N.S.; Gumireddy, K.; Mallireddigari, M.R.; Cosenza, S.C.; Venkatapuram, P.; \nBell, S.C.; Reddy, E.P.; Reddy, M.V.R. Bioorg. Med. Chem.  22005, 13, 3141. \n69 Heravi, M.; Hekmatshoar,  R.; Emamgholizadeh, M. Sulfur Silicon Relat. Elem.  22004, \n179, 1893. \n70 Khilya, O.V.; Frasinyuk, M. S.; Turov, A.V.; Khilya, V.P. Chem. Heterocyclic Comp.  \n2001 , 37, 1029. \n71 Bigi, F.; Chesini, L .; Maggi, R.; Sartori, G. J. Org. Chem.  11999, 64, 1033. \n72 Saha, N.N.; Desai, V. N.; Dhavale, D.D.A. J. Org. Chem.  11999, 64, 1715.  \n73 Garino, C.; Tomita, T.; Pietranc osta, N.; Laras, Y.; Rosas, R. J. Med. Chem.  22006, \n49, 4275.  \n74 Rouessac, F.; Leclerc, A. Synth. Commun.  11993, 23, 1147. \n75 Watson, B.T.; Christiansen, G.E. Tetrahedron Lett.  11998, 39, 6087.  \n76 Hirai, T.; Togo, H. Synthesis  22005, 16, 2664.   \n77 Felf\u00f6ldi, K.; Sutyinszky, M.; Nagy, N.; P\u00e1link\u00f3, I. Synth. Commun.  22000, 30, 1543. \n78 Ganguly, N.; Sukai, A.K.; De, S. Synth. Commun.  22001, 31, 301.  \n297Bibliograf\u00eda \n \n298                                                                                                                            \n79 Anjaneyulu, A.S.R.; Su dharani, G.; Mallavadhani, U.V.; Murthy, Y.L.N. Indian J. Chem.  \n1991 , 30B , 707. \n80 Cairns, N.; Harwood, L.M.; Astles, D.P. Tetrahedron  11992, 48, 7581. \n81 Ravi\u00f1a, E. The evolution of  drug discovery. From traditional medicines to modern \ndrugs. Wiley-VCH (Eds), Germany, 2 2011. \n82 Campos-Toimil, M.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med. Chem.  22002, 12, \n783. \n83 Kostova, I.; Bhatia, S.; Grigorov, O.; Bal kansky, S.; Parmar, V.S .; Prasad, A.K.; Saso, \nL. Curr. Med. Chem.  22011, 18, 3929. \n84 Rambabu, D.; Mulakayala, N.; Ismail, K .; Kumar, R.; Kumar, G.P.; Chaitanya, M. \nBioorg. Med. Chem. Lett.  22012, 22, 6745. \n85 Timonen, J.M.; Nieminen, R.M.; Sareila, O .; Vainiotalo, P.; Moilanen, E.; Aulaskari, \nP.H. Eur. J. Med. Chem.  22011, 46,  3845. \n86 Hai, X.; Xiaofan, L.; Purong , Z.; Li. L.; Chunyan, H.; Hu, Jinping, H.; Zijie, L.; Tao, M.; \nLi, Yan, L.; Chen, Z.; Liu, G. J. Med. Chem.  22010, 53, 1397. \n87 De Clercq, E. Med. Res. Rev.  22000, 20, 323. \n88 Kostova, I. Curr. HIV Res.  22006, 4, 347. \n89 Bing, L.; Ramdas, P.; Ming, D.; Aiello, D.; Barnes, M.H.; Butler, M.M.; Tashjian, T.F.; \nPeet, N.P.; Bowlin, T.L.; Moir, D.T. J. Med. Chem.  22012, 55,  10896. \n90 Belluti, F.; Perozzo, R.; Lauciello, L.; Coli zzi, F.; Kostrewa, D.; Bisi, A.; Gobbi, S.; \nRampa, A.; Bolognesi, M.L.; Recanatini, M.; Brun, R.; Scapozza, L.; Cavalli, A. J. Med. \nChem.  22013, 56,  7516 \n91 Fr\u00e9d\u00e9rick, R.; Robert, S.; Charlier, C.; Ruyc k, J.; Wouters, J.; Pirotte, B.; Masereel, \nB.; Pochet, L. J. Med. Chem.  22005, 48, 7592. \n92 Quezada, E.;  Delogu, G.; Picciau, C.; Sa ntana, L.; Podda, G.; Borges, F.; Garc\u00eda-\nMorales, V.; Vi\u00f1a D.; Orallo, F. Molecules  22010, 15, 270. \n93 Maresca, A.; Temperini, C.; Pochet, L.; Ma sereel, B.; Scozzafava, A.; Supuran, C.T. \nJ. Med. Chem.  22010, 53, 335 \n94 Chilin, A.; Battistutta, R .; Bortolato, A.; Cozza, G .; Zanatta, S.; Poletto, G.; \nMazzorana, M.; Zagotto, G; Uria rte, E.; Guiotto, A.; Pinna, L.; Meggio, F.; Moro, S. J. \nMed. Chem.  22008, 51, 752. \n95 Dall\u2019Acqua, F.; Caffieri, S. Photomed. Photobiol. 1988 , 10, 1. \n96 Dall\u2019Acqua, F. Curr. Probl. Dermatol.  11986, 15, 137. \n97 Momtaz, K.; Fitzpatrick, T.B. Dermatol. Clin. 1 1998, 16, 227. \n98 Abel, E.A. Fototerapia\u201d en Cl\u00ednicas Dermatol\u00f3gicas, Eds.: M. Lebwohl, M. Zanolli, \nInteramericana, McGraw-Hill 1 1995.  \n298Bibliograf\u00eda \n \n299                                                                                                                            \n99 Parrish, J.A.; Fitzpatrick, T.B.; Tanenbaum, L.; Pathak, M.A . N. Engl. J. Med. \nChem. 1974 , 291, 1207. \n100 Dalla Via, L.; Marciani Magno, S. Curr. Med. Chem.  22001, 8, 1405. \n101 El-Motif, A.M. J. Roy. Egyp. Med. Assoc.  11948, 31, 651. \n102 Hoerr, R.; Noeldner, M. CNS Drug Rev.  22002, 8, 143. \n103 Zhou, X.; Wang, X.; Wang , T.; Kong, L.; Xiang, T. Bioorg. Med. Chem.  22008, 16, \n8011. \n104 Seyyede, F.R.; Mehdi, K.; Hamid, N.; Amirhossein, Sa.; A lireza M.; Saeed E.; Alireza \nF.; Abbas S. Eur. J. Med. Chem.  22013, 64, 252. \n105 Preet, A.; Baldev, S.; Nirmal, S. Bioorg. Med. Chem.  22012, 20, 1175. \n106 Naoi, M.; Maruyama, W.; Inaba-Hasegawa, K. Curr. Top. Med. Chem.  22012, 12, \n2177. \n107 Patil, P.O.; Bari, S.B.; Firke, S.D.; Deshmukh, P.K.; Donda, S.T.; Patil, D.A. Bioorg. \nMed. Chem.  22013, 21,  2434.   \n108 Rendenbach-Muller, B.; Schlecker, R.; Traut, M.; Weifenbach, H. Bioorg. Med. \nChem. Lett. 1994 , 4, 1195. \n109 Machado-Vieira, R.; Mallinger, A.G. Mol. Med. Rep.  22012, 6, 915. \n110 Muller, T. Translat. Neurodeg.  22012, 1, 10. \n111 Matos, M.J.; Vi\u00f1a, D.; Quezada, E.; Picci au, C.; Delogu, G.; Or allo, F.; Santana, L.; \nUriarte, E. Bioorg. Med. Chem. Lett.  22009, 19, 3268. \n112 Kang, S.Y.; Sung, S.H.; Park, M.J.; Kim, Y.C. J. Nat. Prod.  22001, 64, 683. \n113 Choudhary, M.I.; Azizzuddi n, M.; Khalid, A.; Sultani, S.Z.; Atta-Ur-Rahman, M. Planta \nMed.  22002, 68, 81. \n114 Piazzi, L.; Cavalli, A.; Coli zzi, F.; Belluti, F.; Bartolini,  M.; Mancini, F.; Recanatini, \nM.; Andrisano, V.; Rampa, A. Bioorg. Med. Chem. Lett.  22008, 18, 423. \n115 Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; \nAndrisano, V.; Valenti, P.; Recanatini, M. J. Med. Chem.  22003, 46, 2279. \n116 Vi\u00f1a, D.; Matos, M.J.; Ya\u00f1ez, M.; Santana, L.; Uriarte, E. MedChemComm  22012, 3, \n213. \n117 Chakrabarti, S.; Sinha, M.; Thakurta, I. G.; Banerjee, P.; Chattopadhyaya, M. Curr. \nMed. Chem.  22013, 20, 4648.   \n118 Di Carlo, G.; Mascolo, N.; Izzo, A.A.; Capasso, F. Life Science  11999, 65, 337. \n119 Prashar, H.; Chawla, A.; Sharma, A.K.; Kharb, R. Int. J. Pharm. Sci. Res.  22012, 3, \n1913.  \n120 Ni, L.; Meng, C.Q.; Sikorski, J.A. Expert Opin. Ther. Pat.  22004, 14, 1669. \n121 Schr\u00f6der, J. Comprehensiv e natural products chemistry , Sankawa U (Ed.), 1 1999. \n122 Robards, K.; Prenzler, P.P.; Trucker, G.; Swatsitarg, P. Food Chem.  11999, 66, 401. \n299Bibliograf\u00eda \n \n300                                                                                                                            \n123 Dhar, D.N. Chemistry of Chalcones and Related Compounds, Wiley, New York, \n1981 . \n124 Mukaiyama, T. Org. Reactions  11982, 28, 203. \n125 Wade, L.G. Organic Chemistry. Upper Sa ddle River, New Jersey: Prentice Hall, \n2005 , 5th Ed., 1056. \n126 Mahrwald, R. Modern Aldol  Reactions, Volumes 1 and 2 . Weinheim, Germany: \nWilley-VCH Verlag GmbH & Co. KGaA, 2 2004, 1-2, 1218. \n127 Climent, M.; Corma, A.; Iborra, S.; Velty, A. J. Catal.  22004, 221, 474. \n128 Solhy, A.; Tahir, R.; Sebti, S.; Skouta, R.; Bousmina, M.; Zaho uily, M.; Larzek, M. \nAppl. Catal. A.  22010, 374, 189. \n129 Perozo-Rond\u00f3n, E.; Mart\u00edn-Aranda, R.M.; Casal, B.; Dur\u00e1n-Valle, C.J.; Lau, W.N.; \nZhang, X.F.; Yeung, K.L. Catal. Today  22006, 114, 183. \n130 Romanelli, G.; Pasquale, G.; Sathicq, \u00c1.; Thomas, H.; Autino, J.; V\u00e1zquez, P. J. Mol. \nCatal. A. Chem. 2 2011, 340, 24. \n131 Kumar, D.; Suresh Sandhu, J.S. Green Chem. Lett. Rev.  22010, 3, 283. \n132 Jayapal, M.; Sreedhar, N. J. Pharm. Sci. Res.  22010, 2, 644. \n133 Cole, A.C.; Jensen, J.L.; Ntai, I.; Tran, K.L.T.; Weaver, K.J .; Forbes, D.C.; Davis, J.H. \nJ. Am. Chem. Soc.  22002, 124, 5962. \n134 Bukhari, S.N.A.; Jasamai, M.; Jantan, I.; Ahmad, W. Mini-Rev. Org. Chem.  22013, \n10, 73. \n135 Eddarir, S.; Cotelle, N.; Bakkour, Y.; Rolando, C. Tetrahedron Lett.  22003, 44, 5359. \n136 Al-Masum, M.; Ng, E.; Wai, M. Tetrahedron Lett.  22011, 52, 1008. \n137 Zou, G.; Guo, J.; Wang, Z.; Huang, W.; Tang, J. Dalton Trans.  22007, 28, 3055. \n138 Bianco, A.; Cavarishia, C., Guiso, M. Nat. Prod. Res.  22006, 20, 93. \n139 Srivastava, Y.K. Ras. J. Chem.  22008, 1, 884. \n140 Bohm, A. Introduction to Flavonoi ds. Harwood Academic Pub: London, 1 1998. \n141 Kumar, A.; Sharma, S.; Tripathi, V.D.; Srivastava, S. Tetrahedron  22010, 66, 9445. \n142 Dimmock, J.R.; Elias, D.W.; Kandepu, N.M. Curr. Med. Chem.  11999, 6, 1125. \n143 Sahu, N.K.; Balbhadra, S.S.; Choudhary, J.; Koholi, D.V. Curr. Med. Chem.  22012, \n19, 209. \n144 Nowakowska, Z. Eur. J. Med. Chem.  22007, 42, 125. \n145 Go, M.L.; Wu, X.; Liu, X.L. Curr. Med. Chem . 22005, 12, 483. \n146 Rahman, M.A. Chem. Sci. J.  22011, 3, 1. \n147 Liaras, K.; Geronikaki, A.; Glamoclija, J.; Ciric, A.; Sekovic, M. Bioorg. Med. Chem.  \n2011 , 19, 3135. \n300Bibliograf\u00eda \n \n301                                                                                                                            \n148 Feldman, M.; Tanabe, S.; Epifano, F.; G enovese, S.; Curini, M.; Grenier, D. J. Nat. \nProd.  22011, 74, 26.  \n149 Narender, T.; Venkateswarlu, K.; Shweta G.; Papireddy K.; Tanvir K.; Awakash S.; \nRajeev K.S.;  Kumkum S.; Wahajuddin,  P.S.S.; Vikash K.; Imran S.M. J. Med. Chem.  \n2013 , 56, 31. . \n150 Lopez, S.N.; Castelli, M.V.; Zacchino, S.A .; Dominguez, J.N.; Lobo, G.; Jaime, C.C.; \nCortes, J.C.G; Ribas, J.C.; Devia, C.; Ana, M.R.; Ricardo, D.E. Bioorg. Med. Chem.  \n2001 , 9, 1999. \n151 Cheenpracha, S.; Karalai, C .; Ponglimanot, C.; Subhadhirasakul, S.; Tewtrakul, S. \nBioorg. Med. Chem.  22006, 14, 1710. \n152 Haudecoeur, R.; Ahmed-Belkacem, A.; Yi, W .; Fortune, A.; Brillet, P.; Boumendjel, A. \nJ. Med. Chem.  22011, 54, 5395. \n153 Navarini, A.L.F.; Chiarandia, L.D.; Mascare llo, A.; Fritzen, M.; Jose Nunes, R.; Yunes, \nR.A.; Crezynski-Prasa, T.B. Eur. J. Med. Chem.  22009, 44, 1630. \n154 Rao, G.V.; Swamy, B.N.; Chandregowda, V.; Reddy, G.C. Eur. J. Med. Chem.  \n2009 , 44, 2239. \n155 Viana, G.S.B.; Bandeira, M.A.M.; Matos, F.J.A. Phytomedicine  22003, 10, 189.  \n156 Jianzhang, W.; Jianling, Li.; Yuepiao, Cai .; Yong, P.; Shulin, Y.; Xiaokun, L.; Guang, \nL. J. Med. Chem.  22011, 54, 8110. \n157 Meng, C.Q.; Ni, L.; Worsencroft, K.J.; Ye , Z.; Weingarten, M.D.; Simpson, J.E.; \nSkudlarek, J.W.; Marino, E.M.; Suen, K. L.; Kunsh, C.; Sounder , A.; Howard, R.B.; \nSundell, C.L.; Wasserman,  M.A.; Sikorski, J.A. J. Med. Chem.  22007, 50, 1304. \n158 Middelton, E.Jr.; Hirota, F.; Savliwala, M.; Drewiecki, G. Biochem. Pharmacol.  11987, \n36, 2048. \n159 Boumendjel, A.; Boccard, J.; Carrupt, P.A.; Nicolle, E.; Blanc, M.; Geze, A.; \nChoisnard, L.; Wouessidjewe, D .; Matera, E.L.; Dumontet, Ch. J. Med. Chem.  22008, \n51, 2307. \n160 Barford, L.; Kemp, K.; Hansen, M.; Kharazmi, A. Int. Inmunopharmacol. 2 2002, 2, \n545. \n161 Ying, P.; Yicun, C.; Qingnan, L.; Xiaoyu, Y.; Jinzhi, W.; Jinhong, Z. Molecules 2013 , \n18, 1693.  \n162 Morel, I.; Lescoat, G.; Cogrel, P.; Sergent, O.; Pasdeloup, N.; Brissot, P.; Cillard, P.; \nCillard, J. Biochem. Pharmacol.  11993, 45, 13. \n163 Remy Kachadourian, R.; Day, B.J.: Pugaz henti, S.; Franklin, C.C.; Genoux-Bastide, \nE.; Mahaffey, G.; Gauthier, C.; Di Pietro, A.; Boumendjel, A. J. Med. Chem.  22012, 55, \n1382.   \n301Bibliograf\u00eda \n \n302                                                                                                                            \n164 Cai, Y-Z.; Sun, M.; Xing, J.; Luo, Q.; Corke, H. Life Sci.  22006, 78, 2872. \n165 Bukhari, S.N.A.; Jantan, I.; Jasamai, M. Mini-Rev. Med. Chem.  22013, 13, 87.  \n166 Bandgar, B.P.; Gawande, S.S.; Bodade, R. G.; Totre, J.V.; K hobragade, C.N. Bioorg. \nMed. Chem.  22010, 18, 1364. \n167 Herencia, F.; Ferrandiz, M.L.; Ubeda, A.; Dominguez, J.N.; Charris, J.E.; Lobo, G.M.; \nAlcaraz, M.J. Bioorg. Med. Chem. Lett.  11998, 8, 1169. \n168 Rojas, J.; Dominguez, J.N.; Charris, J. E.; Lobo, G.M.; Paya M.; Ferrandiz, M.L. Eur. \nJ. Med. Chem.  22002, 37, 699. \n169 Dinkova-Kostova, A.T.; Abeygunawardana, C.; Talalay, P. J. Med. Chem.  11998, 41, \n5287. \n170 Modzelewska, A.; Pettit, C .; Achanta, G.; Davidson, N. E.; Huang, P.; Khana, S.R. \nBioorg. Med. Chem.  22006, 14, 3491. \n171 Mendes, V.; Monteiro, R.R.; Pestana, D.; Teixeira, D.; Ca lhau, C.A.O.; Azevedo, I. J . \nAgric. Food Chem.  22008, 56, 11631. \n172 Opletalov\u00e1, V.; Sedivy, D. Ceska. Slov. Farm.  11999, 48, 252. \n173 Wu, J.H.; Wang, X.H.; Yi, Y.H.; Lee, K.H. Bioorg. Med. Chem. Lett.  22003, 13, 1813. \n174 Greenwood, B.; Mutabingwa, T. Nature  22002, 415, 670. \n175 Hayal, F.; Moseley, E.; Salahuddin, A.; Van Zyl, R.L.; Azam, A. Eur. J. Med. Chem.  \n2011 , 46, 1897. \n176 Tran, T.D.; Park, H.; Kim, H.P.; Ecker, G.F.; Thai, K-M. Bioorg. Med. Chem. Lett.  \n2009 , 19, 1650. \n177 Chimenti, F.; Fioravanti, R.; Bolasco, A.; Rossi, F.; Yanez, M.; Or allo, F.; Ortuso, F.; \nAlcaro, S. J. Med. Chem.  22009, 52, 2818. \n178 Robinson, S. J.; Petzer, An\u00e9l Petz er, J.P.; Bergh, J.J. Lourens, A.C. Bioorg. Med. \nChem. Lett.  22013, 23, 4985. \n179 Desideri, N.; Fioravanti, R .; Monaco, L.P.; Biava, M.; Y\u00e1\u00f1ez, M., Ortuso, F.; Alcaro, S. \nEur. J. Med. Chem.  22013, 59, 91. \n180 Desideri, N.; Bolasco, A., Fioravanti, R.; Monaco, L.P.; Orallo, F. ; Ya\u00f1ez, M.; Ortuso, \nF.; Alcaro, S. J. Med. Chem.  22011, 54, 2155. \n181 Nguyen, N. T.; Nguyen, M.H.K .; Nguyen, H.X.; Nguyen, M.T.H. J. Nat. Prod.  22012, \n75, 1951. \n182 Jun, N.; Hong, G.; Jun, K. Bioorg. Med. Chem.  22007, 15, 2396. \n183 Evans, B.E.; Rittle, K.E.; Bock, M.G.; Dipa rdo, R.M.; Freidinger, R.M.; Whitter, W.L.; \nLundell, G.F.; Veber, D.F.; Anderson, P.S. J. Med. Chem.  11988, 31, 2235. \n184 Delaunois, B.; Cordelie r, S.; Conreux, A. Plant Biotech. J.  22009, 7, 2.  \n185 Likhitwitayawuid K.; Sritularak, B. J. Nat. Prod.  22001, 64,1457.  \n302Bibliograf\u00eda \n \n303                                                                                                                            \n186 He, S.L.; Zheng, J.C.; Lin, M. J. Agric. Biotech.  22004, 12, 102.  \n187 Leiro, J.; \u00c1lvarez, E.; Arranz, J. A.; Laguna, R.; Uriarte, E.; Orallo, F. J. Leukoc. Biol.  \n2004 , 75, 1156. \n188 Langcake, P.; Pryce, R.J. Physiol. Plant Pathol . 11976, 9, 77. \n189 Siemann, E.H.; Creasy, L.L. Am. J. Enol. Vitic . 11992, 43, 49. \n190 Orallo, F. Biol ogical Effects of Cis- versus Trans-Resveratrol, in: Aggarwal, B.B.; \nShishodia, S. (Eds), Resveratrol in Health and Disease, CRC Press, Boca Raton, USA, \n2005 . \n191 Renaud, S.; De Lorgeril, M. Lancet  11992, 339, 1523. \n192 Leger, A.S.; Cochrane, A.L.; Moore, F. Lancet  11979, 1, 1017. \n193 Ribeiro de Lima, M.T.; Waffo-Teguo, P.; Tei ssedre, P.L.; Pujolas, A.; Vercauteren, J.; \nCabanis, J.C.; Merillon, J.M. J. Agric. Food Chem. 1999 , 47, 2666. \n194 Berzas Nevado, J.J.; Contento Salcedo, A.M.; Castaneda Penalvo, G. Analyst 1999  \n124, 61. \n195 Andrus, M.; Liu. J. Tetrahedron Lett.  22006, 47, 5811. \n196 Magrone, T.; Jirillo, E. Curr. Top. Med. Chem.  22011, 11, 1780.  \n197 Y\u00e1nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun.  22006, \n344, 688. \n198 Ebada, S.S; Lajkiewicz, N.; Porco,  J.A: Li-Weber, M; Proksch, P. Progress Chem. \nOrg. Nat. Prod.  22011, 94, 1. \n199 Ribeiro, N; Thuaud, F.; Nebigil, C.; D\u00e9saubry, L. Bioorg. Med. Chem.  22012,  20 \n1857. \n200 King, M.L.; Chiang, C.C.; Ling, H.C.; Fujita, E.; Ochiai, M.; McPhail, A.T. Chem. \nCommun. 1992 , 1150.  \n201 Kim, S.; Salim, A. A.; Swanson, S. M.; Kinghorn, A. D. Anticancer Agents Med. \nChem.  22006, 6, 319. \n202 Proksch, P.; Edrada, R.; Ebel, R.; Bohnenstengel, F.; Nugroho, B. Curr. Org. Chem.  \n2001 , 5, 923. \n203 King, M.L.; Chiang, C.C.; Ling H.C. J. Chem. Soc 1982 , 20, 1150. \n204 Proksch, P.; Giaisi, M.; Treiber, M.K. J. Immunol.  22005, 174, 7075. \n205 Zhu, J.Y.; Lavrik,  I.N.; Mahlknecht, U. Int. J.  Cancer , 22007, 121,1839. \n206 Thuaud, F.; Bernard, Y.; Turkeri, G. J. Med. Chem.  22009, 52, 5176. \n207 Koul, O.; Kaur, H.; Goomber, S.; Wahab, S. J. Applied Entomol.  22004, 128, 177. \n208 Dreyer, M.; Nugroho, B.W.; Bohnenstengel F.I. J. Nat. Prod.  22001, 64, 415. \n209 Piver, B.; Berthou, F.; Dreano, Y.; Lucas, D. Life Sci.  22003, 73, 1199. \n303Bibliograf\u00eda \n \n304                                                                                                                            \n210 Riviere, C.; Papastamoulis, Yo.; Fortin, P- Y.; Delchier, N.; Andr iamanarivo, S.; W-T., \nPierre; Kapche, G.D. W. F.; Amira-Guebalia, H.; Delaunay, J-C.; Merillon, J-M.; Richard, \nT.; Monti, J.P. Bioorg. Med. Chem. Lett.  22010, 20, 3441. \n211 Malona, J.A.; Cariou, K.C.; Frontier, A.J. J. Am. Chem. Soc.  22009, 131, 7560. \n212 Tius, M.A. Eur. J. Org. Chem.  22005, 11, 2193. \n213 Basak, A.K; Shimada, N; Bow, W.F; Vicic, D.A: Tius, M.A. J Am Chem Soc.  22010, \n132, 8266. \n214 Nazarov, I.N.; Zaretskaya, I.I. Izv. Akad. Nauk. SSSR, Ser. Khim  11941, 211. \n215 Spencer III, W.T.; Vaidya, T.; Frontier, A.J. Eur. J. Org. Chem.  22013, 3621. \n216 Malona, J.A.; Cariou, K.; Frontier, A.J. J. Am. Chem. Soc.  22009, 131, 7560.  \n217 Berger, G.O.; Tius, M.A. J. Org. Chem.  22007, 72, 6473. \n218 Ya\u00f1ez M.; Vi\u00f1a, D. Curr. Top. Med. Chem.  22013, 1314,  1692. \n219 Bisi, A.; Gobbi, S.; Be lluti, F.; Rampa, A. Curr. Med. Chem.  22013, 20, 1759. \n220 Amin, K.M.; Awada lla, F. M.; Eissa, A.M.; Abou -Seri, S.M.; Hassan, G.S. Bioorg. \nMed. Chem.  22011, 19, 6087. \n221 Njogu, P.M.; Chibale, K. Curr. Med. Chem.  22013, 20, 1715. \n222 Qiao, Z.; Wang, Q.; Zhang, F.; Wang, Z.; Bowling, T.; Nare, B.; Jacobs, R.T.; Zhang, \nJ.; Ding, D.; Liu, Y.; Zhou H. J. Med. Chem.  22012, 55, 3553. \n223 Guantai, E.M.; Ncokazi, K.; Egan , T.J.; Smith, P.J.; Chibale, K. Bioorg. Med. Chem.  \n2010 , 18, 8243. \n224 Chimenti, F.; Bizzarri, B.; Bo lasco, A.; Secci, D .; Chimenti, P.; Granese, A.; Carradori, \nS.; Rivanera, D.; Scaltri to, M.M.; Sisto, F. Bioorg. Med. Chem. Lett.  22010, 20, 4922. \n225 Burger, A. Prog. Drug. Res.  11991, 37, 287. \n226 Erlenmeyer, H.; Leo, M. Helv. Chim. Acta  11932, 15, 1171.  \n227 Friedman, H.L. Influence of Isosteri c Replacements upon Biological Activity, \nWashington, EUA, National Academy of  Science, 1 1951, n\u00ba 206, p. 295.  \n228 Thornber, C.W. Chem. Soc. Rev. 1979 , 8, 563. \n229 Burger, A. A Guide to the Chemical B asis of Drug Design, NY, EUA,. Wiley, 1 1983; p. \n24-29. \n230 Claisen, L.; Tietze, E. Ber. Dtsch. Chem. Ges.  11926, 59B , 2344. \n231 Yamamoto, H.; Kaneko, S. J. Med. Chem.  11970, 13, 292. \n232 Tenconi, F.; Barzaghi, F. Boll. Chim. Farm.  11964, 103, 569. \n233 Begala, M.; Delogu, G.; M accioni, E.; Podda. G.; Tocco, G.; Quezada, E.; Uriarte, E.; \nFerigo, M.A.; Favretto, D.; Traldi, P. Rapid Comm. Mass Spectr. 2001 , 15, 1000. \n234 Vilar, S.; Quezada, E.; Alcaide, C.; Orallo, F.; Santana, L.; Uriarte, E. QSAR Comb. \nSci. 2007 , 26, 317.  \n304Bibliograf\u00eda \n \n305                                                                                                                            \n235 Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E .; Uriarte, E.; Y\u00e1nez, M.; Vi\u00f1a, D.; Orallo, \nF. J. Med. Chem. 2008 , 51, 6740. \n236 Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz,  H.; Zagotto, G.; So to-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 , 49, 1149. \n237 Vilar, S.; Quezada, E.; Sant ana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, C.; Cano, \nE.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 , 16, 257. \n238 Orallo, F. Biological Effects of Cis- versus Trans re sveratrol, en: B.B. Aggarwal, S. \nShishodia (Eds), Resveratrol in Health and Diseases, CRC Press, Boca Raton, USA, \n2005 , 577. \n239 Matos, M.J.; Teran, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. J. Med. \nChem.  22011, 54, 7127. \n240 Santana, L.; Orallo, F.; Vi\u00f1a, D.; Matos,  M.J.; Quezada, E.; Ya\u00f1ez, M.; Vila, S.; \nUriarte, E. P200900224, 2 2009, Espa\u00f1a. \n241 Matos, M.J. Cumarinas: versatilidad estructural y aplicaciones en Qu\u00edmica \nFarmac\u00e9utica. Tesis Doctoral  22013. \n242 Kamat, S.; D\u00b4Souza, A.; Paknikar, S.; Beauchamp, P. J. Chem. Research (S) 2 2002, \n242. \n243 Perkin, W.H. J. Chem. Soc.  11868, 21, 53. \n244 Girouard, S.; Houle, M.-H.; Grandboi s, A.; Keillor, J.W.; Michnick, S.W. J. Am. \nChem. Soc.  22005, 127, 559. \n245 Matos, M.J.; Vazquez-Rodriguez, S.; Borges, F.; Santana, L.; Uriarte, E. Tetrahedron \nLett. 2 2011, 52, 1225. \n246 Brunet, E.; Alonso, M.T.; Juanes, O.; Velasco, O.; Rodriguez-Ubis, J.C. Tetrahedron , \n2001 , 57, 3105. \n247 Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Acta Cryst.  22013, E69 , o345. \n248 Kuo, P.Y.; Chuang, R.R.; Yang, D.Y. Mol. Divers. 2 2009, 13, 253. \n249 He, W.; Zhang, B.L.; Zhou, S. Y.; Sun, X.L.; Zhang, S.Y. Synth. Comm.  22007, 37, \n361. \n250 Micky, J.A.A.; Farrug, A.A. Indian J Chem.  11997, 36B , 357. \n251 Hamdi, N.; Bouabdallah, F.; Romerosa, A.; Benhassen, R. C. R. Chimie  22010, 13, \n1261. \n252 Pardin, C.; Pelletier, J.N.; Lubell, W.D.; Keillor, J.W. J. Org. Chem.  22008, 73, 5766. \n253 Bera, R.; Dhananjaya, G.; Singh, S.N.; Kumara, R.; Mukkantib, K.; Pal, M. \nTetrahedron  22009, 65, 1300. \n254 Khan, M.S.Y.; Bawa, S. Indian J. Chem.  22001, 40B , 1207. \n305Bibliograf\u00eda \n \n306                                                                                                                            \n255 Jolit, A.; Vazquez-Rodriguez, S.; Yap, G.P.A.; Tius, M. Angew. Chem. Int. Ed.  22013, \n52, 11102. \n256 Matos, M.J.; Vi\u00f1a, D.; Janeiro, P.; Bo rges, F.; Santana, L.; Uriarte, E. Bioorg. Med. \nChem. Lett. 2010 , 20, 5157.  \n257 Vi\u00f1a, D.; Matos, M.J.; Ferino, G.; Cad oni, E.; Laguna, R.; Borges, F.; Uriarte, E.; \nSantana, L. ChemMedChem 2012 , 7, 464. \n258 Matos, M.J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. Bioorg. Med. \nChem. Lett.  22011, 21, 4224. \n259 Serra, S.; Ferino, G.; Matos, M.J.; Va zquez-Rodriguez, S.; Delogu, G.; Vi\u00f1a, D.; \nCadoni, E.; Santana, L.; Uruarte, E. Bioorg. Med. Chem. Lett.  22012, 22, 258. \n260 Matos, M.J.; Vi\u00f1a, D.; Vazquez-Rodr iguez, S.; Uriarte, E.; Santana, L. Curr. Topics \nMed. Chem.  22012, 12, 2210. \n261 Lodovici, M.; Meni chetti, S.; Viglianisi , C.; Giuliani, E. Bioorg. Med. Chem. Lett. \n2006 , 16, 1957. \n262 Heim, K.E.; Tagliaferro , A.R.; Bobilya, D.J. J. Nutr. Biochem.  22002, 13, 572. \n263 Khlebnikov, A.I.; Schepetkin, I.A.; Domina, N.G.; Kirpotina, L.N.; Quinn, M.T. Bioorg. \nMed. Chem.  22007, 15, 1749. \n264 Vogel, S.; Barbic, M.; J\u00fc rgenliemk, G.; Heilmann, J. Eur. J. Med. Chem.  22010, 45, \n2206. \n265 P\u00e9rez-Cruz, F.; Vazquez-Rodriguez, S.; Mato s, M.J.; Herrera-Morales. A.; Villamena, \nF.A.; Das, A.; Gopalakrishnan, B.; Olea -Azar, C.; Santana, L.; Uriarte, E. J. Med. Chem.  \n2013 , 56, 6136. \n266 Vazquez-Rodriguez, S.; Figueroa-Gu\u00ed\u00f1ez, R.; Matos, M.J.; Santana, L.; Uriarte, E.; \nLapier, M.; Maya, J.D.; Olea-Azar, C. Med. Chem. Comm.  22013, 4, 993.  \n267 Matos, M.J.; P\u00e9rez-Cruz, F.; Vazquez-Rodr iguez, S.; Uriarte, E.; Santana, L.; Borges, \nF.; Olea-Azar, C. Bioorg. Med. Chem.  22013, 21, 3900. \n268 Figueroa-Gu\u00ed\u00f1ez, R.; Matos, M.J.; Vazque z-Rodriguez, S.; Santana, L.; Uriarte, E.; \nOlea-Azar, C.; Maya, J.D. Future Med. Chem.  22013, 5, 1. \n269 Bern, C. N. Engl. J. Med.  22011, 354, 2527. \n270 Ba, X.; Gupta, S.; Davidson, M.; Garj, N.J. J. Biol. Chem.  22010, 285, 11596. \n271 Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden J. Pharmacol. \nRev. 22001, 53, 527. \n272 Lopes, L.V.; Sebastiao, A.M.; Ribeiro, J.A. Curr. Top. Med. Chem.  22011, 11, 1087. \n273 Shook, B.C. et all. J. Med.Chem.  22012, 55, 1402. \n274 Okajima, F.; Akbar, M.; Abdul, M. M.; Sho, K.; Tomur a, H.; Kondo, Y. Biochem. \nBiophys. Res. Comm. 1 1994, 203, 1488. \n306Bibliograf\u00eda \n \n307                                                                                                                            \n275 Jacobson, K.A.; Moro, S.; Manthey, J.A.; West, P.L.; Ji, X.D. Adv. Exp. Med. Biol.  \n2002 , 505, 163. \n276 Vazquez-Rodriguez, S.; Matos, M.J.; Santana,  L.; Uriarte, E.; Borges, F.; Kaschler, \nS.; Klotz, K.N. J. Pharm. Pharmacol.  22013, 65, 697. \n277 Vazquez-Rodriguez, S.; Serra, S.; Uriarte, E.; Santana, L.; Vila r, S.; Kaschler, S.; \nKlotz, K.N. Enviado. \n278 Souza, S.M.; Delle Mo nache, F.; Smania, A.Jr. Z. Naturforsch. C.  22005, 60, 693 \n279 Matos, M.J.; Vazquez-Rodriguez, S.; S antana, L.; Uriarte, E.; Fuentes-Edfuf, C.; \nSantos, Y.; Mu\u00f1oz-Crego, A. Molecules  22013, 18, 1394. \n280 Matos, M.J.; Vazquez-Rodriguez, S.; S antana, L.; Uriarte, E.; Fuentes-Edfuf, C.; \nSantos, Y.; Mu\u00f1oz-Crego, A. Med. Chem.  22012, 8, 1140. \n281 Baxa, D.V.; Kawai, K.; Kusuda, R. Fish Pathol.  11986, 21, 251. \n282 Toranzo, A.E.; Magari\u00f1os, B.; Romalde, J.L. Aquaculture  22005, 246, 37. \n283 Vazquez-Rodriguez, S.; Diaz, A.; Matos, M.J.; Serra, S.; Uriarte, E.; Santana, L.; \nMu\u00f1oz-Crego, A.; Santos, Y. Enviado. \n \n \n \n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n307", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}